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Embryonic stem cells are one of the key building blocks of the emerging multidisciplinary 
field of regenerative medicine, and discoveries and new technology related to embryonic 
stem cells are being made at an ever increasing rate. This book provides a snapshot of some 
of the research occurring across a wide range of areas related to embryonic stem cells, 
including new methods, tools and technologies; new understandings about the molecular 
biology and pluripotency of these cells; as well as new uses for and sources of embryonic 
stem cells. The book will serve as a valuable resource for engineers, scientists, and 
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Preface 
The isolation and culture of human embryonic stem cells by Thomson in the late 1990s
has accelerated a paradigm shift in medicine that was started much earlier by Till and
McCulloch in the early 1960s with the discovery of the first stem cells in mice. The
burgeoning field of regenerative medicine will ultimately transform modern human
health care from a molecule‐based focus, which serves to alleviate symptoms, to a cell
and tissue based focus which has the promise of actually restoring function. Although
the potential is enormous, the road is long and there are certainly many milestones
along the way. This book, Embryonic Stem Cells ‐ Basic Biology to Bioengineering and its
companion, Embryonic Stem Cells ‐ Differentiation and Pluripotent Alternatives, serve as a
snapshot of many of the activities currently underway on a number of different fronts.
This book is divided into five parts and provides a foundation upon which future
therapies and uses of embryonic stem cells can be built.
Part 1: Challenges and Possibilities ‐ From New Cell Lines to Alternative Uses of Cryopreserved
Embryos
Chapters 1‐3 offer a broad overview of some of the challenges in bringing embryonic
stem cell based medicine to the clinic, as well as a case study of the derivation of new
embryonic stem cell lines, and an alternative to the use of cryopreserved embryos.
Part 2: Methods, Tools and Technologies for Embryonic Stem Cell Culture, Manipulation and
Clinical Application
Chapters 4‐10 present a wide variety of tools and technologies ranging from large‐
scale bioreactors to scaled‐down bioreactor arrays and synthetic surfaces that can be
used for embryonic stem cell culture. In addition, methods for introducing foreign
genes into embryonic stem cells and controlling gene expression are described. Lastly,
the use of imaging is presented as a tool to measure pluripotency and early
differentiation.
Part 3: Applications of Embryonic Stem Cells in Research and Development
Chapters 11‐13 present methods to generate chimeric mice for use in research, and in
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molecules  involved  in  regulating  not  only  pluripotency  but  cancer  and  early 
embryonic tissues. 
Part 5: Lessons from Development 
Chapters  21‐23  examine  the  knowledge we  have  gained  from  studying  embryonic 
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Embryonic Stem Cells for Therapies –  
Challenges and Possibilities  
Ronne Wee Yeh Yeo and Sai Kiang Lim 
Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR); 
Yong Loo Lin School of Medicine, National University of Singapore 
Singapore 
1. Introduction 
The successful establishment of human embryonic stem cells (hESCs) in culture (Thomson et 
al., 1998) has raised unprecedented public interest and expectation of treating intractable 
diseases such as diabetes, spinal cord injuries, neurodegenerative and cardiovascular 
diseases. Much of this enthusiasm was predicated on the unlimited self-renewal capacity of 
hESCs and their remarkable plasticity in differentiating into every cell type in our body. 
These features presented the tantalizing possibility of an unlimited cell source in 
regenerative medicine to generate any tissues to replace injured or diseased tissues. 
However, translating the potential of hESC into therapies has been challenging. Although 
translation of hESC has been severely impeded by social and political constraints placed on 
hESC research through ethical and religious concerns over the destruction of viable 
blastocysts during hESC isolation, the main challenges have been safety and technical 
issues.  
2. Challenges in ESC therapy 
2.1 Overcoming tumor formation 
The two defining characteristics of ESCs are: 1) their pluripotency, or the potential to 
differentiate into all cell types in the adult body; and 2) their unlimited self-renewal 
capacity, or the ability to remain in an undifferentiated state and divide indefinitely. For 
mESCs, pluripotency is often demonstrated by the production of mESC-derived animals 
through germline transmission by chimeras resulting from injection of the cells into 
blastocysts or through tetraploid complementation. In hESCs, proof of pluripotency has 
been limited to formation of teratomas or teratocarcinomas, which are tumors composed of 
randomly distributed tissues from the three primordial germ layers in immunologically 
incompetent mice (Lensch et al., 2007). Karyotypically normal, low passage hESCs form 
benign teratomas that do not contain undifferentiated tissues and are less invasive (Blum et 
al., 2009; Reubinoff et al., 2000; Thomson et al., 1998) while high passage hESCs which have 
become karyotypically abnormal give rise to highly invasive, malignant teratocarcinomas 
(Herszfeld et al., 2006; Plaia et al., 2006; Werbowetski-Ogilvie et al., 2009; Yang et al., 2008).  
Pluripotency coupled with unlimited self-renewal not only define ESCs, they are also the 
main appeal of ESC as the cell source for regenerative medicine but at the same time, pose 
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significant challenges to the transplantation of differentiated ESCs to replace injured or 
diseased tissues. The propensity of ESC to differentiate into teratomas necessitates the need 
to eliminate any residual ESCs in the differentiated cell preparation. There have been many 
strategies to eliminate residual ESCs or enhance the purity of differentiated ESC 
preparations. The use of heterologous selectable gene markers such as antibiotic resistance 
gene or fluorescent protein markers (Klug et al., 1996; M. Li et al., 1998; Muller et al., 2000; 
Soria et al., 2000) is generally not a strategy of choice as this could introduce potentially 
deleterious gene mutations. Most of the strategies centered around the use of endogenous 
markers that are unique or highly expressed on ESCs and not on their differentiated 
progeny. For example, SSEA-4 and TRA-1-60 which are highly expressed on hESCs have 
shown to be highly efficient in physically removing contaminating ESCs by magnetic or 
fluorescence-activated cell sorters (MACS or FACS) (Fong et al., 2009b). Another strategy 
exploit the flotation density of cell on discontinuous density gradients such as Puresperm- 
or Percoll-based gradients (Fong et al., 2009a). Using a relatively novel strategy, Choo et al. 
has raised antibodies against undifferentiated hESCs (Choo et al., 2008) and identified an 
antibody that was cytotoxic against hESCs by oncosis. This antibody was an IgM that 
recognizes podocalyxin-like protein-1(PODXL).  hESCs that were treated with mAB 84 did 
not form teratoma when transplanted into SCID mice even after 18-24 weeks. Therefore, 
there are viable technologies to remove or reduce residual hESCs in differentiated hESC 
preparation and mitigate the risk of teratoma formation in patients receiving hESC-based 
cell therapy.      
2.2 Overcoming immunorejection 
Like all tissue transplants, hESC-based cell therapy will have to circumvent host immune 
rejection to engraft in the recipients. One proposed strategy was to establish ESC 
repositories with lines expressing the combinations of HLA molecules that are compatible 
with HLA haplotypes present in the population (Nakajima et al., 2007; Taylor et al., 2005). 
Alternatively, the host’s immune system could be manipulated to induce tolerance to 
foreign tissues by ablation of donor-reactive T cell in the thymus, generation of tolerogenic 
dendritic cells and induction of Treg cells [reviewed in (Chidgey et al., 2008)]. However, with 
the development of induced pluripotent stem cell technology that makes the creation of 
“patient-specific” pluripotent cells containing the same genetic material as the recipient a 
highly viable and practical option, the issue of host rejection has become a non issue.  
The quest to create “patient-specific” pluripotent cells began with therapeutic cloning or 
somatic cell nuclear transfer (SCNT) where the diploid nucleus of a somatic cell was injected 
into a haploid enucleated egg to be reprogrammed by soluble factors in the host cell. Upon 
stimulation, the re-programmed cell divides to form a blastocyst with an inner cell mass that 
has identical nuclear genetic composition as the nucleus donor. Although this approach has 
worked to generate ESCs from different animals such as mice, rabbits, cats, sheep, cattle, 
pigs, goats [reviewed in (Wilmut et al., 2002)] and even primates (Byrne et al., 2007), no 
hESC has been generated through this approach as it remains a highly inefficient process 
and the use of human oocytes is ethically controversial (French et al., 2008; J. Li et al., 2009b). 
ESCs generated through SCNT are in principle, heterogeneous in their genetic composition 
as they contain nuclear DNA of the nucleus donor and mitochondrial DNA of the egg donor 
(Evans et al., 1999). This raises the possibility that SCNT-derived ESCs could be rejected by 
the innate immune system of the host with which the ESCs share the same nuclear but not 
mitochondrial genetic material (Ishikawa et al., 2010).  
 




Fig. 1. Mitigating tumor formation and immune rejection. Two of the major challenges to the 
translation of ESCs into clinical applications are teratoma formation by residual 
undifferentiated ESCs in the cell preparation and immune rejection of ESC-derived cells or 
tissues due to incompatible HLA profiles of ESC and recipient. To mitigate the risk of 
teratoma formation, several methods to remove residual hESCs have been developed using 
either physical or biological methods. Some of the physical separation methods are based on 
magnetic- or fluorescence-activated cell sorters (MACS or FACS) that sort against cells with 
ESC-associated surface markers, SSEA-4 and TRA-1-60 or on cellular density using 
discontinuous gradients of Percoll or PureSperm. Alternatively, residual ESCs can be 
destroyed using a cytotoxic antibody (mAb 84) specific for undifferentiated hESCs. To 
prevent immune rejection, one strategy proposed the establishment of ESC repositories to 
carry lines expressing HLA combinations compatible with all possible haplotypes in the 
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teratoma formation, several methods to remove residual hESCs have been developed using 
either physical or biological methods. Some of the physical separation methods are based on 
magnetic- or fluorescence-activated cell sorters (MACS or FACS) that sort against cells with 
ESC-associated surface markers, SSEA-4 and TRA-1-60 or on cellular density using 
discontinuous gradients of Percoll or PureSperm. Alternatively, residual ESCs can be 
destroyed using a cytotoxic antibody (mAb 84) specific for undifferentiated hESCs. To 
prevent immune rejection, one strategy proposed the establishment of ESC repositories to 
carry lines expressing HLA combinations compatible with all possible haplotypes in the 
 
Embryonic Stem Cells – Basic Biology to Bioengineering 
 
6 
population. Alternatively, donor cell tolerance can be induced by manipulating host 
immune defenses, such as eliminating donor-reactive T cells in the thymus, generating 
tolerogenic dendritic cells and inducing Treg cells. An ideal approach would be to generate 
patient-specific ESCs. Some of early efforts include the use of somatic cell nuclear transfer 
(SCNT). More recently, induced pluripotent stem cell (iPSC) technology has enabled with 
great ease the generation of self pluripotent stem cells without the destruction of oocytes or 
embryos, hence bypassing ethical controversies. 
The breakthrough in creating “patient-specific” pluripotent cells was achieved when 
Yamanaka demonstrated  that the introduction of transcription factors which regulate ESC 
self-renewal, including Oct3/4 and Sox2 was sufficient to reprogram somatic cells into ES-
like cells (Takahashi & Yamanaka, 2006). These induced pluripotent stem cells (iPSCs) are 
karyotypically normal with gene expression profiles highly similar to ESCs and can 
differentiate into cells of all three germ layers (Takahashi et al., 2007; Yu et al., 2007). Apart 
from being patient-specific, the major attraction of iPSCs lies in their derivation from 
somatic tissues and not from ethically contentious tissues such as human oocytes or 
embryos. However, retroviral and lentiviral vectors were required to express the 
transcription factors for reprogramming  of the somatic cells and this carries a risk of 
insertional mutagenesis. To circumvent the need for viral vectors, non-viral genetic 
modification approaches were developed (Okita et al., 2008; Soldner et al., 2009; Woltjen et 
al., 2009). Recently iPSCs were obtained via a direct delivery of reprogramming factors into 
cells using poly-arginine protein transduction domains (Zhou et al., 2009) or mRNA (Plews 
et al., 2010), thereby circumventing any form of genetic manipulation. These improvements 
have essentially abrogated the issue of host/donor cell immune compatibility and 
considerably enhanced the prospects of generating patient-specific iPSCs for regenerative 
medicine. However, a recent study demonstrated that some hiPSC derivatives exhibit 
limited expansion capability, increased apoptosis and early cellular senescence as compared 
to their hESC-derived counterparts, raising doubts about the clinical value of this 
reprogramming technology (Feng et al., 2010). Also, it remains to be determined if the 
progeny of these cells, which are genetically identical to the reprogrammed cell, will trigger 
any immune response when reintegrated into the donor. 
2.3 ESC differentiation  
ESC owes its allure as the source of stem cells for regenerative medicine to two important 
potentials: 1) unlimited self-renewal potential and 2) the potential to differentiate into all the 
cell types in an adult. Unfortunately, the recent technological advances to circumvent the 
risks associated with transplantation of ESC-derived cells, namely teratoma formation and 
host immune rejection, were not matched by similar progress in differentiating hESCs into 
cells suitable for regenerative medicine.   In contrast to adult stem cells where hundreds of 
clinical trials have been conducted to evaluate their clinical efficacy, the first testing of a 
hESC-based therapeutic candidate has only just been initiated. In Oct 2010, Geron Corp 
announced the enrollment of the first patient to test the safety of human embryonic stem cell 
(hESC)-derived oligodendrocyte progenitor cells, GRNOPC1, in treating spinal cord injury. 
With the progress made in reducing the risk of teratoma formation by residual ESC in 
differentiated ESC preparations and the generation of patient-specific iPSC, the major 
impediment to the development of hESC-based cell therapies remains the general lack of 
progress in developing protocols for efficient and reproducible differentiation of hESCs into 
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clinically relevant cell types in sufficient quantity and purity suitable for transplantation 
studies in clinically relevant large animal models.  
The pluripotent differentiation potential of hESCs has always been predicated on their 
ability to form teratomas in immune-compromised animals and embryoid bodies consisting 
of tissues from the three germ layers. This ability suggest that differentiation of ESC into the 
various cell types in the adult animal was not contingent on the presence of an embryonic 
microenvironment. Instead, it relies on a rather minimal environment that did not support 
the pluripotent and self-renewing state of the ESCs and bore little resemblance to the 
dynamically evolving microenvironment of a developing embryo. Nevertheless, much effort 
to direct differentiation of hESCs into potentially therapeutic cell types have focused on the 
recapitulation of the embryonic microenvironment based on a yet to be tested rationale that 
the embryonic microenvironment represents the optimal micro-environment for directed in 
vitro differentiation of  ESC. 
2.3.1 Recapitulating embryonic development to induce lineage commitment  
Embryogenesis is a highly dynamic complex process that is still being unraveled despite 
years of intensive research and much progress in elucidating the molecular and cellular 
processes involved in formation of an embryo. From a developmental perspective, the ESC 
represents cells that were frozen in the developmental state of a late-stage embryo just prior 
to differentiation and lineage commitment. The ability of ESC to re-enter the developmental 
process and differentiate when returned to the micro-environment of a blastocyst has 
provided compelling impetus to use the developing embryo to guide and direct in vitro 
differentiation of ESC to a specific cell type. Much effort has therefore been devoted to 
identifying the molecular cues that were involved in the differentiation of pluripotent cells 
in the blastocyst into specific terminally differentiated cells. The underlying rationale has 
always been that a temporal and spatial recapitulation of these cues in vitro will direct 
differentiation of ESC towards a specific cell type. 
An early and critical phase of embryogenesis is gastrulation. During this process, the mono-
layered blastula undergoes a series of transformation to form the tri-layered gastrula. The 
formation of these three germ layers (endoderm, mesoderm and ectoderm) marks the first 
stage of cell fate determination. This is followed by organogenesis when tissues and organs 
are formed from further differentiation of the germ layers. The endoderm gives rise to the 
epithelia of the gut and respiratory system, and organs such as liver and pancreas; the 
mesoderm gives rise to muscles, the circulatory system, bone and connective tissues; and the 
ectoderm gives rise to the nervous system and the epidermis. Similarly, the initial step 
towards deriving functional cells and tissues from ESCs may involve germ layer induction 
in vitro. 
The first visible sign of gastrulation is the formation of the symmetry-breaking structure 
called the primitive streak (PS). Epiblast cells, which are derived from the inner cell mass, 
ingress through the PS to form the mesoderm and definitive endoderm. The remaining 
epiblast cells that do not ingress form the ectoderm. Many molecular factors have been 
implicated in this process and they include members of the large transforming growth factor 
β (TGFβ) and Wnt signaling families (Conlon et al., 1994; Hogan, 1996; Schier, 2003; 
Yamaguchi, 2001). Painstaking research has revealed some of the temporal and spatial 
effects of these factors during embryogenesis and many of these factors exerted similar 
effects on the differentiation of ESC cells. As reviewed by Murry and Keller (Murry & 
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Keller, 2008)], differentiation of ESCs into each of the three germ layers could be induced by 
the same factors known to induce them during gastrulation. For example,  Wnt, Nodal or 
BMP4 which have been shown to be important in the formation of epiblast cells in the PS of 
a developing embryo (Kispert & Herrmann, 1994) could similarly  induce the formation of 
PS-like cells from ESC (Kubo et al., 2004; Lindsley et al., 2006; Ng et al., 2005; Nostro et al., 
2008). As in gastrulation, exposure of the PS-like cells to high levels of Nodal further 
differentiate these cells to a Foxa2hi cells that are comparable to cells in the anterior PS that 
forms the definitive endoderm (D'Amour et al., 2005; Kubo et al., 2004). In contrast, 
exposure to Wnt, low level of activin (which activates Nodal) and BMP4 causes the PS-like 
cells to differentiate into a Flk-1+ posterior PS-equivalent population that forms the 
mesoderm (Nostro et al., 2008). Therefore, the three germ layers can be induced in ESCs by 
exposing the cells to factors known to be important in the formation of these three germ 
layers during embryogenesis. Further, by modulating these factors in a concentration and 
temporal manner that recapitulates early embryonic development, commitment of ESCs to 
one of the germ layers could be enhanced.  
2.3.2 Enhancing lineage commitment 
The intensive research efforts to induce a bias in differentiating pluripotent ESCs towards 
one of the germ layers would, in principle, enhance the subsequent production of specific 
tissue cell types of this germ layer e.g. muscles from mesoderm. However, enhancing 
commitment of differentiating ESC to one of the three germ layers may not be the limiting 
factor in generating clinically useful cell types in sufficient number and purity for 
therapeutic or screening applications. For example, the most efficient derivation of clinically 
useful cell types from ESC is neural cell types and not surprisingly, the first ESC-derived cell 
type to be clinically tested is oligodendrocytes. The relative efficiency of generating neurons, 
astrocytes and oligodendrocytes from ESC probably lies not in the ease of generating neural 
progenitor cells but in the relatively high expansion capacity of ESC-derived neural 
progenitor cells (Dottori & Pera, 2008; Studer, 2009). The high expansion capacity of neural 
progenitor cells would easily circumvent a limiting supply of rare neural progenitor cells 
formed during ESC differentiation and obviates the need to first bias differentiation of 
pluripotent ESCs towards an ectodermal germ lineage. Therefore, the rationale underlying 
the intensive research efforts to bias differentiating pluripotent ESCs towards one of the 
germ layers may be redundant at least for the derivation of neural cell types. Unlike 
ectodermal differentiation which is generally considered the default differentiation pathway 
for ESC, the derivation of mesodermal or endodermal cell types from ESC could still be 
enhanced by the recapitulation of early embryonic development processes to enhance 
mesodermal or endodermal commitment. 
2.3.3 Terminal differentiation of ESC 
In 2005, D'Amour et al reported the use of a multi-stage protocol that attempts to temporally 
recapitulate embryonic development for the differentiation of hESC into insulin-producing 
pancreatic cells for diabetes treatment. During this differentiation regime, they observed the 
formation of sequential transient cell populations with markers that mapped onto the 
developmental pathway of pancreatic endoderm. The final cell population representing 
pancreatic endoderm was transplanted in mice for further differentiation and maturation. 
When these transplanted animals were treated with streptozotocin, the induction of 
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hyperglycemia was attenuated. It was observed that some of the transplanted mice 
developed teratomas, suggesting the cell preparation was heterogenous and contaminated 
with ESCs that could differentiate into all cell types. In contrast, differentiation of mouse 
ESCs to insulin-producing cells is often a three-step protocol consisting of the formation of 
embryoid bodies, spontaneous differentiation into ecto-, endo- and mesoderm lineages and 
finally induction of pancreatic differentiation (Schroeder et al., 2006). However, the cell 
populations generated using this protocol have low insulin content. Using an approach that 
combines elements from this protocol and that used in neural differentiation, we first 
derived highly expansible E-RoSH cell lines with meso-endoderm potential  from 
spontaneously differentiating EBs (Lian et al., 2006; Yin et al., 2004). Like neural stem cells, 
these E-RoSH cell lines are highly proliferative and provide unlimited supply of cells for 
differentiation. Serum starvation and nicotinamide supplementation induce differentiation 
of E-RoSH cells to form a heterogenous, insulin-producing culture. Limiting dilution of such 
cultures yielded independently derived clonal insulin-producing ERoSHK cell lines. These 
cells contain equimolar of insulin and C-peptide that was stably maintained over 30 
passages at a high concentration of 300-500 pmol/106 cells. The insulin-producing ERoSHK 
cells resemble pancreatic cells and display the defining functional properties of bona fide 
pancreatic beta cells (G. Li et al., 2009a). They synthesize and store insulin in typical 
intracellular vesicles. Under stimulation by secretagogues such as glucose, tolbutamide and 
glibenclamide, these cells close their ATP-sensitive K+ channels, leading to membrane 
depolarization, opening of Ca2+ channels and the subsequent release of insulin and C-
peptide in equimolar ratio, a mechanism resembling that of primary beta cells. Most 
importantly, these cells can reverse hyperglycemia when grafted into streptozotocin-treated 
mice. Relative to their progenitor E-RoSH cells, ERoSHK cells also exhibit enhanced activity 
in biochemical pathways that are also highly characteristic of beta cells such as the pentose 
phosphate pathway, clathrin-mediated endocytosis and PPAR signaling (T. S. Chen et al., 
2010).  Importantly, transplantation of ERoSHK cells in hyperglycemic streptozotocin-
treated mice reverses the hyperglycemia and removal of the transplanted cells restores the 
hyperglycemia. The transplanted cells do not form teratomas. Together, these studies 
illustrated the diversity of approaches that have been taken to differentiate ESCs to insulin-
producing cells and the relative potential of each approach in generating the desired end 
product on a scale to support potential therapeutic application. They also prompted doubts 
on the need to recapitulate the precise developmental pathway when differentiating ESC. 
This question was previously raised by Burns et al (Burns et al., 2004). From their 
perspective, developmental events directing duodenal endoderm towards an insulin-
expressing β-cell phenotype are the result of millions of years of evolutionary selection, 
driven by environmental pressures rather than by conscious design. Therefore, instead of 
mapping experimental protocols on to the known developmental pathways of pancreatic 
endocrine cells, they proposed that conscious design may be a less circuitous route to arrive 
at the same end-point. However, in lieu of known developmental pathways, there is no 
obvious source to guide and rationalize such a design. In essence, a conscious design would 
inevitably have to be an empirical approach of careful observation, trial and error, and high 
throughput screens.  
2.3.4 Empirical differentiation of ESC 
Despite a pervasive belief that a high fidelity recapitulation of developmental process 
represents the best strategy for efficient differentiation of pluripotent stem cells to 
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therapeutically useful cell types , the two human ESC-derived cell types ready for testing in 
man were derived by empirically formulated protocols. Fortuitously, some elements in 
these protocols were subsequently found to map onto similar pathways in embryonic 
development. 
In the basic protocol for deriving Geron Corporation’s GRNOPC1 which is already in Phase 
I clinical trial, one of the key elements in inducing neural commitment in ESCs to form 
neurospheres is retinoic acid (RA) (Nistor et al., 2005). RA was first observed to be an   
inducer of neural differentiation in embryonal carcinoma cells (ECs) (Jones-Villeneuve et al., 
1982) before the first retinoic acid receptor (now known as RARa1) was cloned in 1987 
(Giguere et al., 1987; Petkovich et al., 1987). Based on the empirical observation that RA 
induced neural differentiation in P19 tetracarcinoma cells, RA was used to enhance neural 
lineage commitment in ESCs (Bain et al., 1995). Today, RA is often used to enhance neural 
lineage commitment in ESC to generate neurospheres containing neural stem cells and for 
the subsequent terminal differentiation of neurospheres to produce neurons, 
oligodendrocytes and astrocytes. Therefore, the use of RA to induce neural differentiation in 
ESCs was rationalized on empirical observation of their effects on EC cells and this preceded 
the cloning of RA receptors and our understanding of its role in embryonic development. 
To date, there is little evidence that RA plays a significant role in neural differentiation 
during gastrulation. The first RA signaling in the gastrulating vertebrate embryo occurs in 
the posterior mesodermal cells when RA is first synthesized by retinaldehyde 
dehydrogenase 2 (RALDH2) (Niederreither et al., 1997). There is however no RA signaling 
in the anterior regions of the embryo due to the presence of RA metabolizing enzymes such 
as CYP26A1 and CYP26C1 (Hernandez et al., 2007; Ribes et al., 2007; Uehara et al., 2007). In 
fact, RA receptors in the prospective head region of the Xenopus gastrula function as 
transcriptional repressors to prevent inappropriate activation of genes acting as posterior 
determinants. Also, the absence of endogenous RA synthesis in mice affect primarily 
forebrain development but did not compromise the early neural lineage commitment or 
differentiation (Natalia Molotkova et al., 2007; N. Molotkova et al., 2005; Niederreither et al., 
2000; Sirbu et al., 2005). In fact, the pathway for neural differentiation during embryonic 
development could not have informed on the usefulness of insulin, triiodothyroidin, EGF 
and FGF in enhancing the in vitro proliferation and differentiation of ESC-derived 
oligodendrocyte precursors and increase oligodendrocyte survival.  
The second ESC-derived cell type most likely to be tested in man is Advanced Cell 
Technology’s retinal pigment epithelial (RPE) cells which has been given FDA clearance to 
initiate a Phase I/II multicenter clinical trial to treat patients with Dry AMD. The derivation 
of these RPE cells relies primarily on spontaneous differentiation of hESCs (Klimanskaya et 
al., 2004). RPE cells are formed as colonies of pigmented cells when hESCs undergo 
spontaneous differentiation by FGF2 withdrawal or embryoid body formation. These 
colonies of pigmented cells were then picked and expanded using very unremarkable 
culture medium.  
2.3.5 Strategizing differentiation of ESC for therapeutic applications 
The progress of ESC-derived oligodendrocytes and RPE cells to clinical testing attests to the 
robustness and efficiency of the empirically-driven differentiation protocols. In contrast, 
differentiation of ESCs by meticulous mapping on embryonic development pathway has not 
yielded cells that are ready for clinical testing. Despite this dichotomy in outcomes, there is 
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still a prevalent belief that high fidelity recapitulation of embryonic development process is 
the route to generate the most physiologically relevant cells. Embryonic development is a 
time tested success with defined milestones. In contrast, an empirically driven 
differentiation strategy is an inherently inefficient chance event.  
The success of a differentiation strategy based on embryonic development is predicated not 
only on the elucidation but also the recapitulation of the highly dynamic temporal and 
spatial changes in the embryonic microenvironment that is influenced by both intra- and  
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strategies currently being used could be broadly classified into a developmental or an 
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physiologically functional cell type (e.g. pancreatic insulin-producing cells). The empirical 
approach involves the differentiation of ESCs either spontaneously, or using novel factors 
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extra-embryonic factors. Notwithstanding this, translating such a complex differentiation 
strategy to a scalable commercially viable manufacturing process will be an equally 
confounding unknown. On the other hand, developing a differentiation strategy using an 
empirical approach is a chance process of trial and error and fortuitous observation. This 
inherent inefficiency can be circumvented by high throughput screens to identify inducing 
molecules or combinations of molecules. There is also a likelihood that such a strategy 
would provide for a potentially scalable manufacturing process that will support clinical 
applications. 
3. ESC therapeutics: cell versus biologic   
A much overlooked form of ESC-derived therapeutics is biological products or biologics 
from ESC. To date, the predominant or only forms of ESC-derived therapeutics that are 
being evaluated are primarily cell-based. The capacity of ESC to undergo spontaneous 
differentiation in a minimal culture medium to form tissues from all three germ layers 
suggest that differentiating ESCs can produce an inductive and sustaining 
microenvironment for the various cell types that are being formed. It is conceivable that 
some of this microenvironment may also induce or sustain some tissue regeneration and 
repair in adult. However capturing this microenvironment and translating it to a scalable 
manufacturing process would be a challenge. 
Biologic-based therapeutics have several advantages over cell-based therapies. Biologics 
eliminates the need to preserve viability during manufacture, storage and transport, and 
administration to the patient. This substantially reduces the cost and complexity of 
production and delivery. Maintaining cell viability before and after transplantation has 
always been an important consideration in cell-based therapy. Although preserving the 
activity of biologics is not a minor consideration, it is, nevertheless more tractable than 
preserving cell viability. Cell therapy is generally a permanent or long term therapeutic 
sustained by the replicative capacity of the transplanted cells with little recourse for 
termination of therapy except when removal of the graft is possible. In contrast to biologics, 
cell therapy presents increased risks of tumor formation and acute immunological rejections. 
All things considered, ESC-based biologics is an attractive alternative to develop ESC-based 
therapeutics.  
As an illustration of a potential ESC-derived biologic, we have demonstrated that 
mesenchymal stem cells derived from hESCs (Lian et al., 2007) secrete factors (Sze et al., 
2007) that are cardioprotective in pig and mouse models of myocardial 
ischemia/reperfusion injury (Timmers et al., 2008). The active component in this secretion 
was small lipid vesicles of 50-100nm known as exosomes (Lai et al., 2010). Immortalization 
of these mesenchymal stem cells did not compromise the production or activity of the 
exosomes (T.S. Chen et al., 2011). These studies provided for the development of a 
sustainable scalable manufacturing process to produce potentially therapeutic exosomes for 
testing in the clinic.  
4. Conclusion 
ESC is a versatile cell that has exerted significant impact on our understanding and 
investigation of cell biology, differentiation and development. It has provided exciting 
possibilities for the treatment of highly intractable diseases. As the first ESC-derived cell 
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type makes its way into clinical testing, there is an apprehensive hope that ESC will justify 
its hype not only as a therapeutic agent but one that will treat a multitude of intractable 
diseases as wide ranging as its differentiation potential. The establishment of iPSC 
technology by Shinya Yamanaka (Takahashi & Yamanaka, 2006) represents a paradigm shift 
in not only our understanding of stem cell biology but also in overcoming the ethical and 
immune challenges that had stymied the translation of ESC into clinical applications. His 
approach of re-programming terminally differentiated cells into pluripotent stem cells 
contradicted fundamental principles in developmental biology. This approach of exploring 
beyond the obvious and logical using empirical and experimental strategies may be 
necessary to transcend this current bottleneck in generating the quantity and quality of ESC-
derived cells for therapy. 
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In this chapter, it was aimed to report the methods to derive 18 hESC lines which were 
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Turkey by Health Ministry in 2005. Additionally, it was discussed the current legal situation 
of hESC research and perspectives to that issue in Turkey. 
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2003 and September 2005. All donated supernumerary embryos were used after obtaining 
written informed consents from couples. All hESC lines were established only for research 
purpose rather than for any financial interest. This study was approved and controlled by  
the local ethic committee/Internal Review Board of Istanbul Memorial Hospital.  
 
Embryonic Stem Cells – Basic Biology to Bioengineering 
 
18
human embryonic stem cells with features of neoplastic progression. Nat Biotechnol, 
Vol. 27, No. 1, (Jan), pp. (91-97). 
Wilmut, I., Beaujean, N., de Sousa, P.A., Dinnyes, A., King, T.J., Paterson, L.A., Wells, D.N., 
& Young, L.E. (2002). Somatic cell nuclear transfer. Nature, Vol. 419, No. 6907, (Oct 
10), pp. (583-586). 
Woltjen, K., Michael, I.P., Mohseni, P., Desai, R., Mileikovsky, M., Hamalainen, R., Cowling, 
R., Wang, W., Liu, P., Gertsenstein, M., Kaji, K., Sung, H.K., & Nagy, A. (2009). 
piggyBac transposition reprograms fibroblasts to induced pluripotent stem cells. 
Nature, Vol. 458, No. 7239, (Apr 9), pp. (766-770). 
Yamaguchi, T.P. (2001). Heads or tails: Wnts and anterior-posterior patterning. Curr Biol, 
Vol. 11, No. 17, (Sep 4), pp. (R713-724). 
Yang, S., Lin, G., Tan, Y.Q., Zhou, D., Deng, L.Y., Cheng, D.H., Luo, S.W., Liu, T.C., Zhou, 
X.Y., Sun, Z., Xiang, Y., Chen, T.J., Wen, J.F., & Lu, G.X. (2008). Tumor progression 
of culture-adapted human embryonic stem cells during long-term culture. Genes 
Chromosomes Cancer, Vol. 47, No. 8, (Aug), pp. (665-679). 
Yin, Y., Que, J., Teh, M., Cao, W.P., El Oakley, R.M., & Lim, S.K. (2004). Embryonic cell lines 
with endothelial potential: an in vitro system for studying endothelial 
differentiation. Arterioscler Thromb Vasc Biol, Vol. 24, No. 4, (Apr), pp. (691-696). 
Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L., Tian, S., Nie, J., 
Jonsdottir, G.A., Ruotti, V., Stewart, R., Slukvin, II, & Thomson, J.A. (2007). Induced 
pluripotent stem cell lines derived from human somatic cells. Science, Vol. 318, No. 
5858, (Dec 21), pp. (1917-1920). 
Zhou, H., Wu, S., Joo, J.Y., Zhu, S., Han, D.W., Lin, T., Trauger, S., Bien, G., Yao, S., Zhu, Y., 
Siuzdak, G., Scholer, H.R., Duan, L., & Ding, S. (2009). Generation of induced 
pluripotent stem cells using recombinant proteins. Cell Stem Cell, Vol. 4, No. 5, 
(May 8), pp. (381-384). 
2 
 Derivation and Characterization of New 
hESC Lines from Supernumerary Embryos, 
Experience from Turkey 
Zafer Nihat Candan and Semra Kahraman 
Memorial Hospital ART & Reproductive Genetics Unit, Istanbul, 
Turkey 
1. Introduction  
Human embryonic stem cell (hESC) lines, which are derived from inner cell mass (ICM) of 
supernumerary blastocysts-stage embryos, have well known unique properties; long-term 
self-renewing ability with maintenance of an undifferentiated state and pluripotent capacity 
to differentiate into all derivatives of three embryonic germ layers (Hoffman & Carpenter, 
2005; Semb, 2005; Trounson, 2006). Since its first derivation and characterization by 
Thomson et al in 1998, these intrinsic properties have made hESC very popular worldwide 
and, thereby, many studies describing isolation and characterization of new hESC lines have 
been reported (Findikli et al., 2005; Simon et al., 2005; Thomson, 1998). HESCs have been 
considered very valuable and promising cell source for research involving mainly human 
embryogenesis, oncology, drug toxicology and developmental biology as well as for cell 
based regenerative therapies (Edwards, 2004).  
Obviously, studies on hESCs mostly focus on their potential use for treatment of 
degenerative human diseases. However, due to the largely unknown characteristics of 
established lines and the use of animal based material in their cultures, most of the lines 
could not be suitable for prospective transplantation studies (Findikli et al., 2006; Rodriguez 
et al., 2006). Therefore, registration of existing hESC lines with their characteristics in stem 
cell banks would provide database of cell lines, cooperation and co-regulation for 
researchers.  
In this chapter, it was aimed to report the methods to derive 18 hESC lines which were 
established and characterized until the declaration of prohibition on hESC research in 
Turkey by Health Ministry in 2005. Additionally, it was discussed the current legal situation 
of hESC research and perspectives to that issue in Turkey. 
2. Material and methods for derivation and characterization of hESC lines 
Derivation and characterization of all hESC lines were undertaken in Memorial Hospital 
ART &Reproductive Genetics Centre, R&D Laboratory, Istanbul, Turkey between January 
2003 and September 2005. All donated supernumerary embryos were used after obtaining 
written informed consents from couples. All hESC lines were established only for research 
purpose rather than for any financial interest. This study was approved and controlled by  
the local ethic committee/Internal Review Board of Istanbul Memorial Hospital.  
 
Embryonic Stem Cells – Basic Biology to Bioengineering  
 
20
2.1 Source of supernumerary human embryos 
Supernumerary human embryos used for derivation of hESC lines were obtained after in 
vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) and preimplantation 
genetic diagnosis (PGD) cycles. Most of these embryos had poor quality and thereby, were 
considered insufficient for replacement or cryopreservation. 
Preimplantation genetic diagnosis is applied to three groups of patients with variety of 
indications in our clinic. The first group of PGD includes patients who have a high risk of 
transmitting their single gene disorder to their offspring. After diagnosis, abnormal embryos 
were used to derive hESC lines with specific single gene mutation.  
In the second group of PGD cycles, embryos belonging to couples with advanced maternal 
age, a history of recurrent miscarriages and repeated implantation failures are destined to 
chromosomal screening (Kahraman et al., 2000, 2006; Lavon et al., 2008; Munne et al., 2005; 
Verlinsky et al., 2005). Following PGD, chromosomally abnormal embryos were subjected to 
derivation of hESC lines having chromosomal aneuploidies.  
In the third group, PGD is used for identification of embryos for human leukocyte antigen 
(HLA) matching to an affected older sibling who requires hematopoietic stem cell 
transplantation. Furthermore, the HLA matching can be combined with mutational analysis 
for genetic diseases in cases where the sibling is affected with this monogenic disorder and 
waiting for stem cell transplantation. Therefore, in those cases, embryos having mismatched 
HLA type or carrying genetic disorder were used for derivation of hESC lines. 
2.2 Isolation and preparation of feeder cells 
As feeder cells both mouse embryonic fibroblast (MEF) and human foreskin fibroblast (HFF) 
were used during isolation and long term culture of hESC lines. MEFs were isolated from 
embryos of the 12- to 14-day pregnant BALb/c mice (Conner, 2000). To isolate single cell 
suspension of MEF mouse embryos isolated from the sacrificed mice by cervical dislocation 
were dissociated into small pieces with scissor. Then dissociated tissues were trypsinized in 
0.25% trypsin-EDTA (Gibco BRL; Invitrogen, Gaithersburg, MD, USA) for 15min to produce 
single cell suspension.  
Human foreskin fibroblasts were isolated from circumcised tissues of 0-1 year old males. 
Cell isolation was performed as described previously (Hovatta et al., 2003; Richard et al., 
2002). In a brief, following the isolation of dermis from the epidermis by scissor or razor 
blade, tissue was dissected into small pieces and then trypsinized in 0.05% trypsin-EDTA 
(Gibco BRL) for approximately 1 h to dissociate into single cells.  
Both 25 cm2 and 75 cm2 culture flasks were used to culture HFF and MEF lines. These lines 
were grown in feeder cell culture medium, consisting of 85% high glucose DMEM (Gibco 
BRL), 10%FBS (Gibco BRL), 1% penicillin streptomycin-amphotericin (Biological Industries) 
and 2mM L-glutamine (Gibco BRL) at 37C with 5% CO2. Supportive medium was changed 
in every three days. MEF lines could be used in culture of hESC lines up to 6 passages, 
whereas HFFs had supportive potential up to 15 passages.  
Mitotic inactivation of feeder cells was performed after exposing feeder cells to culture 
medium containing 10µg/ml mitomycin C (Sigma-Aldrich, Poole, Dorset, UK) for 2.5-3h. 
Inactivated cells were seeded on a 0.1% gelatin-coated at a concentration of 1.5  105 cells / 
ml. After 2 days incubation organ culture dishes were ready to use as feeder plates. Feeder 
plates could be used for the following 7 d.  
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2.3 Isolation and long-term culture of hESC lines 
Blastocyst stage embryos, that were graded according to the Gardner’s scoring criteria, were 
processed for hESC isolation by either immunosurgery or direct culture (Gardner et al., 
2000; Findikli et al., 2005). Prior to the immunosurgery or direct culture, zona pellucida of 
embryo was removed by the short-term exposure to the 5IU/ml (final conc.) pronase 
(Sigma) containing embryo culture medium for up to 5 min. Immunosurgery was applied 
based on the previously published protocol (Solter and Knowles, 1975). After lysis of 
trophoblastic cells, the resulted intact inner cell mass clumps were placed on feeder cells and 
cultured until to observe the primary hESC colonies.  
In the direct culture method, zona free blastocysts were directly placed on feeder cells and 
cultured until the appearance of outgrowth, which lasted about 6 to 8 days. Then compacted 
outgrowths including cells of hESC-like morphology were mechanically split into small 
clumps. The cell clumps were transferred on new feeder plates. The primary colonies were 
generally observed after about 5 to 7 days (Figure 1A-B).  
HESC lines were cultured at 37 C  in 5% CO2  in the complete stem cell medium (CSCM) 
with the composition of  85% Ko-DMEM ( Gibco BRL), 15% FBS (Hyclone, South, Logan, 
UT, USA), 1 penicillin/streptomycin/amphotericin B (Biological Industries, Haemek, 




Fig. 1. Establishment of hESC line on HFF and MEF feeder cells. Phase contrast microscopy 
of NS-10 line at different stages of development. A) The formation of outgrowth from the 
inner cell mass of blastocyst after direct culture of zona-free blastocyst on HFF. B) Cell 
clump, which was formed after mechanically dissociation of outgrowth, included primary 
hESC like cells. C) Circular primary NS-10 colony on MEF. D) Polarized colony morphology 
of NS-10 on HFF. Original magnifications: (A-D) X 200 
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BRL), 4ng/ml basic fibroblast growth factor (bFGF) (Chemicon, Temecula, CA, USA), β-
mercaptoethanol (0.1 mmol/l; Sigma), and 0.1% insulin transferrin selenium complex (Gibco 
BRL). Culture media was changed daily.  
Undifferentiated hESC colonies were split into small colony pieces mechanically with the 
flame-drawn glass every after 7-8 days of culture. Enzymatic dissociation of hESC was not 
preferred in this study. Each hESC line was cultured at least up to fifteen passages and was 
cryopreserved by vitrification technique according to the previously reported protocols 
(Reubinof et al., 2001; Vanderzwalmen et al., 2003). Briefly, colonies were first mechanically 
split into small pieces and were sequentially vitrified in two solutions including different 
concentration of DMSO and ethylene glycol.  
Cryopreserved hESC lines were warmed sequentially in solutions including 0.5M and 0.25M 
sucrose to control efficiency of vitrification and following warming techniques (Reubinoff et 
al., 2001).  
2.4 Karyotyping and immunocytochemistry of hESC lines 
G-banding technique was used to karyotype hESC lines. HESC colonies were first incubated 
with culture medium including 0.1 µg / ml Colcemid (Biological Industries) for 2 h at 37 °C 
in a %5 CO2. Then colonies were split into small pieces mechanically and incubated in 
0.075M KCI hypotonic solution for 17 minutes at 37°C. Colonies were fixed with methanol-
acetic acid solution (3:1) and processed for G-banding analysis. For each line at least 20 
metaphases were analyzed for confirmation.  
Karyotyping of each line was performed several times to assess whether karyotypes were 
stable during their long term culture. Confirmation of genetic mutation in hESC line derived 
from affected embryo was performed by the same procedures applied for single blastomere 
mutational analysis.  
Surface expression markers (SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81), which are unique 
for undifferentiated hESC lines, were immunochytoemically analyzed according to the 
manufacturer’s instructions (Chemicon) by using flourescein isothiocyanate (FITC)-
conjugated goat anti-mouse secondary antibody (anti-IgG) (Santa Cruz Biotechnology, 
California, USA). Negative controls were performed by addition of phosphate buffer saline 
instead of the primary antibody. All the other reagents were the same as in the slides run for 
specific antibodies, except nucleus of cells were stained by 4',6-diamidino-2-phenylindole 
(DAPI) for visualization.  
Alkaline phosphatase activity (Chemicon) of hESC lines was detected by using the 
Chemicon Alkaline Phophatase Detection kit (Chemicon). Expressions of OCT-4 and 
housekeeping gene, glyceraldehyde-3 phosphate dehydrogenase (GADPH), genes were 
detected by reverse transcriptase PCR (RT-PCR). Briefly, extraction of RNA from 
undifferentiated hESCs and synthesis of cDNA were carried out by using Rneasy Mini Kit 
(Qiagen Gmbh, Strasse, Germany) and Sensiscript RT Kit (Qiagen), respectively. Then, PCR 
and following analysis were performed according to the protocol of Amit et al (Amit et al., 
2002). 
2.5 Differentiation potential of hESC lines 
The differentiation ability of hESC lines were analyzed only by in vitro. For in vitro 
differentiation, embryoid bodies (EBs) were first generated according to previously 
published protocol (Itskovits-Eldor et al., 2000; Carpenter et al., 2003). In a brief, small pieces 
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of undifferentiated hESC colonies were transferred into the non adherent bacterial petri 
dishes and were cultured in CSCM without bFGF for 8-10 days. The resulting EB, which 
theoretically comprise three embryonic germ layers, were then plated on to 0.1% gelatin 
coated plastic petri dishes and cultured for long-term for spontaneous differentiation.  
Differentiation features of hESC lines was examined under phase contrast microscope and 
differentiated cells were analyzed by immunocytochemical staining with markers for 
endoderm (cytokeratin 18, specific marker for epithelial cells, Chemicon), mesoderm 
(troponin I, specific for cardiac muscle; Chemicon) and ectoderm (Nestin, specific marker for 
progenitor of neuron, and MAP2AB, specific marker for mature neuron; Chemicon) 
according to manufacturer’s instruction.  
Additionally, in these lines (OZ, OZ-1 and OZ-2), rhythmically beating of cardiomyocytes 
within spontaneously differentiating embryonic stem cells were further analyzed by 
transmission electron microscopy (TEM). Briefly, cell clumps with spontaneous contractions 
were gently removed from the culture plate and fixed in 2% glutaraldehyde in 0.1 
mol/sodium cacodylate buffer (pH 7.4) for 2 hours. Secondary fixation was performed in 
1% OsO4 in the same buffer for 1.5h. The grids were dehydrated in graded ethanol and 
embedded in Epon 812. The very thin sections about 80 nm were cut and stained with lead 
citrate for 8 min in order to identify the cellular structures of cardiac muscle cells. 
3. Results of hESC study 
Experience of hESC from Memorial Hospital comprise three phrases; derivation of first 
hESC lines in Turkey, which was reported previously (Findikli et al., 2005), using HFF as a 
feeder cell instead of MEF to derive new hESC lines and derivation of hESC lines from 
donated embryos from PGD cycles (Candan & Kahraman, 2010).  
In the first phase, nine hESC lines, which were named NS-1, NS-2, NS-3, NS-4, NS-5, NS-6, 
NS-7, NS-8 and MINE, were derived from 26 donated blastocysts stage human embryos 
with a 34.6% success rate (Table 1). Twenty blastocysts were spare IVF/ICSI embryos and 5 
hESC lines (NS-1, NS-2, NS-3, NS-4 and MINE) were derived from these embryos. The 
remaining 6 embryos had mismatched HLA type and, therefore were not eligible for 
transferring in PGD cycle. From these embryos, 4 hESC lines (NS-5, NS-6, NS-7 and NS-8)   
 
 No.of blastocysts 
No. of stem 
cell line, n, 
(%) 
Names of derived hESC lines 
IVF/ICSI embryos  30 8, (27) NS-1,2,3,8, MINE, and OZ, OZ-1, OZ-2 
PGD  for single gene disorder 8 1, (13) OZ-8 
PGD  for single gene disorder & 
HLA typing 6 4, (67) *NS-4, 5, 6, and 7 
PGD for chromosomal screening 42 7, (17) OZ-3, OZ-4, OZ-5, OZ-6,  OZ-7, NS-9, NS-10 
Immunosurgery method 15 4, (27) NS-1,2,3,4 
Direct culture method 76 16, (21)  
Table 1. A total number of embryos used for hESC lines and overall outcomes   
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2.5 Differentiation potential of hESC lines 
The differentiation ability of hESC lines were analyzed only by in vitro. For in vitro 
differentiation, embryoid bodies (EBs) were first generated according to previously 
published protocol (Itskovits-Eldor et al., 2000; Carpenter et al., 2003). In a brief, small pieces 
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of undifferentiated hESC colonies were transferred into the non adherent bacterial petri 
dishes and were cultured in CSCM without bFGF for 8-10 days. The resulting EB, which 
theoretically comprise three embryonic germ layers, were then plated on to 0.1% gelatin 
coated plastic petri dishes and cultured for long-term for spontaneous differentiation.  
Differentiation features of hESC lines was examined under phase contrast microscope and 
differentiated cells were analyzed by immunocytochemical staining with markers for 
endoderm (cytokeratin 18, specific marker for epithelial cells, Chemicon), mesoderm 
(troponin I, specific for cardiac muscle; Chemicon) and ectoderm (Nestin, specific marker for 
progenitor of neuron, and MAP2AB, specific marker for mature neuron; Chemicon) 
according to manufacturer’s instruction.  
Additionally, in these lines (OZ, OZ-1 and OZ-2), rhythmically beating of cardiomyocytes 
within spontaneously differentiating embryonic stem cells were further analyzed by 
transmission electron microscopy (TEM). Briefly, cell clumps with spontaneous contractions 
were gently removed from the culture plate and fixed in 2% glutaraldehyde in 0.1 
mol/sodium cacodylate buffer (pH 7.4) for 2 hours. Secondary fixation was performed in 
1% OsO4 in the same buffer for 1.5h. The grids were dehydrated in graded ethanol and 
embedded in Epon 812. The very thin sections about 80 nm were cut and stained with lead 
citrate for 8 min in order to identify the cellular structures of cardiac muscle cells. 
3. Results of hESC study 
Experience of hESC from Memorial Hospital comprise three phrases; derivation of first 
hESC lines in Turkey, which was reported previously (Findikli et al., 2005), using HFF as a 
feeder cell instead of MEF to derive new hESC lines and derivation of hESC lines from 
donated embryos from PGD cycles (Candan & Kahraman, 2010).  
In the first phase, nine hESC lines, which were named NS-1, NS-2, NS-3, NS-4, NS-5, NS-6, 
NS-7, NS-8 and MINE, were derived from 26 donated blastocysts stage human embryos 
with a 34.6% success rate (Table 1). Twenty blastocysts were spare IVF/ICSI embryos and 5 
hESC lines (NS-1, NS-2, NS-3, NS-4 and MINE) were derived from these embryos. The 
remaining 6 embryos had mismatched HLA type and, therefore were not eligible for 
transferring in PGD cycle. From these embryos, 4 hESC lines (NS-5, NS-6, NS-7 and NS-8)   
 
 No.of blastocysts 
No. of stem 
cell line, n, 
(%) 
Names of derived hESC lines 
IVF/ICSI embryos  30 8, (27) NS-1,2,3,8, MINE, and OZ, OZ-1, OZ-2 
PGD  for single gene disorder 8 1, (13) OZ-8 
PGD  for single gene disorder & 
HLA typing 6 4, (67) *NS-4, 5, 6, and 7 
PGD for chromosomal screening 42 7, (17) OZ-3, OZ-4, OZ-5, OZ-6,  OZ-7, NS-9, NS-10 
Immunosurgery method 15 4, (27) NS-1,2,3,4 
Direct culture method 76 16, (21)  
Table 1. A total number of embryos used for hESC lines and overall outcomes   
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were derived. Four lines (NS-1, NS-2, NS-3, NS-4) out of 9 hESC lines were obtained by 
immunosurgey and remaining 5 lines were derived by direct culture (Table 1). Two cell 
lines (NS-1 and NS-2) were spontaneous differentiated during their first days of in vitro 
culture. 
In the second phase of hESC research in Istanbul Memorial Hospital, as an alternative to 
MEF, HFF was used as a feeder cell for establishment and long-term culture of new hESC 
lines. Three hESC lines (OZ, OZ-1 and OZ-2) were derived from 10 blastocyst stage spare 
IVF/ICSI embryos by the direct culture technique with a 30% success rate (Table 1). Unlike 
to circular colony morphology of hESC colonies on MEF, hESC colonies on HFF had angular 
shaped morphology, due to the polarity of HFF cells (Figure 1 C-D).  
In the final phase, following PGD, embryos diagnosed as having chromosomal 
abnormalities and single gene mutations were used to establish hESC lines (Table 1). Forty 
two blastocysts with different chromosomal aneuploidies were directly placed either on 
MEF or on HFF. From those embryos 7 hESC lines (OZ-3, OZ-4, OZ-5, OZ-6, OZ-7, NS-9 and 
NS-10) were derived (Table 1 and 2). Of these 7 hESC lines, one line (OZ-3) was derived 
from biopsied embryo whose diagnosis was suspicious. Although chromosomal content of 
biopsied blastomere from this embryo was identified as abnormal (trisomy 15) by FISH, 
because of the fragmentations in nuclear structure of blastomere, we could not interpret the 
result exactly and thereby assumed it as an abnormal (Candan & Kahraman, 2010). 
Three embryos diagnosed as carrying cystic fibrosis and 5 embryos with beta-thalassemia 
were used to isolate hESC lines with genetic disorder. However, only one hESC (OZ-8), 
which had a single gene mutation causing beta-thalassemia, was isolated successfully. Only 
4 hESC lines were isolated by immunosurgery and the remaining hESC lines were derived 
after direct culture of blastocysts on feeder cells (Table 2). Following to either direct culture 
or immunosurgery, the developing three dimensional outgrowths from ICM were split 
mechanically into small clumps and transferred onto new feeder plate. Duration for 
successful derivation of first primary hESC colonies was ranged 15 to 20 days, based on the 
quality of inner cell mass of blastocysts, and application of isolation techniques properly. 
Following the first several passages of primary hESC colonies, flat colonies of cells with a 
distinguishable compacted colony structure, well defined colony border and cellular 
morphology with higher nucleus to cytoplasm ratio and prominent nucleoli were obtained 
(Figure 1C-D). Regardless of type of feeder cells, these unique colony features were similar 
in all hESC. Each of hESC lines were passaged mechanically every after about 7-8d for more 
than 15 passages (Table 2). While passaging hESC colonies, spontaneously differentiated 
cells, which were observed frequently in the central or in the periphery part of colonies, 
were always removed mechanically to maintain undifferentiation state of colonies.  
3.1 Unique features of hESC lines 
All hESC lines were characterized for cell surface expression markers, which are unique to 
undifferentiated human embryonic stem cells. As shown in Figure 2A, established hESC 
lines represented a high level of alkaline phosphates activity. Furthermore, 
immunocytochemical staining revealed that derived 18 hESC lines were positive for SSEA-3, 
SSEA-4, TRA-1-60 and TRA-1-81 (Figure 2B). Negative control slides of 
immunocytochemical staining showed that primary antibodies specifically bound to the 
certain surface antigens (Figure 2C).  
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 NS-3 NS-4 NS-5 NS-6 NS-7 NS-8 NS-9 NS-10 MINE 
Embryo 
source IVF/ICSI IVF/ICSI PGD PGD PGD PGD PGS PGS IVF/ICSI 
Embryo 
grades 4BB 3BA 4AA 4AA 4AB 3AB 4BB 4BA 4BB 
PGD/PGS 











Feeder cell MEF MEF MEF MEF MEF MEF MEF MEF MEF 
Alkaline 
phosphatase + + + + + + + + + 
Immuno-
staining + + + + + + + + + 
SSEA-3 + + + + + + + + + 
SSEA-4 + + + + + + + + + 
TRA-1-60 + + + + + + + + + 
TRA-1-81 + + + + + + + + + 
OCT-4 + + + + + + + + + 
In vitro 
differentiation + + + + + + + + + 
Max. passage 
no. of lines 35 60 39 20 22 22 21 28 49 
Karyotype 46 XY 46 XX 46 XX 46 XY 46 XX 46 XX 46 XY 46 XX 46XX 
          
 OZ OZ-1 OZ-2 OZ-3 OZ-4 OZ-5 OZ-6 OZ-7 OZ-8 
Embryo 
source IVF/ICSI IVF/ICSI IVF/ICSI PGS PGS PGS PGS PGS PGD 
Embryo 
grades 4AA 3AA 4BB 4BB 4AB 3BB 4AC 4BB 4AB 
PGD/PGS 
results - - - 
Undiagnosed 












Type of feeder 
cell HFF HFF HFF HFF HFF HFF MEF MEF MEF 
Alkaline 
phosphatase + + + + + + + + + 
Immuno-
staining + + + + + + + + + 
SSEA-3 + + + + + + + + + 
SSEA-4 + + + + + + + + + 
TRA-1-60 + + + + + + + + + 
TRA-1-81 + + + + + + + + + 
OCT-4 + + + + + + + + + 
In vitro 
differentiation + + + + + + + + + 
Max. passage 
no. of lines 19 15 15 22 17 20 22 18 18 
Karyotype 46 XY 46 XX 46 XX 46 XX 46 XX 46 XY 46 XX 46 XY 46 XX 
Table 2. Unique features of 18 hESC lines. (+) represents that HESC line is shown to be 
positive for those expression markers.  
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from biopsied embryo whose diagnosis was suspicious. Although chromosomal content of 
biopsied blastomere from this embryo was identified as abnormal (trisomy 15) by FISH, 
because of the fragmentations in nuclear structure of blastomere, we could not interpret the 
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Three embryos diagnosed as carrying cystic fibrosis and 5 embryos with beta-thalassemia 
were used to isolate hESC lines with genetic disorder. However, only one hESC (OZ-8), 
which had a single gene mutation causing beta-thalassemia, was isolated successfully. Only 
4 hESC lines were isolated by immunosurgery and the remaining hESC lines were derived 
after direct culture of blastocysts on feeder cells (Table 2). Following to either direct culture 
or immunosurgery, the developing three dimensional outgrowths from ICM were split 
mechanically into small clumps and transferred onto new feeder plate. Duration for 
successful derivation of first primary hESC colonies was ranged 15 to 20 days, based on the 
quality of inner cell mass of blastocysts, and application of isolation techniques properly. 
Following the first several passages of primary hESC colonies, flat colonies of cells with a 
distinguishable compacted colony structure, well defined colony border and cellular 
morphology with higher nucleus to cytoplasm ratio and prominent nucleoli were obtained 
(Figure 1C-D). Regardless of type of feeder cells, these unique colony features were similar 
in all hESC. Each of hESC lines were passaged mechanically every after about 7-8d for more 
than 15 passages (Table 2). While passaging hESC colonies, spontaneously differentiated 
cells, which were observed frequently in the central or in the periphery part of colonies, 
were always removed mechanically to maintain undifferentiation state of colonies.  
3.1 Unique features of hESC lines 
All hESC lines were characterized for cell surface expression markers, which are unique to 
undifferentiated human embryonic stem cells. As shown in Figure 2A, established hESC 
lines represented a high level of alkaline phosphates activity. Furthermore, 
immunocytochemical staining revealed that derived 18 hESC lines were positive for SSEA-3, 
SSEA-4, TRA-1-60 and TRA-1-81 (Figure 2B). Negative control slides of 
immunocytochemical staining showed that primary antibodies specifically bound to the 
certain surface antigens (Figure 2C).  
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D) E)  
Fig. 2. Unique features and karyotyping of OZ-6 hESC line. A) alkaline phosphatase 
staining, B) SSEA-3, SSEA-4, TRA-1-60, TRA-1-81and C) negative control for 
immunostaining of  hESC lines (cells were stained by DAPI for visualization). Expression of 
OCT-4 and housekeeping gene GADPH in hESC lines (OZ, OZ-1-7). E) Karyotype analyze of 
OZ-6 line in passage 5, 46XX. Original magnifications: (A-C) X 200. Abbreviations: OCT-4, 
octamer-4 and GADPH, glyceraldehyde-3 phosphate dehydrogenase. 
Our hESC lines were not analyzed for SSEA-1 expression, a specific marker for mouse 
embryonic stem cells. In consistent with the previous reports, expression intensity of SSEA-3 
among hESC lines was variable and comparably weaker than SSEA-4 which was consistent 
and expressed higher in all hESC lines (Oh et al., 2005). Additionally, OCT-4 expressions 
were higher in all undifferentiated hESC lines when compared to expression level of 
housekeeping gene GADPH (Figure 2D).  
Testing differentiation capacity of each hESC line by embryoid body formation in vitro 
revealed that these lines were capable of differentiating into various cell types derived from 
the three embryonic germ layers (Figure 3). Spontaneous contracting cell clumps, neural 
rosette structures, neural-like cells, epithelial like cells were observed under phase 
microscope and these differentiating cells were discriminated by immunocytochemically 
(Figure 3B). However, cell lines showed a relatively different capacity or tendency to 
differentiate into certain type of cell lineage. 
Rhythmically contractions in cell clusters were started approximately after ten days from 
plating EBs on bacterial culture plates and kept continuing up to six weeks. During this 
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period, beating cell clusters, belonging to OZ, OZ-1 and OZ-2 hESC lines, were further 
analyzed by transmission electron microscopy. Thereby, sarcomere, intercalated disc and 
myofibril structures were well defined in cardiac muscle cells by TEM analysis (Figure 3E).  
Following vitrification and thawing procedures, all cell lines could retain their unique 
properties; long-term extension and pluripotency capacity in vitro.  
 
  




D) E)  
Fig. 3. In vitro differentiation of NS-10 hESC line by embryoid body formation A) Phase 
contrast microscopy of 10-day EBs. Spontaneously differentiating cells B) neuron-like cells, 
positive for neuron specific nestin, C) epithelial-like cells, positive for cytokeratin 18 (green) 
and D) cardiac muscle cells, positive for troponin I. E) TEM photographs of beating 
cardiomyocytes. (A) X 100, (B-D) X200, (E) X12000. 
3.2 Karyotyping and genetic analysis of hESC lines 
Karyotyping analysis of all hESC lines were performed at the 5th passages. HESC lines, 
which were derived from supernumerary embryos after IVF/ICSI cycles and from PGD 
embryos, having genetic disorder and/or having mismatched HLA, had normal karyotypes 
(Figure 2E and Table 2).  
HESC lines derived from chromosomally abnormal embryos were first analyzed by FISH at 
1st passage whether they had detected chromosomal abnormality. Surprisingly, 
chromosomal abnormalities were not confirmed in these lines. Contrarily, analyzed 
chromosomes were euploid in number. Further confirmation was performed by 
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period, beating cell clusters, belonging to OZ, OZ-1 and OZ-2 hESC lines, were further 
analyzed by transmission electron microscopy. Thereby, sarcomere, intercalated disc and 
myofibril structures were well defined in cardiac muscle cells by TEM analysis (Figure 3E).  
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karyotyping at 5th passages of these lines. In consistent with results after FISH at 1st passage, 
karyotyping analysis revealed that in contrast to the diagnosis after PGD their karyotypes 
were normal (Table 2).  
Karyotyping of all hESC lines were performed further passages whether cell lines retained 
normal karyotypes. All hESC lines had stable karyotypes.  
Mutation in OZ-8 hESC cell line with beta thalassemia disorder was confirmed by PCR and 
subsequent sequencing procedures at passage 6. The homozygote single nucleotide transition 
(guanine to adenine nucleotide transition) in second exon of beta-globin gene was detected.   
4. Discussion 
Human embryonic stem cell is one of the most contradictory scientific issues since it was 
first reported by Thomson in 1998. Obviously, this ongoing dispute has been arisen from the 
use of human embryo for derivation of hESC. In regard to that concern, alternative methods 
have been proposed by several researches. However, spare embryos generated for 
reproductive and therapeutic treatments still remain as a main source for hESC derivation. 
Therefore, registering all existing lines in a database, like stem cell bank, may decrease the 
necessities to derive new hESC lines worldwide and eventually ethical concern may be 
alleviated among the public. In that regard, all these hESC lines, which had been established 
and characterized in Istanbul Memorial Hospital until ruling on ban on hESC research by 
Turkish Health Ministry, were registered to European hESCreg in 2008.  
During the hESC derivation study, 86 donated embryos, which were considered insufficient 
for transfer and cryopreservation after IVF/ICSI cycles and were diagnosed as having 
genetic disorder or chromosomal aneuploidies and having mismatched HLA type after PGD 
cycles, were used. 
The derivation efficiency of hESC lines was 20% and success rate was directly related with 
the quality of blastocysts. Four (NS-1, NS-2, NS-3 and NS-4) out of 20 hESC lines were 
successfully derived from 15 blastocysts after immunosurgery. However, two of these lines 
were spontaneously differentiated at the early number of passages. Remaining 16 hESC 
lines were isolated through direct culture of whole blastocysts on feeder cells. These two 
methods had comparable success rates (27% vs 21%, p>0.05).  
All lines described in this chapter had similar colony and cellular morphology. These lines 
expressed unique cell surface expression markers, including SSEA-3, SSEA-4, TRA-1-60 and 
TRA-1-81. They also had high level of alkaline phosphatase activity and expressed OCT-4 
gene, which keeps pluripotency of hESC lines during long-term culture (Figure 2). 
Moreover, these 18 hESC lines were proven to have pluripotent capacity in vitro by EBs 
formation (Figure 3). Therefore, these lines have similar unique properties as previously 
reported existing hESC lines.  
Although all lines were capable of differentiating into derivatives of three embryonic germ 
layers, differentiating characteristic was varied among lines. The prevalence of 
differentiating cardiomyocytes was higher in EBs generated from OZ-3 line, whereas higher 
percentage of neuron-like cells were observed in EBs generated from OZ line. The presence 
of specific cell lines at a various degree in differentiating cell cultures of hESC lines may be 
attributed to the developmental stage of embryo used for derivation, genomic and 
epigenetic differences. 
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In PGD for chromosomal screening cycles, embryos diagnosed as having chromosomal 
abnormalities were likely to be discarded and not to be considered eligible for transfer. In 
consistent with the previous results, in which it was aimed to derive chromosomally 
abnormal hESC lines for investigation of various aspects of early embryonic development, 
all our hESC lines derived from those embryos had normal karyotypes (Munne et al., 2005; 
Lavon et al., 2008). As stated in these studies, this unexpected result has been suggested to 
self correction of embryos during long-term in vitro culture (Hazan et al., 2008; Lavon et al., 
2008).  
As a result of proposed mosaicism and trisomy rescue mechanisms in developing embryos, 
chromosomal self correction may be occurred. In the mosaic embryos, it was suggested that 
euploid blastomeres can grow preferentially to abnormal cells during early embryogenesis 
or alternatively, these normal cells were preferentially allocated to the inner cell mass. 
Therefore, embryo may be subject to self correction mechanism and may evolve to a fetus 
with euploid chromosomal number. In trisomic rescue mechanism, it has been speculated 
that embryos can be corrected in terms of chromosomal number through anaphase-lag, 
nondisjunction, or chromosomal demolition. However, these mechanisms are still 
assumptions and exacts mechanisms should be proven by further studies (Hazan et al., 
2008).  
Furthermore, we speculated that the long-term culture may not only induce the change in 
chromosomal content but also may result in various genetic or epigenetic modifications in 
hESC lines which could eventually impair their pluripotent and self renewal capacity. 
However, due to inured restriction on hESC research, these derived lines could not be 
analyzed regarding to these aspects (Candan et al 2010).  
Embryos, having single gene mutations, are of great importance, while considering as a 
potential source in genetic based researches on understanding the mechanisms of disease 
and developing new drugs (Pickering et al., 2003; Verlinsky et al., 2005). We derived one 
hESC line having mutation, that cause beta thalassemia disorder, from 5 donated embryos 
after PGD. This cell line can provide as a cell source to study the pathology of beta 
thalassemia and its effects on different cell types.  
5. Conclusions 
HESC researches have been increasing continuously since it was first isolated and 
characterized. Although several problems including derivation clinical grade hESC lines, 
risk for teratoma formation, HLA incompatibility of cells and establishment of well defined 
differentiation protocols of hESC lines to certain cell types have been not been solved 
efficiently, there is still hope for coming day in which hESC lines will be used effectively in 
cell replacement therapies to treat such devastating human diseases; myocardial infarcts, 
spinal cord injuries and diabetes. Therefore, hESC lines reported in this chapter could be 
potential cell source for in-vitro studies involving basic molecular and stem cell biology. . 
Moreover, as in our study, derivation of hESC from PGD embryos with intrinsic genetic 
content and the disease profile could be an extremely valuable source for research on 
genetic diseases. 
In this chapter, it is aimed to summarized establishment protocols and features of first 
reported hESC lines in Turkey. Turkey is among the countries in which earlier hESC studies 
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karyotyping at 5th passages of these lines. In consistent with results after FISH at 1st passage, 
karyotyping analysis revealed that in contrast to the diagnosis after PGD their karyotypes 
were normal (Table 2).  
Karyotyping of all hESC lines were performed further passages whether cell lines retained 
normal karyotypes. All hESC lines had stable karyotypes.  
Mutation in OZ-8 hESC cell line with beta thalassemia disorder was confirmed by PCR and 
subsequent sequencing procedures at passage 6. The homozygote single nucleotide transition 
(guanine to adenine nucleotide transition) in second exon of beta-globin gene was detected.   
4. Discussion 
Human embryonic stem cell is one of the most contradictory scientific issues since it was 
first reported by Thomson in 1998. Obviously, this ongoing dispute has been arisen from the 
use of human embryo for derivation of hESC. In regard to that concern, alternative methods 
have been proposed by several researches. However, spare embryos generated for 
reproductive and therapeutic treatments still remain as a main source for hESC derivation. 
Therefore, registering all existing lines in a database, like stem cell bank, may decrease the 
necessities to derive new hESC lines worldwide and eventually ethical concern may be 
alleviated among the public. In that regard, all these hESC lines, which had been established 
and characterized in Istanbul Memorial Hospital until ruling on ban on hESC research by 
Turkish Health Ministry, were registered to European hESCreg in 2008.  
During the hESC derivation study, 86 donated embryos, which were considered insufficient 
for transfer and cryopreservation after IVF/ICSI cycles and were diagnosed as having 
genetic disorder or chromosomal aneuploidies and having mismatched HLA type after PGD 
cycles, were used. 
The derivation efficiency of hESC lines was 20% and success rate was directly related with 
the quality of blastocysts. Four (NS-1, NS-2, NS-3 and NS-4) out of 20 hESC lines were 
successfully derived from 15 blastocysts after immunosurgery. However, two of these lines 
were spontaneously differentiated at the early number of passages. Remaining 16 hESC 
lines were isolated through direct culture of whole blastocysts on feeder cells. These two 
methods had comparable success rates (27% vs 21%, p>0.05).  
All lines described in this chapter had similar colony and cellular morphology. These lines 
expressed unique cell surface expression markers, including SSEA-3, SSEA-4, TRA-1-60 and 
TRA-1-81. They also had high level of alkaline phosphatase activity and expressed OCT-4 
gene, which keeps pluripotency of hESC lines during long-term culture (Figure 2). 
Moreover, these 18 hESC lines were proven to have pluripotent capacity in vitro by EBs 
formation (Figure 3). Therefore, these lines have similar unique properties as previously 
reported existing hESC lines.  
Although all lines were capable of differentiating into derivatives of three embryonic germ 
layers, differentiating characteristic was varied among lines. The prevalence of 
differentiating cardiomyocytes was higher in EBs generated from OZ-3 line, whereas higher 
percentage of neuron-like cells were observed in EBs generated from OZ line. The presence 
of specific cell lines at a various degree in differentiating cell cultures of hESC lines may be 
attributed to the developmental stage of embryo used for derivation, genomic and 
epigenetic differences. 
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In PGD for chromosomal screening cycles, embryos diagnosed as having chromosomal 
abnormalities were likely to be discarded and not to be considered eligible for transfer. In 
consistent with the previous results, in which it was aimed to derive chromosomally 
abnormal hESC lines for investigation of various aspects of early embryonic development, 
all our hESC lines derived from those embryos had normal karyotypes (Munne et al., 2005; 
Lavon et al., 2008). As stated in these studies, this unexpected result has been suggested to 
self correction of embryos during long-term in vitro culture (Hazan et al., 2008; Lavon et al., 
2008).  
As a result of proposed mosaicism and trisomy rescue mechanisms in developing embryos, 
chromosomal self correction may be occurred. In the mosaic embryos, it was suggested that 
euploid blastomeres can grow preferentially to abnormal cells during early embryogenesis 
or alternatively, these normal cells were preferentially allocated to the inner cell mass. 
Therefore, embryo may be subject to self correction mechanism and may evolve to a fetus 
with euploid chromosomal number. In trisomic rescue mechanism, it has been speculated 
that embryos can be corrected in terms of chromosomal number through anaphase-lag, 
nondisjunction, or chromosomal demolition. However, these mechanisms are still 
assumptions and exacts mechanisms should be proven by further studies (Hazan et al., 
2008).  
Furthermore, we speculated that the long-term culture may not only induce the change in 
chromosomal content but also may result in various genetic or epigenetic modifications in 
hESC lines which could eventually impair their pluripotent and self renewal capacity. 
However, due to inured restriction on hESC research, these derived lines could not be 
analyzed regarding to these aspects (Candan et al 2010).  
Embryos, having single gene mutations, are of great importance, while considering as a 
potential source in genetic based researches on understanding the mechanisms of disease 
and developing new drugs (Pickering et al., 2003; Verlinsky et al., 2005). We derived one 
hESC line having mutation, that cause beta thalassemia disorder, from 5 donated embryos 
after PGD. This cell line can provide as a cell source to study the pathology of beta 
thalassemia and its effects on different cell types.  
5. Conclusions 
HESC researches have been increasing continuously since it was first isolated and 
characterized. Although several problems including derivation clinical grade hESC lines, 
risk for teratoma formation, HLA incompatibility of cells and establishment of well defined 
differentiation protocols of hESC lines to certain cell types have been not been solved 
efficiently, there is still hope for coming day in which hESC lines will be used effectively in 
cell replacement therapies to treat such devastating human diseases; myocardial infarcts, 
spinal cord injuries and diabetes. Therefore, hESC lines reported in this chapter could be 
potential cell source for in-vitro studies involving basic molecular and stem cell biology. . 
Moreover, as in our study, derivation of hESC from PGD embryos with intrinsic genetic 
content and the disease profile could be an extremely valuable source for research on 
genetic diseases. 
In this chapter, it is aimed to summarized establishment protocols and features of first 
reported hESC lines in Turkey. Turkey is among the countries in which earlier hESC studies 
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were established first. Today, however, Turkey is one of the countries in which hESC 
researches were prohibited by Government. Unfortunately, so far new legislation or 
regulation has not been declared. However, establishment of new guideline is on the agenda 
of governmental institutions nowadays. Recent lifting of ban on the federal funding for 
hESC research in US and given permission on first clinical trial of hESC may, in fact, affect 
the political opinion and hopefully may inure regulations, which resume hESC researches 
under the control of authority and new guidelines in Turkey.  
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1. Introduction 
It is estimated that 2.1 million married couples or 5 million people in the United States are 
affected by infertility.1 Infertility is defined as failure to get pregnant after one year of 
unprotected intercourse. About 40% of infertility cases are due to a female factor and 40% 
due to a male factor. The remaining 20% are the result of a combination of male and female 
factors, or are of unknown causes.2 Issues of human infertility are extremely complex 
physiologically, psychologically, financially, legally and ethically. It is estimated that 85-90% 
of infertile couples will receive conventional treatment and 10-15% may become candidates 
for various forms of Assisted Reproductive Technologies (ARTs) to assist them in having 
their own biological children. In-vitro fertilization (IVF) is one of the most utilized 
reproductive procedures that has allowed couples to have their own biological children. IVF 
accounts for 99% of ART. This procedure has been effective but it is still inefficient and 
expensive. One aspect of the inefficiency is that numerous embryos have been frozen 
through a process called cryopreservation. It has been estimated that there are 400,000 
embryos frozen and stored since the late 1970s.3 In reality, the actual number of frozen 
embryos is probably closer to 500,000 with an additional 20,000 embryos added yearly.4  
Freezing these embryos has allowed for a limitation on the number of embryos transferred 
to a woman’s uterus which has decreased the number of multiple gestations. It also allows 
couples to use the frozen embryos in the future if the initial cycles are unsuccessful. This is 
not only more effective but also lowers the cost. The issue is now what to do with the 
400,000 to 500,000 frozen embryos that remain as “spares.” Various alternatives have been 
suggested. The embryos could be thawed and then destroyed, continued to be 
cryopreserved indefinitely, used for research, or offered for donation/adoption. All of these 
options present problems medically, legally and ethically, especially for Roman Catholics.  
Medically, the lifespan of a cryopreserved embryo is unknown. The effect of the freezing 
process is also unknown on the quality of the embryo if brought to term. “Studies have 
found that babies created through IVF are twice as likely to be born underweight and with 
major birth defects.”5 With the unknown effects of cryopreservation on embryo 
development the medical issues become even more complex. Legally, only 2% of frozen 
embryos are specifically designated for donation/adoption and 5% are specifically 
designated for destruction or research.6 The legal issues focus on the applicability of contract 
law versus family law because frozen embryos are technically considered “property” not 
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“persons.” Presently, the applicability of contract law or family law remains unclear. In 
addition, to date only three states—Florida, Louisiana and New Hampshire—have adopted 
legislation concerning the disposition or disposal of embryos. Legally and legislatively the 
issue of embryo donation/adoption is ambiguous at best. Ethically, depending on one’s 
view of when personhood begins, frozen embryos may be considered human persons, 
which deserve dignity and respect, or they may have less than human status with no 
particular ethical rights. From an ethical perspective that views personhood beginning at 
fertilization, one could argue that the “rescue” of these embryos could be considered 
ethically acceptable. The problem is that in 2008 the Vatican’s Congregation for the Doctrine 
of the Faith issued an Instruction called  Dignitas Personae, which stated that prenatal 
adoption, “praiseworthy with regard to intention of respecting and defining human life, 
presents however various problems” and is considered unethical.7 If donation/adoption is 
not acceptable by the Magisterium then the only remaining option would be to stop the 
process of cryopreservation and allow the thawed embryos to die with dignity and respect 
under the principle of the extraordinary/ordinary means distinction.  
This article will focus on allowing to die under the principle of extraordinary/ordinary 
means distinction as a viable option to address the 400,000 to 500,000 frozen embryos in the 
United States. The intended purpose of this article is threefold: first, to examine the medical 
issues surrounding the cryopreservation of frozen embryos; second, to give an ethical 
analysis of the arguments for and against allowing to die; and third, to give 
recommendations on how to avoid the continuation of this problem in the future. 
2. Medical aspects 
Infertility is a major problem for many couples in the United States. “About one married 
couple in 12 cannot conceive a child after two years of trying. Infertility stems from many 
factors, including a woman’s age at the first attempt to conceive, damage from pelvic 
inflammatory disease, previous abortions, uterine abnormalities, and a man’s low sperm 
count or low sperm motility.”8 Individually, male and female factors each account for about 
40% of infertility in the United States. Numerous technologies are available to couples from 
artificial insemination by a husband or a donor, to gamete intrafallopian transfer (GIFT), to 
zygote intrafallopian transfer (ZIFT), to in-vitro fertilization. Of these reproductive 
technologies IVF has become the ART of choice for many infertile couples. IVF is an assisted 
reproductive technology which had its first success in 1978 when Drs. Edwards and Steptoe 
in Oldham, England created the first “test tube baby” named Louise Brown. Since that first 
success, IVF technology has been refined and over 3 million babies have been born 
worldwide.9  
There are five basic steps to IVF. 1) Harvesting the eggs from the woman’s ovaries. The woman’s 
ovaries are hyperstimulated using fertility drugs that produce numerous eggs. During this 
period the woman will have regular transvaginal ultrasounds to examine the ovaries and 
blood tests to check hormone levels. 2) Egg retrieval. The eggs are removed from the 
woman’s body using follicular aspiration. Using ultrasound images as a guide the physician 
inserts a thin needle through the vagina and into the ovary and sacs containing the eggs. 
The needle is connected to a suction device, which pulls the eggs and fluid out of each 
follicle, one at a time. In rare cases, a pelvic laparoscopy may be used to remove the eggs. 3) 
Insemination and Fertilization. The man’s sperm is placed with the best quality eggs in a petri 
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dish and stored in an environmentally controlled chamber. The mixing of the sperm and egg 
is called insemination. The sperm usually enters an egg a few hours after insemination. If 
there is a low chance for fertilization, one single sperm can be injected into an egg in a 
procedure called Intracytoplasmic Sperm Injection (ICSI). 4) Embryo culture. The fertilized 
eggs remain in the petri dish for 48 to 72 hours to verify that the embryo is not defective and 
growing properly. If a couple is at high-risk for passing on genetic (hereditary) disorders to 
a child they may consider using Pre-implantation Genetic Diagnosis (PGD). The procedure 
is performed 3-4 days after fertilization. A single cell is removed from each embryo to screen 
it for specific genetic disorders. Those embryos with the genetic disorder are usually 
destroyed. 5) Embryo transfer. Anywhere from 1-4 embryos are placed in the woman’s womb 
3 to 4 days after fertilization. The physician inserts a thin catheter containing the embryos 
into the woman’s vagina, through the cervix, and up into the womb. If the embryo implants 
in the woman’s uterine wall pregnancy will result.10   
The implantation rate is estimated at 10-25%.11 The overall birth rate varies from 11% 
(women over 40) to about 35% (women under 35).12 This clearly shows that a number of 
embryos transferred fail to survive, which is why multiple embryos are transferred per cycle 
and why numerous cycles are required. On average, 2.7 embryos per cycle are transferred in 
women under 35, with an average of 3 in older women. Depending on the embryo quality, 
up to 5-6 embryos can be transferred.13 The average cost of IVF is $12,000-17,000 per cycle. It 
is estimated that 75% of couples who have tried IVF and who spent from $10,000-100,000 
still go home without a baby.14 Risks include the possibility of ovarian hyperstimulation 
syndrome (OHSS), risks in the egg retrieval stage which include reactions to anesthesia, 
bleeding, infection and damage to structures surrounding the ovaries including the bowel 
and bladder, and finally there are the risks associated with multiple pregnancies. Since 1980 
the rate of twins has climbed 70% to 3.2% of births in 2004. Multiple gestations raise the risk 
of preterm births; low-birth-weight babies, with the possibility of death in very premature 
infants; long-term health problems; and pregnancy complications, which include pre-
eclampsia, gestational diabetes, and Caesarean section. Studies have shown that 56% of IVF 
twins born in 2004 weighed less than 5.5 pounds, and 65% were born prematurely, before 37 
weeks of gestation.15  Embryos not transferred in a fresh IVF cycle are usually 
cryopreserved. Freezing these embryos offers individuals the possibility of transferring the 
frozen embryos for later IVF cycles if the previous cycle does not result in a pregnancy. It is 
also cost effective and eliminates the need to undergo the steps needed for a fresh IVF cycle. 
In most cases the best quality embryos are transferred in the fresh cycle and those of a lesser 
quality are frozen for later transfer. It should be noted that some clinics have individual 
freezing and thawing to achieve the exact number of embryos desired for transfer. This 
procedure avoids embryo wastage.  
 The process of cryopreservation has become an integral part of the IVF procedure. 
“Cryopreservation is a process of freezing biological tissues for storage, while minimizing 
cellular damage from freezing and thawing.”16 This technique entails freezing the embryo 
while simultaneously removing the intracellular water and replacing it with a 
cryoprotectant solution which help to protect the embryo during the freezing process. The 
embryos are then placed into cryopreservation straws or vials, which are labeled with the 
patient’s name, the patient’s IVF number, and the date of the freeze. Once the process is 
complete, the embryos are placed in a computer controlled freezing unit. After the freezing 
run is complete, the straws are stored in a special tank filled with liquid nitrogen at a 
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“persons.” Presently, the applicability of contract law or family law remains unclear. In 
addition, to date only three states—Florida, Louisiana and New Hampshire—have adopted 
legislation concerning the disposition or disposal of embryos. Legally and legislatively the 
issue of embryo donation/adoption is ambiguous at best. Ethically, depending on one’s 
view of when personhood begins, frozen embryos may be considered human persons, 
which deserve dignity and respect, or they may have less than human status with no 
particular ethical rights. From an ethical perspective that views personhood beginning at 
fertilization, one could argue that the “rescue” of these embryos could be considered 
ethically acceptable. The problem is that in 2008 the Vatican’s Congregation for the Doctrine 
of the Faith issued an Instruction called  Dignitas Personae, which stated that prenatal 
adoption, “praiseworthy with regard to intention of respecting and defining human life, 
presents however various problems” and is considered unethical.7 If donation/adoption is 
not acceptable by the Magisterium then the only remaining option would be to stop the 
process of cryopreservation and allow the thawed embryos to die with dignity and respect 
under the principle of the extraordinary/ordinary means distinction.  
This article will focus on allowing to die under the principle of extraordinary/ordinary 
means distinction as a viable option to address the 400,000 to 500,000 frozen embryos in the 
United States. The intended purpose of this article is threefold: first, to examine the medical 
issues surrounding the cryopreservation of frozen embryos; second, to give an ethical 
analysis of the arguments for and against allowing to die; and third, to give 
recommendations on how to avoid the continuation of this problem in the future. 
2. Medical aspects 
Infertility is a major problem for many couples in the United States. “About one married 
couple in 12 cannot conceive a child after two years of trying. Infertility stems from many 
factors, including a woman’s age at the first attempt to conceive, damage from pelvic 
inflammatory disease, previous abortions, uterine abnormalities, and a man’s low sperm 
count or low sperm motility.”8 Individually, male and female factors each account for about 
40% of infertility in the United States. Numerous technologies are available to couples from 
artificial insemination by a husband or a donor, to gamete intrafallopian transfer (GIFT), to 
zygote intrafallopian transfer (ZIFT), to in-vitro fertilization. Of these reproductive 
technologies IVF has become the ART of choice for many infertile couples. IVF is an assisted 
reproductive technology which had its first success in 1978 when Drs. Edwards and Steptoe 
in Oldham, England created the first “test tube baby” named Louise Brown. Since that first 
success, IVF technology has been refined and over 3 million babies have been born 
worldwide.9  
There are five basic steps to IVF. 1) Harvesting the eggs from the woman’s ovaries. The woman’s 
ovaries are hyperstimulated using fertility drugs that produce numerous eggs. During this 
period the woman will have regular transvaginal ultrasounds to examine the ovaries and 
blood tests to check hormone levels. 2) Egg retrieval. The eggs are removed from the 
woman’s body using follicular aspiration. Using ultrasound images as a guide the physician 
inserts a thin needle through the vagina and into the ovary and sacs containing the eggs. 
The needle is connected to a suction device, which pulls the eggs and fluid out of each 
follicle, one at a time. In rare cases, a pelvic laparoscopy may be used to remove the eggs. 3) 
Insemination and Fertilization. The man’s sperm is placed with the best quality eggs in a petri 
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dish and stored in an environmentally controlled chamber. The mixing of the sperm and egg 
is called insemination. The sperm usually enters an egg a few hours after insemination. If 
there is a low chance for fertilization, one single sperm can be injected into an egg in a 
procedure called Intracytoplasmic Sperm Injection (ICSI). 4) Embryo culture. The fertilized 
eggs remain in the petri dish for 48 to 72 hours to verify that the embryo is not defective and 
growing properly. If a couple is at high-risk for passing on genetic (hereditary) disorders to 
a child they may consider using Pre-implantation Genetic Diagnosis (PGD). The procedure 
is performed 3-4 days after fertilization. A single cell is removed from each embryo to screen 
it for specific genetic disorders. Those embryos with the genetic disorder are usually 
destroyed. 5) Embryo transfer. Anywhere from 1-4 embryos are placed in the woman’s womb 
3 to 4 days after fertilization. The physician inserts a thin catheter containing the embryos 
into the woman’s vagina, through the cervix, and up into the womb. If the embryo implants 
in the woman’s uterine wall pregnancy will result.10   
The implantation rate is estimated at 10-25%.11 The overall birth rate varies from 11% 
(women over 40) to about 35% (women under 35).12 This clearly shows that a number of 
embryos transferred fail to survive, which is why multiple embryos are transferred per cycle 
and why numerous cycles are required. On average, 2.7 embryos per cycle are transferred in 
women under 35, with an average of 3 in older women. Depending on the embryo quality, 
up to 5-6 embryos can be transferred.13 The average cost of IVF is $12,000-17,000 per cycle. It 
is estimated that 75% of couples who have tried IVF and who spent from $10,000-100,000 
still go home without a baby.14 Risks include the possibility of ovarian hyperstimulation 
syndrome (OHSS), risks in the egg retrieval stage which include reactions to anesthesia, 
bleeding, infection and damage to structures surrounding the ovaries including the bowel 
and bladder, and finally there are the risks associated with multiple pregnancies. Since 1980 
the rate of twins has climbed 70% to 3.2% of births in 2004. Multiple gestations raise the risk 
of preterm births; low-birth-weight babies, with the possibility of death in very premature 
infants; long-term health problems; and pregnancy complications, which include pre-
eclampsia, gestational diabetes, and Caesarean section. Studies have shown that 56% of IVF 
twins born in 2004 weighed less than 5.5 pounds, and 65% were born prematurely, before 37 
weeks of gestation.15  Embryos not transferred in a fresh IVF cycle are usually 
cryopreserved. Freezing these embryos offers individuals the possibility of transferring the 
frozen embryos for later IVF cycles if the previous cycle does not result in a pregnancy. It is 
also cost effective and eliminates the need to undergo the steps needed for a fresh IVF cycle. 
In most cases the best quality embryos are transferred in the fresh cycle and those of a lesser 
quality are frozen for later transfer. It should be noted that some clinics have individual 
freezing and thawing to achieve the exact number of embryos desired for transfer. This 
procedure avoids embryo wastage.  
 The process of cryopreservation has become an integral part of the IVF procedure. 
“Cryopreservation is a process of freezing biological tissues for storage, while minimizing 
cellular damage from freezing and thawing.”16 This technique entails freezing the embryo 
while simultaneously removing the intracellular water and replacing it with a 
cryoprotectant solution which help to protect the embryo during the freezing process. The 
embryos are then placed into cryopreservation straws or vials, which are labeled with the 
patient’s name, the patient’s IVF number, and the date of the freeze. Once the process is 
complete, the embryos are placed in a computer controlled freezing unit. After the freezing 
run is complete, the straws are stored in a special tank filled with liquid nitrogen at a 
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temperature of minus 196 degrees centigrade.17 Many storage facilities use a back-up system 
to minimize the risk of interruption in the freezing process. Liquid nitrogen containers are 
armed with an automatic alarm system to monitor nitrogen levels and prevent premature 
thawing.18 These embryos are looked upon as being in a state of “suspended animation.” 
Cellular activity has ceased, but each embryo is still alive. When the remaining embryos are 
needed a procedure utilizing rapid thawing and removal of the cryopreservative solution 
with simultaneous rehydration is used. The embryos are first warmed in a 98.6 F degree 
solution and the cryoprotectant chemicals are removed.19 
The embryo thawing process is quite complex. “Embryo survival is based on the number of 
viable cells in an embryo after thawing. An embryo has ‘survived’ if >50% of the cells are 
viable. An embryo is considered to ‘partially survive’ if <50% of its cells are viable and to be 
‘atretic’ if all the cells are dead at thaw. Approximately, 65-70% of embryos survive thaw, 
10% partially survive and 20-25% are atretic. Data suggests that embryos with 100% cell 
survival are almost as good as embryos never frozen but only about 30-35% survive this 
fashion. Embryos that are 2, 4 or 8 cells when frozen have about a 5-10% greater survival 
than embryos with an odd number of cells. Donor egg embryos have a 2-5% greater survival 
rate than embryos from infertile women when compared by morphology score”20 The cost 
of cryopreservation is approximately $600-700 a year. The success rate or pregnancy rate 
depends on numerous factors: the number of surviving embryos transferred, the number of 
100% surviving embryos transferred, and the morphology scores of the transferred embryos. 
The delivered pregnancy rates range from 5% (a single poor quality embryo) to 36% (4 high 
quality embryos) when the cycles from 1987 to 2001 were combined. It is estimated that 
embryo cryopreservation adds about 10-30% more pregnancies per retrieval cycle and the 
outcomes of the children are normal.21 The reason for the wide range of costs and success 
rates is because the Assisted Reproductive Technologies industry in the United States is 
unregulated. The success rates and costs can vary from clinic to clinic and there is no 
government oversight examining the widespread differences. 
The advantages of embryo freezing are numerous: reducing the risks of multiple gestations 
potentially increases pregnancy rates, decreasing the number of stimulated treatment cycles 
needed to achieve pregnancy, decreasing the costs of ARTs, etc. The main disadvantage 
according to the 2003 RAND/SART Working Group study centers on the approximately 
400,000 frozen “spare” embryos stored since the 1970’s.22 More recent numbers have the 
number of frozen embryos in excess of 500,000. The 500,000 number seems more realistic 
considering the increase in IVF procedures since 2003. The issue that is confronting parents 
and fertility clinics is what to do with these “spare” embryos medically, legally and 
ethically.  
The RAND/SART survey in 2003 found that of the 400,000 frozen spare embryos 88.2% 
were designated for family building and 2.8% (11,000) were designated for research. Those 
embryos designated for research could produce as many as 275 stem cell lines (cell cultures 
suitable for further development). However, the number would in reality be much lower. Of 
the remaining embryos, it is estimated that 2.3% (10,000) are awaiting donation, 2.2% are 
designated to be discarded, and 4.5% are held in storage for other reasons, including lost 
contact with a patient, patient death, abandonment, and divorce.23 There are numerous 
issues concerning the “spare” frozen embryos. The ART clinics transfer the highest quality 
embryos (those that grow at a normal rate) to the patient during treatment cycles. The 
remaining embryos are usually designated as not of the highest quality. In addition, some of 
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the frozen embryos have been in storage for many years, and when these embryos were 
created the laboratory cultures were not as conducive to preserving embryos as they are 
today. Some embryos would also die in the freeze-thaw process. Considering all these 
issues, the question is how many embryos actually are available for research and 
donation/adoption?  The RAND/SART team estimated that 65% of the approximately 
11,000 embryos designated for research would survive the freeze-thaw process, resulting in 
7,334 embryos. Of those, about 25% (1,834 embryos) would likely be able to survive the 
initial stages of development to the blastocyst stage (a blastocyst is an embryo that has 
developed for at least 5 days). Even fewer could be converted into embryonic stem cell lines. 
Their estimate is about 275 embryonic stem cell lines could be converted from the total 
number of embryos designated for research. The RAND/SART team also estimates that 
2.3% of the 400,000 frozen “spare” embryos designated for donation/adoption, only 23,000-
100,000 embryos could be adopted, thawed and successfully born.24 Having this many 
children potentially available for adoption would help meet the need of couples seeking 
adoption in the United States. The problem is that the adoption process for frozen embryos 
is legally quite ambiguous and very complex. In addition, with the Magisterium of the 
Catholic Church issuing the Instruction Dignitas Personae it appears that donation/adoption 
is no longer acceptable for Catholics. The only viable option for these spare embryos would 
be to allow them to be thawed and to die with dignity and respect under the principle of 
extraordinary/ordinary. The central issue is whether this is an ethically sound viable 
solution for the Roman Catholic Church.  
3. Ethical aspects 
Ethically, the concern about spare embryos focuses on the issue of personhood. If embryos 
are persons then it would be a moral imperative to “rescue” these embryos from their 
current status of being in “frozen animation.” Numerous ethicists, embryologists, legal 
professionals and specifically, the Roman Catholic Church, argue that personhood begins at 
conception or what is known as fertilization. Prior to fertilization we have two human 
gametes—sperm and egg, that are living but are not a living organism. When fertilization 
occurs, something human and living “in a different sense comes into being.”25 
Embryologists argue that “human development begins at fertilization when a male gamete 
or sperm (spermatozoon) unites with a female gamete or oocyte (ovum) to form a single 
cell—zygote. This highly specialized, totipotent cell marked the beginning of each of us as a 
unique individual.”26 The Catholic Church teaches that “human life must be absolutely 
respected and protected from the moment of conception.”27 “Right from fertilization is 
begun the adventure of a human life, and each of its great capacities requires time . . . to find 
its place and to be in a position to act. This teaching remains valid and is further confirmed, 
if confirmation were needed, by recent findings of human biological science which 
recognize that in the zygote resulting from fertilization the biological identity of a new 
human individual is already constituted.”28 The Church argues that at fertilization there is a 
new genetic individual in its own right, one who is whole, bodily, self-organizing, and 
genetically distinct from his or her mother and father.29 Those who argue that personhood 
begins at fertilization would also argue that there is a moral imperative to give these frozen 
embryos the opportunity to be born and to develop because they are persons. Ethicist 
Therese Lysaught believes that embryo donation/adoption is an act that can properly be 
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temperature of minus 196 degrees centigrade.17 Many storage facilities use a back-up system 
to minimize the risk of interruption in the freezing process. Liquid nitrogen containers are 
armed with an automatic alarm system to monitor nitrogen levels and prevent premature 
thawing.18 These embryos are looked upon as being in a state of “suspended animation.” 
Cellular activity has ceased, but each embryo is still alive. When the remaining embryos are 
needed a procedure utilizing rapid thawing and removal of the cryopreservative solution 
with simultaneous rehydration is used. The embryos are first warmed in a 98.6 F degree 
solution and the cryoprotectant chemicals are removed.19 
The embryo thawing process is quite complex. “Embryo survival is based on the number of 
viable cells in an embryo after thawing. An embryo has ‘survived’ if >50% of the cells are 
viable. An embryo is considered to ‘partially survive’ if <50% of its cells are viable and to be 
‘atretic’ if all the cells are dead at thaw. Approximately, 65-70% of embryos survive thaw, 
10% partially survive and 20-25% are atretic. Data suggests that embryos with 100% cell 
survival are almost as good as embryos never frozen but only about 30-35% survive this 
fashion. Embryos that are 2, 4 or 8 cells when frozen have about a 5-10% greater survival 
than embryos with an odd number of cells. Donor egg embryos have a 2-5% greater survival 
rate than embryos from infertile women when compared by morphology score”20 The cost 
of cryopreservation is approximately $600-700 a year. The success rate or pregnancy rate 
depends on numerous factors: the number of surviving embryos transferred, the number of 
100% surviving embryos transferred, and the morphology scores of the transferred embryos. 
The delivered pregnancy rates range from 5% (a single poor quality embryo) to 36% (4 high 
quality embryos) when the cycles from 1987 to 2001 were combined. It is estimated that 
embryo cryopreservation adds about 10-30% more pregnancies per retrieval cycle and the 
outcomes of the children are normal.21 The reason for the wide range of costs and success 
rates is because the Assisted Reproductive Technologies industry in the United States is 
unregulated. The success rates and costs can vary from clinic to clinic and there is no 
government oversight examining the widespread differences. 
The advantages of embryo freezing are numerous: reducing the risks of multiple gestations 
potentially increases pregnancy rates, decreasing the number of stimulated treatment cycles 
needed to achieve pregnancy, decreasing the costs of ARTs, etc. The main disadvantage 
according to the 2003 RAND/SART Working Group study centers on the approximately 
400,000 frozen “spare” embryos stored since the 1970’s.22 More recent numbers have the 
number of frozen embryos in excess of 500,000. The 500,000 number seems more realistic 
considering the increase in IVF procedures since 2003. The issue that is confronting parents 
and fertility clinics is what to do with these “spare” embryos medically, legally and 
ethically.  
The RAND/SART survey in 2003 found that of the 400,000 frozen spare embryos 88.2% 
were designated for family building and 2.8% (11,000) were designated for research. Those 
embryos designated for research could produce as many as 275 stem cell lines (cell cultures 
suitable for further development). However, the number would in reality be much lower. Of 
the remaining embryos, it is estimated that 2.3% (10,000) are awaiting donation, 2.2% are 
designated to be discarded, and 4.5% are held in storage for other reasons, including lost 
contact with a patient, patient death, abandonment, and divorce.23 There are numerous 
issues concerning the “spare” frozen embryos. The ART clinics transfer the highest quality 
embryos (those that grow at a normal rate) to the patient during treatment cycles. The 
remaining embryos are usually designated as not of the highest quality. In addition, some of 
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the frozen embryos have been in storage for many years, and when these embryos were 
created the laboratory cultures were not as conducive to preserving embryos as they are 
today. Some embryos would also die in the freeze-thaw process. Considering all these 
issues, the question is how many embryos actually are available for research and 
donation/adoption?  The RAND/SART team estimated that 65% of the approximately 
11,000 embryos designated for research would survive the freeze-thaw process, resulting in 
7,334 embryos. Of those, about 25% (1,834 embryos) would likely be able to survive the 
initial stages of development to the blastocyst stage (a blastocyst is an embryo that has 
developed for at least 5 days). Even fewer could be converted into embryonic stem cell lines. 
Their estimate is about 275 embryonic stem cell lines could be converted from the total 
number of embryos designated for research. The RAND/SART team also estimates that 
2.3% of the 400,000 frozen “spare” embryos designated for donation/adoption, only 23,000-
100,000 embryos could be adopted, thawed and successfully born.24 Having this many 
children potentially available for adoption would help meet the need of couples seeking 
adoption in the United States. The problem is that the adoption process for frozen embryos 
is legally quite ambiguous and very complex. In addition, with the Magisterium of the 
Catholic Church issuing the Instruction Dignitas Personae it appears that donation/adoption 
is no longer acceptable for Catholics. The only viable option for these spare embryos would 
be to allow them to be thawed and to die with dignity and respect under the principle of 
extraordinary/ordinary. The central issue is whether this is an ethically sound viable 
solution for the Roman Catholic Church.  
3. Ethical aspects 
Ethically, the concern about spare embryos focuses on the issue of personhood. If embryos 
are persons then it would be a moral imperative to “rescue” these embryos from their 
current status of being in “frozen animation.” Numerous ethicists, embryologists, legal 
professionals and specifically, the Roman Catholic Church, argue that personhood begins at 
conception or what is known as fertilization. Prior to fertilization we have two human 
gametes—sperm and egg, that are living but are not a living organism. When fertilization 
occurs, something human and living “in a different sense comes into being.”25 
Embryologists argue that “human development begins at fertilization when a male gamete 
or sperm (spermatozoon) unites with a female gamete or oocyte (ovum) to form a single 
cell—zygote. This highly specialized, totipotent cell marked the beginning of each of us as a 
unique individual.”26 The Catholic Church teaches that “human life must be absolutely 
respected and protected from the moment of conception.”27 “Right from fertilization is 
begun the adventure of a human life, and each of its great capacities requires time . . . to find 
its place and to be in a position to act. This teaching remains valid and is further confirmed, 
if confirmation were needed, by recent findings of human biological science which 
recognize that in the zygote resulting from fertilization the biological identity of a new 
human individual is already constituted.”28 The Church argues that at fertilization there is a 
new genetic individual in its own right, one who is whole, bodily, self-organizing, and 
genetically distinct from his or her mother and father.29 Those who argue that personhood 
begins at fertilization would also argue that there is a moral imperative to give these frozen 
embryos the opportunity to be born and to develop because they are persons. Ethicist 
Therese Lysaught believes that embryo donation/adoption is an act that can properly be 
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described as “rescuing a child orphaned before birth.”30 Ethicists arguing for the “rescue” of 
these children would encourage women to implant these embryos in their wombs in order 
to bring them to term. Some would permit not only married women to do this but also 
single women and even lesbian couples. The moral principle of sanctity of human life would 
overcome any other moral considerations. However, not all, even in the Catholic Church, 
would agree to this ethical analysis. Opponents of this position argue that this would 
amount to material cooperation in an objective immoral action. Not only is the process of 
IVF considered an intrinsic moral evil by the Magisterium of the Catholic Church, but 
allowing for the donation/adoption of these embryos might condone the objective immoral 
procedure and may even encourage the creation of additional embryos through the IVF 
process. The Catholic Church clarified its position on embryo donation/adoption in 2008 in 
the Instruction from the Congregation of the Faith called Dignitas Personae. “The proposal 
that these embryos could be put at the disposal of infertile couples as a treatment for fertility 
is not ethically acceptable for the same reasons which make artificial heterologous 
procreation illicit as well as any form of surrogate motherhood; this practice would also lead 
to other problems of a medical, psychological and legal nature.”31 This statement by the 
Magisterium removes donation/adoption as a viable option for Catholics. The only 
remaining option would be to allow these embryos to die with dignity and respect using the 
extraordinary/ordinary means distinction. To determine if thawing these embryos and 
allowing them to die naturally is ethical and to address the ambiguities and unresolved 
issues surrounding this controversy, the traditional ethical principle of the 
extraordinary/ordinary means distinction will be examined and applied to this situation.  
The history of the Catholic Church’s position on the ordinary-extraordinary means 
distinction dates back to the 16th century Dominican moralists. There are however, some 
who believe it may go back to Thomas Aquinas (1225-1274) a Dominican Friar and Doctor of 
the Roman Catholic Church. Thomas’ belief in the moral measure of all human activity is 
whether it leads to God, the final end. Thus, if something was “too difficult” or “too 
burdensome” what was implied was that it might make loving God too difficult.32   The 
general obligation to preserve life and the possible limits to that obligation are also 
influenced by Thomas’ concept of God’s dominion over the gift of human life, responsible 
stewardship and the positive and negative precepts derived from these.33  Thomas’ 
influence is clearly present, but it is the three Dominican moralists--Francisco De Vitoria, 
Domingo Soto and Domingo Banez--who articulated the foundation of the ordinary-
extraordinary means distinction.  
De Vitoria (1486-1546) examined the limits of treatment in regards to nourishment and 
medicinal drugs. In his seminal work Relectiones Theologicae he states: 
“If a sick man can take food or nourishment with a certain hope of life, he is required to take 
food as he would be required to give it to one who is sick. However, if the depression of 
spirits is so severe and there is present grave consternation in the appetitive power so that 
only with the greatest effort and as though through torture can the sick man take food, this 
is to be reckoned as an impossibility and therefore, he is excused, at least from mortal sin.”34 
De Victoria is not condoning suicide here. A healthy person may not starve him-herself 
because life is problematic. If the means are effective and not burdensome then the person is 
morally obligated to seek nourishment. However, if the person is so sick or depressed that 
eating may become a grave burden, then the person is not morally obliged to eat and does 
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not commit a sin. The essential point here is that De Vitoria recognizes both psychological 
and physiological illness and his notion of grave burden includes both. In regards to 
medicinal drugs, he argues that they are not per se obligatory. The obligation to use them 
rested on the degree of efficacy. One is not obliged to sacrifice one’s whole means of 
subsistence, nor one’s general lifestyle, nor one’s homeland in order to acquire a cure or 
obtain optimum health.35 It appears that De Vitoria adopted the 16th century’s version of the 
“Reasonable Person” criteria. “To fulfill one’s positive obligation to sustain life, it is 
sufficient to perform ‘that by which regularly a man can live.’”36 The moral components that 
appear operative here are not natural as opposed to artificial means, but those means that 
offer a reasonable hope of benefit in regard to cure and return to health. Excessive burdens 
in terms of financial costs or inconvenience of lifestyle are measured by “the semi-objective 
standard of the common person regularly considered,” or what we refer to as the 
“reasonable person standard.”37  If the means used to prolong life were ineffective, if the 
effect was doubtful, or if it involves a grave burden for the person in question, this means 
need not be morally obligatory. 
Prior to the development of modern anesthesia, surgical procedures, especially 
amputations, were quite painful. Domingo Soto (1494-1560) reasoned that surgery such as 
amputation of a limb, because of the excessive pain, ought to be considered categorically 
optional. He argued that such torture was beyond the limits that the “common man” ought 
to be obliged to suffer for the sake of one’s bodily health. Such surgery can make a beneficial 
surgery “morally impossible” to bear.38    Besides the question of pain, Soto also recognizes 
the role that emotions of fear and repugnance could play.39  Soto incorporates the dimension 
of optional versus obligatory, adding if a procedure or treatment was too painful or 
burdensome, it would be morally optional. 
In 1595, Domingo Bañez (1528-1604) was the first to articulate the terms “ordinary” and 
“extraordinary” as they regard obligatory and non-obligatory means of preserving life. He 
argued that if preserving life was reasonable it was obligatory but insisted that one is “not 
bound to extraordinary means but to common food and clothing, to common medicines, to 
certain common and ordinary pain; not, however, to certain extraordinary and horrible 
pain, nor to expenses which are extraordinary in proportion to the status of this man.”40  
One determined if a treatment or medical procedure was ordinary or extraordinary 
according to whether it was proportionate to one’s condition or state in life. “Thus, if 
something were very costly or burdensome or if it did not offer substantial benefit to the 
patient, there was no moral obligation to use it. This standard applied to even life-saving 
measures.”41 The Jesuit moralist Juan Cardinal De Lugo (1583-1660) confirms Bañez’s 
position when he wrote, “…he is not held to the extraordinary and difficult means . . . the 
‘bonum’ of his life is not of such great moment, however, that its conservation must be 
effected with extraordinary diligence. . .”42  De Lugo’s position, like that of the Dominican 
moralists, followed the tradition of the Church that states human life is a good but not an 
absolute good. As a relative good, one’s duty to preserve it is a limited duty. While a person 
has freedom over his or her life, one is never permitted to directly take one’s life. The issue 
becomes to what extent is one obligated to preserve one’s life. 
The traditional understanding of ordinary-extraordinary means remained basically 
unchallenged until the mid-1900s with the advent of advances in medicine and technology. 
How to apply the early distinction of ordinary-extraordinary means to issues like oxygen 
and feeding tubes, especially with permanently unconscious patients became hotly debated 
as early as the 1950s. Jesuit moralist Gerald Kelly was one of the first to examine this issue 
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described as “rescuing a child orphaned before birth.”30 Ethicists arguing for the “rescue” of 
these children would encourage women to implant these embryos in their wombs in order 
to bring them to term. Some would permit not only married women to do this but also 
single women and even lesbian couples. The moral principle of sanctity of human life would 
overcome any other moral considerations. However, not all, even in the Catholic Church, 
would agree to this ethical analysis. Opponents of this position argue that this would 
amount to material cooperation in an objective immoral action. Not only is the process of 
IVF considered an intrinsic moral evil by the Magisterium of the Catholic Church, but 
allowing for the donation/adoption of these embryos might condone the objective immoral 
procedure and may even encourage the creation of additional embryos through the IVF 
process. The Catholic Church clarified its position on embryo donation/adoption in 2008 in 
the Instruction from the Congregation of the Faith called Dignitas Personae. “The proposal 
that these embryos could be put at the disposal of infertile couples as a treatment for fertility 
is not ethically acceptable for the same reasons which make artificial heterologous 
procreation illicit as well as any form of surrogate motherhood; this practice would also lead 
to other problems of a medical, psychological and legal nature.”31 This statement by the 
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The history of the Catholic Church’s position on the ordinary-extraordinary means 
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who believe it may go back to Thomas Aquinas (1225-1274) a Dominican Friar and Doctor of 
the Roman Catholic Church. Thomas’ belief in the moral measure of all human activity is 
whether it leads to God, the final end. Thus, if something was “too difficult” or “too 
burdensome” what was implied was that it might make loving God too difficult.32   The 
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influenced by Thomas’ concept of God’s dominion over the gift of human life, responsible 
stewardship and the positive and negative precepts derived from these.33  Thomas’ 
influence is clearly present, but it is the three Dominican moralists--Francisco De Vitoria, 
Domingo Soto and Domingo Banez--who articulated the foundation of the ordinary-
extraordinary means distinction.  
De Vitoria (1486-1546) examined the limits of treatment in regards to nourishment and 
medicinal drugs. In his seminal work Relectiones Theologicae he states: 
“If a sick man can take food or nourishment with a certain hope of life, he is required to take 
food as he would be required to give it to one who is sick. However, if the depression of 
spirits is so severe and there is present grave consternation in the appetitive power so that 
only with the greatest effort and as though through torture can the sick man take food, this 
is to be reckoned as an impossibility and therefore, he is excused, at least from mortal sin.”34 
De Victoria is not condoning suicide here. A healthy person may not starve him-herself 
because life is problematic. If the means are effective and not burdensome then the person is 
morally obligated to seek nourishment. However, if the person is so sick or depressed that 
eating may become a grave burden, then the person is not morally obliged to eat and does 
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not commit a sin. The essential point here is that De Vitoria recognizes both psychological 
and physiological illness and his notion of grave burden includes both. In regards to 
medicinal drugs, he argues that they are not per se obligatory. The obligation to use them 
rested on the degree of efficacy. One is not obliged to sacrifice one’s whole means of 
subsistence, nor one’s general lifestyle, nor one’s homeland in order to acquire a cure or 
obtain optimum health.35 It appears that De Vitoria adopted the 16th century’s version of the 
“Reasonable Person” criteria. “To fulfill one’s positive obligation to sustain life, it is 
sufficient to perform ‘that by which regularly a man can live.’”36 The moral components that 
appear operative here are not natural as opposed to artificial means, but those means that 
offer a reasonable hope of benefit in regard to cure and return to health. Excessive burdens 
in terms of financial costs or inconvenience of lifestyle are measured by “the semi-objective 
standard of the common person regularly considered,” or what we refer to as the 
“reasonable person standard.”37  If the means used to prolong life were ineffective, if the 
effect was doubtful, or if it involves a grave burden for the person in question, this means 
need not be morally obligatory. 
Prior to the development of modern anesthesia, surgical procedures, especially 
amputations, were quite painful. Domingo Soto (1494-1560) reasoned that surgery such as 
amputation of a limb, because of the excessive pain, ought to be considered categorically 
optional. He argued that such torture was beyond the limits that the “common man” ought 
to be obliged to suffer for the sake of one’s bodily health. Such surgery can make a beneficial 
surgery “morally impossible” to bear.38    Besides the question of pain, Soto also recognizes 
the role that emotions of fear and repugnance could play.39  Soto incorporates the dimension 
of optional versus obligatory, adding if a procedure or treatment was too painful or 
burdensome, it would be morally optional. 
In 1595, Domingo Bañez (1528-1604) was the first to articulate the terms “ordinary” and 
“extraordinary” as they regard obligatory and non-obligatory means of preserving life. He 
argued that if preserving life was reasonable it was obligatory but insisted that one is “not 
bound to extraordinary means but to common food and clothing, to common medicines, to 
certain common and ordinary pain; not, however, to certain extraordinary and horrible 
pain, nor to expenses which are extraordinary in proportion to the status of this man.”40  
One determined if a treatment or medical procedure was ordinary or extraordinary 
according to whether it was proportionate to one’s condition or state in life. “Thus, if 
something were very costly or burdensome or if it did not offer substantial benefit to the 
patient, there was no moral obligation to use it. This standard applied to even life-saving 
measures.”41 The Jesuit moralist Juan Cardinal De Lugo (1583-1660) confirms Bañez’s 
position when he wrote, “…he is not held to the extraordinary and difficult means . . . the 
‘bonum’ of his life is not of such great moment, however, that its conservation must be 
effected with extraordinary diligence. . .”42  De Lugo’s position, like that of the Dominican 
moralists, followed the tradition of the Church that states human life is a good but not an 
absolute good. As a relative good, one’s duty to preserve it is a limited duty. While a person 
has freedom over his or her life, one is never permitted to directly take one’s life. The issue 
becomes to what extent is one obligated to preserve one’s life. 
The traditional understanding of ordinary-extraordinary means remained basically 
unchallenged until the mid-1900s with the advent of advances in medicine and technology. 
How to apply the early distinction of ordinary-extraordinary means to issues like oxygen 
and feeding tubes, especially with permanently unconscious patients became hotly debated 
as early as the 1950s. Jesuit moralist Gerald Kelly was one of the first to examine this issue 
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critically. He defined ordinary means of preserving life as “all medicines, treatments, and 
operations, which offer a reasonable hope of benefit for the patient and which can be 
obtained and used without excessive expense, pain, or other inconvenience.” Extraordinary 
means would be “all medicines, treatments, and operations, which cannot be obtained or 
used without excessive expense, pain, or other inconvenience, or which, if used, would not 
offer a reasonable hope of benefit.”43  The distinctive element of Kelly’s interpretation is that 
it is a patient-centered, quality-of-life approach which is consistent with how the 16th-
century-Dominican moralists viewed this distinction. Kelly concludes that no person is 
morally obligated to use any means, and this would include natural or artificial means, that 
does not offer a reasonable hope of ameliorating the patient’s condition. To clarify this 
distinction, Kelly was asked if oxygen and intravenous feeding must be used to extend the 
life of a patient in a terminal coma. He replies: “I see no reason why even the most delicate 
professional standard should call for their [oxygen and intravenous for a patient in a 
terminal coma] use. In fact, it seems to me that, apart from very special circumstances, the 
artificial means not only need not but should not be used, once the coma is reasonably 
diagnosed as terminal. Their use creates expense and nervous strain without conferring any 
real benefit.”44  
Many believe that the most authoritative historical study on this topic was done by Daniel 
Cronin (who later became Archbishop of Hartford) in his 1958 doctoral dissertation at the 
Gregorian University in Rome entitled, “The Moral Law in Regard to the Ordinary and 
Extraordinary Means of Preserving Life.” After a review of over 50 moral theologians from 
Aquinas to those writing in the early 1950’s Cronin concludes that the Church’s teaching is 
consistent in its view: “Even natural means, such as taking of food and drink, can become 
optional if taking them requires great effort or if the hope of beneficial results (spes salutis) is 
not present.” For a patient whose condition is incurable, he writes, “even ordinary means, 
according to the general norm, have become extraordinary [morally dispensable] for the 
patient [so] the wishes of the patient, expressed or reasonably interpreted, must be 
obeyed.”45 The importance of Cronin’s position is that no means—even food and water—
can ever be classified as absolutely obligatory regardless of the patient’s condition. 
However, some moralists disputed this fact and claimed that food and water were 
absolutely ordinary and even tried to say that was what the tradition taught. 
On November 24, 1957, in a talk delivered to the International Congress of 
Anesthesiologists, Pope Pius XII gave papal approbation to the ordinary-extraordinary 
means tradition that dates back to De Vitoria.  
“Natural reason and Christian morals say that man (and whoever is entrusted with taking 
care of his fellow man) has the right and the duty in case of serious illness to take the 
necessary treatment for the preservation of life and health . . . But normally one is held to 
use only ordinary means—according to circumstances of persons, places, times and 
culture—that is to say, means that do not involve grave burden for oneself or another. A 
more strict obligation would be too burdensome for most men and would render the 
attainment of the higher, more important good too difficult. Life, health, and all temporal 
activities are in fact subordinated to spiritual ends. On the other hand, one is not forbidden 
to take more than the strictly necessary steps to preserve life and health, as long as he does 
not fail in some more serious duty.”46  
Pius XII upholds the traditional ordinary-extraordinary means distinction that “involves 
patient-centered judgments about the quality of life, which must take into account the 
usefulness of the treatment, one’s understanding about death and dying, and the 
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repugnance one may have toward one’s life after subjection to a particular medical 
treatment.”47 It is also important to note that Pius XII emphasized the importance of viewing 
the person holistically. In an address given to the International Union Against Cancer, in 
1956, Pius XII counseled that “before anything else, the doctor should consider the whole 
man, in the unity of his person, that is to say, not merely his physical condition but his 
psychological state as well as his spiritual and moral ideals and his place in history.”48  This 
statement reinforces the traditional understanding of not treating the physiological aspect of 
the body separate from the person. Benefits of a treatment can only be determined within 
the context of a person’s life.49  To preserve life at all cost is to risk idolatry and thus would 
lead a person away from the higher spiritual good which is eternal life. 
A contemporary understanding of the ordinary-extraordinary means distinction was given 
in the 1980 Congregation for the Doctrine of the Faiths’ Declaration on Euthanasia. The 
Declaration follows the tradition on the ordinary-extraordinary means distinction since the 
16th century, which is based on the effect of the treatment on the patient or those responsible 
for the care of the patient. The Declaration reminds us of the duty one has to care for one’s 
own life and to seek such care for others. But there are limits to this obligation. One needs to 
judge the means used by “studying the type of treatment to be used, its degree of 
complexity or risk, its cost and the possibilities of using it, and comparing these elements 
with the result that can be expected, taking into account the state of the sick person and his 
or her physical and moral resources.”50 The Declaration goes on to give four examples: 
patients are permitted to use experimental, advanced medical techniques, which may be a 
service to humanity; patients may interrupt treatments if they fall short of expectations; the 
refusal of a technique that is in use and carries a risk or is burdensome is not equivalent to 
suicide; finally, when death is imminent in spite of the means used, it is permitted in 
conscience to make the decision to refuse forms of treatment that would only secure a 
precarious and burdensome prolongation of life, so long as the normal care due to the sick 
person in similar cases is not interrupted.51 Finally, the Congregation for the Doctrine of the 
Faith reflects the traditional teaching when it writes: “Life is a gift from God, and on the 
other hand death is unavoidable; it is necessary, therefore, that we, without in any way 
hastening the hour of death, should be able to accept it with full responsibility and 
dignity.”52 The only real change is that the document realizes that the terms ordinary and 
extraordinary are imprecise as terms in regards to the rapid advancement of medicine and 
technology. More precise terms would be proportionate and disproportionate.53  
The historical review of the tradition shows a clear distinction between extraordinary and 
ordinary means that involves patient-centered judgments about the quality of life, which 
must take into account the usefulness of the treatment, one’s understanding about death and 
dying, and the repugnance one may have toward one’s life after subjection to a particular 
medical treatment.54 The ethical issue concerning frozen embryos focuses on the foregoing 
of artificial life support from them, which would allow the embryos to die naturally. Some 
might argue that this is a form of euthanasia. Pope John Paul II in Evangelium Vitae states: 
“Euthanasia’s terms of reference, therefore, are to be found in the intention of the will and in 
the methods used.”55 The intention here is not to end the life of the embryo but to forego a 
burdensome treatment and allow the embryo to die naturally with dignity and respect. The 
Pope himself states clearly that euthanasia must be distinguished from the decision to 
forego what he refers to as “aggressive medical treatment.” “Medical procedures which no 
longer correspond to the real situation of the patient, either because they are by now 
disproportionate to any expected results or because they impose an excessive burden on the 
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critically. He defined ordinary means of preserving life as “all medicines, treatments, and 
operations, which offer a reasonable hope of benefit for the patient and which can be 
obtained and used without excessive expense, pain, or other inconvenience.” Extraordinary 
means would be “all medicines, treatments, and operations, which cannot be obtained or 
used without excessive expense, pain, or other inconvenience, or which, if used, would not 
offer a reasonable hope of benefit.”43  The distinctive element of Kelly’s interpretation is that 
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repugnance one may have toward one’s life after subjection to a particular medical 
treatment.”47 It is also important to note that Pius XII emphasized the importance of viewing 
the person holistically. In an address given to the International Union Against Cancer, in 
1956, Pius XII counseled that “before anything else, the doctor should consider the whole 
man, in the unity of his person, that is to say, not merely his physical condition but his 
psychological state as well as his spiritual and moral ideals and his place in history.”48  This 
statement reinforces the traditional understanding of not treating the physiological aspect of 
the body separate from the person. Benefits of a treatment can only be determined within 
the context of a person’s life.49  To preserve life at all cost is to risk idolatry and thus would 
lead a person away from the higher spiritual good which is eternal life. 
A contemporary understanding of the ordinary-extraordinary means distinction was given 
in the 1980 Congregation for the Doctrine of the Faiths’ Declaration on Euthanasia. The 
Declaration follows the tradition on the ordinary-extraordinary means distinction since the 
16th century, which is based on the effect of the treatment on the patient or those responsible 
for the care of the patient. The Declaration reminds us of the duty one has to care for one’s 
own life and to seek such care for others. But there are limits to this obligation. One needs to 
judge the means used by “studying the type of treatment to be used, its degree of 
complexity or risk, its cost and the possibilities of using it, and comparing these elements 
with the result that can be expected, taking into account the state of the sick person and his 
or her physical and moral resources.”50 The Declaration goes on to give four examples: 
patients are permitted to use experimental, advanced medical techniques, which may be a 
service to humanity; patients may interrupt treatments if they fall short of expectations; the 
refusal of a technique that is in use and carries a risk or is burdensome is not equivalent to 
suicide; finally, when death is imminent in spite of the means used, it is permitted in 
conscience to make the decision to refuse forms of treatment that would only secure a 
precarious and burdensome prolongation of life, so long as the normal care due to the sick 
person in similar cases is not interrupted.51 Finally, the Congregation for the Doctrine of the 
Faith reflects the traditional teaching when it writes: “Life is a gift from God, and on the 
other hand death is unavoidable; it is necessary, therefore, that we, without in any way 
hastening the hour of death, should be able to accept it with full responsibility and 
dignity.”52 The only real change is that the document realizes that the terms ordinary and 
extraordinary are imprecise as terms in regards to the rapid advancement of medicine and 
technology. More precise terms would be proportionate and disproportionate.53  
The historical review of the tradition shows a clear distinction between extraordinary and 
ordinary means that involves patient-centered judgments about the quality of life, which 
must take into account the usefulness of the treatment, one’s understanding about death and 
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might argue that this is a form of euthanasia. Pope John Paul II in Evangelium Vitae states: 
“Euthanasia’s terms of reference, therefore, are to be found in the intention of the will and in 
the methods used.”55 The intention here is not to end the life of the embryo but to forego a 
burdensome treatment and allow the embryo to die naturally with dignity and respect. The 
Pope himself states clearly that euthanasia must be distinguished from the decision to 
forego what he refers to as “aggressive medical treatment.” “Medical procedures which no 
longer correspond to the real situation of the patient, either because they are by now 
disproportionate to any expected results or because they impose an excessive burden on the 
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patient and his family.56 If the intentionality is to forego a non-beneficial treatment that the 
surrogate believes is disproportionate and not in the embryo’s best interest, then the 
intentionality is to allow the person to die rather than not to terminate the person directly. 
These embryos will not be abandoned or discarded. Instead they will be cared for lovingly 
during the dying process and treated with the utmost dignity and respect. 
The benefit of a medical procedure or treatment was traditionally viewed as a prudential 
judgment of the patient or surrogate on how a particular treatment or procedure would 
impact on the life of the patient. Benefits and burdens were never judged abstractly. “Not 
only the means (proposed intervention) but the ends toward which the intervention is 
aimed are important in moral analysis.”57 The fact that a particular means was able to 
sustain a human life did not make such a means beneficial to the person. Traditional 
moralists did not restrict benefits merely to sustaining life, but included broader, more 
holistic considerations. Improvements in one’s condition, relief of pain and suffering, 
maximization of comfort, restoration of health, among others all were considered beneficial. 
For DeVitoria and other traditional moralists, the mere preservation of life and vital 
physiological functions was not sufficient in itself to oblige someone to use a certain means. 
The traditional understanding of ordinary-extraordinary means was based on treating the 
whole person, not one part of the person. Just because a treatment could prolong a life did 
not mean that a particular treatment was a benefit. Benefits must be considered worthwhile 
both in quality and duration. In the Catholic moral tradition, a medical treatment was 
beneficial if it restored a patient to a relative state of health. The frozen embryos will not be 
implanted into the womb of the biological mother. The options would be to stay frozen in a 
state of “permanent suspended animation,” be used for stem cell research, be used for other 
forms of experimentation, or be placed for donation/adoption. The Magisterium of the 
Catholic Church has rejected all of these options as ethically acceptable. To allow these 
embryos to stay frozen indefinitely violates the basic dignity and respect of the person. 
Therefore, the only viable option for these frozen embryos would be to stop the process of 
cryopreservation and allow them to die naturally with dignity and respect. One could 
equate the process of cryopreservation to maintain the life of the embryo to the use of a 
mechanical ventilator to maintain the life of a terminal patient. To continue to keep the 
embryos alive through cryopreservation is a form of extraordinary means that is 
disproportionate and offers no reasonable hope of benefit for the embryo. Failure to receive 
a meaningful benefit from a treatment makes said treatment not morally obligatory. 
Allowing a person to die by foregoing aggressive, non-beneficial treatments is not only 
morally permissible, it is also treating the person with dignity and respect. Therefore, it is 
morally and ethically acceptable to allow these embryos to die naturally with dignity and 
respect under the principle of the extraordinary and ordinary means distinction. However, it 
is also imperative that safeguards be put in place that would eliminate creating more 
“spare” embryos in the future.  
4. Conclusion & safeguards 
Cryopreserved embryos are a complex issue that has medical, legal and ethical dimensions. 
Allowing these embryos to die naturally is the only viable option that protects and preserves 
their human dignity. The other viable options: being discarded, destroyed for research, 
abandoned or kept in “suspended animation” indefinitely, are unacceptable because they have 
the potential of harming or intentionally killing these embryos that deserve special respect.  
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To make sure that this situation does not continue in the future, the following 
recommendations and safeguards are proposed: 
1. Only the number of eggs to be placed in the uterus of the mother will be fertilized. 
Embryos must not be subjected to an intentional interruption of their natural growth 
and development. There will no longer be “spare” embryos subjected to 
cryopreservation. Only cryopreservation of gametes would be acceptable. 
2. Laws and legislation must be enacted at the federal level that begins to regulate 
Assisted Reproductive Technologies. Having each state governed by differing sets of 
legislation could cause potential complications associated with the practice of 
donation/adoption. How each state defines jurisdiction and how each state interprets at 
what stage jurisdiction would begin (conception, transfer, or birth) could become highly 
complex. Specifically, guidelines and safeguards must be put in place that protects 
donors, parents, providers, and children born of ART. 
3. Laws and legislation must be enacted that regulates the creation, destruction and 
exploitation of human embryos. An example would be the following: legislation 
established in New Mexico stating that human embryos can only be disposed of 
through implantation, not intentional destruction or through destructive human 
embryo research. b) Embryos must not be subjected to non-therapeutic 
experimentation. 
If we believe that human life deserves dignity and respect, then our failure to allow these 
embryos to die naturally would be medically irresponsible and ethically objectionable, from 
the Catholic perspective. 
5. References 
 
[1] National Center for Health Statistics, “Infertility,” October 31, 2007.  
 http://www.cdc.gov/nchs/fastats/fertile.htm. 
[2] Center for Disease Control and Prevention, “Assisted Reproductive Technology,” June 
2008. Http://www.cdc.gov/ART/  
[3] Rand Law and Health/Society of Assisted Reproductive Technology (SART) Working 
Group, “How Many Frozen Human Embryos Are Available For Research?” May 
2003. http://www.rand.org/pubs/research_briefs/RB9038/index1.html.  
[4] Papanikolaou EG, Camus M, Kolibianakis EM, Van Landuyt L, Van Steirteghem A, 
Devroey P. "In Vitro Fertilization with Single Blastocyst-Stage versus Single 
Cleavage-Stage Embryos.”  New England Journal of Medicine 354 (March 16, 2006): 
1139-1146. 
[5] Lysaught, Therese. “Embryo Adoption?” Human Life Review (2003): 1-4.  
 http://findarticles.com/p/articles/mi_qa3798/is_200310/ai_n9297175/print. 
[6] Collins, Timothy. “On Abandoned Embryos,” The Linacre Quarterly 75 (1) (February 
2008): 1-15. 
[7] Congregation for the Doctrine of the Faith, Instruction Dignitas Personae on Certain 
Bioethical Questions, (September 8, 2008): 1-23, at Section 2, #18. 
[8] Pence, Gregory. Medical Ethics, 5th edition (Boston, MA.: McGraw Hill, 2008): 100. 
[9] Ryan, Caroline. “More Than 3 Million Babies Born From IVF,” BBC News (June 21, 2006): 
1-3. http://news.bbc.co.uk/1/hi/health/5101684.stm.  
 
 
Embryonic Stem Cells – Basic Biology to Bioengineering 
 
42
patient and his family.56 If the intentionality is to forego a non-beneficial treatment that the 
surrogate believes is disproportionate and not in the embryo’s best interest, then the 
intentionality is to allow the person to die rather than not to terminate the person directly. 
These embryos will not be abandoned or discarded. Instead they will be cared for lovingly 
during the dying process and treated with the utmost dignity and respect. 
The benefit of a medical procedure or treatment was traditionally viewed as a prudential 
judgment of the patient or surrogate on how a particular treatment or procedure would 
impact on the life of the patient. Benefits and burdens were never judged abstractly. “Not 
only the means (proposed intervention) but the ends toward which the intervention is 
aimed are important in moral analysis.”57 The fact that a particular means was able to 
sustain a human life did not make such a means beneficial to the person. Traditional 
moralists did not restrict benefits merely to sustaining life, but included broader, more 
holistic considerations. Improvements in one’s condition, relief of pain and suffering, 
maximization of comfort, restoration of health, among others all were considered beneficial. 
For DeVitoria and other traditional moralists, the mere preservation of life and vital 
physiological functions was not sufficient in itself to oblige someone to use a certain means. 
The traditional understanding of ordinary-extraordinary means was based on treating the 
whole person, not one part of the person. Just because a treatment could prolong a life did 
not mean that a particular treatment was a benefit. Benefits must be considered worthwhile 
both in quality and duration. In the Catholic moral tradition, a medical treatment was 
beneficial if it restored a patient to a relative state of health. The frozen embryos will not be 
implanted into the womb of the biological mother. The options would be to stay frozen in a 
state of “permanent suspended animation,” be used for stem cell research, be used for other 
forms of experimentation, or be placed for donation/adoption. The Magisterium of the 
Catholic Church has rejected all of these options as ethically acceptable. To allow these 
embryos to stay frozen indefinitely violates the basic dignity and respect of the person. 
Therefore, the only viable option for these frozen embryos would be to stop the process of 
cryopreservation and allow them to die naturally with dignity and respect. One could 
equate the process of cryopreservation to maintain the life of the embryo to the use of a 
mechanical ventilator to maintain the life of a terminal patient. To continue to keep the 
embryos alive through cryopreservation is a form of extraordinary means that is 
disproportionate and offers no reasonable hope of benefit for the embryo. Failure to receive 
a meaningful benefit from a treatment makes said treatment not morally obligatory. 
Allowing a person to die by foregoing aggressive, non-beneficial treatments is not only 
morally permissible, it is also treating the person with dignity and respect. Therefore, it is 
morally and ethically acceptable to allow these embryos to die naturally with dignity and 
respect under the principle of the extraordinary and ordinary means distinction. However, it 
is also imperative that safeguards be put in place that would eliminate creating more 
“spare” embryos in the future.  
4. Conclusion & safeguards 
Cryopreserved embryos are a complex issue that has medical, legal and ethical dimensions. 
Allowing these embryos to die naturally is the only viable option that protects and preserves 
their human dignity. The other viable options: being discarded, destroyed for research, 
abandoned or kept in “suspended animation” indefinitely, are unacceptable because they have 
the potential of harming or intentionally killing these embryos that deserve special respect.  
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To make sure that this situation does not continue in the future, the following 
recommendations and safeguards are proposed: 
1. Only the number of eggs to be placed in the uterus of the mother will be fertilized. 
Embryos must not be subjected to an intentional interruption of their natural growth 
and development. There will no longer be “spare” embryos subjected to 
cryopreservation. Only cryopreservation of gametes would be acceptable. 
2. Laws and legislation must be enacted at the federal level that begins to regulate 
Assisted Reproductive Technologies. Having each state governed by differing sets of 
legislation could cause potential complications associated with the practice of 
donation/adoption. How each state defines jurisdiction and how each state interprets at 
what stage jurisdiction would begin (conception, transfer, or birth) could become highly 
complex. Specifically, guidelines and safeguards must be put in place that protects 
donors, parents, providers, and children born of ART. 
3. Laws and legislation must be enacted that regulates the creation, destruction and 
exploitation of human embryos. An example would be the following: legislation 
established in New Mexico stating that human embryos can only be disposed of 
through implantation, not intentional destruction or through destructive human 
embryo research. b) Embryos must not be subjected to non-therapeutic 
experimentation. 
If we believe that human life deserves dignity and respect, then our failure to allow these 
embryos to die naturally would be medically irresponsible and ethically objectionable, from 
the Catholic perspective. 
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1. Introduction 
As the North American population demographic shifts towards an older profile, the 
demand for regenerative therapies will rise as more people face age-related degenerative 
diseases ranging from osteoarthritis to neurological disorders such as Parkinson’s disease. 
Current treatment options focus on palliative measures to alleviate symptoms rather than 
addressing the underlying cause. Tissue engineering has emerged as an interdisciplinary 
field of work that aims to restore function to the tissues identified as the underlying cause of 
illness. The most important building blocks used in tissue engineering are living cells. These 
cells are generally obtained from one of two sources — adult tissues or embryos. Adult 
tissues have very sparse and difficult-to-isolate stem cell populations. Further, their use for 
large scale treatment is not realistic due to their limited proliferation capabilities (Thomson 
& Odorico, 2000). Embryonic stem cells (ESCs), in contrast, are rapidly emerging as a 
promising cell source due to their unique characteristics — namely their ability to readily 
proliferate in culture as well as their potential to differentiate into all cell types of the adult 
body.  
A major roadblock that has been anticipated on the path to clinical implementation of ESC 
derived cellular therapies is the labour intensive and highly variable nature of small scale 
cultures. It has been estimated that as many as 26 billion human ESCs may be required as a 
starting point for treating one patient taking into account losses during culture, inefficient 
differentiation protocols, downstream processing and purification of mature cell types 
(Ouyang & Yang 2008). Based on current small scale culture techniques, thousands of static 
tissue culture flasks and several weeks to months of culture time would be required to 
generate this number of cells (Ouyang & Yang 2008). There are notable disadvantages in 
producing this quantity of cells in static tissue culture including heterogeneity between 
flasks, lack of environmental controls, large quantities of materials, large amounts of 
incubator space and the many hours of labour required to maintain the cultures. Several 
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automated bioprocessing systems exist which aim to reduce the amount of labour required 
to maintain static cultures, however these systems are still limited by surface area which is a 
key control on mass transfer of nutrients (Terstegge et al., 2007; Terstegge et al., 2009; 
Thomas et al., 2008). More effective methods are required to generate the large numbers of 
pluripotent ESCs needed for subsequent differentiation into functional tissue types. 
Suspension bioreactors offer a means to scale-up production of ESCs in a controlled culture 
environment not bound by the same surface area limitations as static culture techniques. 
The development of protocols for bioreactor expansion of stem cells has progressed rapidly 
in the past decade. Groups have successfully cultured hematopoietic stem cells, neural stem 
cells, human pancreatic progenitor cells and more recently both mouse and human 
embryonic stem cells in suspension (Zandstra et al., 1994; Kallos et al., 1999; Chawla et al., 
2006; Cormier et al., 2006; Krawetz et al., 2009; Kehoe et al., 2010). Despite the advances in 
bioreactor design, there is still a need for optimization and standardization of suspension 
culture protocols to ensure reproducible and predictable cell populations for use in clinical 
applications. In this chapter our aim is to review recent progress in the large scale culture of 
both murine and human ESCs as well as discuss fundamental bioprocess issues to be 
considered when using stirred suspension bioreactor culture systems. 
2. Mouse embryonic stem cells as a model 
The use of animal models in medical research goes back at least a century (Mouse Genome 
Sequencing Consortium, 2002). New therapies and drugs must be assessed for safety and 
efficacy; however, testing them on humans is not an ethical or realistic option. While single 
cells have proven to be invaluable resources for many studies, intact living animals have full 
organ systems which can undergo complex disease progression dynamics. Different animal 
models serve different purposes — larger animals models such as pigs and dogs allow for 
studies complex systems (i.e. joint loading) whereas smaller ones such as mice are useful for 
studies of genetics and progression of degenerative diseases. Mice have been shown to have 
similar genetics and physiological structures to humans. They naturally develop several 
diseases (cancer and diabetes for example) typically attributed to humans and can also be 
induced to present symptoms of neurological disorders such as Alzheimer’s (see Bedell et 
al., 1997 for a review of mice models for many human diseases). Animal models such as 
mice provide an excellent means for evaluating cell therapies: it is cost effective and 
provides fast results (the murine gestational period is a matter of weeks which allows for 
quick assessment of germline transmission which is paramount in murine ESC derivation 
evaluation). 
Knowledge gained from isolation of mouse ESCs has laid a solid foundation for isolation of 
ESCs from other animals including non-human primates and ultimately humans (Bongso et 
al., 1994; Thomson et al., 1995; Thomson et al., 1998; Reubinoff et al., 2000).  Within our own 
laboratory, work with mouse cell lines has established foundation protocols for human 
studies although the methods have not been directly transferable.  Specifically, successful 
expansion of murine neural stem cells as aggregates in suspension bioreactors (Kallos & 
Behie 1999; Gilbertson et al., 2006) enabled us to develop protocols for human neural stem 
cells (Baghbaderani et al., 2010).  Similarly, expanding murine ESCs as aggregates (Cormier 
et al., 2006; zur Nieden et al., 2007) allowed us to successfully expand pluripotent human 
ESCs as aggregates in suspension bioreactors (Krawetz et al., 2010). The fact that protocols 
are not directly transferrable is expected since cells from different species have been 
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observed to present different growth morphologies, growth kinetics (doubling times, for 
example), as well as different markers for cell pluripotency and differences in associated 
signaling pathways (illustrated in Table 1).  However, from a bioengineering point of view, 
there is still tremendous value in conducting murine experiments first.   
 
 Murine ESCs Human ESCs 
Pluripotency markers   
SSEA-1 + - 
SSEA-3 - + 
SSEA-4 - + 
TRA-1-60 - + 
TRA-1-81 - + 
Oct-4 + + 
Factors that affect 
self renewal 
LIF + Serum—activates 
JAK/STAT3 pathway 1 
 
LIF+BMP (serum free) – 
activates SMAD and/or 
MAPK pathways 1 
bFGF+MEF+SR or high bFGF+SR (no 
MEFs)- suppresses BMP signalling and/or 
upregulates expression of TGF ligands, 




in vivo + + 
Colony morphology Tight rounded multilayered Lose rounded monolayers 
Passaging Single cells Clumps 
Table 1. Summary of culture similarities and differences between mouse and human 
embryonic stem cells. Adapted from National Institutes of Health, 2009; 1 Yu & Thomson, 
2008. bFGF= basic fibroblast growth factor, BMP= bone morphogenetic protein, LIF= 
leukemia inhibitory factor, MEF= mouse embryonic fibroblasts, SR= serum replacement, 
TGF= transforming growth factor beta.  
3. Bioprocess development for suspension culture of ESCs 
Many types of cell culture systems can produce cells and tissues in culture but they can 
generally be grouped into two categories:  1. adherent culture (tissue culture flasks) and 2. 
non-adherent culture. Both cultures can further be classified as stationary (or static), where 
the culture media is not moving, or suspension, where the medium is agitated or perfused 
(Sen et al., 2010).   Conventional culture methods for propagation of ESCs use static tissue 
culture flasks (stationary adherent culture).  As this is the current standard method for ESC 
culture, it is necessary to understand the effect of static culture environment on ESCs before 
successful development of suspension culture protocols. Static culture also provides a 
baseline for comparison of cell production from suspension culture. 
3.1 Adherent culture 
In 1981, Evans and Kaufman reported that isolation and culture of pluripotent cells were 
dependent on: 1) the stage at which pluripotent cells exist in the embryo (in other words, 
day at which cells are harvested from the blastocyst), 2) explantation of sufficiently large 
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automated bioprocessing systems exist which aim to reduce the amount of labour required 
to maintain static cultures, however these systems are still limited by surface area which is a 
key control on mass transfer of nutrients (Terstegge et al., 2007; Terstegge et al., 2009; 
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models serve different purposes — larger animals models such as pigs and dogs allow for 
studies complex systems (i.e. joint loading) whereas smaller ones such as mice are useful for 
studies of genetics and progression of degenerative diseases. Mice have been shown to have 
similar genetics and physiological structures to humans. They naturally develop several 
diseases (cancer and diabetes for example) typically attributed to humans and can also be 
induced to present symptoms of neurological disorders such as Alzheimer’s (see Bedell et 
al., 1997 for a review of mice models for many human diseases). Animal models such as 
mice provide an excellent means for evaluating cell therapies: it is cost effective and 
provides fast results (the murine gestational period is a matter of weeks which allows for 
quick assessment of germline transmission which is paramount in murine ESC derivation 
evaluation). 
Knowledge gained from isolation of mouse ESCs has laid a solid foundation for isolation of 
ESCs from other animals including non-human primates and ultimately humans (Bongso et 
al., 1994; Thomson et al., 1995; Thomson et al., 1998; Reubinoff et al., 2000).  Within our own 
laboratory, work with mouse cell lines has established foundation protocols for human 
studies although the methods have not been directly transferable.  Specifically, successful 
expansion of murine neural stem cells as aggregates in suspension bioreactors (Kallos & 
Behie 1999; Gilbertson et al., 2006) enabled us to develop protocols for human neural stem 
cells (Baghbaderani et al., 2010).  Similarly, expanding murine ESCs as aggregates (Cormier 
et al., 2006; zur Nieden et al., 2007) allowed us to successfully expand pluripotent human 
ESCs as aggregates in suspension bioreactors (Krawetz et al., 2010). The fact that protocols 
are not directly transferrable is expected since cells from different species have been 
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observed to present different growth morphologies, growth kinetics (doubling times, for 
example), as well as different markers for cell pluripotency and differences in associated 
signaling pathways (illustrated in Table 1).  However, from a bioengineering point of view, 
there is still tremendous value in conducting murine experiments first.   
 
 Murine ESCs Human ESCs 
Pluripotency markers   
SSEA-1 + - 
SSEA-3 - + 
SSEA-4 - + 
TRA-1-60 - + 
TRA-1-81 - + 
Oct-4 + + 
Factors that affect 
self renewal 
LIF + Serum—activates 
JAK/STAT3 pathway 1 
 
LIF+BMP (serum free) – 
activates SMAD and/or 
MAPK pathways 1 
bFGF+MEF+SR or high bFGF+SR (no 
MEFs)- suppresses BMP signalling and/or 
upregulates expression of TGF ligands, 




in vivo + + 
Colony morphology Tight rounded multilayered Lose rounded monolayers 
Passaging Single cells Clumps 
Table 1. Summary of culture similarities and differences between mouse and human 
embryonic stem cells. Adapted from National Institutes of Health, 2009; 1 Yu & Thomson, 
2008. bFGF= basic fibroblast growth factor, BMP= bone morphogenetic protein, LIF= 
leukemia inhibitory factor, MEF= mouse embryonic fibroblasts, SR= serum replacement, 
TGF= transforming growth factor beta.  
3. Bioprocess development for suspension culture of ESCs 
Many types of cell culture systems can produce cells and tissues in culture but they can 
generally be grouped into two categories:  1. adherent culture (tissue culture flasks) and 2. 
non-adherent culture. Both cultures can further be classified as stationary (or static), where 
the culture media is not moving, or suspension, where the medium is agitated or perfused 
(Sen et al., 2010).   Conventional culture methods for propagation of ESCs use static tissue 
culture flasks (stationary adherent culture).  As this is the current standard method for ESC 
culture, it is necessary to understand the effect of static culture environment on ESCs before 
successful development of suspension culture protocols. Static culture also provides a 
baseline for comparison of cell production from suspension culture. 
3.1 Adherent culture 
In 1981, Evans and Kaufman reported that isolation and culture of pluripotent cells were 
dependent on: 1) the stage at which pluripotent cells exist in the embryo (in other words, 
day at which cells are harvested from the blastocyst), 2) explantation of sufficiently large 
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numbers of these cells from the embryo and 3) tissue culture conditions conducive to 
propagation (multiplication) of the cells rather than differentiation. These considerations 
have been the basis for isolation of mammalian ESC lines. Currently, however, the focus of 
many groups is on the third point: trying to determine the optimum combination of factors 
to support long term expansion of these cells while maintaining functionality (pluripotency 
and self-renewal). Based on their knowledge of embryonic carcinoma cells, which are 
pluripotent cells isolated from germ cell tumors, Evans and Kaufman isolated the inner cell 
mass of a mouse blastocyst and cultured the cells on a feeder layer of mitotically inactivated 
mouse embryonic fibroblasts (MEFs) in 20% serum containing medium. The resulting cells 
exhibited a normal karyotype in contrast to embryonic carcinoma cells, which did not, and 
thus the first line of mouse ESCs was derived. This reliance on a feeder layer initially 
restricted ESC research to static adherent culture conditions. Some years later it was found 
that conditioned medium was able to support the growth of murine ESCs in the absence of a 
feeder layer (Yu & Thomson, 2008). Subsequent fractionation of conditioned medium led to 
identification of leukemia inhibitory factor (LIF) as one of the key ingredients that 
supported viability (Williams et al., 1988; Smith et al., 1988 as cited in Yu & Thomson 2008). 
Standard lab scale cultures today use gelatin as a substrate for mouse ESC adherence 
together with DMEM-based medium supplemented with LIF. This combination has 
repeatedly demonstrated long term propagation of stable pluripotent cells. Table 2 
summarizes static culture conditions described in recent publications.   
Based on previous methods of ESC derivation, Bongso et al. (1994) isolated the inner cell 
mass of a human blastocyst on a feeder layer of human oviductal epithelial cells in a 
medium containing human LIF and 10% human serum. While initial colonies had promising 
morphologies, the cells either differentiated or died after only two passages. This is an 
example of difficulties encountered in transferring protocols directly between species. 
Shortly after, another group successfully derived a non-human primate ESC line (Thomson 
et al., 1995). The cells isolated from a rhesus monkey embryo were cultured on irradiated 
mouse embryonic fibroblasts in DMEM based medium supplemented with human LIF and 
20% fetal bovine serum (FBS). Although human LIF was used in the initial derivation of 
these cells, it was subsequently removed and the cells were successfully cultured for over a 
year while maintaining a stable karyotype and the ability to differentiate into all three germ 
layers. Conversely, when human LIF was used and MEFs removed, the cells differentiated 
(Thomson et al., 1995).  Based on this success, Thomson then used a similar protocol to 
derive the first human ESC lines using irradiated MEFs and DMEM medium with 10% FBS 
(Thomson et al., 1998). Subsequent work has led to the refinement of medium and 
identification of optimum substrates with many groups now reporting the use of DMEM 
with serum replacement medium or the commercially available defined medium, mTeSR™ 
with matrigel™ (an ECM extract of mouse sarcoma) as the substrate. These culture protocols 
have proven to give rise to stable pluripotent cell populations (Xu et al., 2005; Ludwig et al., 
2006; Levenstein et al., 2006). Table 3 provides a brief summary of static culture conditions 
reported in recent publications of human ESCs. It is apparent that these small scale adherent 
culture conditions are well suited to most laboratory research. However, if we look to the 
future of stem cell based therapies in clinical settings, these small scale culture techniques 
are simply not feasible on a large scale. 
Ouyang & Yang (2008) provided a useful summary of cell numbers estimated to be required 
for different clinical applications. For treatment of an adult with leukemia, they calculated 
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CM (for LIF)- changed every 2 
days 
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Jing 2010 E14Tg2a 0.1% Gelatin DMEM+10%FBS 
 
TrypLE 
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GMEM+15%FBS Not specified 
 
 
Table 2. Summary of recent publications with static maintenance of murine ESCs. DMEM= 
Dulbecco’s Modified Eagle’s Medium, GMEM= Glasgow’s Minimal Essential Medium, KO-
DMEM= KnockOutTM DMEM (Inivitrogen), KSR= KnockOutTM Serum Replacement 
(Invitrogen), ESGRO Complete= defined serum-free medium (Chemicon/Millipore)- 
contains LIF, CHO-CM= Chinese Hamster Ovary Conditioned Medium. Unless otherwise 
stated, culture medium also included LIF, 2-mercaptoethanol and non-essential amino acids. 
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numbers of these cells from the embryo and 3) tissue culture conditions conducive to 
propagation (multiplication) of the cells rather than differentiation. These considerations 
have been the basis for isolation of mammalian ESC lines. Currently, however, the focus of 
many groups is on the third point: trying to determine the optimum combination of factors 
to support long term expansion of these cells while maintaining functionality (pluripotency 
and self-renewal). Based on their knowledge of embryonic carcinoma cells, which are 
pluripotent cells isolated from germ cell tumors, Evans and Kaufman isolated the inner cell 
mass of a mouse blastocyst and cultured the cells on a feeder layer of mitotically inactivated 
mouse embryonic fibroblasts (MEFs) in 20% serum containing medium. The resulting cells 
exhibited a normal karyotype in contrast to embryonic carcinoma cells, which did not, and 
thus the first line of mouse ESCs was derived. This reliance on a feeder layer initially 
restricted ESC research to static adherent culture conditions. Some years later it was found 
that conditioned medium was able to support the growth of murine ESCs in the absence of a 
feeder layer (Yu & Thomson, 2008). Subsequent fractionation of conditioned medium led to 
identification of leukemia inhibitory factor (LIF) as one of the key ingredients that 
supported viability (Williams et al., 1988; Smith et al., 1988 as cited in Yu & Thomson 2008). 
Standard lab scale cultures today use gelatin as a substrate for mouse ESC adherence 
together with DMEM-based medium supplemented with LIF. This combination has 
repeatedly demonstrated long term propagation of stable pluripotent cells. Table 2 
summarizes static culture conditions described in recent publications.   
Based on previous methods of ESC derivation, Bongso et al. (1994) isolated the inner cell 
mass of a human blastocyst on a feeder layer of human oviductal epithelial cells in a 
medium containing human LIF and 10% human serum. While initial colonies had promising 
morphologies, the cells either differentiated or died after only two passages. This is an 
example of difficulties encountered in transferring protocols directly between species. 
Shortly after, another group successfully derived a non-human primate ESC line (Thomson 
et al., 1995). The cells isolated from a rhesus monkey embryo were cultured on irradiated 
mouse embryonic fibroblasts in DMEM based medium supplemented with human LIF and 
20% fetal bovine serum (FBS). Although human LIF was used in the initial derivation of 
these cells, it was subsequently removed and the cells were successfully cultured for over a 
year while maintaining a stable karyotype and the ability to differentiate into all three germ 
layers. Conversely, when human LIF was used and MEFs removed, the cells differentiated 
(Thomson et al., 1995).  Based on this success, Thomson then used a similar protocol to 
derive the first human ESC lines using irradiated MEFs and DMEM medium with 10% FBS 
(Thomson et al., 1998). Subsequent work has led to the refinement of medium and 
identification of optimum substrates with many groups now reporting the use of DMEM 
with serum replacement medium or the commercially available defined medium, mTeSR™ 
with matrigel™ (an ECM extract of mouse sarcoma) as the substrate. These culture protocols 
have proven to give rise to stable pluripotent cell populations (Xu et al., 2005; Ludwig et al., 
2006; Levenstein et al., 2006). Table 3 provides a brief summary of static culture conditions 
reported in recent publications of human ESCs. It is apparent that these small scale adherent 
culture conditions are well suited to most laboratory research. However, if we look to the 
future of stem cell based therapies in clinical settings, these small scale culture techniques 
are simply not feasible on a large scale. 
Ouyang & Yang (2008) provided a useful summary of cell numbers estimated to be required 
for different clinical applications. For treatment of an adult with leukemia, they calculated 
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Reference Cell Lines Substrate Medium Passaging 





Bauwens 2008 H9,  
H2B 






















H9 MEFs DMEM/F12+20%KSR+bFGF TrypLE 
Gibson 2009 H9 MEFs DMEM/F12+20%KSR+bFGF Collagenase 
Hentze 2009 HES2, HES3, 
HES4, 
ESI-014, 017, 
035, 049, 051, 
053 
HFFs KO-DMEM+20%KSR+bFGF Collagenase, 
TrypLE 
Lee 2009 H9, I6, HES2 MEFs KO-DMEM+20%KSR+bFGF Not specified 





Montes 2009 HSI81, 
SHEF1 
Matrigel MSC-CM + bFGF  
HFF-CM +bFGF 
Collagenase 
Nie 2009 H1, H9 MEFs 
Matrigel 
DMEM/F12+20%KSR+bFGF 
MEF-CM + bFGF 
Collagenase 
Oh 2009 HES2, HES3 Matrigel MEF-CM + bFGF Collagenase 
Amit 2010 I3, I4, I6, 
H9.2 
MEF DMEM/F12+15%KSR+bFGF Collagenase 
Chen 2010 HES2, HES3 Matrigel mTeSR, MEF-CM, StemPRO TrypLE 
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Reference Cell Lines Substrate Medium Passaging 
Singh 2010 HES2, HES3, 
ES1049 
HFF KO-DMEM+20%KSR+bFGF TrypLE 








Leung 2011 HES2, HES3 Matrigel MEF-CM+bFGF Enzymatic 
Table 3. Summary of recent publications with static maintenance of human ESCs. bFGF = 
basic fibroblast growth factor, TGFb1= transforming growth factor beta 1, XVIVO10= serum 
free medium (Lonza), HFF-CM= human foreskin fibroblast conditioned medium, MEF-CM= 
mouse embryonic fibroblast conditioned medium, mTeSR= serum-free defined medium 
(STEMCELL Technologies), StemPRO= serum-free defined medium (Invitrogen). 
that 2.1x1010 cells would be required per treatment. If one T-75 culture flask supports the 
production of 2x106 cells in 2-3 days, production of 2.1x1010 cells would require over 10,000 
tissue culture flasks and up to 5 weeks of culture time (Ouyang & Yang, 2008).  They also  
determined flask count and time estimates for Parkinson`s disease and diabetes. In both 
cases similarly large numbers of tissue culture flasks were calculated. The handling of this 
number of tissue culture flasks would be extremely labor-intensive.  Additionally, this type 
of culture lacks continuous monitoring and environmental controls that may result in 
spontaneous stem cell differentiation. Alternatively, suspension bioreactors provide a 
controlled environment to produce the same number of cells. Studies from our lab have 
produced densities of mouse ESCs in suspension of approximately 1-2x106 cells/mL (Alfred 
et al., 2010; Cormier et al., 2006). As such, production of clinical numbers would require 
suspension volumes of the order of liters. 
3.2 Suspension bioreactor culture 
There have been arguments that not enough is known about ESCs to take them out of 
adherent cultures and culture them in suspension conditions as reduced adhesion in 
anchorage dependent cells has been associated with disorganized growth patterns and 
changes in cell-to-cell contact (Freshney, 2000). However, the final test of success for any 
new culture format is the functionality of the cells. Refinement of suspension culture 
protocols to ensure stable karyotypes, continued expression of pluripotency markers as well 
as demonstration of pluripotency through embryoid body and/or teratoma formation is the 
goal of embryonic stem cell bioprocess development.  
It is clear upon review of recent publications that culture conditions vary a great deal 
between mouse and human ESCs as illustrated in Tables 4 and 5, respectively. Mouse ESCs 
were able to readily form aggregates in suspension whereas human ESCs required the 
addition of ROCK inhibitor to survive non-adherent conditions and form aggregates. As for 
differences within each cell type, it is clear that there is greater variation between different 
human ESC protocols than between different mouse ESC protocols. As murine ESCs were 
established years before human ESCs, culture medium and passaging techniques are far 
more standardized and suspension protocols appear to be fairly similar between 
publications. 
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free medium (Lonza), HFF-CM= human foreskin fibroblast conditioned medium, MEF-CM= 
mouse embryonic fibroblast conditioned medium, mTeSR= serum-free defined medium 
(STEMCELL Technologies), StemPRO= serum-free defined medium (Invitrogen). 
that 2.1x1010 cells would be required per treatment. If one T-75 culture flask supports the 
production of 2x106 cells in 2-3 days, production of 2.1x1010 cells would require over 10,000 
tissue culture flasks and up to 5 weeks of culture time (Ouyang & Yang, 2008).  They also  
determined flask count and time estimates for Parkinson`s disease and diabetes. In both 
cases similarly large numbers of tissue culture flasks were calculated. The handling of this 
number of tissue culture flasks would be extremely labor-intensive.  Additionally, this type 
of culture lacks continuous monitoring and environmental controls that may result in 
spontaneous stem cell differentiation. Alternatively, suspension bioreactors provide a 
controlled environment to produce the same number of cells. Studies from our lab have 
produced densities of mouse ESCs in suspension of approximately 1-2x106 cells/mL (Alfred 
et al., 2010; Cormier et al., 2006). As such, production of clinical numbers would require 
suspension volumes of the order of liters. 
3.2 Suspension bioreactor culture 
There have been arguments that not enough is known about ESCs to take them out of 
adherent cultures and culture them in suspension conditions as reduced adhesion in 
anchorage dependent cells has been associated with disorganized growth patterns and 
changes in cell-to-cell contact (Freshney, 2000). However, the final test of success for any 
new culture format is the functionality of the cells. Refinement of suspension culture 
protocols to ensure stable karyotypes, continued expression of pluripotency markers as well 
as demonstration of pluripotency through embryoid body and/or teratoma formation is the 
goal of embryonic stem cell bioprocess development.  
It is clear upon review of recent publications that culture conditions vary a great deal 
between mouse and human ESCs as illustrated in Tables 4 and 5, respectively. Mouse ESCs 
were able to readily form aggregates in suspension whereas human ESCs required the 
addition of ROCK inhibitor to survive non-adherent conditions and form aggregates. As for 
differences within each cell type, it is clear that there is greater variation between different 
human ESC protocols than between different mouse ESC protocols. As murine ESCs were 
established years before human ESCs, culture medium and passaging techniques are far 
more standardized and suspension protocols appear to be fairly similar between 
publications. 
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While these studies illustrate that it is possible to culture human ESCs in suspension (i.e. 
proof of concept), work must be done with respect to optimization and standardization of 
protocols. An understanding of key culture variables is necessary to achieve this. 
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Density 
(cells/mL) 
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(100 mL) 
100 
Table 4. Summary of suspension culture conditions for undifferentiated murine ESCs as 
aggregates. Unless otherwise stated, culture medium also included LIF, 2-mercaptoethanol 
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Table 5. Summary of suspension culture conditions for human ESCs as aggregates. ROCK = 
p160-Rho-associated coiled kinase inhibitor (Y-27632) (Watanabe et al., 2007). 
3.2.1 Suspension bioreactor design considerations 
Traditional reactor types that may be used in biological processes include batch reactors, 
continuous stirred tank reactors, and plug flow reactors. Bioreactors support and control 
living biological entities and therefore require process control and stringent steps to 
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eliminate contamination (Williams, 2002). Mammalian cells are far more sensitive to culture 
conditions and far less stable with respect to maintenance of cell functionality than many 
other cell types such as yeast, bacteria and fungi. Additionally, shear is normally not a 
concern for these cell types whereas ESCs are far more sensitive to their environment. 
Human ESCs for example will spontaneously transform, differentiate or undergo apoptosis 
as a reaction to small changes in culture conditions (Chu & Robinson, 2001). This becomes a 
challenge as mixing is an integral consideration in reactor design for nutrient and oxygen 
mass transfer and the requirement of achieving target shear places an additional constraint 
on agitation speed (Schmidt, 2005). The aim of bioreactor design is to minimize the cost of 
production while retaining the desired quality of the product all within biological, fluid 
mechanical, and mass transfer constraints (van’t Riet & Temper, 1991). With stem cells, the 
objective is to robustly produce large quantities of viable undifferentiated cells for further 
differentiation and purification steps. Downstream processing will be the cost determining 
step and therefore the goal is maximization of product concentration obtained from the 
bioreactors (van’t Riet & Temper, 1991). To accomplish this, some key design areas must be 
considered including: materials (bioreactor walls and agitators), medium (chemical 
composition, pH, temperature), rheological conditions (fluid dynamics and mass transfer 
systems), and residence time of cells within the bioreactor. Issues such as temperature, pH, 
and medium formulation are fairly well defined for human ESC culture (King & Millar, 
2007). Areas that are less understood with respect to suspension culture are those of the 
physical and geometric properties of the bioreactor itself. Parameters falling within this area 
are broad ranging from rheology and hydrodynamics, to mixing and agitator design, to heat 
and mass transfer, to issues of scale up and process control. Throughout the work within 
our lab group we have observed that culture parameters with the largest impact on cell 
populations are agitation rate, inoculation density and oxygen transfer. 
3.2.2 Agitation speed 
The rate of agitation within a stirred suspension bioreactor is an important consideration as 
it affects not only the mixing of oxygen and nutrients within the medium, but it also 
maintains cell aggregate sizes and keeps cells in suspension. However, development of 
effective bioprocesses for suspension culture requires an understanding of the nature of the 
biomass within the reactor. Embryonic stem cells along with many other mammalian cell 
types have been observed as being extremely sensitive to shear (Garcia-Cardena & Adamo, 
2011; Toh & Voldman, 2011). While the medium must be agitated at a speed sufficient to 
ensure nutrient mixing, this speed must also be kept within limits so as not to exert undue 
shear on the sensitive biomass. We therefore need to understand the forces caused by 
agitation, how these forces act on cells, how we can quantify these forces, and the 
relationship between the forces and cell viability. There have been a very few reports on the 
effect of shear in stirred bioreactors on murine ESC growth. Cormier et al., (2006) found that 
aggregate diameter correlated with agitation rate but did not quantify the correlation.  To 
date there have not been any comprehensive investigations into shear effects on growth 
kinetics in human ESC suspension cultures.  
3.2.3 Inoculation density 
Inoculation density is an important parameter that tends to be taken for granted in many 
studies. In our lab, we have seen that when inoculating suspension spinners, too few cells 
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will fail to initiate agglomeration and therefore aggregates do not form and cells die due to 
lack of cell-to-cell interaction. Too many cells may form massive aggregates that create 
issues with oxygen transfer to cells at the aggregate centre (necrosis). Additionally, rapid 
depletion of nutrients in the medium and subsequent rapid build-up of waste materials can 
adversely affect growth and expansion of the cell population (Sen et al., 2010).  
In general, inoculating at the lowest possible cell density allows for maximum cell number 
amplification, however many have observed that this also causes a longer lag phase which 
results in an extended culture period required to reach maximum cell density. Extremely 
low and high initial densities have been observed to affect the exponential growth 
phase with a reduction in specific growth rates (Cormier et al., 2006; Fernandes, TG et al., 
2009).  
A review of literature fails to turn up a great deal of further information on inoculation 
densities with respect to ESC culture. With human ESCs the passaging techniques used 
(passaged as clumps until recently) prevented quantification of cells.  
3.2.4 Nutrient and oxygen uptake 
Oxygen is essential for cell proliferation and viability. In smaller vessels, surface aeration as 
the main mode of oxygen supply is typically sufficient and commonly used due to its 
simplicity. However, as culture volumes increase and cell densities increase, the surface area 
to volume ratios decrease and surface aeration may no longer be sufficient to ensure oxygen 
transport to the cells (Gilbertson et al., 2006; Baghbaderani et al., 2008). Options to increase 
oxygen transport include increasing agitation rate of the impeller, sparging, or medium 
additives such as Perfluorocarbons (PFCs) which increase oxygen solubility within the 
liquid medium. To determine which method is best, the oxygen requirements of the system 
must be determined. 
Starting with the basic mass conservation equation for a specific component within a control 
volume (in this case the oxygen within the liquid cell culture medium), we have: 
 Input + Generation = Output + Accumulation (1) 
The input of oxygen into the medium, also known as the oxygen transfer rate (OTR), by 
using surface aeration only (no sparging) is controlled by the concentration difference 
between the headspace of the vessel and bulk medium oxygen concentration. Since no 
oxygen is released from the system, the output term is zero. The accumulation term refers to 
the rate of change in oxygen concentration within the medium while the generation term 
actually refers to the oxygen uptake rate (OUR) of the cells which is negative to indicate the 
cells are consuming oxygen rather than producing it. With this in mind, the material balance 
becomes:   
 OTR – OUR = 0 + dCO2/dt (2) 
where OTR and OUR are as follows: 
 OTR = kLa CO2 (3) 
 OUR = qO2X (4) 
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eliminate contamination (Williams, 2002). Mammalian cells are far more sensitive to culture 
conditions and far less stable with respect to maintenance of cell functionality than many 
other cell types such as yeast, bacteria and fungi. Additionally, shear is normally not a 
concern for these cell types whereas ESCs are far more sensitive to their environment. 
Human ESCs for example will spontaneously transform, differentiate or undergo apoptosis 
as a reaction to small changes in culture conditions (Chu & Robinson, 2001). This becomes a 
challenge as mixing is an integral consideration in reactor design for nutrient and oxygen 
mass transfer and the requirement of achieving target shear places an additional constraint 
on agitation speed (Schmidt, 2005). The aim of bioreactor design is to minimize the cost of 
production while retaining the desired quality of the product all within biological, fluid 
mechanical, and mass transfer constraints (van’t Riet & Temper, 1991). With stem cells, the 
objective is to robustly produce large quantities of viable undifferentiated cells for further 
differentiation and purification steps. Downstream processing will be the cost determining 
step and therefore the goal is maximization of product concentration obtained from the 
bioreactors (van’t Riet & Temper, 1991). To accomplish this, some key design areas must be 
considered including: materials (bioreactor walls and agitators), medium (chemical 
composition, pH, temperature), rheological conditions (fluid dynamics and mass transfer 
systems), and residence time of cells within the bioreactor. Issues such as temperature, pH, 
and medium formulation are fairly well defined for human ESC culture (King & Millar, 
2007). Areas that are less understood with respect to suspension culture are those of the 
physical and geometric properties of the bioreactor itself. Parameters falling within this area 
are broad ranging from rheology and hydrodynamics, to mixing and agitator design, to heat 
and mass transfer, to issues of scale up and process control. Throughout the work within 
our lab group we have observed that culture parameters with the largest impact on cell 
populations are agitation rate, inoculation density and oxygen transfer. 
3.2.2 Agitation speed 
The rate of agitation within a stirred suspension bioreactor is an important consideration as 
it affects not only the mixing of oxygen and nutrients within the medium, but it also 
maintains cell aggregate sizes and keeps cells in suspension. However, development of 
effective bioprocesses for suspension culture requires an understanding of the nature of the 
biomass within the reactor. Embryonic stem cells along with many other mammalian cell 
types have been observed as being extremely sensitive to shear (Garcia-Cardena & Adamo, 
2011; Toh & Voldman, 2011). While the medium must be agitated at a speed sufficient to 
ensure nutrient mixing, this speed must also be kept within limits so as not to exert undue 
shear on the sensitive biomass. We therefore need to understand the forces caused by 
agitation, how these forces act on cells, how we can quantify these forces, and the 
relationship between the forces and cell viability. There have been a very few reports on the 
effect of shear in stirred bioreactors on murine ESC growth. Cormier et al., (2006) found that 
aggregate diameter correlated with agitation rate but did not quantify the correlation.  To 
date there have not been any comprehensive investigations into shear effects on growth 
kinetics in human ESC suspension cultures.  
3.2.3 Inoculation density 
Inoculation density is an important parameter that tends to be taken for granted in many 
studies. In our lab, we have seen that when inoculating suspension spinners, too few cells 
 
Bioprocess Development for the Expansion of Embryonic Stem Cells 59 
will fail to initiate agglomeration and therefore aggregates do not form and cells die due to 
lack of cell-to-cell interaction. Too many cells may form massive aggregates that create 
issues with oxygen transfer to cells at the aggregate centre (necrosis). Additionally, rapid 
depletion of nutrients in the medium and subsequent rapid build-up of waste materials can 
adversely affect growth and expansion of the cell population (Sen et al., 2010).  
In general, inoculating at the lowest possible cell density allows for maximum cell number 
amplification, however many have observed that this also causes a longer lag phase which 
results in an extended culture period required to reach maximum cell density. Extremely 
low and high initial densities have been observed to affect the exponential growth 
phase with a reduction in specific growth rates (Cormier et al., 2006; Fernandes, TG et al., 
2009).  
A review of literature fails to turn up a great deal of further information on inoculation 
densities with respect to ESC culture. With human ESCs the passaging techniques used 
(passaged as clumps until recently) prevented quantification of cells.  
3.2.4 Nutrient and oxygen uptake 
Oxygen is essential for cell proliferation and viability. In smaller vessels, surface aeration as 
the main mode of oxygen supply is typically sufficient and commonly used due to its 
simplicity. However, as culture volumes increase and cell densities increase, the surface area 
to volume ratios decrease and surface aeration may no longer be sufficient to ensure oxygen 
transport to the cells (Gilbertson et al., 2006; Baghbaderani et al., 2008). Options to increase 
oxygen transport include increasing agitation rate of the impeller, sparging, or medium 
additives such as Perfluorocarbons (PFCs) which increase oxygen solubility within the 
liquid medium. To determine which method is best, the oxygen requirements of the system 
must be determined. 
Starting with the basic mass conservation equation for a specific component within a control 
volume (in this case the oxygen within the liquid cell culture medium), we have: 
 Input + Generation = Output + Accumulation (1) 
The input of oxygen into the medium, also known as the oxygen transfer rate (OTR), by 
using surface aeration only (no sparging) is controlled by the concentration difference 
between the headspace of the vessel and bulk medium oxygen concentration. Since no 
oxygen is released from the system, the output term is zero. The accumulation term refers to 
the rate of change in oxygen concentration within the medium while the generation term 
actually refers to the oxygen uptake rate (OUR) of the cells which is negative to indicate the 
cells are consuming oxygen rather than producing it. With this in mind, the material balance 
becomes:   
 OTR – OUR = 0 + dCO2/dt (2) 
where OTR and OUR are as follows: 
 OTR = kLa CO2 (3) 
 OUR = qO2X (4) 
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where kLa is the volumetric mass transfer coefficient, CO2 is the difference in oxygen 
concentration between oxygen saturation concentration in the bulk medium (CO2* which 
may be determined via Henry’s law for an assumed partial pressure of 20% O2 in normal 
incubator air with 5% CO2) and the measured bulk medium concentration (CO2). The term 
qO2 is the specific oxygen uptake rate of the cells and X is the cell density within the medium 
(Garcia-Ochoa & Gomez., 2009).  
Rearranging Equation 2 yields an expression for the rate of change in oxygen concentration 
within the bulk medium: 
 dCO2/dt = kLa CO2 – qO2X (5) 
As can be seen from the preceding equations, the kLa value is the unknown when 
determining the rate of oxygen transfer. There have been numerous methods described for 
the determination of the mass transfer coefficient depending on the nature of the system: 
factors such as aeration, vessel design, medium composition and the effect of the presence of 
a microorganism must all be taken into account.  
Throughout the literature there have been many attempts to develop empirical relationships 
for the determination of kLa. These relationships are sometimes based on both dimensional 
and dimensionless values. Garcia-Ochoa & Gomez (2009) have presented a very 
comprehensive summary of a number of published correlations for the determination of kLa 
in stirred suspension bioreactors. Upon review, it is apparent there is considerable variation 
between the correlations presented. For example, in 1979, Van’t Riet & Temper proposed a 
correlation based on the power input per unit volume (P/V) but stated there was no 
influence of the impeller geometry and placement within the bioreactor. Subsequent studies 
contradicted this statement by showing that changing the impeller geometry alone caused 
an increase in mass transfer rate and a change in impeller placement also had an effect (See 
Garcia-Ochoa & Gomez, 2009 for a full review). To date there still does not appear to be a 
firm consensus as to which correlation is best suited for the determination of kLa in a stirred 
vessel.  
The wide range of empirical relationships developed may in part be due to the similarly 
wide range of protocols for the experimental determination of kLa. For culturing stem cells, 
the presence of the cells themselves is assumed to have a large impact on mass transfer in 
the system. As such, the biomass present within the system is the main consideration when 
determining kLa values experimentally. There have been thorough reviews elsewhere which 
have described several approaches to experimentally determine kLa (Garcia-Ochoa & 
Gomez., 2009). One example that we have used, described by Baghbaderani et al. (2008), is 
as follows.  Briefly, the assumption is made that at some point in time the reactor reaches 
steady state during which any oxygen entering the medium would be immediately 
consumed by the cells (that is, CO2 equals zero in the medium). At this point the maximum 
cell density is attained and the limiting rate of oxygen transfer is reached. In this instance 
oxygen transfer into the medium equals the oxygen uptake rate of the cells and there would 
be no change in the oxygen concentration in the bulk liquid. In other words the rate of 
change in oxygen concentration is zero (dC/dt=0). Equation 5 then simplifies to: 
 kLa = qO2 X / CO2* (6) 
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The specific oxygen uptake (qO2) of the cells in the system can be determined by measuring 
the oxygen concentration in medium without cells and then placing a known number of 
cells in the medium and sealing off the vessel with no headspace to replenish the oxygen. 
Measurements of the oxygen concentration in the medium are taken over time and the 
resulting rate of oxygen decrease is directly attributed to the uptake by the cells in the 
medium. That is: 
 dCO2/dt = qO2X (7) 
Once the specific uptake rate for a cell type is known, the limiting kLa value for a desired cell 
concentration can be determined. This method, however, obviously does not take into 
account any dimensional effects of the system. As such, Baghbaderani et al. (2008) have 
recommended a correlation put forth by Aunins et al. (1989) for a 500mL Corning spinner 
which takes the following form: 
 kLa = 1.08 Re0.78 [DO2 a / DT] (8) 
Where Re and DO2 are the Reynolds’ number (dimensionless) and diffusion coefficient of 
oxygen (m2 s-1) in the bioreactor medium, a, is the specific mass transfer interfacial area 
(taken as surface area/volume, m-1) and DT is the tank diameter (m). Determining this value 
based on system parameters and then comparing to the kLa determined experimentally for 
the cell type allows for an indication of whether or not oxygen transfer limitations exist 
within the system. 
3.3 Suspension bioreactor culture of ESCs on microcarriers 
Microcarriers are small, usually spherical or nearly spherical beads on which adherent cell 
types may grow. These beads are available in a multitude of materials including gels, 
polymers, and collagen.  Based on their surface topography, they are generally described as 
macroporous (allowing cells to expand within the microcarrier), microporous (cell 
attachment occurs on the surface of the microcarrier, however, cells are exposed to medium 
on the attached surface as well), or non-porous microcarriers (cells are exposed to medium 
only on surfaces not attached to the microcarrier). When added to a suspension bioreactor, 
microcarriers provide high surface area to volume ratio which enables higher cell densities 
compared to that obtained in static culture. This area can be adjusted by varying the number 
of microcarriers in the culture (see Table 6 for a summary of microcarrier types and 
specifications). Microcarriers in cell culture offer several advantages including: better 
control of culture macro-environment within bioreactors compared to static tissue cultures 
and roller bottles, a reduction in labor costs, ease of downstream clinical applications as cells 
can be transplanted while on microcarriers, significant reduction in the space required for a 
given-sized operation and hence higher cell densities per unit volume. In addition, by 
allowing cells to grow on a surface, microcarrier cultures harness all the advantages of a 
static tissue culture system, as well as the controlled environment of a bioreactor system. 
This provides the cells direct exposure to the medium and reduces mass transfer limitations 
of oxygen and nutrients. Comprehensive reviews on microcarrier materials and 
specifications as well as their role in tissue engineering can be found elsewhere (GE 
Healthcare, 2005; Martin et al., 2011).  
Though it has been over four decades since microcarriers were developed (Van Wezel, 
1967), only recently have microcarriers been investigated as suitable scaffold materials for  
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where kLa is the volumetric mass transfer coefficient, CO2 is the difference in oxygen 
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as follows.  Briefly, the assumption is made that at some point in time the reactor reaches 
steady state during which any oxygen entering the medium would be immediately 
consumed by the cells (that is, CO2 equals zero in the medium). At this point the maximum 
cell density is attained and the limiting rate of oxygen transfer is reached. In this instance 
oxygen transfer into the medium equals the oxygen uptake rate of the cells and there would 
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The specific oxygen uptake (qO2) of the cells in the system can be determined by measuring 
the oxygen concentration in medium without cells and then placing a known number of 
cells in the medium and sealing off the vessel with no headspace to replenish the oxygen. 
Measurements of the oxygen concentration in the medium are taken over time and the 
resulting rate of oxygen decrease is directly attributed to the uptake by the cells in the 
medium. That is: 
 dCO2/dt = qO2X (7) 
Once the specific uptake rate for a cell type is known, the limiting kLa value for a desired cell 
concentration can be determined. This method, however, obviously does not take into 
account any dimensional effects of the system. As such, Baghbaderani et al. (2008) have 
recommended a correlation put forth by Aunins et al. (1989) for a 500mL Corning spinner 
which takes the following form: 
 kLa = 1.08 Re0.78 [DO2 a / DT] (8) 
Where Re and DO2 are the Reynolds’ number (dimensionless) and diffusion coefficient of 
oxygen (m2 s-1) in the bioreactor medium, a, is the specific mass transfer interfacial area 
(taken as surface area/volume, m-1) and DT is the tank diameter (m). Determining this value 
based on system parameters and then comparing to the kLa determined experimentally for 
the cell type allows for an indication of whether or not oxygen transfer limitations exist 
within the system. 
3.3 Suspension bioreactor culture of ESCs on microcarriers 
Microcarriers are small, usually spherical or nearly spherical beads on which adherent cell 
types may grow. These beads are available in a multitude of materials including gels, 
polymers, and collagen.  Based on their surface topography, they are generally described as 
macroporous (allowing cells to expand within the microcarrier), microporous (cell 
attachment occurs on the surface of the microcarrier, however, cells are exposed to medium 
on the attached surface as well), or non-porous microcarriers (cells are exposed to medium 
only on surfaces not attached to the microcarrier). When added to a suspension bioreactor, 
microcarriers provide high surface area to volume ratio which enables higher cell densities 
compared to that obtained in static culture. This area can be adjusted by varying the number 
of microcarriers in the culture (see Table 6 for a summary of microcarrier types and 
specifications). Microcarriers in cell culture offer several advantages including: better 
control of culture macro-environment within bioreactors compared to static tissue cultures 
and roller bottles, a reduction in labor costs, ease of downstream clinical applications as cells 
can be transplanted while on microcarriers, significant reduction in the space required for a 
given-sized operation and hence higher cell densities per unit volume. In addition, by 
allowing cells to grow on a surface, microcarrier cultures harness all the advantages of a 
static tissue culture system, as well as the controlled environment of a bioreactor system. 
This provides the cells direct exposure to the medium and reduces mass transfer limitations 
of oxygen and nutrients. Comprehensive reviews on microcarrier materials and 
specifications as well as their role in tissue engineering can be found elsewhere (GE 
Healthcare, 2005; Martin et al., 2011).  
Though it has been over four decades since microcarriers were developed (Van Wezel, 
1967), only recently have microcarriers been investigated as suitable scaffold materials for  
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cultivation of ESCs (as shown in Tables 7 and 8). However, several issues need to be 
resolved before ESCs produced on microcarriers and their progeny can be used in drug 
discovery and regenerative medicine applications, respectively. These issues include 
excessive agglomeration, which has been shown to be detrimental to cell expansion  as a 
result of necrotic centers (Borys and Papoutsakis 1992), mediocre to low cell yields 
(especially for human ESC cultures), as well as the elimination of serum and MEFs used in 
microcarrier cell cultures. Finally, lack of attachment of cells to the microcarriers and the 
formation of cystic structures in suspension (Abranches et al., 2007; Nie et al., 2009; Storm et 
al., 2010) must also be addressed to eliminate heterogeneities in cultures. 
4. Future directions for large scale production of human ESCs 
The publications summarised in Tables 6 and 7 coupled with our own initial successes 
culturing human ESCs in suspension are a promising step towards development of 
strategies for implementation of stem cell therapies on a large scale. However, it is also quite 
apparent that major discrepancies exist in protocols between lab groups. Significant cell- 
manufacturing and regulatory challenges must be overcome before clinical application of 
stem cell therapies will be viable. It must be noted that standards and methodologies are 
only just being developed for efficacy evaluation, product characterization and process 
validation and control. As such, human ESC culture must be approached as a 
multidimensional optimization problem with the goal to increase target cell output while 
decreasing cost and occurrences of adverse events (Kirouac & Zandstra, 2008). In 2008, 
Kirouac & Zandstra suggested that process design and optimization should incorporate: i) 
assessment of relevant cell properties, ii) measurement and control of key parameters, iii) 
robust predictive strategies for evaluating the parameters that may impact culture output, 
iv) approaches to test these many different parameters in a high throughput and scale 
relevant manner.  
Development of predictive strategies includes computer modeling methods to assist in 
prediction of culture outcomes based on various input parameters with their inherent 
uncertainty. To date, many groups have used mathematical modeling techniques to describe 
 cell proliferation in a variety of systems (Mantzaris et al., 2001; Galban & Locke., 
1999;Lemon et al., 2007) as well as differentiation (Lemon et al., 2007; Yener et al., 2008; 
Prudhomme et al., 2004). This modeling approach is limited as only a small number of input 
variables can be considered to maintain the practicality of derived relationships and ease of 
computation. Empirical or correlation models on the other hand, do not rely on 
mathematically describable relationships between input and output variables. Some 
researchers have used factorial design for process optimization by using response surface 
maps that approximate relationships between variables and outcomes (Chung et al., 2006; 
Audet, 2010).  
Both of these modeling approaches are reasonable and practical when the input variables 
are limited and generated data sets are of a manageable size. When these data sets become 
increasingly large, for example, using tools such as microarrays, other methods of analysis 
are beginning to surface. Methods such as neural networks and statistical learning methods 
may prove to be very useful. These algorithms learn by example, or are trained by a data set, 
to assign labels to objects and recognize patterns within very large amounts of data. The use 
of these methods has yet to be fully defined within biological systems but it is apparent that 
the process is underway (Nobel, 2006). 
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cultivation of ESCs (as shown in Tables 7 and 8). However, several issues need to be 
resolved before ESCs produced on microcarriers and their progeny can be used in drug 
discovery and regenerative medicine applications, respectively. These issues include 
excessive agglomeration, which has been shown to be detrimental to cell expansion  as a 
result of necrotic centers (Borys and Papoutsakis 1992), mediocre to low cell yields 
(especially for human ESC cultures), as well as the elimination of serum and MEFs used in 
microcarrier cell cultures. Finally, lack of attachment of cells to the microcarriers and the 
formation of cystic structures in suspension (Abranches et al., 2007; Nie et al., 2009; Storm et 
al., 2010) must also be addressed to eliminate heterogeneities in cultures. 
4. Future directions for large scale production of human ESCs 
The publications summarised in Tables 6 and 7 coupled with our own initial successes 
culturing human ESCs in suspension are a promising step towards development of 
strategies for implementation of stem cell therapies on a large scale. However, it is also quite 
apparent that major discrepancies exist in protocols between lab groups. Significant cell- 
manufacturing and regulatory challenges must be overcome before clinical application of 
stem cell therapies will be viable. It must be noted that standards and methodologies are 
only just being developed for efficacy evaluation, product characterization and process 
validation and control. As such, human ESC culture must be approached as a 
multidimensional optimization problem with the goal to increase target cell output while 
decreasing cost and occurrences of adverse events (Kirouac & Zandstra, 2008). In 2008, 
Kirouac & Zandstra suggested that process design and optimization should incorporate: i) 
assessment of relevant cell properties, ii) measurement and control of key parameters, iii) 
robust predictive strategies for evaluating the parameters that may impact culture output, 
iv) approaches to test these many different parameters in a high throughput and scale 
relevant manner.  
Development of predictive strategies includes computer modeling methods to assist in 
prediction of culture outcomes based on various input parameters with their inherent 
uncertainty. To date, many groups have used mathematical modeling techniques to describe 
 cell proliferation in a variety of systems (Mantzaris et al., 2001; Galban & Locke., 
1999;Lemon et al., 2007) as well as differentiation (Lemon et al., 2007; Yener et al., 2008; 
Prudhomme et al., 2004). This modeling approach is limited as only a small number of input 
variables can be considered to maintain the practicality of derived relationships and ease of 
computation. Empirical or correlation models on the other hand, do not rely on 
mathematically describable relationships between input and output variables. Some 
researchers have used factorial design for process optimization by using response surface 
maps that approximate relationships between variables and outcomes (Chung et al., 2006; 
Audet, 2010).  
Both of these modeling approaches are reasonable and practical when the input variables 
are limited and generated data sets are of a manageable size. When these data sets become 
increasingly large, for example, using tools such as microarrays, other methods of analysis 
are beginning to surface. Methods such as neural networks and statistical learning methods 
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Table 8. Summary of suspension culture conditions for human ESCs on microcarriers. 
Medium components listed are only the base. See references for full medium components. 
As computational methods become more refined along with our understanding of biological 
processes, it is clear that regenerative medicine will benefit. The use of modeling and scale 
up techniques has the potential to bring stem cell based therapies into mainstream 
application and greatly benefit those suffering from debilitating degenerative diseases. 
5. Conclusions 
Overall, though considerable progress has been made in the development of bioprocesses for 
the production of ESCs and their progeny, it is obvious that more basic research is needed 
prior to downstream application of these cells. While protocols developed so far have focused 
on scaling up production of ESCs and their derivatives, other fundamental issues including 
elimination of animal derived products in ESC cultures, immune rejection and tumor 
formation upon transplantation of ESC derivatives must also be addressed. Utilization of 
modeling techniques to address possible outcomes of interaction effects of various variables 
involved will be a cost effective method to address some of these issues.  Finally, it will be 
necessary to develop optimized robust, controllable systems in production facilities designed 
to meet the manufacturing requirements established by various governing bodies. 
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1. Introduction  
Stem cells have great potential for use as a regenerative therapy for degenerative diseases, 
such as diabetes or Parkinson’s. However, to create a large-scale and reproducible protocol, 
large homogeneous cell populations are required. For example, it is estimated that to treat 
one patient with stem cell-derived functional beta-cell equivalents for diabetes would 
require approximately 1 billion homogeneous beta-cell equivalents (Docherty et al. 2007). To 
reproducibly expand ESCs to this order remains a major research hurdle. Suspension 
bioreactors offer major advantages over traditional, static culture methods, including the 
ability to monitor and control important bioprocess parameters such as dissolved oxygen, 
pH, and temperature. In addition, for clinical implementation of a stem cell therapy, 
automation associated with bioreactors will aid in compliance with regulatory protocols 
(Martin et al. 2009). Other advantages of suspension bioreactors over traditional (static) cell 
culture methods, include scalability, enhanced oxygen and nutrient transfer, homogeneity, 
and increased reproducibility. However, the use of larger-scale bioreactors (for example, 
greater than 100 mL working volume) incurs significant expenses as considerable amounts 
of media, cells, and other supplies are required. In addition, extensive time and handling is 
necessary to generate enough cells for inoculation. Small-scale bioreactors (less than 100 mL 
working volume) require fewer cells, are more economical, and require less labour than 
larger bioreactors. The use of small-scale bioreactors potentially permits high-throughput 
experimentation to test operating and growth conditions (media components, agitation rate, 
cell density) and the resulting interactions. 
In a suspension bioreactor, cells are suspended in liquid medium which consists of a 
mixture of water, glucose, amino acids and dissolved oxygen, among other factors. As the 
suspension bioreactor is agitated, the environment within the bioreactor is more 
homogeneous than traditional culture environments, such as a T-flask, where gradients 
occur in the static media. The hydrodynamic environment created by agitation of the 
suspension bioreactor is known to influence cell survival. Excessive amounts of shear stress 
can lead to damage to cell membranes (Betts and Baganz 2006) whereas insufficient amounts 
of shear stress can cause excessive agglomeration (Li et al. 2009). In addition, manipulating 
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1. Introduction  
Stem cells have great potential for use as a regenerative therapy for degenerative diseases, 
such as diabetes or Parkinson’s. However, to create a large-scale and reproducible protocol, 
large homogeneous cell populations are required. For example, it is estimated that to treat 
one patient with stem cell-derived functional beta-cell equivalents for diabetes would 
require approximately 1 billion homogeneous beta-cell equivalents (Docherty et al. 2007). To 
reproducibly expand ESCs to this order remains a major research hurdle. Suspension 
bioreactors offer major advantages over traditional, static culture methods, including the 
ability to monitor and control important bioprocess parameters such as dissolved oxygen, 
pH, and temperature. In addition, for clinical implementation of a stem cell therapy, 
automation associated with bioreactors will aid in compliance with regulatory protocols 
(Martin et al. 2009). Other advantages of suspension bioreactors over traditional (static) cell 
culture methods, include scalability, enhanced oxygen and nutrient transfer, homogeneity, 
and increased reproducibility. However, the use of larger-scale bioreactors (for example, 
greater than 100 mL working volume) incurs significant expenses as considerable amounts 
of media, cells, and other supplies are required. In addition, extensive time and handling is 
necessary to generate enough cells for inoculation. Small-scale bioreactors (less than 100 mL 
working volume) require fewer cells, are more economical, and require less labour than 
larger bioreactors. The use of small-scale bioreactors potentially permits high-throughput 
experimentation to test operating and growth conditions (media components, agitation rate, 
cell density) and the resulting interactions. 
In a suspension bioreactor, cells are suspended in liquid medium which consists of a 
mixture of water, glucose, amino acids and dissolved oxygen, among other factors. As the 
suspension bioreactor is agitated, the environment within the bioreactor is more 
homogeneous than traditional culture environments, such as a T-flask, where gradients 
occur in the static media. The hydrodynamic environment created by agitation of the 
suspension bioreactor is known to influence cell survival. Excessive amounts of shear stress 
can lead to damage to cell membranes (Betts and Baganz 2006) whereas insufficient amounts 
of shear stress can cause excessive agglomeration (Li et al. 2009). In addition, manipulating 
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the amount of shear stress on cells has been found to influence the resulting diameter of 
mammalian neural stem cell aggregates (Sen et al. 2001) which in turn also influences the 
distances through which nutrients must diffuse.  
2. Stem cell culture in suspension bioreactors 
It is well established in literature that stem cells can be cultured in suspension bioreactors 
(Kallos and Behie 1999; Krawetz et al. 2009; Kwon et al. 2003; Niebruegge et al. 2009; 
Schroeder et al. 2005; Youn et al. 2005). As an example, murine embryonic stem cells have 
been successfully expanded in 100 mL suspension bioreactors within specific ranges of 
agitation rates and corresponding shear stresses. The mESCs were expanded over a period 
of 6 days. Three agitation rates were tested: 80, 100 and 120 rpm. mESC expansion was 
found to be greatest at 100 rpm reaching a peak viable cell density of 106 cells/mL. It was 
also observed that aggregate diameters in the 100 rpm bioreactors were smaller than that of 
the 80 rpm bioreactors whereas the 120 rpm bioreactors resulted in excessive cell debris and 
no proliferation indicating substantial damage to the cells (Cormier et al. 2006).  
Cormier et al. also examined the effect of cell culture in suspension bioreactors on 
pluripotency. Immunocytochemistry was examined for several mESC pluripotency markers: 
Oct-4, Nanog and SSEA-1, which are expressed in undifferentiated mESC cells, and 
downregulated once cells differentiate (Murphy and Polak 2002; Tavares et al. 2007). 
Samples were taken from static culture (prior to suspension culture) and on Day 4 of the 
suspension culture (within the exponential growth phase) and positive expression of all 
pluripotency markers were observed in both samples (Cormier et al. 2006).  
mESCs have also been serially passaged in suspension bioreactors (zur Nieden et al. 2007). 
Aggregates were harvested on Day 4 (within the exponential growth phase), dissociated 
into single cells and re-inoculated at a cell density equal to 3.75 × 104 cells/mL. This 
procedure was repeated for seven subsequent passages; static cultures were maintained 
over the same time period. The suspension culture had a cumulative 2.5 billion-fold 
expansion over the 28 day period, whereas a control static culture had a 76.4 trillion fold 
expansion. However, as the static cultures were passaged every two days, there were twice 
as many static passages as suspension passages. Per passage, the suspension culture was 
found to have a 31-fold expansion whereas the static culture had a smaller 10-fold 
expansion. In addition, 37 static culture flasks would be required to obtain the total cell 
number as obtained from one suspension bioreactor (zur Nieden et al. 2007). While the 
amount of static culture flasks could be reduced by using larger static flasks, the 
homogeneity, reproducibility and reduced amount of labour motivate the use of suspension 
bioreactors for clinical applications. 
Suspension bioreactors have been used to produce mesoderm and cardiac cells from hESCs 
however these cells were first cultured under static conditions on a layer of feeder cells and 
transferred into suspension culture after differentiation had begun (Niebruegge et al. 2009). 
The use of feeder cells decreases the amount of reproducibility and increases the risk of 
contamination and immune response; this protocol could not be used for clinical application.  
The expansion of hESCs in a suspension bioreactor has been successful with the addition of 
Rho-associated kinase (ROCK) inhibitor which has been found to diminish dissociation-
induced apoptosis for single cells (Li et al. 2009; Watanabe et al. 2007). Krawetz et al. 
exposed H9 hESCs to ROCK inhibitor for 24 hours and obtained a cell fold expansion of 25 
over 6 days (Krawetz et al. 2009). Kehoe et al. exposed H1 hESCs to ROCK inhibitor for only 
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30 minutes and obtained a cell fold expansion of 5.6 over 7 days (Kehoe et al. 2009). These 
researchers also used different media for the cell culture. In a 50 mL suspension bioreactor, 
Singh et al. (2010) cultured various hESC lines: hES2, hES3, ESI04 and found that culturing 
the cells in the presence of ROCK and a heat shock treatment resulted in the greatest amount 
of cell survival (60% cell survival with ROCK and heat shock treatment, compared to 2% in 
the control case). It was also found that all three cell lines formed comparably sized 
aggregates and resulted in approximate 2-fold cell expansion per passage. However, Singh 
et al. noted cell line differences in the maintenance of pluripotency within the suspension 
bioreactors; pluripotency markers remained high for the hES2 and hES3 lines, but Oct4, Tra-
160 and SSEA4 down regulated for the ESI049 hESC line (Singh et al. 2010). 
Other research groups have reported successful expansion of hESCs in suspension culture 
where the suspension culture in this case is not a suspension bioreactor but rather a shake 
flask (Amit et al. 2010), low-attachment well plate (Olmer et al. 2010) or in some cases, not 
described (Rezaei Larijani et al. 2011; Steiner et al. 2010). The data obtained from these 
researchers provides valuable information about the hESCs ability to differentiate in 
suspension where hESCs were differentiated to neural cells in suspension (Steiner et al. 
2010) and to neural, cardiomyocytes and hepatocytes in suspension (Rezaei Larijani et al. 
2011). Additionally, the ability of hESCs to maintain stable karyotypes and maintain 
pluripotency in suspension was established (Amit et al. 2010; Olmer et al. 2010; Rezaei 
Larijani et al. 2011; Steiner et al. 2010). However, these cell culture strategies are not 
amenable to substantial scale-up for clinical purposes due to heterogeneity and lack of 
control over bioprocess parameters.  
Another option for suspension culture of hESCs is using microcarriers which provide an 
adherent surface for the cells to grow on. hESCs have been successfully expanded in a long-
term (6 months) suspension culture grown on microcarriers; the cells retained their 
pluripotency (as indicated by > 95% expression levels of SSEA4 and TRA-1-60 markers) 
reaching a cell density twice that of a static culture: 1.6 million cells/mL as opposed to 0.8 
million cells/mL (Oh et al. 2009). However, microcarrier cultures are disadvantageous for 
large scale production since the cells must be dissociated from the surface of the 
microcarrier and/or the microcarrier dissolved before clinical use.  
While the results of hESCs cultured in suspension and in suspension bioreactors are 
promising, there is still substantial research to be performed regarding agitation rates, shear 
stress, and media components before hESCs can be successfully expanded in controlled 
bioprocesses to large clinically meaningful populations. 
3. Small-scale bioreactors 
Small-scale systems have traditionally been used for preliminary research such as screening 
a large number of experimental conditions. However, for process scale up, where the 
biological product obtained for a large-scale operation (5 to 100 L for mammalian cells) is 
equivalent to the small scale bioreactor product; many experiments are required to 
determine desired media components and operating conditions. However, the use of 
standard-scale bioreactors (100 mL working volume) incurs significant cost since 
considerable amounts of media, cells, and other supplies are required. In addition, extensive 
time and handling is necessary to generate enough cells for inoculation. A scalable, small-
scale suspension bioreactor system would require fewer cells, and less labour than was 
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the amount of shear stress on cells has been found to influence the resulting diameter of 
mammalian neural stem cell aggregates (Sen et al. 2001) which in turn also influences the 
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It is well established in literature that stem cells can be cultured in suspension bioreactors 
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Schroeder et al. 2005; Youn et al. 2005). As an example, murine embryonic stem cells have 
been successfully expanded in 100 mL suspension bioreactors within specific ranges of 
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of 6 days. Three agitation rates were tested: 80, 100 and 120 rpm. mESC expansion was 
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no proliferation indicating substantial damage to the cells (Cormier et al. 2006).  
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pluripotency. Immunocytochemistry was examined for several mESC pluripotency markers: 
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Samples were taken from static culture (prior to suspension culture) and on Day 4 of the 
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pluripotency markers were observed in both samples (Cormier et al. 2006).  
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Aggregates were harvested on Day 4 (within the exponential growth phase), dissociated 
into single cells and re-inoculated at a cell density equal to 3.75 × 104 cells/mL. This 
procedure was repeated for seven subsequent passages; static cultures were maintained 
over the same time period. The suspension culture had a cumulative 2.5 billion-fold 
expansion over the 28 day period, whereas a control static culture had a 76.4 trillion fold 
expansion. However, as the static cultures were passaged every two days, there were twice 
as many static passages as suspension passages. Per passage, the suspension culture was 
found to have a 31-fold expansion whereas the static culture had a smaller 10-fold 
expansion. In addition, 37 static culture flasks would be required to obtain the total cell 
number as obtained from one suspension bioreactor (zur Nieden et al. 2007). While the 
amount of static culture flasks could be reduced by using larger static flasks, the 
homogeneity, reproducibility and reduced amount of labour motivate the use of suspension 
bioreactors for clinical applications. 
Suspension bioreactors have been used to produce mesoderm and cardiac cells from hESCs 
however these cells were first cultured under static conditions on a layer of feeder cells and 
transferred into suspension culture after differentiation had begun (Niebruegge et al. 2009). 
The use of feeder cells decreases the amount of reproducibility and increases the risk of 
contamination and immune response; this protocol could not be used for clinical application.  
The expansion of hESCs in a suspension bioreactor has been successful with the addition of 
Rho-associated kinase (ROCK) inhibitor which has been found to diminish dissociation-
induced apoptosis for single cells (Li et al. 2009; Watanabe et al. 2007). Krawetz et al. 
exposed H9 hESCs to ROCK inhibitor for 24 hours and obtained a cell fold expansion of 25 
over 6 days (Krawetz et al. 2009). Kehoe et al. exposed H1 hESCs to ROCK inhibitor for only 
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30 minutes and obtained a cell fold expansion of 5.6 over 7 days (Kehoe et al. 2009). These 
researchers also used different media for the cell culture. In a 50 mL suspension bioreactor, 
Singh et al. (2010) cultured various hESC lines: hES2, hES3, ESI04 and found that culturing 
the cells in the presence of ROCK and a heat shock treatment resulted in the greatest amount 
of cell survival (60% cell survival with ROCK and heat shock treatment, compared to 2% in 
the control case). It was also found that all three cell lines formed comparably sized 
aggregates and resulted in approximate 2-fold cell expansion per passage. However, Singh 
et al. noted cell line differences in the maintenance of pluripotency within the suspension 
bioreactors; pluripotency markers remained high for the hES2 and hES3 lines, but Oct4, Tra-
160 and SSEA4 down regulated for the ESI049 hESC line (Singh et al. 2010). 
Other research groups have reported successful expansion of hESCs in suspension culture 
where the suspension culture in this case is not a suspension bioreactor but rather a shake 
flask (Amit et al. 2010), low-attachment well plate (Olmer et al. 2010) or in some cases, not 
described (Rezaei Larijani et al. 2011; Steiner et al. 2010). The data obtained from these 
researchers provides valuable information about the hESCs ability to differentiate in 
suspension where hESCs were differentiated to neural cells in suspension (Steiner et al. 
2010) and to neural, cardiomyocytes and hepatocytes in suspension (Rezaei Larijani et al. 
2011). Additionally, the ability of hESCs to maintain stable karyotypes and maintain 
pluripotency in suspension was established (Amit et al. 2010; Olmer et al. 2010; Rezaei 
Larijani et al. 2011; Steiner et al. 2010). However, these cell culture strategies are not 
amenable to substantial scale-up for clinical purposes due to heterogeneity and lack of 
control over bioprocess parameters.  
Another option for suspension culture of hESCs is using microcarriers which provide an 
adherent surface for the cells to grow on. hESCs have been successfully expanded in a long-
term (6 months) suspension culture grown on microcarriers; the cells retained their 
pluripotency (as indicated by > 95% expression levels of SSEA4 and TRA-1-60 markers) 
reaching a cell density twice that of a static culture: 1.6 million cells/mL as opposed to 0.8 
million cells/mL (Oh et al. 2009). However, microcarrier cultures are disadvantageous for 
large scale production since the cells must be dissociated from the surface of the 
microcarrier and/or the microcarrier dissolved before clinical use.  
While the results of hESCs cultured in suspension and in suspension bioreactors are 
promising, there is still substantial research to be performed regarding agitation rates, shear 
stress, and media components before hESCs can be successfully expanded in controlled 
bioprocesses to large clinically meaningful populations. 
3. Small-scale bioreactors 
Small-scale systems have traditionally been used for preliminary research such as screening 
a large number of experimental conditions. However, for process scale up, where the 
biological product obtained for a large-scale operation (5 to 100 L for mammalian cells) is 
equivalent to the small scale bioreactor product; many experiments are required to 
determine desired media components and operating conditions. However, the use of 
standard-scale bioreactors (100 mL working volume) incurs significant cost since 
considerable amounts of media, cells, and other supplies are required. In addition, extensive 
time and handling is necessary to generate enough cells for inoculation. A scalable, small-
scale suspension bioreactor system would require fewer cells, and less labour than was 
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previously possible with larger suspension bioreactors. High‐throughput cell culture 
experiments at a more economical scale could then be performed for culture optimisation 
(Kostov et al. 2001) and allow for factorial experimental design.  
While substantial research has been completed in the area of scaled-up production 
(Baghbaderani et al. 2008; Fernandes-Platzgummer et al. 2011; Garcia-Ochoa and Gomez 
2009; Gilbertson et al. 2006; Park et al. 2010; Youn et al. 2005; Yu et al. 2009) to increase cell 
cultures to clinically meaningful numbers such as the estimated 1 billion cells per patient 
required for stem cell therapy (Docherty et al. 2007), there has been little development in 
scaling down mammalian cell bioreactor systems. Many scaled-down bioreactors in the 
literature have been developed to culture Escherichia coli (bacteria) or Saccharomyces cerevisiae 
(yeast). Some consist of shaken well plate systems (Duetz 2007; Elmahdi et al. 2003; 
Micheletti et al. 2006). In these systems, bacteria and yeast cultures are more mechanically 
srong and thus they can be agitated at substantially higher rates than mammalian cells 
(Betts and Baganz 2006). In addition, surface tension effects are more pronounced in shaken 
systems than in stirred configurations (Betts and Baganz 2006). Recently, many of the small-
scale systems in literature have been changed from initial shaken models to a stirred design 
(Gill et al. 2008; Islam et al. 2007; Kusterer et al. 2008; Micheletti et al. 2006; Weuster-Botz et 
al. 2005). 
There are many inconsistencies in the literature on the definition of a microbioreactor. This 
report will use the definitions of small-scale bioreactors as outlined in Table 1.  
 
Bioreactor Working Volume 
Nanobioreactor < 1  µL 
Microbioreactor 1 ≤ v <  1000 µL 
Minibioreactor 1 ≤ v < 100 mL 
Standard bioreactor 100 ≤ v <  500 mL 
Large bioreactor ≥ 500 mL 
Table 1. Working Volumes of Bioreactors 
Industrial sized bioreactors can reach sizes much greater than 1L, but currently, large 
bioreactors of this size and beyond have not been needed for embryonic stem cell culture. 
3.1 Bacteria and yeast culture in small-scale bioreactors 
There are a number of different small-scale stirred bioreactor systems currently available in 
the literature all of which contain oxygen and pH sensors. The first was developed by the 
Lye group at University College, London. This bioreactor system was designed to be 
geometrically similar to large scale bioreactors, and driven by a miniature turbine impeller. 
They found that to ensure the impeller was submerged in liquid, and to achieve an agitation 
rate of up to 2000 rpm, the bioreactor was restricted to be 100 mL in size. The impeller was 
magnetically driven, and up to 16 reactors could be operated in parallel with continuous on-
line monitoring and control of pH, dissolved oxygen and temperature. The calculated 
maximum specific growth rate (of E. coli) and final biomass concentrations achieved were 
similar between the small-scale bioreactor and a conventional large-scale 2 L bioreactor. The 
group concluded that results obtained from small-scale parallel experiments in the 
miniature bioreactors can thus be converted to large-scale bioreactors (Gill et al. 2008). While 
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this conclusion is valid, the work was performed on a bioreactor which is considered 
standard-sized for lab-scale mammalian cell experimentation, and the bioreactor system 
presented by the Lye group is not suitable for high-throughput analysis. 
A second small-scale bioreactor system was developed by the Weuster-Botz group from 
Technische Universitat, Germany. This minibioreactor system uses a 48-reactor block of 
magnetically stirred bioreactors each one of the order of 10 mL scale. Dissolved oxygen and 
pH are measured by chemical sensors. Sampling and acid or base additions were carried out 
by a robotic liquid handling system with up to 20 µL sampled every 1 to 4 hours. This 
sample was read by a microtitre plate fluorescence reader, in which the optical density was 
correlated to cell density. The growth characteristics of E. coli and S. cerevisiae were similar at 
the 10 mL and 20 L scale (Kusterer et al. 2008). The above system has recently been modified 
with a new impeller for the culture of mycelium forming microorganisms. These 
cultivations are more prominently affected by shear forces than bacteria or yeast cultures as 
shear stress effects the morphology and productivity of these cells (Hortsch et al. 2010). 
Additionally, the culture broth is a non-Newtonian, shear-thinning fluid (Pollard et al. 2002) 
with lower viscosity at higher shear rates which influences mixing, heat and mass transfer 
processes within the bioreactor. The new impeller developed by this group aimed to ensure 
sufficient gas-liquid mass transfer for the cultured Streptomyces tendae. The impeller is a 
vertical, one-sided paddle which distributes power throughout the reactor, resulting in 
consistent viscosity throughout the reactor. 
The 10 mL bioreactors were agitated at 1200 rpm. Reference cultivations were cultured in a 
3L stirred tank bioreactor (impeller speed was equal to 800 rpm) where the power input was 
held constant between the two bioreactor sizes. The production of nikkomycin Z was 
compared between the two scales and it was found that approximately 300 mg L-1 were 
produced at each size scale (Hortsch et al. 2010). However, while these agitation rates are 
lower than that used for bacterial or yeast cultures, they are still much higher than that 
which mammalian cells could sustain. 
A third small-scale bioreactor system was developed by the Rao group of the University of 
Maryland. A 2 mL minibioreactor was developed, and the volumetric mass transfer 
coefficient (kLa) was kept constant from the small-scale bioreactor up to 1 L, based on the 
rational that higher kLa may yield increased cell growth due to oxygen availability, and kLa 
should thus be kept constant for scalability between the two systems. It was observed that 
oxygen depletion patterns between the two systems were similar during exponential 
growth. The total cost of the bioreactor system was less than US$400 (in 2001); the Rao 
group proposes that it seems possible to develop a bioprocess system where many 
bioprocesses can run in parallel (96 or more) for lower cost than a bench scale bioreactor. 
However, the system was magnetically stirred by a stir-bar located on the bottom of the 
vessel (Kostov et al. 2001). This arrangement, with the stir bar free-floating in the system, 
has been found to be detrimental to mESC expansion; it is hypothesized that the stir bar, 
sitting on the bottom of the vessel, effectively crushes the cells as they are pulled underneath 
(Millar 2009).  
The Rao group has also developed an additional minibioreactor with a working volume of 
10 to 35 mL agitated with an impeller, for the cultivation of bacteria and yeast (Harms et al. 
2006). The design of the bioreactor agitation system has not been published other than to 
specify that the small-scale bioreactors are stirred and each well is controlled by an 
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previously possible with larger suspension bioreactors. High‐throughput cell culture 
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srong and thus they can be agitated at substantially higher rates than mammalian cells 
(Betts and Baganz 2006). In addition, surface tension effects are more pronounced in shaken 
systems than in stirred configurations (Betts and Baganz 2006). Recently, many of the small-
scale systems in literature have been changed from initial shaken models to a stirred design 
(Gill et al. 2008; Islam et al. 2007; Kusterer et al. 2008; Micheletti et al. 2006; Weuster-Botz et 
al. 2005). 
There are many inconsistencies in the literature on the definition of a microbioreactor. This 
report will use the definitions of small-scale bioreactors as outlined in Table 1.  
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There are a number of different small-scale stirred bioreactor systems currently available in 
the literature all of which contain oxygen and pH sensors. The first was developed by the 
Lye group at University College, London. This bioreactor system was designed to be 
geometrically similar to large scale bioreactors, and driven by a miniature turbine impeller. 
They found that to ensure the impeller was submerged in liquid, and to achieve an agitation 
rate of up to 2000 rpm, the bioreactor was restricted to be 100 mL in size. The impeller was 
magnetically driven, and up to 16 reactors could be operated in parallel with continuous on-
line monitoring and control of pH, dissolved oxygen and temperature. The calculated 
maximum specific growth rate (of E. coli) and final biomass concentrations achieved were 
similar between the small-scale bioreactor and a conventional large-scale 2 L bioreactor. The 
group concluded that results obtained from small-scale parallel experiments in the 
miniature bioreactors can thus be converted to large-scale bioreactors (Gill et al. 2008). While 
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this conclusion is valid, the work was performed on a bioreactor which is considered 
standard-sized for lab-scale mammalian cell experimentation, and the bioreactor system 
presented by the Lye group is not suitable for high-throughput analysis. 
A second small-scale bioreactor system was developed by the Weuster-Botz group from 
Technische Universitat, Germany. This minibioreactor system uses a 48-reactor block of 
magnetically stirred bioreactors each one of the order of 10 mL scale. Dissolved oxygen and 
pH are measured by chemical sensors. Sampling and acid or base additions were carried out 
by a robotic liquid handling system with up to 20 µL sampled every 1 to 4 hours. This 
sample was read by a microtitre plate fluorescence reader, in which the optical density was 
correlated to cell density. The growth characteristics of E. coli and S. cerevisiae were similar at 
the 10 mL and 20 L scale (Kusterer et al. 2008). The above system has recently been modified 
with a new impeller for the culture of mycelium forming microorganisms. These 
cultivations are more prominently affected by shear forces than bacteria or yeast cultures as 
shear stress effects the morphology and productivity of these cells (Hortsch et al. 2010). 
Additionally, the culture broth is a non-Newtonian, shear-thinning fluid (Pollard et al. 2002) 
with lower viscosity at higher shear rates which influences mixing, heat and mass transfer 
processes within the bioreactor. The new impeller developed by this group aimed to ensure 
sufficient gas-liquid mass transfer for the cultured Streptomyces tendae. The impeller is a 
vertical, one-sided paddle which distributes power throughout the reactor, resulting in 
consistent viscosity throughout the reactor. 
The 10 mL bioreactors were agitated at 1200 rpm. Reference cultivations were cultured in a 
3L stirred tank bioreactor (impeller speed was equal to 800 rpm) where the power input was 
held constant between the two bioreactor sizes. The production of nikkomycin Z was 
compared between the two scales and it was found that approximately 300 mg L-1 were 
produced at each size scale (Hortsch et al. 2010). However, while these agitation rates are 
lower than that used for bacterial or yeast cultures, they are still much higher than that 
which mammalian cells could sustain. 
A third small-scale bioreactor system was developed by the Rao group of the University of 
Maryland. A 2 mL minibioreactor was developed, and the volumetric mass transfer 
coefficient (kLa) was kept constant from the small-scale bioreactor up to 1 L, based on the 
rational that higher kLa may yield increased cell growth due to oxygen availability, and kLa 
should thus be kept constant for scalability between the two systems. It was observed that 
oxygen depletion patterns between the two systems were similar during exponential 
growth. The total cost of the bioreactor system was less than US$400 (in 2001); the Rao 
group proposes that it seems possible to develop a bioprocess system where many 
bioprocesses can run in parallel (96 or more) for lower cost than a bench scale bioreactor. 
However, the system was magnetically stirred by a stir-bar located on the bottom of the 
vessel (Kostov et al. 2001). This arrangement, with the stir bar free-floating in the system, 
has been found to be detrimental to mESC expansion; it is hypothesized that the stir bar, 
sitting on the bottom of the vessel, effectively crushes the cells as they are pulled underneath 
(Millar 2009).  
The Rao group has also developed an additional minibioreactor with a working volume of 
10 to 35 mL agitated with an impeller, for the cultivation of bacteria and yeast (Harms et al. 
2006). The design of the bioreactor agitation system has not been published other than to 
specify that the small-scale bioreactors are stirred and each well is controlled by an 
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individual stepper motor. The use of an individual motor for each well would provide 
opportunity for agitation rate testing in multiples on a small scale, but not yet to the small 
micro-scale desired in this study. In addition, increasing the number of motors used vastly 
increases the cost and operational complexity of the system. 
A fourth small-scale reactor, developed by the Jensen group at the Massachusetts Institute of 
Technology was also designed for bacteria and yeast culture, and is the smallest stirred 
small-scale reactor to be found in the literature at 0.1 to 1.0 mL in working volume. The most 
recent form of this microbioreactor has the impeller extend upward from the base of the 
reactor; 100 µL volumes were found to replicate the growth kinetics and gene expression 
profiles of E. coli as in a 0.5 L bioreactor (Zhang et al. 2007). While these results are 
promising, an array for parallel experimentation has not yet been developed (a single 
reactor only) and the location of the impeller at the base of the reactor would make 
operation (cleaning and sterilizing) difficult. 
3.2 Mammalian cell culture in small-scale bioreactors 
To date, there has not been any scaled-down stirred, suspension bioreactors published for 
mammalian cell culture. However, there have been developments relating to small-scale 
mammalian cell culture devices to investigate the cell microenvironment (Cimetta et al. 
2009; Figallo et al. 2007; Wu et al. 2006). These devices are not amenable to scaled-up 
production, or high-throughput screening for bioreactor cultivations, since bioreactor 
hydrodynamics are not designed to be similar to a standard bioreactor but they are designed 
rather to study the cell microenvironment. In addition, these systems are perfusion based 
allowing for constant exchange of nutrients for waste; while this is beneficial for cell culture, 
it is in contrast to the batch cultivations of a stirred-tank bioreactor which this chapter has 
focused on.  
Small-scale hollow-fiber devices for use as a bioartificial liver are also being developed 
(Gramer and Britton 2002; Rodriguez et al. 2008). However, these reactors are designed for 
cell product secretion, and not for cell expansion, and again are not amenable to scaled-up 
expansion of stem cells.  
There have been developments for mammalian cell culture in small-scale shaken 
bioreactors. Chinese Hamster Ovary (CHO) cells were cultivated in a small-scale shaken 
bioreactor, equipped with a ventilation cap. The small-scale bioreactor has a footprint of a 24 
well-plate, and each vial has a working volume of 6 mL (Isett et al. 2007). The cell growth 
and metabolite profiles in th 6 mL bioreactor were found to be similar when compared to a 
large-scale 2 L bioreactor culture where 85% of the viable cell density of CHO cells cultured 
in the small-scale bioreactor was within 20% of the viable cell density of CHO cells cultured 
in the 2L bioreactor (Chen et al. 2008). While this is a promising result, the size scale remains 
a barrier to high throughput screening, and no engineering calculations were done to show 
a comparison of the bioreactor hydrodynamics between the two size scales.  
Girard et al. (2001) also cultured CHO cells in a small-scale shaken bioreactor; the cells were 
cultured in the wells of a twelve-well microtiter plate and shaken on a rotational shaker 
plate. As the well plates are stackable, several hundred small-scale bioreactor experiments 
were able to be reproducibly completed. Cell density was measured with the use of 
fluorescence measurements, which allows for non-invasive sampling. In this study, the 
formation of cellular aggregates was compared between the shaken well plate small-scale 
bioreactor (2 mL working volume) and a 3 L stirred bioreactor and the resulting cell 
aggregate size was found to be comparable. The two systems were also compared with 
respect to production of protein where the small-scale bioreactor resulted in double the 
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production of protein from the standard bioreactor. However, the results also indicated that 
evaporation was a problem within the small-scale bioreactor which led to inconsistencies in 
the results (Girard et al. 2001).  
CHO cells have also been cultivated in a 700 µL microbioreactor; cultures were inoculated in 
small chambers of a plastic card with diffusible walls for oxygen and carbon dioxide mass 
transfer. The cards were then rotated. The cell culture behaved similarly to a 3 L large-scale 
bioreactor, where the correlation factor, R2, between the two scales for the resulting viable 
cell density was equal to 0.84. In addition, the small-scale bioreactor was used to analyse the 
process in a high throughput manner; finding that supplementing the media substantially (p 
< 0.05) affected the cells resulting in a higher cell mass. However, due to the small volumes 
used, Legmann et al. noticed significant differences in the cell counts from the 
microbioreactors (Legmann et al. 2009).  
By using agitation induced by thermal convection, a 250 μL microbioreactor has been 
developed for expansion of human hematopoietic stem cells. The temperature gradient 
within the microbioreactor was small ranging from 36.0 to 36.015°C, where the heat source 
was provided at the base of the reactor. This resulted in temperatures suitable for 
mammalian cell culture. Experimental tests comparing the microbioreactor culture to a static 
control resulted in no statistically significant effect on the cell proliferation rate (Luni et al. 
2010). Thus, while this microbioreactor yields successful cell expansion, it does not result in 
the large degree of enhanced cell expansion seen in suspension bioreactors as compared to 
static controls such as the 31-fold expansion observed in a standard 100 mL bioreactor as 
compared to 10-fold expansion in a static control (Cormier et al. 2006). Thermal convection 
mixing may provide a cell culture environment not significantly different from the static 
control. In addition, this system would be difficult to scale up because increasing large 
temperature gradients would be required which could be higher than viability threshold 
temperatures for mammalian cells. 
3.3 Small-scale bioreactors operating in parallel 
While the creation of a small-scale bioreactor for cell culture is indeed beneficial for 
research, small-scale bioreactors must be capable of operating in parallel with many other 
small-scale bioreactors for high-throughput experimentation and factorial analysis. The 
degree of parallel application found in small-scale bioreactors throughout the literature is 
presented in Table 2. Most small-scale bioreactors found in the literature are not yet 
amenable to high-throughput analysis while maintaining consistent hydrodynamic 
environments as a stirred standard scale bioreactor.  
 
Research Bioreactor Scale Number of Bioreactors  Operating in Parallel 
Gill et al. 2008 Standard (100 mL) 4-16 
Kusterer et al. 2008 Minibioreactor (12 mL) 48 
Isett et al. 2007 Minibioreactor (6 mL) 24 
Girard et al. 2001 Minibioreactor (2 mL) 12-144 
Legmann et al. 2009 Microbioreactor (700 μL) 180 
Table 2. Parallel Application of Small-Scale Bioreactors. The number of bioreactors at each 
size scale is presented.  
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reactor only) and the location of the impeller at the base of the reactor would make 
operation (cleaning and sterilizing) difficult. 
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2009; Figallo et al. 2007; Wu et al. 2006). These devices are not amenable to scaled-up 
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hydrodynamics are not designed to be similar to a standard bioreactor but they are designed 
rather to study the cell microenvironment. In addition, these systems are perfusion based 
allowing for constant exchange of nutrients for waste; while this is beneficial for cell culture, 
it is in contrast to the batch cultivations of a stirred-tank bioreactor which this chapter has 
focused on.  
Small-scale hollow-fiber devices for use as a bioartificial liver are also being developed 
(Gramer and Britton 2002; Rodriguez et al. 2008). However, these reactors are designed for 
cell product secretion, and not for cell expansion, and again are not amenable to scaled-up 
expansion of stem cells.  
There have been developments for mammalian cell culture in small-scale shaken 
bioreactors. Chinese Hamster Ovary (CHO) cells were cultivated in a small-scale shaken 
bioreactor, equipped with a ventilation cap. The small-scale bioreactor has a footprint of a 24 
well-plate, and each vial has a working volume of 6 mL (Isett et al. 2007). The cell growth 
and metabolite profiles in th 6 mL bioreactor were found to be similar when compared to a 
large-scale 2 L bioreactor culture where 85% of the viable cell density of CHO cells cultured 
in the small-scale bioreactor was within 20% of the viable cell density of CHO cells cultured 
in the 2L bioreactor (Chen et al. 2008). While this is a promising result, the size scale remains 
a barrier to high throughput screening, and no engineering calculations were done to show 
a comparison of the bioreactor hydrodynamics between the two size scales.  
Girard et al. (2001) also cultured CHO cells in a small-scale shaken bioreactor; the cells were 
cultured in the wells of a twelve-well microtiter plate and shaken on a rotational shaker 
plate. As the well plates are stackable, several hundred small-scale bioreactor experiments 
were able to be reproducibly completed. Cell density was measured with the use of 
fluorescence measurements, which allows for non-invasive sampling. In this study, the 
formation of cellular aggregates was compared between the shaken well plate small-scale 
bioreactor (2 mL working volume) and a 3 L stirred bioreactor and the resulting cell 
aggregate size was found to be comparable. The two systems were also compared with 
respect to production of protein where the small-scale bioreactor resulted in double the 
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production of protein from the standard bioreactor. However, the results also indicated that 
evaporation was a problem within the small-scale bioreactor which led to inconsistencies in 
the results (Girard et al. 2001).  
CHO cells have also been cultivated in a 700 µL microbioreactor; cultures were inoculated in 
small chambers of a plastic card with diffusible walls for oxygen and carbon dioxide mass 
transfer. The cards were then rotated. The cell culture behaved similarly to a 3 L large-scale 
bioreactor, where the correlation factor, R2, between the two scales for the resulting viable 
cell density was equal to 0.84. In addition, the small-scale bioreactor was used to analyse the 
process in a high throughput manner; finding that supplementing the media substantially (p 
< 0.05) affected the cells resulting in a higher cell mass. However, due to the small volumes 
used, Legmann et al. noticed significant differences in the cell counts from the 
microbioreactors (Legmann et al. 2009).  
By using agitation induced by thermal convection, a 250 μL microbioreactor has been 
developed for expansion of human hematopoietic stem cells. The temperature gradient 
within the microbioreactor was small ranging from 36.0 to 36.015°C, where the heat source 
was provided at the base of the reactor. This resulted in temperatures suitable for 
mammalian cell culture. Experimental tests comparing the microbioreactor culture to a static 
control resulted in no statistically significant effect on the cell proliferation rate (Luni et al. 
2010). Thus, while this microbioreactor yields successful cell expansion, it does not result in 
the large degree of enhanced cell expansion seen in suspension bioreactors as compared to 
static controls such as the 31-fold expansion observed in a standard 100 mL bioreactor as 
compared to 10-fold expansion in a static control (Cormier et al. 2006). Thermal convection 
mixing may provide a cell culture environment not significantly different from the static 
control. In addition, this system would be difficult to scale up because increasing large 
temperature gradients would be required which could be higher than viability threshold 
temperatures for mammalian cells. 
3.3 Small-scale bioreactors operating in parallel 
While the creation of a small-scale bioreactor for cell culture is indeed beneficial for 
research, small-scale bioreactors must be capable of operating in parallel with many other 
small-scale bioreactors for high-throughput experimentation and factorial analysis. The 
degree of parallel application found in small-scale bioreactors throughout the literature is 
presented in Table 2. Most small-scale bioreactors found in the literature are not yet 
amenable to high-throughput analysis while maintaining consistent hydrodynamic 
environments as a stirred standard scale bioreactor.  
 
Research Bioreactor Scale Number of Bioreactors  Operating in Parallel 
Gill et al. 2008 Standard (100 mL) 4-16 
Kusterer et al. 2008 Minibioreactor (12 mL) 48 
Isett et al. 2007 Minibioreactor (6 mL) 24 
Girard et al. 2001 Minibioreactor (2 mL) 12-144 
Legmann et al. 2009 Microbioreactor (700 μL) 180 
Table 2. Parallel Application of Small-Scale Bioreactors. The number of bioreactors at each 
size scale is presented.  
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Applying parallel operation to bioreactors from a single prototype results in a number of 
complications. For example, Gill et al. found that the magnetically agitated bioreactor 
impeller design must be altered when creating a parallel application to avoid interacting 
magnetic fields. Due to the impeller design changes, the researchers found that the 
bioreactors must be agitated at speeds greater than 1000 rpm to maintain a homogeneous 
gas bubble distribution within the culture media (Gill et al. 2008). Maintaining sterility has 
also been noted as an obstacle to parallelization, in particular during culture sampling. 
Kusterer et al. found that washing the components encountering sampling needles with a 
mixture of 70% ethanol (v/v) and 20% acetone (v/v) to be sufficient (Kusterer et al. 2008). 
However, cross-contamination between samples must also be avoided where each vessel 
must be treated as an individual sample with individual sampling ports. Girard et al. 
accomplished this through measuring cell growth via green fluorescent protein expressing 
cells and a fluorescence plate reader (Girard et al. 2001). Success with this method is thus 
dependent on a green fluorescent protein expressing cell line. Isett et al. also used 
fluorescence to monitor dissolved oxygen level (Isett et al. 2007). While Legmann et al. were 
able to successfully culture the mammalian cells in parallel microbioreactors,  
the hydrodynamics of the microbioreactor developed would not relate to a standard 
bioreactor. 
3.4 Hydrodynamic environment of small-scale bioreactors 
The hydrodynamic environment in a bioreactor is known to be a function of the bioreactor 
and impeller geometries, agitation rate, medium viscosity and volume (Flickinger and Drew 
1999; King and Miller 2007; Marks 2003; Sen et al. 2002). When scaling reactors up, from lab 
scale to an industrial scale, it is common to hold several parameters constant to maintain a 
consistent hydrodynamic environment. This method may also be used for scaling down the 
size of reactors. It is common to maintain dimensional similarity (Flickinger and Drew 1999) 
such as a liquid height to reactor diameter ratio. However, these calculations do not 
consider the effect of shear stress on mammalian cells. These cells are very sensitive to shear 
stress due to the absence of a cell wall; high agitation rates can adversely affect mammalian 
cell growth (Betts and Baganz 2006). 
While research results from the literature suggest small-scale bioreactors as potential 
technology for use in high throughput screening (Barrett et al. 2010; Betts and Baganz 2006; 
Kumar et al. 2004) and cells cultured in small-scale reactors have reached cell densities 
similar to that of large-scale bioreactors (Gill et al. 2008; Kusterer et al. 2008; Zhang et al. 
2007), there remains a knowledge gap of the fluid behaviour between the two scales. For 
example, correlations and dimensionless numbers used to characterize systems at the large-
scale may not be applicable at the small scale. The Reynolds number, often used to 
characterize fluid systems, has been found to not be applicable at the micro-scale (Betts et al. 
2006; Micheletti and Lye 2006; Vallejos et al. 2006). In addition, shear stress has been found 
to be a critical factor to maintaining cell cultures in suspension in bioreactors (Sen et al. 
2001). The maximum shear stress on an aggregate in suspension is calculated as a function 
of fluid density and power dissipated per unit mass (Cherry and Kwon 1990; Sen et al. 2002) 
which is in turn a function of the Power Number. A correlation between the Power Number, 
Reynold’s Number, and the reactor geometry has been developed (Nagata 1975). The 
Reynold’s Number and Power Number are dimensionless numbers which act as a 
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representation of physical forces. The Reynold’s Number (Re) is a ratio of inertial to viscous 
forces, and is calculated as: 
               �� � ����           (1) 
Where  is the fluid density (kg/m3), U is the fluid velocity (m/s), D is a characteristic 
length of the system (m) and  is the fluid viscosity (Pa*s). The Power Number relates the 
resistance force to the intertial force, and is calculated for a reactor system as follows, using 
the shear stress within the system.  
The maximum shear stress for a suspended sphere (aggregate) in turbulence can be found 
from the following equation (Cherry and Kwon 1990; Sen et al. 2002): 
              ���� � �����√��   (2) 
where ����  is the maximum shear stress on an aggregate (Pa), and  is the power dissipated 
per unit mass (m2/s3), which is calculated as: 
       � � ����     (3) 
where P is the power consumed (kg m2/s3), and VL is the liquid volume (m3). The power 
consumed can be calculated as: 
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where PN is the Power Number (dimensionless). The power number has been correlated to 
be a function of the Reynolds number and the physical properties of the bioreactor. The 
empirical correlation is as follows for an unbaffled tank with paddle impellers (Nagata 
1975): 
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where W is the impeller width (m),  Dt is the tank diameter (m) and Di is the impeller 
diameter (m).  
When calculations are performed with these correlations to try to determine the shear forces 
on cells within the small-scale bioreactors, the resulting agitation rate needed to maintain 
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impeller design must be altered when creating a parallel application to avoid interacting 
magnetic fields. Due to the impeller design changes, the researchers found that the 
bioreactors must be agitated at speeds greater than 1000 rpm to maintain a homogeneous 
gas bubble distribution within the culture media (Gill et al. 2008). Maintaining sterility has 
also been noted as an obstacle to parallelization, in particular during culture sampling. 
Kusterer et al. found that washing the components encountering sampling needles with a 
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However, cross-contamination between samples must also be avoided where each vessel 
must be treated as an individual sample with individual sampling ports. Girard et al. 
accomplished this through measuring cell growth via green fluorescent protein expressing 
cells and a fluorescence plate reader (Girard et al. 2001). Success with this method is thus 
dependent on a green fluorescent protein expressing cell line. Isett et al. also used 
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such as a liquid height to reactor diameter ratio. However, these calculations do not 
consider the effect of shear stress on mammalian cells. These cells are very sensitive to shear 
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scale may not be applicable at the small scale. The Reynolds number, often used to 
characterize fluid systems, has been found to not be applicable at the micro-scale (Betts et al. 
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2001). The maximum shear stress on an aggregate in suspension is calculated as a function 
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which is in turn a function of the Power Number. A correlation between the Power Number, 
Reynold’s Number, and the reactor geometry has been developed (Nagata 1975). The 
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representation of physical forces. The Reynold’s Number (Re) is a ratio of inertial to viscous 
forces, and is calculated as: 
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length of the system (m) and  is the fluid viscosity (Pa*s). The Power Number relates the 
resistance force to the intertial force, and is calculated for a reactor system as follows, using 
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from the following equation (Cherry and Kwon 1990; Sen et al. 2002): 
              ���� � �����√��   (2) 
where ����  is the maximum shear stress on an aggregate (Pa), and  is the power dissipated 
per unit mass (m2/s3), which is calculated as: 
       � � ����     (3) 
where P is the power consumed (kg m2/s3), and VL is the liquid volume (m3). The power 
consumed can be calculated as: 
  � � �������   (4) 
 
where PN is the Power Number (dimensionless). The power number has been correlated to 
be a function of the Reynolds number and the physical properties of the bioreactor. The 
empirical correlation is as follows for an unbaffled tank with paddle impellers (Nagata 
1975): 




   (5) 
where  
    �� � �� � ��� ���� �
��
�� � ����
� � ����  (6) 
 �� � ����   (7) 
 �� � ��� � � ���� � ����
� � ���� ����    (8) 
 �� � ��� � ���� � ��� �
��
�� � ����
� � � �����
�
  (9) 
 
 
where W is the impeller width (m),  Dt is the tank diameter (m) and Di is the impeller 
diameter (m).  
When calculations are performed with these correlations to try to determine the shear forces 
on cells within the small-scale bioreactors, the resulting agitation rate needed to maintain 
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the same shear as present in the larger bioreactor is much too high to sustain mammlian cell 
growth. Specifically, these correlations strongly depend on the Reynolds number. The use of 
a specific Reynolds number as a guide for the transition from laminar to turbulent flow has 
been found inapplicable to small-scale systems such as a microbioreactor (Betts et al. 2006; 
Micheletti and Lye 2006; Vallejos et al. 2006). At larger scales, the Reynold’s number clearly 
represents the transition from laminar to turbulent flow. In addition, as these correlations 
were developed for a large-scale reactor, they may also not be applicable on a very small-
scale.  
3.5 Oxygen environment in small-scale bioreactors 
Typically, stem cell bioreactors use surface aeration to supply oxygen to the suspended cells. 
The surface area to volume ratio in smaller bioreactors is much larger than the standard 100 
mL bioreactors, as shown in Table 3. For embryonic stem cells in suspension culture, the 
mass transfer of oxygen has been found not to be a limiting factor (Cormier et al. 2006). 
 
 
Dimension Standard Bioreactor (100 mL) 
Microbioreactor 
(250 L) 
Volume (m3) 1.00E-04 2.50E-07 
Surface Area (m2) 2.68E-03 3.12E-05 
Surface Area/Volume (m-1) 2.68E+01 1.25E+02 
 
 
Table 3. Surface area to volume ratio of the standard 100 mL bioreactor and an example 
microbioreactor. 
The following calculations were performed to characterize the mass transfer of oxygen to 
mESCs in a 250 L microbioreactor. The oxygen consumption rate of mESCs in suspension 
has been previously measured (zur Nieden et al. 2007). Assuming a peak cell density of 106 
cells/mL and a 250 L working volume, the peak consumption rate of oxygen of the cells in 
a microbioreactor vial can be determined. A total vessel volume of 1 mL is assumed. By 
using the ideal gas law, the amount of oxygen in the headspace (0.75 mL) is equal to 2.95x10-
5 mol (0.94 mg). Assuming no oxygen transfer from the surrounding environment, where 
the oxygen in the headspace is the only oxygen available to the cells, and knowing the total 
oxygen consumption of the microbioreactor (Table 4), the amount of time required for the 
oxygen in the headspace to completely deplete was found to be 34 days, given a constant 
cell density of 106 cells/mL. While it is unlikely that the cells would remain at a constant cell 
density, this density is the maximum found in standard 100 mL bioreactors, and thus 
represents a worst case scenario. It is more likely that the cell density would initially begin 
at a much smaller value, and then as the cells expanded the cell density would increase to 
106 cells/mL. In addition, as the microbioreactor vial would be opened much more 
frequently than this for sampling or media changes, there is thus an abundant supply of 
oxygen available to the cells.  
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Description Value 
Specific Oxygen Consumption Rate 4 x 10-17  ��� ��������  
Cell Density 106 cells/mL 
Media Volume 0.25 mL 
Total Cells 2.5 x 105 cells 
Total Oxygen Consumption 1 x 10-11  ��� ���  
Table 4. Oxygen consumption by murine embryonic stem cells in a microbioreactor. The cell 
density is assumed to be the peak cell density found by Cormier et al. 2006 and the oxygen 
consumption rate is as determined by zur Nieden et al. 2007.  
The above calculations assume no mass transfer resistance from the bulk gas, through the 
liquid media to the cells, and that the consumption of oxygen by the cells is the limiting 
step. To instead consider the mass transfer of oxygen from the headspace to the liquid 
media as the limiting step, the following equation may be used to calculate the oxygen 
transfer rate: 
   ��� � �������� � ���   (10) 
Where ��� is the volumetric mass transfer coefficient (h-1), ���� is the saturation 
concentration of oxygen in the liquid (mol/L) and C� is the steady state bulk concentration 
of oxygen in the liquid (mol/L). The value for the mass transfer coefficient was the same as 
used by Millar (2009) (k�a  = 2h-1). The solubility of oxygen (from standard air) in water 
used was C��� = 2.5 x 10-4 mol/L or 8 mg/L (Lenntech 2009). The steady state bulk 
concentration was calculated using a mass balance, and found to be equal to 8.85 x 10-6 
mol/L (0.28 mg/L). With these values, an oxygen transfer rate of 4.82 x 10-4 mol/Lh was 
found. Using this oxygen transfer rate, in combination with the amount of oxygen in the 
headspace calculated earlier in this section (2.95x10-5 mol), it was calculated that with the 
mass transfer of oxygen as the limiting step, there is enough oxygen in the microbioreactor 
to supply the media with oxygen for 244 hours (10 days). This value, while smaller than that 
found when the cell consumption was considered the limiting step, is still long enough for 
cell culture experiments, where cell counts are normally taken once per day, where the 
oxygen supply to the headspace would then be replenished.  
Thus for the majority of cell culture experiments, a closed microbioreactor system provides a 
sufficient supply of oxygen. For long term experiments, or if cell samples were not taken 
more frequently than once per week, an oxygen supply may need to be considered as an 
alternative design. 
4. Conclusions  
Embryonic stem cells are considered to be a source of cells with tremendous potential for 
regenerative medicine, as they are capable of self-renewal and can differentiate into any cell 
type. The bioprocessing of these cells (i.e. creating reliable protocols for cell expansion and 
differentiation) is a critical component of developing therapies ready for clinical 
implementation. Suspension bioreactors are understood to be a scalable, reproducible and 
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cells/mL and a 250 L working volume, the peak consumption rate of oxygen of the cells in 
a microbioreactor vial can be determined. A total vessel volume of 1 mL is assumed. By 
using the ideal gas law, the amount of oxygen in the headspace (0.75 mL) is equal to 2.95x10-
5 mol (0.94 mg). Assuming no oxygen transfer from the surrounding environment, where 
the oxygen in the headspace is the only oxygen available to the cells, and knowing the total 
oxygen consumption of the microbioreactor (Table 4), the amount of time required for the 
oxygen in the headspace to completely deplete was found to be 34 days, given a constant 
cell density of 106 cells/mL. While it is unlikely that the cells would remain at a constant cell 
density, this density is the maximum found in standard 100 mL bioreactors, and thus 
represents a worst case scenario. It is more likely that the cell density would initially begin 
at a much smaller value, and then as the cells expanded the cell density would increase to 
106 cells/mL. In addition, as the microbioreactor vial would be opened much more 
frequently than this for sampling or media changes, there is thus an abundant supply of 
oxygen available to the cells.  
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The above calculations assume no mass transfer resistance from the bulk gas, through the 
liquid media to the cells, and that the consumption of oxygen by the cells is the limiting 
step. To instead consider the mass transfer of oxygen from the headspace to the liquid 
media as the limiting step, the following equation may be used to calculate the oxygen 
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of oxygen in the liquid (mol/L). The value for the mass transfer coefficient was the same as 
used by Millar (2009) (k�a  = 2h-1). The solubility of oxygen (from standard air) in water 
used was C��� = 2.5 x 10-4 mol/L or 8 mg/L (Lenntech 2009). The steady state bulk 
concentration was calculated using a mass balance, and found to be equal to 8.85 x 10-6 
mol/L (0.28 mg/L). With these values, an oxygen transfer rate of 4.82 x 10-4 mol/Lh was 
found. Using this oxygen transfer rate, in combination with the amount of oxygen in the 
headspace calculated earlier in this section (2.95x10-5 mol), it was calculated that with the 
mass transfer of oxygen as the limiting step, there is enough oxygen in the microbioreactor 
to supply the media with oxygen for 244 hours (10 days). This value, while smaller than that 
found when the cell consumption was considered the limiting step, is still long enough for 
cell culture experiments, where cell counts are normally taken once per day, where the 
oxygen supply to the headspace would then be replenished.  
Thus for the majority of cell culture experiments, a closed microbioreactor system provides a 
sufficient supply of oxygen. For long term experiments, or if cell samples were not taken 
more frequently than once per week, an oxygen supply may need to be considered as an 
alternative design. 
4. Conclusions  
Embryonic stem cells are considered to be a source of cells with tremendous potential for 
regenerative medicine, as they are capable of self-renewal and can differentiate into any cell 
type. The bioprocessing of these cells (i.e. creating reliable protocols for cell expansion and 
differentiation) is a critical component of developing therapies ready for clinical 
implementation. Suspension bioreactors are understood to be a scalable, reproducible and 
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reliable method for cell expansion in the biotechnology industry. It is well established that a 
small-scale bioreactor system would be beneficial for stem cell research. Microbioreactor 
systems available in the literature, primarily developed for bacterial and yeast cultures, 
were reviewed and the applications for mammalian, or stem cell cultures were considered. 
However, the fluid environment at this scale remains largely uncharacterised, and 
bioreactor scale-down for cell culture has been shown to not be a linear process. 
Hydrodynamic studies and modeling of the shear and mass transfer environment at this 
small-scale would benefit this field in the development of a small-scale bioreactor applicable 
for embryonic stem cell expansion and differentiation.  
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1. Introduction  
Human embryonic stem cells (hESCs) have two properties that distinguish them from other 
cell types: self-renewal, the ability to propagate indefinitely in culture, and pluripotency, the 
ability to differentiate into any type of specialized cells found in the human body. These 
properties provide the foundation for the development of hESC-derived cell-based 
therapeutics, where specific cell types derived by differentiation of hESCs become a 
therapeutic agent that cures the disease or restores the function of damaged organs or tissue. 
To make this a reality, several technologies must be developed to provide an unlimited and 
consistent supply of hESC-derived cells for clinical use. These include robust and scalable 
methods for production of undifferentiated hESCs, differentiation of the hESCs into 
desirable cell types, recovery, purification, storage and transportation of the derived cells to 
the location of use, and methods and techniques for delivery of the therapeutic cells to a 
human body to provide health benefits. 
Since the derivation of the first hESC lines by Thomson, J. et al. (Thomson, 1998) and 
Reubinoff, B. et al. (Reubinoff et al., 2000), hundreds of new lines have been established and 
propagated under various cell culture conditions. Historically, hESCs were maintained in 
complex culture systems under poorly defined conditions comprising mouse or human 
feeder cell layers and medium containing fetal bovine serum (FBS) or serum replacement to 
provide an extracellular matrix (ECM)-rich environment for cell adhesion, as well as soluble 
growth factors for self-renewal. It is highly desirable that the cell culture systems utilized for 
therapeutic cells, including cell culture surfaces and the media, are well defined (all 
components are known and characterized and their abundance is controlled) and of non-
animal origin or xeno-free (do not contain biological materials of a non-human nature). 
Establishment of the first human embryonic stem cell line (Thomson, 1998) was 
accomplished by extending to hESCs a cell culture system developed for culturing mouse 
embryonic stem cells that is based on inactivated mouse embryonic fibroblasts (MEF) as a 
feeder layer. Soon after the first reports on isolation of human pluripotent cells came 
realization that feeder-free cell culture is essential for production of cells for transplantation 
(Donovan & Gearhart, 2001; Pera et al., 2000); (Pedersen, 2002). Back in 2000 this looked like 
a challenge that would require a very long time to overcome, as 19 prior years of using 
MEFs to support stem cell culture of non-human cells did not result in significant 
understanding of what exactly MEFs provide for stem cells. To make matters worse, there 
was experimental evidence showing that neither MEF conditioned medium nor ECM 
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secreted by MEFs alone was sufficient to produce the same outcomes (Thomson, 1998). Ten 
years later, a fully synthetic cell culture surface (Corning® SynthemaxTM Surface), which 
allows xeno- and serum-free culture and differentiation of therapeutic quality stem cells 
under chemically defined conditions, became commercially available to address this 
problem.  
In this chapter, we will review the evolution of hESC culture conditions from complex un-
defined feeder layer surfaces and FBS-containing medium used initially to derive and 
maintain hESC in culture, to fully defined, xeno-free culture systems described by multiple 
independent studies in the past few years.  The focus of our review will be a development of 
an element of the cell culture system, a fully defined, xeno-free cell culture surface, and the 
benefits of a fully synthetic cell culture surface for propagation and differentiation of human 
embryonic stem cells.  
Authors of this chapter are Corning Incorporated employees and have financial conflicts of 
interest. 
2. Importance and significance of a fully defined cell culture system  
The envisioned applications of hESCs, such as cell therapy and drug discovery, require 
growth and differentiation of hESCs on a large scale. Despite numerous ongoing clinical 
trials involving adult and human embryonic stem cells as a source of cells for a variety of 
therapies, there are fundamental challenges in large scale manufacture of hESCs that need to 
be addressed. These challenges include measurement metrics defining purity and the 
quality of the produced cells for a particular therapy application, complexity and variability 
of cell culture environment for different stem cells and their derivatives, and a need for 
automation of hESCs culture to bring the required consistency and repeatability into the cell 
therapy process (Thomas & Williams, 2009).   
A recent review of cell culture procedures for hESCs (Fernandes et al., 2010) reports that in 
the vast majority (>80%) of cell culture studies published in 2009, hESCs were grown either 
on MEFs and cell lines derived from MEFs, or human feeder cells. In less than 18% of the 
studies the cells were cultured on other surfaces, ~16.5% of which used MatrigelTM, an 
extracellular matrix isolated from Engelbreth-Holm-Swarm (EHS) mouse sarcoma (Becton 
Dickinson, Bedford, MA).  
In the US, regulation of production and marketing of stem cell based therapies falls under 
FDA (Food and Drug Administration) jurisdiction. FDA repeatedly expressed concerns in 
regards to the potential use of stem-cell products derived from hESC that were isolated and 
cultured on MEFs (Halme & Kessler, 2006) and indicated the necessity of testing these cells 
for adventitious agents to meet FDA xenotransplantation guidelines. Another source of 
animal-derived biological material is non-human serum, which is frequently used in cell 
culture. FDA views fetal bovine serum (FBS) as a possible source of the prion that causes 
bovine spongiform encephalopathy and requires that FBS is produced in a country certified 
to be free of this disease (Kirschstein & Skirboll, 2001).  
Cell culture surfaces, as a part of the cell culture system, should meet FDA guidelines and 
address hESCs process scalability issues. The desirable attributes for hESC cell culture 
surfaces for an animal product-free cell culture are an absence of animal derived materials 
and ideally even human derived materials (as those too may be subject to batch-to-batch 
variability and contamination with human pathogens), and compatibility with a defined, 
serum-free media. Other typical cell culture surface attributes include absence of 
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extractables, particulates, and other contaminants, compatibility with conventional 
sterilization techniques (typically gamma irradiation), stability at room temperature, 
similarity to common tissue culture treated (TCT) polystyrene and other cell culture 
surfaces, and, ideally, the surface needs to be ready for use, rather than require further 
preparation and manipulation.  
3. Progress in hESC culture conditions 
The first significant improvement in hESC culture conditions was reported by Geron 
Corporation in 2001 (Xu et al., 2001). When Matrigel and gelatine were tested as surfaces for 
hESC lines H1, H7, H9 and H14 using MEF conditioned medium, all cells attached to 
Matrigel, formed tight colonies separated by differentiated cells, and propagated. In 
contrast, the cells on gelatine showed poor survival and appeared differentiated after one 
passage. Since the major constituents of Matrigel are laminin, collagen IV, heparan sulfate 
proteoglycans, and entactin/nidogen (Kleinman et al., 1982, Kleinman, 1986 #244), the 
authors then explored individual ECM components of Matrigel and observed great 
similarity between Matrigel and laminin cultured cells. 
Further investigation of hESC culture using media conditioned with cells other than MEFs 
(STO, an immortal mouse embryonic fibroblast; NHG190, a transfected mouse embryonic 
cell line; BJ5ta, an immortalized human foreskin fibroblast cell line; an immortalized 
human retinal epithelial cell line) revealed that only Matrigel (or laminin) and MEF 
conditioned medium maintain long-term propagation of undifferentiated hESCs, as cells 
under other conditions differentiated within 1 to 7 passages. There was no difference 
found in integrin expression profiles between cells cultured on MEFs, Matrigel, or 
laminin, and cells under all three of these cell culture conditions expressed 6 and 1 
integrins consistent with integrin mediated hESC attachment to laminin. The cultured 
cells were positive for Tra-1-60 and Tra-1-81, negative for SSEA-1, and formed teratomas 
with various differentiated cells in immunodefficient mice. These data demonstrated the 
capability of a MEF-free surface to support proliferation of hESCs in an undifferentiated 
state.  
While Matrigel was a significant improvement over MEFs, its mouse origin and undefined 
and variable nature makes it highly undesirable as a substrate for therapeutic hESC scale 
up. It was also found that current hESC lines derived on MEF and cultured on Matrigel in 
the presence of animal serum have nonhuman sialic acid Neu5Gc, a potential immunogen, 
incorporated into their cell membranes (Martin et al., 2005). Exposure of the cells to human 
sera with antibodies specific for Neu5Gc resulted in binding of immunoglobulin and 
complement deposition, which would lead to cell killing in vivo, thus significantly reducing 
the efficacy of cell therapy. After reviewing several approaches, Martin et al. concluded that 
it is easier and safer to start over and derive hESC lines without exposing cells to animal 
products containing Neu5Gc.  
The elimination of animal derived products from hESC culture requires a xeno-free cell 
culture surface and medium. The interdependence of the cell culture surface and medium in 
providing optimal conditions for cell culture performance made progress in this field 
iterative. Short term solutions involved human feeder cells (Genbacev et al., 2005), (Choo et 
al., 2004), and serum replacement or serum-free medium (Amit et al., 2000).  
The next significant milestone in development of hECS culture was achieved in 2005 (Xu et 
al., 2005), when Geron demonstrated proliferation of H7 and H9 hESCs in serum-free 
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medium on Matrigel. Geron evaluated 15 growth factors and their combinations at various 
doses in a medium containing 80% Knockout–Dulbecco’s modified Eagle’s medium, 20% 
KnockoutTM serum replacement (Invitrogen, Carlsbad, CA), 1 mM L-glutamine, 0.1 mM β-
mercaptoethanol, 1% nonessential amino acids. Although the exact composition of 
KnockoutTM formulation is a commercial secret, the product is a more-defined growth 
supplement (Price et al., 1998) that reduces the spontaneous differentiation of ESCs. Basic 
fibroblast growth factor (bFGF) was found to support growth of hESCs without conditioned 
medium. 
This was followed up by a study conducted at Prof. J. A. Thomson’s lab that disclosed a 
complete composition of serum- and xeno-free medium, TeSR1, for hESC culture (Ludwig et 
al., 2006). The medium is based on DMEM/F12 medium supplemented with bFGF, TGF-1, 
LiCl, -aminiobutyric acid, and pipecolic acid. It contains only six polypeptides (Table 1) and 
none of them is of animal origin. Ludwig et al. also screened a variety of human ECM proteins 
individually and in combination to establish that a substrate coated with a mixture of collagen 
IV, fibronectin, laminin, and vitronectin can support growth of H1 and H9 hESC lines for at 
least 7 months. The stem cells cultured under these conditions did not test positive for the 
presence of nonhuman sialic acid. Despite these advances, the importance of further 
optimization of the cell culture surface was recognized, as the purified human matrix 
components are expensive and could potentially be contaminated with human pathogens.  
When compared to different human ECM proteins, as well as human and animal sera 
matrices (Hakala et al., 2009), Matrigel was found to be a superior hESC culture surface. The 
comparison was performed using conventional and modified hESC culture media that 
included human foreskin fibroblast-conditioned culture medium, chemically defined 
mTeSR1 medium and its xeno-free counterpart, TeSR1 medium. Judging by the maximum 
passage number attainable, hESC morphology, and expression of stem cell markers, Hakala 
concluded that a xeno-free, fully defined, and reproducible feeder cell–free hESC culture 
method still remained to be developed.  
 
Polypeptide Conc. mM 
bFGF 5.77 10-6 
TGF 1 2.35 10-8 
Human Insulin 3.92 10-3 
Human Holo-Transferrin 1.37 10-4 
Human Serum Albumin 1.95 10-1 
Glutathione  6.38 10-3 
Table 1. Polypeptides in TeSR1, (Ludwig et al., 2006) 
4. Synthetic surfaces for hESCs 
Typically cells are cultured on a polystyrene surface that is rendered hydrophilic (e.g. TCT 
and Corning CellBIND culture ware) by various plasma treatments. It is recognized that 
cell attachment occurs through interactions between integrins, cell adhesion receptors, and 
extracellular matrix proteins. To enable cell attachment to a surface, ECM proteins need to 
be immobilized on that surface first.  
The proteins adsorb onto a surface from the culture medium, in which case serum 
supplement is a source of ECM proteins. However, when hESCs are cultured on a TCT 
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surface in serum supplemented medium (80% Dulbecco modified Eagle’s medium 
supplemented with 20% fetal bovine serum), they undergo differentiation within a passage 
or two (Thomson, 1998). Alternatively, the ECM could be secreted by the cultured cells. 
Unlike other cell types, hESCs do not secrete a sufficient amount of ECM to sustain 
themselves in an undifferentiated state (Braam et al., 2008). Therefore, development of a 
synthetic surface for hESC culture under serum free conditions is not a trivial task (Couture, 
2010), (Elefanty & Stanley, 2010).  
The approaches to develop a solution to the problem described above can be grouped into 
three categories. First is to design a surface that facilitates ECM protein adsorption. The second 
is to identify a specific extracellular matrix protein that could be manufactured at a significant 
scale and coated onto conventional cell culture surfaces. The third approach entails 
development of a biomimetic surface that mimics the function of extracellular matrix proteins. 
4.1 Polymer surfaces facilitating ECM protein adsorption. 
Attempts to develop a surface for hESC culture using conventional polymers involved 
investigation of improved processing methods for polystyrene (Mahlstedt et al.). When 
TCPS (tissue culture polystyrene) was etched using radio frequency oxygen plasma for 5 
min at pressures below 20 mT, HUES7 and NOTT1 hESC lines attached and proliferated on 
the surface for at least 10-14 passages in MEF conditioned medium showing doubling times 
similar to those for cells cultured on Matrigel and expressing hESC pluripotency markers. 
BD PrimariaTM and Corning CellBIND surfaces were tested in a similar experiment as 
controls and also demonstrated the ability to support hESC culture to some extent. Quartz 
crystal microbalance analysis showed an increase in the amount of adsorbed proteins from 
conditioned medium onto the plasma etched surface, which was related to the improved cell 
culture performance. The proposed underlying mechanism is an increased hydrophilicity of 
the surface that enables replacement of small albumin, which is the first protein to adsorb 
onto the surface due to its abundance in serum, over time with less abundant, higher 
molecular weight, cell adhesive proteins. Attempts to culture hESCs on this surface using 
mTeSR1 or StemPro® hESC defined media were unsuccessful, as these media do not contain 
cell adhesion ECM proteins. 
Similar material properties were achieved through organic synthesis. Villa-Diaz (Villa-Diaz 
et al., 2010) identified a polymer, poly[2-(methacryloyloxy)ethyl dimethyl-(3-
sulfopropyl)ammonium hydroxide, which, when coated on polystyrene, supported the 
undifferentiated proliferation of BG01 and H9 hESC lines for over 25 passages in MEF-
conditioned medium. The surface did not support hESC culture in mTeSR1 medium, while 
mixed result were observed in StemPro medium, the composition of which is not disclosed. 
A more recent study (Brafman et al., 2010) described screening of 90 polymers for their 
ability to support hESC culture. Brafman identified only one polymer, poly(methyl vinyl 
ether-alt-maleic anhydride) (PMVE-alt-MA), that HUES1 and HUES9 cells attached to and 
proliferated for five passages in StemPro medium. The expression levels of endogenous 
ECM proteins and integrins in hESCs grown on PMVE-alt-MA were found to be 
significantly higher compared to hESCs grown on Matrigel, suggesting that the cells were 
generating ECM proteins required for their attachment to the surface.  
4.2 Extracellular matrix protein coatings 
Multiple publications demonstrated that Matrigel could be replaced, under certain 
conditions, with a mixture of collagen, fibronectin, laminin, and vitronectin (Ludwig et al., 
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comparison was performed using conventional and modified hESC culture media that 
included human foreskin fibroblast-conditioned culture medium, chemically defined 
mTeSR1 medium and its xeno-free counterpart, TeSR1 medium. Judging by the maximum 
passage number attainable, hESC morphology, and expression of stem cell markers, Hakala 
concluded that a xeno-free, fully defined, and reproducible feeder cell–free hESC culture 
method still remained to be developed.  
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2006), or even individual ECM proteins including laminin, fibronectin, or vitronectin (Table 
2). As evidenced by the data, conditioned medium can support hESC proliferation in an 
undifferentiated state on most common ECM proteins. However, transition to defined 
media such as mTeSR1, TeSR1, X-VIVO™ 10 seems to restrict the choice to laminin or 
vitronectin. 
Laminin is a major constituent of Matrigel, and it was the first pure ECM protein identified 
to support hESC attachment and proliferation of the hESCs (Xu et al., 2001). Fairly recently, 
a detailed study by Braam et al. demonstrated the ability of vitronectin to support hESC 
culture in mTeSR1 medium and investigated the underlying mechanism (Braam et al., 2008). 
E-Cadherin, a cell-cell adhesion glycoprotein, also was shown to enable attachment and 
propagation of H9 cells in mTeSR1 medium (Nagaoka et al., 2010).  
 











(Xu et al., 2001), 
Laminin H1 X-VIVO 10 + GF 40 (Li et al., 2005) 
Laminin KhES-1, KhES-2, hES-3 MEF conditioned 10 (Miyazaki et al., 2008) 
Laminin HS420, HS207, HS401, H1, H9 
Variants of TeSR1 
and mTeSR1 5-20 (Rodin et al., 2010) 
Fibronectin H9, BG01 HESCO 8 (Lu et al., 2006) 
Fibronectin I-3, I-6, H9 Knockout SR >50 (Amit et al., 2004) 
Collagen I H1, H9 SDEC conditioned 5 (Jones et al. 2010) 
Collagen I HUES-1 Shef 1 hESF9 
21 
15 (Furue et al., 2008) 
Vitronectin MEL1, MEL2, hES1 StemPro >10 (Prowse et al., 2010) 
Vitronectin HUES1, HES2, HESC-NL3 mTeSR1 12 (Braam et al., 2008) 
Vitronectin H9 mTeSR1 10 (Rowland et al., 2010) 
Vitronectin HES-3, H1 mTeSR1 >30 (Yap et al., 2011) 
Vitronectin CHA6, H9 mTeSR1 >30 (Yoon et al., 2010) 
E-Cadherin H9 mTeSR1 37 (Nagaoka et al., 2010) 
Table 2. ECM surfaces for hESC culture. 
Miyazaki et al., (Miyazaki et al., 2008) investigated attachment of  three hESC lines (KhES-1, 
KhES-2, and KhES-3) to various recombinant laminins (511, 411, 332, 211, and 111) in MEF 
conditioned medium and observed a significant discrepancy in cell attachment to these 
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laminins with laminin 332 showing the best performance across these cell lines. Others 
reported recombinant laminin-511 to be a good substrate for HS420, HS207, and HS401 cell 
lines (Rodin et al., 2010).  
Although extracellular matrix protein coatings are frequently used for hESC culture in 
research labs, application of these coatings to hESC scale up is not straightforward. 
Recombinant proteins are fairly expensive to produce and purify. They are prone to batch-
to-batch variabity, need to be coated onto a surface under aseptic conditions, and they can 
degrade or denature upon dehydration. Published protocols indicate that coatings of 
purified proteins require optimization (Yap et al., 2011); for example, a defined thickness 
threshold needs to be achieved to enable hESCs attachment and proliferation rates similar to 
those observed on Matrigel coatings. Formation of such a coating requires a significant 
period of time (hours) under aseptic conditions. Utilization of the protein for the coating is 
very inefficient, as >50% of it remains in the solution. All this makes purified protein cell 
culture surfaces expensive and limits their scalability.  
4.3 Biomimetic surfaces for stem cells 
The interest in synthetic biomimetic surfaces was initiated by a discovery of the RGD 
(arginine-glycine-aspartic acid) peptide sequence present in most ECM proteins. When 
coupled to a surface, the RGD sequence promotes cell attachment (Pierschbacher & 
Ruoslahti, 1984). A large variety of polymer materials incorporating RGD peptides have 
been designed and studied (Hersel et al., 2003). 
Cells attach to the ECM through integrins, cell adhesion receptors (Humphries et al., 2006), 
(Hynes, 2002). Integrins support a broad spectrum of cellular functions including 
proliferation and differentiation, and can bind to such ECMs as collagen, fibronectin, 
laminin, vitronectin, and N-linked glycoproteins, (e.g. osteopontin and bone sialoprotein). 
They can also interact with other cells through vascular- or intracellular- cell adhesion 
molecules (VCAM and ICAM). The integrins are heterodimeric molecules consisting of  
and  subunits. There are twenty four known  combinations, which can be divided into 
several subfamilies based on evolutionary relationships. The orthologs of human integrins 
recognizing the RGD amino acid sequence and laminins can be traced back to primitive 
organisms, while other integrins must have evolved with increasing organism complexity.  
From such a perspective, it is not surprising that hESCs primarily express integrins 
recognising the RGD sequence and laminin (Braam et al., 2008), (Meng et al., 2010), 
(Rowland et al., 2010), (Prowse et al., 2011). Braam et al., evaluated integrin expression in 
three hESC lines (HES2, HUES1, and HESCNL3) using fluorescence-activated cell sorting 
analysis. While integrin chains 1, 4, 10, and 3 and integrins 91 and V6 were either 
not detected or detected at very low levels, cells expressed integrin chains 2, 3, 5, 6, 
11, 1 and integrin V5. This leaves the following combinations of integrin chains to 
enable cell attachment: 21, 31, 51, 61, 111, V5, and V1. These 
combinations, designated in Figure 1 as small orange circles, comprise cell surface receptors 
for all major ECM components.  
It was also found, as discussed in the previous section, that attachment through either 
laminin or RGD binding integrins (Li et al., 2005), (Rodin et al., 2010), (Wong et al., 2010), 
(Braam et al., 2008), (Rowland et al., 2010), (Yoon et al., 2010), (Yap et al., 2011) is sufficient 
to support undifferentiated proliferation of hECS in serum-free, chemically defined 
medium.  
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Fig. 1. Mammalian intergrins and their ligands (Humphries et al., 2006) 
For these reasons, surfaces with immobilized laminin and RGD peptides were studied as 
synthetic surfaces for hESC proliferation (Li et al., 2006), (Derda et al., 2007), (Melkoumian et 
al., 2010) (Derda et al., 2010), (Klim et al., 2010). Li et al. was first to demonstrate that grafting 
the RGD containing peptide, Ac-KGGNGEPRGDTYRAY, from bone sialoprotein to 
acrylamide-acrylic acid copolymer can support short term attachment and proliferation of 
HSF-6 hESCs in MEF conditioned KSR-supplemented medium. The colonies of hESCs 
expressed Oct-4 and SSEA-4 markers of undifferentiated hESCs after five days in culture and 
maintained the same morphology as those cultured under the same conditions on Matrigel.  
Derda et al. extensively studied laminin-derived peptides (Derda et al., 2007) in an attempt 
to identify specific sequences supporting hESC attachment. Using a self-assembled 
monolayers technique, the authors discovered several peptides enabling attachment and 
short term proliferation (6 days) of hESCs, again though, in MEF conditioned medium. The 
most important finding, which facilitated further advancement in the field, was an 
observation that hESCs, in comparison to other cells, require relatively high surface peptide 
densities due to low expression levels of corresponding integrins.  
This suggests a hypothesis where a critical number of integrins on the cell surface are needed 
to be simultaneously engaged to enable optimal hESC adhesion. At low surface peptide 
density the probability of such engagement is reduced. We (Melkoumian et al., 2010) focused 
efforts on peptide-acrylate surfaces (PASs), as did others (Li et al., 2006), and pursued high 
peptide densities through optimization of acrylate polymer and peptide conjugation. The 
developed poly(hydroxyethyl methacrylate-co-carboxyethyl acrylate) coating provides a 
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significant amount of functional groups for peptide conjugation, while its swellable nature 
enhances presentation and accessibility of the conjugated peptide for integrin binding. 
Co-conjugating a small amount of fluorescently labelled peptide together with a cell binding 
peptide and comparing the fluorescence intensities to a calibration curve generated by 
drying down the same mixture of peptides onto the acrylate surface, we estimated that a 
BSP peptide (Table 3) density of 6-9 pmol/mm2 is sufficient to enable cell culture 
performance in X-VIVO 10 medium similar to Matrigel (Melkoumian et al., 2010), (Figure 2).  
An alternative approach in enabling hESC adhesion and proliferation was demonstrated by 
Kohlar, et al., (Kolhar et al., 2010), who employed cyclic RGD peptides to improve the 
strength of peptide – integrin binding to achieve a similar outcome. The reported peptide 
densities, 0.1–0.3 fmol/mm2, are significantly lower. Nevertheless, stronger integrin binding 
to cyclic peptide allows development of a sufficient number of peptide-integrin interactions 



































































c)      d) 
Fig. 2. Conjugated peptide surface density assessment; a) Fluorescence scan of dried down 
peptides representing various peptide densities; b) Fluorescence of conjugated peptide 
mixture; c) BSP peptide concentration (mM)-dependent H7 cell number after 5 days in 
culture in X-VIVO™ 10 + 80 ng/ml bFGF + 0.5 ng/ml TGF1 medium on PAS in 6-well 
plate, conjugated with serial dilution of BSP peptide. Cell seeding density was 1 x 106 cells 
per well; d) Peptide density calibration curve; (Melkoumian et al., 2010), supplementary 
Figure 1A and Figure 1B. 
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densities, 0.1–0.3 fmol/mm2, are significantly lower. Nevertheless, stronger integrin binding 
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c)      d) 
Fig. 2. Conjugated peptide surface density assessment; a) Fluorescence scan of dried down 
peptides representing various peptide densities; b) Fluorescence of conjugated peptide 
mixture; c) BSP peptide concentration (mM)-dependent H7 cell number after 5 days in 
culture in X-VIVO™ 10 + 80 ng/ml bFGF + 0.5 ng/ml TGF1 medium on PAS in 6-well 
plate, conjugated with serial dilution of BSP peptide. Cell seeding density was 1 x 106 cells 
per well; d) Peptide density calibration curve; (Melkoumian et al., 2010), supplementary 
Figure 1A and Figure 1B. 
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When a series of RGD peptides (Table 3) from various ECM proteins (bone sialoprotein, 
vitronectin, and fibronectin) was conjugated to the acrylate coating and tested for their 
ability to support hESC culture, only BSP and VN peptides supported attachment and 
proliferation of H1 and H7 hESCs similar to Matrigel (Melkoumian et al., 2010). None of the 
fibronectin peptides provided adequate cell attachment. According to Humphries et al., BSP 
protein engages the same integrins, V5 and V3, as vitronectin suggesting the same 
integrin activation by both BSP and VN peptides, (see Figure 1). Braam et al. (Braam et al., 
2008) reported binding of hESCs to vitronectin through V5 integrin and showed it being 
sufficient for cell self-renewal under chemically defined conditions. Since V3 integrin was 
not detected in that study, it is highly likely that BSP and VN peptides enable hESC 
attachment through V5 integrin, as it is the only remaining choice for BSP peptide, 
(Figure 1). This interaction is fairly specific and that specificity is governed by RGD flanking 
sequences. 
Peptide based cell culture surfaces are not limited to integrin interactions, but can also be 
designed to take advantage of multiple attachment mechanisms. Recently Klim at el., (Klim 
et al., 2010) demonstrated self-assembled monolayer peptide biomimetic surfaces that 
included peptides binding to glycosaminoglycans. The cell culture surface presenting 
vitronectin peptide GKKQRFRHRNRKG was found to support attachment and proliferation 
of H9, H13, and H14 cells in mTeSR1 medium in the presence of ROCK inhibitor.  
 
Sequence Abbreviation Reference 
Ac-KGGNGEPRGDTYRAY BSP (Oldberg et al., 1988) 
Ac-KGGPQVTRGDVFTMP VN (Suzuki et al., 1985) 
GRGDSPK FN-1 (Pierschbacher & Ruoslahti, 1984) 
Ac-KGGAVTGRGDSPASS FN-2 (Pierschbacher & Ruoslahti, 1984) 
BSP, bone sialoprotein; VN, vitronectin; FN, fibronectin. 
Table 3. Peptide sequences conjugated to acrylate coatings; (Melkoumian et al., 2010) 
 
 
Fig. 3. Consistency of doubling time for H7 cells grown on Corning SynthemaxTM and 
MatrigelTM. 
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The fact that hESCs can be cultured under defined conditions on a variety of substrates, 
from complex ECM protein mixtures to single peptide surfaces, demonstrates the native 
ability of undifferentiated hESCs to propagate without the need for a very precise and 
complex signalling through adhesion receptors (Klim et al., 2010), (Ying et al., 2008). 
One of the desirable and anticipated advantages of synthetic surfaces is improved 
consistency and reproducibility of cell culture performance. Non-biological, small molecular 
weight compounds required for manufacture of synthetic surface can be consistently 
obtained in high quantity and purity and can be manipulated in a conventional industrial 
setting. When compared to proteins, short peptides can be easily manufactured via chemical 
synthesis. Purification and quality assurance are dramatically less complex for peptides. 
Short peptides do not denature and exhibit higher stability towards chemical and physical 
agents, thus, overall providing a scalable manufacturing platform for hESC cell culture 
surfaces, enabling cell therapy applications. This will translate into industrial processes 
resulting in consistent cell culture surface, as it did for tissue culture treated polystyrene 
surfaces. We observed a clear improvement in cell culture consistency at the early stages of 













+ cells Passages 
H7 
X-VIVO 10 
Synthemax 41 ± 5 92 ± 4 85 100 
21 
Matrigel 50 ± 12 92 ± 3 96 100 
mTeSR1 
Synthemax 55 ± 21 90 ± 4 66 - 
11 
Matrigel 69 ± 26 83 ± 8 56 - 
StemPro 
Synthemax 31 ± 6 96 ± 0 - - 
5 
Geltrex 31 ± 5 97 ± 0 - - 
NutriStem™ 
Synthemax 32 ± 9 92 ± 3 - - 
5 
Matrigel 35 ± 4 92 ± 6 - - 
H1 X-VIVO 10 
Synthemax 46 ± 8 82 ± 5 78 ± 4 91 
14 
Matrigel 53 ± 16 80 ± 8 83 ± 6 84 
H9 mTeSR1 
Synthemax 43 ± 3 93 ± 5 73 ± 4 - 
5 
Matrigel 44 ± 6 95 ± 4 76 ± 2 - 
BG01v mTeSR1 
Synthemax 40 ± 6 86 ± 6 - - 
11 
Matrigel 44 ± 6 89 ± 5 - - 
Table 4. hESC long-term expansion on Synthemax™ in defined media: X-VIVO™ 10 (Lonza, 
+ 80ng/ml bFGF + 0.5ng/ml TGFb1); mTeSR1 (Stem Cell Technologies); NutriStem™ 
(StemGent); StemPro hESC SFM (Invitrogen).  
Since the publication in Nature Biotechnology (Melkoumian et al., 2010) gamma sterilization 
methods were developed for the peptide acrylate surface and the surface was 
commercialized under the Corning® SynthemaxTM Surface trade name. It is being offered in 
two grades (therapeutic and research) in a number of formats including 6-well plates, T-75 
and T-225 flasks. The utility of the surface has been demonstrated for additional cell lines 
including H9 and BGO1v. In addition to X-VIVO 10 and mTeSR1, the surface was found 
compatible with StemPro and NutriStem media. Multipassage hESC data on Synthemax 
surface is summarized in Table 4. 
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For hESC-based therapeutics it is critical to have a defined, scalable culture system for both 
the expansion and differentiation stages of cell production. The picture would not have been 
complete without testing Synthemax surface for hESC differentiation. After passaging cells 
14 times on PAS surface, cells were treated with Activin A and BMP4 as previously 
described (Laflamme et al., 2007) to investigate differentiation into cardiomyocytes. The 
experiment resulted in spontaneously beating cell aggregates expressing the cardiomyocyte-
specific markers, Nkx2.5 and -actinin, and shows that the BSP peptide acrylate surface 
supports both expansion and differentiation of hESC to therapeutic progenitor cells, (see 
Figure 4).  
 
 
      
a)               b) 
Fig. 4. Cardiomyocyte differentiation of H7 hESC on BSP-PAS surface: Immunofluorescent 
staining (a) and flow cytometry analyasis (b) of differentiated cells for cardiomyocyte-
specific markers, Nkx 2.5 shown in red and -actinin shown in green. 
5. Conclusions 
Although a variety of recombinant protein coatings in combination with a defined serum-
free cell culture medium have been shown to provide a good cell culture system for hESCs, 
the limited scalability of most of these systems limits their use for cell therapy applications. 
Peptide acrylate surfaces based on a pure synthetic chemistry approach offer consistency, 
reproducibility, scalability, safety, and eventually lower cost for hESC-derived cell therapy 
applications. 
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1. Introduction 
Human embryonic stem cells (hESCs) are promising materials for both basic and applied 
research fields such as human developmental biology and drug discovery because of their 
capacity for long-term self-renewal and differentiation into virtually all types of cells and 
tissues (Thomson et al., 1998; Hoffman & Carpenter, 2005). For example, with regard to their 
applications for drug development research, these cells can be used test whether drugs 
under development are efficacious against specific diseases by using hESCs-derived disease 
models which show disease phenotypes (Barbaric et al., 2010; Laustriat et al., 2010). 
Genetic manipulation is a useful strategy for generating cellular disease models. Random 
integration of exogenous genes into the genome of hESCs is the most straightforward and 
easiest method. Random integration, however, often results in inactivation or silencing of 
integrated genes in hESCs (Ellis, 2005; Liew et al., 2007; Xia et al., 2007) and also might alter 
the cellular phenotypes due to insertional mutagenesis, which disrupts gene functions in 
undefined gene regions (Hacein-Bey-Abina et al., 2003; Nienhuis et al., 2006). Furthermore, 
the reliability of data may be compromised by differences in the transgene integration sites 
when comparing multiple transgenic cell lines. Introducing transgenes by gene targeting is 
one way to avoid undesired gene silencing and insertional mutagenesis, but the targeting 
efficiency in hESCs is notoriously low (Zwaka and Thomson, 2003; Urbach et al, 2004; Irion 
et al, 2007; Di Domenico et al, 2008; Ruby et al, 2009). Therefore, a lot of time and effort may 
be required to obtain gene-targeted hESC clones. To address these issues, several strategies 
have been explored. Researchers have identified usable native sites for gene integration in 
the human genome. Bacteriophage phiC31 integrase, or adeno-associated virus type 2 
(AAV2), can mediate plasmid integration into pseudo-attP sites or the adeno-associated 
virus integration site 1 locus in the genome, respectively (Thyagarajan et al., 2008; Smith et 
al., 2008). However, the human genome possesses 23 different pseudo-attP sites, so the 
integration site cannot be specifically controlled, and the AAV2-mediated targeting 
efficiency is still low (4.16%). In contrast, foreign sequences such as bacterial loxP and yeast 
FRT are useful for gene integrations into the genome. Both loxP and lox2272 sequences can 
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have been explored. Researchers have identified usable native sites for gene integration in 
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(AAV2), can mediate plasmid integration into pseudo-attP sites or the adeno-associated 
virus integration site 1 locus in the genome, respectively (Thyagarajan et al., 2008; Smith et 
al., 2008). However, the human genome possesses 23 different pseudo-attP sites, so the 
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efficiency is still low (4.16%). In contrast, foreign sequences such as bacterial loxP and yeast 
FRT are useful for gene integrations into the genome. Both loxP and lox2272 sequences can 
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be introduced at the silence-resistance sites of hESCs, but the selection efficiency of 
recombination-mediated cassette exchange is relatively low (two out of 92 clones) (Du et al., 
2009). As a result, it is thus considered that there is room for improvement in the targeting 





Fig. 1. Schematic diagrams of the conventional random integration and site-directed 
integration. (A) Conventional random integration requires selection of the proper clone(s) 
from among a large number of clones. This puts a burden on researchers to scale-up, 
differentiate and check the quality of each individual clone. (B) The site-directed integration 
produces clones by manipulating the only docking site. Hence, all clones can be used. 
In this chapter, a site-directed integration system based on homologous recombination (HR) 
and Cre recombinase-mediated site-specific integration is described. First, gene targeting 
was performed to introduce a docking site containing two loxP sites and a hygromycin 
resistance gene without the first methionine codon into the hypoxanthine 
phosphoribosyltransferase 1 (HPRT) locus. Next, a gene of interest was inserted into the 
docking site by Cre recombinase. Correct insertion into the docking site confers hygromycin 
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resistance. Using this strategy, when an EGFP expression cassette (CAG promoter-driven 
EGFP) was inserted into the HPRT-docking site of the hESC line, the EGFP fluorescence was 
detected in all of the hygromycin-resistant clones. Furthermore, when a single vector 
carrying both an rtTA expression cassette and a Tetracycline (Tet) Response Element (TRE)-
driven EGFP was introduced into the docking site, doxycyclin (Dox) could induce EGFP 
expression in the hygromycin resistant clones in a dose-dependent manner, and the clones 
did not leak EGFP expression in the absence of Dox. 
Every time a transgene is inserted into the HPRT locus, carrying out conventional gene 
targeting is impractical because of the low HR efficiency, whereas the new site-directed 
integration system has greatly improved efficiency. Once the hESC lines with the docking 
site in the HPRT locus are generated by HR, any gene of interest can be integrated into the 
HPRT locus with nearly 100% efficiency. Furthermore, all clones created by this system have 
the same genetic background. This enables the effects among different genes integrated at 
the HPRT locus to be evaluated without consideration of data from multiple cell lines, 
unlike the usual need for comparison among randomly integrated hESC lines. Therefore, the 
new site-directed integration system makes it possible to produce transgenic hESC lines 
quickly and thus obtain reliable research results (Fig. 1). 
2. Site-directed integration of transgenes for hESCs and its future 
applications 
2.1 Homologous recombination for hESCs 
To integrate the docking site for site-directed gene integration, we first carried out HR for 
hESCs. We chose the HPRT locus as the transgene integration site because, along with 
ROSA26 and others, this locus is considered to always allow transgene expression in the 
mouse genome (Bronson et al., 1996; Zambrowicz et al., 1997; McCreath et al., 2000). In 
addition, previous reports have shown the success of HR to the HPRT locus of hESCs 
(Zwaka & Thomson, 2003).  
To generate the HPRT-targeting vector, the 5’- and 3’- homologous arms (7.0 kb and 2.0 kb 
respectively) were amplified from KhES-1 genomic DNA by polymerase chain reaction (PCR) 
using KOD FX (TOYOBO, Japan, also known as KOD Xtreme, supplied from Merck). This 
targeting vector contained a loxP site flanked by a neomycin resistance gene expression 
cassette, and another loxP site was located 5’ to a promoter-less hygromycin resistance gene 
lacking the start ATG codon. These elements thus became the docking site for gene integration. 
To exclude the effects of external transcription factors, the docking site was inserted between 
two DNase I-hypersensitive site 4 (HS4) insulators (Chung et al., 1993) (Fig. 2). After the 
targeting vector was linearized by cutting the NotI site at the distal end of the 5’arm, it was 





Fig. 2. The structure of the targeting vector for the human HPRT locus.  
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be introduced at the silence-resistance sites of hESCs, but the selection efficiency of 
recombination-mediated cassette exchange is relatively low (two out of 92 clones) (Du et al., 
2009). As a result, it is thus considered that there is room for improvement in the targeting 
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Fig. 2. The structure of the targeting vector for the human HPRT locus.  
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For electroporation, two confluent 100 mm dishes of KhES-1 (2-4 x 106) cells were 
completely dissociated using 0.05% trypsin and 0.2 mM EDTA. Cells were mixed with 10 g 
of linearized targeting vector, electroporated in GenePulser Xcell (BioRad) using the 
following settings: square mode, 250 V, 4 ms x 2, 5 s interval, and then dispensed into a 60 
mm dish plated with neomycin-resistant feeders (mouse embryonic fibroblasts (MEFs)). 
Two days after electroporation, the cells were treated with 50 g/ml G418 (Sigma). The next 
day, the G418 concentration was increased to 100 g/ml. Selection was performed for 10-14 
days post-electroporation. 
Out of the 424 G418-resistant clones screened, six (1.42%) had undergone the desired 
homologous recombination event (Table 1) (Sakurai et al., 2010). HR was confirmed by PCR 
and a Southern blotting analysis (Sakurai et al., 2010). One targeted clone, named K1-HS, 
was randomly selected and used for subsequent gene replacement. We also carried out gene 
targeting for KhES-1 sub-line 1 (Hasegawa et al., 2006) and this targeting efficiency was 




Table 1. HPRT gene targeting experiments in hESCs. 
2.2 Site-directed gene integration 
To perform site-directed integration for the HPRT locus, we constructed the pInsert vector 
as a basic vector, which contained the EF1 promoter, a Kozak sequence (Kozak, 1987), an 
ATG codon and a loxP site in this order (Fig. 3A). To examine whether this site-directed 
integration system was functional, we tried to integrate an EGFP expression vector into the 
HPRT locus and constructed the pInsert-Tif-CAG-EGFP vector, which carries an EGFP 
transgene under the control of the CAG promoter and a Cor insulator, with the tandem core 
element of the chicken HS4 beta globin insulator (Otsuki et al., 2005) (Fig. 3B). 
Electroporation was used to introduce the plasmids into the cells. Five micrograms of a Cre 
expression vector (pEF1-Cre) and 20 g of the pInsert-Tif-CAG-EGFP vector were used for 
each electroporation procedure. The number of cells (K1-HS), the methods used for cell 
dissociation, and the electroporation settings were the same as those used for the gene 
targeting experiments. The ESCs were then plated onto hygromycin-resistant MEFs 
(Dainippon Sumitomo Pharma, Japan). Hygromycin selection (40 g/ml, Invitrogen) was 
started two days after electroporation, and was performed for 10-14 days post-
electroporation. 
In the presence of hygromycin, survival is highly skewed towards clones that have 
undergone the correct recombination event. This is because our method requires the 
reconstitution of the hygromycin resistance gene by Cre-mediated recombination between 
the EF1 promoter-ATG sequence in a plasmid vector carrying the transgene of interest and 
a promoter-less hygromycin resistance gene lacking a start codon in the targeted HPRT 
 
 




Fig. 3. (A) A vector developed for site-directed integration, pInsert. (B) The strategy used for 
site-directed integration. Cre recombinase-mediated integration of the pInsert vectors 
carrying a gene of interest confers hygromycin resistance. 
locus (Fukushige & Sauer, 1992; Beard et al., 2006). In this case, only clones in which the 
CAG-EGFP cassette is integrated into the docking site on the HPRT locus can survive under 
hygromycin selection. All hygromycin resistant clones therefore theoretically express EGFP, 
because the HPRT locus supports strong, ubiquitous expression of inserted sequences, and it 
is not subject to any gene-silencing effects. 
In five transfection experiments, a total of 186 hygromycin-resistant clones were obtained, 
and all of them were EGFP-positive (Table 2) (Sakurai et al., 2010). Eight clones were 
randomly selected from the hygromycin-resistant clones, and all of them expressed similar 
levels of EGFP. The correct and single-copy integration were confirmed by PCR and a 
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Table 2. Efficiency of EGFP expression in the site-directed integration using a pInsert-Tif-
CAG-EGFP vector. 
Southern analysis (Sakurai et al., 2010). The correctly integrated clones were expected to 
have lost their neomycin resistance due to cassette exchange. As expected, all clones (80 
clones that were randomly chosen from the initial 186) were neomycin-sensitive (Sakurai et 
al., 2010). The pInsert-Tif-CAG-EGFP integrated clones maintained their expression of EGFP 
for at least 6 months in an undifferentiated state in the presence of hygromycin (data not 
shown). When these cells were differentiated into neurons, it was possible to detect EGFP 
expression in the resulting neurons (Fig. 4).  
 
 
Fig. 4. Neural differentiation of a pInsert-Tif-CAG-EGFP integrated clone. Bar = 100 m. 
2.3 Inducible gene expression based on the site-directed integration 
We attempted to introduce all components of the Tet-inducible gene expression system into 
the docking site at the HPRT locus. Site-directed integration was performed by co-
transfection of a pInsert vector carrying CAG-rtTA, the Cor insulator and TREtight-EGFP 
(pInsert-CTOR-EGFP) (Fig. 5), with a pEF1-Cre. Fifty micrograms of pInsert-CTOR-EGFP 
was used for this experiment, and the other methods were the same as were used for the 
site-directed integration of pInsert-Tif-CAG-EGFP (Sakurai et al., 2010). 
Treatment with Dox for 2 days after the emergence of hygromycin-resistant colonies 
resulted in a dose-dependent induction of EGFP expression (Sakurai et al., 2010). Two clones 
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Fig. 5. (A) pInsert-CTOR and (B) pInsert-CTOR-EGFP vectors for the first-generation Tet-
inducible gene expression system based on the site-directed integration. 
that were randomly selected exhibited similar responsiveness to Dox (Sakurai et al., 2010). 
Their correct integration of pInsert-CTOR-EGFP was confirmed by PCR and a Southern 
blotting analysis (Sakurai et al., 2010). One of the two clones was further analyzed in 
additional experiments, and it could form embryoid bodies (EBs) and retained the ability to 
differentiate into representative cells of all three germ layers (Sakurai et al., 2010). Taken 
together, these results indicate that these ESCs maintain their pluripotency after a second 
round of genetic modification and clonal selection. 
Although we put two insulators on both sides of the TRE-EGFP cassette in the pInsert-
CTOR-EGFP integrants to avoid the leaky expression of EGFP, the results indicated that the 
faint EGFP signals could still be detected in the absence of Dox (Sakurai et al., 2010). 
Furthermore, although a FACS analysis showed that most of the Dox-treated live ESCs 
expressed EGFP, the fluorescent micrographs displayed their EGFP expression in a patchy 
fashion (Sakurai et al., 2010). Therefore, we tried to improve the pInsert-CTOR vector for 
practical use. 
2.4. pInsert-Tet5 vector: the reliable Tet-on system 
We investigated methods to diminish the leaky expression of transgenes downstream of the 
TRE. We examined the orientation of the TRE-EGFP cassette and the types of insulators. We 
did not modify the CAG-rtTA cassette because its structure was the same as the CAG-EGFP 
cassette of the pInsert-Tif-CAG-EGFP vector that demonstrated a robust expression of 
EGFP. As a result, we developed a pInsert-Tet5 vector with undetectable expression of 
EGFP in the absence of Dox. 
The pInsert-Tet5 vector was generated by exchanging the Cor insulator of pInsert-CTOR for 
the HS4 insulator with orientation in opposition to the HS4 insulators of the K1-HS cells 
(Fig. 6A). The pInsret-Tet5-EGFP was introduced into K1-HS cells with pEF1-Cre, and 
transfected cells were selected by hygromycin treatment (Fig. 6B). The experimental method 
was the same as that used for the pInsert-CTOR-EGFP. After the emergence of hygromycin-
resistant cells, Dox was added for induction of EGFP expression (Fig. 7A). Unlike the 
pInsert-CTOR-EGFP integrated clones with their patchy expression, the fluorescent 
micrographs indicated that EGFP was expressed in most of the cells in the colonies in 
response to Dox treatment (Fig. 7A).  
We picked up three pInsert-Tet5-EGFP integrated clones randomly and analyzed their 
responsiveness to Dox. All three clones expressed a similar level of EGFP when they were 
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treated with Dox for 3 days (Fig. 7B). In the absence of Dox, the fluorescence intensities of all 
clones were the same as their parental K1-HS, indicating that the pInsert-Tet5-EGFP 
integrants do not leak any significant level of EGFP expression in the absence of Dox (Fig. 
7B). Moreover, we further analyzed clone 3, and could induce EGFP expression in a Dox 
dose-dependent manner (Fig. 7C). Single-copy integration of a pInsert-Tet5-EGFP vector 





Fig. 6. (A) The pInsret-Tet5 vector used to generate a reliable Tet-On system. The insulator 
of this vector (HS4) was changed from that of the pInsert-CTOR vector (Cor). (B) The 
strategy for site-directed integration of pInsert-Tet5-EGFP. The TRE-EGFP cassettes are 
wedged between two HS4 insulators to avoid the leaky expression of EGFP. 
 
Efficient Integration of Transgenes and Their Reliable Expression in Human Embryonic Stem Cells 113 
 
 
Fig. 7. (A) Dox-inducible EGFP induction of a pInsert-Tet5-EGFP integrated hygromycin-
resistant clone. (B) The FACS analysis of three pInsert-Tet5-EGFP integrated clones. All of 
them expressed a similar level of EGFP when they were treated with 2 g/ml of Dox for 3 
days. Furthermore, the pInsert-Tet5-EGFP integrants did not leak any detectable EGFP in the 
absence of Dox. (C) The dose-dependent induction of EGFP expression by Dox. Cells were 
treated with 100, 250, 500, 1000 or 2000 ng/ml Dox for 3 days. (D) The Southern blotting 
analysis. Genomic DNA was digested by EcoRV and hybridized with an EGFP probe. M: Size 
marker, 3: Clone 3, N: Non-integrated genome. The expected band size was 7.5 kb.  
We believe that the combination of K1-HS and pInsert-Tet5 is a feasible Dox-inducible gene 
expression system. To establish even greater feasibility for using this system, we plan to 
examine to accuracy of the transgene integration, Dox responsiveness in differentiated cells, 
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epigenetic modification near the docking site, and genomic structure of pInsert-Tet5 
integrated locus. There is a possibility that several copies of the pInsert vector may insert in 
tandem into the docking site in the site-directed integration system. In the case of pInsert-
Tet5, tandem integration of pInsert-Tet5 vectors may abolish the reliable regulation by Dox, 
because the gene of interest would be downstream of the EF1 promoter, without 
intervening insulators. Therefore, it will be necessary to pick up a few hygromycin-resistant 
clones and to confirm their correct integration of the pInsert-Tet5 vector. 
2.5 Future applications of the site-directed integration system in human pluripotent 
stem cells 
The drug discovery and development process is time-consuming and costly. Nevertheless, 
the average success rate of approval is approximately 11% after clinical trials (Kola and 
Landis, 2004). The major causes of failure are a lack of efficacy and toxicity in humans (Kola 
and Landis, 2004). Animal disease models can provide a wealth of information about the 
complexity of various disease processes, but efficacious lead compounds for these models 
are often found to be inefficacious during human clinical trials (Kola and Landis, 2004). 
Moreover, animal models do not always indicate the toxicity of compounds in humans 
because of the differences in the biological processes in humans and animals (Martignoni et 
al., 2006). These facts demonstrate the need for more predictive drug screening systems 
(Kola and Landis, 2004; Ebert and Svendsen, 2010). In this regard, human pluripotent stem 
cells are considered to be a promising cell source for drug screening because of the virtually 
limitless supply of normal human cells that can be differentiated into any specific cell type. 
2.5.1 Disease modeling and efficacy screening 
There are several approaches that have been designed to create in vitro disease models using 
pluripotent stem cells. One is that ESCs carrying serious genetic disorders can be 
differentiated into cells with disease-related phenotypes. Preimplantation genetic diagnosis 
(PGD) can identify embryos with genetic defects. The generation of disease-specific hESC 
lines via PGD has already been reported. For example, there are hESC lines with cystic 
fibrosis, myotonic dystrophy type I, Huntington’s disease, adrenoleukodystrophy, 
Dushenne muscular dystrophy, Becker muscular dystrophy, fragile-X syndrome and 
thalassaemia (Pickering et al., 2005; Verlinsky et al., 2005; Mateizel et al., 2006; Stephenson et 
al., 2009). Differentiation of these disease-specific hESC lines into each of the specific cell 
types that manifest disease phenotypes may make it possible to screen for factors that 
restore the normal phenotype and to identify factors associated with disease initiation or 
progression. Furthermore, many induced pluripotent stem cells (iPSCs) have been generated 
from adult patients with incurable diseases and it is also hoped that they will provide new 
sources for drug screening (Dimos et al., 2008; Park et al., 2008; Ebert et al., 2009; Lee et al., 
2009; Soldner et al., 2009; Ye et al., 2009; Maehr et al., 2009; Ye et al., 2009). 
Using pluripotent stem cells carrying disease-linked genes and a high-throughput screening 
system, small-molecule compounds or humoral factors can be identified as potential 
therapeutic drugs (Barbaric et al., 2010). However, in order to more effectively screen for 
intracellular proteins or artificial peptides that are involved in or affect the disease process, 
the site-directed integration system may be more useful. In this section, we describe an 
example of an application of the site-directed integration system for drug screening and 
disease mechanism research. 
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First, as shown in Fig. 8, the docking site was targeted to the HPRT locus of diseased ES/iPS 
cells. Although the targeting efficiency of the docking site by electroporation is relatively 
low (Table 1), more efficient gene targeting method for human ESC/iPS cells using helper-
dependent adenoviral vectors or zinc-finger nuclease has recently been reported (Suzuki et 
al., 2008; Lombardo et al., 2007; Zou et al., 2009) and applying these targeting methods may 
resolve these technical problems. Next, libraries of pInsert vectors which contain expression 
cassettes of cDNAs coding for various proteins or artificial peptides are constructed. 
Insertion of each pInsert vector into the targeted docking site confers stable expression of 
exogenous proteins in the diseased ES/iPS cells. These ES/iPS cells should show the 
phenotypes of the disease after differentiation. However, if differentiated cells show normal 
phenotypes, this means that the disease phenotype has been resolved, suggesting that 
expressing the specific exogenous protein influences the disease process. Such exogenous 




Fig. 8. A schematic diagram for discovering potential disease-curing proteins or peptides 
using pInsert vector libraries and disease-specific ES/iPS cells. 
However, although a number of disease-specific ES/iPS cell lines have been established, 
only a few studies have demonstrated that the differentiated cells showed disease 
phenotypes (Ebert et al., 2009; Lee et al., 2009), while many disease-specific ES/iPS cells did 
not show any disease phenotypes, perhaps because of the late onset or multi-factorial nature 
of such diseases. Therefore, long-term culture might be needed before the disease 
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al., 2009). Differentiation of these disease-specific hESC lines into each of the specific cell 
types that manifest disease phenotypes may make it possible to screen for factors that 
restore the normal phenotype and to identify factors associated with disease initiation or 
progression. Furthermore, many induced pluripotent stem cells (iPSCs) have been generated 
from adult patients with incurable diseases and it is also hoped that they will provide new 
sources for drug screening (Dimos et al., 2008; Park et al., 2008; Ebert et al., 2009; Lee et al., 
2009; Soldner et al., 2009; Ye et al., 2009; Maehr et al., 2009; Ye et al., 2009). 
Using pluripotent stem cells carrying disease-linked genes and a high-throughput screening 
system, small-molecule compounds or humoral factors can be identified as potential 
therapeutic drugs (Barbaric et al., 2010). However, in order to more effectively screen for 
intracellular proteins or artificial peptides that are involved in or affect the disease process, 
the site-directed integration system may be more useful. In this section, we describe an 
example of an application of the site-directed integration system for drug screening and 
disease mechanism research. 
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First, as shown in Fig. 8, the docking site was targeted to the HPRT locus of diseased ES/iPS 
cells. Although the targeting efficiency of the docking site by electroporation is relatively 
low (Table 1), more efficient gene targeting method for human ESC/iPS cells using helper-
dependent adenoviral vectors or zinc-finger nuclease has recently been reported (Suzuki et 
al., 2008; Lombardo et al., 2007; Zou et al., 2009) and applying these targeting methods may 
resolve these technical problems. Next, libraries of pInsert vectors which contain expression 
cassettes of cDNAs coding for various proteins or artificial peptides are constructed. 
Insertion of each pInsert vector into the targeted docking site confers stable expression of 
exogenous proteins in the diseased ES/iPS cells. These ES/iPS cells should show the 
phenotypes of the disease after differentiation. However, if differentiated cells show normal 
phenotypes, this means that the disease phenotype has been resolved, suggesting that 
expressing the specific exogenous protein influences the disease process. Such exogenous 




Fig. 8. A schematic diagram for discovering potential disease-curing proteins or peptides 
using pInsert vector libraries and disease-specific ES/iPS cells. 
However, although a number of disease-specific ES/iPS cell lines have been established, 
only a few studies have demonstrated that the differentiated cells showed disease 
phenotypes (Ebert et al., 2009; Lee et al., 2009), while many disease-specific ES/iPS cells did 
not show any disease phenotypes, perhaps because of the late onset or multi-factorial nature 
of such diseases. Therefore, long-term culture might be needed before the disease 
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phenotypes will emerge or the disease will be initiated. However, overexpression of disease-
linked genes in K1-HS cells using the site-directed integration system might enable an 
accelerated onset of disease phenotypes, and if overexpression of the disease-related gene 
leads to cell death, the pInsert-Tet5 vector system represents a suitable method because it 
can control gene expression by Dox, allowing for short-term gene expression. 
2.5.2 Toxicity screening 
Toxicity screening may be the most advanced application of pluripotent stem cells for drug 
screening. Public-private collaborations such as Stem Cells for Safer Medicine or Stem Cells 
and Drug Discovery Institute have been launched to enable consistent differentiation of 
stem cells into particular cell types with physiologically relevant phenotypes suitable for 
toxicology testing. Cardiomyocytes derived from human ES/iPS cells have already begun to 
be used for drug-induced cardiotoxicity screening (Asai et al., 2010). 
In the drug development process, it is necessary to evaluate the metabolism of the novel 
compound in hepatocytes, because the liver is the main detoxification organ in the body. 
The models used at present are primary hepatocytes or immortalized cell lines such as 
HepG2, which present major limitations in terms of supply and their relevance to normal 
metabolic reactions, respectively (Wilkening et al., 2003; Laustriat et al., 2010). Recently, 
Inamura et al. reported the efficient generation of hepatoblasts from human pluripotent 
stem cells (Inamura et al., 2011). However, it is still difficult to obtain homogeneous 
populations of mature hepatocytes, and contamination with other unwanted cell types 
decreases the reliability of the toxicity data. Using a pInsert vector equipped with a lineage-
specific selection marker and an HS4 insulator downstream of loxP may enable the 
reproducible production of concentrated hepatocytes. 
2.5.3 Applications for cellular medicine 
Human pluripotent stem cells are expected to provide sources for cellular therapy as well as 
drug screening. Geron Corporation already started a phase I clinical trial of transplantation 
of oligodendrocyte progenitor cells derived from hESCs to patients with spinal cord injury 
(http://www.geron.com/GRNOPC1Trial/). However, when transplanting differentiated 
cells from human ES/iPS cells, it is necessary to consider the potential for uncontrollable 
overproliferation and tumor formation due to implantation of small numbers of 
undifferentiated cells. Using the pInsert-Tet5-like vector equipped with an undifferentiated 
state-specific promoter instead of the CAG promoter and a proper suicide gene downstream 
of TRE may resolve this problem (Fig. 9). Because the undifferentiated cells will die in the 
presence of Dox, administration of Dox to transplant recipients can remove the 
undifferentiated cells. 
When differentiated cells are provided for cellular therapy, it is important to determine how 
to differentiate the hES/iPS cells efficiently into a single type of cells. If differentiation 
promoting factors are identified, they could be useful in the production of hES/iPS cell-
derived differentiated cells. However, there have been only a few studies using high-
throughput screening methods to discover small molecules that increase the differentiation 
of hES/iPS cells into specific cell lineages (Borowiak et al., 2009; Zhu et al., 2009). Our 
pInsert-Tet5 vector can also identify proteins with activities promoting differentiation. First, 
pInsert-Tet5 libraries which are equipped with a variety of cDNAs downstream of TRE can 
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be introduced into K1-HS cells. Hygromycin-resistant clones can then be induced to desired 
differentiation lineages, and then Dox can be added at various stages of differentiation. 
Differentiation-promoting factors at the different stages can then be identified by 
sequencing the cDNAs from clones whose differentiation efficiency has been increased by 
the administration of Dox.  
 
 
Fig. 9. A theoretic method to remove any remaining undifferentiated cells after 
transplantation using the inducible gene expression system based on the pInsert vector. 
3. Conclusion 
We have performed gene targeting in hESCs to introduce a transgene docking site into the 
HPRT locus, and have demonstrated high efficiency Cre-mediated integration of a given 
construct into this docking site. Moreover, we have developed a Tet-On system with 
undetectable background expression based on this site-directed integration. This review also 
discussed the potential applications of our site-directed integration system for drug 
discovery, toxicity screening and cell-based therapy. 
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undifferentiated cells. Using the pInsert-Tet5-like vector equipped with an undifferentiated 
state-specific promoter instead of the CAG promoter and a proper suicide gene downstream 
of TRE may resolve this problem (Fig. 9). Because the undifferentiated cells will die in the 
presence of Dox, administration of Dox to transplant recipients can remove the 
undifferentiated cells. 
When differentiated cells are provided for cellular therapy, it is important to determine how 
to differentiate the hES/iPS cells efficiently into a single type of cells. If differentiation 
promoting factors are identified, they could be useful in the production of hES/iPS cell-
derived differentiated cells. However, there have been only a few studies using high-
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be introduced into K1-HS cells. Hygromycin-resistant clones can then be induced to desired 
differentiation lineages, and then Dox can be added at various stages of differentiation. 
Differentiation-promoting factors at the different stages can then be identified by 
sequencing the cDNAs from clones whose differentiation efficiency has been increased by 
the administration of Dox.  
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transplantation using the inducible gene expression system based on the pInsert vector. 
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We have performed gene targeting in hESCs to introduce a transgene docking site into the 
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construct into this docking site. Moreover, we have developed a Tet-On system with 
undetectable background expression based on this site-directed integration. This review also 
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1. Introduction 
The application of embryonic stem (ES) cells to research and therapy has been a landmark 
development in science. Cell therapy using ES cells depends on the progress of the stable 
culture conditions and differentiation induction methods. ES cells were first obtained 
directly from inner cell masses (ICMs) of blastocysts by Evans and Kaufman (1981), and 
Martin (1981). These cells can self renew to produce stem cell itself and repopulate into 
many different tissues, including the somatic- and germ-cell lineages in chimeras (Bradley et 
al., 1984). After developing the methods for establishing the ES (mES) cell lines of mice, ES 
cell lines of other species including primates and human were also established (Thomson et 
al., 1995, 1998). Although ES cells can be obtained from 8-cell stage embryos or morula, they 
are more easily obtained from blastocyst stage embryos (Delhaise et al., 1996; Strelchenko et 
al., 2004). Now the sources of ES cells have been extended to include epiblast cells (Nichols 
and Smith, 2011) (Fig. 1). 
 
 
Fig. 1. The origins of embryonic stem cell. A, blastomeres of 8-cell and morula stage 
embryos; B, inner cell mass of blastocyst; C, epiblast cells of implanting embryo. 
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2. Human and mouse embryonic stem cells 
2.1 Mouse embryonic stem cell 
mES cells have been used mainly in the generation of mutant mice and in investigating 
cellular differentiation and the physiological role of genes during embryogenesis and 
development. These things can be accomplished through gene targeting and transmission of 
the acquired characters. Transmission of foreign genes to the next generation can be 
accomplished with incorporation of foreign genes into the germ cell-lineage (Bradley et al., 
1984; Wang et al., 1996). Specific gene deficient mice can be developed by manipulation of 
the genes in ES cells and introduce of ES cells into ICM (Hooper et al., 1987; Kuehn et al., 
1987; Wang et al., 1996). Mutations targeting specific genes by homologous recombination in 
ES cells have been designed and initially achieved using hypoxanthine-guanine 
phosphoribosyl transferase (HPRT) (Doetschmann et al., 1987). Germ line transmission of a 
targeted mutation in a gene other than HPRT was first obtained with c-abl (Schwartzberg et 
al., 1989) and 2-microglobulin (Zijlstra et al., 1989). To date, several hundred genes have 
been disrupted by homologous recombination in ES cells. The application of these 
techniques provided a way to evaluate the physiological roles of specific genes in ontogeny. 
In addition, conditional knockout mice are developed using ES cells and are used to analyze 
gene functions in a specific tissue or developmental stage. These approaches have provided 
much novel information and several important tools to study human development 
including ES cell therapies. 
2.2 Early data from embryonic carcinoma cells 
Human ES (hES) cells have become a key word in basic sciences and applied sciences. 
Before the optimal conditions were established for ES cell cultures, most of the basic 
knowledge about ES cells came from studies on embryonic carcinoma (EC) cells (Jakob, 
1984; Rossant and Papaioannou, 1984; Smolich and Papkoff, 1994). The first human EC cell 
line was established in vitro in 1985 (Sekiya et al., 1985). EC cells can spontaneously 
differentiate into somatic cells, germ cells and extraembryonic cells (Zákány et al. 1984), and 
have self-renewal ability (Andrews, 1987; Rosenstraus et al., 1984). During differentiation of 
EC cells into other cell types, proliferation is prerequisite, and apoptosis of EC cell 
derivatives accompany this process (Azizi et al., 2010; Mummery et al., 1984). After starting 
differentiation, the expression levels of some genes are determined at the levels of 
transcription and translation. In 1984, Schindler and Sherman reported the profile of protein 
and mRNA expression in murine EC cells, and the expression patterns of specific genes 
were explored during differentiation of EC cells (Scott et al., 1984; Silvan et al., 2009). 
Additionally, studies on proteins and carbohydrates have been performed to characterize 
the EC cells and their induced descendants (Amano et al., 2010; Andrews et al., 1984; 
Jemmerson et al., 1985). The role of the extracellular matrix is also examined during 
differentiation induction of EC cells (Grabel, 1984; Wartiiovaara et al., 1984) as the 
karyoplasm in EC cell gene expression (Gautsch, 1982). Differentiation induction of EC cells 
has been successful with various substances, such as retinoic acid, dibutyryl cyclic AMP 
(Jones-Villeneuve et al., 1983; Muramatsu and Muramatsu, 1983), dimethyl sulfoxide 
(Edwards et al., 1983) and coculture with specific cell types (Allin, 1984). Bell et al (1984) 
used growth factors to induce EC cell differentiation in target tissues.   
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2.3 Stemness and the differentiation of embryonic stem cells 
Although ES cells share some characteristics with EC cells, they have important differences 
(Chamber and Smith, 2004). The in vitro developmental potency and differentiation of ES 
cells have been studied since the mid-1980s. The developmental potency of ES cells was 
studied in vitro by Doetschman et al (1985). Additionally, the pluripotency and the 
characteristics of ES cells in vitro were analyzed in depth. ES cells lack differentiation-
inhibitory activity (DIA) unlike cells of cell lines, and they can differentiate into a wide 
variety of cell types. ES cells have an apparently normal diploid karyotype during long-term 
culture, can extensively colonize embryos without causing tumors or developmental 
anomalies, and can form normal gametes when differentiated into the germ line (Kaufman 
et al., 1983; Martin, 1981; Suda et al., 1987). The purified and cloned myeloid leukemia 
inhibitory factor (LIF) can exhibit DIA in the maintenance of competent mES cell lines 
(Smith et al., 1988; Williams et al., 1988). However, the requirement for maintaining 
stemness varies with the source of the ES cells. Primate ES cells stay in an undifferentiated 
state when grown on embryonic fibroblast feeder layers but differentiate or die in the 
absence of feeder cells, despite the presence of recombinant leukemia inhibitory factor 
(Thomson et al., 1995).  
Studies on the differentiation of stem cells during organogenesis have a long history (Ruch, 
1967). ES cell differentiation in vitro is controlled by exogenous factors, particularly 
paracrine factors (Heath and Smith, 1986; Spence et al., 2010). Various cell types can be 
induced from embryoid bodies using paracrine factors (Risau et al., 1988). During 
differentiation induction, various genes, such as genes of transcription factors, are up-
regulated or down-regulated (Dyson et al., 1989). The up-regulated transcription factors 
trigger a series of gene expression changes for the formation of a specific cell type (Kopp et 
al., 2008). 
3. Potency of embryonic stem cell in clinic 
3.1 Sources of human embryonic stem cells 
Through the accumulating knowledge on pluripotency and on the control of cellular 
differentiation, a fundamental understanding of developmental biology at the cellular and 
molecular levels has been expanded. It represents a gateway to major future clinical 
applications of these principles. The levels of transcription factors including nuclear 
receptors in ES cells are critical in the maintenance of stemness or differentiation of ES cells 
(Jeong and Mangelsdorf, 2009; Redshaw and Strain, 2010). Certain nuclear receptors are 
involved in the maintenance of ES cells in cooperation with Oct3/4, Nanog and Klf4 upon 
exogenous signals. Liver receptor homolog 1 (LRH1) and estrogen-related receptor beta 
(ERR) have functional roles in the maintenance of stemness of ES cells. On the other hand, 
germ cell nuclear factor (GCNF) and retinoic acid receptors (RARs) promote ES cell 
differentiation (Jeong and Mangelsdorf, 2009). The Sall gene family that encodes a group of 
developmental transcription factors controls the embryonic development and is also 
involved in the determination of ES cell fate. Sall1 knockout mice die perinatally with 
kidney dysgenesis or agenesis. Sall3 knockout mice have plate deficiency and abnormalities 
in cranial nerves. Sall4 mutation causes Acro-renal-ocular syndrome and Duane-radial ray 
syndrome. Sall4 also plays a role in the maintenance of stemness of ES cells through 
controlling its own expression and the expression of OCT4 (Yang et al., 2010). Identifying 
such switching molecules that regulate ES cell self-renewal versus differentiation can 
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the EC cells and their induced descendants (Amano et al., 2010; Andrews et al., 1984; 
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differentiation induction of EC cells (Grabel, 1984; Wartiiovaara et al., 1984) as the 
karyoplasm in EC cell gene expression (Gautsch, 1982). Differentiation induction of EC cells 
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(Jones-Villeneuve et al., 1983; Muramatsu and Muramatsu, 1983), dimethyl sulfoxide 
(Edwards et al., 1983) and coculture with specific cell types (Allin, 1984). Bell et al (1984) 
used growth factors to induce EC cell differentiation in target tissues.   
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2.3 Stemness and the differentiation of embryonic stem cells 
Although ES cells share some characteristics with EC cells, they have important differences 
(Chamber and Smith, 2004). The in vitro developmental potency and differentiation of ES 
cells have been studied since the mid-1980s. The developmental potency of ES cells was 
studied in vitro by Doetschman et al (1985). Additionally, the pluripotency and the 
characteristics of ES cells in vitro were analyzed in depth. ES cells lack differentiation-
inhibitory activity (DIA) unlike cells of cell lines, and they can differentiate into a wide 
variety of cell types. ES cells have an apparently normal diploid karyotype during long-term 
culture, can extensively colonize embryos without causing tumors or developmental 
anomalies, and can form normal gametes when differentiated into the germ line (Kaufman 
et al., 1983; Martin, 1981; Suda et al., 1987). The purified and cloned myeloid leukemia 
inhibitory factor (LIF) can exhibit DIA in the maintenance of competent mES cell lines 
(Smith et al., 1988; Williams et al., 1988). However, the requirement for maintaining 
stemness varies with the source of the ES cells. Primate ES cells stay in an undifferentiated 
state when grown on embryonic fibroblast feeder layers but differentiate or die in the 
absence of feeder cells, despite the presence of recombinant leukemia inhibitory factor 
(Thomson et al., 1995).  
Studies on the differentiation of stem cells during organogenesis have a long history (Ruch, 
1967). ES cell differentiation in vitro is controlled by exogenous factors, particularly 
paracrine factors (Heath and Smith, 1986; Spence et al., 2010). Various cell types can be 
induced from embryoid bodies using paracrine factors (Risau et al., 1988). During 
differentiation induction, various genes, such as genes of transcription factors, are up-
regulated or down-regulated (Dyson et al., 1989). The up-regulated transcription factors 
trigger a series of gene expression changes for the formation of a specific cell type (Kopp et 
al., 2008). 
3. Potency of embryonic stem cell in clinic 
3.1 Sources of human embryonic stem cells 
Through the accumulating knowledge on pluripotency and on the control of cellular 
differentiation, a fundamental understanding of developmental biology at the cellular and 
molecular levels has been expanded. It represents a gateway to major future clinical 
applications of these principles. The levels of transcription factors including nuclear 
receptors in ES cells are critical in the maintenance of stemness or differentiation of ES cells 
(Jeong and Mangelsdorf, 2009; Redshaw and Strain, 2010). Certain nuclear receptors are 
involved in the maintenance of ES cells in cooperation with Oct3/4, Nanog and Klf4 upon 
exogenous signals. Liver receptor homolog 1 (LRH1) and estrogen-related receptor beta 
(ERR) have functional roles in the maintenance of stemness of ES cells. On the other hand, 
germ cell nuclear factor (GCNF) and retinoic acid receptors (RARs) promote ES cell 
differentiation (Jeong and Mangelsdorf, 2009). The Sall gene family that encodes a group of 
developmental transcription factors controls the embryonic development and is also 
involved in the determination of ES cell fate. Sall1 knockout mice die perinatally with 
kidney dysgenesis or agenesis. Sall3 knockout mice have plate deficiency and abnormalities 
in cranial nerves. Sall4 mutation causes Acro-renal-ocular syndrome and Duane-radial ray 
syndrome. Sall4 also plays a role in the maintenance of stemness of ES cells through 
controlling its own expression and the expression of OCT4 (Yang et al., 2010). Identifying 
such switching molecules that regulate ES cell self-renewal versus differentiation can 
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provide insights into the nature of the ES cell (Navarro et al., 2010). Chromatin methylation 
is one example of how an epigenetic modification can modulate ES cell fate (Christophersen 
and Helin, 2010). 
In the late of 1990s the possibility of using ES cells for medicine was suggested (Gearhart, 
1998). The use of stem cells in regenerative medicine already has a long history, for example, 
in bone marrow transplantation and skin grafting. With the establishment of human 
embryonic stem (hES) cell lines, future clinical applications based on their developmental 
and regenerative abilities will become possible. hES cells were first established in 1998 by 
Thomson and colleagues. As in primate ES cells, the feeder layer seems essential for 
maintaining the hES cell lines. It is suggested that TGF-beta and myofibroblasts can support 
the propagation of hES cells in vitro (Kumar et al., 2010). 
Previously, the source of hES cells was restricted to morula and blastocysts but this is no 
longer the case. In 2006, induced pluripotent stem (iPS) cells were generated from mouse 
embryonic or adult fibroblasts by the retrovirus-mediated introduction of four transcription 
factors, Oct3/4, sox2, c-Myc, and Klf4 (Takahashi and Yamanaka, 2006). In 2007, iPS cells 
were established from human fibroblasts via introduction by the same four factors 
(Takahashi et al., 2007), and by using a slightly different combination of genes (Yu et al., 
2007). Human iPS cells are similar to human ES cells in many aspects, e.g., morphology and 
proliferation ability. Furthermore, mouse iPS cells are competent for adult chimeric mice 
and germline transmission. Growth potential, gene expression patterns, and the epigenetic 
status of iPS cells are similar to those observed in hES cells. iPS cells can differentiate into all 
three germ layers through embryoid bodies and to teratomas. In addition, they have been 
differentiated directly into neurons, beating cardiomyocytes in vitro (Carvajal-Vergara et al., 
2010) and others (Liu et al., 2011).  
3.2 Applied developmental biology 
A fertilized mammalian oocyte is totipotent and develops into the fetus and placenta 
concurrently losing its totipotency. During cleavage, the transition from maternal to 
embryonic genome activation encompassed in early stage embryos and cleaving embryos 
can gain the competence to become blastocysts (Hamatani et al., 2004). The competency to 
accomplish implantation and further development is gained during the periimplantation 
stages. For that process, the epithelium like structure, trophectoderm is formed and interacts 
with the epithelium of the uterine endometrium. On the other hand, the cells isolated within 
the blastoceol become inner cell mass (ICM) (Johnson and Mcconnell, 2004). ICM is a mass 
of cells having pluripotency and its cells can differentiate into all cell types of adult and 
extraembryonic membranes (Fernanez-Tresquerres et al., 2010). In specific in vitro 
conditions, ICM cells can keep their potency and maintain their proliferation ability 
(Yamanakaet al., 2006).  
Grouped cell movement and sequential spatio-temporal expressions of gene sets was 
observed after implantation. As a consequence of gastrulation, the embryos have three germ 
layers, endoderm, mesoderm and ectoderm (Hassoun et al., 2010; Luxardi et al., 2010). This 
process is accomplished with the forming of the axis (Rocha et al., 2010). For example, 
Med12, a large protein complex of 30 subunits interacting with transcription factors, is 
essential in correct Wnt/-catenin and Wnt/planar cell polarity signaling (Rocha et al., 2010; 
Taatjes et al., 2004). 
Most cells of embryos are eventually committed through triggering to a particular 
developmental pathway from which they rarely depart (Belting et al., 2004). Cell 
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determination is a stepwise process, and that full determination is preceded by a state of 
bias. This bias is either conformed or modified through cell interactions later in 
development. It is accomplished through community effect, lateral inhibition among 
equivalent cells, and embryonic induction which is the interaction between nonequivalent 
cells (Artavanis-Tsakonas et al., 1999). The determined state is almost stably passed on 
during mitosis. These are matched with the default progression and/or induced 
progression.  
A specific type cell is derived from a preexisting progenitor or stem cell for the specific area 
(Belting et al., 2004; Frieberg, 1996).  Designed modification of a group of ES cells to a 
specific cell type is mostly achieved by step by step induction through morphogens or 
intracellular signaling molecules as shown during organogenesis (Osakada and Takahashi, 
2011). The accumulation of knowledge regarding tissue genesis and organogenesis during 
gastrulation will give rise to the accomplishment of goals across other fields.  
The revolutionary advances in developmental biology have extended the utility of ES cells 
to both therapy and industry. As applied to the study of developmental biology (Lehtonen 
et al., 1989), the stemness and developmental potency of ES cells can be applied to various 
fields of medicine (Gearhart, 1998; Saxena et al., 2010). Thus far, stem cell biology has 
focused on identifying novel pathways such as those that maintain pluripotency and induce 
specific cell types. However, to date, it is not yet feasible to use ES cells in medicine or to 
strictly control their differentiation to a specific cell type in humans. To readily apply ES 
cells in therapy or other industries, the improvement of efficient protocols to direct stem cell 
differentiation into well-defined lineages is critical (Heng et al., 2004). 
4. Approaches to modulate embryonic stem cell properties 
To obtain a specific cell type, it is critical to understand the interactions of multiple genes 
and the associated factors that are involved in the differentiation and de-differentiation of 
ES cells. When we use inducers to generate a specific cell type from the embryoid body (EB) 
or directly from ES cells, it is difficult to generate single cell types at one time (Lu et al., 2009; 
Park and Lee, 2007). As shown in gastrulation and organogenesis, most morphogens and 
inducers are secreted into the intercellular fluid and into induced concentration-dependent 
specific gene expressions in neighboring cells (Wolpert, 1978). Therefore, in most cases of 
induction by inducer, unexpected results can occur during the induction of a cell type from 
an ES cell or embryoid bodies (EBs). 
Selective activation of the gene sets is essential to get a unique function of a specific cell. One 
of the best ways to accomplish this is through the delivery of a construct which contains 
target genes and expression-control sequences (Ishizaka et al., 2002). Among them 
intracellular signaling mediators and transcription factors are key molecules to get a specific 
cell type and they are main target for differentiation induction. To meet these requirements, 
many experimental conditions and gene delivery systems have been used. However, ES 
cells cannot be translocated to high affinity variable regulators such as a molecule of DNA, 
RNA or proteins. To overcome this problem, various approaches have been developed. 
When we classified according to their characteristics, mediators are either chemical, 
physical, or viral. 
Induced pluripotent stem cell (iPS) is a good example of a cell type in which transgene 
delivery and induction by transcription factors has been successful (Meissner et al., 2007; 
Park et al., 2008). However, those strategies introduce changes in DNA sequences or 
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provide insights into the nature of the ES cell (Navarro et al., 2010). Chromatin methylation 
is one example of how an epigenetic modification can modulate ES cell fate (Christophersen 
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maintaining the hES cell lines. It is suggested that TGF-beta and myofibroblasts can support 
the propagation of hES cells in vitro (Kumar et al., 2010). 
Previously, the source of hES cells was restricted to morula and blastocysts but this is no 
longer the case. In 2006, induced pluripotent stem (iPS) cells were generated from mouse 
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were established from human fibroblasts via introduction by the same four factors 
(Takahashi et al., 2007), and by using a slightly different combination of genes (Yu et al., 
2007). Human iPS cells are similar to human ES cells in many aspects, e.g., morphology and 
proliferation ability. Furthermore, mouse iPS cells are competent for adult chimeric mice 
and germline transmission. Growth potential, gene expression patterns, and the epigenetic 
status of iPS cells are similar to those observed in hES cells. iPS cells can differentiate into all 
three germ layers through embryoid bodies and to teratomas. In addition, they have been 
differentiated directly into neurons, beating cardiomyocytes in vitro (Carvajal-Vergara et al., 
2010) and others (Liu et al., 2011).  
3.2 Applied developmental biology 
A fertilized mammalian oocyte is totipotent and develops into the fetus and placenta 
concurrently losing its totipotency. During cleavage, the transition from maternal to 
embryonic genome activation encompassed in early stage embryos and cleaving embryos 
can gain the competence to become blastocysts (Hamatani et al., 2004). The competency to 
accomplish implantation and further development is gained during the periimplantation 
stages. For that process, the epithelium like structure, trophectoderm is formed and interacts 
with the epithelium of the uterine endometrium. On the other hand, the cells isolated within 
the blastoceol become inner cell mass (ICM) (Johnson and Mcconnell, 2004). ICM is a mass 
of cells having pluripotency and its cells can differentiate into all cell types of adult and 
extraembryonic membranes (Fernanez-Tresquerres et al., 2010). In specific in vitro 
conditions, ICM cells can keep their potency and maintain their proliferation ability 
(Yamanakaet al., 2006).  
Grouped cell movement and sequential spatio-temporal expressions of gene sets was 
observed after implantation. As a consequence of gastrulation, the embryos have three germ 
layers, endoderm, mesoderm and ectoderm (Hassoun et al., 2010; Luxardi et al., 2010). This 
process is accomplished with the forming of the axis (Rocha et al., 2010). For example, 
Med12, a large protein complex of 30 subunits interacting with transcription factors, is 
essential in correct Wnt/-catenin and Wnt/planar cell polarity signaling (Rocha et al., 2010; 
Taatjes et al., 2004). 
Most cells of embryos are eventually committed through triggering to a particular 
developmental pathway from which they rarely depart (Belting et al., 2004). Cell 
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determination is a stepwise process, and that full determination is preceded by a state of 
bias. This bias is either conformed or modified through cell interactions later in 
development. It is accomplished through community effect, lateral inhibition among 
equivalent cells, and embryonic induction which is the interaction between nonequivalent 
cells (Artavanis-Tsakonas et al., 1999). The determined state is almost stably passed on 
during mitosis. These are matched with the default progression and/or induced 
progression.  
A specific type cell is derived from a preexisting progenitor or stem cell for the specific area 
(Belting et al., 2004; Frieberg, 1996).  Designed modification of a group of ES cells to a 
specific cell type is mostly achieved by step by step induction through morphogens or 
intracellular signaling molecules as shown during organogenesis (Osakada and Takahashi, 
2011). The accumulation of knowledge regarding tissue genesis and organogenesis during 
gastrulation will give rise to the accomplishment of goals across other fields.  
The revolutionary advances in developmental biology have extended the utility of ES cells 
to both therapy and industry. As applied to the study of developmental biology (Lehtonen 
et al., 1989), the stemness and developmental potency of ES cells can be applied to various 
fields of medicine (Gearhart, 1998; Saxena et al., 2010). Thus far, stem cell biology has 
focused on identifying novel pathways such as those that maintain pluripotency and induce 
specific cell types. However, to date, it is not yet feasible to use ES cells in medicine or to 
strictly control their differentiation to a specific cell type in humans. To readily apply ES 
cells in therapy or other industries, the improvement of efficient protocols to direct stem cell 
differentiation into well-defined lineages is critical (Heng et al., 2004). 
4. Approaches to modulate embryonic stem cell properties 
To obtain a specific cell type, it is critical to understand the interactions of multiple genes 
and the associated factors that are involved in the differentiation and de-differentiation of 
ES cells. When we use inducers to generate a specific cell type from the embryoid body (EB) 
or directly from ES cells, it is difficult to generate single cell types at one time (Lu et al., 2009; 
Park and Lee, 2007). As shown in gastrulation and organogenesis, most morphogens and 
inducers are secreted into the intercellular fluid and into induced concentration-dependent 
specific gene expressions in neighboring cells (Wolpert, 1978). Therefore, in most cases of 
induction by inducer, unexpected results can occur during the induction of a cell type from 
an ES cell or embryoid bodies (EBs). 
Selective activation of the gene sets is essential to get a unique function of a specific cell. One 
of the best ways to accomplish this is through the delivery of a construct which contains 
target genes and expression-control sequences (Ishizaka et al., 2002). Among them 
intracellular signaling mediators and transcription factors are key molecules to get a specific 
cell type and they are main target for differentiation induction. To meet these requirements, 
many experimental conditions and gene delivery systems have been used. However, ES 
cells cannot be translocated to high affinity variable regulators such as a molecule of DNA, 
RNA or proteins. To overcome this problem, various approaches have been developed. 
When we classified according to their characteristics, mediators are either chemical, 
physical, or viral. 
Induced pluripotent stem cell (iPS) is a good example of a cell type in which transgene 
delivery and induction by transcription factors has been successful (Meissner et al., 2007; 
Park et al., 2008). However, those strategies introduce changes in DNA sequences or 
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disorder in genomic equivalence. Moreover, viral systems are suspected to have life-
threatening effects of immunogenicity and carcinogenicity. In addition, the efficiency of 
gene transfer in hES cells is still poor compared with other cell lines (Cao et al., 2010; 
Wasungu and Hoekstra, 2006). 
For these reasons, many scientists hesitate to use these strategies in medicine and have 
searched for new ways to control ES cell differentiation. Functional protein is easily turned 
over in the cytoplasm and regulates the function of a cell without disturbing the genetic 
background. Therefore, if we develop an easy way of introducing the transcription factors, 
intracellular signaling molecules or drug molecules into ES cells, ES cells will become a safe 
medicine. 
4.1 Delivery of nucleotides in to ES cells 
Introduction of regulating DNA or RNA into ES cells can be mediated by chemicals. Leaped 
progress in chemical mediated method has led to successful expression-construct delivery. 
Chemical mediators include diethylaminoethyl-dextran (DEAE-D), calcium phosphate, 
cationic lipid (liposome), cationic polymer, polylysine, histone, chitosan and peptides. 
The delivery of DNA or RNA with calcium phosphate was developed by Graham and van 
der Eb (1973) and has become a common method (Marucci et al., 2011). The mixture of DNA 
construct, calcium ion and phosphate are presented to cells in culture and the cells import 
the mixture through endocytosis. DEAE-D was developed by Pagano and Vaheri in 1965 for 
enhancing the infectivity of poliovirus RNA for cell culture. DEAE-D is a polycation, and 
the mixture of DNA and DEAE-D is positively charged. It is known that the mixtures are 
transferred into cytoplasm through endocytosis. Cationic lipids for DNA-transfection 
procedures were developed in 1987 (Felgner et al., 1987) and have become one of the most 
common methods (Templeton et al., 1997). Cationic lipids form liposome and the surface of 
liposome is positively charged. Cationic polymers are a group of highly water-soluble 
molecules such as polyethyleneimine (PEI) and dendrimers (Boussif et al., 1995; Dunlap et 
al., 1997). There are several types of cationic polymers; linear (polylysine, spermine, and 
histone), branched (polyethyleneimine, dendrimers) and spherical (Chitosan) (Zhao et al., 
2006). Cationic polymer self-assemble with DNA and generate tortoidal or spherical 
particles (Tang and Szoka, 1997). Polyplexes are engulfed by cells. Cationic peptide carriers 
are a new development and are expected to have an important role in gene delivery in vivo 
and in vitro. The peptides bind with DNA through ionic interaction to the phosphate 
backbone and additional noncovalent bonds. The transport mechanisms are endosomolytic 
(Chen et al., 2001) or membrane-penetrating (Xia et al., 2001). This method is not commonly 
used to carry the DNA or RNA constructs but the modular design of proteins is a good 
method for gene delivery (Xavier et al., 2009).  
Among the chemical mediated methods, mostly cationic lipids are employed in ES cells 
(Liou et al., 2010; Ma et al., 2004). One of the merits of the cationic lipid methods is that it is 
simple to apply. Methods which are optimized to ES cells or EB are a developing field (Liou 
et al., 2010; Ma et al., 2004; Villa-Diaz et al., 2010). In the case of the other chemical 
mediators, the efficiency is quite low or inadaptable to ES cells (Hong et al., 2004). On the 
other hand, combined methods are developed in ES cells such as peptide-liposome 
(Torchilin et al., 2003) 
On the other hand, physical forces such as, pressure, sound, shock, wave, or electrical pulse 
are used to deliver constructs. The history of using physical methods for gene delivery is 
 
Embryonic Stem Cells: Introducing Exogenous Regulators into Embryonic Stem Cells 129 
relatively short. The good points of these methods are saving cost, reducing risk through the 
large amount of DNA, and standardizing the quantity and procedure of gene delivery. The 
restriction of physical delivery includes restriction of delivery into the nucleus and internal 
organs or tissues that are difficult to reach. The microinjection method is one widely used 
procedure to delivery DNA or RNA constructs directly into the cells. Using injection pipette 
the constructs are introduced into the cytosol or microorganells of the target cell and it 
makes it possible to study the complicated cellular processes, structure, and function. 
Usually direct DNA inoculation by conventional needle injection and hydrodynamics 
deliver the naked plasmid DNA into cells, tissues or organs in vivo. These are very 
restricted, so far (Davis et al., 1993; Zhang et al., 1999). The genetic shotgun was introduced 
for gene delivery in 1990 (Armaleo et al., 1990). In this protocol, microscopic tungsten 
spheres are used to deliver DNA or RNA constructs. This method has been used to transfect 
plants cells, muscle cells, and various cultured cells including epithelial cells, endothelial 
cells, and monocytes (Chou et al., 2004). Gene delivery using electroporation is the most 
versatile method and can be applied to a wide variety of cell types. A short-pulsed electric 
field can result in the cellular uptake of DNA. Ultrasound is another physical energy source 
to open the membrane. Using this energy, new gene delivery methods have been developed. 
It facilitates the transfer of DNA into cells and across tissues. Its efficiency is very high and 
intraturmoral injection of DNA followed by focused ultrasound increased the expression of 
the target gene (Watanabe et al., 2010). The polymer-encapsulated microsphere delivery 
system developed the DNA construct in a manner of controlled drug-delivery. It can deliver 
the constructs in a manner that has site-specificity, is nuclease-safe, and provides a sustained 
release of DNA without repeated administration (Little et al., 2004). Polymer-encapsulated 
microsphere delivery may be useful in therapy in vivo (Little et al., 2004). 
Among the physical force mediated transduction methods, electroporation has been used as 
a standard transfection method for mES cells because its efficiency is quite high (Ma et al., 
2004). However, its use has also been limited because the viability of the transfected cells is 
quite low (Matsuoka et al., 2007; Svingen et al., 2009). The other limit is that ES cells have to 
located in a spedific chamber to get treatment. However, with the progression of the 
electroporation system, it is possible to get a large fraction of transiently transfected cells 
with minimal loss of cell viability and pluripotency (Moore et al., 2010). The microinjection 
method, conventional needle injection, hydrodynamics deliver, genetic shotgun, ultrasound 
and polymer-encapsulated microsphere delivery systems are not yet commonplace and, 
although further research is needed, it is expected that physical mediators will be good tools 
for working with ES cells. 
Virus mediate foreign gene delivery is observed in nature. Viruses have host specificity and 
the efficiency of viral infection can be increased by higher titers while avoiding 
immunosurveillance by an infected host. Using those characteristics, viral genomes have 
been developed as gene-delivery vehicles, since the early 1980s (Berkner, 1988; Shimotohno 
and Temin, 1981). Viral vectors include the adenoviruses, adeno-associated viruses, herpes 
simplex viruses, baculoviruses, lentiviruses, retroviruses and alphaviruses (Robbins and 
Ghivizzani, 1998; Couto and High 2010). The characteristics of vectors are dependent on 
their origins. Varial mediated gene delivery is a powerful method used with ES cells. iPS 
cells are a good example of viral mediate gene delivery of functional DNA constructs 
(Meissner et al., 2007; Park et al., 2008). 
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disorder in genomic equivalence. Moreover, viral systems are suspected to have life-
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the mixture through endocytosis. DEAE-D was developed by Pagano and Vaheri in 1965 for 
enhancing the infectivity of poliovirus RNA for cell culture. DEAE-D is a polycation, and 
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procedures were developed in 1987 (Felgner et al., 1987) and have become one of the most 
common methods (Templeton et al., 1997). Cationic lipids form liposome and the surface of 
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molecules such as polyethyleneimine (PEI) and dendrimers (Boussif et al., 1995; Dunlap et 
al., 1997). There are several types of cationic polymers; linear (polylysine, spermine, and 
histone), branched (polyethyleneimine, dendrimers) and spherical (Chitosan) (Zhao et al., 
2006). Cationic polymer self-assemble with DNA and generate tortoidal or spherical 
particles (Tang and Szoka, 1997). Polyplexes are engulfed by cells. Cationic peptide carriers 
are a new development and are expected to have an important role in gene delivery in vivo 
and in vitro. The peptides bind with DNA through ionic interaction to the phosphate 
backbone and additional noncovalent bonds. The transport mechanisms are endosomolytic 
(Chen et al., 2001) or membrane-penetrating (Xia et al., 2001). This method is not commonly 
used to carry the DNA or RNA constructs but the modular design of proteins is a good 
method for gene delivery (Xavier et al., 2009).  
Among the chemical mediated methods, mostly cationic lipids are employed in ES cells 
(Liou et al., 2010; Ma et al., 2004). One of the merits of the cationic lipid methods is that it is 
simple to apply. Methods which are optimized to ES cells or EB are a developing field (Liou 
et al., 2010; Ma et al., 2004; Villa-Diaz et al., 2010). In the case of the other chemical 
mediators, the efficiency is quite low or inadaptable to ES cells (Hong et al., 2004). On the 
other hand, combined methods are developed in ES cells such as peptide-liposome 
(Torchilin et al., 2003) 
On the other hand, physical forces such as, pressure, sound, shock, wave, or electrical pulse 
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4.2 Delivery of functional proteins 
DNA constructs are powerful mediators for induction of ES cell differentiation. However, 
genetic modification by exogenous DNA construct can cause unidentified side effects. The 
development of a safe and efficient differentiation controller is, therefore, an urgent 
requirement for the effective implementation of stem cells in therapy and industry. As an 
efficient differentiation controller, functional proteins such as signal transduction proteins 
and transcription factors are suggested, because they degrade rapidly in physiological 
condition and can maintain or modulate the cell types.  
The molecular size of the protein is huge compared with the amino acid and cannot freely 
pass the cell membrane or nuclear membrane. To deliver proteins, cationic lipids and 
cationic polymers also have been applied (Murthy et al., 2003; Verdurmen and Brock, 2011). 
However, their translocation efficiency is variable, depending on the cell type and the size 
and quality of the mixtures. Besides, the functional proteins cannot be translocated into the 
karyoplasms. Peptides are also a useful candidate for the translocation of peptides into 
cytoplasm but it also has limitations in medical or biological application. However, they 
have aroused great interest and have continuously progressed. 
Cell-penetrating peptides (CPPs) are synthesized peptides derived from various proteins. 
CPPs can transport small molecules, peptides and proteins in the form of recombinants and 
mixtures (Sawant and Torchilin, 2010). Some transcription factors have a domain with 
strongly basic heteropeptides, containing at least four arginines and lysines, which functions 
as a nuclear localization signal (Boulikas, 1994; Henkel et al., 1992). Drosophila transcription 
factor Antennapedia (Antp) also has the ability to translocate across the cell membranes 
(Balayssac et al., 2006). A mildly hydrophobic segment located approximately 30 residues 
downstream of the signal peptide is critical in membrane permeability in an E. coli protein 
(Nilsson et al., 1993). Those sequences interacting with lipid bilayers are called CPPs. They 
can carry functional cargo in the form of transcription factors or drugs (Lin et al., 1995). 
CPPs are also referred to as cell-permeable peptides, protein transducing domains (PTDs), 
or Trojan horse peptides. Thus far, the designed CPPs are more than two hundred including 
a galparan analog (Pooga et al., 1998), poly-arginine (Wadia and Dowdy, 2003), TAT-PTD, 
penetratin, buforin 2, transportan, transportan 10, MAP, pVec, R8, R11, KALA, K-FGF, PEP-
1, and Synb1 (Chugh et al., 2010; Dietz and Bähr, 2005; Pooga and Langel, 2005) (Table 1).  
CPPs are able to ferry much larger proteins, chemicals, DNA or RNA, directly into living 
cells (Dietz, 2010; Jung et al., 2007; Kwon et al., 2009). 
Applying CPPs to basic sciences, medicine and industry has been attempted. CPPs can 
translocate a specific protein into the cytoplasm in mixed form or recombinant protein form. 
Using a recombinant cell-permeable Cre protein (His-TAT-NLS-Cre), recombination can be 
efficiently induced in mES cell-derived cells. Fortunately, the permeable Cre protein has no 
overt side effects on proliferation and neural differentiation (Haupt et al., 2007). Yang and 
colleagues (2009) worked with a library of poly-(beta-amino ester) end-modified derivatives. 
These derivatives were developed and optimized for high transfer efficiency in hES cell-
derived cells, human adipose-derived stem cells (hADSCs) and human mesenchymal stem 
cells (hMSCs). In the presence of 10% serum, the transfer efficiency was 27  2% in hMSCs, 
24  3% in hADSCs and 56  11% in hSECds (Yang et al., 2009). Recently human iPS cells 
were successfully established with CPP-conjugated reprogramming proteins (Kim et al., 
2009). However, the importation efficiency was poor.  
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CPP Cys-CPP Sequence Numer of Class of CPP Lys Arg 
Tat-PTD GRKKRRQRRRPPQ 2 6 Cationic 
Penetratin (ATF) RQIKIWFQNRRMKWKK 4 3 Cationic 
M918 MVTVLFRRLRIRRASGPPRVRV 0 7 Cationic 
KALA WEAKLAKALAKALAKHLAKALAKALKACEA 7 0 Cationic 
R7 RRRRRRR 0 7 Cationic 
R8 RRRRRRRR 0 8 Cationic 
R11 RRRRRRRRRRR 0 11 Cationic 
MAP KLALKLALKALKAALKLA 5 0 Amphipathic 
pEP-1 KETWWETWWTEWSQPKKKRKV 5 1 Amphipathic 
Buforin 2 TRSSRAGLQFPVGRVHRLLRK 1 5 Amphipathic 
Transportan 10 (P10) AGYLLGKINLKALAALAKKIL 4 0 Chimeric 
Transportan GWTLNSAGYLLGK
bINLKALAAL
AKKIL 4 0 Chimeric 
pVec LLIILRRRIRKQAHAHSK 2 4 Chimeric 
K-FGF AAVALLPAVLLALLAP 0 0 Hydrophobic sequences 
3-S AAVALLPAVLLALLAP 0 0 Hydrophobic sequences 
SynB1 RGGRLSYSRRRFSTSTGR 0 6 Antimicrobial sequence 
NLS ALWKTLLKKVLKAPKKKRKVC 8 1 Antimicrobial sequence 
b: attachment of Cys(Npys) on the  
Table 1. Sequences and features of some cell-penetrating peptides 
To promote the transduction of functional proteins into cytoplasm and karyoplasms of ES 
cells, the transduction abilities of various types of CPPs have been analyzed in mES cells 
(Jung et al., 2007). In these studies, the effects of the site of the CPP and the His tag in 
functional recombinant protein were first analyzed. We chose two expression vectors, one 
with an N-terminal His tag (6xHis-tag) and the other with a C-terminal tag (Fig. 2). Buforin 2 
cannot mediate the translocation of conjugated EGFP into the cytoplasm of R1 mES cells 
whether the His tag is located N-terminally (Buforin 2-EGFP-N) or C-terminally (Buforin 2-
EGFP-C). In contrast, pEP-1-EGFP-N translocates into the cytoplasm of R1 ES cells but pEP-
1-EGFP-C does not. pEP-1-EGFP-C mainly localized at the plasma membrane. The 
translocational efficiency of a CPP depends on the amino acid sequence and the length of 
the CPP. Buforin 2 is a 21-residue peptide containing a +7 net charge 
(TRSSRAGLQFPVGRVHRLLRK) and is a membrane-permeabilizing antimicrobial peptide 
(Takeshima et al., 2003). Its structure is amphipathic, consisting of an N-terminal random 
coil region, an extended helical region, a hinge, and a C-terminal regular -helical region. 
The membrane permeability is dependent on the -helical content of the peptides (Park et 
al., 2000). Although it efficiently translocates into HeLa cells (Takeshima et al., 2003), it can-
not penetrate ES cells whether the 6xHis-tag is located N-terminally or C-terminally (Fig. 3). 
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In HeLa cells, buforin 2-mediated translocation of proteins is concentration-dependent but 
temperature-independent (Takeshima et al., 2003). pEP-1 is a 21-residue peptide with a +6 
net charge (KETWWETWWTEWSQPLKKRKV), and is a membrane-permeabilizing 
antimicrobial peptide and is amphipathic. pEP-1 can be translocated into cytoplasm and 
karyoplasms of R1 mES cells when the 6x His is located N-terminally (pEP-1-EGFP-N), as in 
COS-7 cells (Petrescu et al., 2009), but pEP-1-EGFP-C cannot penetrate the R1 cell membrane 
(Fig. 3) (Jung et al., 2007). The translocation of Buforin 2-EGFP-N, Buforin 2-EGFP-C, pEP-1-
EGF-N and pEP-1-EGF-C does not depend on their concentrations (Fig. 4) (Jung et al., 2007). 
Translocation into the cell by pEP-1 dose not depend on energy (Henriques et al., 2007). It is 
suggested that electrostatic interactions are most important in the pEP-1 membrane 
interactions (Henriques et al., 2007). Although both Buforin 2 and pEP-1 are amphipathic, 
their translocation effects in ES cells differ. Additionally, the penetration affinity of pEP-1 is 
changed by the 6xHis-tag. Based on these observations, it is suggested that the N-terminal 
location of His on pEP-1 is responsible for its cell-penetrating efficiency. Therefore, the 
penetration effects of CPPs in ES cells are different from other cell types, such as epithelial-
derived cell lines or stroma-derived cell lines (Jung et al., 2007; Petrescu et al., 2009; 
Takeshima et al., 2003). 
Although 6xHis-tag is important in the efficiency of pEP-1 penetration into ES cells, the best 
strategy to express functional proteins in cells is to use a vector with a C-terminal tag. Based 
on the previous analysis, R7, MAP, pVec, K-FGF and yPFY were chosen as CPP and 
analyzed for their ability to transport EGFP through the plasma membrane of ES cells. R7 is 
an arginine-rich peptide with a +7 net charge. pVec is an 18-amino-acid peptide with a +8 
net charge and is derived from the murine vascular endothelial-cadherin protein (Elmquist 
et al. 2010; Hällbrink et al., 2001). N-terminal hydrophobic part of pVEC is crucial for 
efficient cellular translocation (Elmquist et al., 2006). MAP (KLAL, model amphipathic  
 
 
Fig. 2. Constructs of recombinant EGFP, CPP-EGFP-N and Pep-1-EGFP-C. In this construct, 
we wanted to use 6xHis-tag for purify and identification. Because it is known that 6xHis-tag 
usually do not disturb the formation of 3-dimensional structure and function of gene 
products. It is possible that His has + charge and it can effect on the role of CPP. Therefore 
we tested the possible effects of 6x His on the ability of CPPs. 
 









Fig. 3. Translocation of EGFP-N and -C (A-1 and A-2, respectively), Buforin 2-EGFP-N and -C 
(B-1 and B-2, respectively), and pEP-1-EGFP-N and -C (C-1 and C-2, respectively) into R1 mES 
cells 24 hr after treatment. In natural culture condition, EGFP could not pass the cell 
membrane and the R1 ES cell did not take it through endocytosis. Site of 6xHis-tad did not 
give effect on the Buforin-2 transduction ability in mES cells but it gave effect on the pEP-1 
transduction ability in mES cells.  
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Fig. 4. Efficiency of transfection depends on the kinds of but independent on the 
concentration of Buforin 2 and pEP-1-EGFPs.  
CPP-EGFPs were administered at various concentrations (1; 5g/ml, 2; 50 g/ml; 3; 500 
g/ml) and observed after 12 hr. Vehicle (A), EGFP (B) and EGFP (B-b), Buforin 2-EGFP (C), 
pEP-1-EGFP (D) was administered to R1 mES cells and detected using confocal microscopy. 
-a means the N terminal 6xHis-tag and –b means the C terminal 6xHis-Tag. 
peptide) is an amphipathic helical peptide with a +5 net charge (Hällbrink et al., 2001). A 
positive charge as well as helicity and amphipathicity are all required for efficient 
translocation (Wolf et al., 2006). K-FGF and yPFY have no net positive charge. In our 
laboratory, pET-20b(+)deXhoI modified of pET-20b was used to construct CPP-EGFPs. To 
get the recombinant CPP-EGFPs, BL21 E. coli were used and purified with Ni2+-affinity 
column (Qiagen). R1 mES cells were maintained in ES medium containing 1000 IU LIF.  R7-
EGFP-C, MAP-EGFP-C, pVec-EGFP-C, K-FGF-EGFP-C and yPFY-EGFP-C (each 10 ng/ml) 
were incubated with R1 mES cells for 6 hr in ES medium containing 10% fetal calf serum 
and then analyzed for translocation with confocal microscope. Propidium iodide was used 
to stain the nucleus. Interestingly, all of them were localized both to the cytoplasm and 
karyoplasms (Fig. 5) (Cheon et al., manuscript in preparation). Based on these results, it is 
suggested that all these carriers can be applied in ES cells.  
Recently, it was discovered that R7 mediates the translocation of functional proteins into the 
cytoplasm of stem cells (Jo et al., 2010). Short-form human ESRRB was cloned in R7-pET-
20b(+)deXhoI, and recombinant RT-ESRRB was purified in BL21(DE3)pLysS. R7-ESRRB-
6xHis successfully translocated into the cytoplasm and karyoplasm (Fig. 6), and increased 
the expression of OCT4, NANOG and SOX2 (Fig. 7).  
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Fig. 5. Translocation of CPP-eGFP into R1 ES cells. 
(A-F) mES cells were treated with 10ng/ml EGFP (A), R7-EGFP (B), yPFY-EGFP (C), MAP-
EGFP (D), K-FGF-EGFP (E), or pVec-EGFP (F) for 6 hr at 37C. After treatment, all cells were 
stained with propidium iodide. 1 is eGFP images and 2 is the merged images.  
 
Fig. 6. R7-hESRRB-His6 protein can penetrate the plasma membrane within 5 hr after 
treatment and are completely localized in the nucleus within 24 hr after treatment. 
(A-C) the cells were not treated with R7-hESRRB-His6 protein but were immunostained 
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(A-F) mES cells were treated with 10ng/ml EGFP (A), R7-EGFP (B), yPFY-EGFP (C), MAP-
EGFP (D), K-FGF-EGFP (E), or pVec-EGFP (F) for 6 hr at 37C. After treatment, all cells were 
stained with propidium iodide. 1 is eGFP images and 2 is the merged images.  
 
Fig. 6. R7-hESRRB-His6 protein can penetrate the plasma membrane within 5 hr after 
treatment and are completely localized in the nucleus within 24 hr after treatment. 
(A-C) the cells were not treated with R7-hESRRB-His6 protein but were immunostained 
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with anti-His-Taq(6X) antibody; (D-F) the cells were immunostained with anti-His-Taq(6X) 
antibody 5 hours after treatment with R7-hESRRB-His6 protein; (G-I) the cells were 
immunostained with anti-His-Taq(6X) antibody 24 hours after treatment with R7-hESRRB-
His6 protein. Images were captured using a confocal microscope (Carl Zeiss LSM 510 
META, Zeiss, Jena, Germany) at ×1,000 magnification.  
 
 
Fig. 7. Treatment with R7-hESRRB-His6 protein for 8 days (192 hr) increases the expression 
of OCT4, NANOG and SOX2.  
A, real-time PCR for the expression of OCT4, NANOG and SOX2; B, agarose gel 
electrophoresis and EtBr staining after real-time PCR. Statistically significant differences 
between each group are denoted by different letters (P<0.05)  
4.3 Usage of nanobeads as carriers of functional proteins 
The amount of translocated functional protein is also an important factor in directing the 
induction of ES cells into specific cell types or maintaining ES cell stemness. In addition, the 
stability of the CPP-proteins is limited under physiological conditions. The translocation of 
CPP-proteins into cytoplasm can be inhibited by serum (Furuhata et al., 2006). Therefore, to 
control ES cell differentiation, it is necessary to regulate the amount of translocated 
functional protein. To prolong the lifespan of CPPs or CPP-conjugates, they have been 
modified but this approach has limits (Grunwald et al., 2009). 
Recently, nanoparticle techniques have been applied to medicine. Due to the physical and 
chemical characteristics of nanoparticles, they are more effective at targeting difficult-to-reach 
sites and have a better side effect profile. Hence, smaller doses of nanomedicines are needed to 
achieve the same therapeutic effect (Hock et al., 2011; Kuai et al., 2010; Neundorf, 2008). These 
advantages of nanoparticles as carriers are also evident in the study of ES cells. Poly(-amino 
esters) can fulfill the role of translocation mediator of a VEGF plasmid into hES cells (Yang et 
al. 2009). A chimeric protein, GFP-FRATtide, attached to a hydrophobically modified 15-nm 
silica nanoparticle is efficiently delivered to the cytosol of human embryonic kidney cells and 
rat neural stem cells (Shah et al., 2011). Tran and colleagues studied the effects of nanoparticles 
on morphological differentiation in mES cells (Tran et al., 2007). However, so far, the efficiency 
of this technique is not high in ES cell studies. 
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Another strategy to use nanoparticles is to apply the metabolic characteristics of ES cells and 
the characteristics of membranes to the nanoparticles. ES cells can use glucose and require 
glucose for further development. During the development of preimplantation embryos, the 
mammalian embryo needs a constant supply of energy substrates to remain viable. Usually, 
mammalian oocytes receive substrates, especially energy substrates, from the oviduct and 
uterus because they do not store much substrate in the cytoplasm during oogenesis. 
Glucose, lactate and pyruvate are essential components in preimplantation embryo culture 
media, and there are stage-specific preferences for them. Glucose may permit the expression 
of metabolic enzymes and transporters in compacting morula that are capable of generating 
the energy required for blastocyst formation. In addition, metabolites of glucose may be 
involved in cellular activity during the development of preimplantation embryos. 
Periimplantation embryos need glucose (Biggers and Summers, 2008). Therefore, ES cells 
can take up glucose as well as glycated proteins. Glucose-coated polymeric nanobeads have 
been prepared by dispersion polymerization (Jung et al., 2009). As a model protein, 
enhanced green fluorescent protein was ligated to the nanobeads and successfully 
translocated into mES cells (Fig. 8, Fig. 9). It is suggested that glucose-coated nanobeads 
could be a general cargo for the intracellular delivery of various macromolecules in ES cells.  
 
 
Fig. 8. Translocation experiments of the EGFP-ligated beads into R1 mouse embryonic stem 
cells. 
A, the confocal microscopic images. 1-a and 1-b, cells treated with EGFP alone; 2-a and 2-b, 
cells treated with non-coated beads; 3-a and 3-b, cells treated with 5%-glucose-coated beads; 
4-d and 4-m, cells treated with 10%-glucose-coated beads; 1-a, 2-a, 3-a, and 4-a are dark field 
images; 1-b, 2-b, 3-b, and 4-b are merged images (dark-bright fields). The merged images 
show that the cells are localized at the fluorescent regions. B, the relative intensities of the 
translocated EGFP. The intensities were measured using confocal microscopy (average ± SD; 
the measurements were repeated seven times and averaged).  
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Fig. 9. TEM photomicrograph of EGFP-ligated glucose beads in R1 mouse embryonic stem 
cells. Arrows indicate the translocated beads.  
In addition, these nanobeads could be more stable in the blood stream and tissue fluids 
compared than CPPs. On the other hand, if we add more functions in nanobeads, it can be 
carry a designed amount of functional protein. For example, shuttle signaling and self 
degradation can be helpful. To apply glucose nanobeads to in vitro and in vivo systems, 
further studies are needed, such as optimizing their homing and controlling the transporting 
amounts in karyoplasms and cytoplasm. 
5. Summary 
ES cells have been used to study the differentiation of various cell types and tissues in vitro, 
such as neural cells, hematopoietic lineages, cardiomyocytes, hepatocytes, -cells, and 
epithelium. In addition, ES-derived cells have been successfully transplanted into fetal and 
adult mice, where they have demonstrated morphological and functional integration 
(Kennedy et al., 1997). However, their use is still in the beginning stages in humans. It is 
difficult to translate laboratory advancements to human therapy because there are many 
obstacles to using ES cells in medicine (Piscaglia et al., 2010; Rossi et al., 2010). DNA 
construct mediated induction of ES cell-differentiation can cause unexpected side effects in 
the body. Therefore the best way is to use the functional proteins which regulate cellular 
characteristics such as transcription factors. Those factors can express their functional role, 
when they are located in proper sites, cytoplasm or karyoplasms. CPPs can be transported 
into cytoplasm and karyoplasms. 
This means that a membrane penetrating carrier is needed for the protein-application to get 
a specific cell type from ES cells. Based on this, CPP may be a clue to get such a goal. A 
nanobead which can easily translocate the cell membrane is also a clue to achieve such a 
goal. Although to apply the CPPs or specific nanoparticle-cargo in cell therapy using 
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protein, further studies are needed. These studies would open up new methods of therapy 
which are safe and economic. However, research on all aspects of ES cell biology will soon 
overcome these obstacles and make their use in therapy more safe and effective. 
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1. Introduction 
Microinjection is well recognized as an ideal but technically difficult method for the direct 
introduction of any molecules into single cells (King, 2004; Matsuoka et al., 2006). The 
difficulty depends on the cell size, intracellular structure, and the physical properties of the 
cell surface. Egg cells are an easy target because of their large size of 100–200 μm. Blastocysts 
are also a large target for the injection of embryonic stem (ES) cells (Fig. 1 (A)). For 
blastocysts, the tip diameter of an injector is 5 μm or greater. On the other hand, fibroblasts 
are as small as 20–30 μm but comparatively easy targets because their cell surface appears to 
be firm. Moreover they appear to be resilient against deep insertion of an injection capillary. 
By contrast, plant cells are larger than fibroblasts but much more difficult targets. Plant cells 
usually have large vacuoles in the intracellular space and therefore microinjection should be 
performed into a thin space between the cell membrane and the vacuole. Typical examples 
are tobacco cultured cells, BY-2, with a size of 40×80 μm (Fig. 1 (B)) and rice protoplasts with 
a diameter of 30–50 μm. By comparison, ES cells are extraordinarily difficult targets because 
of their small size (15–20 μm) (Fig. 1 (C)) and sticky cell surface. In fact, microinjection of a 
plasmid vector into ES cells was not successfully performed by a microinjection expert until 
our experiment performed in 2005 (Matsuoka et al., 2005).  
Before then, microinjection speed was no higher than 10 cells per h and the success rate was 
7–8%. In the case of ES cells, the success rate was only 0.2%. Therefore, it was essential to 
increase the throughput of the method for the purpose of single-cell studies. Thus, we 
developed a useful robot that could support the microinjection operator; a single-cell 
manipulation supporting robot (SMSR) (Matsuoka et al., 2005). Using the SMSR, the 
injection speed increased to 100 cells per h and its success rate reached as high as 10%, even 
when operated by non-specialist personnel. The quantity of DNA ejected from the injection 
capillary was estimated to be no greater than 50 fg, and consequently the quantity of DNA 
actually introduced into a cell was in the fg range. Moreover, when an enhanced green 
fluorescent protein (EGFP) expression vector was injected into ES cells, the EGFP expression 
intensity changed in line with the varied concentration of the vector in the injection 
capillary. This method has been termed femtoinjection because it has enabled semi-
quantitative injection at the femtogram level (Matsuoka et al., 2007).  
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in ES cell studies. The single cell indicates an isolated cell as well as a particular target cell 




Fig. 1. Microinjection into various cells. (A) Injection of mouse ES cells into a blastocyst; (B) 
injection of a fluorescent dye (lucifer yellow) into the cytosol of a tobacco cultured cell, BY-2, 
showing phase-contrast image (B1) and fluorescence image (B2); (C) injection into a mouse 
ES cell.  
2. Why is femtoinjection important? 
One of the important objectives of bio-research is to understand the functional role of 
biomolecules that impact on cellular life as a whole. Many biological functions such as 
enzymatic activities, signal transduction, and transcriptional and translational activities 
have been individually proven by employing conventional molecular biological methods. 
However, in many cases, these methods require destruction of the cells and thus it is 
difficult to observe the final impact on a living cell. Moreover, in many cases, investigational 
assays are carried out in vitro which provides a completely different environment to that 
inside a cell.  
For instance, the concentrations of macromolecules such as proteins and nucleic acids inside 
living cells are extremely high (Zimmerman & Trach, 1991), and under such specific 
conditions biomolecules behave differently, when compared with in vitro experiments. This 
is known as the macromolecular crowding effect, and it has been shown that a wide variety 
of intracellular processes such as protein folding, the association of ribosomes, and the 
binding of polymerase to DNA are affected by this effect (Hancock, 2004; Zimmerman & 
Minton, 1993; Zimmerman & Trach, 1988). Furthermore, the localization of biomolecules, 
which creates the gradation of concentrations and separated reactions in a cell, must be 
considered as an essential factor for investigating the original activities, despite being very 
difficult to reconstruct in vitro. Moreover, molecules do not work alone but interact with 
other molecules, some of which may be unknown factors, leading to sequential reactions.  
Thus, conventional methods are indeed limited for the investigation of the functional roles 
in a living cell and so the development of a new method has been required. One of the most 
straightforward methods is the microinjection of molecules of interests into a living cell. In 
fact, microinjection was used to obtain specific data about their functional roles in living 
cells. However, the performance of ordinary microinjection was insufficient because it was 
difficult to produce quantitative data. Thus, we have long been engaged in the development 
of a high-performance microinjection method as described below.  
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3. SMSR and “suguwaculture” 
The SMSR was designed according to the experience of microinjection experts. The most 
important functions are the operation modes of an injection capillary. The speed and timing 
of a push–pull motion is dependent on the cell size, the physical properties of the cell 
surface, and the experience of the operator. Thus, the operational parameters can be 
adjusted to optimum values for different conditions. The most recent version of the SMSR is 
shown in Fig. 2. 
 
 
Fig. 2. Schematic of the SMSR.  
Microinjection includes not only the insertion of a micropipette into a target cell but also 
various associated operations such as X–Y stage manipulation, microscope focus 
adjustment, selection and transformation of a target single cell, exchange of a micropipette, 
and recording of microscopic images. These operations may be classified into two 
categories: operations performed by observation with a microscope (on-microscope 
operations) and operations performed without a microscope (off-microscope operations). 
Frequently changing between on-microscope and off-microscope operations is annoying 
and time-consuming. The concept of SMSR is to enable the operator to concentrate their 
attention only on the microinjection by facilitating associated operations.  
To realize this concept, an X–Y coordinate registration system for each target cell was 
essential. We developed a disposable coordinate standard (CS) chip by ejecting melted 
polystyrene into a metal mold (Yamada et al., 2008). The chip size was 16.0 mm × 6.0 mm, 
and the chip surface was divided into four parts of different height and width (Fig. 3 (A), 
(B)). An adhesive tape was pasted onto the chip (Fig. 3 (C)) so that it could be attached to a 
culture dish simply by removing a cover sheet and placing it beneath the dish. The edges of 
these parts could be recognized as straight lines 2 μm in width under the microscope (Fig. 2 
(D), (E)). The culture dish depicted in Fig. 2 (F) is a popular one and one which is used in 
our laboratory. The thickness of the CS chip is no thicker than 0.3 mm because the height of 
the bottom rim of commercially available culture dishes is in the range 0.4–1.4 mm. 
Many cell scientists are concerned about the dish material and its surface treatment, because 
theses factors can influence the growth and physiological properties of the test samples 
(cells and tissues). Once they are able to obtain successful results using a particular type of 
dish, they will continue to use dishes of the same type. Therefore, it is extremely important 
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In this chapter we describe the potential applications of femtoinjection to single-cell analysis 
in ES cell studies. The single cell indicates an isolated cell as well as a particular target cell 
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3. SMSR and “suguwaculture” 
The SMSR was designed according to the experience of microinjection experts. The most 
important functions are the operation modes of an injection capillary. The speed and timing 
of a push–pull motion is dependent on the cell size, the physical properties of the cell 
surface, and the experience of the operator. Thus, the operational parameters can be 
adjusted to optimum values for different conditions. The most recent version of the SMSR is 
shown in Fig. 2. 
 
 
Fig. 2. Schematic of the SMSR.  
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that the CS chip can be applied to any type of dish. Moreover the CS chip must not contact 
the test samples directly. Our new CS chip meets these requirements and cannot be replaced 
by other devices such as multiple microwells and multiple pore plates, some of which are 





Fig. 3. Coordinate standard chip. Reproduced from Micros. Microanal. (2008) 14, 236-42 with 
permission from Cambridge University Press. 
A standard protocol for single-cell experiments such as microinjection or image capture is as 
follows. Initially, the X–Y coordinates of 50–100 target single cells per culture dish are 
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consecutively registered, after which an operator can signify Cell1, Cell2, …, and Celln in the 
relevant order to the microscopic view center simply by clicking a foot switch. Alternatively, 
an operator can select a particular cell number, Celli, directly by selecting the i-th “Cell 
number” with a mouse. If the dish is removed from the automatic stage and replaced some 
time later, the rapid cell search function can be used because of the registered X–Y axes. 
Such applications include, for instance, the simultaneous use of multiple culture dishes, cell 
culture in a separate incubator, and image capture with a different microscope (Fig. 4). 
Therefore, operators can easily search any single cell in any culture dish on any microscope 
at any time. Such a system is remarkably useful for various modes of single-cell experiment. 
We have named this system “Suguwaculture”, which means instantly (sugu in Japanese) 
recognizable (wakaru in Japanese) culture.  
 
 
Fig. 4 Time-lapse single-cell experiments with multiple apparatus using the Suguwaculture 
system. (A) single-cell experiments such as cell registration and cell manipulation on the 
automatic stage of an inverted microscope, (B) culture in an incubator, (C) microinjection, 
(D), and (E) time-lapse image captures with other optical apparatus. Reproduced from 
Micros. Microanal. (2008) 14, 236-42 with permission from Cambridge University Press. 
4. What can be done by femtoinjection?  
4.1 Semi-quantitative introduction of macromolecules of any size 
DNA solution in a glass capillary was ejected into a micro water drop and the quantity of 
DNA in the water drop was determined by quantitative real-time polymerase chain 
reaction. The ejected quantity was influenced by the diameter of the capillary tip and the 
intensity and period of pressure. The optimum conditions of the tip diameter, the pressure 
strength, and the pressure application period were typically 0.5–0.8 μm, 0.70 kgf/cm2, and 
30 ms, respectively. For DNA concentrations of 10, 50, and 100 ng/μl under optimum 
conditions, the ejected quantity changed accordingly within the range 5–50 fg. Therefore, the 
quantity of DNA actually introduced into an ES cell was estimated to be no greater than the 
fg level (Matsuoka et al., 2007). 
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Fig. 5. Semi-quantitative relationship between the EGFP expression intensity and the vector 
concentration in a capillary in the range 1–50 ng/μl (A), and a higher range from 10–300 
ng/μl (B). Error bar indicates mean ± SD (n=10).  
An EGFP expression vector was injected into ES cells to visualize the gene expression. The 
fluorescence of EGFP appeared after 24 h of culture not only in the injected cell but also in 
the neighboring cells that were daughter cells or their further descendent cells. The 
fluorescence intensity was averaged over the whole area of the target single cell or the single 
cluster containing the initial target cell. Thus, the calculated intensity of EGFP fluorescence 
was thought to be proportional to the quantity of the gene successfully introduced into the 
cell. In fact, the EGFP fluorescence intensity increased as the vector concentration increased 
from 1 to 300 ng/μl (Fig. 5) (Saito & Matsuoka, 2010) 
If the average of multiple cells is used, methods such as lipofection and electroporation 
might show a semi-quantitative introduction performance. By comparison, we investigated 
the performance of lipofection using an EGFP expression vector (pCAG-EGFP). Mouse ES 
cells were suspended in a solution containing pCAG-EGFP (5 μg DNA/50 μl medium) and 
a cell fusion-inducing agent, lipofectamine 2000 (15 μl/35 μl medium). After incubation at 
37ºC for 24 h, fluorescent cell colonies were selected arbitrarily for microscopic image 
analysis. The fluorescence intensity was integrated and averaged over each colony. Thus, 
the obtained values were then averaged to quantify the gene expression intensity. Then the 
concentration of pCAG-EGFP or lipofectamine was varied from 1/100 to 100 times the 
initial concentrations. As depicted in Fig. 6, the optimum condition could be determined but 
it was difficult to find a proper range in which a quantitative or semi-quantitative 
relationship could be satisfied. 
4.2 Semi-quantitative introduction of multiple factors 
Control of the relative expression intensity of multiple genes is of great importance. To 
demonstrate such semi-quantitative control, we investigated a particular case of two genes: 
EGFP and DsRed. We prepared pCAG-EGFP, a DsRed expression vector (pCAG-DsRed), 
and a composite vector, pCAG-EGFP-IRES-DsRed, in which both genes were constructed in 
tandem (Fig. 7 (A)). When a solution containing pCAG-EGFP and pCAG-DsRed at the same 
concentration (5 ng/μl) was injected into an ES cell, the fluorescence intensity of EGFP 
appeared to be much higher than that of DsRed (Fig.7(B)). In the case of pCAG-EGFP-IRES-
DsRed, the fluorescence image was similar (Fig. 7 (C)).  
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Fig. 6. Relationship between the EGFP expression intensity and the vector concentration in a 
cell suspension for lipofection. Error bar indicates mean ± SD (n=20).  
The molecular size of EGFP protein is 25.4 kDa and the EGFP can pass through the nuclear 
membrane, because the cut-off size of the nuclear membrane is thought to be 50 kDa. 
Therefore, EGFP distributes both in the cytosol and the nucleus. By contrast, DsRed needs to 
form a tetramer to become a fluorescent protein. The molecular size of the DsRed tetramer 
(DsRedT4) is 103.6 kDa. The tetramer is likely to be formed immediately in the cytosol, 
because fluorescent DsRed was distributed predominantly in the cytosol. Assuming that the 
fluorescence intensities of the respective fluorescent units, EGFP and DsRedT4, are the 
same, the relative fluorescence intensity of EGFP to DsRed should be 4:1 if the gene copy 
number is the same.  
In fact, however, the intensity of EGFP expression was roughly 10 times higher than that of 
DsRed in the case of either separate vectors (Fig. 7 (D)) or the composite vector (Fig. 7 (E)). 
Next we mixed pCAG-EGFP and pCAG-DsRed at a ratio of 1:10 and injected the mixture 
into ES cells. Consequently the gene expression intensity of both genes was the same (Fig. 7 
(F)). This result demonstrates that it is feasible to control the relative expression intensity of 
multiple genes easily as desired by regulating a ratio of the mixture. 
4.3 Temporal and spatial control of injection in a cell colony 
In order to analyze the functional role of a single cell in a cluster or colony of multiple cells, 
it is necessary to introduce a gene or other marker into a particular target single cell and 
then continue microscopic observation. In the case of the ES cell, an isolated single cell 
grows to be a colony with a diameter of approximately 50 μm after culture for 72 h. 
Therefore, we prepared such colonies of ES cells and demonstrated temporal and spatial 
control of femtoinjection into a target single cell.  
The first case was the injection of a fluorescent dye, Dextran-Alexa 488 (1 μg/μl, MW 70 
kDa). The success of physical introduction into only a single cell was confirmed by the 
diffusion pattern of the dye (Fig. 8 (A)). The culture was continued for a further 42 h. Then 
injection of the same dye into two single cells was performed. The physical introduction of 
the dye was successful at this time too (Fig. 8 (B)). Such an injection into any single cell 
located at the surface of a colony was possible. 
 





Fig. 5. Semi-quantitative relationship between the EGFP expression intensity and the vector 
concentration in a capillary in the range 1–50 ng/μl (A), and a higher range from 10–300 
ng/μl (B). Error bar indicates mean ± SD (n=10).  
An EGFP expression vector was injected into ES cells to visualize the gene expression. The 
fluorescence of EGFP appeared after 24 h of culture not only in the injected cell but also in 
the neighboring cells that were daughter cells or their further descendent cells. The 
fluorescence intensity was averaged over the whole area of the target single cell or the single 
cluster containing the initial target cell. Thus, the calculated intensity of EGFP fluorescence 
was thought to be proportional to the quantity of the gene successfully introduced into the 
cell. In fact, the EGFP fluorescence intensity increased as the vector concentration increased 
from 1 to 300 ng/μl (Fig. 5) (Saito & Matsuoka, 2010) 
If the average of multiple cells is used, methods such as lipofection and electroporation 
might show a semi-quantitative introduction performance. By comparison, we investigated 
the performance of lipofection using an EGFP expression vector (pCAG-EGFP). Mouse ES 
cells were suspended in a solution containing pCAG-EGFP (5 μg DNA/50 μl medium) and 
a cell fusion-inducing agent, lipofectamine 2000 (15 μl/35 μl medium). After incubation at 
37ºC for 24 h, fluorescent cell colonies were selected arbitrarily for microscopic image 
analysis. The fluorescence intensity was integrated and averaged over each colony. Thus, 
the obtained values were then averaged to quantify the gene expression intensity. Then the 
concentration of pCAG-EGFP or lipofectamine was varied from 1/100 to 100 times the 
initial concentrations. As depicted in Fig. 6, the optimum condition could be determined but 
it was difficult to find a proper range in which a quantitative or semi-quantitative 
relationship could be satisfied. 
4.2 Semi-quantitative introduction of multiple factors 
Control of the relative expression intensity of multiple genes is of great importance. To 
demonstrate such semi-quantitative control, we investigated a particular case of two genes: 
EGFP and DsRed. We prepared pCAG-EGFP, a DsRed expression vector (pCAG-DsRed), 
and a composite vector, pCAG-EGFP-IRES-DsRed, in which both genes were constructed in 
tandem (Fig. 7 (A)). When a solution containing pCAG-EGFP and pCAG-DsRed at the same 
concentration (5 ng/μl) was injected into an ES cell, the fluorescence intensity of EGFP 
appeared to be much higher than that of DsRed (Fig.7(B)). In the case of pCAG-EGFP-IRES-
DsRed, the fluorescence image was similar (Fig. 7 (C)).  
Functional Control of Target Single Cells  




Fig. 6. Relationship between the EGFP expression intensity and the vector concentration in a 
cell suspension for lipofection. Error bar indicates mean ± SD (n=20).  
The molecular size of EGFP protein is 25.4 kDa and the EGFP can pass through the nuclear 
membrane, because the cut-off size of the nuclear membrane is thought to be 50 kDa. 
Therefore, EGFP distributes both in the cytosol and the nucleus. By contrast, DsRed needs to 
form a tetramer to become a fluorescent protein. The molecular size of the DsRed tetramer 
(DsRedT4) is 103.6 kDa. The tetramer is likely to be formed immediately in the cytosol, 
because fluorescent DsRed was distributed predominantly in the cytosol. Assuming that the 
fluorescence intensities of the respective fluorescent units, EGFP and DsRedT4, are the 
same, the relative fluorescence intensity of EGFP to DsRed should be 4:1 if the gene copy 
number is the same.  
In fact, however, the intensity of EGFP expression was roughly 10 times higher than that of 
DsRed in the case of either separate vectors (Fig. 7 (D)) or the composite vector (Fig. 7 (E)). 
Next we mixed pCAG-EGFP and pCAG-DsRed at a ratio of 1:10 and injected the mixture 
into ES cells. Consequently the gene expression intensity of both genes was the same (Fig. 7 
(F)). This result demonstrates that it is feasible to control the relative expression intensity of 
multiple genes easily as desired by regulating a ratio of the mixture. 
4.3 Temporal and spatial control of injection in a cell colony 
In order to analyze the functional role of a single cell in a cluster or colony of multiple cells, 
it is necessary to introduce a gene or other marker into a particular target single cell and 
then continue microscopic observation. In the case of the ES cell, an isolated single cell 
grows to be a colony with a diameter of approximately 50 μm after culture for 72 h. 
Therefore, we prepared such colonies of ES cells and demonstrated temporal and spatial 
control of femtoinjection into a target single cell.  
The first case was the injection of a fluorescent dye, Dextran-Alexa 488 (1 μg/μl, MW 70 
kDa). The success of physical introduction into only a single cell was confirmed by the 
diffusion pattern of the dye (Fig. 8 (A)). The culture was continued for a further 42 h. Then 
injection of the same dye into two single cells was performed. The physical introduction of 
the dye was successful at this time too (Fig. 8 (B)). Such an injection into any single cell 
located at the surface of a colony was possible. 
 











Fig. 7. Quantitative relationship in simultaneous introduction of EGFP and DsRed 
expression vectors. (A) Constructs of vectors; (B), (C) Examples of fluorescent images of 
EGFP and DsRed, respectively; (D), (E), (F) Relative intensities of EGFP and DsRed 
fluorescence. Error bar indicates mean ± SD (n=10).  
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Fig. 8. Injection of Dextran-Alexa 488 (A, B) or Dextran-Alexa 488 and pCAG-DsRed (C, D) 
into a target single cell of an ES cell colony. Injection was performed after culture for 72 h. 
(A, C) Immediately after injection; (B, D) 42 h after injection. (A–C) (a) Dextran-Alexa 488, 
(b) phase-contrast image, (c) superposition of a and b; (D) (a) Dextran-Alexa 488, (b) DsRed, 
(c) phase-contrast image, (d) superposition of a, b, and c.  
The next case was the simultaneous injection of a gene expression vector together with a 
fluorescent dye. A solution containing pCAG-DsRed (50 ng/μl) and Dextran-Alexa 488 was 
injected into a single cell in a colony (Fig. 8 (C)). The diffusion pattern of Dextran-Alexa 488 
became a marker of the success of physical introduction. After incubation for 24 h, the 
expression of DsRed was observed in the same cell in which the diffusion of Dextran-Alexa 
488 was observed (Fig. 8 (D)). This indicates the physical and physiologic success of 
injection. 
4.4 Spatial control of injection site in a cell: cytosol or nucleus 
When a plasmid vector is introduced into a cell, the vector has to be transported to the 
nucleus. Therefore, its expression efficiency will be enhanced if the vector is introduced 
directly into the nucleus rather than into the cytosol. The nucleus is located in the center of a 
cell. The direct injection into the nucleus requires a deeper insertion of an injection capillary. 
Such an insertion, however, seems to decrease the likelihood of cell viability. Next we 
investigated the possibility of non-lethal insertion into the nucleus of ES cells. 
Dextran-Alexa 488 was injected into single cells of a DsRed-expressing ES cell line. This cell 
line shows red fluorescence only in the cytosol, because DsRedT4 cannot pass through the 
nuclear membrane (Fig. 9 (A)). For the same reason, Dextran-Alexa 488 cannot either. 
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cell. The direct injection into the nucleus requires a deeper insertion of an injection capillary. 
Such an insertion, however, seems to decrease the likelihood of cell viability. Next we 
investigated the possibility of non-lethal insertion into the nucleus of ES cells. 
Dextran-Alexa 488 was injected into single cells of a DsRed-expressing ES cell line. This cell 
line shows red fluorescence only in the cytosol, because DsRedT4 cannot pass through the 
nuclear membrane (Fig. 9 (A)). For the same reason, Dextran-Alexa 488 cannot either. 
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Consequently if Dextran-Alexa 488 is introduced into the cytosol, the cytosol will become 
yellow. On the other hand, if the dye is introduced into the nucleus, the cytosol will remain 
red and the nucleus will become green. Indeed, two patterns were observed as depicted in 






Fig. 9. Injection of Dextran-Alexa 488 into a single cell of a DsRed-expressing ES cell line. (A) 
Experimental protocol; (B) example of introduction into the cytosol; (C) example of 
introduction into the nucleus. (a) Dextran-Alexa 488, (b) DsRed, (c) phase-contrast image, 
(d) superposition of a, b, and c.  
Next, we investigated the effect of direct injection on the expression efficiency of an injected 
vector. The yellowish green fluorescent protein Venus was selected as a demonstrative gene 
production because Venus fluorescence was expected more stable and intense than EGFP. 
The Venus-expression vector and Dextran-Fluorescein (MW 70 kDa) were injected into 
DsRed-expressing ES cells. The results are summarized in Fig. 10.  
Injection was performed into 306 single cells, and 180 cells maintained viability. Dextran-
Fluorescein was observed in 158 of 180 cells. This indicates that the success rate of physical 
introduction of the fluorescent dye was 52% (158/306). In these 158 cells, 117 injections were 
into the cytosol, whereas 41 were injected into the nucleus. The expression rate of the Venus 
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gene was no higher than 27% (31/117) in the case of cytosolic injection. By contrast, the rate 
reached 83% (34/41) for nucleic injection. These results strongly suggest that the direct 
introduction of a vector into the nucleus is effective for the enhancement of gene expression 




Fig. 10 Comparison of gene expression efficiencies attained by injection into the cytosol and 
nucleus. 
5. Analysis of a DNA nuclear targeting sequence as a potential enhancer of 
the expression of a femtoinjected exogenous gene in ES cells 
In order to enhance the expression efficiency of an injected gene, it is effective to inject it 
directly into the nucleus, as described above. However, deep insertion into the nucleus is 
likely to cause serious damage to the cell. Therefore, an alternative method is required to 
promote transportation of the gene toward the nucleus. A simple and promising approach is 
to add a specific sequence into a vector, using a so-called DNA nuclear targeting sequence 
(DTS) (Dean, 1997; Dean et al., 1999a, 1999b) (Fig. 11).  
A DTS is a specific sequence recognized by transcriptional factors. Therefore, the injected 
vector is expected to form a complex with the specific or general transcriptional factor. Since 
the transcriptional factors are imported into the nucleus by an intrinsic active transport 
system, the vector–DTS complex may also be imported into the nucleus via the same system. 
Consequently the transport of the vector into the nucleus is expected to be promoted to 
result in the enhancement of its expression.  
For instance, the 72 base pairs of the simian virus 40 (SV40) promoter/enhancer sequence 
(SV40-DTS) was reported to be a DTS (Dean, 1997), which enhanced the nuclear import so 
that the efficiency of the gene expression increased compared to without the DTS. Since this 
sequence has the binding site of ubiquitously expressed transcriptional factors, it has been 
suggested that the introduced vector DNA forming a complex with these transcriptional 
factors passes through a nuclear pore with the help of the importin family which recognizes 
nuclear localization signals of transcriptional factors (Miller & Dean, 2009; Miller et al., 
2009). Although it has been revealed that SV40-DTS functions as a DTS in various types of 
cells, the function in ES cells remains unclear, probably due to the difficulty of the injection 
of a vector into the cytoplasm.  
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nucleus. 
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Fig. 11. The enhancement of gene expression efficiency of femtoinjected plasmid by utilizing 
protein life dynamics. The femtoinjected plasmid is drugged into a nucleus via the intrinsic 
transportation system recognizing a nuclear localization signal of transcriptional factors 
after forming a plasmid-protein complex. Thus the plasmids are actively delivered in 
nucleus, expressing the gene efficiently. Reproduced from Biochem. Biophys. Res. Commun. 
(2010) 400), 554-8 with permission from Elsevier. 
 
 
Fig. 12. Effect of SV40-DTS on the gene expression efficiency in ES cells. The plasmids 
containing SV40-DTS express a probe gene (EGFP) efficiently in ES cells. Reproduced from 
Biochem. Biophys. Res. Commun. (2010) 400), 554-8 with permission from Elsevier. 
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However, with femtoinjection, it is now feasible to investigate the effect of a DTS on the 
efficiency of gene expression in ES cells (Funabashi et al., 2010). An EGFP expression vector 
(SV40-DTS positive vector or control vector encoding no DTS) and Dextran-Texas Red (MW 
40 kDa) were injected into ES cells. According to the protocol described in section 4.4, the 
injected site was determined (i.e., cytosol or nucleus). The MW of Dextran-Texas Red is 
similar to the cut-off size of the nuclear membrane (MW ca. 50 kDa), Dextran-Texas Red can 
hardly diffuse into the nucleus. The efficiency of gene expression was defined as “the 
number of cells in which EGFP expression was observed per number of cells in which the 
EGFP gene was femtoinjected into the cytoplasm determined by the observation of Dextran-
Texas Red”. As shown in Fig. 12, comparison of gene expression efficiency between the 
SV40-DTS positive vector-injected ES cells and ES cells injected with the control vector 
clearly revealed the effect of SV40-DTS. This was the first report to identify the role of DTS 
in ES cells (Funabashi et al., 2010). 
Inspired by the success of the investigation, we hypothesized that a sequence recognized by 
ES cell-specific transcriptional factors should function as an ES cell-specific DTS. Oct3/4 
binding Sox2 regulatory region 2 (SRR2) has been reported to be a distal enhancer for Sox2 
expression where the Oct3/4 and Sox2 complex is bound (Tomioka et al., 2002). As both 
Sox2 and Oct3/4 are well-known ES cell-specific transcriptional factors for maintaining 
pluripotency (Masui et al., 2007; Niwa et al., 2000; Niwa, 2007), it is expected that the 81 bp 
of SRR2 (Fig. 13) functions as a DTS (termed SRR2-DTS) and that it promotes the 
transportation of the plasmid giving rise to the efficiency of gene expression. 
 
 
Fig. 13. Sequence of Sox2 regulatory regions 2 (SRR2). SRR2 is an 81 bp sequence containing 
Oct3/4 and Sox2 binding sequences. Reproduced from Biochem. Biophys. Res. Commun. 
(2010) 400), 554-8 with permission from Elsevier. 
In the case of MIN6 cells (mouse insulinoma cells (Miyazaki et al., 1990)) which express 
neither Sox2 nor Oct3/4, no difference is observed in terms of the gene expression efficiency 
regardless of the types of introduced plasmids as shown in Fig. 14 (A), whereas ES cells 
femtoinjected with the SRR2-DTS-positive plasmid exhibit higher gene expression efficiency 
than ES cells injected with the SRR2-DTS-negative plasmid (Fig. 14 (B)). This result supports 
our hypothesis that the enhancement of gene expression observed is due to the expression of 
these ES cell-specific transcriptional factors.  
The observed phenomenon can possibly be explained as follows. The mRNAs of ES cell-
specific transcriptional factors Oct3/4 and Sox2 were exported to the cytoplasm, and then 
translated into proteins. These proteins met the femtoinjected plasmids which had SRR2-
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DTS forming the complex on the sequence. This complex was drugged into the nucleus via 
the nucleic pore transportation system in which the nuclear localization signals on these 
transcriptional factors were recognized by importin family members. This active 
transportation of the plasmid resulted in the higher gene expression efficiency. Indeed, it 
has been reported that Oct3/4 and Sox2 are actively transported into the nucleus by 
importin α1/β1 complex and possibly by importin β1, respectively (Yasuhara et al., 2007, 
2009), in ES cells. It has also been suggested that these importins will function work on the 
SV40-DTS depending transportation (Dean, 1997; Dean et al., 1999; Lam & Dean, 2010; 
Miller et al., 2009). Thus, both sequences function as DTSs in ES cells. In particular, it has 
been suggested that SRR2-DTS functions as an ES cell-specific DTS.  
 
 
Fig. 14. Effect of SRR2 region on the gene expression efficiency in MIN6 cells (A) and ES 
cells (B). There was no effect of SRR2 sequence on the gene expression efficiency in the case 
of MIN6 cells while clear enhancement was observed in case of ES cells. Reproduced from 
Biochem. Biophys. Res. Commun. (2010) 400), 554-8 with permission from Elsevier. 
Femtoinjection has enabled injection into living single ES cells of all substances including 
ions, fluorescent dyes, and nucleic acids, which range from low molecular weight chemicals 
to macromolecules, as long as they are soluble. On the other hand, it is not yet feasible to 
aim for high resolution injection sites such as small organelles in mammalian cells. The 
intrinsic transport system inside living cells such as the protein life dynamics utilized here is 
expected to help the distribution of introduced substances to the place where one desire to 
send for.  
6. Femtoinjection assay for differentiation-inducing factors based on a 
morphological indicator  
With regard to quantitative gene expression control, how to maintain the undifferentiated 
state of ES cells is of particular interest. Several genes such as Oct3/4, Sox2, and Nanog are well 
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recognized as undifferentiated cell markers (Masui et al., 2007; Niwa, 2007). However, it is also 
recognized that none of them alone is an exclusive marker. Rather the undifferentiated state 
seems to be maintained by an appropriate balance of their expression intensities. To prove this 
supposition, the simultaneous control of expression intensities of these genes is thought to be 
an effective method. Femtoinjection is particularly useful for this purpose.  
First, we varied the expression intensity of Oct3/4 alone by femtoinjection of Oct3/4 
expression vector into ES cells (Matsuoka & Saito, 2010). As a non-invasive marker of 
differentiation, we introduced the perimeter-to-radius ratio (PR ratio) as a novel 
morphologic indicator (Fig. 15). Generally ES cells are circular but change into a 
morphologically complex shape once differentiated. The PR ratio can sensitively reflect such 
a change. If the cell shape is a true circle, the PR ratio is 6.28; however, it becomes greater as 
the cell shape becomes more complex.  
 
 
Fig. 15. Definition of PR ratio for quantitative expression of morphologic complexity. 
Reproduced from ECS Transactions (2009) 16, 9-14 with permission from The 
Electrochemical Society. 
As shown in Fig. 16, an Oct3/4 expression vector containing an EGFP reporter gene (pCAG-
Oct3/4-IRES-EGFP) was injected into single cells of mouse ES cells. As a control, an EGFP 
expression vector was injected into single cells in the same manner. At the same time, no 
injection control cells were prepared and observed in parallel. After injection, cell 
morphology was recorded every 24 h and the PR ratio was determined. In some cases, the 
PR ratio increased at 24 h but returned to the initial level at 48 h or later. In other cases, it 
increased continuously throughout the observation period for 72 h. Both with and without 
injection control, the PR ratio was 7.3–8.0 until 72 h. Based on these results, we defined the 
differentiated state as follows: PR ratio became greater than 8.0 and remained at this level at 
72 h. According to this definition, the differentiation rate was determined as (number of 
differentiated cells/number of EGFP positive cells at 24 h) × 100%.  
Figure 17 shows an example of injection of pCAG-Oct3/4-IRES-EGFP at a concentration of 
600 ng/μl in the injection capillary. At a concentration of 300, 600, or 1200 ng/μl, the 
differentiation rate was 2/6 (33%), 5/7 (71%), and 6/7 (86%), respectively. Though the 
number of test samples is small, this result suggests that the increase in Oct3/4 expression 
intensity is effective for the promotion of differentiation of ES cells. 
For the up-regulation of a target gene expression or a specific protein effect, the introduction 
of the over-expression vector is thought to be a useful method, as demonstrated above. The 
introduction of mRNAs or target proteins is thought to be a more direct way to cause the 
up-regulation effects. On the other hand, the down-regulation of a target gene expression 
may be produced by the introduction of siRNA or shRNA. The introduction of inhibitors 
against the molecules of interests including antibodies and dominant negatives may also be 
an effective way to produce the down-regulation effects. In either case, the quantitative 
introduction of respective factors is essential for the regulation.  
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Fig. 16. Protocol for femtoinjection of Oct3/4 expression vector.  
 
 
Fig. 17. Morphologic changes in the ES cell colony induced by injection of Oct3/4 expression 
vector. The concentration of pCAG-Oct3/4-IRES-EGFP in the injection capillary was 600 
ng/μl. Scale bar indicates 20 μm. Reproduced from ECS Transactions (2009) 16, 9-14 with 
permission from The Electrochemical Society. 
7. Marking vibrating muscle fiber cells with non-harmful fluorescent dyes 
We have previously cultured mouse ES cells and tried to prepare muscle fibers. In the 
course of the study, it was interesting to find that the polyamines spermine could induce 
remarkable growth of multi-layer muscle fibers (Fig. 18) (Sasaki et al., 2008). The growth 
process was so unique that we have been deeply engaged in gene expression and functional 
analyses. With regard to the pulsation function, it should be of fundamental significance to 
analyze how to acquire synchronously pulsation potency. Therefore, we considered it 
necessary to analyze the cell-to-cell communication in a cell sheet during synchronous 
pulsation and during rest. Thus, we intended to challenge the injection into single cell in 
muscle fiber during its pulsation as well as when rest.  
Femtoinjection into a particular target cell in an ES cell colony was demonstrated in section 
4.3. Such injection into a target single cell is also possible in a cell cluster composed of 
differentiated cells of different sizes and shapes, as long as the outline of a target single cell 
can be observed microscopically. In the present case of pulsating cells, however, it seemed 
to be almost impossible. Next we re-examined various parameters relevant to injection  
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Fig. 18. Muscle fiber prepared from mouse ES cells with spermine treatment. (A) Multilayer 
sheet of contractile muscle fiber; (B) fluorescence image of striated muscle fibers stained 
using an antibody to α-actinin that was detected with an Alexa Fluor-labeled secondary 
antibody. 
performance and finally succeeded in injecting a pulsating single cell in the muscle fiber, as 
described below. 
We aimed to suppress the pulsation intensity by cooling the muscle fiber for a while and to 
then perform injection, before warming it to room temperature. To confirm the cooling 
effect, it was necessary to monitor the pulsation intensity. The optical intensity at a 
particular position in the muscle fiber was measured continuously and its relative change 
was quantified to express the pulsation intensity at the measured position. Figure 19 shows   
 
 
Fig. 19. Influence of cooling on the pulsation of a muscle fiber. 
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a record obtained during the temperature variations. The cells cultured at 37ºC were rapidly 
cooled to 4ºC. The pulsation intensity decreased to between a half and one-third. Then the 
cells were warmed gradually to room temperature. After 24 h from the start of warming, the 
cells recovered their initial pulsation intensity to the original level. Therefore, cooling to 4ºC 
for a short period of time had no obvious effect on the intrinsic pulsation function. 
Another point to be considered with regard to muscle fibers is the physical properties of the 
cell membrane. Then the tip parameters were modified to adapt to muscle fiber. Finally the 
tip diameter of an injection capillary was made smaller and the tip length was made shorter 
than for capillaries used for ES cells. Using this capillary, a solution of Alexa 488 (1 μg/μl, 
MW 643) and/or Dextran-Texas Red (10 μg/μl, MW 3,000) was injected into the target 
single cells simultaneously. Dextran-Texas Red stayed within a small area around the 
injection point that was supposedly within the target cell (Fig. 20). Therefore, only the 
injection into the target cell was considered successful. On the other hand, Alexa 488 
distributed to a wider area (approximately 200 μm×100 μm). However, the diffusion area 
was not a simple circular pattern but an irregular one. Such an irregular diffusion pattern 
was unexpected. The present results are still preliminary but suggest a heterogeneous 
distribution of gap junctions with different opening diameters. 
 
 
Fig. 20. Femtoinjection of Alexa 488 and Dextran-Texas Red into a single pulsating cell of a 
muscle fiber.  
8. Automatic injection system  
SMSR is a useful machine but its further improvement is required to produce a fully 
automatic system. To accomplish this, it is essential to detect a stop signal for the injector 
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when the injector tip has just penetrated the cell membrane. Next we devised an electric 
circuit to measure the intracellular potential sensitively without a high degree of electrical 
noise. The measured potential change was thought to be a useful control signal for the 
injector drive. In order to measure the electrical potential and at the same time introduce a 
marker dye into a target cell, a double barrel capillary was used (Matsuoka et al., 2006).  
A glass capillary with a θ-shaped cross section (outer diameter 1 mm) was heated and pulled 
to make the tip diameter smaller than 1 μm using a laser puller. One channel of the capillary 
was filled with a solution of 0.5 M KCl. A Ag/AgCl wire was then inserted into the capillary to 
produce a potential measuring electrode (MeaE) (Fig. 21). The reference electrode for MeaE 
was a commercially available Ag/AgCl electrode (RE). The other channel was filled with a 
solution containing 0.5 M KCl and 1 mM lucifer yellow. A Pt wire was inserted into the 
capillary to produce a dye-introducing electrode (IntE). The counter electrode (CE) for the IntE 
was prepared by filling a glass tube with 3% agar gel containing 0.5 M KCl. 
 
 
Fig. 21. Schematic diagram of an automatic microinjector positioning system. MeaE: 
potential measuring electrode, IntE: dye-introducing electrode, RE: reference electrode for 
MeaE, CE: counter electrode for IntE, Iso: isolator, PG: pulse generator, EM: electrometer, 
SC/MD: signal converter and pulse motor driver, PM: pulse motor, OM: oil pressure 
manipulator, Rec: recorder. Reproduced from Bioelectrochemistry (2006) 69, 187-92 with 
permission from Elsevier. 
A microinjector was propelled manually and carefully penetrated into a mouse ES cell. The 
output potential of the MeaE changed sharply to -16 mV (Fig. 22 (A)). It returned to the 
initial level when removed from the cell. The value of -16 mV is defined as the intracellular 
potential and is equivalent to the cell membrane potential if the intracellular space is 
assumed to be homogeneous. The mean and standard deviation (SD) of the intracellular 
potential for 35 sample ES cells were -16.3 mV and 5.6 mV, respectively (Fig. 22 (B). A steady 
intracellular potential is available but the level is variable from cell to cell. Therefore, an 
absolute value cannot be used as the sign of cell membrane penetration.  
Instead, we intended to use the differential of potential change as a stop signal for the pulse 
motor (Fig. 23). Thus, the microinjector was correctly positioned in the cell without losing 
cell viability. Its success rate was 73% for ES cells. After positioning the microinjector in the 
cell, lucifer yellow was introduced by electrophoresis via the IntE. Under this condition, the 
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noise. The measured potential change was thought to be a useful control signal for the 
injector drive. In order to measure the electrical potential and at the same time introduce a 
marker dye into a target cell, a double barrel capillary was used (Matsuoka et al., 2006).  
A glass capillary with a θ-shaped cross section (outer diameter 1 mm) was heated and pulled 
to make the tip diameter smaller than 1 μm using a laser puller. One channel of the capillary 
was filled with a solution of 0.5 M KCl. A Ag/AgCl wire was then inserted into the capillary to 
produce a potential measuring electrode (MeaE) (Fig. 21). The reference electrode for MeaE 
was a commercially available Ag/AgCl electrode (RE). The other channel was filled with a 
solution containing 0.5 M KCl and 1 mM lucifer yellow. A Pt wire was inserted into the 
capillary to produce a dye-introducing electrode (IntE). The counter electrode (CE) for the IntE 
was prepared by filling a glass tube with 3% agar gel containing 0.5 M KCl. 
 
 
Fig. 21. Schematic diagram of an automatic microinjector positioning system. MeaE: 
potential measuring electrode, IntE: dye-introducing electrode, RE: reference electrode for 
MeaE, CE: counter electrode for IntE, Iso: isolator, PG: pulse generator, EM: electrometer, 
SC/MD: signal converter and pulse motor driver, PM: pulse motor, OM: oil pressure 
manipulator, Rec: recorder. Reproduced from Bioelectrochemistry (2006) 69, 187-92 with 
permission from Elsevier. 
A microinjector was propelled manually and carefully penetrated into a mouse ES cell. The 
output potential of the MeaE changed sharply to -16 mV (Fig. 22 (A)). It returned to the 
initial level when removed from the cell. The value of -16 mV is defined as the intracellular 
potential and is equivalent to the cell membrane potential if the intracellular space is 
assumed to be homogeneous. The mean and standard deviation (SD) of the intracellular 
potential for 35 sample ES cells were -16.3 mV and 5.6 mV, respectively (Fig. 22 (B). A steady 
intracellular potential is available but the level is variable from cell to cell. Therefore, an 
absolute value cannot be used as the sign of cell membrane penetration.  
Instead, we intended to use the differential of potential change as a stop signal for the pulse 
motor (Fig. 23). Thus, the microinjector was correctly positioned in the cell without losing 
cell viability. Its success rate was 73% for ES cells. After positioning the microinjector in the 
cell, lucifer yellow was introduced by electrophoresis via the IntE. Under this condition, the 
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rate of viable cells became 16%. Such a loss of viability was thought to be due to an electrical 
potential that was inevitably loaded onto the cell membrane during the electrophoretic 
introduction of lucifer yellow. 
 
 
Fig. 22. Intracellular potential (ICP) of mouse ES cells. (A) ICP change profile obtained 
during the penetration of an injector into the cell (white triangle) and the removal of the 
injector from the cell (black triangle); (B) steady-state value of ICP from 35 cells. Reproduced 
from Bioelectrochemistry (2006) 69, 187-92 with permission from Elsevier. 
 
Fig. 23. Potential change (A) and its differential (B) during the penetration of an injector 
through the cell membrane. White box: an injector is moving during this period; black box: 
the injector stops and stayed there during this period. The ordinate of (B) indicates the 
differentiated and properly amplified value of (A). Reproduced from Bioelectrochemistry 
(2006) 69, 187-92 with permission from Elsevier. 
9. Conclusion 
As a result of the development of SMSR, femtoinjection is now a practical methodology. 
Femtoinjection has enabled the semi-quantitative introduction of any size of 
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macromolecules, simultaneous introduction of multiple factors, temporal and spatial control 
of injection in a cell colony, and spatial control of the injection site whether into the cytosol 
or nucleus. The results described in this chapter provide some understanding of the 
significance of single-cell studies. Technological progress will further improve the spatio-
temporal precision. Consequently this method can provide us with novel insight into cell 
functions, especially in ES cell studies, with regard to how to maintain the undifferentiated 
state and how to produce specific functional cells.  
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1. Introduction 
Under appropriate culture conditions human embryonic stem cells (hESCs) can retain an 
undifferentiated state during numerous passages (Thomson et al., 1998). In the 
undifferentiated state, hESCs express characteristic markers like NANOG, OCT4, TDGF1, 
DNMT3B, GABRB3, and GDF3, and are maintained by plating undifferentiated cells or 
colonies of cells into new culture dishes with fresh medium every 7 to 10th day (Adewumi et 
al., 2007). Following periods exceeding 7 to 10 days in culture without passage, the cell 
population tends to become heterogeneous with differentiation starting to occur within a 
given colony or in various parts of a culture dish. The tendency for undergoing 
differentiation is independent of whether feeder cells, protein matrixes, or special plastic 
surfaces are used and what specific hESC medium is employed. Although an increasing 
density of cells during culture has been suggested to be one reason for spontaneous 
differentiation of cells to occur, it is also well known that morphologically perfect 
undifferentiated hESCs often appear in very high density in the same culture dish, even 
when differentiation has started to occur (Laursen et al., 2007). The transition from the 
undifferentiated state to more differentiated cell types appears to take place as a gradual 
process in colonies of hESCs, and it is currently not known how the ultrastructural 
organization of cells changes along with the differentiation process as defined from 
immunohistochemical differentiation markers.  In the present study we have performed a 
spatiotemporal investigation on the differentiation of hESC colonies by electron 
microscopical and immunohistochemical approaches. 
2. Materials and methods 
2.1 Culture of human embryonic stem cell lines LRB008, LRB010 and LRB017 
The hESC lines LRB008, LRB010, and LRB017 were established at the Laboratory of 
Reproductive Biology, Copenhagen University Hospital from surplus embryos donated by 
couples undergoing IVF treatment after informed consent. The study was approved by the 
regional ethical committee of Copenhagen and Frederiksberg Municipalities (permission no. 
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The hESC lines LRB008, LRB010, and LRB017 were established at the Laboratory of 
Reproductive Biology, Copenhagen University Hospital from surplus embryos donated by 
couples undergoing IVF treatment after informed consent. The study was approved by the 
regional ethical committee of Copenhagen and Frederiksberg Municipalities (permission no. 
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KF 01-188/03). Donated embryos that developed to the blastocyst stage, were used to derive 
hESC lines following isolation of the inner cell mass isolated by manual dissection using 
hypodermic needles. The zona pellucida was digested by pronase (1mg/mL) (Sigma-
Aldrich, P8811), and the inner cell masses (ICMs) were isolated by immunosurgery. The 
immunosurgery was performed by incubation in rabbit anti-whole serum antibody (Sigma-
Aldrich, H8765) diluted 1:3 in KnockOut Dulbeccos’s modified Eagles medium (KO-DMEM) 
(Invitrogen, 10829-018) for 30 min, followed by three successive washes in KO-DMEM and 
incubation in guinea pig serum (State Serum Institute, Copenhagen) diluted in 1:5 KO-
DMEM. The ICMs and the derived cell lines were cultured on mitotically inactivated mouse 
embryonic fibroblast (MEF) cells in hESC medium based on KO-DMEM supplemented with 
knockout serum replacement (15% of final concentration), L-glutamine (2 mmol/L), β-
mercaptoethanol (0.1 mmol/L), MEM non-essential aminoacids (0.1 mmol/L), 
Penicillin/Streptomycin (50U/g/mL), and basic fibroblast growth factor (bFGF, 4 ng/mL).  
The cells were cultured in a humidified atmosphere consisting of 6% CO2, 7% O2 and 87% N2 
at 37ºC. Cell lines were normally passaged onto fresh MEF feeders once a week, when 
confluence reached around 70-80%. Passage of cells was carried out by mild trypsin 
treatment (0.05% trypsin in EDTA). An exception to MEFs as supportive feeders was the use 
of mitotically inactivated human foreskin fibroblast (hFF) in experiments where cell lines 
LRB008 and LRB017 were harvested for scanning electron microscopy (SEM).   
2.2 Parallel sampling of colonies from the same culture dishes 
For optimal concurrency in the collection of material for electron microscopy and 
immunohistochemistry, the experimental design was based on parallel sampling from the 
same culture dishes as illustrated in Figure 1. Colonies from the hESC line LRB010 were 
cultured for a period of either 6, 8, 11, 14 or 17 days. Samples were pooled in groups of early 
stage (6 and 8 days), intermediate stage (11 and 14 days), and late stage (17 days) colonies, 
according to duration of cultures at harvest. In addition, colonies of two other hESC lines, 
LRB008 and LRB017, were cultured and harvested after 7 and 14 days, for 
immunohistochemistry and investigation of colony surface ultrastructure by scanning 
electron microscopy (SEM). 
 
 
Fig. 1. The principle of parallel sampling. 
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The large greyscale phase contrast micrograph shows the bottom of a culture dish with 
growth of the hESC line LRB010 on a HFF feeder cell layer. Three black holes can be 
observed next to each other, where hESC colonies have been removed manually by 
hypodermic needles for fixation in glutaraldehyde and subsequent ultrastructural studies. 
The light micrograph shown in the inset depicts a semithin survey section (2 µm) with part 
of a fixed colony embedded in epoxy resin and stained with toluidine blue. After removal of 
tissue samples for electron microscopy, the remaining layer within the culture dish was 
fixed with Bouin’s fixative for immunohistochemistry. Phase contrast micrograph: Scale bar 
= 5 mm. Light micrograph insert: Scale bar = 25 µm.  
2.3 Processing of tissue for transmission electron microscopy (TEM) 
Cultured hESC lines were detached using hypodermic needles and fixed in 3% 
glutaraldehyde in 0.1 M Na-phosphate buffer (pH 7.3) for 1-2 h at 4ºC. Following fixation, 
specimens were transferred into 0.1 M Na-phosphate buffer (pH 7.3) and stored at 4ºC for later 
processing. Specimens were embedded in 4% agar at 45ºC (Bacto-agar, Difco Laboratories, 
Detroit, USA) under stereo microscopy and post-fixed in 1% OsO4 in 0.1 M Na-phosphate 
buffer (pH 7.3) for 1 h at room temperature followed by wash in 0.1 M Na-phosphate buffer 
(pH 7.3) for 5 min. Tissue samples were stained en-bloc with 1% uranyl acetate in MilliQ water 
(MilliRO Plus and MilliQ PF Plus Water Purifications Systems, Millipore A/S, Hedehusene, 
Denmark), dehydrated in a series of ascending concentrations of ethanol (50% for 10 min, 70% 
for 10 min, 96% for 10 min, 99% for 3x20 min). Following the dehydration steps, samples were 
embedded in Epon (TAAB 812 Embedding resin, Medium), using propylene oxide as an 
intermedium, and polymerized for 48 h at 60ºC. Semithin sections (2 µm) were cut on an 
ultramicrotome (Reichert Ultracut UCT, Leica) using glass knifes prepared on a knifemaker 
(LKB Bromma 7800). Sections were then stained with 1% basic toluidine blue for evaluation by 
bright-field light microscopy until a satisfactory part of the colony was exposed. Sections of 
interest were re-embedded (Hyttel and Madsen, 1987) for further ultrathin sectioning (70 nm) 
on an ultramicrotome (Reichert Ultracut UCT, Leica) using a diamond knife (Jumdi, 2 mm). 
The ultrathin sections were contrast stained using 2% uranyl acetate in MilliQ water and lead 
citrate (Reynolds, 1963), collected on 150 mesh copper grids covered with a 
parlodion/amylacetate film, and examined using a transmission electron microscope (CM100, 
Philips, Darmstadt, Netherlands). 
2.4 Processing of tissue for scanning electron microscopy (SEM) 
Cultures of hESCs grown on glass coverslips were fixed in 3% glutaraldehyde diluted in 0.1 
M Na-phosphate buffer (pH 7.3) for approximately 1 h at 4ºC, then transferred into 0.1 M 
Na-phosphate buffer (pH 7.3) and stored at 4ºC. On the day of further processing the 
specimens were washed 3x5 min in 0.1 M Na-phosphate buffer (pH 7.3), post-fixed in 1% 
OsO4 in 0.1 M Na-phosphate buffer (pH 7.2) followed by additional 3x5 min washings in 0.1 
M Na-phosphate buffer (pH 7.3). Glass coverslips with hESC colonies were then transferred 
from plastic growth plates into glass dishes and dehydrated in a series of ascending 
concentrations of acetone (25% for 10 min, 40% for 10 min, 60% for 10 min, 75% for 10 min, 
90% for 10 min, 100 % for 3x20 min). Glass coverslips with colonies were too large to fit into 
chambers of the critical point dryer and therefore had to be fractioned into smaller pieces 
under stereo microscope. The intermediate fluid acetone, was eliminated from the cells 
using a critical point dryer (EMS850, Electron Microscopy Sciences, Hatfield, Pennsylvania, 
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KF 01-188/03). Donated embryos that developed to the blastocyst stage, were used to derive 
hESC lines following isolation of the inner cell mass isolated by manual dissection using 
hypodermic needles. The zona pellucida was digested by pronase (1mg/mL) (Sigma-
Aldrich, P8811), and the inner cell masses (ICMs) were isolated by immunosurgery. The 
immunosurgery was performed by incubation in rabbit anti-whole serum antibody (Sigma-
Aldrich, H8765) diluted 1:3 in KnockOut Dulbeccos’s modified Eagles medium (KO-DMEM) 
(Invitrogen, 10829-018) for 30 min, followed by three successive washes in KO-DMEM and 
incubation in guinea pig serum (State Serum Institute, Copenhagen) diluted in 1:5 KO-
DMEM. The ICMs and the derived cell lines were cultured on mitotically inactivated mouse 
embryonic fibroblast (MEF) cells in hESC medium based on KO-DMEM supplemented with 
knockout serum replacement (15% of final concentration), L-glutamine (2 mmol/L), β-
mercaptoethanol (0.1 mmol/L), MEM non-essential aminoacids (0.1 mmol/L), 
Penicillin/Streptomycin (50U/g/mL), and basic fibroblast growth factor (bFGF, 4 ng/mL).  
The cells were cultured in a humidified atmosphere consisting of 6% CO2, 7% O2 and 87% N2 
at 37ºC. Cell lines were normally passaged onto fresh MEF feeders once a week, when 
confluence reached around 70-80%. Passage of cells was carried out by mild trypsin 
treatment (0.05% trypsin in EDTA). An exception to MEFs as supportive feeders was the use 
of mitotically inactivated human foreskin fibroblast (hFF) in experiments where cell lines 
LRB008 and LRB017 were harvested for scanning electron microscopy (SEM).   
2.2 Parallel sampling of colonies from the same culture dishes 
For optimal concurrency in the collection of material for electron microscopy and 
immunohistochemistry, the experimental design was based on parallel sampling from the 
same culture dishes as illustrated in Figure 1. Colonies from the hESC line LRB010 were 
cultured for a period of either 6, 8, 11, 14 or 17 days. Samples were pooled in groups of early 
stage (6 and 8 days), intermediate stage (11 and 14 days), and late stage (17 days) colonies, 
according to duration of cultures at harvest. In addition, colonies of two other hESC lines, 
LRB008 and LRB017, were cultured and harvested after 7 and 14 days, for 
immunohistochemistry and investigation of colony surface ultrastructure by scanning 
electron microscopy (SEM). 
 
 
Fig. 1. The principle of parallel sampling. 
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The large greyscale phase contrast micrograph shows the bottom of a culture dish with 
growth of the hESC line LRB010 on a HFF feeder cell layer. Three black holes can be 
observed next to each other, where hESC colonies have been removed manually by 
hypodermic needles for fixation in glutaraldehyde and subsequent ultrastructural studies. 
The light micrograph shown in the inset depicts a semithin survey section (2 µm) with part 
of a fixed colony embedded in epoxy resin and stained with toluidine blue. After removal of 
tissue samples for electron microscopy, the remaining layer within the culture dish was 
fixed with Bouin’s fixative for immunohistochemistry. Phase contrast micrograph: Scale bar 
= 5 mm. Light micrograph insert: Scale bar = 25 µm.  
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Detroit, USA) under stereo microscopy and post-fixed in 1% OsO4 in 0.1 M Na-phosphate 
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(LKB Bromma 7800). Sections were then stained with 1% basic toluidine blue for evaluation by 
bright-field light microscopy until a satisfactory part of the colony was exposed. Sections of 
interest were re-embedded (Hyttel and Madsen, 1987) for further ultrathin sectioning (70 nm) 
on an ultramicrotome (Reichert Ultracut UCT, Leica) using a diamond knife (Jumdi, 2 mm). 
The ultrathin sections were contrast stained using 2% uranyl acetate in MilliQ water and lead 
citrate (Reynolds, 1963), collected on 150 mesh copper grids covered with a 
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USA) by several flushings with liquid CO2. Subsequently, critical point drying was performed. 
Pieces of coverslips with dried colonies were then mounted on specimen holders and coated 
with 5 nm gold/palladium in a sputter coater (SC7640 Suto/Manual High Resolution Sputter 
Coater, Quorum Technologies, Newhaven, UK). Specimens were evaluated using a scanning 
electron microscope (FEI Quanta 200, FEI Company, Eindhoven, The Netherlands). 
2.5 Processing of tissue for immunohistochemistry 
Colonies of the three hESC lines (LRB008, LRB010 and LRB017) were cultured under 
conditions as described above for 6, 7, 8, 11, 14 and 17 days and fixed in Bouin’s fixative in situ 
in the culture dish following removal of material intended for electron microscopy.  After 1 to 
2 hours of fixation the fixative was replaced with 70 % ethanol and 24 – 48 hours later the 70 % 
ethanol was replaced with 90 % ethanol. Following overnight dehydration in 90 % ethanol, the 
samples were exposed to 99 % ethanol for 12 hours. Then the colonies were gently dissected 
free from the bottom using a Cell Scraper (Nunc) starting from the periphery. Colonies were 
then lifted carefully from the bottom of the culture dish to a small metal embedding mould 
into which xylene was pipetted.  After 1 hour’s exposure to xylene, paraffin was gently added 
to the embedding mould. Following paraffin embedding specimens were cut in 3-5 µm thick 
serial horizontal sections, strictly in parallel to the bottom of the cultures (Brøchner et al., 2010). 
Every 10th section was stained by toluidine blue.  
Prior to immunohistochemistry, non-specific binding was inhibited by incubation for 30 
minutes with blocking buffer (ChemMate antibody diluent S2022, DakoCytomation, Glostrup, 
Denmark) at room temperature. The sections were incubated overnight at 4ºC with rabbit 
polyclonal or mouse monoclonal antibodies against OCT4, occludin, ZO-1, claudin-5, β-
catenin, E-cadherin, N-cadherin, vimentin and nestin (details in Table 1).  The sections were 
then washed with TBS and incubated for 30 minutes with the REAL EnVisionTM Detection 
System, Peroxidase/DAB+, Rabbit/Mouse, (K5007) from DakoCytomation. The sections were 
counterstained with Mayer’s hematoxylin and dehydrated in graded alcohols followed by 
xylene and coverslipped with DPX mounting media. Control sections were incubated 
with mouse IgG1, IgG2a or irrelevant rabbit antibodies, as well as subjected to omission of 
primary or secondary antibodies. Regarding OCT4, preincubation was performed 1 hour 
before incubation with the corresponding peptide in the proportion 1 to 5. 
 
Antigen Manufacturer Code nr. Antibody-species 
β-catenin TriChem 17C2 Mouse IgG2a ÷ 1:1000 
Claudin-5 Abcam Ab 5106 Rabbit M6 1:100 
E-cadherin Abcam Ab1416 Rabbit M6 1:50 
N-cadherin Abcam Ab12221 Rabbit M6 1:500 
Nestin Chemicon MAB 5326 Mouse, IgG1 ÷ 1:500 
Occludin Abcam Ab64482 Rabbit M6 1:75 
OCT4 Abcam Ab 19857 Rabbit TEG 1:400 
Vimentin Dako M0725 Mouse M6 1:100 
ZO-1 Zymed Z-R1 Rabbit ÷ 1:400 
Table 1. Primary antibodies, manufactures, code numbers and dilutions. 
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The cells and colonies grown on MEF feeders or hFF feeders in a culture medium with bFGF 
added developed well, with a typical morphology of undifferentiated stem cells showing 
areas of large single nucleated cells with scanty cytoplasm interspersed with cells of more 
differentiated morphology depending on culture age. 
3.1 Transmission electron microscopy 
Early stage colonies: In 2 µm survey sections from Epon-embedded material, the colonies 
appeared multi-layered with the highest numbers of cell layers in the center, flattening 
towards the periphery. Three different cell compartments within the colony were chosen for 
closer ultrastructural examinations, as illustrated by rectangles in Fig. 2, and consisted of: 1) 
an apical compartment with cells facing the culture medium; 2) a basal compartment 
containing cells anchoring the colony to the feeder cell layer, and; 3) a compartment in the 
center of the colony demarcated by apical and basal cells. In the apical compartment (Fig. 
2C-E), cells were polarized with a large apical cytoplasm, rich in organelles, and nuclei 
located basally. Cells were connected to each other by apical junctional complexes – zonulae 
occludentes (tight junctions) and zonulae adherentes (adherens junctions), with abundant 
association of intermediary filaments of the cytoskeleton. Microvilli were observed 
projecting from the cell surfaces. Below the apical epithelial covering of the colony, a 
population of cells with a large nucleus to cytoplasm ratio and poor in organelles, 
representing a typical undifferentiated ESC-like morphology, resided in the center of the 
colony (Fig. 2B). Cell membranes of the basal cell compartment did not show any sign of 
junctional specializations, and higher magnification confirmed a continuous even spacing 
between the plasma membranes of the basal cells (Fig. 2F and G). 
Intermediate stage colonies: The 2 µm survey sections showed a colony thickness of one or few 
cell layers. The colony harvested the 11th day of culture was still attached to a monolayer of 
MEF feeder cells with a distinct basement membrane separating them. Towards the apical 
surfaces, well developed tight and adherens junctions at the lateral plasma membrane 
connected cells of the apical compartment. Below the junctional complex, well-developed 
gap junctions and maculae adherentes (desmosomes) could be observed. All junctional 
complexes were closely associated with extensive bundles of intermediate filaments (Fig. 
3C-D and 4D). In basal regions, adjacent cells were interdigitating and showed many gap 
junctions, whereas tight junctions, adherens junctions, and desmosomes were lacking (Figs. 
3A, B, E & F and 4A, B, C & E). 
Late stage colonies: In 2 µm survey sections, basal and center compartments were easily 
identified. Remnants of the basement membrane, but no feeder cells, were observed beneath 
the basal cells of the colony (Fig. 5A). The apical compartment contained a population of 
cells with obvious epithelial specializations such as junctional complexes with associated 
desmosomes, polarized organelle rich cytoplasm with basally located nuclei, and microvilli 
covering the apical surfaces. As was the case for early and intermediate stage colonies, a 
network of intermediary filaments radiated from sites of junctional complexes, where gap 
junctions were also present (Fig. 5C-E). At this late stage, a population of cells with ESC-like 
undifferentiated morphology similar to the ones previously described was still present (Fig. 
5B). 
Specializations linking adjacent plasma membranes of the basal compartment apart from 
obvious gap junctions were not observed (Fig. 5F-G). 
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before incubation with the corresponding peptide in the proportion 1 to 5. 
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Fig. 2. Transmission electron micrographs of hESC line LRB010 cultured for 6 days (early). 
(A) Semithin cross section illustrating 3 different spatial compartments within the colony: 
Upper rectangle represents the localization of an apical compartment facing the culture medium 
in vitro, lower rectangle illustrates a population of basal cells anchoring the colony to the feeders, 
and the rectangle in the centre represents cells in between the apical and the basal compartment. 
Stained with toluidine blue. Ap, apical; Ba, basal. Scale bar = 25 µm. (B) Representative area 
from the center compartment with cells of typical undifferentiated morphology. N, nucleus; 
Nu, nucleolus. Scale bar = 5 µm. (C) Apical region of the colony with tight junction 
specializations shown in inserts. Scale bar = 5 µm. (D) Tight junction complex from insert in C 
(left). Scale bar = 500 nm. (E) Tight junctions from inset in C (right). Scale bar = 1 µm. (F) Basal 
region of the colony with a representative junction framed. Scale bar = 2 µm. (G) High 
magnification of inset in (F) showing no signs of junction specializations. Scale bar = 250 nm. 
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Fig. 3. Transmission electron micrographs of hESC line LRB010 cultured for 11 days 
(intermediate).  
(A) Light microscopy of semithin cross section of colony with framed area spanning the 
apical and basal compartments magnified in B-F. Ap, apical; Ba, basal. Scale bar = 50 µm. (B) 
Apical and basal regions further magnified are framed. MEF, mouse embryonic fibroblast 
feeder layer; N, nucleus; Nu, nucleolus. Scale bar = 10 µm. (C) Junctional complex with 
distinct gap junction (GJ). Scale bar = 250 nm. (D) Tight- and adherens junction (TJ) with 
associated desmosome (De). Scale bar = 250 nm. (E) Basal region showing interdigitating 
processess without junctional specializations. BM, basement membrane. Scale bar =10 µm. 
(F) Higher magnification of insert in E. Scale bar = 1 µm. 
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Fig. 3. Transmission electron micrographs of hESC line LRB010 cultured for 11 days 
(intermediate).  
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Fig. 4. Transmission electron micrographs of hESC line LRB010 cultured for 14 days 
(intermediate).  
(A) Light microscopy of semithin cross section of colony marking representative area (frame) 
chosen for further analysis. Ap, apical; Ba, basal. Scale bar = 50 µm. (B) Marked locations 
(frame) of junctional areas seen in (C-E). BM, basement membrane. Scale bar = 20 µm. (C) Gap 
junction (GJ) in connection to inderdigitations in the basal region of the colony. Scale bar = 500 
nm. (D) Tight- and adherens junction with prominent intermediary filament cytoskeleton. 
Scale bar = 250 nm. (E) Abundant gap junctions (GJ) at the basal region. Scale bar = 500 nm. 
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Fig. 5. Transmission electron micrographs of hESC line LRB010 cultured for 17 days (late). 
(A) Light microscopy of semithin overview section showing areas representative of apical, 
central and basal compartments of the colony. Ap, apical; Ba, basal. Scale bar = 20 µm. (B) 
Central compartment containing cells of typical undifferentiated morphology. N, nucleus. 
Scale bar = 5 µm. (C) Apical compartment where top layer of cells are bound together by 
apical junctional complexes (arrows). Two of the junctions can be seen in D-E. Scale bar = 10 
µm. (D) Tight junction (C, left). Scale bar = 500 nm. (E) Tight- and adherens junction (C, 
right) with distinct desmosome. Scale bar = 250 nm. (F) Basal compartment.  Scale bar = 5 
µm. (G) Basal region without specializations. Basement membrane is marked by arrows. M, 
mitochondria; L, lipid droplet. Scale bar = 1 µm.  
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Fig. 5. Transmission electron micrographs of hESC line LRB010 cultured for 17 days (late). 
(A) Light microscopy of semithin overview section showing areas representative of apical, 
central and basal compartments of the colony. Ap, apical; Ba, basal. Scale bar = 20 µm. (B) 
Central compartment containing cells of typical undifferentiated morphology. N, nucleus. 
Scale bar = 5 µm. (C) Apical compartment where top layer of cells are bound together by 
apical junctional complexes (arrows). Two of the junctions can be seen in D-E. Scale bar = 10 
µm. (D) Tight junction (C, left). Scale bar = 500 nm. (E) Tight- and adherens junction (C, 
right) with distinct desmosome. Scale bar = 250 nm. (F) Basal compartment.  Scale bar = 5 
µm. (G) Basal region without specializations. Basement membrane is marked by arrows. M, 
mitochondria; L, lipid droplet. Scale bar = 1 µm.  
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3.2 Scanning electron microscopy 
Although 7 day-old colonies (LRB008 and LRB017) and feeders presented cracks resulting 
from the dehydration and critical drying processes, plenty of undamaged colony surface 
area was available for further examination. At low magnification, the colonies appeared as a 
flattened sheet of cells with a distinct boundary to the feeder cell layer they were grown on 
(Fig. 6A-B). The majority of the colony surface consisted of a fairly homogenous, flattened 
cell layer, but marked differences could be noted between individual cells in the flattened 
cell layer, with some cells having smooth surfaces, while others appeared with more rough 
surfaces covered by microvilli (Fig. 6C). Other surface areas displayed a more uniform  
 
 
Fig. 6. Scanning electron micrographs of hESC lines LRB008 and LRB017 grown on human 
foreskin fibroblasts for 7 days in culture.  
(A) Colony with arrowheads indicating border between colony and feeder layer. hFF, 
human foreskin fibroblasts; hESC, human embryonic stem cells. Scale bar = 500 µm. (B) 
Inset in (A) showing higher magnification of the periphery with arrow indicating border 
between colony and feeder layer. Scale bar = 200 µm. (C) Colony showing marked 
differences in cell surfaces. Some cells appear smooth surfaced (s), while others have a 
rougher surface (r) coved by microvillous extensions. Scale bar = 20 µm. (D) Microvillous 
surface in the periphery of the colony showing a cilium (Ci) extending from it, and a polar 
midbody (PM) still connecting dividing daughter cells. Scale bar = 2 µm. 
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distribution of microvilli, and the presence of individual cilia could be documented (Fig. 
6D). Commonly, both cell lines exhibited superficial cytoplasmic bridges still connecting 
dividing daughter cells, with distinct polar midbodies (Fig. 6D). 
Low magnification images of the 14 day-old colonies revealed great differences in the 
overall morphology of the two different cell lines investigated. One colony (LRB008) formed 
big bulging areas of cells growing in layers into the culture medium, while the other 
(LRB017) retained the flattened sheet-like appearance even after 14 days in culture (Fig. 7A-
D). In the bulging areas of LRB008, separate cells clearly grew on top of each other, some 
forming structures protruding from the surface (Fig. 7A-B). Superficial cytoplasmic bridging 
between dividing cells was seen in LRB008, but not in LRB017. The rather uniform cell layer 
of LRB017 occasionally showed rounded protrusions of the plasma membrane, often in 
clusters (Fig. 7D). Furthermore, a varied microvillous covering could be observed through 
out the colonies of both cell lines on bulging as well as homogenous flat areas. 
 
 
Fig. 7. Scanning electron micrographs of hESC lines LRB008 and LRB017 grown on human 
foreskin fibroblasts for 14 days in culture.  
(A) Bulging (Bu) areas of differentiation on LRB008 after 14 days of culture. Scale bar = 100 
µm. (B) Higher magnification of inset in A showing differentiating cells protruding from the 
surface. Scale bar = 20 µm. (C) Colony of LRB017 partly detached from the glass coverslip 
(GC) they were grown on. Scale bar = 400 µm. (D) Higher magnification of hESCs from (C) 
with areas of membrane protrusions marked by arrowheads. Scale bar = 5 µm.   
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Fig. 8. Expression of ZO-1, nestin and β-catenin shown by immunohistochemistry in 
sections from hESC line LRB010 cultured for 6 days.  
In (A) stained for ZO-1 the apical compartment (AC) is separated from the culture medium 
by a tight junctional complex (arrows). The central compartment (CC) and the basal 
compartment (BC) show no distinct reactivity. (B) The basal compartment (BC) is strongly 
positive for nestin, whereas the central compartment (CC) is characterized by cells of typical 
undifferentiated morphology. Note the pattern of differentiation from the center towards 
the basal compartment indicating a gradual change from hESCs to nestin-positive 
neuroectodermal cells. Some of the many mitotic figures in the apical compartment (AC) 
situated at the apical surface facing the culture medium are indicated by arrowheads. (C) A 
tangential section through the apical compartment (AC) illustrates the strong β-catenin-
reactivity associated with the adherens junctions. Note the many mitotic figures 
(arrowheads), which are also seen in the same region in cross-sectioned colonies 
(arrowheads in B). A, B & C: same magnification. Scale bar = 25 µm. 
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Fig. 9. Expression of ZO-1, nestin and E-cadherin shown by immunohistochemistry in 
tangential sections from hESC line LRB010 cultured for 17 days.  
(A): The apical compartment (AC) in the center of the figure, stained for ZO-1 shows a well-
developed tight junctional complex (arrows). A lateral compartment (LC) marked by a 
punctuated line and an outer epithelial compartment (OEC) are not stained. (B) The entire 
pseudo-stratified epithelium of the apical compartment is strongly positive for nestin.  A 
new lateral compartment (LC) marked by a punctuated line is slightly positive for nestin, 
but strongly positive for vimentin and N-cadherin (not shown). (C) A single-layered outer 
epithelial compartment (OEC) and its extension towards the upper left of the figure show 
positive reactivity for E-cadherin, whereas both apical (AC) and lateral compartments (LC)  
are unstained. A,B & C: same magnification. Scale bar = 25 µm.   
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It was possible to distinguish three different compartments in most colonies already from 
day 6: (1) An apical epithelial-like polarized layer facing the culture medium; (2) a basal cell 
layer facing the feeder cell layer; and (3) a central compartment enclosed by the apical and 
basal cell layers consisting of ‘classical’ hESCs with ‘undifferentiated morphology’ (Fig. 8 A-
B). The youngest colony showed the presence of markers for tight junctions (occludin, 
claudin-5 and ZO-1 - Fig. 8A), and adherens junctions (E-cadherin associated with β-catenin 
– Fig. 8C) in the apical polarized epithelial-like cell layer. This was in marked contrast to the 
epithelioid ‘classical’ hESCs of the central compartment characterized by absence of markers 
for tight junctions. All cells exhibited positive OCT4-staining of their nuclei pointing to 
heterogeneity of the early hESCs, i.e. an epithelial-like cell type with junctional complexes 
facing the outside compartment (the culture medium) and an epithelioid cell type without 
classical junctional complexes, but with strong OCT4 reactivity in their nuclei. The basal cell 
layer, on the other hand, exhibited a distinct reactivity for the neuroectodermal marker 
nestin (Fig. 8B), but markers for tight junctions were absent. A gradual change in the pattern 
of differentiation from a nestin-negative, but OCT4-positive central compartment towards a 
strongly nestin-positive basal compartment indicating a gradual change from an OCT4-
positive hESC population to a neuroectodermal cell population existed as illustrated in Fig. 
8B. 
In older colonies (17 days) immunohistochemical analysis revealed that the majority of the 
differentiating cells had lost their OCT4-positivity, indicating that the central compartment 
with ‘classical’ hESCs showing ‘undifferentiated morphology’ had disappeared in most 
colonies.  An apical epithelial-like pseudostratified layer facing the culture medium was still 
present. The apical regions of the lateral cell membranes were joined by tight junctions as 
shown by a positive reactivity for occludin, claudin-5, and ZO-1 (Fig. 9A). In some cases the 
entire apical layer was densely stained for nestin (Fig. 9B), whereas the apical regions of 
other colonies showed a very strong staining for vimentin with some more basally located 
nestin-positive cells (not shown). A single layered outer compartment was characterized by 
a lack of staining for vimentin and nestin but by a positive staining reaction for E-cadherin 
(Fig. 9C). In a newly developed lateral compartment adjacent to the apical and above the 
central compartment cells showed a strongly positive N-cadherin and vimentin-staining but 
no staining for E-cadherin (Fig. 9C) suggesting an epithelial-mesenchymal transition (EMT) 
resulting in migratory vimentin-positive mesenchymal-like cells. 
4. Discussion  
Although living hESCs often appear homogenously undifferentiated in their colony 
formation, as observed in phase contrast microscopy, the present study demonstrates that 
various differentiation events occur already within a few days after passage both at the 
ultrastructural and light microscopic level. Usually it is sufficient to maintain hESCs in an 
undifferentiated state by a passage of cells every 5-7 days. However, here we demonstrate 
that already within the early stage colonies, around the time of normal passage, a 
pronounced compartmentalization has taken place within colonies, suggesting spatial and 
temporal dimensions of differentiation. In all colonies examined, irrespective of the culture 
period and spatial configuration of the colony, the apical layer of cells, which is in direct 
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contact with the culture medium, formed an apico-basolateral polarized sheet of tightly 
interconnected cells resembling a columnar epithelium and thus providing solid 
documentation for a morphological specialization linking adjacent cells by junctional 
complexes consisting of tight and adherens junctions, shown by EM and 
immunohistochemistry. Such an epithelial coating, forming a barrier to the external 
environment, might provide deeper lying cells with a selective transcellular uptake of 
nutrients and other media components, thus creating a microenvironment supporting the 
undifferentiated state. A central compartment, containing cells with typical undifferentiated 
ESC-morphology, was indeed observed with EM and immunohistochemistry in both early 
and medium stage colonies, indicating long-term retention of an environment permissive of 
undifferentiated cell growth, regardless of surrounding peripheral differentiation. Indeed 
these observations might also explain why morphological undifferentiated hESC in culture 
dishes that has been grown for a prolonged period of time of perhaps two weeks or more is 
often found in the central and basal compartments which are in direct contact with bottom 
of the culture dish without tight junctions underneath layers of more differentiated cells on 
top of the colony.    
Based upon studies of short-term feeder free cultures, Ullmann et al. (2007) proposed a 
colony structure almost identical to the early stage colony in this study. The 
immunostainings for E-cadherin, a marker for epithelial adherens junctions, were localized 
only to the uppermost cell layer of a multilayer, whereas it disappeared peripherally, where 
vimentin positive cells began to appear. This provides evidence for an epithelial-
mesenchymal transition (EMT) in the peripheral regions where the colonies flattens into a 
monolayer. However, according to our TEM investigations, these peripheral monolayers of 
the intermediate stage colonies grown on MEF exhibited junctional complexes, hence 
suggesting an epithelial nature.  
Colonies organized with confined undifferentiated cells and peripheral differentiation 
was confirmed by a shift in immunoreactivity from the pluripotency marker SSEA-4 to a 
marker of differentiation SSEA-1 towards the periphery (Johkura et al., 2004). This down-
regulation in pluripotency markers was to some extent also indicated in the short-term 
feeder free cultures referred to above, where the intensity in immunostainings of the key 
pluripotency markers OCT4 and NANOG decreased in peripheral regions (Ullmann et al., 
2007). Despite an apparent decrease in the amount of the key transcription factors, 
expression levels were still substantial, raising the question whether a deviation from the 
undifferentiated morphology to a more epithelial-like morphology is accompanied by 
decrease in potency. Additionally, increased amounts of laminin in the periphery of the 
colonies confirmed accumulation of extracellular matrices under standard culture 
conditions (Johkura et al., 2004), most likely as a constituent of the basement membrane 
secreted by differentiated epithelial cells. One of the intermediate (11 days in culture) and 
the late stage colonies had distinct basement membranes. The basement membrane of the 
intermediate stage colony harvested at the 14th day of culture was supposedly teared of at 
harvest. This was indicated by the damaged appearance basally. Neither did our 
observations indicate presence of a basement membrane beneath the most basal cells of 
the multilayered early stage colony, possibly explaining colony detachment from feeders 
without damaging structures of the basal cell layer or lifting up accompanying feeders. 
The location of the basement membrane in the late stage colony (Fig. 5), with its 
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multilayered appearance, suggests that it could be a single-cell layer cut in a transverse 
section deviating somewhat from the perpendicular plane, thus increasing the interface of 
the section. On the other hand, a model of a multilayered colony consisting of several 
layered compartments cannot be excluded.  
Gap junctions were identified both as part of the apical junctional complex (Fig. 4D), 
spanning all stages, but also in basal regions of the presumed monolayer in one of the 
intermediate stage colonies (Fig. 4E). A definite cell-to-cell coupling is demonstrated 
between epithelial cells of the apical compartment of murine cells of the ICM which are 
connected to each other (Lo & Gilula, 1979). The present study suggests that this also may 
apply to human ICMs. In accordance, Sathananthan et al. (2002) points out that a high 
degree of ultrastructural similarity exists between cells of the ICM and hESCs with 
undifferentiated morphology. Hence a gap junctional coupling could be expected between 
cells within the compartment of cells with undifferentiated morphology. Indeed, gap 
junctions were found by TEM within the undifferentiated compartment (micrographs not 
included), also demonstrating cell-to-cell coupling to exist between these cells. Whether 
the apical epithelial compartment is gap junctionally coupled to the underlying cells with 
undifferentiated morphology remains to be determined. Differentiation processes are 
normally associated with the progressive loss of communication between different tissues, 
for example as observed in between the ICM and the trophectoderm (Lo & Gilula, 1979). 
This suggests the possibility of two separate compartments intra-connected by gap 
junctions without coupling to each other. Huettner et al. (2006) demonstrated extensive 
gap junction communication in hESC colonies by dye injections and physiological 
recordings together with documentation of different connexins by immunocytochemistry 
and RT-PCR, assuming colonies to consist of uniform monolayers of undifferentiated cells 
corresponding to apical epithelial cells.  
In order to document possible differences among different hESC lines, two other cell lines, 
LRB008 and LRB017, were included to improve our knowledge about the general colony 
outline and surface structures from a SEM point of view. At least after 7 days, this analysis 
confirmed that the periphery is composed of a primarily homogenous flat monolayer 
comparable to single-cell layers visualised by TEM.  Cell line LRB017 showed a distinct 
accumulation of cells in the center of the colony. This was more difficult to identify in cell 
line LRB008, because the area in question had suffered considerable damage from 
processing of the sample, which in itself could indicate a thicker cell layer more vulnerable 
to shrinkage during dehydration. These observations agreed very well with the previously 
proposed colony structure described by Ullmann et al. (2007), but contradicted the saucer-
shaped colony structure described by Sathananthan et al. (2002),  in spite of identical culture 
conditions and time of harvest for the latter. The impact of duration of cultures is well 
illustrated by the 14-day old cultures. These showed a more chaotic growth of 
differentiating cells protruding from the surface in a highly irregular pattern in LRB008 (Fig. 
7A-B), while LRB017 maintained a flattened growth. Single or clustered rounded 
protrusions in the cell membrane, in particular the 14-day-old cultures (Fig. 7D), showed 
similarity to the coarse particles and halos previously identified by phase contrast 
microscopy consisting of apoptotic cells and bodies (Johkura et al., 2004). This suggests a 
pronounced cell death at this late stage. The fact that the entire colonies, in general, were 
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covered with microvilli with varying heterogeneity, and often with microvilli-free cells 
interspersed, suggests that the extent of epithelial specialization of the medium-facing cell 
layer. Heterogenous cell surfaces between groups of cells, as well as between single adjacent 
cells, very well correspond to results from a study demonstrating regional differences in 
expression of specific markers for hESCs (Laursen et al., 2007). Recently, one group 
published findings of primary cilia on surfaces of 33 and 90 percent of the hESCs of two 
different cell lines, H1 and LRB003, respectively (Kiprilov et al., 2008). Additionally, cilia 
were shown to co-localize with OCT4 staining, thus indicating their pluripotency with the 
assumption of the associated hedgehog signalling machinery to be important in the 
maintenance of the undifferentiated/self-renewable state. Following 7 days in culture, with 
the same culture conditions and using two other hESC lines derived also derived in our 
laboratory, only one single cilium was found. This raises the question of importance of cilia 
in regulation of hESCs as proposed by Kiprilov et al. (2008), and definitely demonstrates 
differences among hESC lines.  
To EMT, or not to EMT – in vivo and in culture. During in vivo embryogenesis and organ 
development the process initially termed epithelial-mesenchymal transformation (Hay, 
2005), now referred to as epithelial-mesenchymal transition (EMT), (Kalluri & Weinberg, 
2009; Thiery et al., 2009) is a key event. EMT is a biological process that allows an epithelial 
cell to undergo multiple biochemical changes that enable it to assume a mesenchymal cell 
phenotype, which includes enhanced migratory capacity, invasiveness, elevated resistance to 
apoptosis, and increased production of extracellular matrix components (Kalluri and Weinberg, 
2009). Early in the third week of human embryonic development, epiblast cells lateral to the 
primitive streak begin to move into the streak, where they undergo an EMT, i.e. the 
epithelial epiblast cells elongate and detach from their neighbours and then migrate away 
below the primitive streak as individual loosely organized mesendodermal progenitors. 
This process of gastrulation represents the first EMT after implantation (Thiery et al., 2009). 
After gastrulation the remaining epithelial epiblast cells, which did not enter the primitive 
streak and therefore did not undergo the initial EMT, form epidermal and neural territories 
progressively along the rostrocaudal axis. The differentiating neural plate is flanked by the 
prospective neural crest and further laterally by the prospective surface ectoderm, which 
constitutes the remaining areas of the ectoderm. Neural crest cells from the neural crest 
territory in the dorsal neural tube then delaminate in a process of primary EMT (Thiery et 
al., 2009). However, what has not really been emphasized so far, is the lack of EMT in the 
initial differentiation of epiblast cells directly into the remaining ecto- and neuroectodermal 
germ layer – an in vivo process of Epiblast-ectodermal transformation (EET) corresponding 
to an in vitro process of ESC-ectodermal transformation. 
In a previous in vitro study of regional differences in the expression of markers  
during differentiation of hESC lines (LRB001-004), we noticed a distinct and direct 
transformation from undifferentiated OCT4 positive hESCs to SSEA1-positive fully 
differentiated epithelial cells (Laursen et al., 2007), and in a very recent investigation of six 
different LRB-cell lines we observed a similar abrupt transformation between OCT4-positive 
hESC regions and areas with either ectodermal p63-positive cells or neuroectodermal nestin-
positive cells, while a direct transition into either meso- or endodermal marker positive cells, 
was not seen (Brøchner et al., 2011). In the present in vitro study we found an OCT4-postive 
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multilayered appearance, suggests that it could be a single-cell layer cut in a transverse 
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and RT-PCR, assuming colonies to consist of uniform monolayers of undifferentiated cells 
corresponding to apical epithelial cells.  
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covered with microvilli with varying heterogeneity, and often with microvilli-free cells 
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different LRB-cell lines we observed a similar abrupt transformation between OCT4-positive 
hESC regions and areas with either ectodermal p63-positive cells or neuroectodermal nestin-
positive cells, while a direct transition into either meso- or endodermal marker positive cells, 
was not seen (Brøchner et al., 2011). In the present in vitro study we found an OCT4-postive 
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epithelial-like cell type with a well-defined junctional complex facing the outside compartment 
which strongly resemble an in vivo embryonic epiblast cell type, whereas the pluripotent cells 
without junctional complexes in the central compartment of early cultures resemble an  
ICM-like cell type. The gradual pattern of differentiation from the center towards both 
apical and basal compartments indicates a direct shift from hESCs to columnar epithelial 
epiblast-like cells and to nestin-positive neuroectodermal cells in the basal compartment.   
5. Conclusion 
In conclusion, the epithelial coating of the colony might serve two different purposes: (1) 
The tight junction component of the junctional complex forms a barrier for transepithelial 
transport between the culture medium and the internal environment of the colony; thus the 
epithelial cells could provide cells in central and basal compartments with nutrients and 
other media components, probably via a specific receptor mediated transcellular epithelial 
transport, in order to create a microenvironment supporting the undifferentiated stage of 
underlying cells within the central compartment. (2) There seems to be a direct 
transformation of pluripotent hESCs into ecto- and neuroectodermal germ layer cells, while 
the adherens component of the junctional complex is instrumental in directing the further 
differentiation of hESCs into mesodermal and endodermal lineages via an epithelial-
mesenchymal transition (EMT). 
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1. Introduction 
A chimera is an animal that has two or more populations of genetically distinct cells that 
originated in different embryos, fetuses, or individuals of the same or different species. 
During recent decades, embryos, the inner cell mass (ICM), teratocarcinoma stem cells, 
embryonal carcinoma stem cells, embryonic stem (ES) cells (ESCs), primordial germ cells, 
spermatogonial stem cells, extraembryonic endoderm (XEN) cells (Kunath et al., 2005), 
induced pluripotent stem cells (iPSCs) (Boland et al., 2009; Kang et al., 2009; Takahashi & 
Yamanaka, 2006; Zhao et al., 2009), epiblast stem cells (EpiSCs) (Brons et al., 2007; Tesar et 
al., 2007), and other cells have been used to generate chimeric embryos that can develop into 
chimeras once transferred to a foster mother. 
To date, three methods can be applied to produce ESC-derived chimeric embryos: (1) 
aggregation, (2) microinjection, and (3) coculture. This review uses mouse ES cells as an 
example to describe and compare existing methods for generating chimeric embryos. 
2. Methods for generating chimeric embryos 
Long before successful generation of chimeric embryos using mouse ES cells (Evans & 
Kaufman, 1981; Martin, 1981), large chimeric morulae were first generated using zona 
pellucida (ZP)-free (denuded) pre-implantation embryos aggregated mechanically in a small 
drop of medium (Tarkowski, 1961). However, Tarkowski’s mechanical method (via a pipette) 
is technically difficult and tedious for broken and removed the ZP one by one. Later, a study 
indicated that mouse ZP can be digested and removed easily using pronase (~1 min) and 
pipettes (Mintz, 1962). A subsequent study demonstrated that using acidic Tyrode’s solution 
(pH 2.5) to dissolve mouse ZP is a relatively simpler and cheaper method (Nicolson et al., 
1975). A batch of intact whole embryos (~25) submerged in the acidic Tyrode’s solution for 
approximately 10 seconds is sufficient to partially dissolve the ZP, and the embryos can then 
be transferred to a buffered medium to wash away the denuded embryos via pipettes. 
Aggregation has since become one of the major methods for generating chimeric embryos. 
Unfortunately, once blastocysts form, generating chimeric blastocysts via the aggregation 
method is generally impossible. However, one may introduce cells into the cavities of 
blastocysts to obtain chimeric embryos. It was the first report that chimeric embryos 
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produced using the five-instrument microsurgical method to introduce ICMs or cells into 
the blastocyst cavity (Gardner, 1968). Apparently, the five-instrument method is too 
complex for routine operation. Thereafter, the two-micropipette microinjection method was 
developed (Moustafa & Brinster, 1972).  
Since aggregation and microinjection methods are commonly used to produce chimeric 
embryos; techniques, equipment, and protocols have been modified and improved. For 
technical details of current methods, including cells, embryos, instruments, and equipment 
for making micropipettes and generating chimeric embryos, see previous articles  
(Bradley, 1987; Nagy et al., 2003; Nagy et al., 2010; Papaioannou & Johnson, 2000; 
Papaioannou & Dieterlen-Lievre, 1984; Pluck and Klasen, 2009). The website 
(http://www.mshri.on.ca/nagy/default.htm#) of Professor Nagy at the Samuel Lunenfeld 
Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada, also provides technical 
protocols for generating chimeric mouse and ESC-derived mouse via aggregation between 
ES cells and diploid (2n) or tetraploid (4n) 2.5-day post-coitum (dpc) embryos. 
Although the aggregation and microinjection methods are effective for producing chimeric 
embryos, due to instrumental and technical limitations, they are unsuited to mass production. 
Thereafter, the coculture method was developed (Wood et al., 1993a; Wood et al., 1993b).  
2.1 Comparison of conventional methods for generating chimeric mice 
Currently, the most common technique for generating chimeric embryos is direct 
microinjection of ES cells into the cavity of 3.5-dpc blastocysts. Microinjection is a highly 
stable and reproducible method that can generate good germline transmitted chimeras. 
However, this method has various limitations. First, an expensive micromanipulation 
system is required. Second, intensive training is needed to master micromanipulation skills. 
Third, the microinjection step is time-consuming, averaging only 20–40 blastocysts/h, 
limiting production to 50–100 blastocysts daily (Bradley, 1987; Hogan et al., 1994; Nagy et 
al., 2003). Therefore, generating chimeras usually requires pay-based services. Although 
using Piezo-driving (Kawase et al., 2001) to introduce ES cells into the cavity of blastocysts 
may have relatively better efficiency in producing chimeras, it is rarely applied as it requires 
a high skill level and an extra expensive device. 
Well sandwich aggregation is the second most popular method for generating chimeric 
embryos. This method is also a highly stable, reproducible, and easy method for generating 
chimeras and has a germline transmission efficiency nearly equivalent to that of blastocyst 
microinjection (Bradley, 1987; Hogan et al., 1994; Nagy et al., 2003; Papaioannou & Johnson, 
2000). Well sandwich aggregation does not require expensive and sophisticated instruments, 
and is easily learned and implemented. Those familiar with using a mouth pipette can use this 
method routinely in a laboratory. However, two or more embryos (either XX or XY) are 
required for aggregation to create a single reconstructed embryo, which is disadvantageous for 
inbred mice, as only 6–10 embryos can be recovered from each mouse through superovulation. 
Although single embryo aggregation is a viable option, its efficiency in generating chimeras 
varies and is inferior to methods using two or more embryos. Therefore, very few studies have 
used single embryo aggregation to generate chimeric embryos. 
Another alternative for generating chimeric embryos is coculturing 2.5-dpc denuded single 
4-cell embryos to morulae with ES cells on dish surfaces (Shimada et al., 1999; Wood et al., 
1993a) or in droplets (Ueda et al., 1995). However, the efficiency of generating chimeras via 
this method is far inferior to that of microinjection and well sandwich aggregation. Only a 
few studies have used this method to generate chimeric embryos. 
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Table 1 summarizes and compares conventional methods for generating chimeric embryos. 
 




Equipment Very expensive Inexpensive Inexpensive Very cheap 
Skill level Very high Low Low Very low 
Time needed to 
learn the 
technique3 
2–3 months 2–3 weeks 2–3 weeks 1–2 weeks 




and not more than 
50–100 blastocysts/d 
~30 pairs/h ~40 embryos/h >100 embryos/h 
1Cultured overnight then reconstructed chimeric embryos are recovered for transfer or other treatments. 
2Cocultured for 3–4 h, the embryo-ESC aggregates are recovered and cultured overnight to produce 
chimeric embryos. 
3Persons must be familiar with cell and embryo culturing as well as mouth pipetting. 
4Enriched ES cells and recovered intact embryos are ready for use. 
Table 1. Comparison of conventional methods for generating chimeric embryos 
2.2 Vial coculture method for generating chimeric mice 
Although the microinjection method produced good and reliable results, it is hard to 
practice by a laboratory. Therefore, outsourcing to a core facility or commercial company is 
common. Unfortunately, service charges are high at approximately US$1,000–3,000/case. 
Conversely, the aggregation method is easily applied and inexpensive. However, this 
method must be applied in a one-by-one manner and is tedious. The conventional coculture 
method is also easily applied and is inexpensive. Furthermore, this method facilitates 
routine mass production of chimeric embryos. Unfortunately, outcomes are not as reliable 
and good as those of the microinjection and well sandwich aggregation methods. In 
conventional coculture protocols, denuded embryos on a dish surface have only two-
dimensional ES-cell contact surfaces, resulting in only 55–64% of denuded embryos 
adhering to ES cells (Ueda et al., 1995; Wood et al., 1993a). Obviously, an improved 
coculturing method is needed that can achieve results as good as or better than those by the 
microinjection and well sandwich aggregation methods. Moreover, an improved 
coculturing method should be easily applied, cheap, and suited to mass production. 
Recently, my laboratory developed an alternative simple, very cheap, and reproducible 
method for mass production of chimeric embryos by coculturing 2.5-dpc denuded 8-cell 
embryos and compacting morulae with ES cells in 1.7-mL Eppendorf vials (micro test tube); 
this method has fewer technological and instrument-based limitations than conventional 
methods. Although depressed microwells made by a darning needle had three-dimensional 
possibility for denuded embryos and ES cells to contact each other, however, in the vial 
coculturing system, the large number of enriched ES cells surrounding the denuded 
embryos from every direction may improve the overall adherence. Furthermore, gravity 
may also contribute to enhanced ES cell adherence via this method. The resulting chimeras 
show significantly high levels of chimerism and high germline transmission rates (Lee et al., 
2007). Table 2 lists an example schedule and protocol for the vial coculture method. Figures 
1 and 2 show vial coculturing results.  
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Date Time Target Treatment 
Friday ~16:30 Donor females 
superovulated 
PMSG 5–10 units/ip 
Sunday ~16:30 hCG 5–10 units/ip; donor females are mated with studs 
Monday am 
Donor females Plug checked 
ES cells  Thawed or pass in high density to 0.1% gelatin-coated dishes 
Tuesday ~16:30 
Recipients (ICR, 
CD-1, or F1 
hybrid) 
Estrus females mated with vasectomized 
males  
Wednesday 
am Recipients  Plug checked 
~08:30 ES cells Enriched via the double plating method 
~08:40 35-mm cell culture dish 
HK (20.85 mM hepes-buffered KSOM, 285 
± 10 mOsm/kg H2O) droplets under light-
weight mineral oil prepared; room 
temperature (RT) 
~09:00 Donor females Recovery of the 2.5-dpc embryos, which are kept in HK at RT until used 
~10:00 ES cells 
The first round of enriched cells harvested 
and re-suspended to a cell medium for the 
second standing 
~10:25 Enriched ES cells 
Cells are harvested and stored at 4°C until 
the concentration is adjusted for 
coculturing 
~10:40 
6-cell embryos to 
compacting 
morulae 
ZP are removed using the acidic Tyrode’s 
solution  
~11:00 1.7-mL vials 
Approximately 0.8 mL enriched ES cells 
are transferred to vials; after ~5 min, 
denuded embryos are added for 





10-μL droplets of KSOM-AA or KSOM-
AA containing 1% FBS are prepared and 
put in an incubator under 5% CO2 at 37°C  





embryo-ESC aggregates are washed to 
droplets of KSOM-AA or KSOM-AA 
containing 1% FBS for culturing 
overnight; 5% CO2, 37°C incubator 
Thursday am or pm Recipients  
Chimeric embryos are transferred to 
uterus horns of 2.5-dpc pseudopregnant 
recipients 
Sunday  Recipients Pups are born after ETed for 17 days 
1One person can finish the vial coculturing easily. 
Table 2. Schedule and protocol for the vial coculture method for generating chimeric mice1 
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2.2.1 Technical considerations for vial coculture method 
To ensure that cells adhered to the denuded embryos are the ES cells mainly, any 
enrichment method for ES cells can be used. When using the double-plating selection 
method, approximately 96% of harvested cells expressed bright-green fluorescence, and 
approximately 92% of these cells were <12 μm in diameter (Lee et al., 2007). The method is 
easily implemented, and is selective, effective, and reproducible in removing debris, dead 
cells, and feeder cells from the prepared ES single-cell suspension. 
Different volumes of Eppendorf vials are available for coculturing. I recommend the 1.7-mL 
vial due to the size is good for handling. Approximately 0.8-mL aliquots of enriched ES cells, 
either fresh or thawed; ~5.0 × 105 cells/mL in KSOM-AA alone or KSOM-AA containing 1% 
fetal bovine serum (FBS) are added to sterile polypropylene 1.7-mL vials with snap caps. After 
left to stand for 5 min, ≦200 denuded 6-cell embryos to morulae are gently and circularly 
blown from beneath the medium surface into the vial via a mouth pipette, and then coculture 
in an incubator under 5% CO2 at 37°C for 3 ± 1 h. Denuded 2- to 4-cell embryos are unsuitable 
for coculturing, as blastomeres sometimes can easily separate during coculturing. 
Additionally, the relatively smaller diameters of blastomeres make recovery difficult. 
However, adherent cells are consistently observed in separated blastomeres. Conversely, 
segregation of blastomeres of electrofused tetraploid (4n) 3- to 4-cell embryos does not occur. 
After the coculturing is ended, precipitate in vials is aspirated gently and loose cells on 
embryonic surfaces are removed by washing using a mouth pipette. Denuded embryos 
adhered to ES cells are recovered. Following coculturing for 3 h in 1.7-mL Eppendorf vials, 
>90% of denuded 6-cell embryos to morulae adherent ES cells can be recovered. Moreover, 
approximately 90% of recovered embryos adhered tightly to ES cells and approximately 5–
10% (the percentage increases as the number of embryos in the same vial increases) of 
recovered aggregates had 2 or 3 embryos clustered around and adhered to ES cells. 
Aggregates have >3 embryos, if necessary, can be separated by gentle pipetting using a 
mouth pipette. During coculturing, approximately 10% of denuded 8-cell embryos 
developed into compacting morulae. Experimental data show that cell adherence could 
reach 100% when ES cell concentrations are increased, or when the coculturing period is 
extended. The embryo-ESC aggregates are washed directly in either KSOM-AA or KSOM-
AA containing 1% FBS droplets (10 µL) under light-weight paraffin oil on bacteriological 
dishes. Two to four embryo-ESC aggregates are carefully allocated to different corners of the 
same droplet to prevent possible adhesion and are cultured overnight in an incubator at 
37°C under 5% CO2 until transfer to uterine horns of 2.5-dpc pseudopregnant recipients. 
Mouse preimplantation embryos and ES cells require different in vitro culture requirements. 
Essentially, ES cells require at least 5% FBS (Wakayama et al., 1999) to maintain survival and 
possible pluripotency unless cultured in knockout serum replacement (KSR) (Goldsborough 
et al., 1998). It has been showed that poor ES cell viability after overnight coculturing in M16 
or KSOM media (Huang et al., 2008; Kondoh et al., 1999). Although, M16 supplemented 
with FBS, could enhance chimera generation (Kondoh et al., 1999). Unfortunately, the viable 
fetuses derived from the FBS (5-15%) groups were significantly fewer than that derived from 
the FBS-free control group (Arny et al., 1987; Caro and Trounson, 1984; Khosla et al., 2001). 
Khosla et al. (2001) indicated that FBS exerts a direct adverse effect on genes responsible for 
postimplantation development.  
To summarize, coculturing 2.5-dpc denuded 6-cell embryos to morulae with ES cells in 1.7-
mL Eppendorf vials for approximately 3 h is a simple and effective alternative method for 
mass production of chimeric embryos. Table 3 compares conventional methods and the vial 
coculture method for generating chimeric embryos and germline transmitted chimeric mice. 
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Fig. 1. Enrichment of ES cells and development of denuded embryo-ESC aggregates. a: 
Attaching and/or attached cells were recovered after the original single-cell suspension of 
the mouse ES cell, ESC 26GJ9012-8-2, cultured on a 100-mm dish in a 5% CO2 incubator at 
37°C for 80 min. b: Over 94% of cells expressed the green fluorescence protein (GFP). c, d: 
After denuded 8-cell embryos, morulae, and ESC 26GJ9012-8-2 cells were cocultured in an 
1.7-mL Eppendorf vial for 2 h, recovered embryos had adherent green fluorescing ES cells 
on their surfaces. The left bright and right green fluorescent images show the same view of 
14 embryos, including 2 8-cell embryos, 2 compacting morulae with zona pellucida (as the 
control; c), 5 single-embryo-cell aggregates, 3 2-embryo-cell aggregates, and 2 3-embryo-cell 
aggregates (some kind sandwich aggregation). e, f: After culturing aggregates from panels c 
and d overnight in droplets of KSOM-AA containing 1.0% FBS, the aggregates had cells 
with surface green fluorescence mingling in the developing compacting and compacted 
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chimeric morulae. g, h: After further overnight culturing, chimeric morulae from panels e 
and f developed into chimeric blastocysts displaying green fluorescence cells primarily in 
the ICM. Scale in panel a: bar = 50 µm. Scale in panels b–h: bar = 100 µm. (Reproduced with 
permission from Lee et al., 2007. Theriogenology 67:228–237.) 
 
 
Fig. 2. Chimeras with high percentages of coat color distribution and germline transmission 
generated using the Eppendorf vial coculture method. In this experiment, chimeric morulae 
and/or blastocysts developed from aggregates of ICR × B6CBAF1 embryos and ESC 
26GJ9012-8-2 cells were transferred to pseudopregnant ICR 2.5-dpc uterine horns. The pups 
born alive had high percentages of coat color and green fluorescence expression. a, b: Pups 
derived from fresh ESC 26GJ9012-8-2 cells. c, d: Pups derived from thawed ESC 26GJ9012-8-
2 cells. e: Green fluorescence was widely expressed on internal organs of mature chimeras. 
The control mouse had no green fluorescence expression. f: Pups expressing green 
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fluorescence, following phenotypically normal male chimeras, were naturally mated with 
ICR to achieve high germline transmission rates. (Reproduced with permission from Lee et 












Pups born alive after 
chimeric embryos 
ETed2 (A) 
~60% ~30% ~20% ~25% 

























Total efficiency of 
germline 
transmission3 
(A × B × C × D) 
~4.5% ~3.3% ~1.1% ~4.5% 
1Data are compiled from previous studies. 
2Pups born alive/chimeric embryos transferred.  
3Germline transmitted male chimeras/chimeric embryos transferred. The total efficiency of germline 
transmission is highly variables depends on ES cells used, donor embryos used, persons did, and mouse 
facilities managed. 
Table 3. Comparative efficiency of different methods for generating germline transmitted 
chimeric mice1 
2.3 Generation of ESC-derived mice 
Authentic ES cells are defined by three cardinal properties: unlimited symmetrical self-
renewal in vitro; comprehensive contribution to primary chimeras; and generation of 
functional gametes for genome transmission (Buehr et al., 2008). However, using 4n 
complementation for generating ESC-derived mice is regarded as the most solid criterion for 
ES cell pluripotency. The criterion is also accepted for generation of iPSC-derived mice 
(Boland et al., 2009; Kang et al., 2009; Zhao et al., 2009). 
The mouse pluripotent ES cells can be established from zygotes, blastomeres, and ICMs (Lee 
et al., 2011). However, the originate of ES cells limit its developmental potential to embryo 
proper mainly (Beddington & Robertson, 1989). Tetraploid embryos typically stop their 
development during the early stage of gestation and do not develop beyond the mid-
gestation period due to a lack of the embryo proper, but persist in extraembryonal 
membranes (Eakin & Behringer, 2003; Kaufman & Webb, 1990; Snow, 1975; Tarkowski et al., 
1977). Combining 4n embryos and 2n ES cells is logical as 4n embryos may complement the 
deficient extraembryonal differentiation of ES cells while allowing full expression of their 
potential for fetal development (Nagy et al., 1990). Thereafter, a viable and fertile ESC-
derived mouse was generated (Nagy et al., 1993).  
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Since ESC-derived mice were generated successfully using 4n 4-cell embryos aggregated 
with 2n ES cells (Nagy et al., 1990; Nagy et al., 1993), well sandwich aggregation is the main 
choice to do that (Eggan et al., 2002; Li et al., 2005; Ohta et al., 2008; Schoonjans et al., 2003; 
Ueda et al., 1995). The second popular method is microinjecting ES cells into 4n blastocysts 
(Eggan et al., 2001; Kirchain et al., 2008; Li et al., 2005; Lin et al., 2010; Schwenk et al., 2003; 
Wang et al., 1997; Wang & Jaenisch, 2004). 
Most tetraploid-ESC neonates derived from hybrid ES cells developed into fertile adults 
(Eggan et al., 2001). Conversely, most studies revealed that ESC-derived pups from inbred 
ES cells died shortly after delivery. However, one study demonstrated that inbred ES cells 
can generate ESC-derived mice (Schoonjans et al., 2003). Furthermore, the Caesarean section 
is required to overcome the failure of respiratory problems of ESC-newborns (Nagy et al., 
1993). Apparently, this is a tedious work and is not a practical protocol for routine 
operation. Previous studies suggested that the recipient mothers can be subject to natural 
delivery instead of Caesarean section (Lee et al., 2003; Li et al., 2005). However, this is not 
suitable for any ES cell. 
Previous studies also revealed that an ESC-derived mouse have host embryo contamination 
(Eggan & Jaenisch, 2003; Li et al., 2005), poor viability, and other minor abnormalities such 
as altered growth rate and body weight. However, adults had normal morphological, 
physiological, and neurological characteristics (Schwenk et al., 2003). 
Using 4n complementation method, 4n embryos require produced of 2n 2-cell embryos 
usually by electrofusion and are less viable than normal 2n embryos. Thus, the generation 
efficiency of ESC-derived mice is relatively low at approximately 1–5%. One reason for this 
low efficiency may be the low cell number of 4n blastocysts. Using 3–5 aggregated 4n 
embryos, the efficiency in generating ESC-derived mice can be increased 2–3 times (Ohta et 
al., 2008). Additionally, the modified method would be applicable to any ES cell, including 
general ES cells used for gene targeting (Ohta et al., 2008).  
Although ES cells can produce viable and fertile ESC-derived mice, this is an inefficient 
process; many tetraploid-ESC aggregates die before reaching term, even when early passage 
ES cells are used (Nagy et al., 1993). Therefore, this approach cannot be considered as a 
feasible approach for routinely achieving germline transmission from ES cells (Nagy et al., 
1993). Reasonably, other alternatives might be developed. 
2.4 Generation of ESC-derived F0 mice 
After the blastocyst microinjected with ES cells that can adhere to and mingle in ICMs, then 
co-develop to an embryo proper including germ cells. The same phenomenon was also 
observed when 2.5-dpc embryos aggregated with ES cells. The mechanisms underlying this 
phenomenon have been investigated. Unfortunately, this mechanism remains unclear. 
However, data from studies of chimeric embryos suggest a combined contribution of 
multiple factors, including geometrical effects of cell size and polar or apolar positioning 
(Hillman et al., 1972; Johnson & Ziomek, 1981; Saburi et al., 1997; Tarkowski & Wroblewska, 
1967). Notably, this phenomenon may also reflect the possibility that ES cells are naturally 
more committed to an ICM fate (Wood et al., 1993a).  
Previous studies have demonstrated that ES cells adhering to the surfaces of 8-cell embryos 
or compacting morulae are generally localized in the ICM of blastocysts following culturing 
(Lee et al., 2007; Shimada et al., 1999; Wood et al., 1993a; Wood et al., 1993b). Repentigny 
and Kothary (2010) recently microinjected ES cells into the perivitelline space (PVS) of 
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fluorescence, following phenotypically normal male chimeras, were naturally mated with 
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zygotes. They showed that at the 2- to 4-cell stage embryos, injected ES cells remain in the 
PVS and are not incorporated into embryos. The ES cells begin partial blastomere 
incorporation into an embryo at the 8-cell embryo. Finally, at the compacted morula, ES cells 
are almost completely incorporated into an embryo. At the blastocyst, ES cells form an ICM 
(Repentigny & Kothary, 2010). Whether ES cells can replace ICMs completely and develop 
thereafter as an ESC-derived mouse is worthy of investigation. 
Compared with 3.5-dpc blastocyst microinjection, an alternative method that microinjects 
ES cells into the tight space between ZP and blastomeres (the subzonal cavity) of 2.5-dpc 
8-cell embryos has been reported (Tokunaga & Tsunoda, 1992). Experimental results 
showed that the proportion of male chimeric mice capable of germline transmission 
increased significantly. Furthermore, 100% coat color chimeric mice with germline 
transmission were produced. Unfortunately, the meaning of 100% coat color chimerism 
was not investigated (Tokunaga & Tsunoda, 1992). Papaioannou and Johnson (1993, 2000) 
have been mentioned that the result of microinjecting ES cells into 2.5-dpc 8-cell embryos 
was comparable to but not better then microinjection of 3.5-dpc blastocysts. Notably, 
microinjecting 2.5-dpc embryos are more difficult than microinjecting 3.5-dpc blastocysts 
due to the tight and small subzonal cavity and possible damage to blastomeres, 
explaining why only a few follow-up studies exist.  
Laser-assisted microinjection of 7–9 ES cells into the subzonal cavity of 2n 8-cell embryos 
may enhance microinjection and efficiently yield F0 generation mice (100% coat color 
chimerism) that are fully ESC-derived and healthy, exhibiting 100% germline transmission 
and containing no more than 0.1% host embryo contamination (Poueymirou et al., 2007). 
They suggested that the F0 mouse is equivalent to the ESC-derived mouse. A subsequent 
study indicated that 8–10 ES cells Piezo (toxic mercury in a microinjection pipette used) 
microinjected into the subzonal cavity of 2n 4- or 8-cell embryos also generated F0 ES cell 
offspring (Huang et al., 2008).  
The efficiency of generating ESC F0 mice is much better than using ESC-derived mice via ES 
cell assemble with 4n embryos (Eakin & Hadjantonakis, 2006; Eggan et al., 2001; Li et al., 
2005; Nagy et al., 1993; Ueda et al., 1995; Wang & Jaenisch, 2004). However, these methods 
need an expensive laser or Piezo-driving equipment and additional training is required to 
acquire the necessary skills. The disadvantages of both methods limit their applications. 
Recent studies, which used conventional microinjection to introduce ES cells into 2- to 8-cell 
embryos, produced 100% coat color chimeras (Kraus et al., 2010; Ramirez et al., 2009). 
However, the technical problems still exist.  
The Eppendorf vial coculture method can generate massive amounts of chimeric embryos. 
The resulting chimeric mice show approximately 40% of pups born alive with almost 100% 
ES cells coat color distribution (Lee et al., 2007). The major disadvantage of the coculture 
method is variable adhesion of ES cells onto the surfaces of denuded embryos. In practice, 4-
cell embryos to morulae are recovered from superovulated 2.5-dpc donor mice. The 
denuded 8-cell embryos and morulae are good for vial coculturing. However, the 4-cell 
embryo is not suitable for vial coculturing, because blastomeres usually separate during 
coculturing.  
The 2n ES cells microinjected into, aggregated with, or cocultured with 2.5-dpc denuded 2n 
8-cell embryos and/or morulae can generate germline transmitted F0 mice. New methods 
with the higher efficiency may be worth developing to overcome the limitations and 
disadvantages of existing approaches. 
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2.5 The hypertonic microinjection method for generating chimeric mice 
For conventional microinjecting ES cells to 2.5-dpc 3-cell embryos to morulae, the tight 
subzonal cavity is a major technical hurdle. Theoretically, increasing the space of the 
subzonal cavity can solve this problem. 
Zona pellucida is a rigid glycoprotein that resists both hypertonic and hypotonic solutions. 
In contrast, the volume of an embryo proper changes in proportion to osmolarity of 
solutions (Leibo, 1980). In other words, the space of the subzonal cavity increases when 
embryos are in hypertonic solutions. Notably, a high sucrose concentration is virtually non-
toxic to embryos and oocytes (Kasai et al., 1983; Kasai et al., 1992; Kuleshova et al., 1999). 
Therefore, pre-blastocyst embryos in a microinjection medium can increase the space of the 
subzonal cavity proportionally to the added sucrose concentration and that may pose no 
threat to embryos for hours. Accordingly, my laboratory is developing a method in which 
ES cells are hypertonically microinjected into 2.5-dpc embryos. Table 4 gives an example 
schedule and protocol for this method. The hypertonic microinjecting ES cells into 2.5-dpc 
embryos and fertile chimeras are shown at Fig. 3. 
 
Date Time Target Treatment 
Friday ~16:30 Donor females 
superovulated 
PMSG 5–10 units/ip 
Sunday ~16:30 hCG 5–10 units/ip; Donor females are mated with studs 
Monday am 
Donor females Plug checked 
ES cells Thawed or pass in a high density to 0.1% gelatin-coated dishes 
Tuesday ~16:30 Recipients (ICR, CD-1, or F1 hybrid) 
Estrus females mated with vasectomized 
males 
Wednesday 
am Recipients  Plug checked 
~08:00 ES cells Enriched via the double plating method 
~08:20 60-mm cell culture dish 
HK, EK2, and KSOM-AA droplets under 
light-weight mineral oil prepared; RT 





Microinjection pipette with a beveled tip 
and spike: outer diameter, 18–20 μm; 
inner diameter, 13–15 μm. Holding 
pipette: outer diameter, 50–70 μm; inner 
diameter, 22–25 μm 
~09:50 ES cells 
The first round of enriched cells 
harvested and re-suspended in a cell 
medium for the second standing 
~10:20 Enriched ES cells 
Harvested cells are kept at 4°C until re-
suspended in high density in a hepes-
buffered microinjection medium3 
containing 0.2 M sucrose4  
~10:40 Microinjection chambers  
A ~80-μL droplet of 0.2 M sucrose 
microinjection medium under light-
weight mineral oil is prepared. 
 
Embryonic Stem Cells – Basic Biology to Bioengineering 
 
202 
zygotes. They showed that at the 2- to 4-cell stage embryos, injected ES cells remain in the 
PVS and are not incorporated into embryos. The ES cells begin partial blastomere 
incorporation into an embryo at the 8-cell embryo. Finally, at the compacted morula, ES cells 
are almost completely incorporated into an embryo. At the blastocyst, ES cells form an ICM 
(Repentigny & Kothary, 2010). Whether ES cells can replace ICMs completely and develop 
thereafter as an ESC-derived mouse is worthy of investigation. 
Compared with 3.5-dpc blastocyst microinjection, an alternative method that microinjects 
ES cells into the tight space between ZP and blastomeres (the subzonal cavity) of 2.5-dpc 
8-cell embryos has been reported (Tokunaga & Tsunoda, 1992). Experimental results 
showed that the proportion of male chimeric mice capable of germline transmission 
increased significantly. Furthermore, 100% coat color chimeric mice with germline 
transmission were produced. Unfortunately, the meaning of 100% coat color chimerism 
was not investigated (Tokunaga & Tsunoda, 1992). Papaioannou and Johnson (1993, 2000) 
have been mentioned that the result of microinjecting ES cells into 2.5-dpc 8-cell embryos 
was comparable to but not better then microinjection of 3.5-dpc blastocysts. Notably, 
microinjecting 2.5-dpc embryos are more difficult than microinjecting 3.5-dpc blastocysts 
due to the tight and small subzonal cavity and possible damage to blastomeres, 
explaining why only a few follow-up studies exist.  
Laser-assisted microinjection of 7–9 ES cells into the subzonal cavity of 2n 8-cell embryos 
may enhance microinjection and efficiently yield F0 generation mice (100% coat color 
chimerism) that are fully ESC-derived and healthy, exhibiting 100% germline transmission 
and containing no more than 0.1% host embryo contamination (Poueymirou et al., 2007). 
They suggested that the F0 mouse is equivalent to the ESC-derived mouse. A subsequent 
study indicated that 8–10 ES cells Piezo (toxic mercury in a microinjection pipette used) 
microinjected into the subzonal cavity of 2n 4- or 8-cell embryos also generated F0 ES cell 
offspring (Huang et al., 2008).  
The efficiency of generating ESC F0 mice is much better than using ESC-derived mice via ES 
cell assemble with 4n embryos (Eakin & Hadjantonakis, 2006; Eggan et al., 2001; Li et al., 
2005; Nagy et al., 1993; Ueda et al., 1995; Wang & Jaenisch, 2004). However, these methods 
need an expensive laser or Piezo-driving equipment and additional training is required to 
acquire the necessary skills. The disadvantages of both methods limit their applications. 
Recent studies, which used conventional microinjection to introduce ES cells into 2- to 8-cell 
embryos, produced 100% coat color chimeras (Kraus et al., 2010; Ramirez et al., 2009). 
However, the technical problems still exist.  
The Eppendorf vial coculture method can generate massive amounts of chimeric embryos. 
The resulting chimeric mice show approximately 40% of pups born alive with almost 100% 
ES cells coat color distribution (Lee et al., 2007). The major disadvantage of the coculture 
method is variable adhesion of ES cells onto the surfaces of denuded embryos. In practice, 4-
cell embryos to morulae are recovered from superovulated 2.5-dpc donor mice. The 
denuded 8-cell embryos and morulae are good for vial coculturing. However, the 4-cell 
embryo is not suitable for vial coculturing, because blastomeres usually separate during 
coculturing.  
The 2n ES cells microinjected into, aggregated with, or cocultured with 2.5-dpc denuded 2n 
8-cell embryos and/or morulae can generate germline transmitted F0 mice. New methods 
with the higher efficiency may be worth developing to overcome the limitations and 
disadvantages of existing approaches. 
 
Methods to Generate Chimeric Mice from Embryonic Stem Cells 
 
203 
2.5 The hypertonic microinjection method for generating chimeric mice 
For conventional microinjecting ES cells to 2.5-dpc 3-cell embryos to morulae, the tight 
subzonal cavity is a major technical hurdle. Theoretically, increasing the space of the 
subzonal cavity can solve this problem. 
Zona pellucida is a rigid glycoprotein that resists both hypertonic and hypotonic solutions. 
In contrast, the volume of an embryo proper changes in proportion to osmolarity of 
solutions (Leibo, 1980). In other words, the space of the subzonal cavity increases when 
embryos are in hypertonic solutions. Notably, a high sucrose concentration is virtually non-
toxic to embryos and oocytes (Kasai et al., 1983; Kasai et al., 1992; Kuleshova et al., 1999). 
Therefore, pre-blastocyst embryos in a microinjection medium can increase the space of the 
subzonal cavity proportionally to the added sucrose concentration and that may pose no 
threat to embryos for hours. Accordingly, my laboratory is developing a method in which 
ES cells are hypertonically microinjected into 2.5-dpc embryos. Table 4 gives an example 
schedule and protocol for this method. The hypertonic microinjecting ES cells into 2.5-dpc 
embryos and fertile chimeras are shown at Fig. 3. 
 
Date Time Target Treatment 
Friday ~16:30 Donor females 
superovulated 
PMSG 5–10 units/ip 
Sunday ~16:30 hCG 5–10 units/ip; Donor females are mated with studs 
Monday am 
Donor females Plug checked 
ES cells Thawed or pass in a high density to 0.1% gelatin-coated dishes 
Tuesday ~16:30 Recipients (ICR, CD-1, or F1 hybrid) 
Estrus females mated with vasectomized 
males 
Wednesday 
am Recipients  Plug checked 
~08:00 ES cells Enriched via the double plating method 
~08:20 60-mm cell culture dish 
HK, EK2, and KSOM-AA droplets under 
light-weight mineral oil prepared; RT 





Microinjection pipette with a beveled tip 
and spike: outer diameter, 18–20 μm; 
inner diameter, 13–15 μm. Holding 
pipette: outer diameter, 50–70 μm; inner 
diameter, 22–25 μm 
~09:50 ES cells 
The first round of enriched cells 
harvested and re-suspended in a cell 
medium for the second standing 
~10:20 Enriched ES cells 
Harvested cells are kept at 4°C until re-
suspended in high density in a hepes-
buffered microinjection medium3 
containing 0.2 M sucrose4  
~10:40 Microinjection chambers  
A ~80-μL droplet of 0.2 M sucrose 
microinjection medium under light-
weight mineral oil is prepared. 
 
Embryonic Stem Cells – Basic Biology to Bioengineering 
 
204 
Date Time Target Treatment 
Thousands of enriched ES cells, then 3-
cell embryos to compacting morulae 
added to the droplet of microinjection 
medium in a row. 
~10:55 60-mm cell culture dish 
HK, EK, and KSOM-AA droplets under 






Setup for microinjection 
~11:20 Microinjection chamber 
Sucking hundreds of ES cells into a 
microinjection pipette within 5~10 min5 
~11:30 Microinjection begins  
Approximately 5–30 ES cells are 
microinjected at RT into the large 
subzonal cavity of 3-cell embryos to 
compacting morulae  
~12:30 Microinjection finishes 
After 60–150 2.5-dpc embryos are 
microinjected within 1 h6, injected 
embryos are washed to and culture  
in EK droplets for ~1 h; 5% CO2, 37°C 
incubator  
~13:50 microinjected embryos 
Wash to fresh EK or KSOM-AA droplets 
for overnight culturing; 5% CO2, 37°C 
incubator 
Thursday am or pm Recipients7  
Chimeric embryos are transferred to 
uterus horns of 2.5-dpc pseudopregnant 
recipients 
Sunday  Recipients7 Pups born after ETed for 17 days 
1Base on one person finish the hypertonic microinjection. However, two persons are more efficiently 
and practically. 
2EK (6.5% KSR without FBS): 37.5% KSR ESC medium (20% KSR) and 62.5% KSOM-AA (285 ± 10 
mOsm/kg H2O) 
3Any hepes-buffered microinjection medium can be used. My laboratory usually uses EHK (37.5% KSR 
ESC medium and 62.5% HK) as the microinjection medium no matter how ES cells are culturing either 
in FBS- or KSR-ESC media.  
4Most enriched ES cells in 0.2 M sucrose EHK (500 ± 10 mOsm/kg H2O) are approximately 9–11 μm in 
diameter. Therefore, the diameter of microinjection pipette is smaller than a conventional pipette. 
5Cleaned and enriched ES cells are very important when sucking cells into a microinjection pipette. 
Otherwise, a single cell suspension, which has many cells with large diameters or sticky debris, will 
slow loading, generating a microinjection bottleneck. 
6The randomly sucked embryos by a holding micropipette do not need to adjust the position for 
microinjecting ES cells into the subzonal cavity, which can be completed in less then 30 seconds. 
7Embryos with ZP can be transferred into the oviducts of 0.5-dpc recipients (Ramirez et al., 2009). Pups 
will be born after being subjected to ET for 19 days. 
Table 4. Schedule and protocol for the hypertonic microinjection method for generating 
chimeric mice1 
 




Fig. 3. The generation of germline transmitted chimeric mice via the hypertonic 
microinjecting ES cells into a subzonal cavity of ICR × ICR 2.5-dpc embryos. The chimeric 
embryos were transferred into the pseudopregnant ICR 2.5-dpc uterine horns. a: The 2.5-dpc 
4- to 8-cell stage embryos in isotonic KSOM-AA (285 ± 10 mOsm/kg H2O) have tight 
subzonal cavities. b: Embryos and enriched ES cells (ESC 26GJ9012-8-2, P14) in 0.2 M 
sucrose EHK (37.5% KSR ESC medium and 62.5% hepes-KSOM) hypertonic injection 
medium (500 ± 10 mOsm/kg H2O) show large subzonal cavities. c, d: Injecting and injected 
embryos in hypertonic injection medium. e, f: After injected approximately 25 ES cells into 
embryos, which were washed to isotonic EK (37.5% KSR ESC medium and 62.5% KSOM-
AA). The bright (e) and bright plus green fluorescent (f) images show the same view of 11 
injected embryos. g: The green fluorescence expressing germline transmitted chimeric 
mouse was generated by injecting ESC 26GJ9012-8-2 cells to 4-cell embryos. h: Chimeric 
pups born alive after approximately 15 ESC98B33 cells (P5) were injected into 4-cell embryos 
and cultured overnight in EK. The ESC98B33 cell was derived from C57BL/6J 0.5-dpc 
denuded zygotes cultured on human foreskin fibroblast (Hs68) feeders and KSR ESC 
medium containing 2i (0.5 μM PD0325901 and 3 μM CHIR99021) and 10 μM ACTH 
fragments 1–24. i: A chimeric mouse with 100% coat color distribution was generated after 
approximately 20 ESC98B27 cells (P8) were injected into compacting morulae and cultured 
overnight in KSOM-AA. The ESC98B27 cell was derived from an isolated single blastomere 
of a C57BL/6J 1.5-dpc 2-cell embryo cultured on Hs68 feeders and KSR ESC medium 
containing 2i. Scale in panels a, e, f: bar = 100 µm. Scale in panels b–d: bar = 50 µm. 
Preliminary data demonstrate that ES cells microinjected into the subzonal cavity of 2.5-dpc 
embryos in a microinjection medium containing 0.2 M sucrose (~500 mOsm/kg H2O) can 
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compacting morulae  
~12:30 Microinjection finishes 
After 60–150 2.5-dpc embryos are 
microinjected within 1 h6, injected 
embryos are washed to and culture  
in EK droplets for ~1 h; 5% CO2, 37°C 
incubator  
~13:50 microinjected embryos 
Wash to fresh EK or KSOM-AA droplets 
for overnight culturing; 5% CO2, 37°C 
incubator 
Thursday am or pm Recipients7  
Chimeric embryos are transferred to 
uterus horns of 2.5-dpc pseudopregnant 
recipients 
Sunday  Recipients7 Pups born after ETed for 17 days 
1Base on one person finish the hypertonic microinjection. However, two persons are more efficiently 
and practically. 
2EK (6.5% KSR without FBS): 37.5% KSR ESC medium (20% KSR) and 62.5% KSOM-AA (285 ± 10 
mOsm/kg H2O) 
3Any hepes-buffered microinjection medium can be used. My laboratory usually uses EHK (37.5% KSR 
ESC medium and 62.5% HK) as the microinjection medium no matter how ES cells are culturing either 
in FBS- or KSR-ESC media.  
4Most enriched ES cells in 0.2 M sucrose EHK (500 ± 10 mOsm/kg H2O) are approximately 9–11 μm in 
diameter. Therefore, the diameter of microinjection pipette is smaller than a conventional pipette. 
5Cleaned and enriched ES cells are very important when sucking cells into a microinjection pipette. 
Otherwise, a single cell suspension, which has many cells with large diameters or sticky debris, will 
slow loading, generating a microinjection bottleneck. 
6The randomly sucked embryos by a holding micropipette do not need to adjust the position for 
microinjecting ES cells into the subzonal cavity, which can be completed in less then 30 seconds. 
7Embryos with ZP can be transferred into the oviducts of 0.5-dpc recipients (Ramirez et al., 2009). Pups 
will be born after being subjected to ET for 19 days. 
Table 4. Schedule and protocol for the hypertonic microinjection method for generating 
chimeric mice1 
 




Fig. 3. The generation of germline transmitted chimeric mice via the hypertonic 
microinjecting ES cells into a subzonal cavity of ICR × ICR 2.5-dpc embryos. The chimeric 
embryos were transferred into the pseudopregnant ICR 2.5-dpc uterine horns. a: The 2.5-dpc 
4- to 8-cell stage embryos in isotonic KSOM-AA (285 ± 10 mOsm/kg H2O) have tight 
subzonal cavities. b: Embryos and enriched ES cells (ESC 26GJ9012-8-2, P14) in 0.2 M 
sucrose EHK (37.5% KSR ESC medium and 62.5% hepes-KSOM) hypertonic injection 
medium (500 ± 10 mOsm/kg H2O) show large subzonal cavities. c, d: Injecting and injected 
embryos in hypertonic injection medium. e, f: After injected approximately 25 ES cells into 
embryos, which were washed to isotonic EK (37.5% KSR ESC medium and 62.5% KSOM-
AA). The bright (e) and bright plus green fluorescent (f) images show the same view of 11 
injected embryos. g: The green fluorescence expressing germline transmitted chimeric 
mouse was generated by injecting ESC 26GJ9012-8-2 cells to 4-cell embryos. h: Chimeric 
pups born alive after approximately 15 ESC98B33 cells (P5) were injected into 4-cell embryos 
and cultured overnight in EK. The ESC98B33 cell was derived from C57BL/6J 0.5-dpc 
denuded zygotes cultured on human foreskin fibroblast (Hs68) feeders and KSR ESC 
medium containing 2i (0.5 μM PD0325901 and 3 μM CHIR99021) and 10 μM ACTH 
fragments 1–24. i: A chimeric mouse with 100% coat color distribution was generated after 
approximately 20 ESC98B27 cells (P8) were injected into compacting morulae and cultured 
overnight in KSOM-AA. The ESC98B27 cell was derived from an isolated single blastomere 
of a C57BL/6J 1.5-dpc 2-cell embryo cultured on Hs68 feeders and KSR ESC medium 
containing 2i. Scale in panels a, e, f: bar = 100 µm. Scale in panels b–d: bar = 50 µm. 
Preliminary data demonstrate that ES cells microinjected into the subzonal cavity of 2.5-dpc 
embryos in a microinjection medium containing 0.2 M sucrose (~500 mOsm/kg H2O) can 
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generate chimeric embryos with high percentages of chimerism (including 100% coat color 
and/or GFP expression) and viable, healthy, germline transmitted mice (Fig. 3). These 
preliminary results also indicate that hypertonic microinjection is at least comparable to 
conventional, laser, and Piezo microinjection methods for generating germline-transmitted 
chimeras. 
Technically, the differences between conventional microinjection and hypertonic 
microinjection are that later method uses the 0.2 M sucrose microinjection medium, a 
microinjection pipette with a smaller diameter, and very fast microinjection. The developing 
hypertonic microinjection method may be an useful alternative for generating chimeric or F0 
mice. 
2.6 Optimal method of generating chimeras depends on embryo stage 
Depending on embryo stage, germline transmitted chimeric mouse or F0 mouse are generated 
by microinjection, well sandwich aggregation, or coculture methods. Typically, embryos 
recovered from 0.5-dpc (zygotes) and 1.5-dpc (2-cell embryos) mice for use in generating 
chimeras are usually no better than 2.5-dpc and 3.5-dpc (Repentigny & Kothary, 2010). In 
practice, therefore, 3.5-dpc and 2.5-dpc embryos are more commonly used. For blastocysts, 
conventional microinjection is the only choice. For pre-blastocyst embryos, almost all methods 
are possible. However, the optimal method may differ. The comparative efficiency of methods 
for generating germline transmitted chimeric mouse or F0 mouse is summarized at the Table 
5, which also might be adopted for generation of ES cell-derived mouse via 4n embryos. 
 
Embryo stage 
2.5-dpc  3.5-dpc 
3-cell to 5-cell 
embryo 







microinjection + + +  + +++ 
Hypertonic 
microinjection ++ +++ +++  + +− 
Laser-assisted 
microinjection + + +  + +− 
Piezo-driving 
microinjection + + +  + +− 
Well sandwich 
aggregation ++ +++ +++  − − 
Single embryo 
aggregation +− + +  − − 
Conventional 
coculture +− + +  − − 
Vial coculture + +++ +++  − − 
1Methods are compared in terms of efficiency in generating germline transmitted chimeras, required 
equipment, required skills, and operational time.  
2+++: best; ++: 2nd choice; +: 3rd choice; +−: not suggested −: not good at all. 
3Compacting and compacted morulae can be cultured in Ca++-, Mg++-free PBS for 30–60 min to reveal the 
blastomeres. In some cases, approximately 10 ES cells can be directly microinjected into an embryo proper. 
Table 5. Comparative efficiency of methods for generating germline-transmitted chimeric 
mouse or F0 mouse1,2 
 




Currently, the most common techniques for generating chimeric mice or ESC-derived mice 
are microinjection or well sandwich aggregation. Single denuded embryo aggregation or 
coculturing with ES cells are less common alternatives because the efficiency in generating 
chimeras is inferior to that of microinjection and well sandwich aggregation. Thus, both 
methods are rarely employed. However, due to systemic limitations and the disadvantages 
of conventional microinjection, aggregation, and coculturing, new methods are needed. 
Recently, my laboratory developed an alternative simple, inexpensive, and reproducible 
method for mass production of chimeric embryos by coculturing 2.5-dpc denuded 8-cell 
embryos and/or compacting morulae with ES cells in 1.7-mL Eppendorf vials (micro test 
tube). This vial coculture method has significantly fewer technological and instrumental 
problems than existing methods. The resulting chimeras have significant levels of chimerism 
(including 100% coat color chimerism) and high germline transmission rates. 
Previous studies showed that microinjecting ES cells into 2.5-dpc 8-cell embryos could 
produce 100% coat color chimerism. However, due to the tight space between ZP and 
blastomeres, one must be very careful to avoid damaging blastomeres while microinjecting. 
Thus, the method is rarely adopted. Using a laser pulse or Piezo-driving equipment to assist 
introducing ES cells into the subzonal cavity of 8-cell embryos could have superior 
efficiency in generating ESC-derived F0 chimeras (100% coat color chimerism), which are 
equivalent to ESC-derived mice. However, only few studies have adopted either method 
due to the skill and/or extra expensive instruments needed.  
Recently, my laboratory revealed that ES cells microinjected into the subzonal cavity of 2.5-
dpc embryos in a microinjection medium supplemented with 0.2 M sucrose could efficiently 
generate chimeric embryos with high percentages of chimerism and viable, healthy, 
germline transmitted F0 ES-cell mice.  
Both vial coculture and hypertonic microinjection methods are useful alternatives for 
producing germline chimeric or F0 mice effectively, efficiently, and reliably.  
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1. Introduction 
1.1 Toxicity assays 
For most of their lives, humans are exposed to a variety of chemicals from different sources. 
The characterization of chemicals’ toxicity implies the necessity to have available reliable 
testing methods to assess their capability to produce adverse effects on living organisms. 
Thus, it is necessary to acquire a battery of relevant internationally agreed methods to be 
employed by governments, industry and independent laboratories to assess the safety of 
chemicals. Presently, a set of validated tests is widely used to analyze the toxicity of 
chemicals and pharmaceutical drugs and to ensure their safety, and is recognized for this 
purpose (OECD, 2008; Stummann et al., 2009). 
OECD Guidelines require in vivo studies to comply with the human health risk assessment 
process before registering and authorizing the use of chemicals. Toxicity guidelines 
characterize the adverse effects against the target organism that are attributable to exposure 
to the tested chemical with two main purposes in mind: the hazard identification and risk 
assessment deriving from exposure to the assessed chemical (Estevan et al., 2011). 
Currently, the OECD has at least one in vivo validated guideline for testing the following 
endpoints: skin sensitization, skin and eye irritation and corrosion, mutagenicity, acute 
toxicity, target organ systemic toxicity (repeated daily dose for 28 days, 90 days, and for 
more than 12 months), carcinogenicity and toxicity to reproduction (screening, 
teratogenicity and two generations). All these OECD Guidelines have to be usually applied 
for a safe and consistent risk assessment, even when the chemical’s hazard is not related to 
the tested target system. In this way, some of the most relevant tests are 
reproduction/developmental studies because the endpoints assessed in these protocols and 
the non-observed-adverse-effect levels (NOAELs) obtained are typically taken into account 
not only for reproductive toxicity testing, but also for the risk assessment of general 
systemic effects. For example, the NOAELs of systemic maternal toxicity in the 
teratogenicity study are frequently considered for risk characterization in short-term 
exposure scenarios.  
Guidelines for testing toxicity to reproduction are also highly relevant because the effects of 
chemicals or drugs on germ cells or early embryos may lead to infertility or impaired 
development of pre-implantation embryos, and might result in embryotoxic or teratogenic 
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effects in the progeny (Spielmann, 2005; Krtolica et al., 2009). This is the reason why toxicity 
to reproduction is required in all government regulations for the authorization and 
regulation of most chemicals. For example, extensive screening and multi-generation studies 
(including teratogenicity, fertility and development) are required for registering 
agrochemicals. 
1.2 Necessity of cellular assays in toxicology 
It is obvious that the application of an in vivo test is very expensive, time-consuming and 
involves lots of ethical concerns relating to the use of animals for experimentation purposes. 
Nevertheless, we now go on to illustrate these concerns with some figures. Höfer and 
coworkers (2004) estimated the number of animals needed to apply each in vivo test. It can 
be easily concluded that the number of animals needed to test a single chemical with all the 
above-mentioned available tests is around 4,710. Fleischer (2007) also estimated that the cost 
of this set of tests would be around € 1,800,000.  
Apart from this, the relevance of many in vivo toxicological assays is questionable as regards 
human health because there are times when the animal model is not representative because 
of inter-species differences in pharmacokinetics and toxicokinetics (Wobus and Löser, 2011). 
Such inter-species differences have been detected, for example, in the cases of 13-cis retinoic 
acid (Hendrickx, 1998) and thalidomide (Nau, 1993; Tzimas et al., 1994). Specifically, the 
dramatic consequences of the teratogenic effects of thalidomide on humans urgently lead to 
the need for new, optimized human-specific test systems. 
Therefore due to the aforementioned economical, logistical and ethical concerns, it is 
obvious that the availability of fast, safe, reliable and high throughput alternatives to animal 
experimentation methods would be extremely welcomed by industry, researchers and 
regulatory bodies. Cellular methods fit all these requirements and, due to the availability of 
cellular cultures for all tissues, these methods are good candidates to be employed for 
testing toxicity in all the possible target organ systems (liver, skin, heart, reproduction, etc.).   
1.3 Roles of stem cells in toxicological studies 
Stem cells may play several relevant roles in cellular assays for testing toxicity, and these 
roles can be played in either embryotoxicity or in organogenesis for testing toxicity in adult 
tissues (Figure 1). Indeed, embryonic stem cells (ESC) or reprogrammed-induced 
pluripotent stem cells (iPSC) can be employed through forced directed differentiation 
protocols as a source of adult human cells cultures (hepatocytes, neurons, and others) that 
would be further used for the in vitro testing of respective target organ toxicity 
(hepatotoxicity, neurotoxicity, etc.). This application is useful because it avoids the sacrifice 
of animals for experimentation purposes, allows the use of human cells which usually have 
a limited availability and avoids the need for the above-mentioned interspecies 
extrapolation. This application of stem cells related with organogenesis will be commented 
and explained in more detail in another section of this chapter. Nonetheless, it is relevant to 
remark that the recent iPSC applications in toxicology and drug research provide new 
alternatives to the standard routine tests performed by industry and offer new chemical 
safety assessment strategies (Laustriat et al., 2010; Trosko and Chang, 2010). 
The other role of stem cells in toxicological studies relates to embryotoxicity. Indeed, the 
testing methods relating to these applications take advantage of ESCs to differentiate in adult 
tissues and help the studies into how these differentiation processes are altered by exposure to 
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the tested chemical (Figure 1). The most important and relevant factor for embryotoxicity 
testing is that ESCs mimic early in vivo embryonic development processes and show tissue-
specific expression profiles (Wobus and Löser, 2011). In combination with three-dimensional 
cultures supported by extracellular matrix proteins, stem cell-based systems can mimic the 
microenvironment of the in vivo niche, which is especially relevant in humans for testing 
embryotoxicity (Trosko and Chang, 2010) and for organogenesis (Miki et al., 2011; Lock and 
Tzanakakis., 2009) and further assay of toxicity on the generated cell cultures. 
Developmental toxicity assays with stem cells occupy a prominent position within the 
available battery of cellular assays since some studies have demonstrated that stem cells can 
be used to understand the processes underlying organogenesis, as shown in the case of the 
heart (Miller et al., 2008). Therefore, the study of the interferences in stem cell differentiation 
caused by chemicals can be used to detect potential developmental toxicants. An additional 
advantage of these models is that genetic molecular approaches enable not only for an 
exhaustive analysis of which genes are affected by each substance, but also for the 
subsequent research into the mechanisms of action underlying the teratogenic or 
embryotoxic effects caused by the assessed chemical (Pamies et al., 2011). 
Details of ESCs-based embryotoxicity testing methods will be provided in the following 
sections of this chapter, but can be divided into four categories (Table 1): the validated 
Embryonic Stem cell Test (EST); variations of the EST using molecular endpoints as 




EST ESAC, 2002; Glenschow et al., 2000, 
2002 and 2004  
Variations of validated EST with molecular end-
points 
Bremer et al., 2001; Buesen et al., 2009; 
Osman et al., 2010; Romero-Lucena., 
2010; Seiler et al., 2004; Stummann et 
al., 2007; van Dartel et al., 2009; 2010a, 
2010b, 2011a, 2011b 
ACDC Barrier et al., 2010; Jeffay et al., 2010 
Human cell-based embryotoxicity Addler et al., 2008a, 2008b  
Table 1. Embryotoxicity testing methods employing embryonic stem cells 
The cellular methods for testing embryotoxicity deserve special mention because, despite 
the validated in vivo OECD guidelines for testing toxicity to reproduction covering fertility, 
teratogenicity and development, there are no specific guidelines available for exclusively 
testing embryotoxicity (Pamies et al., 2011). Indeed, this is a major gap because a guideline 
for this purpose would allow the detection of developmental toxins in early development 
stages without awaiting teratogenicity. 
There are other well-established alternative methods for testing embryotoxicity with 
endpoints relating to differentiation, such as the frog embryo teratogenesis assay on 
xenopus (Bantle et al., 1990), the chicken embryo toxicity screening test on chicken embryos 
(Jelinek et al., 1985), the micromass assay using mouse embryonic mesenchymal cells (Flint, 
1993; Spielmann, 2005), and the mammalian whole embryo culture assay using mouse 
(Sadler et al., 1982) or rat (Schmidt, 1985; Cockroft and Steele, 1987) embryos. Nevertheless, 
all these methods are not based on stem cells and are not of interest in this book.  
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the tested chemical (Figure 1). The most important and relevant factor for embryotoxicity 
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Fig. 1. Role of stem cells in toxicity testing. 
1.4 Earlier toxicity assays with stem cells 
Some of the earliest attempts for testing cytotoxicity, embryotoxicity or teratogenicity 
screening using mammalian cells date back to between two and three decades (Kimmel et 
al., 1982; Schwetz et al., 1991). The most important drawback of all these assays is that they 
rely on somatic cells, which do not entirely reflect the reaction of embryonic cells to toxic 
compounds (Wobus and Löser, 2011). 
Embryotoxicity tests include the analysis of the toxic effects of chemicals on embryonic cells 
in differentiation, whereas cytotoxicity assays measure the chemical-induced alterations of 
metabolic pathways or the structural integrity of cells, which may or may not be directly 
related to cell differentiation (Wobus and Löser, 2011). Both cytotoxicity and embryotoxicity 
assays have been applied with pluripotent stem cells. The determination of cytotoxic effects 
of chemicals based on the colorimetric MTT test for cellular growth and survival (Mosmann, 
1983) was performed with murine ESCs (Laschinski et al., 1991), showing greater sensitivity 
to selected embryotoxic agents than mouse adult cells (fibroblasts). 
In order to overcome the limitations of cytotoxicity assays to determine embryotoxic effects, 
the ESC-derived embryoid body (EB) model was introduced (Wobus et al., 1988; Wobus et 
al., 1991). The ESCs differentiated in EBs for 5-7 days develop in vitro into the progenitor 
cells of all three primary lineages of ectoderm, mesoderm and endoderm (Wobus and 
Boheler, 2005). The fundamentals of the EB model were that early developmental processes 
simulated by EB differentiation would be affected by exposure to toxic chemicals and, 
consequently, specific differentiation processes would be inhibited or accelerated. 
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One of the first experiences to illustrate how embryonic cells could be used for testing 
embryotoxicity was the case of retinoic acid. There is evidence that retinoic acid in vivo acts 
as morphogen by forming a concentration-dependent gradient along embryonic axes, thus 
affecting the antero-posterior patterning of the body axis and limbs (Kessel and Gruss, 
1991). High concentrations of retinoic acid applied to mouse ESCs during early EB 
differentiation (days 0-2) revealed increased neural-specific transcript levels and 
significantly induced neuronal differentiation (Fraichard et al., 1995; Strubing et al., 1995), 
whereas retinoic acid application at lower concentrations applied between days 2 and 5 
induced mesodermal, specifically skeletal muscle and partially cardiac differentiation 
(Wobus et al., 1994). This is in line with the developmental processes in the EB where the 
maximum expression levels of neural plate morphogenesis genes like brachyury and the 
expression of genes associated with dorsal mesoderm specification were observed at around 
day 3 of EB formation (Wobus et al., 1994; Dani et al., 1997). Cardiac and vascular smooth 
muscle cells both originated (at least partially) from the lateral plate mesoderm, and were 
induced by retinoic acid when applied on days 5-7 and 7-11, respectively (Drab et al., 1997). 
Obviously, the specific temporal response of the different cell types within the EB to retinoic 
acid correlated with the retinoic acid receptor gene expression (Rohwedel et al., 1999). These 
early studies provided the basis to subsequently establish the so-called EST method. 
2. The embryonic stem cell method test (EST) 
In the past, several groups have used murine ESC to establish an in vitro embryotoxicity 
assay. Laschinsky et al. (1991) compared cytotoxicity in both ESC and mouse fibroblasts to 
assess the embryotoxic potential of teratogenic agents. The data showed that ESC were more 
sensitive to toxic agents than adult cells. Newall and Beedles (1994) measured both the 
cytotoxicity and the colony-forming potential of ESC after 7 days of culture in the presence 
of teratogenic agents. In these assays, only a few embryotoxic agents could be correctly 
classified. This was probably due to the fact that only two endpoints were selected for the 
biostatistical assessment in the ESC assays, which seems insufficient. To overcome the 
limitations of the previously mentioned ESC tests, a third endpoint value, alterations in cell 
differentiation, was introduced and linked to the two former ones (cytotoxicity in embryonic 
and adult cells). These three endpoints allow the test compounds to be classified into three 
in vivo embryotoxicity categories. 
2.1 Basis of the method 
The fundamentals for the test are that the in vitro tests of basal cytotoxicity are sufficiently 
predictive for the rodent in vivo LD50 assay (Ekwall, 1999; Spielmann et al., 1999) and that 
ESCs show alterations in their in vitro differentiation pattern when exposed to embryotoxic 
chemicals during EB differentiation (Wobus et al., 1994). The EST method is based on the 
potential of D3 mouse ESC to differentiate into beating cardiomyocytes and in determining 
how this differentiation is altered by exposure to chemicals, together with the cytotoxic 
insults in these cells and in a mouse adult cells model. 
Two permanent mouse cell lines are used: D3 embryonic stem cells to represent embryonic 
tissue and 3T3 fibroblasts to represent adult tissue. The test was developed when D3 mouse 
ESC were discovered to be able to form EBs in the absence of the cytokine leukemia 
inhibiting factor which, after 10 days of culture, spontaneously differentiated into 
cardiomyocytes.  
 




Induced pluripotent stem cells 


























Fig. 1. Role of stem cells in toxicity testing. 
1.4 Earlier toxicity assays with stem cells 
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al., 1991). The ESCs differentiated in EBs for 5-7 days develop in vitro into the progenitor 
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simulated by EB differentiation would be affected by exposure to toxic chemicals and, 
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day 3 of EB formation (Wobus et al., 1994; Dani et al., 1997). Cardiac and vascular smooth 
muscle cells both originated (at least partially) from the lateral plate mesoderm, and were 
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ESCs show alterations in their in vitro differentiation pattern when exposed to embryotoxic 
chemicals during EB differentiation (Wobus et al., 1994). The EST method is based on the 
potential of D3 mouse ESC to differentiate into beating cardiomyocytes and in determining 
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The basis of the EST protocol is summarized in Figure 2. The test comprised the 
morphological analysis of beating clusters in differentiating EBs (seeded in single wells of 
multiwell plates) and the determination of those concentrations of the test substance at 
which cardiac differentiation was inhibited by 50% after 10 days of exposure (ID50). The 
cytotoxic effects on D3 and 3T3 cells were estimated by determining those concentrations of 
the test substance at which proliferation was inhibited by 50% after 10 days of exposure, 
yielding IC50 D3 and IC50 3T3, respectively. On the basis of these 3 endpoints, a biostatistical 
prediction model formed by three different functions helped assign the tested chemical to 
one embryotoxicity category (strong, weak or non embryotoxic) (Genschow et al., 2000; 
Genschow et al., 2002; Spielmann et al., 2001) (Figure 1). This method is currently validated 
by the European Centre for Validation of Alternative Methods (ECVAM) as a screening 
assay for potentially embryotoxic chemicals (ESAC, 2002).  
2.2 EST performance  
The testing of the 20 test chemicals employed in the EST validation study provided 78% 
accuracy (correct classifications related to the in vivo data) (Genschow et al., 2004). The 
highest precisions were detected for weak and strong embryotoxic chemicals, which were 
correctly detected in 83% and 81% of cases, respectively (Genschow et al., 2000). The poorest 
precision was recorded for the detection of non embryotoxic compounds (70%). Finally, the 
predictability for strongly embryotoxic chemicals was 100%, while that for non- and weakly 
embryotoxic compounds was similar (70 and 72%, respectively), which is considered 
sufficiently high. 
2.3 Limitations of EST 
EST has several limitations. Since D3 mouse ESCs are differentiated as EBs in ‘‘hanging 
drops’’, this test is laborious and time-consuming. EST does not consider molecular 
endpoints to detect cardiac differentiation (formation of beating cardiomyocytes) (Schmidt 
et al., 2001; Piersma, 2004), and it is an assessment based exclusively on histological 
considerations which introduces a high degree of variability. The inclusion of differentiation 
markers of the ectoderm, mesoderm and endoderm lineages and the analysis of the tissue-
specific gene expression have been recommended as additional endpoints for the purpose of 
improving EST’s predictability on the basis of better differentiation assessment. 
As with most in vitro methods, the EST is limited by lack of metabolic competence. This lack 
has been recognized as another potential factor to affect the EST’s experimental outcome 
and the correct classification of tested substances (Verwei et al., 2006). Experiments which 
attempted to add the S9 mix, the mix usually applied as a source of exogenous metabolic 
activation enzymes, failed because it is toxic for D3 mouse ESC. Therefore, the consortium of 
the ReProTect project (Integrated Project of the European Union funded within the 6th 
Framework Programme, including 35 partners focused on alternatives to animal tests for 
reproductive toxicity with the scope of pre-validating and validating the brightest ones) 
recommended other test systems to analyze the potential toxicity of those compounds that 
require metabolic activation (Marx-Stoelting et al., 2009). Other relevant limitation of the 
EST is that this is also incapable of detecting teratogenic chemicals with mechanisms acting 
beyond the initial embryo differentiation steps.  
This method needs an intermediate level of technical difficulty because it requires two 
endpoints and the cultures of two different cell lines. In addition, it does not yield 
 
Embryonic Stem Cells in Toxicological Studies 
 
219 
information about the morphological alterations caused by the teratogen as other methods 
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Fig. 2. Embryonic Stem cell test (EST) method. 
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information about the morphological alterations caused by the teratogen as other methods 
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Fig. 2. Embryonic Stem cell test (EST) method. 
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3. Proposed variations of the EST based on molecular endpoints 
As stated in the previous section, the EST has several limitations, one of which is the most 
relevant: lack of molecular endpoints for a reliable assessment of the degree of 
differentiation achieved by EBs. Indeed, ECVAM has recommended the inclusion of 
molecular endpoints in the EST with a view to improving its performance (Spielman et al., 
2006). A great deal of work has been done to follow this recommendation in an attempt to 
introduce gene expression as biomarkers of differentiation. A second line of work has also 
been introduced, that of reducing the technical complexity of the EST using a single cell 
line.  
3.1 Use of biomarkers of differentiations as endpoints 
Previous studies about lineage-dependent effects of retinoic acid on ESC differentiation 
(Wobus et al., 1994) and the application of reporter gene constructs controlled by cardiac-
specific promoters (Kolossov et al., 1998) have demonstrated that an ESC differentiation 
model is suitable to be analyzed at a cellular level. Genes coding for tissue-specific proteins 
are expressed in the course of ESC differentiation in a pattern which closely resembles the 
time pattern observed during mouse embryogenesis (Rohwedel et al., 2001). For example, 
cardiac-specific transcription factor Nkx2.5, expressed in cardiac precursor cells during 
embryogenesis in vivo, is the first cardiac-specific gene expressed during EB development in 
parallel to the α1 subunit of the L-type Ca2+ channel (Fässler et al., 1996), followed by the 
expression of α- and β-myosin heavy chain isoforms. 
The recent progress made in improving the EST has underlined previous demands to 
implement new embryotoxicity testing strategies using ESCs by analyzing tissue-specific 
genes via the reporter gene expression, automated high-throughput screening for changes in 
gene and protein expression patterns using microchip arrays for transcriptome and 
proteome analyses, and the application of human ESCs (Rohwedel et al., 2001). 
Reporter gene assays for developmental toxicity, specifically for cardiac toxicity (Bremer et 
al., 2001), have been included in the EST. Cardiac markers α-myosin heavy chain and α-actin 
(both quantified by fluorescence-activated cell sorting (FACS)) have been successfully 
employed instead of the microscopic observation of beating EBs to determine cardiac 
differentiation after exposing D3 EBs to model embryotoxic test substances (Seiler et al., 
2004; Seiler et al., 2006). The FACS-based EST has been successfully adopted for assessing 
developmental toxicity (Buesen et al., 2009). While the molecular FACS-EST shows the same 
sensitivity as the validated EST for the classification of chemicals, test duration is reduced 
and almost identical ID50 values were obtained for ten representative compounds of the 
three classes, indicating that FACS analyses values can serve as a new EST toxicological 
endpoint.  
Other potential biomarker genes of embryotoxicity that may be used in early development 
stages are Pnpla6, α-fetoprotein, nestin and Vgfa. All these genes displayed statistically 
significant reductions in their respective expressions after 5 days of exposure to a non 
cytotoxic dose of 50 ng/ml of embryotoxic 5-fluorouracil (Table 2) (Romero, 2010). These 
marker genes also offer an advantage over the conventional EST method as they are 
recordable after 5 days of exposure instead of the 10 days of differentiation needed for 
obtaining a beating cardiomyocytes. Alpha-fetoprotein has also been independently 
reported as a very sensitive biomarker of exposure to 5-fluorouracil (Pamies et al., 2010). 
 








Table 2. Expression of several marker genes after 5 days exposure of D3 mouse embryonic 
stem cells in differentiation to 50 ng/ml embryotoxic 5-fluorouracil. The gene expression 
was indicated as a percentage as regards a differentiated control under the same 
conditions, but in the absence of 5-fluorouracil. In all cases, differences in expression as 
regards the control were statistically significant for at least p<0.05. (Data taken from 
Romero, 2010). 
Inclusion of additional differentiation endpoints, specifically of the neural lineage, has been 
requested by researchers and authorities (Spielmann et al., 2006). The purpose of using such 
systems is to correctly classify the substances that were not identified as embryotoxic in the 
conventional EST. Inclusion of parameters for neuronal differentiation into the EST would 
allow, for example, classification in accordance with the in vivo data of methylmercury as a 
highly embryotoxic, whereas the conventional EST failed to correctly classify this compound 
(Stummann et al., 2007). In order to increase the number of molecular markers as endpoints 
of embryotoxicity testing, real-time Taqman RT-PCR analyses have been adopted for the 
EST in pilot studies (zur Nieden et al., 2004). 
Peters and co-workers determined the relative embryotoxic potential by using a modified 
EST screening system (Peters et al., 2008). In this study, 12 compounds were investigated in 
a modified EST performed in 96-well plates. Test substances were applied on day 3 of 
culture for 10 days, and the assay did not involve the preparation of EBs. This newly revised 
high throughput EST allowed the analysis of a larger number of substances, less manual 
work, yet it yielded data comparable to those obtained with the conventional EST. 
Present efforts to improve the EST now address the application of additional lineage-specific 
markers to define additional toxicological endpoints. Other than cardiac markers, markers 
of neuronal, bone and cartilage development are included. However, this will prolong the 
test duration from 7-10 to 30, or even 32 days (Marx-Stoelting et al., 2009). In the future, 
novel molecular endpoints and reporter-based systems will have to be included in the EST 
(Rohwedel et al., 2001; Marx-Stoelting et al., 2009; Spielmann, 2009). Such improvements 
will also be required to establish EST-like tests with human ESCs. 
3.2 Use of transcriptomics and proteomics as endpoints 
The identification of embryotoxic compounds on the basis of analyzing the alterations they 
cause in the expression of genes and proteins relating to the differentiation of embryonic 
stem cells has been proved possible (van Dartel et al., 2009; 2010a; 2010b; 2011a; 2011b; and 
Oshman et al., 2010). By following this methodology in a procedure that includes a 4-day 
assay (three days for embryonic body formation and one additional day to expose cells to 
the assessed chemical), the set of genes called "van_Dartel_heartdiff_24h" was able to 
correctly predict the embryotoxicity of 83% of the assessed chemicals (ten correct predictions 
of a total of 12 assessed chemicals, where two non embryotoxic chemicals were wrongly 
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classified as embryotoxic) (van Dartel et al., 2011a). In the same study, the group of genes 
called "EST biomarker genes" correctly predicted the embryotoxicity of eight of the 12 
assessed chemicals (67%). Here the mistakes corresponded to one non embryotoxic and 
three embryotoxic chemicals, respectively (van Dartel et al., 2011a). 
Protein markers can also be used to detect exposure to embryotoxic chemicals. Osman and 
coworkers found that the embryonic bodies formed from day 3 of differentiation of D3 cells, 
which were further exposed to embryotoxic monobutyl phthalate for 24 hours, expressed 33 
proteins in a differential way, including cardiomyocytes biomarkers (whose expression was 
repressed if compared with controls) and chromatin modulator enzymes (Osman et al., 
2010).  
3.3 The ACDC method 
The Adherent Cell Differentiation and Cytotoxicity (ACDC) assay is a test to establish a 
model system to assess the chemical effect using a single cell culture (instead of two as the 
EST does) in order to improve feasibilities for throughput assays (Barrier et al., 2010). The 
ACDC assay uses quantitative markers for both the differentiation degree and cell 
proliferation. In this assay, pluripotent J1 mouse ESCs are plated in a 96-multiwell plate and 
further cultured in differentiation medium for 9 days. Afterward, each well is assessed for 
the cell number and differentiation to cardiomyocytes (using quantitative in-cell Western 
analysis for myosin heavy chain protein normalized with the cell number). This method has 
already proved suitable for testing the effects of haloacetic acids and their major metabolites 
(Jeffay et al., 2010), but has still not been validated. 
4. Human stem cells for screening cytotoxicity and embryotoxicity 
Development of human ESC-based in vitro systems for testing the embryotoxicity of 
chemicals implies significant progress. The use of human ESCs in in vitro methods would 
enhance their predictability and avoid problems associated with the interpretation of the 
results obtained with animal-based assays in a human context (Wobus and Löser, 2011). For 
example, species-specific differences between mouse and human pre-implantation 
development, as in DNA methylation, DNA repair and the expression of those genes 
involved in drug metabolism, may interfere with the correct interpretation of animal studies 
regarding their significance to humans (Krtolica et al., 2009). The use of human ESC-based 
test systems could avoid the incorrect classification of chemicals due to inter-species 
variations and would, consequently, improve consumers’ safety. 
Adler and co-workers (2008a) provided proofs that human ESCs are a relevant in vitro 
model for developmental toxicity testing. They studied the cytotoxic effects of well-known 
embryotoxicants on human ESC, human ESC-derived progenitors and human foreskin 
fibroblasts. As observed in the respective murine cells, all-trans retinoic acid and 13-cis 
retinoic acid had a stronger cytotoxic effect on pluripotent stem cells than on fibroblasts, 
while the mesenchymal progenitors deriving from human ESC displayed the strongest 
sensitivity to both compounds. While all-trans retinoic acid and 13-cis retinoic acid 
substances revealed comparable cytotoxic effects on human ESC in this study, only all-trans 
retinoic acid was seen to be cytotoxic in mouse ESC in previous analyses. This suggests the 
necessity of developing human ESC-based assays to assess human-specific developmental 
toxicity.  
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In a second study, Adler and co-workers arranged the test system according to the EST, but 
used human instead of mouse ESC (Adler et al., 2008b). The cytotoxic effects of the two well-
known developmental toxicants, 5-fluorouracil and all-trans retinoic acid, on human ESCs 
and human fibroblasts were similar to those previously observed in mice systems. However, 
testing for the potential cytotoxic effects on pluripotent stem cells does not suffice to detect 
the developmental toxicity of chemicals that affect developmental processes (Rohwedel et 
al., 2001). These authors proposed markers of undifferentiated cells such as Oct4, hTert and 
Dusp6, as well as markers of neural plate morphogenesis and early cardiogenesis, such as 
Brachyury and GATA-4 for monitoring cardiac differentiation, thus demonstrating that these 
markers may have the potential to serve as endpoints for developmental toxicity studies 
using a humanized EST (Adler et al., 2008b). 
Despite the progress made, numerous problems have to be solved before human ESC-based 
assays can be implemented into routine procedures for the developmental toxicity testing of 
drugs and chemicals. These problems include the establishment of reliable and reproducible 
differentiation procedures that can be performed in a high-throughput format. The 
predictability, the sensitivity and specificity of the respective test systems for a wider panel 
of chemicals are still to be shown. In addition, very few substances have been tested in the 
different approaches. Furthermore, human ESC-based systems may have the capacity to 
predict human-specific embryotoxic effects which cannot be measured with mouse cell 
systems due to species-specific differences. However, the superiority of human ESC-based 
systems over existing animal in vitro tests for developmental toxicity has still to be shown 
and, in this context, the use of different human ESC lines would prove advantageous. 
5. Induced pluripotent stem cells in toxicological studies 
iPSC play a prominent role in their use as a tool in toxicity tests in the embryotoxicity field 
or as a source of cellular tissues for testing toxicity in adult tissues (Figure 1). These two 
applications are particularly interesting when used with human cells because they will 
eliminate uncertainties deriving from the necessary inter-species interpolation when animal 
cells are used. 
5.1 Applications in embryotoxicity studies 
The successful reprogramming of adult somatic cells into a ESC-like state through genetic 
manipulation (Yu et al., 2007; Takahashi et al., 2007) offers a new opportunity for toxicology 
assay development as reprogrammed somatic cells possess very similar characteristics to 
those of human ESC. Nevertheless, some questions arise as to the use of iPSC for 
toxicological assays. One is whether the different epigenetics of reprogrammed iPSC (Surani 
et al., 2008; Han and Sidhu, 2008) might influence responses to a toxic insult. The other 
challenge is that the derivation of iPSC involves permanent genetic modifications to somatic 
cells due to the use of the viral transduction of recombinant DNA (Yu et al., 2007; Takahashi 
et al., 2007). Integration of recombinant DNA into the genome of iPSC lines might lead these 
cells or their differentiated progenies to behave differently from normal human cells, 
particularly when exposed to toxic challenge. 
The application of human iPSC in embryotoxicity testing might be a promising tool, as well 
as ESC (Heng et al., 2009). However on the basis of the recently reported inconveniences 
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caused by reprogramming, future work has to show whether human iPSC will be applicable 
and offer advantages over human ESC in the developmental toxicology field (Gore et al., 
2011). 
In the future, it is possible that iPSC lines for toxicology screening may also be derived from 
reprogramming primary explanted hepatocytes and cardiomyocytes because such somatic 
lineages have wide-ranging applications in both toxicology and pharmacology screenings 
(Heng et al., 2009). 
5.2 Applications in organogenesis and target organ toxicity testing 
The ability to generate iPSC from somatic cells by the forced expression of reprogramming 
factors Oct3/4 and Sox2, along with either Klf4 or Nanog and Lin28, raises the possibility of 
generating patient-specific cell types of all lineages. Differentiated cell types produced from 
patient’s iPS cells have many potential therapeutic applications, including their use in tissue 
replacement and gene therapy (Si-Tayeb et al., 2010). They also provide a platform for drug 
toxicity screenings. Generation of hepatocytes from iPSC is a particularly appealing goal 
because this parenchymal cell of the liver is associated with several congenital diseases 
(Burlina, 2004) and is the main site of xenobiotic control. 
Mouse iPSC were generated from fibroblasts (Si-Tayeb et al., 2010), and embryos were then 
produced from this iPSC tetraploid complementation using transgenic mice which 
ubiquitously express enhanced green fluorescent protein (EGFP). When embryos were 
generated from mouse iPSC, from which EGFP is absent, all the embryos, including their 
livers, lacked the EGFP expression except in extra embryonic tissues. A thorough 
examination of iPSC-derived embryos and their livers revealed that they appeared to be 
identical to controls. These livers were examined, and the expression of those proteins that 
are characteristic of specific cell types was identified to reveal that, like the control fetal 
livers, the iPSC-derived livers contained hepatocytes (HNF4a positive), endothelial cells 
(GATA4 positive), sinusoidal cells (LYVE1 positive) and Kuppfer cells/macrophage (F4/80 
positive). 
In the cardiogenesis field, the latest studies have revealed that mouse iPSC can differentiate 
into cardiomyocytes by EBs formation or through the use of collagen IV-coated dishes and 
feeder cells (Narazaki et al., 2008; Mauritz et al., 2008). However, it is unknown whether 
iPSC can differentiate into cardiomyocytes without EBs formation and without using 
collagen IV-coated dishes or feeder cells. In addition, myocardial cell differentiation 
efficiency has still not been determined as being uniform or diverse in different iPS cell lines 
(Kaichi et al., 2010). 
The transcription factors, such as GATA4 and Nkx2.5, expressed in the lateral mesoderm 
play important roles in the following heart developmental processes (Molkentin et al., 1997; 
Kasahara et al., 1998). The activities of cardiac transcription factors are regulated, in part, by 
histone acetyltransferases and histone deacetylases (HDACs). In the treatment of ES cells 
with trichostatin A (TSA), a specific HDAC inhibitor has been reported which not only 
induces the acetylation of both GATA4 and histones, but facilitates their differentiation into 
cardiomyocytes (Kawamura et al., 2005). 
In the very near future, it is expected that other cellular types other than hepatocytes and 
cardiocytes can be successfully obtained, as shown in Figure 1. These cell cultures would 
also be suitable for use in toxicity studies as platforms for testing in vitro toxicity on adult 
cells. 
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6. Conclusions and final remarks 
Stem cells are an excellent platform for testing embryotoxicity in vitro on the basis of these 
cells’ capacity to mimic the embryo formation process. Nevertheless, much effort and hard 
work is still needed to find good suitable endpoints for monitoring different differentiation 
stages. There is also the urgent need to go ahead with the characterization of those models 
employing human cells, either ESC or those from reprogrammed iPSC. 
Stem cells also represent a good opportunity to generate adult tissues to test toxicity in such 
tissues,  which again is especially relevant in humans. Nevertheless, the development of 
good differentiation protocols to allow the generation of a variety of cell types apart from 
hepatocytes and cardiocytes is still needed.  
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differentiation model. FASEB J 11:905–915. 
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including the selection of a practical battery of cell tests for prediction of acute 
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caused by reprogramming, future work has to show whether human iPSC will be applicable 
and offer advantages over human ESC in the developmental toxicology field (Gore et al., 
2011). 
In the future, it is possible that iPSC lines for toxicology screening may also be derived from 
reprogramming primary explanted hepatocytes and cardiomyocytes because such somatic 
lineages have wide-ranging applications in both toxicology and pharmacology screenings 
(Heng et al., 2009). 
5.2 Applications in organogenesis and target organ toxicity testing 
The ability to generate iPSC from somatic cells by the forced expression of reprogramming 
factors Oct3/4 and Sox2, along with either Klf4 or Nanog and Lin28, raises the possibility of 
generating patient-specific cell types of all lineages. Differentiated cell types produced from 
patient’s iPS cells have many potential therapeutic applications, including their use in tissue 
replacement and gene therapy (Si-Tayeb et al., 2010). They also provide a platform for drug 
toxicity screenings. Generation of hepatocytes from iPSC is a particularly appealing goal 
because this parenchymal cell of the liver is associated with several congenital diseases 
(Burlina, 2004) and is the main site of xenobiotic control. 
Mouse iPSC were generated from fibroblasts (Si-Tayeb et al., 2010), and embryos were then 
produced from this iPSC tetraploid complementation using transgenic mice which 
ubiquitously express enhanced green fluorescent protein (EGFP). When embryos were 
generated from mouse iPSC, from which EGFP is absent, all the embryos, including their 
livers, lacked the EGFP expression except in extra embryonic tissues. A thorough 
examination of iPSC-derived embryos and their livers revealed that they appeared to be 
identical to controls. These livers were examined, and the expression of those proteins that 
are characteristic of specific cell types was identified to reveal that, like the control fetal 
livers, the iPSC-derived livers contained hepatocytes (HNF4a positive), endothelial cells 
(GATA4 positive), sinusoidal cells (LYVE1 positive) and Kuppfer cells/macrophage (F4/80 
positive). 
In the cardiogenesis field, the latest studies have revealed that mouse iPSC can differentiate 
into cardiomyocytes by EBs formation or through the use of collagen IV-coated dishes and 
feeder cells (Narazaki et al., 2008; Mauritz et al., 2008). However, it is unknown whether 
iPSC can differentiate into cardiomyocytes without EBs formation and without using 
collagen IV-coated dishes or feeder cells. In addition, myocardial cell differentiation 
efficiency has still not been determined as being uniform or diverse in different iPS cell lines 
(Kaichi et al., 2010). 
The transcription factors, such as GATA4 and Nkx2.5, expressed in the lateral mesoderm 
play important roles in the following heart developmental processes (Molkentin et al., 1997; 
Kasahara et al., 1998). The activities of cardiac transcription factors are regulated, in part, by 
histone acetyltransferases and histone deacetylases (HDACs). In the treatment of ES cells 
with trichostatin A (TSA), a specific HDAC inhibitor has been reported which not only 
induces the acetylation of both GATA4 and histones, but facilitates their differentiation into 
cardiomyocytes (Kawamura et al., 2005). 
In the very near future, it is expected that other cellular types other than hepatocytes and 
cardiocytes can be successfully obtained, as shown in Figure 1. These cell cultures would 
also be suitable for use in toxicity studies as platforms for testing in vitro toxicity on adult 
cells. 
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6. Conclusions and final remarks 
Stem cells are an excellent platform for testing embryotoxicity in vitro on the basis of these 
cells’ capacity to mimic the embryo formation process. Nevertheless, much effort and hard 
work is still needed to find good suitable endpoints for monitoring different differentiation 
stages. There is also the urgent need to go ahead with the characterization of those models 
employing human cells, either ESC or those from reprogrammed iPSC. 
Stem cells also represent a good opportunity to generate adult tissues to test toxicity in such 
tissues,  which again is especially relevant in humans. Nevertheless, the development of 
good differentiation protocols to allow the generation of a variety of cell types apart from 
hepatocytes and cardiocytes is still needed.  
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1. Introduction 
The word teratoma is derived from the Greek teratos which means “deformity” or 
“monster” and –oma which means “tumor”. Thus, the teratoma is a monster tumor. A more 
recent definition which is more elaborate and perhaps more politically correct is an 
encapsulated tumor with tissue or organ components that can be traced to derivatives of the 
three primordial germ layers; ectoderm, mesoderm, and endoderm (Rosai and Ackerman 
2004). It is easy to understand why this tumor was coined “monster” since macroscopically 
teratomas can appear as a conglomeration of tissue with different colors and textures some of 
which may be recognizable as gross anatomical structures such as hair, teeth, and limbs. The 
most extreme examples actually resemble a distorted fetus (fetiform). The initial descriptions 
of sacrococcygeal teratomas date back to ancient tablets written by Egyptian fetoscopists 
around 2500 B.C. These oddities were often attributed great significance when interpreted in 
concert with the concurrent cultural and religious beliefs. For example, ancient Egyptians 
interpreted a third foot in the middle as signifying great prosperity for the land (Oosterhuis et 
al. 2007). These cases likely represented rare sacrococcygeal teratomas containing a fully 
formed foot which has been reported in the modern medical literature (Legbo, Opara, and 
Legbo 2008). Seventeenth century illustrations demonstrate hair sprouting from a teratoma 
and at that time teratomas were thought to arise from nightmares or witchcraft while in the 
19th century they were thought to arise from perverse sexual practices (Oosterhuis et al. 2007; 
Gatcombe et al. 2004).  More recent (late nineteenth and early twentieth century) theories 
invoke cell biology principles purporting the derivation of teratomas from primitive germ 
cells. Indeed some current definitions will expand the above general definition to include their 
histogenesis from pluripotent stem cells (Oosterhuis et al. 2007). 
While at first glance, most teratomas microscopically appear as disorganized masses with 
recognizable tissue types contributed from the three basic germ layers, very little is really 
known about their composition and how they form and this information may hold 
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cells. Indeed some current definitions will expand the above general definition to include their 
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important clues to normal and abnormal development. Studying the cellular and tissue 
milieu within teratomas both in vivo and ex vivo would help in beginning to answer several 
important questions that we will address in the following sections. With this in mind, the 
objectives for this chapter are: 
Derivation of teratomas from stem cells and factors that influence their growth and 
development:  This section will address the tumorigenicity of embryonic stem cells and their 
relationship to cancer cells, some reasons why experimental teratomas have not been a hot 
focus of investigation, and factors that influence experimental teratoma formation (stem cell 
phenotype [e.g. embryonic, induced pluripotent stem cells (ES cells, iPS cells], genetic 
differences in stem cell lines, cellular and metabolic factors (e.g. mitochondrial metabolism), 
nature of the host where the teratoma grows, and site of injection (microenvironment)).  
Current technology for tracking stem cell fate, monitoring teratoma formation, and 
delineation of specific tissue types in vivo:  Ensuring embryonic cell transplantation safety 
by non-invasive in vivo detection and monitoring is a pressing need if ES cells will be used 
in the clinic. This section will review current methodologies for imaging of teratomas both 
in vivo and ex vivo. We will present some of our data using high-resolution MRI to quantify 
and delineate specific tissue types within teratomas.  
Histopathology of teratomas: This section will discuss the myriad of tissues present in 
teratomas and their significance. An overview of the most common tissue types, tissues 
rarely found, and primitive organs seen microscopically in experimentally derived 
teratomas will be presented.  
Teratomas in the study of embryonic development: We have examined teratomas derived 
from mouse, non-human primate, and human embryonic stem cells and have observed 
similarities and differences in quantities of tissue types derived from the three germ layers 
that in all likelihood have developmental implications across species. We will discuss our 
methods for semiquantifying specific tissue types from serial histological sections. We will 
present some data resulting from collaborative efforts with biomedical engineers at 
Carnegie Mellon University on the automated identification and quantification of tissue 
types from digital images of histological sections of teratomas.  This section will also discuss 
the use of teratomas as potential models for providing insight into the molecular and genetic 
mechanisms of development and tissue lineage commitment.  
Teratomas as models of disease:  This section will outline how teratomas may be used as 
sources of tissue for studying specific diseases. Disease specific genetic alterations of ES cells 
allow for production of tissue that can recapitulate in vivo diseased tissue/organs. We will 
discuss the use of teratomas as platforms for studying the toxic effects of 
compounds/molecules/intrauterine environment on embryonic development. We present 
some of our recent data using ES cells as a model for Alzheimer’s disease.  
Teratomas in the study of tumorigenesis:  This section will address the recent novel unifying 
theory of teratoma, germ cell tumor, and other tumor formation. We also introduce 
teratomas as substitute platforms for studying tumor growth and behavior. 
2. Derivation of teratomas from stem cells and factors that influence their 
growth and development  
2.1 Roots of the monster: Embryonic stem cells and cancer cells: One in the same? 
In the experimental setting, teratomas can be derived from several cell types including 
embryonic stem cells (ES cells), embryonic carcinoma cells (EC cells), embryonic and 
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primordial germ cells (PGCs), and induced pluripotent cells (iPS cells) (Aleckovic and 
Simon 2008; Blum and Benvenisty 2008, 2009; Kooreman and Wu). Embryonic stem cells 
share phenotypic and genetic characteristics of cancer cells including the ability for self 
renewal, prolonged proliferation in vitro, lack of contact inhibition, telomerase activity and 
the ability to invoke angiogenesis. However, human ES cells (hES cells) are karyotypically 
normal (i.e. diploid), often a major difference between cancer cells. In order to maintain their 
ability to self renew and perpetuate indefinitely, they require special culture conditions 
(specialized feeder cells or conditioned media on feeder free substrates such as matrigel). 
HES cells have certain molecular and genetic features used to characterize them including 
genetic and immunohistochemical expression of pluripotency transcription factors Nanog, 
Oct4, and Sox2, and expression of surface antigens SSEA3, SSEA4, TRA-1-60, TRA-1-81. The 
triumvirate of Nanog, Oct4, and Sox2 act to promote expression of self-renewal genes while 
repressing differentiation genes. Loss of Oct4 results in failure of the inner cell mass to 
develop; while loss of Sox2 and Nanog results in defective/lack of epiblast formation and 
subsequent differentiation towards trophectoderm and primitive endoderm. Several genes 
used to generate iPS cells are also linked to cancer. These include Oct4 and Sox2 which in 
combination with either Nanog and Lin28 or Myc and Klf4 can transform the somatic cell 
back to pluripotency. (Blum and Benvenisty 2008; Chambers and Tomlinson 2009; Knoepfler 
2009; Kooreman and Wu ; Lanza 2006; Loh, Ng, and Ng 2008).  
ES cells have unique epigenetic features. They maintain unique demethylated CpG islands  
allowing for increased expression of genes compared to differentiated cells. A similar 
phenomenon is present in cancer cells where a small reduction in methylation is sufficient to 
induce cancer and conversely many cancers show hypermethylation leading to inhibition of 
gene expression. Many tumor suppressor genes are also hypermethylated and silenced in 
hES cells. Certain onco-fetal genes such as survivin (BIRC5) are enhanced in 
undifferentiated hES cells and teratomas derived from them. Deletion of survivin promotes 
apoptosis in cultured hES cells and in the teratomas derived from them. Survivin is a 
protein which imparts anti-apoptotic activity and may be involved in protecting cells in 
harsh environments and is expressed in many cancers. The anti-apoptotic activity of 
survivin is generated by inhibition of caspase activity. Caspases have a key role in 
destructing Nanog implying that survivin by inhibiting caspase activity may have a role in 
hES cell self-renewal. These findings suggest that untransformed hES cells are possibly 
tumorigenic since they already have genetic hallmarks of tumors despite having no 
mutational transformation. (Blum and Benvenisty 2008, 2009; Chambers and Tomlinson 
2009; Knoepfler 2009; Kooreman and Wu ; Loh, Ng, and Ng 2008; Yu and Thomson 2008). 
2.2 Teratomas: The reviled monster 
Since first derived from the blastocyst of the developing mouse by Martin Evans and 
Mathew Kaufman at Cambridge and Gail Martin at UCSF independently in 1981, ES cell 
lines have been derived from non-human primates (1995) and then from humans by James 
Thomson in 1998 at the University of Wisconsin (Yu and Thomson 2008). In the mouse the 
same cells that produce teratomas in the experimental setting when placed back into the 
developing blastocyst (the blastocyst complementation assay) integrate into the embryo 
without tumor production and contribute to the formation of tissues derived from the three 
primordial germ layers (by definition pluripotent) and also the germ line. In fact, this is the 
test of pluripotency for potential mouse ES cells (mES cells)-the ability to form a chimera 
(Prelle, Zink, and Wolf 2002). Primarily due to ethical restraints, the chimera test of 
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important clues to normal and abnormal development. Studying the cellular and tissue 
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pluripotency is not the method used to assess whether given cells are pluripotent for non-
human primate and human cells. The gold standard has been the ability of a given collection 
of cells to form teratomas when injected into immunodeficient mice. This test and the 
production of this tumor has produced great consternation in the evolving world of 
regenerative medicine for several reasons that predominantly include time and cost 
(Dolgin). The main goal of regenerative medicine thus far has been to guide stem cells 
(whatever their origin) to differentiate into specific tissue types (e.g. cartilage, islets, heart 
muscle) to be used as new tissue for repair of injured or aging tissue. The teratoma is the 
antithesis of this philosophy; once again living up in a more figurative sense to its word 
origin roots--a monster!   
Teratoma formation by stem cells remains the last frontier to conquer before effective 
clinical trials using stem cells can be widely accepted. Already several examples exist of the 
clinical use of stem cells in animals resulting in teratoma formation (Knoepfler 2009). Cells 
for clinical use can be grown and issues concerning immune rejection of cells have been 
alleviated due to the emergence of iPS cells, cells derived from nuclear transfer, and human 
Wharton jelly stem cells (Menendez, Bueno, and Wang 2006). Several papers have addressed 
specific measures developed at the genetic and cell sorting level to combat this undesirable 
“side effect” if you will (Koch, Jordan, and Platt 2006; Kooreman and Wu ; Cao et al. 2007; 
Bulic-Jakus et al. 2006). Recently, some sentiment has arisen amongst stem cell investigators 
to abandon the teratoma assay as the measure of pluripotency in favor of 
molecular/bioinformatics approaches. In Dolgin’s recent article, Owen Witte, Director of the 
Broad Stem Cell Research Center at UCLA calls the teratoma assay; “the most ridiculous 
assay on the planet”.  
Most literature centered on teratomas derived experimentally from embryonic stem cells 
portrays teratomas as a means to an end or as an unwanted side effect in the clinic. This may 
explain the relative paucity of literature that specifically examines the factors that influence 
teratoma development from stem cells in the experimental setting. However, the specific 
articles that have focused on the teratoma shed valuable attention on how specific variables 
seem to affect the growth and characteristics of teratomas.  
2.3 Stem cell phenotype 
A single paper comparing the rates of teratoma formation using several embryonic stem cell 
types known to produce teratomas (e.g. mES, non-human primate (nhpES), hES cells) while 
controlling for variables such as site of injection, number of cells injected, phenotype of the 
host has not been published. The paper by Hentze et al comes close as it includes several 
hES cell lines, injection sites, cell numbers, and included semiquantitative histopathological 
analysis of the teratomas (Hentze et al. 2009). In a brief report, Gutierrez-Aranda et al 
(Gutierrez-Aranda et al.) demonstrated that human iPS cells produced teratomas sooner and 
at a higher rate per injection than human embryonic stem cells. In their study they used 
seven different hES cell lines and 4 iPS cell lines. They performed subcutaneous or 
intratesticular injections of 1 x 106 cells suspended in 30% matrigel. All mice (100%) injected 
with iPS cells developed teratomas regardless of injection site compared to 81% and 94% 
efficiency of teratoma production for subcutaneous and intratesticular injection of hES cells 
respectively. In addition, iPS cells developed tumors much more quickly at both sites of 
injection compared to hES cells. These authors claimed no differences in histological 
composition of teratomas based on site of injection. However, specific notation of any 
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histological differences in teratomas when compared between cell types (hES and iPS cells) 
was not made but presumably was not different. Histological analysis was defined by 
microscopic morphology and immunohistochemical markers of specific tissue lineages, but 
was not quantified. They did not report any teratocarcinomas or islands of undifferentiated 
cells in any of their teratomas. In our empiric evaluation of several teratomas (Castro and 
Ozolek unpublished observations) derived from iPS cells we have noted significant areas of 
undifferentiated, malignant appearing cells that would qualify the lesions as 
teratocarcinomas. The karyotype of the iPS cells used to derive the teratomas that we have 
examined was not available. Differences in mitochondrial metabolism within 
undifferentiated embryonic stem cells may also influence their ultimate fate. Schieke et al 
demonstrated that mES cells with the highest resting mitochondrial membrane potential 
had high metabolic rates, high resting oxygen consumption, lower rates of mesodermal 
differentiation in the absence of pluripotency culture conditions, and produced larger 
teratomas by weight compared to genetically identical mES cells with the lowest resting 
mitochondrial membrane potentials. Rapamycin treatment to inhibit mTOR activity 
produced the same results as the population of mES cells with the lowest resting 
mitochondrial membrane potential indicating a direct effect of rapamycin on mitochondrial 
function. The authors speculate that since mitochondrial metabolism is directly related to 
the production of reactive oxygen species and genomic instability, stem cell populations 
within organisms might show preferential selection of stem cells with low metabolism as a 
means to prevent deleterious genomic events over the lifespan of the organism (Schieke et 
al. 2008). This concept is important and may have implications for tumor development in 
humans as we will discuss in section 7. 
2.4 Genetic aberrations of stem cell lines and teratoma formation 
In the above article by Gutierrez-Aranda, they speculate the difference in teratoma 
production efficiency and latency between iPS and hES cells was due to subtle genetic 
differences not able to be detected by conventional G-banding karyotyping and that more 
sensitive techniques would need to be employed to answer this question (Gutierrez-Aranda 
et al.) . Two of their lines (one iPS and one hES cell line) were aneuploid, but apparently did 
not show any differences in the histological composition of teratomas derived from them 
compared to euploid cell lines. The aneuploidy was not further specified.  HES cells can 
undergo chromosomal derangements when cultured for extended periods. The most 
common aberrations noted include gains of chromosomes 12, 17, and X but others have been 
noted (Blum and Benvenisty 2008). However few studies have shown or addressed the issue 
of teratoma production from stem cells known to harbor genetic aberrations. An interesting 
paper by Karin Gertow et al at the Karolinska Institute from 2007 demonstrated hES cells 
with trisomy 12 derived from the HS181 line in culture maintained under pluripotent 
conditions (Gertow et al. 2007). HES cells with trisomy 12 were found intermingled with 
diploid cells or could be found as the predominant cell type in some colonies. Several 
interesting results from this paper:  The percentage of trisomy 12 cells in culture increased 
with passage number. The overall amount of tissues present in teratomas was roughly the 
same between teratomas derived from predominantly diploid versus predominantly 
trisomy 12 hES cells with the exception of increased renal tissue in trisomy 12 teratomas. 
The authors postulated that since approximation of metanephric mesenchyme with neural 
tubes induces development of renal tubules, reciprocal interactions between the 
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metanephric mesenchyme and abundant neural elements might be responsible for renal 
development. Interestingly, Nanog, whose expression is in large part responsible for 
maintaining pluripotency in ES cells is located on chromosome 12 and overexpression has 
been shown to induce primitive ectoderm (of which neuroectoderm is a constituent) (Darr, 
Mayshar, and Benvenisty 2006).  
In a study by Herszfeld et al at the Monash Institute of Medical Research and the Australian 
Stem Cell Centre from 2006, they examined the expression of CD30 in cell lines from germ 
cell tumors and in hES cells grown in culture (Herszfeld et al. 2006). CD30 is a member of 
the TNF receptor superfamily, is present on Reed-Sternberg cells, activated lymphocytes, 
decidual cells, and is a biomarker of embryonal carcinoma in diagnostic pathology. As 
expected, RT-PCR products and expression of CD30 was found in the embryonal carcinoma 
line cells while none was present in the hES cell lines. However, under certain culture 
conditions (serum free) hES cell lines demonstrated karyotypic abnormalities and overgrew 
the diploid population. These karyotypic abnormalities included duplications of 1q, trisomy 
12, balanced translocation between chromosomes 1 and 6 and a lesion on the long arm of 
chromosome 1 involving duplications of q2 and an inverted duplication of q3-4 
(Interestingly, many of these chromosomal aberrations are present in human germ cell 
tumors). Teratomas formed by these abnormal cell lines still differentiated into all three 
tissue types, but had a higher proportion of primitive undifferentiated cells compared to 
diploid ES cells; a feature seen in teratocarcinomas. In one hES cell line mosaic for trisomy 
12, combined indirect immunofluorescence for CD30 and FISH for the alpha-centromeric 
probe for chromosome 12 showed clear concordance between CD30 expression and the 
presence of an extra copy of chromosome 12. In addition, CD30 positive cells had lower 
levels of both spontaneous and induced apoptosis. The authors conclude that the emergence 
of CD30 expression in aneuploid cell lines may be an adaptive response of the cells to stress 
permitting survival under suboptimal conditions at the expense of DNA damage.  
Prokhorova et al showed defective pluripotency in a hES cell line that had acquired trisomy 
20 after 30 passages (Prokhorova et al. 2009). Teratomas (and embryoid bodies in culture) 
from this line were significantly smaller in size and had a decreased ratio of differentiated to 
undifferentiated tissues. Tissues present were more primitive and showed ill-defined 
glandular structures compared to teratomas derived from euploid hES cells. Similarly, Bloch 
et al demonstrated that 129/Sv mice injected with mES cells with a homozygous deficiency 
of β-1 integrin developed very small teratomas or did not develop teratomas compared to 
heterozygous deficient β-1 integrin or wild-type ES cells (Bloch et al. 1997). Other findings in 
β1-null teratomas included abnormal distribution of extracellular matrix proteins, partially 
detached basement membranes, and lack of ES cell derived endothelial cells in teratoma 
blood vessels. Interestingly, a consistent finding mentioned in a few studies is that blood 
vessels within teratomas are a chimera between host-derived and ES cell derived endothelial 
cells. This is in contrast to other tissues present in teratomas that are invariably derived 
nearly entirely from the exogenous ES cells (Gerecht-Nir et al. 2004; Gerecht-Nir et al. 2003; 
Gertow et al. 2004; Goldberg Cohen et al. 2006). 
2.5 Site of injection 
Several anatomical sites of the immunodeficient mouse are used for injection of stem cells for 
the teratoma assay. These have been chosen for their accessibility to injection, immune 
privilege status, and ample space to contain a large tumor that still allows the host animal to 
live and function. The most common sites for injection include intratesticular, subcutaneous, 
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intramuscular, and kidney capsule. Again, only a few studies have specifically addressed 
comparison of teratomas from different graft sites. Prokhorova et al injected several hES cells 
lines at four different sites (subcutaneous, intramuscular, kidney capsule, intratesticular) 
(Prokhorova et al. 2009). Subcutaneous injections were done with cells suspended in 30% 
matrigel and without matrigel. The highest efficiency of teratoma formation occurred for 
kidney capsule injections (10/10, 100%) followed by subcutaneous injections using cells 
suspended in 30% matrigel (64/68, 94%), followed by intratesticular (60%), subcutaneous 
without matrigel (33%), and intramuscular (12.5%). It should be noted, however, that all 
injections were done with approximately 1 x 106 cells although for the kidney capsule 
injections the number of cells injected was not explicitly defined. The number of injections and 
efficiencies were difficult to compare due to the wide variation in the number of injections for 
each site (range 5 [intratesticular] to 68 [subcutaneous with matrigel]). Several cell lines were 
used and it is unclear if all cell lines were used for all injection sites. This study also did not 
find any differences in teratoma composition by histological examination, but again tissue 
types were not quantified. Cooke et al demonstrated that intrahepatic injections of hES cells 
and EC cells produced rapid tumors 5-8 times larger than those obtained by subcutaneous 
injections (Cooke, Stojkovic, and Przyborski 2006). Intrahepatic tumors displayed more cystic 
areas with immature and mature tissue types, higher expression of SSEA3 (embryonic stem 
cell marker), and lower expression of nestin (intermediate filament present in early tissues 
with neuronal specification and other tissues) compared to subcutaneous tumors. They 
postulated that the microanatomy of the liver with open vascular spaces (sinusoidal system) 
and growth factors (e.g. stem cell factor) produced in the liver contribute to the rapid growth 
of teratomas. In our experience, we have achieved between 67% and 86% efficiency of 
teratoma formation when injecting between 5 x 105 and 1 x 106 nhpES cells using the 
intratesticular location.  Some evidence suggests that a post-ischemic environment at least in 
the central nervous system promotes teratoma formation. Seminatore et al transplanted 
neuroprogenitors (NPGs) derived from hES cells at various stages of differentiation ranging 
from early NPGs to differentiated NPGs into rats with either no ischemic lesion or rats with 
small or large ischemic lesions (Seminatore et al.). The early NPGs had embryoid body-like 
structures that exhibited characteristics of pluripotent stem cells and expressed markers of 
pluripotent stem cells. Teratomas formed in the formed in the central nervous system of rats of 
rats injected with NPGs with embryoid-body like structures regardless of the presence or 
absence of an ischemic lesion. In addition, large ischemic lesions significantly promoted the 
survival of transplanted early NPGs compared to sham. The authors propose that the post-
ischemic environment produces a variety of factors that promote the survival, growth, and 
differentiation into teratomas from an undifferentiated population of ES cells. In the study by 
Hentze et al from Singapore, they injected several hES cells lines into kidney capsule, 
intramuscular, subcutaneous, intraperitoneal, testis, liver, and epididymal fat pad. These 
authors confirmed the necessity of matrigel for development of teratomas in subcutaneous 
locations and the teratomas derived from these locations usually lacked large cystic cavities 
compared to other sites. In their experiments with a limited number of teratomas, 
intramuscular injections also produced tumors rapidly without significant cyst formation 
(Hentze et al. 2009). 
2.6 Number of cells injected 
A few studies have been specifically designed in attempts to answer the question of how 
many undifferentiated ES cells have to be present in an injection of differentiated cells 
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metanephric mesenchyme and abundant neural elements might be responsible for renal 
development. Interestingly, Nanog, whose expression is in large part responsible for 
maintaining pluripotency in ES cells is located on chromosome 12 and overexpression has 
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Mayshar, and Benvenisty 2006).  
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expected, RT-PCR products and expression of CD30 was found in the embryonal carcinoma 
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cells. This is in contrast to other tissues present in teratomas that are invariably derived 
nearly entirely from the exogenous ES cells (Gerecht-Nir et al. 2004; Gerecht-Nir et al. 2003; 
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2.5 Site of injection 
Several anatomical sites of the immunodeficient mouse are used for injection of stem cells for 
the teratoma assay. These have been chosen for their accessibility to injection, immune 
privilege status, and ample space to contain a large tumor that still allows the host animal to 
live and function. The most common sites for injection include intratesticular, subcutaneous, 
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intramuscular, and kidney capsule. Again, only a few studies have specifically addressed 
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and EC cells produced rapid tumors 5-8 times larger than those obtained by subcutaneous 
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areas with immature and mature tissue types, higher expression of SSEA3 (embryonic stem 
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with neuronal specification and other tissues) compared to subcutaneous tumors. They 
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and growth factors (e.g. stem cell factor) produced in the liver contribute to the rapid growth 
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intratesticular location.  Some evidence suggests that a post-ischemic environment at least in 
the central nervous system promotes teratoma formation. Seminatore et al transplanted 
neuroprogenitors (NPGs) derived from hES cells at various stages of differentiation ranging 
from early NPGs to differentiated NPGs into rats with either no ischemic lesion or rats with 
small or large ischemic lesions (Seminatore et al.). The early NPGs had embryoid body-like 
structures that exhibited characteristics of pluripotent stem cells and expressed markers of 
pluripotent stem cells. Teratomas formed in the formed in the central nervous system of rats of 
rats injected with NPGs with embryoid-body like structures regardless of the presence or 
absence of an ischemic lesion. In addition, large ischemic lesions significantly promoted the 
survival of transplanted early NPGs compared to sham. The authors propose that the post-
ischemic environment produces a variety of factors that promote the survival, growth, and 
differentiation into teratomas from an undifferentiated population of ES cells. In the study by 
Hentze et al from Singapore, they injected several hES cells lines into kidney capsule, 
intramuscular, subcutaneous, intraperitoneal, testis, liver, and epididymal fat pad. These 
authors confirmed the necessity of matrigel for development of teratomas in subcutaneous 
locations and the teratomas derived from these locations usually lacked large cystic cavities 
compared to other sites. In their experiments with a limited number of teratomas, 
intramuscular injections also produced tumors rapidly without significant cyst formation 
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destined for therapeutic purposes to produce a teratoma. Cao et al in 2007 demonstrated 
that a minimum of 500-1000 mouse ES cells containing a double fusion reporter construct of 
Firefly luciferase enzyme (Fluc) and green fluorescent protein (eGFP) were necessary for 
teratoma formation after subcutaneous injection (Cao et al. 2007). This same number of cells 
was also able to generate a faint signal allowing for in vivo bioluminescence live imaging. 
Fewer cells resulted in no detectable bioluminescence on in vivo imaging and no teratoma 
formation. For the subcutaneous injections, the number of ES cells injected ranged from 1 to 
10,000 increasing by a factor of 10. The ES cells were combined with mouse embryonic 
fibroblasts and matrigel to equal 100,000 cells for injection into adult nude mice. This same 
group two years later performed similar experiments using undifferentiated H9 hES cells. In 
this study at least 100,000 (1 x 105) cells was necessary for teratoma formation after 
intramyocardial injection into adult into adult severe combined immunodeficient (SCID) 
mice and at least 10,000 cells were necessary for teratoma formation after intramuscular 
injection (5/7 tumors).   
While not specifically addressed in most studies as a variable, the manner of dissociation of 
ES cells in preparation for injection or transplantation likely plays a key role in the final 
number of cells necessary to produce a teratoma. Hentze et al also demonstrated that an 
increasing number of injected hES cell colonies and single cells produced teratomas more 
quickly in a linear fashion. In their experiments, hES cell colonies were injected in 
conjunction with approximately 106 human foreskin fibroblasts. Teratoma formation was 
dependent on the cell line used and its adaptation to trypsin digestion. They found that a 
collagenase passaged hES cell line did not form teratomas after single cell trypsin digestion 
(Hentze et al. 2009). It is known that ES cells show increased apoptosis and cell death when 
dissociated into single cells compared to leaving cells in clusters or clumps. Single cell 
suspensions may require higher cell numbers to compensate for cell loss. 
2.7 Host immunological status 
Much less literature has specifically addressed the role of the host animal in teratoma 
formation. Most investigators use some form of immunodeficient mouse. For our teratoma 
injections, we have used a severe combined immunodeficient mouse strain that is 
superimposed on a non-obese diabetic background (NOD-SCID) from Jackson Laboratory. 
These mice lack T and B cell function within a normal hematopoietic background. Of the 
studies referenced in this section that specifically address teratoma formation from ES cells, 
little consistency is present in the strain of immunodeficient mouse used for cell 
transplantation or injection. This is illustrated in the following table: 
 
Study Host 
(Lee et al. 2009) SCID mouse 
(Cao et al. 2007) Nude athymic rats 
(Kishi et al. 2008) NOD-SCID and NOD-SCID/γnull (NOG) 
(Gutierrez-Aranda et al.) NOD-SCID IL2Rγ-/- 
(Seminatore et al.) 
Sprague-Dawley rats (exogenous 
immunosuppression with cyclosporine, 
azathioprine and methylprednisolone 
(Prokhorova et al. 2009) NOD/MrkBomTac-Prkdc
scid and NOD/LtSz-
Prkdcscid 
(Cooke, Stojkovic, and Przyborski 2006) Adult male nude (nu/nu) mice 
Table 1. Immunodeficient hosts used for experimental teratoma formation 
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The SCID mouse has functional deficits in T and B cells, the NOD/SCID IL2Rγ (NOG) 
mouse lacks functional T, B, and NK cells as well as lacking response to cytokine signals, 
and the nude mouse lacks T cells. The effect of these immune capabilities on 
undifferentiated ES cells that are transplanted or injected into them is unknown. As a related 
aside, work by Koch et al demonstrated that only 20% of undifferentiated ES cells treated 
with human serum formed teratomas in immunocompromised mice compared to ES cells 
not treated or treated with heat inactivated serum. They show that the alternate complement 
pathway is responsible at least in part for dampening the tumorigenic potential of 
undifferentiated ES cells (Koch, Jordan, and Platt 2006).  
In summary, it is clear that both endogenous and exogenous factors contribute to efficiency 
of teratoma production and composition. It is also clear that more work needs to be done to 
unravel how specific conditions affect the formation and composition of teratomas. This will 
include carefully controlled studies and an efficient means to carefully compare the 
histological composition of the resulting teratomas.   
3. Current technology for tracking stem cell fate, monitoring teratoma 
formation, and delineation of specific tissue types in vivo 
3.1 Tracking stem cells and monitoring teratoma formation in vivo 
Many investigations producing teratomas have been motivated by finding ways to detect their 
formation in vivo and molecular modifications to ES cells to prevent their occurrence. This 
makes obvious sense since their occurrence in the therapeutic setting is undesirable and would 
not be detectable for weeks to perhaps months after placement or injection of stem cells. The 
field of molecular imaging has emerged as a means to study organs and track lesions (such as 
teratomas) both structurally and functionally. In the field of tissue regeneration/engineering it 
has been used to track the fate of exogenous stem cells or their differentiated progeny. In vivo 
imaging technologies include magnetic resonance imaging (MRI), computed tomography 
(CT), positron emission tomography/CT (PET/CT), single photon emission computed 
tomography (SPECT), charged coupled device (CCD) camera, and ultrasound. Molecular 
imaging has evolved to allow better understanding of disease using imaging probes tied to a 
molecular target that can subsequently be followed and imaged in vivo. Two main methods 
exist for tracking cells or molecular/genetic functions of cells:  One, labeling cells directly and 
two, via use of reporter gene constructs (Kooreman and Wu).  
The first labeling modality involves the use of nanoparticles or quantum dots which emit 
specified wavelengths of light and are photostable. However, delivery to cells can be 
difficult, nanoparticles tend to aggregate in the cytosol, and can bind to other molecules. 
Another modality is iron particle imaging where superparamagnetic iron oxide particles 
(SPIOs) or ultrasmall superparamagnetic iron oxide particles (USPIOs) can be incubated 
with cells in culture, taken up by cells, and can be followed after injection using MRI. Cells 
labeled in such a way have been detected in vivo for up to two months. The major drawback 
is that these particles can be taken up by macrophages and therefore false positive signals 
can be detected by MRI for extended periods. A third labeling modality is radionuclide 
imaging. Here cells are given a radioactive compound and imaged using PET or other 
radioactive detection methods. The main drawback is that cells can be tracked for at most 
several days and the radionuclide can leak into other cells.  
Reporter gene imaging has shown great promise since the stable integration of reporter 
genes allows progeny of cells to be tracked. These can take the form of an enzyme that 
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destined for therapeutic purposes to produce a teratoma. Cao et al in 2007 demonstrated 
that a minimum of 500-1000 mouse ES cells containing a double fusion reporter construct of 
Firefly luciferase enzyme (Fluc) and green fluorescent protein (eGFP) were necessary for 
teratoma formation after subcutaneous injection (Cao et al. 2007). This same number of cells 
was also able to generate a faint signal allowing for in vivo bioluminescence live imaging. 
Fewer cells resulted in no detectable bioluminescence on in vivo imaging and no teratoma 
formation. For the subcutaneous injections, the number of ES cells injected ranged from 1 to 
10,000 increasing by a factor of 10. The ES cells were combined with mouse embryonic 
fibroblasts and matrigel to equal 100,000 cells for injection into adult nude mice. This same 
group two years later performed similar experiments using undifferentiated H9 hES cells. In 
this study at least 100,000 (1 x 105) cells was necessary for teratoma formation after 
intramyocardial injection into adult into adult severe combined immunodeficient (SCID) 
mice and at least 10,000 cells were necessary for teratoma formation after intramuscular 
injection (5/7 tumors).   
While not specifically addressed in most studies as a variable, the manner of dissociation of 
ES cells in preparation for injection or transplantation likely plays a key role in the final 
number of cells necessary to produce a teratoma. Hentze et al also demonstrated that an 
increasing number of injected hES cell colonies and single cells produced teratomas more 
quickly in a linear fashion. In their experiments, hES cell colonies were injected in 
conjunction with approximately 106 human foreskin fibroblasts. Teratoma formation was 
dependent on the cell line used and its adaptation to trypsin digestion. They found that a 
collagenase passaged hES cell line did not form teratomas after single cell trypsin digestion 
(Hentze et al. 2009). It is known that ES cells show increased apoptosis and cell death when 
dissociated into single cells compared to leaving cells in clusters or clumps. Single cell 
suspensions may require higher cell numbers to compensate for cell loss. 
2.7 Host immunological status 
Much less literature has specifically addressed the role of the host animal in teratoma 
formation. Most investigators use some form of immunodeficient mouse. For our teratoma 
injections, we have used a severe combined immunodeficient mouse strain that is 
superimposed on a non-obese diabetic background (NOD-SCID) from Jackson Laboratory. 
These mice lack T and B cell function within a normal hematopoietic background. Of the 
studies referenced in this section that specifically address teratoma formation from ES cells, 
little consistency is present in the strain of immunodeficient mouse used for cell 
transplantation or injection. This is illustrated in the following table: 
 
Study Host 
(Lee et al. 2009) SCID mouse 
(Cao et al. 2007) Nude athymic rats 
(Kishi et al. 2008) NOD-SCID and NOD-SCID/γnull (NOG) 
(Gutierrez-Aranda et al.) NOD-SCID IL2Rγ-/- 
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The SCID mouse has functional deficits in T and B cells, the NOD/SCID IL2Rγ (NOG) 
mouse lacks functional T, B, and NK cells as well as lacking response to cytokine signals, 
and the nude mouse lacks T cells. The effect of these immune capabilities on 
undifferentiated ES cells that are transplanted or injected into them is unknown. As a related 
aside, work by Koch et al demonstrated that only 20% of undifferentiated ES cells treated 
with human serum formed teratomas in immunocompromised mice compared to ES cells 
not treated or treated with heat inactivated serum. They show that the alternate complement 
pathway is responsible at least in part for dampening the tumorigenic potential of 
undifferentiated ES cells (Koch, Jordan, and Platt 2006).  
In summary, it is clear that both endogenous and exogenous factors contribute to efficiency 
of teratoma production and composition. It is also clear that more work needs to be done to 
unravel how specific conditions affect the formation and composition of teratomas. This will 
include carefully controlled studies and an efficient means to carefully compare the 
histological composition of the resulting teratomas.   
3. Current technology for tracking stem cell fate, monitoring teratoma 
formation, and delineation of specific tissue types in vivo 
3.1 Tracking stem cells and monitoring teratoma formation in vivo 
Many investigations producing teratomas have been motivated by finding ways to detect their 
formation in vivo and molecular modifications to ES cells to prevent their occurrence. This 
makes obvious sense since their occurrence in the therapeutic setting is undesirable and would 
not be detectable for weeks to perhaps months after placement or injection of stem cells. The 
field of molecular imaging has emerged as a means to study organs and track lesions (such as 
teratomas) both structurally and functionally. In the field of tissue regeneration/engineering it 
has been used to track the fate of exogenous stem cells or their differentiated progeny. In vivo 
imaging technologies include magnetic resonance imaging (MRI), computed tomography 
(CT), positron emission tomography/CT (PET/CT), single photon emission computed 
tomography (SPECT), charged coupled device (CCD) camera, and ultrasound. Molecular 
imaging has evolved to allow better understanding of disease using imaging probes tied to a 
molecular target that can subsequently be followed and imaged in vivo. Two main methods 
exist for tracking cells or molecular/genetic functions of cells:  One, labeling cells directly and 
two, via use of reporter gene constructs (Kooreman and Wu).  
The first labeling modality involves the use of nanoparticles or quantum dots which emit 
specified wavelengths of light and are photostable. However, delivery to cells can be 
difficult, nanoparticles tend to aggregate in the cytosol, and can bind to other molecules. 
Another modality is iron particle imaging where superparamagnetic iron oxide particles 
(SPIOs) or ultrasmall superparamagnetic iron oxide particles (USPIOs) can be incubated 
with cells in culture, taken up by cells, and can be followed after injection using MRI. Cells 
labeled in such a way have been detected in vivo for up to two months. The major drawback 
is that these particles can be taken up by macrophages and therefore false positive signals 
can be detected by MRI for extended periods. A third labeling modality is radionuclide 
imaging. Here cells are given a radioactive compound and imaged using PET or other 
radioactive detection methods. The main drawback is that cells can be tracked for at most 
several days and the radionuclide can leak into other cells.  
Reporter gene imaging has shown great promise since the stable integration of reporter 
genes allows progeny of cells to be tracked. These can take the form of an enzyme that 
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interacts with an exogenous probe to give rise to a signal, a cell surface receptor, a 
transmembrane protein that mediates intracellular uptake of radioisotopes, or storage 
protein that concentrates endogenous contrast elements. The expression of reporter genes 
could be linked to genes of therapeutic or developmental pathway interest and cell progeny 
tracked by in vivo imaging. Depending on the reporter gene construct, detection can be 
through ultrasensitive CCD cameras (bioluminescence imaging; BLI), PET, and MRI. In the 
realm of small animal imaging (e.g. immunodeficient mice), several reporter gene constructs 
have been developed. The double fusion construct of The double fusion construct of Fluc 
and eGFP is commonly (eGFP) is commonly used. The animal is given a reporter probe, D-
luciferin, which in combination with ATP is oxidized to oxyluciferin, AMP, and light at 560 
nm. This reaction is catalyzed by the luciferase enzyme (Fluc) (Marques and Esteves da Silva 
2009). The emitted low energy photons are detected by ultrasensitive CCD cameras. The 
green fluorescence protein allows for detection in postmortem histology. Triple fusion 
reporter constructs have also been designed that use Fluc, a monomeric red fluorescent 
protein (mRFP) (for cell sorting purposes), and a herpes simplex virus truncated thymidine 
kinase (HSVttk) for deep tissue PET imaging. The HSVttk phosphorylates its substrate; a 
fluoridated (18F) hydroxymethyl butyl guanine generating photons detected by PET. 
Reporter-suicide gene constructs could also theoretically allow detection and elimination of 
transplanted cells targeting those destined for teratoma formation. In the case of the reporter 
construct containing HSVttk, administration of ganciclovir to mice for several weeks can 
result in lack of teratoma formation. Ganciclovir makes use of its specificity for the viral 
thymidine kinase and is converted to a toxic drug by phosphorylation by the viral 
thymidine kinase. Thus, cells infected with the virus produce highly-toxic triphosphates that 
lead to cell death (Kooreman and Wu).  
Transgenes specifically designed for MRI have some advantages in that MRI produces 
three-dimensional images compared to BLI and ultrasensitive CCD camera. A number of 
MRI reporter genes have been developed including tyrosinase, transferrin receptor, β-
galactosidase, and ferritin (Gilad et al. 2007). Ferritin reporter genes have shown no effect on 
ES cell tumorigenicity or pluripotency and in comparison to SPIOs can be tracked much 
longer in vivo although the signal is orders of magnitude less than SPIOs and thus might be 
better suited for applications requiring long term monitoring (i.e. gene therapy, tracking cell 
differentiation or other pathways) (Liu et al. 2009; Cohen et al. 2009). A theoretical drawback 
of reporter gene constructs is interference of normal cellular function by integration of genes 
into the nuclear genome. 
PET imaging has the advantages of spatial/temporal resolution and high sensitivity. Cao et 
al were able to visualize teratomas in vivo using a radiolabeled RGD (arginine-glycine-
aspartate consensus motif present in proteins of the extracellular matrix) that binds to αvβ3 
integrin during angiogenesis. They demonstrated in vivo imaging of established teratomas 
in athymic mice after injection of 64Cu-DOTA-RGD4 whereas teratomas could not be 
detected by PET using 18F-FLT (binds to thymidine kinase) or 18F-FDG (glucose analog) (Cao 
et al. 2009). As noted previously, however, long term tracking of cell fate or development of 
teratomas is unlikely with this modality due to the transient nature of the radionuclides.  
While these imaging modalities and reporter gene constructs are being used to track 
teratoma formation and eliminate it, these modalities and methodologies could also be used 
to study the teratoma itself particularly in the areas of development and even tumorigenesis. 
Linking reporter genes with fluorescent proteins to genes of interest involved in specific 
pathways of developments or cancer would be extremely revealing.  
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3.2 Our experience with magnetic resonance microscopy 
In our study of teratomas, the main imaging modality used has been high-resolution MRI 
(Castro et al.). Our goal in using this imaging technique has been to identify multiple tissue 
types in vivo and to correlate MRI intensities with histology. MRI performed at resolutions 
<100 m per 2D voxel has been designated Magnetic Resonance Microscopy (MRM), and is 
used as a tool for virtual histological studies. Advancements in MRM have increased the 
resolution at which biological samples are imaged to as low as 10-16 m in 2D images and 
20-50 m in 3D volume acquisitions. Many different "virtual tissue stains" can be imparted 
on MR histology sections by selecting imaging parameters that take advantage of MR 
contrast mechanisms. In our studies, teratomas have been imaged after removal from the 
euthanized mouse host and formalin fixation (see (Castro et al.) for details) using a 30 mm 
diameter 89 mm vertical-bore 11.7T Bruker AVANCE imaging system (Bruker BioSpin 
Corporation, Billerica, MA) housed at Carnegie Mellon University.  
MRM datasets were roughly correlated with histology to determine what tissue types and 
structures were reliably identified using MR microscopy. Structures and tissues that could be 
identified from MRM images with little or no ambiguity were adipose tissue, cyst, cartilage, 
and epidermal lining. Successful registrations allowed homogeneous tissue patches in 
histology to be correlated with pixel intensity values in T2-weighted images. Tissues with low 
intensity in MR images, defined as 3-22% of maximum (cyst) intensity, included adipose and 
necrotic tissues, mature bone/cartilage, and neuroectoderm. Tissues with medium intensity 
(22-52% of maximum intensity) included neuroectoderm, immature bone/cartilage, skin, 
muscle, and gastrointestinal. High-intensity tissues (53-100% of maximum intensity) were 
limited to cystic lining/fluid and gastrointestinal lining.  As can be seen, considerable overlap 
of intensity and tissue types are present (Figure 1). The ability to transform high resolution 
MRM images to its corresponding histological appearance would be extremely valuable in the 
study of tissue development in teratomas in a longitudinal fashion. The ability to produce such 
“virtual histology” requires that MRM images are precisely aligned to their corresponding 
histological sections from the serially sectioned teratoma. Next the MRM image characteristics 
(intensity etc.) would have to be correlated with the images characteristics of the tissue in the 
histological sections. Several hurdles need to be addressed 1)  Precise alignment of each 
histological section with the corresponding MRM images requires alignment in three-
dimensions and 2)  even with high-resolution scans the voxel dimensions are 42 um x 89um x 
180 for MRM and 3.53 um x 3.53 um x 5 um for a typical histological section; a 1-2 orders of 
magnitude discrepancy. Single image registration between MRM and histology required 
tedious and vigilant sample alignment, but did allow for correlation between MR image 
intensity values and histological tissue types. An additional advantage of MRM is that it can 
deliver accurate volumetric measurements because true 3D images are obtained, and the 
sample is unaltered by histological processing. 
These higher resolutions did not allow us to uniquely identify any additional tissue types 
directly from MR images, when compared with clinical imaging. However, MRM may allow 
direct, non-invasive identification of additional tissue types, because they did reveal texture 
patterns not visible in low-resolution MRI. Unidentified textures including radial patterns 
with alternating dark-bright spokes, faint stacks of filamentous parallel lines, dark finger-
like projections, faint concentric lines against bright backgrounds, and dark patches with 
interior textures such as bright speckles or membrane-like lines. Correlating these textures 
and other regional patterns with the tissues they represent in histology, especially aided 
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interacts with an exogenous probe to give rise to a signal, a cell surface receptor, a 
transmembrane protein that mediates intracellular uptake of radioisotopes, or storage 
protein that concentrates endogenous contrast elements. The expression of reporter genes 
could be linked to genes of therapeutic or developmental pathway interest and cell progeny 
tracked by in vivo imaging. Depending on the reporter gene construct, detection can be 
through ultrasensitive CCD cameras (bioluminescence imaging; BLI), PET, and MRI. In the 
realm of small animal imaging (e.g. immunodeficient mice), several reporter gene constructs 
have been developed. The double fusion construct of The double fusion construct of Fluc 
and eGFP is commonly (eGFP) is commonly used. The animal is given a reporter probe, D-
luciferin, which in combination with ATP is oxidized to oxyluciferin, AMP, and light at 560 
nm. This reaction is catalyzed by the luciferase enzyme (Fluc) (Marques and Esteves da Silva 
2009). The emitted low energy photons are detected by ultrasensitive CCD cameras. The 
green fluorescence protein allows for detection in postmortem histology. Triple fusion 
reporter constructs have also been designed that use Fluc, a monomeric red fluorescent 
protein (mRFP) (for cell sorting purposes), and a herpes simplex virus truncated thymidine 
kinase (HSVttk) for deep tissue PET imaging. The HSVttk phosphorylates its substrate; a 
fluoridated (18F) hydroxymethyl butyl guanine generating photons detected by PET. 
Reporter-suicide gene constructs could also theoretically allow detection and elimination of 
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construct containing HSVttk, administration of ganciclovir to mice for several weeks can 
result in lack of teratoma formation. Ganciclovir makes use of its specificity for the viral 
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thymidine kinase. Thus, cells infected with the virus produce highly-toxic triphosphates that 
lead to cell death (Kooreman and Wu).  
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galactosidase, and ferritin (Gilad et al. 2007). Ferritin reporter genes have shown no effect on 
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better suited for applications requiring long term monitoring (i.e. gene therapy, tracking cell 
differentiation or other pathways) (Liu et al. 2009; Cohen et al. 2009). A theoretical drawback 
of reporter gene constructs is interference of normal cellular function by integration of genes 
into the nuclear genome. 
PET imaging has the advantages of spatial/temporal resolution and high sensitivity. Cao et 
al were able to visualize teratomas in vivo using a radiolabeled RGD (arginine-glycine-
aspartate consensus motif present in proteins of the extracellular matrix) that binds to αvβ3 
integrin during angiogenesis. They demonstrated in vivo imaging of established teratomas 
in athymic mice after injection of 64Cu-DOTA-RGD4 whereas teratomas could not be 
detected by PET using 18F-FLT (binds to thymidine kinase) or 18F-FDG (glucose analog) (Cao 
et al. 2009). As noted previously, however, long term tracking of cell fate or development of 
teratomas is unlikely with this modality due to the transient nature of the radionuclides.  
While these imaging modalities and reporter gene constructs are being used to track 
teratoma formation and eliminate it, these modalities and methodologies could also be used 
to study the teratoma itself particularly in the areas of development and even tumorigenesis. 
Linking reporter genes with fluorescent proteins to genes of interest involved in specific 
pathways of developments or cancer would be extremely revealing.  
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3.2 Our experience with magnetic resonance microscopy 
In our study of teratomas, the main imaging modality used has been high-resolution MRI 
(Castro et al.). Our goal in using this imaging technique has been to identify multiple tissue 
types in vivo and to correlate MRI intensities with histology. MRI performed at resolutions 
<100 m per 2D voxel has been designated Magnetic Resonance Microscopy (MRM), and is 
used as a tool for virtual histological studies. Advancements in MRM have increased the 
resolution at which biological samples are imaged to as low as 10-16 m in 2D images and 
20-50 m in 3D volume acquisitions. Many different "virtual tissue stains" can be imparted 
on MR histology sections by selecting imaging parameters that take advantage of MR 
contrast mechanisms. In our studies, teratomas have been imaged after removal from the 
euthanized mouse host and formalin fixation (see (Castro et al.) for details) using a 30 mm 
diameter 89 mm vertical-bore 11.7T Bruker AVANCE imaging system (Bruker BioSpin 
Corporation, Billerica, MA) housed at Carnegie Mellon University.  
MRM datasets were roughly correlated with histology to determine what tissue types and 
structures were reliably identified using MR microscopy. Structures and tissues that could be 
identified from MRM images with little or no ambiguity were adipose tissue, cyst, cartilage, 
and epidermal lining. Successful registrations allowed homogeneous tissue patches in 
histology to be correlated with pixel intensity values in T2-weighted images. Tissues with low 
intensity in MR images, defined as 3-22% of maximum (cyst) intensity, included adipose and 
necrotic tissues, mature bone/cartilage, and neuroectoderm. Tissues with medium intensity 
(22-52% of maximum intensity) included neuroectoderm, immature bone/cartilage, skin, 
muscle, and gastrointestinal. High-intensity tissues (53-100% of maximum intensity) were 
limited to cystic lining/fluid and gastrointestinal lining.  As can be seen, considerable overlap 
of intensity and tissue types are present (Figure 1). The ability to transform high resolution 
MRM images to its corresponding histological appearance would be extremely valuable in the 
study of tissue development in teratomas in a longitudinal fashion. The ability to produce such 
“virtual histology” requires that MRM images are precisely aligned to their corresponding 
histological sections from the serially sectioned teratoma. Next the MRM image characteristics 
(intensity etc.) would have to be correlated with the images characteristics of the tissue in the 
histological sections. Several hurdles need to be addressed 1)  Precise alignment of each 
histological section with the corresponding MRM images requires alignment in three-
dimensions and 2)  even with high-resolution scans the voxel dimensions are 42 um x 89um x 
180 for MRM and 3.53 um x 3.53 um x 5 um for a typical histological section; a 1-2 orders of 
magnitude discrepancy. Single image registration between MRM and histology required 
tedious and vigilant sample alignment, but did allow for correlation between MR image 
intensity values and histological tissue types. An additional advantage of MRM is that it can 
deliver accurate volumetric measurements because true 3D images are obtained, and the 
sample is unaltered by histological processing. 
These higher resolutions did not allow us to uniquely identify any additional tissue types 
directly from MR images, when compared with clinical imaging. However, MRM may allow 
direct, non-invasive identification of additional tissue types, because they did reveal texture 
patterns not visible in low-resolution MRI. Unidentified textures including radial patterns 
with alternating dark-bright spokes, faint stacks of filamentous parallel lines, dark finger-
like projections, faint concentric lines against bright backgrounds, and dark patches with 
interior textures such as bright speckles or membrane-like lines. Correlating these textures 
and other regional patterns with the tissues they represent in histology, especially aided 
 
 




Fig. 1. High-resolution magnetic resonance imaging of teratomas. Teratomas derived from 
non-human primate ES cells were extracted, fixed and imaged. Hypointense (green; first 
and fourth columns) and cystic areas (yellow; first and third columns) are segregated and 
volumes assigned. In the second row, first column, the vertical rods are toothpicks placed 
into the teratoma at the time of imaging used as fiduciary markers for alignment studies. 
The far right colum shows a representative 2D slice. 
 by computational statistical methods, could identify additional tissue types with varying 
levels of confidence, directly from MRM of teratomas. Computational textural and shape 
analysis trained over many teratomas, as well as higher resolutions, may offer improved 
tissue identification by better resolving and considering these subtle texture variations.  
4. Histopathology of teratomas 
It seems that whenever we have inspected sections from teratomas under the microscope, 
we have found something, some structure that wasn’t present (or seemingly wasn’t present) 
on previous viewing. This is part of what makes them special and fascinating lesions to 
study. This emphasizes the numerous and varied developmental programs that are in 
motion simultaneously as these tumors grow. Few papers have carefully described and/or 
quantified the numerous specific tissue types present in most teratomas derived from ES 
cells. The description and quantification of tissue types will be critical if teratomas are to be 
used as models of development or subtle comparisons of teratomas derived under different 
experimental conditions are to be unraveled. We have identified the majority of tissue types 
from the hematoxylin and eosin (H&E) slides without the need for ancillary studies. Briefly, 
we emphasize two critical aspects of the histopathological analysis that allow for optimal 
examination of teratomas. One, we underscore the importance of having well-processed and 
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well-stained H&E sections. This sounds easy, but in reality even though the histological 
equipment and techniques have been available for decades, the production of excellent 
slides for accurate tissue assessment, image production and analysis requires great 
experience within the laboratory. Well-processed tissue includes having the entire teratoma 
well-fixed (for several days preferably in paraformaldehyde or 10% phosphate buffered 
formalin for best penetration and antigenic preservation), serially sectioned at 2-3 mm using 
130 mm tissue blades, and processed so that it is free of tissue drying and microtome cutting 
artifacts. This is particularly important since generally speaking, these tumors are large thus 
generating a tissue section with a large cross-sectional area compared to a small tissue 
biopsy. We recommend using a regressive H&E stain that provides for excellent nuclear 
detail and more consistent staining from batch to batch compared to a progressive staining 
technique (Carson 1997). Two, for detailed critical studies of teratomas, it is essential to have 
a versatile and experienced pathologist examine all of the tissue sections of the tumor 
carefully. The pathologist should be comfortable with the microscopic examination of a 
wide variety of organ systems including perinatal and/or pediatric specimens and 
experienced in identifying seemingly inconsequential structures within the milieu of tissues 
present. Perinatal and/or pediatric clinical pathology disciplines tend to have specimens 
that include fetal organs, organs with developmental arrest/neoplasia, extraembryonic 
tissues, and clinical teratomas.  
Tissue components seen in our experimental teratomas and their germ layer derivation are 
shown in the table below. 
 
ECTODERM MESODERM ENDODERM 




Retinal* Striated muscle Liver* 
Pigmented cells* Smooth muscle Respiratory epithelium 
Mature neuroglial Cartilage Gastrointestinal epithelium 
Immature neuroglial Bone Thyroid* 
Skin  Adipose Glandular (unspecified) 
tissue 
Squamous epithelium Kidney* Yolk sac 
 Skin dermis  
 Bone marrow *-rarely or never seen in our 
teratomas 
Table 2. Representative tissues seen in our teratomas and their germ layer origin 
Only one previous study extensively examined in depth a series of teratomas derived from 
ES cells in the experimental setting. Gertow et al from the Karolinska Institute published 
their extensive analysis of teratomas derived from one hES cell line in 2004 (Gertow et al. 
2004). This is really the first and only one of few papers that performed and documented 
extensive histopathological, immunohistochemistry, and FISH studies of teratomas derived 
from hES cell lines. They analyzed 5 teratomas including the application of 30 antibodies to 
specific antigens associated with various stages of tissue development from all three 
primordial germ layers. They found several interesting results:  One, the vast majority of 
cells comprising the teratoma was derived from the stem cells with the exception of 
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well-stained H&E sections. This sounds easy, but in reality even though the histological 
equipment and techniques have been available for decades, the production of excellent 
slides for accurate tissue assessment, image production and analysis requires great 
experience within the laboratory. Well-processed tissue includes having the entire teratoma 
well-fixed (for several days preferably in paraformaldehyde or 10% phosphate buffered 
formalin for best penetration and antigenic preservation), serially sectioned at 2-3 mm using 
130 mm tissue blades, and processed so that it is free of tissue drying and microtome cutting 
artifacts. This is particularly important since generally speaking, these tumors are large thus 
generating a tissue section with a large cross-sectional area compared to a small tissue 
biopsy. We recommend using a regressive H&E stain that provides for excellent nuclear 
detail and more consistent staining from batch to batch compared to a progressive staining 
technique (Carson 1997). Two, for detailed critical studies of teratomas, it is essential to have 
a versatile and experienced pathologist examine all of the tissue sections of the tumor 
carefully. The pathologist should be comfortable with the microscopic examination of a 
wide variety of organ systems including perinatal and/or pediatric specimens and 
experienced in identifying seemingly inconsequential structures within the milieu of tissues 
present. Perinatal and/or pediatric clinical pathology disciplines tend to have specimens 
that include fetal organs, organs with developmental arrest/neoplasia, extraembryonic 
tissues, and clinical teratomas.  
Tissue components seen in our experimental teratomas and their germ layer derivation are 
shown in the table below. 
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2004). This is really the first and only one of few papers that performed and documented 
extensive histopathological, immunohistochemistry, and FISH studies of teratomas derived 
from hES cell lines. They analyzed 5 teratomas including the application of 30 antibodies to 
specific antigens associated with various stages of tissue development from all three 
primordial germ layers. They found several interesting results:  One, the vast majority of 
cells comprising the teratoma was derived from the stem cells with the exception of 
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endothelial cells comprising feeding vessels and focal areas resembling choroid plexus. Two, 
they found no cells expressing markers of undifferentiated pluripotent cells. Three, most 
teratomas had multilineage tissues derived from all three germ layers meaning that different 
stages of development of the same general tissue type (i.e. mature and immature neuroglial) 
or different types of the same tissue were present (endochondral, intramembranous bone). 
Teratomas had extensive and predominant neural development with areas of cartilage, 
bone, and epithelial development usually within structures reminiscent of bronchi or 
intestine but derived from both ectoderm and endoderm. A minority of teratomas showed 
kidney development. Four, more immature areas had higher proliferation rates while 
mature areas had lower proliferation rates. Five, certain tissue types segregated with one 
another. Six, differentiation was higher in teratomas grown for longer periods. The latter 
three points seem to point to some organized pattern following a developmental program. 
Blum and Benvenisty from the Hebrew University in Jerusalem recently combined three 
different hES cell lines and produced teratomas that demonstrated equal contributions to 
tissues from all three lines (Blum and Benvenisty 2007). In addition, analysis of specific 
structures within the teratomas using laser capture and microsatellite and sex chromosome 
analysis demonstrated that some structures were polyclonal; that is derived from two cell 
lines indicating an inductive phenomenon rather than cell autonomous development.  
Over the last several years, our group has focused on derivation and study of embryonic 
stem cells. The group has worked with mES cells, hES cells, and has derived several ES lines 
from non-human primates including several rhesus and baboon lines (Ben-Yehudah et al. ; 




Fig. 2. Representative tissues seen in experimental teratomas derived from human, monkey, 
and baboon ES cell lines. Human teratomas (A-E):  A-neuroepithelium, B-pigmented neural 
tissue (retinal), C-bowel, D-respiratory or bowel wall, E-primitive kidney. Rhesus teratomas 
(F-J):  F-mature neuroglia, G-skin, H-immature striated muscle, I-immature bronchus, J-
bowel wall with ganglion or myenteric plexus (arrow). Baboon teratomas (K-O):  K-
pigmented neural, L-skin, M-immature skeletal muscle, N-primitive gland adjacent to 
hyaline cartilage, O-primitive gland surrounded by primitive mesenchyme (H&E stained 
tissue sections). 
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More extensive histopathological analysis of teratomas derived from nhpES cells revealed at 
least 23 different and recognizable tissue entities. (The majority of tissue types present can 
be seen in Figure 1 of (Castro et al.)). All three germ layers were not only represented (by 
definition a teratoma) but represented by tissues of the same type at various stages of 
development and maturation. Neural tissue was represented by primitive neuroepithelium, 
immature neuroblastic areas, and mature neuroglial tissue resembling brain as well as 
mature myenteric plexus and ganglia. Skeletal muscle (mesoderm) showed immature 
myotubes, maturing striated fibrils, and mature striated muscle. Adipose tissue included 
immature fat containing lipoblasts and areas of mature adipose tissue. Endodermal 
derivatives included very primitive glandular structures lined by columnar cells with apical 
nuclei and basal clear cytoplasm (so called “piano key” epithelial cells of yolk sac), less 
primitive yet still undefined glandular epithelium surrounded by primitive mesenchyme, 
and well-defined pseudostratified ciliated (respiratory-type) and intestinal epithelium. 
Immature and mature types of the same tissue could be present in the same teratoma. Only 
one teratoma had a well-formed tooth organ present. 
In summary, teratomas present a dazzling array of tissues at varying stages of development. 
Tissue recognition, quantification, and delineation of developmental stage are fundamental 
to their study as models of development, disease, and tumorigenesis. 
5. Teratomas in the study of embryonic development 
5.1 Quantification of tissues from experimental teratomas 
A tumor has been produced in an immunodeficient mouse injected with cells, excised, 
plopped into formalin, sectioned, a few blocks produced which are sectioned onto slides 
and examined by the investigator or in some cases a pathologist to determine if tissues from 
all three germ layers are present. For the most part, if a derived cell line can produce a 
teratoma and thus prove that the cell line is pluripotent then the teratoma has done its job. 
The blocks are filed and that is the end. That fact that Muller et al wrote an article calling to 
standardize not only the reporting of teratoma production but also standardizing the assay 
speaks to the somewhat nonchalant attitude towards these lesions (Muller et al.). More 
recent literature has espoused a different look at the teratoma; as a lesion that models 
development or perhaps failed development since cells are taken out of their normal niche 
and neighborly contacts (Aleckovic and Simon 2008; Menendez, Bueno, and Wang 2006). 
Several reasons both practical and theoretical make teratomas an appealing strategy to 
study development. One, human embryos are inaccessible for studying early development. 
Embryos at very early stages of development are not available and ethical constraints are 
enormous. Two, mouse and human development differ significantly such that using mouse 
models to recapitulate human development is inaccurate. Three, in vitro differentiation of 
hES cells into embryoid bodies does not reach the complexity of embryonic development. 
The fact that isolated mouse ES cells can be injected back into a developing blastocyst and 
continue to contribute to normal embryo formation speaks volumes about how differences 
in the cellular and environmental milieu can have drastic changes in developmental 
potential. Some of these cellular and environmental cues in vivo may still be in play even 
after some degree of cell dissociation in the formation of the experimental teratoma. 
We believe that identifying and quantifying the tissue milieu within teratomas both in vivo 
and ex vivo begin to answer fundamental descriptive questions regarding embryonic 
development both normal and aberrant. The manual quantification of the myriad of tissues 
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present in most teratomas is a daunting and time consuming task considering the size of the 
tissue sections of most teratomas (150 mm2), the number of blocks generated per teratoma 
(8-12), and the number of tissue types present (>23). A further daunting task is attempting to 
reconstruct the teratoma in three-dimensional space to visualize the spatial relationships of 
these tissues to one another. We have done this so far using a semiquantitative approach 
based on the microscopic assessment of each tissue section.  For each section, the amount of 
each representative tissue belonging to a specific germ layer (i.e. ectoderm, mesoderm, and 
endoderm) is estimated from each slide of a serially sectioned teratoma using the following 
scale:  1-[1-20%], 2-[21-40%], 3-[41-60%], 4-[61-80%], and 5-[81-100%]. Estimated percentages 
are based on how much of the area of the tissue section is represented by that particular 
tissue. The median of the percentage range is taken for all blocks for each tissue type. For 
each germ layer, the medians representing the percentage range of the tissue types derived 
from that germ layer were summed and an overall percentage range assigned to that germ 
layer. Previously, we have performed semiquantification of tissue types in a limited number 
of teratomas derived from derived from mES, nhpES, and hES cells with the results in the 
following table: 
 
 NHP (n=8) MOUSE (n=3) HUMAN (n=2) 
Incubation (d) 77.8 (13.8) 68.3 (26.3) 70.5 (6.4) 
Size (cm) 1.8 (0.3)* 1.9 (0.6) 2.6 (0.1)* 
EC (median) 3 5 2 
ME (median) 2 1 4 
EN (median) 1 1 1 
Table 3. Semiquantification of germ layer contributions in experimental teratomas from 
different species 
No differences were seen for incubation days between teratomas derived from nhpES, mES, 
or hES cells. The human teratomas sampled were significantly larger than either nhp or mES 
cell derived lesions. Both nhpES and mES cell derived teratomas demonstrated higher 
median percentage of ectoderm derived tissue present in their teratomas compared to hES 
derived teratomas. However, hES cell derived teratomas demonstrated higher percentages 
of mesoderm derived tissues than nhpES or mES cell derived teratomas. No differences 
were seen for percentage of endoderm derived tissues between nhpES and mES cell derived 
teratomas. Significant differences at a p-value of 0.02 were seen between the percentage of 
endoderm derived tissues from nhpES and mES cells compared to hES cell derived 
teratomas (Ozolek et al. Presented at the 2007 International Society for Stem Cell Research 
Annual Meeting). While a limited analysis, some trends may exist. One, endoderm seems to 
be the least prevalent component within teratomas regardless of the species of ES cell from 
which they are derived. It may be that endodermal derivatives as a whole comprise a small 
percentage (by weight or volume) of eventual tissues and organs in these species or that the 
developmental program for certain endodermal derivatives is either not fully established or 
is aberrant. It is interesting that in our experience with examining numerous teratomas 
derived experimentally from ES cells, very few contain significant amounts of thyroid, liver, 
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or pancreas—all of endodermal origin. Two, the amount of ectodermal derivatives seems to 
inversely correlate with the length of gestation (and by extension length of lifespan) for each 
species and correlates with the degree of nervous system maturity necessary for survival 
immediately after birth. The amount of mesodermal derivatives shows just the opposite. 
One could speculate that the mouse for example has a teleological need to have a more 
mature central nervous system relative to birth and would need ectodermal derivatives 
(nervous system, nerves, ganglia, etc.) to be the more abundant and more developed tissue. 
Our analysis of a large group of teratomas derived from two pedigreed “families” of nhpES 
cells (same male sperm donor and two different females; 3 ES cell lines in one family and 4 
ES cell lines in the other family) demonstrated similar percentage ranges for tissues from 
each of the germ layers (ectoderm-2, mesoderm-3, and endoderm-1 by the above scoring 
system) for teratomas of one family compared to the other family (Castro and Ozolek, 
unpublished data).  In all cases, injections of cells were done in both testes usually resulting 
in two teratomas. Most of these teratoma pairs showed a high concordance of similar tissue 
types and distributions between each other. Tissue by tissue comparison of teratomas from 
each of the two families showed no differences in the number of teratomas having a specific 
tissue with the exception of immature neuroglial tissue which was present in all teratomas 
from “family 2” and in only half of the teratomas from “family 1” (Castro and Ozolek, 
unpublished data). These teratomas show a slight predominance of tissue types derived 
from mesoderm mostly mesenchyme and muscle, followed by ectodermal derivatives 
(neuroglial and skin) followed by endodermal derivatives represented primarily by 
respiratory-type or intestinal epithelium (Figure 3). These results have several implications. 
One, the teratoma doesn’t appear to develop in a single synchronous fashion, in other 
words; each specific tissue type is not synchronous in its development. Two, some tissue 
structure (organ formation) is apparent mostly exhibited by bronchial or intestinal 
development. In fact, in some instances the cross section of an intestinal segment observed 
in isolation from its surroundings could not be distinguished from that taken from a mature 
animal or human including the presence of myenteric neuroglial plexuses. Three, very few 
of these teratomas derived from nhpES cells that we have examined contain significant 
islands of developed pancreas, thyroid, liver (endoderm) or kidney (mesoderm); all 
observations also noted by Gertow et al in their teratoma analysis noted above (Gertow et al. 
2004).  
However, it should be mentioned that Hentze et al also performed similar 
semiquantification of germ layer percentages in teratomas generated from undifferentiated 
and differentiated ES cells (cardiomyocytes and beta cells). They found that mesoderm was 
the predominant tissue type in all teratomas followed by endoderm then ectoderm. Their 
brief description of the method used for semiquantifying germ layers was similar to ours in 
that they estimated tissue as a percentage of the tissue area of the slide. According to their 
methods, they first cut the teratomas into 0.5 gram pieces, then fixed and processed for 
histology (Hentze et al. 2009). Quantification of tissue from multiple small fragments could 
prove more challenging and time consuming if one is to examine the whole teratoma. 
Another source of discrepancy might revolve around how cysts were quantified. The 
majority of cysts present in a teratoma are going to be endodermal derivatives. In our 
methods we discounted the lumen as contributing to tissue area since it was an empty space 
filled with fluid and not actual tissue. The actual tissue element or mucosal lining would 
actually be a very small percentage of the total tissue present. One could argue the validity 
of either methodology. 
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present in most teratomas is a daunting and time consuming task considering the size of the 
tissue sections of most teratomas (150 mm2), the number of blocks generated per teratoma 
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developmental program for certain endodermal derivatives is either not fully established or 
is aberrant. It is interesting that in our experience with examining numerous teratomas 
derived experimentally from ES cells, very few contain significant amounts of thyroid, liver, 
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Fig. 3. Common histological themes and interesting observations in experimental teratomas. 
A-primitive bronchial development (center), B-bowel wall complete with mucosa, lamina 
propria, and two layers of smooth muscle layered in opposite directions (what would 
normally be found in mammalian bowel), C-ganglion/myenteric plexus amidst smooth 
muscle (between arrows), D-primitive glands composed of cells with hyperchromatic nuclei, 
high nuclear-to-cytoplasmic ratio and basal cytoplasmic clearing (upper right gland) 
reminiscent of yolk sac (H&E stained tissue sections). 
5.2 Automated image analysis for detecting and quantifying tissue in experimental 
teratomas 
As noted earlier, the prospect of manually quantifying tissue types within these teratomas is 
daunting. Our analysis of the teratomas derived from the nhpES cells took innumerable 
hours of careful microscopic examination, tabulation, and collation of data and this was only 
a semiquantitative analysis based on estimated percentages of tissues. Using more rigorous 
methods would have yielded slightly more accurate data, but would certainly have required 
two to three times the man hours to accomplish. The ability to accurately and quickly 
quantify tissues within numerous sections of a teratoma will be critical to identify consistent 
spatial relationships of tissues with each other, temporal heterogeneity of tissues in three-
dimensions and going forward the ability to compare tissue types across multiple teratomas. 
These authors found only one study that has specifically addressed the issue of quantifying 
tissues within teratomas using automated imaging/image analysis technologies. Oh and 
colleagues from Singapore have developed a software platform called TeratomEye that 
employs three separate algorithms for identifying muscle, gut, and neural tissue with a user-
friendly graphical interface (Oh et al. 2009). For muscle, color was used as the main 
discriminator. For gut, the presence of a lumen was critical in selecting candidates followed 
by comparison to a set of images of gut and non-gut epithelium. For neural tissue, the same 
process used for gut tissues was employed. Using these methodologies, they were able to 
identify muscle accurately 90% of the time with over 90% sensitivity and specificity, gut 
tissue 87.5% of the time with greater than 80% sensitivity and specificity, and for neural 
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tissue 47.6%. It is unclear from the images provided in the paper whether all of the epithelium 
lining structures with lumens was indeed gut epithelium or perhaps early respiratory or other 
types of epithelium. The images of neural tissue demonstrated only neuroepithelium (with 
neuroepithelial rosettes) but not maturing or mature neuroglial tissues. A fruitful collaboration 
with Drs. Kovacevic, Rohde, and several graduate students at the Center for Bioimage 
Informatics of the Department of Biomedical Engineering at Carnegie Mellon University has 
resulted in several approaches to the problem of tissue quantification in teratomas. Our work 
has focused on the two critical components of this analysis: segmentation and identification 
(classification) of tissues. The ability to automatically identify the boundaries of tissue types 
and isolate tissues is crucial for both rapid identification and quantification of tissue types. 
This is of course easier said than done since the teratoma does not always follow our rules, but 
rather produces tissues closely intermingled with each other often without clear and well-
defined boundaries (e.g. striated muscle, mesenchyme, adipose tissue, immature cartilage, 
immature neural). Segmentation is a critical step in many image analysis pipelines particularly 
if one is focused on the image analysis of one or several specific regions or areas of interest. In 
the initial phases of our collaborations, segmentation of tissue types was done manually by the 
pathologists who by doing so not only identified the region of interest but also provided the 
ground truth identification for each tissue type. The group at Carnegie Mellon University has 
made significant strides in developing a segmentation tool that can be applied across a variety 
of image platforms with minimal customization or “tweaking” necessary by the user based on 
the type of application (Chen et al. A pixel classification system for segmenting biomedical 
mages using intensity neighborhoods and dimension reduction. in press Proc IEEE Int Symp 
Biomed Imaging 2011 and Chen et al. A general system for automatic biomedical image 
segmentation using intensity neighborhoods. in press Int J Biomed Imaging, 2011) (Figure 4).  
 
 
Fig. 4. Automated segmentation tool for distinguishing several common classes of tissues 
present in teratomas. A-Hematoxylin and eosin stained section of experimental teratoma. 
Image obtained using a Pathscan II whole slide scanner (Meyer Instruments, Inc. Houston, 
TX). Cartilage, bone, and adipose tissue (arrows) are readily discernible. B-Ground truth 
segmented by pathologist: cartilage (red), bone (green), and adipose (yellow). C-Automated 
segmentation of same image using methods described in text. Note that for adipose tissue in 
particular, the automated segmentation selected additional areas of adipose not initially 
segmented by hand (representative regions shown by white arrows). 
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From an image analysis perspective, tissue segmentation from routinely processed tissue 
stained with a conventional hematoxylin and eosin stain is challenging due to complex 
variation in texture, color, shape, and structure of the tissues of interest. 
Briefly, this newer approach is achieved within a supervised learning strategy where pixels 
of a few segmented images are used to train a classifier capable of accurately determining 
the class (background, tissues of interest) of each pixel in unlabeled images of the same kind. 
These algorithms use pre-defined window sizes at a given pixel in which pixels inside the 
window are regarded as neighbors and intensity neighborhood vectors are constructed by 
reordering the pixels’ intensities inside the window into a vector. Using these methods 
significantly better classification accuracy is achieved across the board for several prototype 
tissues seen in teratomas compared to other methodologies. 
 
Statistical 
Measure Bone Cartilage Fat Background 
Our Method 59.70% 73.18% 91.09% 88.93% 
Color K-means 29.79% 51.06% 58.73% 55.20% 
Table 4. Comparison of quantitative automated segmentation methods for tissue within 
teratomas 
Other approaches aimed at tissue identification have been developed through this 
collaboration that include use of multiresolution classification, histogram/Earth Mover’s 
Distance, pixel-level classification, and histopathology vocabulary. Multiresolution 
classifiers have been used since the images (standard H&E) possess many features that are 
localized in both space and frequency. For these analyses, the image is first converted to 
grayscale, decomposed into multiresolution subspaces, and features extracted (Haralick 
texture features and others). A neural network classifier and weighting algorithm are 
employed to produce a class. Using texture and nuclear features, classification accuracy for 
several classes of tissues within teratomas approached 88%. The addition of color features 
improved classification accuracy to over 90% (Bhagavatula et al.). Another approach using 
the histogram of pixels over the span of a given tissue of interest coupled with a K-nearest 
neighbor classifier and earth mover’s distance produced an average accuracy of 92% for 
single tissue types (Castro and Bhagavatula. Multiresolution classification of tissue types in 
teratomas derived from human and non-human embryonic stem cells. Presented at the 
International Society for Stem Cell Research Annual Meeting 2009). The implementation of a 
tissue classifier based on the translation of words used to describe histopathological features 
has proven to be quite robust. In this classification scheme, the pathologist gives each tissue 
type a verbal description of visual descriptors in order of importance for definitively 
identifying that particular tissue. For instance in the case of neuroepithelial/neuroectoderm, 
the verbal descriptors ranked in order of importance to visually identifying it as 
neuroepithelial/neuroectoderm were the following: 
1. Dark blue rim (pseudostratified nuclei) that appears several cells thick 
- Nuclei elongated, oval shape oriented perpendicular to base circumference  
2. Round, oval, elliptical macro structure 
3. Central lumen (may be light pink and/or white) 
This effectively describes the Flexner-Wintersteiner rosettes of primitive neuroepithelium. 
This was done for 15-20 different tissue types. The engineer then translated those verbal 
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descriptors into engineering synonyms. The pathologist then checked to see if these 
translated descriptions were still sufficient to classify the tissues. Based on this process a 
collection of vocabulary terms was assembled shown below: 
 
Background/Fiber colors Nuclear shape 
Cytoplasm color Nuclear organization 
Clear areas (lumens) Nuclear orientation 
Nuclear color Macro shape 
Nuclear density Background texture 
Table 5. Vocabulary terms used for automated tissue classification 
Using this approach an average classification accuracy of 97.75% was achieved over a 10-
fold cross-validation for 4 tissue types (Bhagavatula et al Automated identification of tissues 
for digital pathology in press Transactions on Image Processing, 2011). 
5.3 Role of immunohistochemistry in tissue identification and quantification 
To this point little has been mentioned about ancillary histological techniques that may be of 
assistance in the classification and quantification of tissue types within teratomas. This has 
been for good reason since the goal of our image analysis collaborations has been to develop 
software platforms that can segment, identify, and quantify tissue from images derived 
from routinely processed tissue. This means the ability to segment, identify, and classify 
with high accuracy tissues from the same sections that pathologists’ eyes have been using to 
classify tissues in teratomas and make diagnoses in surgical pathology for decades. The 
implications are that teratoma analyses can be done without more expensive ancillary 
histological techniques and increase specificity of tissue identification since as we will see 
using antibody mediated ancillary methods are not necessarily specific for one tissue type. 
Having said this, the use of ancillary techniques particularly immunohistochemistry can be 
very valuable not only for tissue identification and quantification but also key in elucidating 
developmental pathways. Hundreds of antibodies are available for these purposes with 
many suitable for formalin-fixed paraffin embedded (FFPE) tissue. The keys to using 
immunohistochemistry for applications such as tissue identification and quantification are 
the selection of the antibody, using proper immunohistochemistry techniques, and 
interpretation of staining. No one antibody stains all tissue derived from each germ layer. 
Thus, “pan-endodermal” or “pan-ectodermal” antibodies do not exist. In fact, the process is 
more difficult when considering the teratoma since tissues from all three primordial germ 
layers are not only present but are present in a developmentally heterogeneous fashion. This 
means that a single tissue type can be represented as it might appear histologically in early 
fetal life, late fetal life, and into childhood/adolescence/adulthood. Vimentin for instance is 
a commonly used antibody in both diagnostic and research arenas and is considered a 
marker of tissues derived from mesoderm or of mesenchymal origin and is used extensively 
in diagnostic soft tissue pathology. The antibody reacts to an intermediate filament that is 
present in most if not all fetal cells in early development and thus non-specific. NeuN is a 
marker of post-mitotic mature neurons, however, all mature neurons are not stained with 
NeuN (exceptions include cerebellar Purkinje cells, olfactory bulb mitral cells, and retinal 
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descriptors into engineering synonyms. The pathologist then checked to see if these 
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fold cross-validation for 4 tissue types (Bhagavatula et al Automated identification of tissues 
for digital pathology in press Transactions on Image Processing, 2011). 
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software platforms that can segment, identify, and quantify tissue from images derived 
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fetal life, late fetal life, and into childhood/adolescence/adulthood. Vimentin for instance is 
a commonly used antibody in both diagnostic and research arenas and is considered a 
marker of tissues derived from mesoderm or of mesenchymal origin and is used extensively 
in diagnostic soft tissue pathology. The antibody reacts to an intermediate filament that is 
present in most if not all fetal cells in early development and thus non-specific. NeuN is a 
marker of post-mitotic mature neurons, however, all mature neurons are not stained with 
NeuN (exceptions include cerebellar Purkinje cells, olfactory bulb mitral cells, and retinal 
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photoreceptor cells) and immature neurons are not stained. The situation can be even more 
complicated when considering actin antibodies since 6 isoforms of actin are present, four of 
which are in muscle (alpha isoforms) and two in non-muscle (beta, gamma isoforms 
involved with the cytoskeleton and cell mobility). Therefore, a commonly used antibody 
such as muscle specific actin clone HHF35 will detect the alpha and gamma isoforms but not 
cells with the beta isoform. Smooth muscle actin, clone 1A4 detects not only smooth muscle 
but myofibroblasts and myoepithelial cells also. Antibodies are available that will detect 
actins in smooth, skeletal, and cardiac muscle. Detection of endodermal derivatives 
particularly yolk sac using IHC can be even more problematic. Antibodies to cytokeratins 
can be used to detect epithelial linings but are generally not specific for derivatives of 
endoderm (Dabbs 2006). Alpha-fetoprotein is produced by immature hepatocytes (liver), 
endoderm, and yolk sac elements but because of its solubility after alcohol-based processing 
can be variably present upon immunohistochemical staining.  Glypican-3 is one of a family 
of cell surface heparan sulfate proteoglycans that is abundantly expressed in fetal life. In 
diagnostic pathology, this antigen has been shown to detect yolk sac elements (to the 
exclusion of embryonal carcinoma, germinoma and most cases of choriocarcinoma and 
teratoma elements) within human teratomas (Liu et al. ; Zynger et al. 2008). SALL4 also 
stains most yolk sac elements and is a nuclear stain but it is not as specific as it will also stain 
seminoma and embryonal carcinoma (Liu et al.). Taking into account the broad 
developmental spectrum of tissues present in teratomas, available antibodies (that have 
been tested true in FFPE tissues), and cost-to-benefit ratio (number of consecutive sections 
that must be done, staining, reagents, antibody cost, interpretation), the following table 
(Table 6) lists several antibodies that should highlight the majority of tissues present in a 
teratoma and provide delineation of germ layer derivation. Consecutive sections from each 
block of a serially sectioned teratoma could be stained with each antibody and reasonably 
accurate quantification of staining can then be performed using any number of image 
analysis software packages that can threshold by color/pixel intensity. We say “reasonably 
accurate” since antibodies only highlight the antigen they were raised against. One should 
be aware that the vast majority of antigens are typically present in one or at most two 
compartments of the cell thus an antibody to a particular antigen may only highlight the 
nucleus (in the case of most transcription factors) leaving the cytoplasm and membrane 
unstained or may highlight the membrane and not the cytoplasm or nucleus. Image analysis 
techniques that use threshold intensities will only segment the stained areas and not include 
the remainder of the cell thereby underestimating the number of pixels that contribute to 
that specific tissue. This point is illustrated in Figure 5. 
Other tissue/developmental stage specific antibodies to consider that are also readily available 
for FFPE tissues would include myogenin or myoD1 (immature skeletal muscle; marker for 
rhabdomyosarcoma in diagnostic pathology), thyroid transcription factor (TTF-1; 
lung/thyroid), CD31 (PECAM-1; endothelial cells), NeuN (Neuronal Nuclei; mature post-
mitotic neurons), Sox2 (neuroepithelium within neuroepithelial rosettes, primitive endoderm 
including yolk sac), S100 (early glia, schwannian stroma of myenteric plexuses, chondrocytes, 
adipocytes), NCAM (CD56; neural cell adhesion molecule, immature neuroglia), NFP 
(neurofilament protein, neurons), Ki-67 (proliferation marker for cells in any portion of the cell 
cycle). Antibodies to Oct4, Nanog, SSEA3, SSEA4, TRA-1-60, and TRA-1-81 are also available 
for detection of antigens associated with pluripotency, although these antigens are not 
typically present in teratomas (but can be seen in undifferentiated areas of teratocarcinomas).  
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Fig. 5. Sample immunohistochemistry of experimental teratomas. A-Vimentin stained 
section of skin surrounded by adipose and connective tissue. Vimentin highlights most 
tissue present but excludes the epithelium (vimentin, 40X), B-Vimentin stained section of 
neuroglia. In this context vimentin highlights most of the fibrillary background and the 
cytoplasm of select cells some with cytoplasmic processes (darkly stained cells). These may 
represent developing astroglia or neural stem cells (vimentin, 200X), C-Cytokeratin 20 stain 
of epithelial structures. CK 20 is a low molecular weight Type I acidic cytokeratin that is 
present mainly in colon, pancreas, ovarian surface, and bladder epithelium. In this case the 
epithelium is focally highlighted (CK20, 100x), D-Cytokeratin 7 stain of same epithelium in 
(C). CK 7 is present in lung, breast, ovarian epithelium, mesothelium, and endometrium 
(CK7, 100x). E-All muscle actin stain surrounding mucinous epithelium (AMA, 40X), F-S100 
stain of neuroglia highlights cellular and fibrillary staining of area adjacent to more 
primitive neuroepithelium (S100, red chromogen, 100X), G-NeuN stain of neuroglia 
showing crisp primarily nuclear staining of neurons (NeuN, 400X), H-PGP 9.5 stain of 
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photoreceptor cells) and immature neurons are not stained. The situation can be even more 
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accurate” since antibodies only highlight the antigen they were raised against. One should 
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unstained or may highlight the membrane and not the cytoplasm or nucleus. Image analysis 
techniques that use threshold intensities will only segment the stained areas and not include 
the remainder of the cell thereby underestimating the number of pixels that contribute to 
that specific tissue. This point is illustrated in Figure 5. 
Other tissue/developmental stage specific antibodies to consider that are also readily available 
for FFPE tissues would include myogenin or myoD1 (immature skeletal muscle; marker for 
rhabdomyosarcoma in diagnostic pathology), thyroid transcription factor (TTF-1; 
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(neurofilament protein, neurons), Ki-67 (proliferation marker for cells in any portion of the cell 
cycle). Antibodies to Oct4, Nanog, SSEA3, SSEA4, TRA-1-60, and TRA-1-81 are also available 
for detection of antigens associated with pluripotency, although these antigens are not 
typically present in teratomas (but can be seen in undifferentiated areas of teratocarcinomas).  
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neuroglia highlighting neurons and probable neuroblasts (PGP 9.5, 400x), I-glia fibrillary 
acidic protein (GFAP) stain of human teratoma highlighting some primitive 
neuroepithelium (GFAP, 200x), J-Glypican-3 stain of yolk sac tumor (taken from child with 
yolk sac tumor) (glypican-3, 200x), K-SALL4 stain of same focus of tumor seen in (J). Note 
nuclear staining pattern (SALL4, 200x), L-Ki-67 proliferation marker of neuroepithelium 
highlights nearly all cells in this focus (Ki-67, nuclear, 200x). Slides of yolk sac tumor in J and 
K kindly provided by Dr. S. Ranganathan, Children’s Hospital of Pittsburgh. 
In summary, the preceding sections have only scratched the surface of understanding 
specific developmental processes. Much of our effort has focused on being able to identify 
and quantify tissues within these tumors as a means of comparing tumors under 
experimental conditions. We believe this is a key analysis if teratomas are to be studied to 
better understand early developmental pathways and the impact of genetic and 
environmental perturbations on development. Automated image analysis may be crucial in 
providing the framework for which comparison of tissue composition and quantity can be 
made between experimental teratomas. 
6. Teratomas as models of disease: 
Since the isolation of hES cells in 1998, the application of hES cells to human health issues 
and their potential in this regard has grown exponentially. Directed differentiation of ES 
cells has produced specific tissue types that may be used for tissue engineering and tissue 
regeneration. ES cells may be helpful in drug testing, environmental mutagenesis, and 
toxicity of chemical/physical agents on organ systems and the developing embryo (Ahuja, 
Vijayalakshmi, and Polasa 2007). They could assist in the identification of molecules that 
facilitate differentiation into lineage-specific precursors. Applications for developmental 
biology, disease modeling, and cancer biology are all being investigated (Aleckovic and 
Simon 2008; Menendez, Bueno, and Wang 2006). In many of these applications, in vitro 
growth and manipulation of the stem cell population is sufficient and desirable. Early but 
restricted developmental potential is realized with embryoid body formation by hES cells in 
vitro. However, for some applications particularly when more prolonged growth or 
developmental potential is necessary, in vitro models may not be sufficient. Conclusions 
drawn from murine models of development/aberrant development, cancer, drug toxicity, 
and other human ailments will always spur some degree of doubt as to their relevance in 
the human.  
The study of tissue development in teratomas could provide a platform for investigating the 
effects of ingested toxins on the early stages of embryonic development of many different 
tissue types derived from all three germ layers. This has great significance in understanding 
the effects of maternal exposure to agents and conditions such as alcohol, tobacco, illicit 
drugs, starvation, and poor nutrition on the developing fetus. The Barker hypothesis states 
that fetal and embryonic organ functions can be affected by an altered intrauterine 
environment and these alterations of organ function determine a setpoint of physiological 
and metabolic responses that predispose to diseases in adults (Gluckman et al. 2005; Lau 
and Rogers 2004; Miles, Hofman, and Cutfield 2005). Several epidemiological studies have 
documented increased deaths due to coronary artery disease and high blood pressure in 
adults who were born with low birth weights compared to those with birth weights in high 
percentiles. Intrauterine growth restriction has been linked to impaired glucose tolerance 
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and diabetes in adulthood, reduced nephron count, hypertension, and thymic dysfunction. 
Indeed, small-for-gestational age infants show differences in growth and nutritional 
hormonal status with decreased levels of insulin-like growth factors, insulin-like growth 
factor binding proteins, leptin and others (Lau and Rogers 2004; Miles, Hofman, and 
Cutfield 2005). As a model of early human development, analysis of the teratoma derived 
from hES cells that have been subjected to various agents in culture (nicotine, alcohol) or 
treatment of the immunodeficient mouse host used for growing the teratoma could prove 
valuable in studying the molecular events of developing tissues in stressed or adverse 
intrauterine environments. 
We have demonstrated accumulation of Tau protein in neurons within teratomas established 
from a mutant hES cell line produced by transfection with a mutant presenilin gene 
(unpublished observations) (Figure 6). This opens the door for teratomas to be used to study 
specific diseases including neurodegenerative diseases after genetic modification of hES cells. 
 
 
Fig. 6. Tau staining of hES cell line transfected with mutant presenilin gene. A-Staining 
predominantly in neuroglia adjacent to neuroepithelial rosette (upper right) (Tau, 400x), B-
This same area stains with neural cell adhesion molecule signifying its immature state 
(NCAM, 200x). 
Careful analysis of teratomas would begin to unlock the effects on developing tissues 
resulting from alterations of chromosomal number or specific gene(s). The above mentioned 
study by Prokhorova et al (Prokhorova et al. 2009) clearly illustrates that alterations of 
chromosomal number in hES cells can result in dramatic changes in teratoma gross 
phenotype. 
Eiges et al established a hES cell line with full CGG expansion at the FMR1 locus from 
preimplanation embryos obtained by IVF from a premutation carrier female who had a 
brother with Fragile X syndrome. Using teratomas derived from this cell line, they were able to 
show that FMR1 inactivation (and subsequent decrease in Fragile X mental retardation protein 
(FMRP)) was dependent on differentiation of cells (Eiges et al. 2007). Mensah et al produced a 
trisomy 21 mES cell line and demonstrated that compared to the wild-type mES cells, 
teratomas derived from the trisomy 21 cells had significantly decreased amounts of 
neuroectodermal tissue, decreased mRNA for Tubb3 (neuron-specific gene) and gfap (glial 
gene), as well as reduced populations of both neuronal and glial cells (Mensah et al. 2007). 
7. Teratomas in the study of tumorigenesis 
7.1 The unifying theory of teratoma, germ cell tumor, and cancer in humans: More 
than speculation and theory? 
We have already reviewed briefly the close link between ES cells and cancer cells. Mariusz 
Ratajczak and his group from Louisville have proposed a unifying theory of teratoma, germ 
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(FMRP)) was dependent on differentiation of cells (Eiges et al. 2007). Mensah et al produced a 
trisomy 21 mES cell line and demonstrated that compared to the wild-type mES cells, 
teratomas derived from the trisomy 21 cells had significantly decreased amounts of 
neuroectodermal tissue, decreased mRNA for Tubb3 (neuron-specific gene) and gfap (glial 
gene), as well as reduced populations of both neuronal and glial cells (Mensah et al. 2007). 
7. Teratomas in the study of tumorigenesis 
7.1 The unifying theory of teratoma, germ cell tumor, and cancer in humans: More 
than speculation and theory? 
We have already reviewed briefly the close link between ES cells and cancer cells. Mariusz 
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cell tumor, and cancer development in humans. Actually, this idea is not new since several 
scientists in the 19th and early 20th century have proposed that some tumors result from 
embryonic rests or germ cells. More recent ideas have the origin of human teratomas and 
germ cell tumors from displaced visceral yolk sac elements (extraembryonic cell theory), 
primordial germ cells, and embryonic cells. Recent evidence from imprinting studies shows 
that primordial germ cells are likely candidates for the cell of origin of pediatric germ cell 
tumors (Gatcombe et al. 2004; Gonzalez-Crussi, Armed Forces Institute of Pathology (U.S.), 
and Universities Associated for Research and Education in Pathology. 1982; Gonzalez-
Crussi, Winkler, and Mirkin 1978; Kristensen et al. 2008; Oosterhuis and Looijenga 2005; 
Oosterhuis et al. 2007; Schneider et al. 2001). What is new is that the purported cell to 
support these past theories may have been found. Ratajczak has isolated from murine bone 
marrow and organs a population of very small cells (5-6 um diameter) that have phenotypic 
features of embryonic stem cells including expression of Nanog and Oct4, high telomerase 
activity, lack of major histocompatibility antigen-1 expression, abundant euchromatin, and 
lack antigenic expression of hematopoietic or other stem cells. These cells had probably been 
excluded by flow cytometry in previous experiments trying to isolate stem cells from tissues 
due to their small size. These cells termed VSELs or very small embryonic/epiblast-like cells 
share imprinting patterns similar to those of primordial germ cells (PGCs) with 
upregulation of growth-repressive maternally imprinted genes (H19, p57, IgfR2) and 
downregulation of growth promoting paternally imprinted genes (Igf2, Rasgrf1). VSELs 
remain dormant within tissues and act as a reservoir for tissue specific stem cells that 
become activated upon tissue injury. The VSELs isolated by Ratajczak regain some of the 
somatic imprinting profile after about two weeks in culture but also lose expression of Oct4 
and thus do not form teratomas in vivo ((Shin et al. 2009) and personal communication, 
Mariusz Ratajczak, M.D., Ph.D.). They have found certain culture conditions (C2C12 murine 
myoblast feeders) where VSELs will form embryoid bodies and stain for fetal alkaline 
phosphatase. They propose that transduction of VSELs with DNA methyltransferase may 
change imprinting to favor expression of growth promoting and proliferation genes 
(Ratajczak, Liu et al.) thus promoting experimental teratoma formation. A recent article by 
Parte et al demonstrates isolation of a similar population of very small embryonic-like 
pluripotent stem cells from ovarian surface epithelium (Parte et al.).  
These authors promote that VSELs are the missing link between the germ line origin of 
cancer and the current stem cell theory of cancer. Teratomas/teratocarcinomas may form 
from Oct4+ VSELs that remain dormant in tissues (maintain somatic imprinting and may 
require additional mutations). Other germ cell tumors may develop from PGCs or VSELs 
with persistent genomic imprinting and additional mutations. Pediatric small round blue 
cell tumors (tumors with multipotential phenotypes such as hepatoblastoma, Wilms tumor) 
could be derived from mutated VSELs in tissues (epigenetic changes; i.e. loss of imprint in 
H19-Igf2 locus in Beckwith-Wiedemann). Solid tumors may arise perhaps due to chronic 
inflammation and/or tissue injury that recruit circulating and/or dormant VSELs into 
damaged tissues with possible heterokaryon formation and the formation of aneuploid cells. 
(Ratajczak, Shin, and Kucia 2009; Ratajczak, Shin et al. ; Ratajczak et al. 2008; Shin et al. 
2009).  
7.2 Teratomas as aids in the study of cancer 
An interesting proposal by Tzukerman et al uses teratomas not necessarily as a model for 
tumorigenesis/cancer pathogenesis but as an environmental platform for studying tumor 
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growth and behavior (Tzukerman et al. 2003). They question the validity of in vitro models 
to study tumor growth and invasive capability and current in vivo models that use 
immunocompromised mice. They postulate that murine in vivo models do not mimic what 
a tumor might do in a human host surrounded by human cells. Their study demonstrated 
that human ovarian cancer cells injected into teratomas derived from hES cells integrate into 
and invade surrounding human tissue (within the teratoma) and stimulate neoangiogenesis. 
They suggest that this type of analysis would be the intermediary step between in vitro and 
murine in vivo testing of anti-neoplastic agents and human clinical trials. Anti-neoplastic 
agents could be tested on tumors within a milieu of human cells derived from teratomas.  
8. Conclusion 
One of the obvious differences between teratomas and a developing human embryo is that 
we can look at a developing embryo and say (at some point) that the embryo will develop 
into a human being. We cannot say the same for the teratoma. We really don’t know what a 
teratoma can or will develop into. The dissociation of the blastocyst in reality disarms the 
entire orderly developmental program forever and when blastocyst cells are collected, 
reaggregated, and rearranged in a foreign host they simply do not know which end should 
be up.  
Human beings and all life for that matter are amazing in their construction and 
unconsciously coordinated physiological functions. Form and function are seamlessly 
woven into a biological tapestry. Teratomas derived from embryonic stem cells are likewise 
amazing tumors, a visual masterpiece under the microscope; modern or abstract tissue art if 
you will.  Like many examples in the biomedical world, we know who they are but really 
know very little about what they are. At this point they are more like art in that they have 
been interpreted individually; “in the eye of the beholder” if you will for the purposes of 
delineating the presence of three germ layers. Teratomas may be able to help answer many 
questions. How much of each specific tissue type is present? Do the tissues present 
recapitulate normal development in three-dimensional space and time?  How are the tissues 
present affected in type and quantity when derived from ES cells that have been 
manipulated genetically (induced chromosomal aberration, addition/deletion of specific 
genes) and environmentally (that is, by drugs or toxins, nutrients)?  Do all ES cell lines have 
the equal potential of differentiating successfully into a specific cell type that could be 
potentially used to treat specific diseases such as Diabetes or Parkinson’s disease?  How 
does ES cell phenotype, cell number, site of injection, and host affect tissue formation in 
teratomas?  What are the growth kinetics of teratomas?  What influences success rate of 
teratoma formation?  How do teratomas develop?  What growth factors influence teratoma 
growth and tissue development?  Do specific developmental programs (tissue or germ layer 
specific) always show specific developmental potentials?  Why does a developmental 
spectrum (developmentally heterogeneous) of tissues exist within a single teratoma?  Why 
do some “organs” develop more fully than others (i.e. intestine versus kidney)?  Why are 
some tissues hardly ever seen (i.e. liver, thyroid)?  Why do teratomas have difficulty 
forming blood vessels derived entirely from the injected ES cells?  Do teratomas differ in 
their tissue composition between species?  At the root of finding the answers to many of 
these questions will be the ability to carefully, accurately, quantitatively, and quickly 
delineate tissue types and three-dimensional tissue arrangements both in vivo and ex vivo. 
Thus techniques for imaging in vivo and ex vivo and image analysis of histological sections 
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cell tumor, and cancer development in humans. Actually, this idea is not new since several 
scientists in the 19th and early 20th century have proposed that some tumors result from 
embryonic rests or germ cells. More recent ideas have the origin of human teratomas and 
germ cell tumors from displaced visceral yolk sac elements (extraembryonic cell theory), 
primordial germ cells, and embryonic cells. Recent evidence from imprinting studies shows 
that primordial germ cells are likely candidates for the cell of origin of pediatric germ cell 
tumors (Gatcombe et al. 2004; Gonzalez-Crussi, Armed Forces Institute of Pathology (U.S.), 
and Universities Associated for Research and Education in Pathology. 1982; Gonzalez-
Crussi, Winkler, and Mirkin 1978; Kristensen et al. 2008; Oosterhuis and Looijenga 2005; 
Oosterhuis et al. 2007; Schneider et al. 2001). What is new is that the purported cell to 
support these past theories may have been found. Ratajczak has isolated from murine bone 
marrow and organs a population of very small cells (5-6 um diameter) that have phenotypic 
features of embryonic stem cells including expression of Nanog and Oct4, high telomerase 
activity, lack of major histocompatibility antigen-1 expression, abundant euchromatin, and 
lack antigenic expression of hematopoietic or other stem cells. These cells had probably been 
excluded by flow cytometry in previous experiments trying to isolate stem cells from tissues 
due to their small size. These cells termed VSELs or very small embryonic/epiblast-like cells 
share imprinting patterns similar to those of primordial germ cells (PGCs) with 
upregulation of growth-repressive maternally imprinted genes (H19, p57, IgfR2) and 
downregulation of growth promoting paternally imprinted genes (Igf2, Rasgrf1). VSELs 
remain dormant within tissues and act as a reservoir for tissue specific stem cells that 
become activated upon tissue injury. The VSELs isolated by Ratajczak regain some of the 
somatic imprinting profile after about two weeks in culture but also lose expression of Oct4 
and thus do not form teratomas in vivo ((Shin et al. 2009) and personal communication, 
Mariusz Ratajczak, M.D., Ph.D.). They have found certain culture conditions (C2C12 murine 
myoblast feeders) where VSELs will form embryoid bodies and stain for fetal alkaline 
phosphatase. They propose that transduction of VSELs with DNA methyltransferase may 
change imprinting to favor expression of growth promoting and proliferation genes 
(Ratajczak, Liu et al.) thus promoting experimental teratoma formation. A recent article by 
Parte et al demonstrates isolation of a similar population of very small embryonic-like 
pluripotent stem cells from ovarian surface epithelium (Parte et al.).  
These authors promote that VSELs are the missing link between the germ line origin of 
cancer and the current stem cell theory of cancer. Teratomas/teratocarcinomas may form 
from Oct4+ VSELs that remain dormant in tissues (maintain somatic imprinting and may 
require additional mutations). Other germ cell tumors may develop from PGCs or VSELs 
with persistent genomic imprinting and additional mutations. Pediatric small round blue 
cell tumors (tumors with multipotential phenotypes such as hepatoblastoma, Wilms tumor) 
could be derived from mutated VSELs in tissues (epigenetic changes; i.e. loss of imprint in 
H19-Igf2 locus in Beckwith-Wiedemann). Solid tumors may arise perhaps due to chronic 
inflammation and/or tissue injury that recruit circulating and/or dormant VSELs into 
damaged tissues with possible heterokaryon formation and the formation of aneuploid cells. 
(Ratajczak, Shin, and Kucia 2009; Ratajczak, Shin et al. ; Ratajczak et al. 2008; Shin et al. 
2009).  
7.2 Teratomas as aids in the study of cancer 
An interesting proposal by Tzukerman et al uses teratomas not necessarily as a model for 
tumorigenesis/cancer pathogenesis but as an environmental platform for studying tumor 
Teratomas Derived from Embryonic Stem Cells  
as Models for Embryonic Development, Disease, and Tumorigenesis 
 
257 
growth and behavior (Tzukerman et al. 2003). They question the validity of in vitro models 
to study tumor growth and invasive capability and current in vivo models that use 
immunocompromised mice. They postulate that murine in vivo models do not mimic what 
a tumor might do in a human host surrounded by human cells. Their study demonstrated 
that human ovarian cancer cells injected into teratomas derived from hES cells integrate into 
and invade surrounding human tissue (within the teratoma) and stimulate neoangiogenesis. 
They suggest that this type of analysis would be the intermediary step between in vitro and 
murine in vivo testing of anti-neoplastic agents and human clinical trials. Anti-neoplastic 
agents could be tested on tumors within a milieu of human cells derived from teratomas.  
8. Conclusion 
One of the obvious differences between teratomas and a developing human embryo is that 
we can look at a developing embryo and say (at some point) that the embryo will develop 
into a human being. We cannot say the same for the teratoma. We really don’t know what a 
teratoma can or will develop into. The dissociation of the blastocyst in reality disarms the 
entire orderly developmental program forever and when blastocyst cells are collected, 
reaggregated, and rearranged in a foreign host they simply do not know which end should 
be up.  
Human beings and all life for that matter are amazing in their construction and 
unconsciously coordinated physiological functions. Form and function are seamlessly 
woven into a biological tapestry. Teratomas derived from embryonic stem cells are likewise 
amazing tumors, a visual masterpiece under the microscope; modern or abstract tissue art if 
you will.  Like many examples in the biomedical world, we know who they are but really 
know very little about what they are. At this point they are more like art in that they have 
been interpreted individually; “in the eye of the beholder” if you will for the purposes of 
delineating the presence of three germ layers. Teratomas may be able to help answer many 
questions. How much of each specific tissue type is present? Do the tissues present 
recapitulate normal development in three-dimensional space and time?  How are the tissues 
present affected in type and quantity when derived from ES cells that have been 
manipulated genetically (induced chromosomal aberration, addition/deletion of specific 
genes) and environmentally (that is, by drugs or toxins, nutrients)?  Do all ES cell lines have 
the equal potential of differentiating successfully into a specific cell type that could be 
potentially used to treat specific diseases such as Diabetes or Parkinson’s disease?  How 
does ES cell phenotype, cell number, site of injection, and host affect tissue formation in 
teratomas?  What are the growth kinetics of teratomas?  What influences success rate of 
teratoma formation?  How do teratomas develop?  What growth factors influence teratoma 
growth and tissue development?  Do specific developmental programs (tissue or germ layer 
specific) always show specific developmental potentials?  Why does a developmental 
spectrum (developmentally heterogeneous) of tissues exist within a single teratoma?  Why 
do some “organs” develop more fully than others (i.e. intestine versus kidney)?  Why are 
some tissues hardly ever seen (i.e. liver, thyroid)?  Why do teratomas have difficulty 
forming blood vessels derived entirely from the injected ES cells?  Do teratomas differ in 
their tissue composition between species?  At the root of finding the answers to many of 
these questions will be the ability to carefully, accurately, quantitatively, and quickly 
delineate tissue types and three-dimensional tissue arrangements both in vivo and ex vivo. 
Thus techniques for imaging in vivo and ex vivo and image analysis of histological sections 
 
Embryonic Stem Cells – Basic Biology to Bioengineering 
 
258 
need to be investigated with full vigor and intensity. Targeting specific genes to track 
expression of known early embryological pathways within teratomas will be the key to 
unlocking developmental fate and for studying specific human chromosomal and genetic 
diseases.     
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In recent years stem cells become a major topic both publicly and scientifically owing to 
their promise to cure diseases and restore organ functionality. Yet our understanding of the 
biology of stem cells and their inherent features is largely lagging behind the great promise 
of using these cells in transplantation therapies. In this chapter we highlight several aspects 
of the biology of stem cells/induced pluripotent stem (iPS) cells that are often overlooked. 
We define stem cells not only by their developmental capacities, namely, self-renewal and 
multi-lineage differentiation, but also by their inherent features. We present new 
bioinformatic data and draw the stem cell picture based on recent knowledge emerging 
from studying stem cells in plant and animal systems with emphasis on chromatin 
structure. We highlight some of the potentially hazardous pathways associated with cellular 
dedifferentiation (iPS cells) and with culturing stem cells. Notably, genomic modification 
associated with iPS cells is often discussed with respect to the methodology of introducing 
reprogramming genes into the host cells, namely, lentiviral/retroviral transduction, while 
ignoring the potential genomic modification naturally associated with dedifferentiation or 
with stress events. Based on our understanding of cellular processes accompanied stress 
response and cellular dedifferentiation we discuss strategies for improving the quantity and 
quality of iPS cells.  
2. Inherent features of stem cells 
2.1 What are stem cells? 
One major, long recognized, pitfall in stem cell biology is that stem cells are commonly 
defined by their developmental potentialities, namely, self-renewal and multitype 
differentiation, rather than by their intrinsic features (Potten & Loeffler, 1990; McKay, 2000). 
This often leads to the erroneous assumption that reentry of stem cells to the cell cycle for 
the purpose of the so-called ‘self-renewal’ represents an inherent feature of stem cells. 
Consequently, the term stem cell culture has been established, leading biologists to 
incorrectly assume that stem cell features can be fully maintained under culture conditions 
(Grafi & Avivi, 2004). Considering that animal somatic cells are capable to become stem cells 
via dedifferentiation (Kurisaki et al., 2010), the traditional developmental capacity-based 
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definition of stem cells may be useless in distinguishing between genuine stem cells and 
somatic cells that have the capacity to become stem cells. Obviously, defining stem cells by 
their inherent features or signature rather than their developmental capabilities is necessary.  
The signature of a given differentiated cell is commonly reflected in its gene expression 
profile. The attempts to uncover the ‘stem cell signature’ or the ‘stemness genes’ via 
transcriptome analysis of different stem cell culture lines were failed as these experiments 
yielded different ‘signatures’ and non-overlapping ‘stemness genes’ (Ramalho-Santos et al., 
2002; Ivanova et al., 2002; Fortunel et al., 2003). This again highlighted the problem of 
defining stem cells by their developmental capacity, namely, self-renewal (cultured cells) 
(Grafi & Avivi, 2004). Contrary to the idea that stem cells represent a unique entity that is 
characterized by the expression of specific set of ‘stemness’ genes, it has been suggested that 
stem cells represent a unique transient state characterized by promiscuous expression of 
marker genes (Zipori, 2004). Consequently, several possibilities could describe the 
transcriptional landscapes of stem cells: (i) differentiation/lineage-specific genes are not 
expressed in stem cells, (ii) differentiation/lineage-specific genes are widely expressed in 
stem cells but at a very low level, and (iii) differentiation/lineage-specific genes are not 
expressed but assume a transcriptionally competent chromatin state (Zipori, 2004; Meshorer 
& Misteli, 2006; Efroni et al., 2008). The later is supported by the fact that stem cells, like 
dedifferentiating cells, acquire open, decondensed chromatin architecture, which is essential 
though not sufficient for initiating gene transcription (Williams et al., 2003; Grafi, 2004; 
Gaspar-Maia et al., 2011) as well as by the finding that some non-expressed genes or genes 
expressed at low levels in embryonic stem (ES) cells are primed but their transcription is 
attenuated by a unique combination of permissive and restrictive chromatin marks (Azuara 
et al., 2006; Bernstein et al., 2006). Apparently open chromatin configuration appears to be 
an intrinsic feature of stem cells that can be used to distinguish between actual stem cells 
and potential stem cells.  
2.2 Chromatin structure and regulation in brief 
The basic structural unit of chromatin is the nucleosome, which is composed of DNA 
wrapped around histone octamer made of two of each of core histone proteins, namely, 
H2A, H2B, H3 and H4. All core histone proteins share a common structural motif called the 
histone fold consisting of three alpha helices connected by short loops (Arents & 
Moudrianakis, 1995). The X-ray crystal structure of the nucleosome core particle showed 
that interactions between core histone proteins or between histone octamer and duplex 
DNA are largely dependent on the histone fold motif. The histone amino-terminal tail is 
unstructured and protruding outside the nucleosomal disk where it can contact with 
neighboring nucleosomes or with proteins or protein complexes that affect chromatin 
structure and function. The structure of chromatin is highly dynamic, facilitating the 
transition between permissive and repressive chromatin. This dynamic structure is 
controlled by multiple types of reversible chemical modifications that occur on the DNA 
(cytosine methylation) or on the DNA interacting core histone proteins. Most modifications 
of histone proteins occur on the N-terminal tails and include acetylation, methylation, 
phosphorylation, and ubiquitination. These chemical modifications can directly affect the 
interaction with DNA or generate binding sites for recruitment of proteins or protein 
complexes that affect the structure and function of chromatin and consequently 
differentiation and development. Gene promoters can be found in three fundamental states 
determined by their histone modification marks, namely, restrictive (e.g., methylated 
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H3K9/K27), permissive (e.g., methylated H3K4, acetylated H3K9) or both restrictive and 
permissive (e.g., methylated H3K27, methylated H3K4, also known as ‘bivalent’ state). For 
example, SET domain-containing histone methyltransferase proteins, such as Clr4 (Cryptic 
locus regulator) in Schizosaccharomyces pombe and SUV39H1 and SUV39H2 in humans are 
enzymes that methylate histone H3 specifically at lysine 9 (Rea et al., 2000). This methylation 
generates a binding site for Heterochromatin protein 1 (HP1) (Bannister et al., 2001; Lachner 
et al., 2001), which is required for the establishment of a condensed, repressive chromatin. 
Conversely, histone acetylation or methylation of histone H3 at lysine 4 are often associated 
with 'open' chromatin configuration and gene transcription (Eberharter & Becker, 2002; Lee 
& Workman, 2007; Eissenberg & Shilatifard, 2010). More recently it has been shown that 
some non-expressed genes or genes expressed at low levels in ES cells carry both permissive 
(H3K4me3; trimethylated H3K4) and restrictive (H3K27me3; trimethylated H3K27) 
chromatin marks (Azuara et al., 2006; Bernstein et al., 2006). This unique ‘bivalent’ 
chromatin state suggests a model in which many tissue-specific regulatory genes are 
‘primed’ but their transcription is delayed until entry into a specific differentiation pathway 
that dictate either activation (e.g., recruitment of H3K27 demethylases) or silencing (e.g., 
recruitment of H3K4 demethylses) of the gene locus (Lan et al., 2008). Notably, bivalent 
domains were found to occur also in the rice genome in somatic cells where a large 
proportion of genes possessing the repressive mark H3K27me3 also contained permissive 
marks of H3K4me3 and H3K9ac (acetylated H3K9) (He et al., 2010).  
2.3 Chromatin modifiers and the establishment of stem cell state 
Stem cells as well as dedifferentiating cells have been shown to maintain their chromatin in 
an open, decondensed configuration relative to differentiated cells (reviewed in Gaspar-
Maia et al., 2011). Accordingly, chromatin decondensation appears to be a hallmark of cells 
engaged in switching fate, a process, which requires the acquisition of a stem cell-like state, 
which is essential for normal development. For example, during fertilization, 
decondensation of sperm chromatin is essential for the formation of the male pronucleus, 
which is necessary for successful fertilization (Longo & Anderson, 1968). Interestingly, 
sperm chromatin decondensation can be mimicked in Xenopus egg extracts and requires 
nucleoplasmin, an acidic, thermostable, abundant nuclear protein capable of binding histone 
proteins (Laskey et al., 1978; Philpott et al., 1991; Katagiri & Ohsumi, 1994). Similarly, 
Xenopus egg extracts can induce chromatin decondensation of heterologous somatic nuclei. 
It has been shown that nuclei derived from chicken erythrocytes incubated in Xenopus egg 
extract were induced to replicate their DNA, a process preceded by two sequential phases of 
chromatin decondensation (Blank et al., 1992). Chromatin decondensation was reported in 
cells of regenerating tissues of the tubeworm Owenia fusiformis 12 h after amputation (Fontes 
et al., 1980), a stage, which might correlate with cellular dedifferentiation whereby somatic 
cells at the amputation site withdraw from their differentiated state and acquire stem cell-
like state (Grafi, 2004). In plants, chromatin decondensation was found to be associated with 
cellular dedifferentiation induced following exposure to various stress conditions (e.g., 
protoplasting, exposure to dark) (Zhao et al., 2001; Tessadori et al., 2007; Damri et al., 2009, 
Grafi et al., 2011).  
The evidence that stem cells may assume a more open chromatin conformation is dated 
about 40 years ago with the description of the morphological characteristics of the so-called 
stem cells in the bone marrow by Murphy et al. (1971). Using electron microscopy 
examination of 3-day post hypoxic marrow, they found that the large mononuclear cells are 
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definition of stem cells may be useless in distinguishing between genuine stem cells and 
somatic cells that have the capacity to become stem cells. Obviously, defining stem cells by 
their inherent features or signature rather than their developmental capabilities is necessary.  
The signature of a given differentiated cell is commonly reflected in its gene expression 
profile. The attempts to uncover the ‘stem cell signature’ or the ‘stemness genes’ via 
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2.2 Chromatin structure and regulation in brief 
The basic structural unit of chromatin is the nucleosome, which is composed of DNA 
wrapped around histone octamer made of two of each of core histone proteins, namely, 
H2A, H2B, H3 and H4. All core histone proteins share a common structural motif called the 
histone fold consisting of three alpha helices connected by short loops (Arents & 
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H3K9/K27), permissive (e.g., methylated H3K4, acetylated H3K9) or both restrictive and 
permissive (e.g., methylated H3K27, methylated H3K4, also known as ‘bivalent’ state). For 
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It has been shown that nuclei derived from chicken erythrocytes incubated in Xenopus egg 
extract were induced to replicate their DNA, a process preceded by two sequential phases of 
chromatin decondensation (Blank et al., 1992). Chromatin decondensation was reported in 
cells of regenerating tissues of the tubeworm Owenia fusiformis 12 h after amputation (Fontes 
et al., 1980), a stage, which might correlate with cellular dedifferentiation whereby somatic 
cells at the amputation site withdraw from their differentiated state and acquire stem cell-
like state (Grafi, 2004). In plants, chromatin decondensation was found to be associated with 
cellular dedifferentiation induced following exposure to various stress conditions (e.g., 
protoplasting, exposure to dark) (Zhao et al., 2001; Tessadori et al., 2007; Damri et al., 2009, 
Grafi et al., 2011).  
The evidence that stem cells may assume a more open chromatin conformation is dated 
about 40 years ago with the description of the morphological characteristics of the so-called 
stem cells in the bone marrow by Murphy et al. (1971). Using electron microscopy 
examination of 3-day post hypoxic marrow, they found that the large mononuclear cells are 
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characterized by a fine nuclear chromatin (leptochromatic) with some peripheral 
condensation. Likewise, electron microscopy inspection of the erythropoietic cells of the 
chick showed that stem cells are characterized by large nuclei and homogenous 
euchromatin, while maturation is accompanied by an increase in nuclear condensation 
indicated by areas of heterochromatin (MacRae & Meetz, 1970). Also, ultrastructure of 
developing erythrocytes in the bone marrow of human adults showed that in the earliest 
stages, the nucleoplasm was chiefly composed of euchromatin, while during maturation 
heterochromatin was rapidly increased concomitantly with a reduction in nuclear size 
(Miura et al., 1974). Furthermore, using micrococcal nuclease, Weintraub (1978) showed that 
the nucleosome repeat length (NRL) increases from 190 to 212 basepairs during 
erythropoiesis in the chick, which was accompanied by a significant increase in the 
concentration of red cell specific histone H5, a linker histone necessary for stabilization of 
higher order chromatin structure (Robinson & Rhodes, 2006). This increase in NRL has 
recently been shown to be required for the formation of the 30 nm DNA fiber-induced 
chromatin compaction (Routh et al., 2008). Notably, similarly to animal stem cells, 
ultrastructural observations of the nuclei in the shoot apex (the plant stem cell niche) of the 
plant Tradescantia paludosa showed that a large proportion of the chromatin is organized as 
less condensed, diffused euchromatin fibrils (Booker & Dwivedi, 1973). 
It has been demonstrated that chromatin decondensation of somatic nuclei in Xenopus egg 
extracts requires the chromatin-remodeling nucleosomal adenosine triphosphatase (ATPase) 
ISWI (Kikyo et al., 2000). More recently, it has been shown that embryonic stem cells are 
extensively engaged in global gene transcription, due in part to overrepresentation of 
chromatin-remodeling genes and the general transcription machinery; this activity is 
diminished upon differentiation (Efroni et al., 2008). Knockdown by RNAi of the SWI/SNF 
remodeling factor BRG1 and of the ISWI-related chromodomain helicase DNA binding 
protein 1-like (Chd1l) resulted in impairment of ES cell differentiation and proliferation 
(Efroni et al., 2008). Indeed, knockdown of Chd1 in ES cells established its importance for 
maintaining open chromatin, pluripotency of embryonic stem cells, as well as for 
reprogramming of somatic cell to pluripotent state (Gaspar-Maia et al., 2009). Furthermore, 
reprogramming of somatic cells by the expression of the four transcription factors, Oct4, 
Sox2, Klf4 and c-Myc is facilitated by combined expression of chromatin remodeling 
components of the BAF (Brg1/Brahma-associated factor) complex (Singhal et al., 2010). 
2.4 Pattern of chromatin modifier gene expression in stem cells and dedifferentiating 
cells 
Open chromatin configuration emerges as a fundamental theme in pluripotent stem cell 
biology, and should be primarily served as a major attribute for defining the stem cell state. 
This open chromatin conformation is crucial for maintaining the stemness state, which 
might confer stem cells with the capacity for rapid switching into the appropriate 
transcriptional program upon induction of differentiation and with the flexibility needed for 
differentiation into multiple cell types. Thus, in looking for molecular features defining stem 
cells we should highlight the molecular components regulating chromatin structure, namely 
chromatin modifier genes (CMGs). There are two possible ways for maintaining the unique 
chromatin state characteristic of stem cells, which we define as quantitative and qualitative 
approaches. The quantitative approach suggests that the flexibility needed for stem cells to 
differentiate into multiple cell types can be achieved by promiscuous expression of CMGs, 
while the qualitative approach suggests that the open chromatin conformation characteristic 
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of stem cells is maintained by selective expression and repression of genes that promote the 
formation of permissive and restrictive chromatin, respectively.  
The quantitative approach gains support from analysis of the gene expression profiles of 
the plant shoot apical meristem (SAM) stem cells (Yadav et al., 2009). By introducing 
fluorescent reporters into SAM-enriched Arabidopsis background line, Yadav et al. (2009) 
have isolated by FACS three distinct cell types of the SAM stem cell niche and analyzed 
the transcriptome profiles of these cells. One major attribute of SAM stem cells appears to 
be a flexible chromatin state demonstrated by the overrepresentation of genes involved in 
chromatin organization (Yadav et al., 2009). Remarkably, further analysis of the available 
microarray dataset of the SAM stem cells revealed that among the 445 CMGs, which were 
represented on the ATH1 array, stem cells showed the expression of 297 genes whose 
expression signal is higher than 256 (>28). This unusual expression of chromatin modifier 
genes in SAM stem cells might confer the flexibility required for maintaining the 
pluripotent state of stem cells. 
Apparently, this widespread expression of CMGs observed in SAM stem cells is not 
mimicked in dedifferentiating plant cells. Transcriptome profiling of dedifferentiating 
protoplast cells (Damri et al., 2009) showed that among the 465 CMGs, which were 
represented on the ATH1 array only 95 genes displayed an expression signal higher than 
256 (>28). However, close examination of these CMGs highlighted the qualitative approach 
revealing that many of the genes that were down-regulated in dedifferentiating protoplasts, 
such as histone deacetylase encoding genes SRT2, HDA14 and HDT4, as well as linker 
histone genes Hon1 and Hon2 are implicated in chromatin compaction, while many of the 
CMGs that were up-regulated, such as histone acetyltransferase encoding genes HAF1, 
HAC5 and HAG3 as well as histone demethylase genes JMJ21 and JMJ13 are implicated in 
chromatin decondensation. Thus the expression profile of CMGs favors the acquisition of an 
open chromatin conformation in dedifferentiating cells.  
Since open chromatin configuration characterizes stem cells as well as dedifferentiated cells 
in plants and animals, the study of these cells in plants might have bearing to understanding 
inherent biological features of animal stem cells. 
2.5 CMGs as a tool for monitoring pluripotency 
We hypothesized that these features of quantitative and qualitative CMG expression of 
SAM stem cells and dedifferentiating cells, respectively, might hold also for human stem 
cells and dedifferentiating cells and could serve as a distinguishing feature between animal 
cells displaying various levels of pluripotency. To assess the qualitative approach, we first 
predefined a set of human CMG families, which were selected based on their predicted 
chromatin function, namely, histone deacetylases (HDACs) involved in heterochromatin 
formation, histone acetyltransferases (HATs), which are involved in euchromatin formation 
and the jumonji family of histone demethylases implicated in both euchromatin and 
heterochromatin formation. We then checked the expression level of these predefined CMGs 
(listed in Table 1) in a recently published meta-analysis of human gene expression datasets 
(Lukk et al., 2010). In this study, the authors collected and integrated high-quality data from 
5,372 samples from 206 different studies, all generated using Affymetrix U133A arrays and 
deposited in public databases. Using text mining and curation, the authors binned the 
samples in 369 biological groups, each representing a particular cell or tissue type, disease 
state or cell line. Additionally, samples were grouped more crudely according to different 
criteria, one of which divided the samples into four meta-groups: Cell lines, Neoplasms, 
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characterized by a fine nuclear chromatin (leptochromatic) with some peripheral 
condensation. Likewise, electron microscopy inspection of the erythropoietic cells of the 
chick showed that stem cells are characterized by large nuclei and homogenous 
euchromatin, while maturation is accompanied by an increase in nuclear condensation 
indicated by areas of heterochromatin (MacRae & Meetz, 1970). Also, ultrastructure of 
developing erythrocytes in the bone marrow of human adults showed that in the earliest 
stages, the nucleoplasm was chiefly composed of euchromatin, while during maturation 
heterochromatin was rapidly increased concomitantly with a reduction in nuclear size 
(Miura et al., 1974). Furthermore, using micrococcal nuclease, Weintraub (1978) showed that 
the nucleosome repeat length (NRL) increases from 190 to 212 basepairs during 
erythropoiesis in the chick, which was accompanied by a significant increase in the 
concentration of red cell specific histone H5, a linker histone necessary for stabilization of 
higher order chromatin structure (Robinson & Rhodes, 2006). This increase in NRL has 
recently been shown to be required for the formation of the 30 nm DNA fiber-induced 
chromatin compaction (Routh et al., 2008). Notably, similarly to animal stem cells, 
ultrastructural observations of the nuclei in the shoot apex (the plant stem cell niche) of the 
plant Tradescantia paludosa showed that a large proportion of the chromatin is organized as 
less condensed, diffused euchromatin fibrils (Booker & Dwivedi, 1973). 
It has been demonstrated that chromatin decondensation of somatic nuclei in Xenopus egg 
extracts requires the chromatin-remodeling nucleosomal adenosine triphosphatase (ATPase) 
ISWI (Kikyo et al., 2000). More recently, it has been shown that embryonic stem cells are 
extensively engaged in global gene transcription, due in part to overrepresentation of 
chromatin-remodeling genes and the general transcription machinery; this activity is 
diminished upon differentiation (Efroni et al., 2008). Knockdown by RNAi of the SWI/SNF 
remodeling factor BRG1 and of the ISWI-related chromodomain helicase DNA binding 
protein 1-like (Chd1l) resulted in impairment of ES cell differentiation and proliferation 
(Efroni et al., 2008). Indeed, knockdown of Chd1 in ES cells established its importance for 
maintaining open chromatin, pluripotency of embryonic stem cells, as well as for 
reprogramming of somatic cell to pluripotent state (Gaspar-Maia et al., 2009). Furthermore, 
reprogramming of somatic cells by the expression of the four transcription factors, Oct4, 
Sox2, Klf4 and c-Myc is facilitated by combined expression of chromatin remodeling 
components of the BAF (Brg1/Brahma-associated factor) complex (Singhal et al., 2010). 
2.4 Pattern of chromatin modifier gene expression in stem cells and dedifferentiating 
cells 
Open chromatin configuration emerges as a fundamental theme in pluripotent stem cell 
biology, and should be primarily served as a major attribute for defining the stem cell state. 
This open chromatin conformation is crucial for maintaining the stemness state, which 
might confer stem cells with the capacity for rapid switching into the appropriate 
transcriptional program upon induction of differentiation and with the flexibility needed for 
differentiation into multiple cell types. Thus, in looking for molecular features defining stem 
cells we should highlight the molecular components regulating chromatin structure, namely 
chromatin modifier genes (CMGs). There are two possible ways for maintaining the unique 
chromatin state characteristic of stem cells, which we define as quantitative and qualitative 
approaches. The quantitative approach suggests that the flexibility needed for stem cells to 
differentiate into multiple cell types can be achieved by promiscuous expression of CMGs, 
while the qualitative approach suggests that the open chromatin conformation characteristic 
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of stem cells is maintained by selective expression and repression of genes that promote the 
formation of permissive and restrictive chromatin, respectively.  
The quantitative approach gains support from analysis of the gene expression profiles of 
the plant shoot apical meristem (SAM) stem cells (Yadav et al., 2009). By introducing 
fluorescent reporters into SAM-enriched Arabidopsis background line, Yadav et al. (2009) 
have isolated by FACS three distinct cell types of the SAM stem cell niche and analyzed 
the transcriptome profiles of these cells. One major attribute of SAM stem cells appears to 
be a flexible chromatin state demonstrated by the overrepresentation of genes involved in 
chromatin organization (Yadav et al., 2009). Remarkably, further analysis of the available 
microarray dataset of the SAM stem cells revealed that among the 445 CMGs, which were 
represented on the ATH1 array, stem cells showed the expression of 297 genes whose 
expression signal is higher than 256 (>28). This unusual expression of chromatin modifier 
genes in SAM stem cells might confer the flexibility required for maintaining the 
pluripotent state of stem cells. 
Apparently, this widespread expression of CMGs observed in SAM stem cells is not 
mimicked in dedifferentiating plant cells. Transcriptome profiling of dedifferentiating 
protoplast cells (Damri et al., 2009) showed that among the 465 CMGs, which were 
represented on the ATH1 array only 95 genes displayed an expression signal higher than 
256 (>28). However, close examination of these CMGs highlighted the qualitative approach 
revealing that many of the genes that were down-regulated in dedifferentiating protoplasts, 
such as histone deacetylase encoding genes SRT2, HDA14 and HDT4, as well as linker 
histone genes Hon1 and Hon2 are implicated in chromatin compaction, while many of the 
CMGs that were up-regulated, such as histone acetyltransferase encoding genes HAF1, 
HAC5 and HAG3 as well as histone demethylase genes JMJ21 and JMJ13 are implicated in 
chromatin decondensation. Thus the expression profile of CMGs favors the acquisition of an 
open chromatin conformation in dedifferentiating cells.  
Since open chromatin configuration characterizes stem cells as well as dedifferentiated cells 
in plants and animals, the study of these cells in plants might have bearing to understanding 
inherent biological features of animal stem cells. 
2.5 CMGs as a tool for monitoring pluripotency 
We hypothesized that these features of quantitative and qualitative CMG expression of 
SAM stem cells and dedifferentiating cells, respectively, might hold also for human stem 
cells and dedifferentiating cells and could serve as a distinguishing feature between animal 
cells displaying various levels of pluripotency. To assess the qualitative approach, we first 
predefined a set of human CMG families, which were selected based on their predicted 
chromatin function, namely, histone deacetylases (HDACs) involved in heterochromatin 
formation, histone acetyltransferases (HATs), which are involved in euchromatin formation 
and the jumonji family of histone demethylases implicated in both euchromatin and 
heterochromatin formation. We then checked the expression level of these predefined CMGs 
(listed in Table 1) in a recently published meta-analysis of human gene expression datasets 
(Lukk et al., 2010). In this study, the authors collected and integrated high-quality data from 
5,372 samples from 206 different studies, all generated using Affymetrix U133A arrays and 
deposited in public databases. Using text mining and curation, the authors binned the 
samples in 369 biological groups, each representing a particular cell or tissue type, disease 
state or cell line. Additionally, samples were grouped more crudely according to different 
criteria, one of which divided the samples into four meta-groups: Cell lines, Neoplasms, 
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Non-neoplastic diseases, and Normal. We have downloaded the entire gene expression 
matrix from the ArrayExpress repository (accession number E-MTAB-62), and reduced it to 
include only the 1033 samples of the "Normal" meta-group, and the 40 CMGs indicated in 
Table 1. Subsequently, probe sets which represented the same gene were consolidated as 
follows: (1) probe sets with signal intensity lower than 5 (in log2 scale) in all 1033 samples 
were removed, provided that at least one probe set for the same gene had signal intensity 
higher than 5 (in log2 scale) in at least one of the samples. (2) The signal intensities of the 
remaining probe sets were averaged to yield a single expression value per gene per sample. 
The resulting matrix was loaded into Partek Genomics SuiteTM. To allow for gene-wise 
comparison of expression profiles, expression values were standardized such that the mean 
and standard deviation of each gene's values were 0 and 1, respectively. The standardized 
dataset was subjected to bi-directional hierarchical clustering using Euclidean distance and 
complete linkage. Finally, sample annotations indicating 6 meta-groups (brain, cell line, 
hematopoietic system, incompletely differentiated, muscle, solid tissue) and operating 
laboratory were added. As shown in Fig. 1, based on their expression pattern, the CMGs 
were clearly clustered into three major clades. Most intriguing is clade 1 displaying  
 
 
Fig. 1. Bi-directional hierarchical clustering of 40 CMGs expression in 1033 normal human 
tissues derived from public datasets compiled by Lukk et al. (2010). Gene-wise standardized 
expression level is shown as colored squares on a red-black-green scale (from up- to down-
regulation, respectively). Samples are labeled by two color columns indicating their meta-
group and operating laboratory. The three clustered CMG groups (1-3) displaying peculiar 
upregulation in a specific sample clade (A, B, D) are boxed yellow.  
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upregulation of 18 CMGs out of the 40 examined as they form a homogenous cluster of 
samples (clade A in Fig. 1) derived almost entirely from the hematopoietic system reported 
by various labs. Notably, 14 out of the 18 CMGs in clade 1 are implicated in euchromatin 
formation and gene activation (Table 1). Interestingly, 10 out of the 14 CMGs belong to the 
jumonji protein family of histone demethylases, most of which (8 genes) are implicated in 
removal of repressive methyl group and formation of euchromatin (Table 1). In clade 2, 9 
CMGs are upregulated, most of which are implicated in heterochromatin formation (Table 
1). This group defines a cluster (clade D in Fig. 1) composed of samples derived from the 
hematopoietic system (mostly differentiated lymphocytes, macrophages and granulocytes), 
cell line, solid tissue and incompletely differentiated cells. Clade 3 is characterized by the 
expression of 13 CMGs distributed almost equally between genes implicated in eu- and 
heterochromatin and defines a cluster (clade B in Fig. 1) composed of diverse samples 
derived mostly from the brain but also from hematopoietic system, muscle and solid tissue. 
Based on this analysis and the capacity for open chromatin configuration (Table 1) we 
predict that clade A represents a group of cells most of which from the hematopoietic 
system with the highest pluripotency level, clade B has moderate and clade D has the lowest 
pluripotency level. Clade C generates a cluster of cells derived from the brain, solid tissue 
and muscle with no clear clustering of the CMGs. 
To evaluate the strength of our prediction we analyzed the expression pattern of the 
predefined CMGs in a microarray dataset (GSE18290) obtained for early stages of human 
embryos, which include one-, two-, four-, and eight-cell stage embryos, morula stage and 
the blastocyst stage (Xie et al., 2010). The raw CEL files of the respective Affymetrix Human 
Genome U133 Plus 2.0 Arrays were downloaded from NCBI GEO and further preprocessed 
using RMA in Partek Genomics SuiteTM. Expression values of 38 out of the 40 predefined 
CMGs were standardized and subjected to gene wise hierarchical clustering using Euclidean 
distance and complete linkage. The resulting heat map shown in Fig. 2 revealed a sharp 
transition in the expression of CMGs between four- and eight-cell embryos, which might 
reflect transition from high pluripotency level (totipotency) to a more reduced one. The 
finding that blastomers derived from two- and four-cell embryos retain totipotency (Van de 
Velde et al., 2008) may support this notion. The abrupt transition in pattern of CMG 
expression is consistent with the largest changes in transcriptome profile observed between 
four- and eight-cell stages of human embryos (Xie et al., 2010) as well as with the timing of 
zygote genome activation (ZGA) in humans, which commences between the four- and eight-
cell stages of embryo development concomitantly with the degradation of maternal 
transcripts (Braude et al., 1988; Nothias et al., 1995). Based on the expression pattern of 
CMGs, cell samples could be divided into two major groups, namely group A, which is 
composed of one-to four-cell embryos displaying 18 (probably maternal) CMGs (clade 2), 
most of which (12 out of 18) are implicated in euchromatin formation and gene 
transcription. Group B is composed of eight-cell embryos, morula and blastocyst displaying 
upregulation of 20 CMGs (probably zygotic transcripts, clade 1) distributed equally between 
CMGs implicated in eu- and heterochromatin formation. Based on this analysis, it appears 
that overrepresentation of CMGs whose products are associated with open chromatin and 
gene transcription characterizes cells with high pluripotency level and thus supporting our 
hypothesis. We suggest that this attribute may faithfully serve as a tool for assessing the 
pluripotency level of the cell. 
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Non-neoplastic diseases, and Normal. We have downloaded the entire gene expression 
matrix from the ArrayExpress repository (accession number E-MTAB-62), and reduced it to 
include only the 1033 samples of the "Normal" meta-group, and the 40 CMGs indicated in 
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were removed, provided that at least one probe set for the same gene had signal intensity 
higher than 5 (in log2 scale) in at least one of the samples. (2) The signal intensities of the 
remaining probe sets were averaged to yield a single expression value per gene per sample. 
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and standard deviation of each gene's values were 0 and 1, respectively. The standardized 
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upregulation of 18 CMGs out of the 40 examined as they form a homogenous cluster of 
samples (clade A in Fig. 1) derived almost entirely from the hematopoietic system reported 
by various labs. Notably, 14 out of the 18 CMGs in clade 1 are implicated in euchromatin 
formation and gene activation (Table 1). Interestingly, 10 out of the 14 CMGs belong to the 
jumonji protein family of histone demethylases, most of which (8 genes) are implicated in 
removal of repressive methyl group and formation of euchromatin (Table 1). In clade 2, 9 
CMGs are upregulated, most of which are implicated in heterochromatin formation (Table 
1). This group defines a cluster (clade D in Fig. 1) composed of samples derived from the 
hematopoietic system (mostly differentiated lymphocytes, macrophages and granulocytes), 
cell line, solid tissue and incompletely differentiated cells. Clade 3 is characterized by the 
expression of 13 CMGs distributed almost equally between genes implicated in eu- and 
heterochromatin and defines a cluster (clade B in Fig. 1) composed of diverse samples 
derived mostly from the brain but also from hematopoietic system, muscle and solid tissue. 
Based on this analysis and the capacity for open chromatin configuration (Table 1) we 
predict that clade A represents a group of cells most of which from the hematopoietic 
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that overrepresentation of CMGs whose products are associated with open chromatin and 
gene transcription characterizes cells with high pluripotency level and thus supporting our 
hypothesis. We suggest that this attribute may faithfully serve as a tool for assessing the 
pluripotency level of the cell. 
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HDAC4 Histone deacetylase Hetero + - - 
UBE2B H2B ubiquitination Eu + - - 
HDAC9 Histone deacetylase Hetero + - - 
MYST3 HAT Eu + - - 
KDM2A H3K36 demethylase Hetero + - - 
KDM6B H3K27 demethylase Eu + - - 
UTY H3K27 demethylase Eu + - - 
KDM3A H3K9 demethylase Eu + - - 
JMJD1C H3K9 demethylase Eu + - - 
CREBBP HAT Eu + - - 
EP300 HAT Eu + - - 
HSPBAP1 Jumonji protein unknown + - - 
JHDM1D H3K9/K27 demethyl. Eu + - - 
MYST1 HAT Eu + - - 
PHF2 H3K9 demethylase Eu + - - 
KAT2B HAT Eu + - - 
KDM3B H3K9 demethylase Eu + - - 
PHF8 H3K9/K27 demethyl. Eu + - - 
KDM5B H3K4 demethylase Hetero - - + 
HDAC1 Histone deacetylase Hetero - - + 
HDAC3 Histone deacetylase Hetero - - + 
UBE2A H2B ubiquitination Eu - - + 
HAT1 Cytoplasmic HAT unknown - - + 
HDAC2 Histone deacetylase Hetero - - + 
HIF1AN Jmj protein Hetero? - - + 
KDM1 H3K4 demethylase Hetero - - + 
ELP3 HAT Eu - - + 
HDAC6 Histone deacetylase Hetero - + - 
KDM5C H3K4 demethylase Hetero - + - 
HR Jumonji protein unknown - + - 
HDAC11 Histone deacetylase Hetero - + - 
MYST2 HAT Eu - + - 
KAT2A HAT Eu - + - 
MYST4 HAT Eu - + - 
TAF1 HAT Eu - + - 
JMJD4 unknown unknown - + - 
HDAC7 Histone deacetylase Hetero - + - 
KDM8 H3K36  demethylase Hetero - + - 
KAT5 HAT Eu - + - 
HDAC5 Histone deacetylase Hetero - + - 
Table 1. Summary of the expression pattern of CMGs in the different clustered groups 
(shown in Fig. 1) and their predicted chromatin function. Eu, Euchromatin, HAT, histone 
acetyltransferase; Hetero, heterochromatin 
 




Fig. 2. Clustering of 38 CMGs expression in human embryos at various developmental 
stages derived from public datasets compiled by Xie et al. (2010, GSE18290). Gene-wise 
standardized expression level is shown as colored squares on a red-black-green scale (from 
up- to down-regulation, respectively). The two clustered CMG groups (upper dendrogram) 
displaying peculiar upregulation in a specific sample group (A and B) are boxed yellow. 
CMGs highlighted green and red are predicted to be involved in formation of euchromatin 
and heterochromatin, respectively. 
3. Hazardous pathways associated with cellular dedifferentiation (iPS cells) 
and with culturing stem cells 
It is now quite accepted that reprogramming of somatic cells in culture as well as culturing 
of stem cells are prone to hazardous genomic modifications and thus undermine their 
potential use in regenerative medicine. The complexity of hES cells is highlighted by the fact 
that injection of these cells (in their un-transformed state) into immunodeficient mice 
induced teratoma formation - a practice commonly used as a stringent assay to prove their 
existence. Indeed, animal embryonic stem cells often displayed genomic abnormalities in 
culture, which frequently resulted in malignant transformation (Lefort et al. 2009; Ben David 
& Benvenisty, 2011). Similarly, human iPS cells (Takahashi & Yamanaka, 2006), like human 
ES cells can acquire genetic abnormalities in the culture (Mayshar et al. 2010). These genetic 
aberrations are presumed to arise in part from culture adaptation while others are suspected 
to originate from the parent somatic cell. The later may be overcome by derivation of 
somatic cells from embryonic tissue (Ben-David et al., 2010). Yet, derivation of somatic cells 
from embryos, such as mouse embryonic fibroblasts (MEFs) did not improve significantly 
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reprogramming efficiency or reduced genetic and epigenetic abnormalities (Marión et al., 
2009). Cell type of origin has a major effect on the properties of mouse iPS cells at early-
passages, where iPS cells retain a transient epigenetic memory of their somatic cells of origin 
demonstrated by their differential gene expression and differentiation capacity, while at late 
passages these differences were attenuated (Polo et al., 2010). 
Reprogramming of somatic cells to generate iPS cells is believed to commence with the 
introduction of the so-called ‘pluripotent genes’ into cultured somatic cells. Commonly, 
researchers are not aware that reprogramming has already initiated in somatic cells when they 
are removed from the soma and placed in tissue culture environments. Cell culturing of 
primary cells might impose an extreme stress over the cells resulting in reprogramming, 
dedifferentiation and acquisition of pluripotency prior to reentry of somatic cells [e.g., mouse 
embryonic fibroblasts (MEFs)] to the cell cycle (Fig. 3) – a stage, which is often overlooked. 
This aspect of cell culturing has been highlighted by Barbra McClintock (1984) in her Nobel 
article ‘The significance of responses of the genome to challenge’. McClintock (1984) has 
recognized the potential for hazardous genetic variation that can be induced following 
exposure of cells to stress (e.g., cell culturing, virus infection) stating “Some responses to stress 
are especially significant for illustrating how a genome may modify itself when confronted 
with unfamiliar conditions. Changes induced in genomes when cells are removed from their 
normal locations and placed in tissue culture surroundings are outstanding examples of this. 
The establishment of a successful tissue culture from animal cells, such as those of rat or 
mouse, is accompanied by readily observed genomic restructuring.” McClintock predicted 
that these aberrant genome responses to stress are likely to be induced by mobilization of 
transposable elements. Therefore, we should consider the possibility that the genotype(s) of 
somatic cells entering the cell cycle may not be identical to the genotype of the original somatic 
cells; a genotype(s) conferring increasing fitness for tissue culture conditions may prevail. 
 
 
Fig. 3. Reprogramming of somatic cells. The removal of somatic cells from the body is 
stressful and might induce dedifferentiation (reprogramming) and acquisition of stem cell-
like state prior to reentry into the cell cycle (G1-S transition). Note that due to genetic 
variation induced during dedifferentiation the genotype of cells entering the cell cycle may 
be different from the genotype of the original somatic cells.  
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In animals, somatic cell nuclear transfer (SCNT) as well as iPSCs, both are dedifferentiation-
driven processes appear to be very limited (Tamada & Kikyo, 2004; William & Plath, 2008). 
This is probably due, at least in part, to a high frequency of p53-mediated DNA damage 
response and p53-dependent apoptosis, which are acting to ensure genomic integrity 
(Marión et al., 2009). Although, it is presumed that failure in reprogramming is selective for 
those cells with preexisting DNA damage, it cannot be excluded that DNA damage or 
‘irreversible genomic modifications’ are induced in cells (e.g., protoplasts, primary MEFs) in 
the course of stress-induced cellular dedifferentiation (Fig. 3) or cell culturing via DNA 
recombination and DNA transposition (Pouteau et al., 1991; Hirochika, 1993; Grafi et al., 
2007; Grafi, 2009; Grafi et al., 2011). Almost half of the human genome is composed of 
transposable elements, some of which still retain their capacity for transposition into genes, 
which could lead to genetic instability and human diseases (reviewed in Belancio et al. 
2009). Indeed, Alu and Line-1 expression and retrotransposition have been reported in 
human ES cells and in human neural progenitor cells (Garcia-Perez et al., 2007; Coufal et al., 
2009; Macia et al., 2011). Notably, some of these retroelements are often activated in various 
cell lines following exposure to stress (reviewed in Oliver & Greene, 2009).  
Presently, it is not clear why the genome become vulnerable under certain stress conditions. 
One possibility is that following exposure to stress the genome is reacting by extensive and 
stochastic reorganization culminating in global chromatin decondensation and acquisition 
of dedifferentiated, stem cell-like state (reviewed in Grafi, 2009). Stochastic epigenetic 
modifications may release constraints over transposable elements resulting in their 
activation and transposition into other chromosomal sites. Stress-induced decrease in 
methylation of repetitive elements [long interspersed nucleotide element (LINE)-1 and Alu 
repetitive elements] was reported in blood samples derived from elderly individuals 
following exposure to traffic particles (Baccarelli et al., 2009). A whole-genome profiles of 
DNA methylation of several human iPS cell lines, showed aberrant reprogramming of DNA 
methylation; regions proximal to centromeres and telomeres display incomplete 
reprogramming of non-CG methylation, and differences in CG methylation and histone 
modifications (Lister et al., 2011).  
4. Discussion 
The capacity of somatic cells to dedifferentiate and acquire stem cell-like state is an 
important goal toward developing an efficient tool for use in regenerative medicine. Yet, the 
process of dedifferentiation is complex and unsafe resulting from increased incidents of 
DNA transposition/recombination-induced genetic variation and genome instability (Grafi, 
2009). In addition, the findings that both embryonic stem cells (ESCs) and iPS cells show 
higher frequencies for genetic abnormalities relative to other cell lines limit their suitability 
for clinical use in regenerative medicine (Mayshar et al., 2010; Laurent et al., 2011). The 
generation of iPS cells from somatic cells by various means emerged as one reasonable 
approach for generating autologous iPS cells for clinical applications. This methodology 
solves the problem of transplant rejection and also moral concerns often raised regarding 
the use of ES cells. However, the process of generating iPS cells is very inefficient, has very 
low rate of success and may be subjected to hazardous genetic variation (Grafi, 2009) 
leading, at least partly, to p53-dependent cell death (Marión et al., 2009). The limited success 
in iPS cells is enigmatic inasmuch as dedifferentiation is an integral process of development 
both in plants and animals. It underlies the regenerative capacity of certain vertebrates 
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(Brockes & Kumar, 2008) as well as of plants (reviewed in Grafi, 2004) and, at least partly, 
the capacity for transdifferentiation, that is, the conversion of one cell type to another (Tosh 
& Slack, 2002).  
We should consider the fact that the capacity for switching cell fate in animals suggests that 
the machinery needed for this transition is already exist in the framework of the cell 
including the pluripotent genes (e.g., OCT4, SOX2) whose ectopic expression in cultured 
cells may induce formation of pluripotent stem cells. Hence, why introducing these genes 
exogenously instead of activating the endogenous ones? Accumulating data suggest that 
reprogramming does not require the ‘four factors’ (OCT4, SOX2, KLF4, c-Myc) and can be 
carried out with only one factor OCT4 (Kim et al., 2009). This raises the question whether 
reprogramming is achieved due to ectopic expression of pluripotent genes or due to 
endogenous ones being activated as a consequence of the procedure itself (viral 
transduction), namely, virus-induced chromatin reorganization (Monier et al., 2000). Indeed, 
induction of pluripotency does not necessarily require exogenous factors and can be carried 
out by extracts derived from stem cells or undifferentiated human NCCIT carcinoma cells 
(Taranger et al., 2005). More recently it has been shown that pretreatment of somatic cells 
with chromatin modulators, namely, DNA methyltransferase and histone deacetylase 
inhibitors can improve reprogramming and the formation of hESC-like colonies by 
embryonic stem cell extracts (Han et al., 2010). Chromatin architecture is a fundamental 
theme in pluripotency and as such should be the primary means for activation of silent 
genes whose products involved in establishing of the pluripotent state. Support to this view 
are the open chromatin configuration characteristic of stem cells and the finding that 
chromatin remodeling factors play a critical role in maintaining open chromatin and 
reprogramming of somatic cells to pluripotent state (Efroni et al., 2008; Gaspar-Maia et al., 
2009). Accordingly, it has recently been shown that chromatin-remodeling components of 
the BAF complex facilitate the reprogramming of somatic cells into pluripotent state 
(Singhal et al., 2010).  
5. Conclusions 
The use of CMGs for reprogramming of somatic cells has not been exploited sufficiently. We 
should consider manipulating of the activities of chromatin modifiers capable of facilitating 
the formation of open chromatin conformation. Emphasis should be given to those genes 
whose products actively remove repressive marks from histone tails, such as histone 
demethylases (Table 1), as a necessary step toward opening of otherwise closed chromatin. 
In this respect, together with existing tools such as the PluriTest (Muller et al., 2011), our 
bioinformatic data suggest that the transcription profile of CMGs can be formulated into a 
robust bioinformatic tool for assessing the pluripotency level of cells.  
Obviously, the removal of cells (e.g., stem cells, somatic cells) from their normal location in 
the body and placing them under tissue culture conditions is hazardous and should be 
avoided, unless we find the way(s) to control the extent of genetic variation induced during 
dedifferentiation and cell culturing. An alternative approach has been suggested by 
Abramovich et al. (2008) in their article entitled ‘Have we reached the point for in vivo 
rejuvenation?’ The authors suggested to try and imitate natural rejuvenation processes and 
to test the possibility of inducing dedifferentiation and the pluripotent state in somatic cells 
in vivo. Future challenges will be to gain knowledge and find the appropriate means for 
inducing dedifferentiation at specific tissue or organ in vivo for efficient and safe 
regenerative medicine. 
 




This chapter is dedicated to the memory of Dr. Amir Abramovich, a brilliant scientist who 
passed away untimely and who was so enthusiastic about the potential use of the process of 
dedifferentiation for the purpose of in vivo rejuvenation.  
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induction of pluripotency does not necessarily require exogenous factors and can be carried 
out by extracts derived from stem cells or undifferentiated human NCCIT carcinoma cells 
(Taranger et al., 2005). More recently it has been shown that pretreatment of somatic cells 
with chromatin modulators, namely, DNA methyltransferase and histone deacetylase 
inhibitors can improve reprogramming and the formation of hESC-like colonies by 
embryonic stem cell extracts (Han et al., 2010). Chromatin architecture is a fundamental 
theme in pluripotency and as such should be the primary means for activation of silent 
genes whose products involved in establishing of the pluripotent state. Support to this view 
are the open chromatin configuration characteristic of stem cells and the finding that 
chromatin remodeling factors play a critical role in maintaining open chromatin and 
reprogramming of somatic cells to pluripotent state (Efroni et al., 2008; Gaspar-Maia et al., 
2009). Accordingly, it has recently been shown that chromatin-remodeling components of 
the BAF complex facilitate the reprogramming of somatic cells into pluripotent state 
(Singhal et al., 2010).  
5. Conclusions 
The use of CMGs for reprogramming of somatic cells has not been exploited sufficiently. We 
should consider manipulating of the activities of chromatin modifiers capable of facilitating 
the formation of open chromatin conformation. Emphasis should be given to those genes 
whose products actively remove repressive marks from histone tails, such as histone 
demethylases (Table 1), as a necessary step toward opening of otherwise closed chromatin. 
In this respect, together with existing tools such as the PluriTest (Muller et al., 2011), our 
bioinformatic data suggest that the transcription profile of CMGs can be formulated into a 
robust bioinformatic tool for assessing the pluripotency level of cells.  
Obviously, the removal of cells (e.g., stem cells, somatic cells) from their normal location in 
the body and placing them under tissue culture conditions is hazardous and should be 
avoided, unless we find the way(s) to control the extent of genetic variation induced during 
dedifferentiation and cell culturing. An alternative approach has been suggested by 
Abramovich et al. (2008) in their article entitled ‘Have we reached the point for in vivo 
rejuvenation?’ The authors suggested to try and imitate natural rejuvenation processes and 
to test the possibility of inducing dedifferentiation and the pluripotent state in somatic cells 
in vivo. Future challenges will be to gain knowledge and find the appropriate means for 
inducing dedifferentiation at specific tissue or organ in vivo for efficient and safe 
regenerative medicine. 
 




This chapter is dedicated to the memory of Dr. Amir Abramovich, a brilliant scientist who 
passed away untimely and who was so enthusiastic about the potential use of the process of 
dedifferentiation for the purpose of in vivo rejuvenation.  
We thank Eitan Rubin for bioinformatics discussions and Vadim Fraifeld for critical reading 
of the chapter. This work was supported by The Israel Science Foundation (ISF) grant No. 
476/09 to G.G. and V.C.-C. 
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1. Introduction 
At the pre-implantation blastocyst stage of development, the mammalian embryo is 
composed of a unique collection of cells of which three major populations predominate. The 
outermost layer the trophectoderm (TE) gives rise to the placenta, which acts to sustain the 
developing fetus connecting it to the mother host. The next is a cluster of cells known as the 
inner cell mass (ICM) these cells are said to be pluripotent (Fig. 1). A third group of cells 
known as the primitive endoderm, surrounds the ICM cells at the epiblast stage. As 
development proceeds the ICM cells rapidly divide and eventually begin to differentiate 
forming the three embryonic germ layers (ectoderm, mesoderm and endoderm). Effectively 
these pluripotent ICM cells are the precursors of all adult tissues. As these pluripotent cells 
commit to a specific cellular lineage, they lose their pluripotency. Embryonic stem (ES) cells 
are euploid pluripotent cell lines isolated directly from cultured preimplantation embryos. 
The first stable ES cell lines were isolated by immunosurgery from the ICM of implantation-
delayed, mouse blastocysts (Martin, 1981; Evans and Kaufman, 1981). Mouse ES cells are 
very closely related to early ICM cells in terms of their developmental potential (Beddington 
and Robertson, 1989). This chapter will focus on mouse ES cells (mES) unless otherwise 
stated. Three features characterize mES cells; 
1. They are isolated directly from the embryo (Robertson, 1987). 
2. They can colonize the germ line when introduced to the embryo. 
3. They possess unrestricted proliferative potential (Suda et al., 1987). 
These features effectively mean that under appropriate conditions, a karyotype stable self-
renewing, pluripotent population of cells can be propagated indefinitely in vitro. mES cells 
have other characteristics, which prove useful when comparing embryo derived stem cells 
to their differentiated progenies. mES cells have a euploid (2n) chromosome complement, a 
feature that allows their participation in germ cell development and the formation of 
chimeras (Bradley et al., 1984; Evans, 1994). The functional demonstration of mES cell 
developmental potential through chimera formation is the definitive proof of the 
pluripotent nature of the cell population in question. Biomarkers are often used as indicators 
of the stem cell state due to the time consuming and technically more difficult nature of 
getting functional proof of stemness. Many of the common markers are transcription factors 
expressed in the ICM and mES cells and have been shown to have functional roles in self-
renewal and in the maintenance of pluripotency, in both isolated stem cells or the ICM. The 
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surface markers expressed depend on species of origin, but common markers include 
members of the stage specific embryonic antigen (SSEA) family, alkaline phosphatase and 
Oct4 (Andrews, 2002; Pera et al., 2000; Shamblott et al., 1998). SSEA-1 is expressed in mouse 
preimplantation embryos from the eight-cell stage until the embryo differentiates into germ 
layers when it remains only in the ectodermal lineage (Solter and Knowles, 1979; Resnick et 
al., 1992; Pelton et al., 2002). Some of the best-characterized examples include the POU 
domain transcription factor Oct4, the homeodomain protein Nanog and the high-mobility 
group transcription factor Sox2. Of the three factors mentioned our understanding of Oct4 is 
best developed. Oct4 deficient embryos fail to initiate fetal development, indicating that 
Oct4 is essential for embryo development (Nichols et al., 1998). In mES cells there is an 
altered level of expression upon differentiation, a profile for down-regulation into TE and 
up-regulation in endoderm correlates with the Oct4 profile of expression in vivo embryos 
(Palmieri et al., 1994). mES cells can be maintained in an undifferentiated state in vitro with 
relative ease. They represent pluripotent embryonic cells, which are present only transiently 
in vivo. This enables their use as an in vitro model to elucidate the mechanisms of 
differentiation that these pluripotent cells undergo in vivo. The regulatory signaling and 
transcription networks that play a role in pluripotency and self-renewal it would seem have 
been conserved between mouse and human ES (hES) cells, however many differences also 
are found. As distinct from mES cells, hES cells do not appear to express high levels of 
SSEA1, but do have high levels of SSEA-3, −4, TRA-1–60 and TRA-1–81 (Brimble et al., 2007; 
Reubinoff et al., 2000). Other difference also exist, both cell types have a high ratio of nuclear 
to cytoplasmic volume, mES cells grow in nests and form three dimensional embryoid 
bodies while hES cells often grow in colonies as thin layers. Furthermore hES cells unlike 
mES can be maintained in a self-renewal cycle in the absence of the cytokine LIF or a feeder 
layer. Recently a population of cells with pluripotent capability was isolated from a post-
implantation mouse epiblast at the later stages of development (Brons et al., 2007; Tesar et 
al., 2007). These epiblast stem cells (EpiS cells) do not require LIF support as ICM derived 
mES cells do (Rossant, J. 2007; Nagy et al., 2003). Morphologically EpiS cells are more like 
hES cells than mES cells as they tend to grow as thin flat layers. Considering these difference 
and others, the idea that mES and hES cells while both pluripotent, may in fact represent 
different and distinct stages in development.  
Early studies with mES cells showed that the use of mitotically inactivated STO cells (Ware 
and Axelrad, 1972; Hooper, 1997) was essential in the maintenance of self-renewal and the 
pluripotent state. Later it was found that the requirement for the feeder layer could be 
circumvented by the addition of the cytokine LIF in the presence of serum. In the absence of 
feeder layers or LIF, mES cells differentiate into a variety of cell types (Doetschman et al., 
1985) depending on the developmental cue or signaling pathway activated. The process of 
differentiation can be seen as a loss of pluripotency and mES like their in vivo counterparts 
are capable of multi-lineage differentiation. mES cells undergo a controlled pattern of 
differentiation when injected and reintegrated into a pre-implantation blastocyst. Under 
these circumstance mES cells respond as ICM cells to in vivo differentiation cues and fully 
participate in normal development. Furthermore they are capable of forming a wide range 
of normal cells including germ cells (Bradley et al., 1984; Robertson et al., 1986). In vitro mES 
cells can be induced to differentiate, by culturing cells in suspension or in a monolayer 
system under the effect of chemical inducers such as retinoic acid (Robertson, 1987). When 
mES cells are propagated under conditions that discourage their attachment to the 
substratum they form small aggregates, termed embryoid bodies (EBs). These three 
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dimensional colonies organize in such a way that an endodermal layer develops on the 
outer surface and are now known as "simple embryoid bodies". The inner stock of cells 
remain undifferentiated not unlike the early events of embryogenesis, where the 
trophectoderm differentiates from the peripheral cells of the morula, while the inner cells 
remain pluripotent.  
 
 
Fig. 1. Key transcription factors involved in self-renewal of ES cells. 
Differentiated mES cells from EBs can give rise to a wide variety of cell types including 
neuronal (Bain et al., 1995), hematopoietic (Suwabe et al., 1998), endothelial (Yamashita et al., 
2000), cardiac (Maltsev et al., 1993), smooth muscle (Yamashita et al., 2000), chondrogenic 
(Kramer et al., 2000) and osteoblastic cells (Buttery et al., 2001). For stem cells there is a 
constant balancing act that must be maintained between self-renewal and the pluripotent 
phenotype versus cell lineage commitment and differentiation. 
An understanding of the pathways and controlling factors involved in these fundamental 
cellular events is essential if we are to exploit the full potential of embryo derived stem cells 
for therapeutic uses in disease treatments and regenerative medicine in the future. This 
potential is real as it is clear that embryo derived stem cells are capable of unlimited self-
renewal capacity and can differentiate into potentially any of over 200 cell types. The 
potency of these cells is maintained by a number of key regulatory factors, signaling 
pathways and extracellular signaling agents. The combination and interplay of these 
elements establishes a patterns of gene expression that sustains the pluripotent phenotype of 
ES cell. Some of the key regulators are transcription factors such as Oct4, Sox2 and Nanog, 
the signaling cascades involving phosphatidylinositol 3-kinase (PI3K) and the signaling 
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molecules like LIF and Wnt proteins. Embryonic stem cells have great therapeutic potential 
however to fully realize the potential of these cells the signaling pathways that participate in 
controlling ES cell behavior must be better understood.  
2. Pluripotency and Self-renewal 
 In the developing embryo, pluripotent cells first appear in the ICM, in the mouse blastocyst 
this is approximately at day 3.5 of embryonic development (E3.5). These cells persist as late 
as the pre-gastrulation stage. Thus in vitro mES cells represent a very transient population of 
cells existing for a very short period of time in vivo. Experimental extraction of these cells 
facilitates the expansion and maintenance of the pluripotent state in vitro. mES cells are 
pluripotent, which is defined as the ability to differentiate into all cell lineages that make up 
the adult organism (Buehr et al., 2003). Functional assessment of the pluripotency of mES 
cells can be determined by the capability of the cells to reintegrate, into the ICM of E3.5 
blastocysts contributing to all cell lineages. Strict pluripotency has been shown only in the 
mouse, where mES cells completely integrate producing a high rate of chimerism in all 
tissues. In the presence of fetal serum, activation of STAT3 by LIF is sufficient to maintain 
mES cells in an undifferentiated state (Williams et al., 1988; Matsuda et al., 1999) however, 
this is not the case for hES cells (Dahéron et al., 2004). Potentially parallel pathways are at 
play in mouse and human ES cells through which ES cells achieve similar end points and 
sustain pluripotency. This characteristic is sustained by the ability of ES cells to self-renew. 
ES cells are capable of differentiation but also symmetrical division generating two identical 
undifferentiated pluripotent daughter cells. In real terms mES cells can be expanded 
indefinitely (years) in a self-renewal cycle, once culture conditions prevent differentiation. It 
appears that maintaining a pluripotent state during mES cell self-renewal is through active 
suppression of differentiation and the promotion of proliferation. The differentiation of mES 
cells can be induced by the ectopic expression of certain transcription factors. Forced 
expression of Gata6 in mES cells drives differentiation toward primitive endoderm lineages 
(Fujikura et al., 2002), while increasing Cdx2 results in trophectoderm formation (Niwa et 
al., 2005). Thus, the expression of genes promoting self-renewal, cell proliferation and 
suppressing cellular differentiation pathways must be stably maintained and passed on to 
each daughter cell. The regulation of self-renewal is of great interest and importance in 
developing our basic understanding but also for the development of regimes for cellular 
therapy. The ability to control and maintain the expansion of pluripotent cells is a 
cornerstone, if the true clinical potential of ES cell-derived therapies is to be realized for 
regenerative medicine. mES (Martin, 1981) and hES (Thomson et al., 1998) cells are similar in 
this regard although not absolutely identical, the molecular machinery and pathways 
involved is equally complex but involves a number of distinct players in each case (Sato et 
al., 2003). A good example of this is the vitamin A metabolite, all-trans-retinoic acid which 
has the effect of silencing self-renewal and driving a differentiation agenda for both mES 
and hES cells lines (Chen and Gudas, 1996; Mongan and Gudas, 2007). The self-renewal 
pathways in ES cells comprise complex networks of strategic actions of extracellular agents 
(including the presence or absence in culture of serum), intracellular signaling pathways 
and the control of key transcription factors. In vitro, LIF supports self-renewal and 
pluripotency of mES cells through activation of STAT3 (Smith et al., 1998), removal of LIF or 
suppression of STAT3 results in differentiation (Niwa et al., 1998). LIF receptor knockout 
mouse embryos are capable of passing the developmental stage required for mES cell 
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derivation. Thus in vivo it is obvious that there is no magic bullet but other factors are also 
involved in this process (Nichols et al., 2001). The cytokine LIF was among one of the 
earliest molecules found to be associated with the maintenance of stem cell self-renewal in 
vitro and in vivo. More recently other factors have become known including the bone 
morphogenetic proteins (BMPs) 2 and 4 and glycogen synthase kinase-3. Under serum free 
culture conditions, mES cells require the presence of both LIF and BMPs to facilitate 
continued self-renewal (Ying et al., 2003). It appears that linked pathways are at play, LIF 
supporting self-renewal and proliferation, while BMP4 up-regulates members of the Id gene 
(inhibition of differentiation) family (Ying et al., 2003). Signaling pathway crosstalk with 
PI3K signaling has also been shown to play a part in self-renewal. The transcription factors 
Oct4, Sox2, and Nanog are now widely accepted as having a central role in promoting self-
renewal and sustaining the undifferentiated phenotype (Ying et al., 2003). As if to 
emphasize the reliance of self-renewal on networked interactions, recent work has shown 
that a key set of promoter sequences bind Oct4, Sox2, and Nanog in ES cells (Chambers and 
Tomlinson, 2009; Avilion et al., 2003; Masui et al., 2007; Niwa et al., 2005). This however is 
not the total picture as further extensions of the co-dependence of the self-renewal network 
is coming to light all the time, interestingly some of these newer interactions are 
independent of the established tri-umbret of Oct4, Sox2, and Nanog (Ivanova et al., 2006). 
Other work is providing evidence to suggest that two independent pathways may be as 
play in ES cells. The established Oct4, Sox2, and Nanog networks may be acting to suppress 
differentiation and thus sustain pluripotency. While other transcription networks play a role 
in repression of specific cell lineage differentiation. Further extension of these 
interconnecting pathways includes the addition of the role of miRNA-encoding genes 
(Marson et al., 2008). In the following sections the role of specific transcription factors and 
signaling pathways will be expanded upon in the context of their role in the self-renewal of 
ICM derived mES cells.  
2.1 Transcriptional networks 
2.1.1 Oct4 
Oct4 is a member of the POU (Pit-Oct-Unc) transcription factor family that regulates the 
expression of target genes by binding to a octameric sequence (Scholer et al., 1990). The key 
features of this family are the POU domain consisting of two sub-domains each of which 
bind to DNA. However the C-terminal is cell specific and may be essential for the 
expression of target gene in an orderly fashion as embryonic development proceeds. It is 
well established that the Oct4 gene (encoded by Pou5f1) is constitutively expressed in 
undifferentiated mES cells, in all pluripotent cells during mouse embryo development and 
is also an essential factor required in the generation of iPS cells (Niwa et al., 2000). Oct4 is 
also known as Oct3, Oct3/4, Otf3, and Otf4. In the mouse, Oct4 expression is up regulated 
beginning at the 4-cell stage and becomes localized to the pluripotent cell population (Yeom 
et al., 1996). The expression of Oct4 is common to human and mouse ES cells, and 
furthermore expression diminishes in both as cells differentiate. In vivo Oct4 knockout 
mouse embryos crash and do not develop beyond the blastocyst stage, they lack a 
pluripotent ICM cell population (Nichols et al., 1998), strongly suggesting a central role for 
Oct4 in maintaining pluripotency. In cells were Oct4 is repressed or in Oct4 knockouts, mES 
cells differentiate towards a trophoectodermal lineage. It has been reported that Oct4 
inhibits trophectoderm lineage formation via an interaction with Cdx2 forming of an 
inhibitory complex (Niwa et al., 2005). Conversely up regulation or over-expression of Oct4 
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molecules like LIF and Wnt proteins. Embryonic stem cells have great therapeutic potential 
however to fully realize the potential of these cells the signaling pathways that participate in 
controlling ES cell behavior must be better understood.  
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al., 2005). Thus, the expression of genes promoting self-renewal, cell proliferation and 
suppressing cellular differentiation pathways must be stably maintained and passed on to 
each daughter cell. The regulation of self-renewal is of great interest and importance in 
developing our basic understanding but also for the development of regimes for cellular 
therapy. The ability to control and maintain the expansion of pluripotent cells is a 
cornerstone, if the true clinical potential of ES cell-derived therapies is to be realized for 
regenerative medicine. mES (Martin, 1981) and hES (Thomson et al., 1998) cells are similar in 
this regard although not absolutely identical, the molecular machinery and pathways 
involved is equally complex but involves a number of distinct players in each case (Sato et 
al., 2003). A good example of this is the vitamin A metabolite, all-trans-retinoic acid which 
has the effect of silencing self-renewal and driving a differentiation agenda for both mES 
and hES cells lines (Chen and Gudas, 1996; Mongan and Gudas, 2007). The self-renewal 
pathways in ES cells comprise complex networks of strategic actions of extracellular agents 
(including the presence or absence in culture of serum), intracellular signaling pathways 
and the control of key transcription factors. In vitro, LIF supports self-renewal and 
pluripotency of mES cells through activation of STAT3 (Smith et al., 1998), removal of LIF or 
suppression of STAT3 results in differentiation (Niwa et al., 1998). LIF receptor knockout 
mouse embryos are capable of passing the developmental stage required for mES cell 
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derivation. Thus in vivo it is obvious that there is no magic bullet but other factors are also 
involved in this process (Nichols et al., 2001). The cytokine LIF was among one of the 
earliest molecules found to be associated with the maintenance of stem cell self-renewal in 
vitro and in vivo. More recently other factors have become known including the bone 
morphogenetic proteins (BMPs) 2 and 4 and glycogen synthase kinase-3. Under serum free 
culture conditions, mES cells require the presence of both LIF and BMPs to facilitate 
continued self-renewal (Ying et al., 2003). It appears that linked pathways are at play, LIF 
supporting self-renewal and proliferation, while BMP4 up-regulates members of the Id gene 
(inhibition of differentiation) family (Ying et al., 2003). Signaling pathway crosstalk with 
PI3K signaling has also been shown to play a part in self-renewal. The transcription factors 
Oct4, Sox2, and Nanog are now widely accepted as having a central role in promoting self-
renewal and sustaining the undifferentiated phenotype (Ying et al., 2003). As if to 
emphasize the reliance of self-renewal on networked interactions, recent work has shown 
that a key set of promoter sequences bind Oct4, Sox2, and Nanog in ES cells (Chambers and 
Tomlinson, 2009; Avilion et al., 2003; Masui et al., 2007; Niwa et al., 2005). This however is 
not the total picture as further extensions of the co-dependence of the self-renewal network 
is coming to light all the time, interestingly some of these newer interactions are 
independent of the established tri-umbret of Oct4, Sox2, and Nanog (Ivanova et al., 2006). 
Other work is providing evidence to suggest that two independent pathways may be as 
play in ES cells. The established Oct4, Sox2, and Nanog networks may be acting to suppress 
differentiation and thus sustain pluripotency. While other transcription networks play a role 
in repression of specific cell lineage differentiation. Further extension of these 
interconnecting pathways includes the addition of the role of miRNA-encoding genes 
(Marson et al., 2008). In the following sections the role of specific transcription factors and 
signaling pathways will be expanded upon in the context of their role in the self-renewal of 
ICM derived mES cells.  
2.1 Transcriptional networks 
2.1.1 Oct4 
Oct4 is a member of the POU (Pit-Oct-Unc) transcription factor family that regulates the 
expression of target genes by binding to a octameric sequence (Scholer et al., 1990). The key 
features of this family are the POU domain consisting of two sub-domains each of which 
bind to DNA. However the C-terminal is cell specific and may be essential for the 
expression of target gene in an orderly fashion as embryonic development proceeds. It is 
well established that the Oct4 gene (encoded by Pou5f1) is constitutively expressed in 
undifferentiated mES cells, in all pluripotent cells during mouse embryo development and 
is also an essential factor required in the generation of iPS cells (Niwa et al., 2000). Oct4 is 
also known as Oct3, Oct3/4, Otf3, and Otf4. In the mouse, Oct4 expression is up regulated 
beginning at the 4-cell stage and becomes localized to the pluripotent cell population (Yeom 
et al., 1996). The expression of Oct4 is common to human and mouse ES cells, and 
furthermore expression diminishes in both as cells differentiate. In vivo Oct4 knockout 
mouse embryos crash and do not develop beyond the blastocyst stage, they lack a 
pluripotent ICM cell population (Nichols et al., 1998), strongly suggesting a central role for 
Oct4 in maintaining pluripotency. In cells were Oct4 is repressed or in Oct4 knockouts, mES 
cells differentiate towards a trophoectodermal lineage. It has been reported that Oct4 
inhibits trophectoderm lineage formation via an interaction with Cdx2 forming of an 
inhibitory complex (Niwa et al., 2005). Conversely up regulation or over-expression of Oct4 
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results in mES cell moving towards primitive endoderm (Niwa et al., 2000). These divergent 
effects of Oct4 suggest that it regulates the transcription of genes involved in coordination of 
multiple cellular functions and early cell fate decisions. Thus the actual level of Oct4 
expression is important and a key level of expression is required to sustain pluripotency and 
self-renewal. In mES cells the expression of Oct4 is supported by the action of LIF and down 
regulated by the chemical inducer all-trans retinoic acid (Faherty et al., 2005; 2007). 
Suppression of STAT3 and accelerated expression of Oct4 also causes mES cells to 
differentiate (Niwa et al., 1998; Niwa et al., 2000). The role is Oct4 as a so called master 
regulator in sustaining pluripotency and self-renewal of mES cells is well known, however it 
is not a solo run (Nichols et al., 1998; Boyer et al., 2005). Oct4 alone without LIF, is not 
sufficient to sustain self-renewal and prevent mES cell differentiation, suggesting that 
additional factors also play a part. More recently it has been shown that Oct4 expression 
prevents stem cell differentiation by sustaining the expression of other pluripotency factors 
and inhibiting gene expression of lineage specific factors. Known targets for Oct4 include 
Fgf4, Rex1/Zfp42, and Sox2 (Zeng et al., 2004; Tomioka et al., 2002). Oct4 has been shown to 
act in concert with other factors and its DNA binding often occurs in conjunction with the 
HMG-family protein Sox2, an additional factor required for maintaining mES cell stemness 
(Chambers and Smith, 2004; Pesce and Schöler, 2001). Oct4 is a key regulator of ES cell fate, 
particularly in maintaining a pluripotent state. The requirement appears to be that Oct4 
protein levels are constrained within the narrow band. It is clear that Oct4 has a critical role 
in sustaining pluripotency, however its control is unclear. The control of the level of 
expression appears somewhat auto-regulatory (Chew et al., 2005), but also depends on other 
factors including the transcription factor Nanog providing a feedback loop to sustain self-
renewal (Pan et al., 2006) 
2.1.2 Nanog 
Nanog is an homeobox containing transcription factor of approximately 280 amino acids. In 
the developing mouse embryo Nanog plays a key role in determining the fate of the ICM 
cells, acting to sustain pluripotency and preventing differentiation (Chambers et al., 2003). 
Nanog was identified as a factor, which when over expressed, supported pluripotency even 
in the absence of a LIF based signal. In the embryo Nanog expression is first seen at the 
compacted morulae stage before becoming restricted to the ICM, post-implantation stage 
Nanog expression is drastically reduced. In vitro, Nanog expression is abundant in 
pluripotent cell types but absent from adult tissues (Chambers et al., 2003). As with their in 
vivo counterparts upon differentiation of mES cells the expression of Nanog is 
downregulated. Nanog-null embryos fail soon after implantation, stem cells derived from 
such embryos are pluripotent but are found to quickly differentiate (Chambers et al., 2003; 
Mitsui et al., 2003). Over-expression of Nanog without any other intervention is sufficient to 
sustain self-renewal even without LIF albeit the self-renewal capacity under these conditions 
is reduced. Under the same conditions the level of active STAT3 is not appreciably altered, 
furthermore increased STAT3 signaling does not appear to alter Nanog expression. These 
data would suggest that Nanog is neither a target for STAT3, or does it regulate STAT3 
activity. However at one least report suggests Nanog is a direct downstream target for 
STAT3 in the maintenance of pluripotency (Suzuki et al., 2006). BMP signaling normally acts 
during embryonic development to induce mesoderm formation, but effects in mES cells can 
be quite different (Winnier et al., 1995). In mES cells low levels of BMPs in the absence of LIF 
promote mesoderm, while in the presence of LIF, mES cell pluripotency is sustained (Ying et 
 
Signaling Pathways in Mouse Embryo Stem Cell Self-Renewal 
 
289 
al., 2003). BMP signaling is facilitated by downstream effectors including SMAD1, an 
effector which Nanog has been shown to interact with and leads to inhibition of BMP 
signaling (Suzuki et al., 2006). What is being proposed is that BMPs are at least initially pro-
mesoderm lineage formation as evidenced by up-regulation of Brachyury a mesoderm 
marker. When activated STAT3 interacts with Brachyury and increases Nanog expression, 
the elevated levels of Nanog inhibit BMPs via SMAD1 interaction and thus maintain the 
undifferentiated pluripotent state. Nanog is now accepted as an important component in 
regulating the pluripotent phenotype however the mechanism of its own control and how it 
effects other genes is not entirely elucidated. It has been shown that Oct4 and Sox2 can bind 
to the Nanog promoter in vitro and in vivo (Rodda et al., 2005) suggesting that Oct4/Sox can 
act to up regulate Nanog expression. However other studies have shown that Nanog 
expression can be maintained in the absence of Oct4, thus other factors must contribute to 
the regulation. One such factor is a member of the forkhead family FoxD3, which is found in 
mES cells and the early embryo. FoxD3 knockout embryos have a similar fate as Nanog 
knockouts (Hanna et al., 2002). The exact mechanism by which Nanog is regulated and how 
it effects control of mES cell pluripotency is unknown, however it appears independent of 
STAT3 activation or the requirement for BMP4 at least when in serum free culture 
conditions. Nanog is capable of activating the Oct4 promoter forming a negative feedback 
loop upregulating Oct4 at times and suppressing Oct4 when levels are above normal (Pan et 
al., 2006). Furthermore it has been shown that Nanog is capable of activating Rex1 a target 
for Oct4 and Sox2 (Shi et al., 2006). Furthermore it has also been suggested that Nanog may 
interact with Wnt and BMP4 signaling independent of LIF which may help explain why the 
forced expression of Nanog in the absence of LIF sustains a level of self-renewal (Chambers 
et al., 2003; Mitsui et al., 2003). The regulation and comprehensive elucidation of the role of 
Nanog requires more experimental work before we can paint a true picture of its overall role 
in pluirpotency. 
2.1.3 Sox2  
Sox2 is a DNA-binding protein of the HMG family. In the mouse Sox2 is expressed 
predominatley at the blastocyst stage (Avilion et al., 2003). However unlike Oct4, Sox2 has a 
major role to play also later in development and in adult stem cells (Wood and Episkopou, 
1999; Zappone et al., 2000). At early stages of development and in mES cells, Sox2 activates 
target genes through interaction with Oct4. Sox2 knockouts are lethal to mouse embryos and 
they fail to fully develop, furthermore ES cells derived from these embryos are unable to 
proliferate or self-renew (Avilion et al., 2003). As outlined for Oct4, a precise level of Sox2 
appears to be key for pluripotency and to sustain self-renewal. Many studies have 
highlighted how Oct4 and Sox2 can in a direct way drive the expression of genes required 
for pluripotency including positive feedback on their own expression and that of Nanog 
(Chew et al., 2005; Tomioka et al., 2002). Together with the transcription factor Klf4, they 
activate the expression of Lefty1 (Nakatake et al., 2006). In mES cells a wide range of studies 
have focused on and delineated the functional role of Oct4, less is known about Sox2. Recent 
studies are beginning clear up the role of Sox2. As might have been anticipated mES cells 
deficient in Sox2 lose pluripotency and quickly differentiate supporting the perceived role of 
Sox2 in maintaining self-renewal. What is interesting is that in the Sox2 protein deficient 
system Oct-Sox enhancers are still active and up-regulation of Oct4 alone is sufficient to 
rescue these cells from differentiation. Thus it has been suggested that potentially other 
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results in mES cell moving towards primitive endoderm (Niwa et al., 2000). These divergent 
effects of Oct4 suggest that it regulates the transcription of genes involved in coordination of 
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activity. However at one least report suggests Nanog is a direct downstream target for 
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al., 2003). BMP signaling is facilitated by downstream effectors including SMAD1, an 
effector which Nanog has been shown to interact with and leads to inhibition of BMP 
signaling (Suzuki et al., 2006). What is being proposed is that BMPs are at least initially pro-
mesoderm lineage formation as evidenced by up-regulation of Brachyury a mesoderm 
marker. When activated STAT3 interacts with Brachyury and increases Nanog expression, 
the elevated levels of Nanog inhibit BMPs via SMAD1 interaction and thus maintain the 
undifferentiated pluripotent state. Nanog is now accepted as an important component in 
regulating the pluripotent phenotype however the mechanism of its own control and how it 
effects other genes is not entirely elucidated. It has been shown that Oct4 and Sox2 can bind 
to the Nanog promoter in vitro and in vivo (Rodda et al., 2005) suggesting that Oct4/Sox can 
act to up regulate Nanog expression. However other studies have shown that Nanog 
expression can be maintained in the absence of Oct4, thus other factors must contribute to 
the regulation. One such factor is a member of the forkhead family FoxD3, which is found in 
mES cells and the early embryo. FoxD3 knockout embryos have a similar fate as Nanog 
knockouts (Hanna et al., 2002). The exact mechanism by which Nanog is regulated and how 
it effects control of mES cell pluripotency is unknown, however it appears independent of 
STAT3 activation or the requirement for BMP4 at least when in serum free culture 
conditions. Nanog is capable of activating the Oct4 promoter forming a negative feedback 
loop upregulating Oct4 at times and suppressing Oct4 when levels are above normal (Pan et 
al., 2006). Furthermore it has been shown that Nanog is capable of activating Rex1 a target 
for Oct4 and Sox2 (Shi et al., 2006). Furthermore it has also been suggested that Nanog may 
interact with Wnt and BMP4 signaling independent of LIF which may help explain why the 
forced expression of Nanog in the absence of LIF sustains a level of self-renewal (Chambers 
et al., 2003; Mitsui et al., 2003). The regulation and comprehensive elucidation of the role of 
Nanog requires more experimental work before we can paint a true picture of its overall role 
in pluirpotency. 
2.1.3 Sox2  
Sox2 is a DNA-binding protein of the HMG family. In the mouse Sox2 is expressed 
predominatley at the blastocyst stage (Avilion et al., 2003). However unlike Oct4, Sox2 has a 
major role to play also later in development and in adult stem cells (Wood and Episkopou, 
1999; Zappone et al., 2000). At early stages of development and in mES cells, Sox2 activates 
target genes through interaction with Oct4. Sox2 knockouts are lethal to mouse embryos and 
they fail to fully develop, furthermore ES cells derived from these embryos are unable to 
proliferate or self-renew (Avilion et al., 2003). As outlined for Oct4, a precise level of Sox2 
appears to be key for pluripotency and to sustain self-renewal. Many studies have 
highlighted how Oct4 and Sox2 can in a direct way drive the expression of genes required 
for pluripotency including positive feedback on their own expression and that of Nanog 
(Chew et al., 2005; Tomioka et al., 2002). Together with the transcription factor Klf4, they 
activate the expression of Lefty1 (Nakatake et al., 2006). In mES cells a wide range of studies 
have focused on and delineated the functional role of Oct4, less is known about Sox2. Recent 
studies are beginning clear up the role of Sox2. As might have been anticipated mES cells 
deficient in Sox2 lose pluripotency and quickly differentiate supporting the perceived role of 
Sox2 in maintaining self-renewal. What is interesting is that in the Sox2 protein deficient 
system Oct-Sox enhancers are still active and up-regulation of Oct4 alone is sufficient to 
rescue these cells from differentiation. Thus it has been suggested that potentially other 
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members of the Sox family may substitute for Sox2 in the co-activation process mediated in 
partnership with Oct4. What has become clear is that Sox2 plays a role in regulating many 
transcription factors that can affect Oct4 levels including Nanog. Furthermore in cellular 
reprogramming studies up-regulation of Oct4 in combination with Sox2 is sufficient to 
generate pluripotent cells (Takahashi and Yamanaka, 2006; Okita et al., 2007). Some 
fascinating studies looking at global protein phophorylation patterns in hES cells have 
revealed some interesting dynamics in the Oct4 and Sox2 pattern of activation (Burdon et 
al., 2002). Thus exploring phophorylation pathways from extracellular signals to gene 
transcription effects will be key to furthering our understanding of self-renewal, in this 
context, pathways like those involving LIF and PI3K will be key to disentangling the 
signaling and transcription circuits involved. 
3. Signal transduction pathways 
3.1 Leukemia inhibitory factor (LIF) 
LIF is expressed in mouse preimplantation embryos from fertilization to the blastocyst stage 
but not in TE cells (Nichols et al., 1996). LIF transcripts are also found in mES cells (Rathjen 
et al., 1990) and endometrial glands of the mouse uterus which stops once implantation has 
occurred. Mouse LIF gene knockouts result in growth retardation and fertilized blastocysts 
fail to implant (Stewart et al., 1992). Historically mES cells were derived and maintained on a 
feeder layer of embryonic fibroblast. Subsequently it was found that the use of conditioned 
media from these fibroblast cultures was sufficient to maintain mES cell self-renewal. It was 
then shown that a the active agent produced by the feeder layer capable of blocking mES 
cell differentiation was in fact a cytokine later identified as leukemia inhibitory factor (LIF) 
(Smith et al., 1988). LIF is the best-characterized effector of self-renewal in mES cells. It is a 
multifunctional cytokine, which has a wide variety of effects on various cell types (Hilton 
and Gough, 1991). The name LIF is based on initial observations that in vitro it is capable of 
inducing irreversible differentiation of the murine leukemia cell line M1 to macrophages. 
LIF is a highly glycosylated single chain polypeptide and a member of IL6 cytokine family 
(Taga and Kishimoto, 1997). LIF is known to be secreted by a number of cell types including 
fibroblasts, lymphocytes spleen and liver cells (Gough and Williams, 1989). LIF is a very 
potent agent, in vitro 10-9g/L-1 (defined as 50U/mL-1) induces approximately 50% of a 
population of M1 cells (murine leukemia cell line) to differentiate. LIF induces a wide 
variety of effects on different cell types e.g. LIF has been shown to sustain the survival of 
murine primordial germ cells (DeFelici and Dolci, 1991) and stimulate the proliferation of 
myoblasts in culture. It has also been shown to affect bone growth and remodeling in vitro 
(Lorenzo et al., 1990; Wilson et al., 1992; Gearing et al., 1992; Ip et al., 1992; Taga and 
Kishimoto, 1997).  
The cellular actions of LIF are effected via a specific cell membrane receptor. The LIF 
receptor is a heterodimeric complex composed of a glycoprotein subunit gp130 and the 
receptor subunit LIFR (also called LIFRβ) (Ernst and Jenkins, 2004). Studies in mES have 
shown that the gp130 subunit is the essential component in transmitting self-renewal signals 
(Nakamura et al., 1998). Binding of LIF to the LIFR subunit induces dimerization with gp130, 
resulting in the formation of a high affinity receptor complex. The activated receptor 
switches on the constitutively bound tyrosine kinase Janus kinase (JAK). Activated JAK, 
phosphorylates both receptor subunits forming SH2 domain bind sites, which are capable of 
recruiting other signal transduction partners.  
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The SH2 domains facilitate the binding of signal transducers and activators of transcription 
(STAT) 1 and STAT3, which are phosphorylated by JAKs (Stahl et al., 1995). The activated 
STAT proteins form homodimers or heterodimers which then move to the nucleus, where 
they act as transcription factors (Auernhammer and Melmed, 2000). STAT3 is the principal 
STAT protein activated in mES cells stimulated with LIF (Niwa et al., 1998). Activation of 
STAT3, has been shown to be critical for LIF/gp130 dependent self-renewal in mES cells 
(Niwa et al., 1998). Using a tamoxifen inducible form of STAT3 (fusion of STAT3 to estrogen 
receptor) it has been shown that activation of STAT3 is capable of sustaining self-renewal of 
mES in the presence of serum (Mastuda et al. 1999).  
In the absence of fetal calf serum, in the presence of activated STAT3, BMP4 signaling 
maintains pluripotency. However, for hES cells LIF-STAT3 signaling cannot maintain 
pluripotency (Reubinoff et al., 2000) additional factors independent of LIF-STAT3 are 
required including basic fibroblast growth factor (bFGF) in the presence of Noggin which 
acts as a BMP pathway inhibitor. The exact mechanism of LIF-STAT3-dependent mES cell 
self-renewal is still not fully elucidated although models are arising (Fig. 2). A notable target 
for STAT3 is the transcription factor Myc (Cartwright et al., 2005) which along with others 
(Klf4, Oct4 and Sox2) has a role in cellular reprograming of somatic cells to a pluripotent 
state (Takahashi and Yamanaka, 2006). The forced up regulation of Myc supports self-
renewal in the absence of LIF. Whereas cessation of LIF signaling results in a decrease in 
Myc expression presumably through a down-regulation of STAT3. Apart from the above-
mentioned STATs a wide range of other downstream effector molecules can be activated 
through LIF receptor activation including extracellular regulated kinases (ERK), mitogen-
activated protein kinases (MAPK) and phosphatydilinositol-3 kinase (PI3K). The network of 
interactions between intracellular pathways and extracellular ligands continues to develop a 
pace, with numerous overlaps being identified. In this context another kinase, glycogen 
synthase kinase 3 (GSK3) a key enzyme in the Wnt pathways is quickly activated resulting 
in Myc phosphorylation and its degradation. The activity of GSK3 may be controlled by 
PI3K either directly or indirectly due to LIF signaling. Another possible network connection 
is that between LIF, PI3K and the Wnt pathway in self-renewal comes from the data that 
shows improved results in the derivation of mES cells in the presence of the GSK3 inhibitor 
BIO. Thus from a signaling perspective multiple pathways may be involved in the 
maintenance of low levels of GSK3 activity to promote pluripotency and mES cell self-
renewal. The array of signaling pathways and the level of crosstalk that exist between them 
and the LIF-STAT3 pathway in mES is slowly being deciphered giving us a clearer picture of 
the connections between LIF signaling and the transcriptional machinery controlling self-
renewal. 
3.2 PI3K Pathway 
Phosphatidylinositol 3 kinases (PI3Ks) are recognized to modulate a wide range of cellular 
functions from growth, proliferation and self-renewal to simple metabolic control. They are 
a family of enzymes, which phosphorylate the 3′-OH position of the inositol ring of 
phosphoinositides. In 1987 (Whitman et al., 1987) identified two distinct 
phosphatidylinositol kinases (PIKs) isolated from fibroblasts. They further demonstrated 
that one of these enzymes associated with activated tyrosine kinase receptors. They called 
this kinase type I PIK. Subsequently the same group showed that the most abundant form of 
the previously identified enzymes, type II PIK, phosphorylates the D-4 position on the 
inositol ring and that type I PIK phosphorylated the inositol ring at the D-3 position. 
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Fig. 2. LIF signal pathways and it integration into transcription machinery of self-renewal. 
Adapted from Niwa et al., 2009 
Currently the family is divided into 3 classes based on structure and substrate preference 
(Wymann and Pirola, 1998; Vanhaesebroeck et al., 2001). Class I PI3Ks form heterodimers, 
consisting of a ∼110 kDa catalytic subunit, and a regulatory subunit. The regulatory subunit 
comes in 4 main flavours (p85a, p55a, p50a, p85b, p55g) and a catalytic subunit in 3 major 
types (p110a, p110b, p110d) (Engelman et al., 2006). In vivo the primary substrate is 
phosphatidylinositol-4,5, bisphosphate (PtdIns(4,5)P2 or PIP2), which is converted to 
phosphatidylinositol-3,4,5, triphosphate (PtdIns(3,4,5)P3 or PIP3) (Cantley, 2002). This class 
of PI3Ks are activated by an array of plasma membrane receptors (for a review see Wymann 
et al., 2003). Class II PI3Ks produce PI(3)P and PI(3,4)P2 in vitro, but in vivo targets are less 
clear but the enzyme itself has been localized to the Golgi network. Class III PI3Ks produce 
only PI(3)P. Much of what we know about the functions of PI3K is because a potent and 
quite specific inhibitor is available. Wortmannin and LY294002 act as competitive ATP 
binders targeting the ATP-binding site of catalytic p110 subunit. The most interesting early 
finding was that wortmannin in the low nanomolar range blocked the respiratory burst of 
neutrophils (Baggiolini et al., 1987). Studies on purified enzymes have shown that the 
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mammalian PI3K is the most sensitive to wortmannin (Yano et al., 1993). The use of these 
inhibitors has proved invaluable in the study of PI3K and its cellular effects (reviewed by 
Nakanishi et al., 1995). The best known product of PI3K action is PIP3 which has been 
shown to be an important second messenger capable of recruiting AKT and involved in 
numerous cellular pathways associated with growth, proliferation and survival (Cantley, 
2002). The production of PIP3 facilitates the recruitment of pleckstrin homology (PH) domain 
containing proteins an important example of which is the protein kinase Akt which itself has 
multiple intracellular targets (Toker, 2002). Commonly in transformed cells the PI3K/Akt 
pathway is directly activated by the loss of PTEN, a negative regulator of PIP3 formation 
and an identified tumor suppressor. Maybe unsurprisingly in mES cells the role of PI3Ks 
was highlighted by the fact that in PTEN null mES cells, accelerated cell cycle progression 
was observed (Sun et al., 1999) which can be blocked by the PI3K inhibitor LY294002. 
However a role for PI3K signaling events has also been identified in the maintenance of 
pluripotency in mES cell derived for a number of species (Fig. 3) (Armstrong et al., 2006). 
Blocking PI3K signaling events results in elevated ERK/MAPK signaling (Paling et al., 2004) 
and there is evidence to suggest that ERK (Hamazaki et al., 2006) and Wnt (Sato et al., 2003) 
signaling are required to sustain pluripotency in both mouse and human ES cell lines. In the 
  
 
Fig. 3. Potential role for PI3K in self-renewal and LIF signaling in ES cells. 
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case of mES cells inhibition of PI3K pathways can induce differentiation in the presence or 
absence of LIF (Paling et al., 2004; Armstrong et al., 2006). However interestingly up 
regulation of Akt signaling is sufficient to maintain pluripotency of m ES cells (Watanabe et 
al., 2006). Another linkage for PI3K signaling and self-renewal comes from evidence that 
Nanog expression as well a number of Nanog target genes are modulated by PI3K signaling. 
Results have shown that the loss of pluripotent phenotype associated with PI3K blockage by 
LY294002 can be rescued by exogenous Nanog expression. Also regulation of GSK3 activity 
acting downstream of PI3Ks plays a role in Nanog expression. The evidence is clearly points 
out that PI3Ks play an important role in the signaling and maintenance of Nanog 
expression. PI3K effects are not limited directly to Nanog alone, inhibition of PI3K pathways 
results in the repression of rfx4, an identified Nanog target (Storm et al., 2007). However, 
interestingly, of the triad of master factors Oct4, Sox2, and Nanog, it appears that Nanog 
alone is sensitive to PI3K signaling pathways. However recently it has been shown that 
suppression of PI3K leads to a reduction in other self-renewal transcription factors including 
Klf4 (Storm et al., 2009), one of the targets in iPS generation. The role of PI3K in ES cells is 
complicated by the fact that self-renewal and cell proliferation are linked, and PI3Ks have 
been cast in major roles for both cellular processes. 
3.3 Wnt pathway 
The name “Wnt” comes from the fusion of the two names, int (based on the proto-oncogene 
integration-1 (Tanaka et al., 2002) and wg (based on wingless the segment polarity gene in 
Drosophila). The Wnt proteins are defined by amino acid sequence rather than by noted 
functional activities, but all Wnts share a number of common properties like numerous 
glycosylation sites and target sequences for secretion (Nusse and Varmus, 1992). Upon Wnt 
binding to its specific receptor, a signaling cascade is activated ultimately upregulating Wnt 
target genes. The Wnt signaling system is a highly conserved network controlling numerous 
other signaling transduction pathways from embryonic development to adult tissue 
homeostasis. Approximately 19 different WNT proteins have been identified acting on at 
least three different signaling pathways (Nusse and Varmus, 1992). The three pathways are 
the canonical Wnt pathway, acting via β-catenin and Tcf/Lef factors; the planar cell polarity 
(PCP) pathway; and the Wnt-Ca2þ pathway (Staal et al., 2008). This section will focus only 
on the canonical pathway. β-catenin is a well-known cytoplasmic protein and has a role in 
cell-cell adhesion acting to link membrane bound cadherins to the actin elements in the 
cytoskeleton. However it is now known to also act as a signaling molecule inside cells as 
part of the canonical Wnt signaling pathway (Reya and Clevers, 2005). In the absence of 
Wnt, β-catenin exists in a phosphorylated state in a complex marked for degradation by the 
ubiquitin-associated proteases. The β-catenin degradation complex includes the tumor 
suppressor proteins adenomatous polyposis coli gene (APC), Axin, and GSK3. Wnt 
signaling involves the Wnt ligand binding to the membrane receptor named Frizzled (Fz). 
Frizzled is a seven transmembrane receptor and the first receptor identified to bind the Wnt 
ligand (Bhanot et al., 1996). Activation of signal transduction by Wnt binding the Fz receptor 
requires a co-receptor attachment with a member of the low-density lipoprotein (LDL) 
family called Lrp5 and −6, this interaction is required for activation of the canonical Wnt 
signaling pathway (Li and Bu, 2005). Activation of Fz by Wnt results in the protection of β-
catenin from proteosomal degradation. Thus the action of Wnt is to maintain the 
intracellular levels of β-catenin which then translocates to the nucleus where it forms a 
transcription complex with one of a number of transcription factors including Tcf1, Tcf3, 
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Tcf4, or Lef1 (Okamura et al., 1998). Tcf1 is found mainly in T lymphocytes, Tcf4 is widely 
expressed and found in stem cells of gut while Tcf3 is expressed in mES cells. In mES cells 
there is growing but often-conflicting evidence that Wnt signaling pathways are important 
components of mES cell self-renewal. Wnt pathways have been shown to sustain 
pluripotency but also are important for of adult progenitor cell proliferation. The focus on 
Wnt signaling and its role in pluripotency comes from studies using the GSK3 inhibitor 5-
bromoindirubin-3-oxime (BIO) (Fig. 4) (Meijer et al., 2003; Sato et al., 2003).  
 
 
Fig. 4. Wnt signal pathway role in self-renewal. 
Inhibition of GSK3 prolongs the existence of β-catenin, causing it to accumulate, increasing 
the pool, which can translocate to the nucleus and activate gene expression. BIO has been 
shown to be able to maintain pluripotency of mouse and human ES cells in the absence of 
LIF (Sato et al., 2003). In a similar vain activation of Wnt signaling indirectly by removing 
the inhibitory effect of APC sustains pluripotency, suggesting the Wnt signaling is required 
for self-renewal (Kielman et al., 2002). In addition, treatment with Wnt3a was found to 
stimulate hES cell proliferation (Singla et al., 2006). Oct4 over-expression increased β-catenin 
transcriptional activity in progenitor cells. The Wnt controlled transcription factor Tcf3 has 
been shown to repress Nanog and thus promote differentiation. More recent studies have 
shown that Lef1 acting along with β-catenin is able to up-regulate Oct4 expression and 
interact with Nanog and thus promote self-renewal. All these data suggest that Wnt/β-
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catenin signaling has some role in the mES cell self-renewal (Takao et al., 2007). In obvious 
contrast to LIF and BMP signaling in mouse and human ES cells there is no difference 
between the cell types with regard to Wnt/β-catenin signaling self-renewal (Hao et al., 
2006). However, contrary to the above-portrayed role of Wnt in self-renewal, Wnt action has 
been shown to facilitate differentiation of mES cells into neural precursors and increases the 
expression of Brachyury a mesoderm marker (Yamaguchi et al., 1999). More work is 
required to elucidate the role of Wnt signaling in mES cell self-renewal and pluripotency 
and potential other effect for the non-canonical Wnt pathways. 
4. Summary and conclusion 
Even after prolonged periods and numerous expansions in culture ES cells retain the ability 
to respond to normal developmental signals and display no apparent bias for any one cell 
lineage when reintegrated to a developing embryo. Constructing a stable and coherent map 
of how ES cells achieve such a feat is a major challenge that must be met if the true potential 
of these cells is to be realized in a clinical setting. A fundamental breakthrough in this area 
came with the generation of a tetracycline-suppressible Oct4 transgene in late 2000. This 
study clearly defined the effect of Oct4 loss on ES cell self-renewal (Niwa et al., 2000). 
Silencing Oct4 resulted in ES cells differentiation into trophectoderm but most surprisingly 
an increase in Oct4 levels resulted in differentiation into mesoderm and endoderm cell 
linages (Niwa et al., 2000). Sox2 null ES cells differentiate into trophoectodermal type lineage 
(Masui et al., 2007). In the absence of Sox2 expression Oct/Sox targets were sustained, 
leading to the suggestion that other Sox proteins may replace the role of Sox2. Somewhat 
like Oct4 but less clear cut it would seem from over-expression studies in mES cells that up-
regulation of Sox2 results in formation of neural lineages (Kopp et al., 2008; Zhao et al., 
2004). Nanog was initially identified as a molecule capable of supporting the pluripotent 
phenotype of ES cells in the absence of LIF (Chambers et al., 2003). Suppression of Nanog 
results in increase differentiation (Chambers et al., 2007; Ivanova et al., 2006). Sufficient 
evidence indicates that the levels of Oct4, Sox2, and Nanog, govern to a large extent the 
pluripotency of ES cells (Chambers and Smith, 2004). Interestingly the accumulated work on 
these factors also points to the fact that Oct4 and Sox2 may perhaps drive a process of 
differentiation countering the self-renewal process. Oct4 and Sox2 increase the production of 
fibroblast growth factor 4 (FGF4), a growth factor that pushes ES cells toward differentiation 
by making them more susceptible to leverage by specific lineage commitment factors. All 
the while Nanog works to resist ES cells differentiation. Artificial high levels of Nanog 
through constitutive expression systems prevent ES cell differentiation even when FGF 
signaling is active (Chambers et al., 2003; Ying et al., 2003). However the true role of Nanog 
and its functional relationship to Oct4 and Sox2 is increasingly more complex. The level of 
Nanog found in individual normal ES cells shows a high degree of heterogeneity and Nanog 
knockouts can sustain self-renewal and are pluripotent (Chambers et al., 2007). In general 
though it appears that cells that are deficient in Nanog have a high propensity to 
differentiate (Chambers et al., 2007; Mitsui et al., 2003). Our understanding of the 
extracellular signaling interactions with these transcriptional networks is to date very 
unclear. The closest we are coming to tying these elements together is looking at work done 
on LIF signaling in ES cells. ES cells traditionally maintained on feeder cell layers in the 
presence of serum or a defined serum replacement with the addition of LIF for mouse, and 
bFGF for human ES cells. These less than wholly defined conditions are entirely problematic 
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for many reasons. A fundamental understanding of the pathways involved for both mouse 
and human stem cells is beginning to emerge. Niwa et al (2009) have shown that the LIF 
signaling is tightly linked into the transcriptional machinery of ES cell self-renewal. The 
Stat3 pathway activates Sox2 but not Nanog, while the PI3K–Akt pathway, effects 
predominately Nanog. Maintaining a pluripotent phenotype can be viewed as a getting the 
right balance between continued appropriate proliferation and inhibition of differentiation 
and/or cell death. Thus a key mechanism to sustaining ES cells in a pluripotent state may be 
to push and pull all at once i.e. push self-renewal factors and simultaneously block 
differentiation pathways. An example of this strategy is the effect of GSK3 inhibition in 
conjunction with inhibition of mitogen-activated protein kinase (MEK which facilitates long-
term self-renewal of mouse ES cells with no requirement for cytokines). As we get closer to 
understanding the pathways in mouse ES cells in particular the issue of difference in 
comparison to human lines become all the more apparent. Human ES cells are significantly 
different from mouse ES cells in phenotype and signaling pathway profiles. There is the 
suggestion that the human cell lines may represent a later stage (epiblast stage, Epi Stage 
Cells (EpiSCs)) of development compared to the mouse lines. LIF for example does not 
support either human ES cells or EpiSCs, but does support mES cell self-renewal (Xu et al., 
2005). Thus as we elucidate the pathways of pluripotency and self-renewal we will have to 
be mindful of the cells under study and the stage of development they represent. However 
these are not insurmountable tasks and growing volumes of data are beginning to delineate 
the signaling pathways and transcriptional networks controlling cell growth, proliferation 
and self-renewal. Only when we can clearly map the interactions of the many elements 
involved some competing and often conflicting signal pathways and key transcription 
regulators can we understand self-renewal and fully realise the potential of the pluripotent 
phenotype. 
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1. Introduction 
Embryonic stem cells were isolated from the mouse in 1981. Two landmark papers (Evans & 
Kaufman, 1981; Martin, 1981) described the isolation from the blastocyst of a cell line, that 
grew rapidly, was maintained by passaging, had a normal karyotype unlike embryonal 
carcinoma cells and could be induced to differentiate into a wide variety of cell types by 
injecting them into the mouse or by culturing them in the absence of feeder cells in vitro. The 
most important property of these embryonic stem cells was the ability to differentiate into 
most cell types. This is termed “pluripotency”. Understanding the molecular mechanisms of 
pluripotency will enable scientist to utilise stem cells more effectively, particularly in the 
field of tissue repair and regeneration (Murry & Keller, 2008). One approach towards the 
understanding of this molecular mechanism is to look at its protein interaction. 
This chapter will explain what a protein interaction network is and why it is used for 
looking at pluripotency. It will cover methods used to build protein-interaction networks 
and the methods of validations for these protein interactions. The chapter will also present 
an integrated dataset that merges the current understanding into one protein interaction 
network. Base on this integrated network, we will discuss what constitutes key factors in 
pluripotency, how these key factors are connected in the network and the protein 
machineries that they recruit to set up the pluripotent state. Finally, the chapter will look at 
the future challenges in the completion and utilization of the protein interaction network for 
the manipulation of pluripotency.     
2. What is the protein interaction network? 
A protein interaction network comprises proteins as nodes and protein-protein interactions 
as undirected links between the nodes. Drawing networks allows researchers to manage and 
interpret large datasets. Interpretation of the dataset is done by adopting concepts from 
other fields such graph theory to describe network properties. Such interpretations can 
explain how the structure of the network is serving its biological function. For example, in 
the field of graph theory, several parameters can be computed for a network. These 
parameters describe the architecture of the network so that it can be compared to other 
networks. This can provide some insights into the behaviour of the network particularly if it 
is compared to a network that is similar and already better understood. The most 
fundamental parameter of a network is the number of links a node has. This is referred to as 
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‘the degree of a node’ and is a variable that is designated by “k”. To describe all the nodes in 
the network, the number of nodes having different degree can be presented as a distribution 
curve (Figure 1). Depending on the pattern of the distribution curve, networks can be 
grouped into different classes (Barabasi & Oltvai, 2004). Random networks show a Poisson 
distribution (Figure 1A). Scale-free networks show a power law distribution (Figure 1B).   





Fig. 1. Networks and their corresponding graphs. (A) Random network shows a normal 
distribution and (B) Scale-free network shows a power-law distribution when their number 
or fraction of nodes with different number of links are plotted. 
In scale-free networks, most of the nodes will have very few links and only a few nodes will 
have many links (Figure 1B).  Systems that are approximately scale-free include many 
biological networks like the yeast proteome, the prokaryote and eukaryote transcription 
network, all metabolic networks, and even the internet (Albert, 2005; Barabasi, 2009). 
Networks of this class show robustness against failure of single components. Besides degree 
distribution, some other network properties include the average number of neighbours, the 
average or characteristic path length, the network diameter and the clustering coefficient 
(Barabasi & Oltvai, 2004). Classifying networks by its degree distribution is one way graph 
theory can be used to associate universal laws or organizational principals to networks. 
Understanding network principals makes it easier to predict protein functions; to generate 
testable hypothesis; and to simulate manipulations of protein components to see if it gives 
desired consequences. 
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3. Building the protein interaction network 
3.1 Methods used to build the network 
Different methods can be used to build a protein interaction network. The simplest method 
is to build the network based on available information about protein interactions from the 
literature. A second method is to include interactions based on extrapolations of protein 
interactions in other organisms to the orthologs in the organism of interest. However, both 
of these methods are limited to known interactions. In addition, the second method may 
result in the inclusion of false interactions due to wrongly mapped orthologs or lost of 
conservation of interactions. 
To discover protein-protein interactions without a priori knowledge and for network 
construction, a high throughput method is needed. For this, there are two tested 
approaches. There is the yeast 2-hybrid approach and the affinity purification-mass 
spectrometry approach. Interactors are identified by sequencing the plasmids encoding for 
the proteins (for the yeast 2-hyrbid approach) or by mass spectrometry (for the affinity 
purification approach). Both of these approaches have been tested in the construction of a 
protein interaction network for the yeast proteome (Gavin, et al., 2006; Gavin, et al., 2002; 
Ho, et al., 2002; Ito, et al., 2001; Uetz, et al., 2000). For the construction of a pluripotency-
associated protein interaction network, the aim is to have only the components of 
pluripotency in this network. Hence this should be a subnetwork of the proteome. Oct3/4, a 
key factor for pluripotency is selected as the bait from which other proteins may be 
discovered. The network grows when proteins that interact with Oct3/4 are used as the next 
bait; and by iteration the protein interaction network for pluripotency can be completed. 
Caution should be taken during iteration of this process to avoid extending the network into 
the interactions of non pluripotency-associated proteins. Most of the datasets for embryonic 
stem cell pluripotency-associated network are generated by affinity purification-mass 
spectrometry. Use of the yeast 2-hybrid approach has been attempted on Oct3/4. But the 
number of interactors discovered via this approach (Li, et al., 2008) was significantly lower 
than that discovered via affinity purification-mass spectrometry. This suggests that Oct3/4 
may recruit most of the subunits of macromolecules through only a few direct interactors or 
requires more interactors for contacts to be stabilized. Indirect interactors or cooperative 
interactors of Oct3/4 will not be discovered by the yeast 2-hybrid approach, which identifies 
only binary interactions. 
3.2 Methods used to validate the network 
A major concern with the use of affinity purification-mass spectrometry or yeast 2-hybrid 
approaches is the presence of false positives. In the yeast 2-hyrbid system, biologically 
irrelevant interactions can happen between two proteins inside the yeast nucleus to give a 
false-positive signal. In affinity purification-mass spectrometry, false positives are caused by 
background proteins that are not completely removed during affinity purification. Although 
mock purifications are included in experiments to allow identification of background 
proteins, there is a limitation in the mass spectrometer to capture all the peptides in a 
sample for identification. As such, sampling of the peptide population is not saturated. This 
causes estimations of relative abundance of proteins to be inaccurate and hence 
discrimination of noise from signal based on relative abundance of proteins in the actual 
versus the mock purifications also becomes inaccurate.  
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In view of these shortcomings of the approaches, validation of datasets becomes very 
important. The most direct method of validating a protein-protein interaction is by 
reciprocal co-precipitation. This can be done by expressing the two proteins in a cell culture 
system. However, some of these interactions are indirect and occur via a third protein, 
which if not present in the cell, would yield negative results in co-precipitation analysis. 
Even after direct association has been verified, it is important to further examine the 
functional significance of the interaction. Not all physical interactions have functional 
significance. For example, both Oct1 and Oct3/4 can interact with Sox2, but only the 
Oct3/4-Sox2 complex activates Fgf4 expression (Yuan, et al., 1995). Hence, multiple 
validations are necessary to verify that a protein has a role in pluripotency. Validations that 
have been employed include: (i) evidence for the presence of the interactor in embryonic 
stem cells; (ii) evidence that the interactor and the bait co-exist in a common subcellular 
location; (iii) indication that the level of abundance of the interactor changes upon 
differentiation; (iv) indication that the interactor regulates the genes of known embryonic 
stem cell transcription factors or vice versa; (v) gain or loss of pluripotency of embryonic stem 
cells when the gene of the interactor is knocked-out, is suppressed by RNA interference, or is 
overexpressed. For this validation, pluripotency can be monitored by alkaline phosphatase 
staining, by embryonic stem cell morphology, by Oct3/4 or Nanog transcript level, by 
profiling of lineage markers and by the expression of stage-specific embryonic antigen (SSEA) 
1, 3 and 4. Finally, validation can also be done by looking at the loss-of-function phenotypes in 
mice. For this, the gene of the interactors can be knocked-out, suppressed by RNA interference 
or overexpressed. Given that gene redundancy or functional redundancy is a phenomenon of 
pluripotency, validations that show no effect with a single gene knock-out could be further 
evaluated by double or triple knock-out of related genes. 
4. Analysis of current datasets 
Although the earliest protein-protein interaction network in embryonic stem cells was based 
on Nanog as that first bait protein, datasets of later work were mostly built upon Oct3/4 
(Liang, et al., 2008; Pardo, et al., 2010; van den Berg, et al., 2010; Wang, et al., 2006). Other 
proteins that have been used as baits are Sall4, Tcfcp2l1, Dax1, Esrrb, Rex1, Nac1 and Zfp281 
(van den Berg, et al., 2010). These proteins were used because they were found to interact with 
Oct3/4. To gain a more complete view of the pluripotency protein interaction network, 
datasets from the four published protein interaction networks of the embryonic stem cell was 
integrated as one (Figure 2). Integration of these datasets gives a network comprising 239 
proteins. Of these, 131 proteins were directly associated to Oct3/4. As expected, the 
distribution of the nodes according to their degree of links follows a power law distribution 
curve (Figure 2). Theoretically, this would suggest that pluripotency is mediated by a highly 
robust mechanism that is insensitive to the loss of many of its individual components.  
However, at this stage more work is required before such conclusion can become fully 
accepted. This is because the protein interaction network is currently incomplete. At this 
stage, the network structure can be strongly skewed by the methods used to generate the 
network (Futschik, et al., 2007). The observation that essential proteins like Oct3/4, tend to 
be more highly connected than nonessential proteins could be a true property or a 
consequence of their having been more thoroughly studied, or a combination of the two 
(Hakes, et al., 2008). As data accumulates, the power of system biology to catalogue and 
integrate data will become more meaningful (Pieroni, et al., 2008).  
 




Fig. 2. The pluripotency-associated protein interaction network of mouse embryonic stem cells. 
The network is derived from a combined dataset from four publications (Liang, et al., 2008; 
Pardo, et al., 2010; van den Berg, et al., 2010; Wang, et al., 2006). Bigger and brighter colored 
nodes represents proteins with more links. Simple network parameters are indicated in the 
box. A graph showing that the nodes have a power law distribution for their number of links. 
The graph also indicated Oct3/4 as the node at the tail end of the distribution on the graph. 
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4.1 The key factors in pluripotency 
From the literature, Oct3/4 is already known to be a key factor in pluripotency. In mice, loss 
of Oct3/4 results in embryos that fail to form a pluripotent inner cell mass (Nichols, et al., 
1998). The inner cell mass in these embryos takes on a trophoblast lineage and subsequently 
fails to proliferate. In adult cells, provision of Oct3/4 together with various cocktails of 
transcription factors induces pluripotency (Nakagawa, et al., 2008; Takahashi & Yamanaka, 
2006). While the other components of these cocktails can change, the inclusion of Oct3/4 is 
indispensible. The level of Oct3/4 is also important in the subsequent maintenance of 
pluripotency. While decrease of Oct3/4 to half its physiological level leads to conversion of 
embryonic stem cells to trophectoderm, an increase of Oct3/4 by less than two fold of its 
physiological dosage leads to conversion of embryonic stem cells into primitive endoderm 
and mesoderm (Niwa, et al., 2000). Finally, as the embryo develops, the level of Oct3/4 
decreases in the cells that differentiate; but in germ cells where pluripotency is kept, Oct3/4 
expression is maintained (Scholer, et al., 1990; Scholer, et al., 1989). Taken together, this is 
evidence for the role of Oct3/4 in inducing and in maintaining pluripotency. While the key 
role of Oct3/4 in pluripotency is obvious and does not need construction of the protein 
interaction network to point this out. The emergence of other protein hubs (nodes with high 
number of links) can suggest new key factors. Following Oct3/4, are two other proteins, 
Esrrb and Tcfcp2l1 that have 82 and 87 links respectively. The importance of Esrrb in 
pluripotency is corroborated by the observation that this protein can help in the induction of 
pluripotency in fibroblast (Feng, et al., 2009). Although there are no similar observations for 
Tcfcp2l1, its hub position in the network would suggest that this protein might be another 
important coordinator of pluripotency.  
Recently, the use of RNA interference has offered a means to functionally screen the 
genome. This would be a complimentary approach to the protein interaction network to find 
key factors of pluripotency. To find genes that are needed for maintenance of pluripotency, 
individual genes are knock-down by RNA interference. Combining the datasets from 
several studies (Ivanova, et al., 2006; Zhang, et al., 2006), including two which were genome-
wide screens (Ding, et al., 2009; Hu, et al., 2009), led to the identification of a total of 166 
proteins. In concurrence with the identification of Esrrb as a hub protein in the protein 
interaction network, the same protein was found to be one of the 166 proteins that were 
important for the maintenance of pluripotency (Table 1). However, a total of only 15 genes, 
inclusive of Esrrb, from the list of 166 are in the protein interaction network. This suggests 
that there are other key components found via RNA interference that are not yet discovered 
by protein-protein interaction. On the reverse, there are 224 proteins in the protein 
interaction network that are not found by RNA interference. These proteins could be 
involved in the induction of pluripotency but not in maintenance of it. Alternatively, these 
proteins may not have been identified via RNA interference because there can be 
redundancy of function, which is one mechanism for the robustness of the network. 
For human embryonic stem cell, no protein interaction network based on yeast 2-hybrid or 
affinity p4urification-mass spectrometry approaches have been generated. However, 
determinants of human embryonic stem cell pluripotency have been identified by a genome-
wide RNA interference screen (Chia, et al., 2010). The screen identified a total of 566 genes 
and a protein interaction network base on these has been reported. Information regarding 
possible interactions between any of the 566 genes was mapped based on the online 
database STRING, which stores known interaction and includes transfers from orthologous 
  
 




Table 1. Pluripotency-associated genes found via RNA interference assay of mouse 
embryonic stem cells. Proteins that are also found in the protein interaction network are 
shaded grey. 
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Fig. 3. The pluripotency-associated protein interaction network of human embryonic stem 
cell. Genes for pluripotency are discovered from RNA interference assay and interactions 
are based on the STRING database that also considers interactions from orthologs. Bigger 
and brighter colored nodes represents proteins with more links. The nodes with the top 
connectivity are colored blue. POU5F1 is colored purple for easy identification. The network 
has a power law distribution for their degree of links. Network parameters are indicated in 
the box.  
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interactions. Among the 566 genes, a total of 279 genes have some form of protein-protein 
interaction within the group and this network is shown in Figure 3.  
The human network also shows a power law distribution (Figure 3). The hubs in the 
network are POLR2E with 26 links, MY06 with 19 links and EP300 and CDC42 both with 18 
links. Notably human OCT4 is not one of the hubs. Again this is most probably an artifact of 
the incomplete network due to the lack of publications on OCT4 interactions. Although 
human OCT4 did not show up as a key factor, it is known to be important in pluripotency of 
human embryonic stem cell. Hence this emphasizes the need for more work in the 
construction of the network before reliable deductions can be made. 
 
 
Fig. 4. The mouse embryonic stem cell protein interaction network for the transcription 
factors constructed based on the experimental datasets of four separate publications (Liang, 
et al., 2008; Pardo, et al., 2010; van den Berg, et al., 2010; Wang, et al., 2006).  
4.2 How key factors network? 
Proteins such as Oct3/4 and Esrrb are transcription factors and they appear to be key factors 
in pluripotency. On the genome, these transcription factors show clustering at embryonic 
stem cell-specific genes, supporting the notion that their collaborations forms codes for 
ensuring selective transcriptional activation (Chen, et al., 2008; Kim, et al., 2008). It remains 
to be confirmed if these clusterings require direct protein-protein interactions or simply are 
clustering at the same location. Protein-protein interaction between these transcription 
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factors could provide structural changes required for regulation of gene expression for 
pluripotency. It was suggested that collaborations involving more transcription factors 
would activate embryonic stem cell-specific genes. While transcription factors with little 
interactions would activate more general genes.  
From the integrated dataset, proteins with the GO annotation “transcription factor” 
constitute a total of 78. Figure 4 shows a protein-interaction network of these transcription 
factors. Certainly, there are transcriptions factors that are important to pluripotency that do 
not cluster into the highly interactive zone because the network is incomplete. For example, 
Sox2 is important for regulating pluripotency genes but does not have many mapped 
collaborators probably because the Sox2-interactome has yet to be investigated by any lab. 
The current network therefore serves as a guide for future research directions. 
 
 
Fig. 5. The nucleosome remodeling deacetylase (NuRD) complex and its interactions with 
transcription factors in the pluripotency protein interaction network. 
4.3 How key factors recruit protein machineries 
The nucleosome remodeling histone deacetylase (NuRD) complex (Ahringer, 2000) was the 
most prominent complex identified in the embryonic stem cell protein-interaction network 
(Liang, et al., 2008; Pardo, et al., 2010; van den Berg, et al., 2010). All the components of this 
complex are in the network and each of the components interacts with one or more of the 
five transcription factors that was studied in greater detail (van den Berg, et al., 2010), 
namely Nanog, Esrrb, Oct4, Tcfcp2l1, and Sall4 which are themselves already tightly 
associated with one another (Figure 5).  
This suggests that the transcription factors co-recruit the same machinery, NuRD for histone 
deacetylation as a gene repression mechanism to regulate pluripotency. Indeed case studies 
have shown that NuRD has specific developmental roles rather than being required for 
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general cellular functions (Ahringer, 2000; Ch'ng & Kenyon, 1999; Mannervik & Levine, 
1999). Besides NuRD, other complexes have been reported in the study by Pardo et al. 
(Pardo, et al., 2010). Most of these are involved in chromosome remodeling. Confirmation of 
these findings would surely expand our knowledge of the extent to which each of these 
complexes contributes to pluripotency. This is because there is also converse evidence that 
chromosomal remodeling factors like the Polycomb Group and Polycomb Repressive 
Complex are not required for maintenance of pluripotency in embryonic stem cells (Azuara, 
et al., 2006; Boyer, et al., 2006; de Napoles, et al., 2004; Lee, et al., 2006; Montgomery, et al., 
2005; Niwa, 2007; O'Carroll, et al., 2001). It is believed that the chromatin of the embryonic 
stem cell is “loose” so as to allow free accessibility to transcription factors, but at the same 
time repressors are there to serve to prevent spontaneous differentiation of the embryonic 
stem cells. Having the different chromatin modifiers inserted into the protein interaction 
network may help to clarify their role in pluripotency. Besides the chromatin modifiers, the 
basic transcriptional machinery was also found to be recruited to the protein interaction 
network by Esrrb (van den Berg, et al., 2010). However this mechanism appears not to be 
utilized by the other transcription factors in the network. It remains to be seen if this 
mechanism is directly related to the regulation of pluripotency. 
5. Future challenges 
Ironically, pluripotency is best demonstrated by its loss. A population of cells is pluripotent 
if it can differentiate into many cell types; but once that happens, pluripotency is lost. In the 
embryonic stem cell, molecules for pluripotency work to balance two opposing features: the 
readiness to differentiate and the prevention of differentiation. To understand the molecular 
mechanism of pluripotency, we need to keep in mind this concept of pluripotency. In 
simulations, pluripotency should demonstrate these two opposing forces.  In the current 
protein interaction network both of these features of pluripotency are not distinguished. 
Furthermore, it is necessary to consider the multifunctionality of proteins. In this case, 
looking at proteins for the assignment of “jobs” may be more confusing than helpful. 
Alternatively, assignment of processes may be more meaningful if this was done to the 
edges of the network rather than the nodes. This approach of analysis can be illustrated by 
the following example. The interaction (edge) between Oct3/4 and Cdx2 serves the purpose 
of “gene repression”; and the interaction (edge) between Oct3/4 and Sox2 serves the 
purpose of “gene activation”. Hence instead of annotating both functions to the Oct3/4 
node, the annotations can be on the edges.  
A protein interaction network by virtue of the protocols employed is a single snapshot of the 
protein-protein interactions of a population of cells at any given time. To understand how 
embryonic stem cells have the ability to differentiate into different cell types, further 
information will have to be integrated. The final protein interaction network should include 
information on protein subcellular location and protein concentration. All this information 
in the network will change as a function of time as the cell undergoes cell cycling and when 
the cell undergoes fate changes. A study on the system-level changes across the three 
mechanistic layers: epigenetic, transcriptional and translational during fate change in mouse 
embryonic stem cells show that changes in nuclear protein levels are not accompanied by 
concordant changes in the corresponding mRNA levels, suggesting that translational and 
post-translational mechanisms, rather than transcriptional regulation play important roles, 
during lost of pluripotency. (Lu, et al., 2009). For full understanding and successful 
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simulation, information from the protein interaction network, the gene regulatory network 
and microRNA networks of ES cell should be fed back into one another. Integration of 
protein-protein interaction networks with transcriptional profiling networks has been done 
in yeast and has led to the discovery of new network features which are described as party 
hubs and date hubs (Vidal, et al., 2011). Party hubs are nodes that are coexpressed with its 
protein partners and date hubs are nodes that are not always transcribed at the same time 
and place as its partners. Biologically, party and date hubs may represent two kinds of 
protein-protein interactions. Transient protein-protein interactions that occur between 
transcription factors or between transcription factors and other protein complexes are date 
hubs. Static protein-protein interactions that occur between protein subunits of a stable 
protein complex are party hubs. The first type of interaction usually encodes instructions or 
messages while the second type of interaction functions mainly to execute the processes as a 
module. Identifying these interactions allow us to further understand how cell fate decisions 
are made and how these decisions are executed.  
In view of the large number of proteins that have been associated with pluripotency. It is 
possible that there are also alternate means of achieving pluripotency. After all, 
pluripotency is a cellular state rather than a cellular composition. Proteins like Ronin 
(Dejosez, et al., 2008; Zwaka, 2008), which show strong associations with pluripotency, may 
operate via a separate network. 
As data accumulation continues towards the point where the boundaries of the 
pluripotency-associated protein interaction network are felt, extra efforts will be needed 
towards looking for interactions amongst low concentration proteins and towards 
validation of this network. With a more complete embryonic stem cell protein interaction 
network, new hypothesis can be formulated. As more system biology data is generated from 
other fields, it will also become possible to compare between non-pluripotent and 
pluripotent networks. The embryonic stem cell protein interaction network, when ready, 
will serve as a point of comparison with other stem cells, with differentiated cells and with 
cancer cells. Such comparisons can potentially bring out unique features in each of these 
cellular conditions. Finally, in view of the differences between human and mice, the same 
work will have to be repeated with human embryonic stem cells. Knowledge gained from 
the challenges in mouse embryonic stem cell research ensues much faster progress with the 
human embryonic stem cell project. 
6. Conclusion 
Overall, we see great promise in getting answers and insights from a mature protein 
interaction network. Currently a total of 239 proteins form the mouse embryonic stem cell 
protein interaction network. More work is required in the construction of this network and 
this must be closely accompanied with attempts to annotate the purpose and nature of the 
interaction as discussed above. Another 151 proteins discovered to have a role in 
pluripotency by genome-wide RNA interference screening are yet to be connected to the 
protein interaction network. Multiple validations to confirm the involvement of these 
proteins in pluripotency are also necessary. In the network, the transcription factors show 
collaboration amongst themselves. A core group of transcription factors show recruitment of 
the same machinery, i.e. the NuRD. Some studies suggest that other chromatin modification 
machineries are also recruited. The role of these machineries remains to be investigated. 
When the network is reasonably saturated, system biology analysis should give greater 
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insight into network properties. Inclusion of information on dynamic properties of the 
protein interaction network would also facilitate predictive capabilities 
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1. Introduction 
In the preimplantation mammalian embryo, cells of the inner cell mass can differentiate into 
any cell type present in the more mature embryo. As of 1981, in mice and 1998 in humans, it 
has been recognized that embryonic stem cells (ESCs) with a prolonged proliferative capacity 
can be derived from the inner cell mass in vitro (Evans and Kaufman 1981; Thomson, 
Itskovitz-Eldor et al. 1998). ESCs are pluripotent cells that can contribute to all tissues in vivo 
and to the three primary germ layers as well as extraembryonic tissues in vitro. Because 
pluripotency is maintained in these cells even after prolonged periods of culture, human ESCs 
have great therapeutic potential for tissue regeneration. Indeed, embryonic and adult stem 
cells (SCs) hold great promise for regenerative medicine, tissue repair, and gene therapy. 
Careful molecular characterization of embryonic pluripotency should help to optimize and 
scale up the in vitro production of ESCs for clinical applications. 
The mechanisms regulating self-renewal and cell fate decisions in mammalian stem cells are 
poorly understood. As compared with differentiated cell types, stem cells express a 
significantly higher number of genes (represented by expressed sequence tags) of unknown 
function. The properties that distinguish stem cells from other cells are largely unknown, 
and the identification of signals that regulate stem cell differentiation remains fundamental 
to our understanding of cellular diversity. 
Embryonic and adult stem cells have many similarities at the transcriptional level. The 
overlapping set of expressed gene products represents a molecular signature of stem cells 
(Bhattacharya, Miura et al. 2004; Assou, Le Carrour et al. 2007). A list of human and mouse 
genes involved in stemness has been generated (Assou, Le Carrour et al. 2007) and includes 
92 stemness genes known to be expressed in mouse or human ESCs, e.g., OCT3/4, NANOG, 
Cripto/TDGFI, Cx43 and Galanin (Richards, Tan et al. 2004). Work in the field of 
embryogenesis has also contributed to our understanding of the function of these 
pluripotency-associated genes. The four most significantly overexpressed genes in 
undifferentiated embryonic tissues are Galanin, POU5FI, NANOG and DPPA4 (Zeng, Miura 
et al. 2004). In most studies, galanin has been highlighted as the most abundant transcript in 
ES culture as well as human and rodent embryonic tissues (Anisimov, Tarasov et al. 2002; 
Zeng, Miura et al. 2004). Both galanin and galanin receptors are expressed in ES cells, 
indicating a potential functional role for this protein (Tarasov, Tarasova et al. 2002). This 
chapter will be devoted to a description of the galanin expression profiles in embryonic 
tissues and stem cells as well as its possible functional role. 
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Galanin was first identified from porcine intestinal extracts in 1978 by Professor Viktor Mutt 
and colleagues at the Karolinska Institute, Sweden, using a chemical assay technique that 
detects peptides according to their C-terminal alanine amide structures. Galanin is so-called 
because it contains an N-terminal glycine residue and a C-terminal alanine (Hokfelt and 
Tatemoto 2008). The structure of galanin was determined in 1983 by the same team 
(Tatemoto, Rokaeus et al. 1983), and galanin cDNA was first cloned from a rat anterior 
pituitary library in 1987 (Vrontakis, Peden et al. 1987). Galanin is a biologically active 
neuropeptide that is widely distributed in the central and peripheral nervous systems and 
the endocrine system. The N-terminus of galanin is highly conserved between species 
(almost 90% among vertebrates, with the first 15 amino acids being identical, indicating the 
likely importance of this molecule (Vrontakis 2002). Consistent with this sequence 
conservation, the first 15 amino acids of galanin are sufficient for agonistic receptor binding.  
Galanin is proteolytically processed from a 124-amino acid precursor peptide, 
preprogalanin, along with a 59- or 60-amino acid peptide known as galanin message 
associate peptide (GMAP) (Rokaeus and Brownstein 1986; Vrontakis, Peden et al. 1987; 
Evans and Shine 1991). Preprogalanin is encoded by a single-copy gene organized into 6 
small exons (fig.1) spanning about 6 kb of genomic DNA (Kofler, Liu et al. 1996). The 
intron:exon organization of the galanin gene is conserved in all species studied thus far 
(Vrontakis 2002). Transcriptional studies of the galanin gene in multiple species concluded 
that the tissue-specific expression of this gene is achieved by enhancers as well as silencer  
 
 
Fig. 1. Organization of the rat preprogalanin gene. A: Schematic representation of the rat 
preprogalanin gene. B: the position of the six exons with respect to the rat preprogalanin 
cDNA  are shown. Abbreviations are as follows: ATG, translation initiation site; AATAAA, 
(Lang, Gundlach et al. 2007) the poly (A); TATA,TATA box;TSS, transcription start site; SIG, 
signal peptide; GAL, galanin; GAMP, galanin message associated peptide (Maria Vrontakis 
and Hong Zhang unpublished data) 
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sequences, which restrict expression to the appropriate cell type (Kofler, Evans et al. 1995; 
Corness, Burbach et al. 1997; Jiang, Spyrou et al. 1998; Rokaeus and Waschek 1998). We have 
sequence the 5’ flanking region of the rat galanin gene (Zhang, 1998) and have shown that 
the rat galanin promoter region contains some consensus sequences for known transcription 
factors. Up streamed of the modified TATA box, there is a conserved half-element (TGACG) 
for the protein CREB, which typically mediates gene expression by binding to the cyclic 
AMP response element (CRE).  In the rat galanin promoter region, there are also several AP-
1 binding sequences for the Jun/Fos protein families. Upstream of the CREB binding site 
there is a c-Ets element for the Ets factors. Furthermore, both negative and positive 
regulatory elements exist in the rat galanin gene. The negative regulatory elements 
appeared to be tissue specific since they are located differently in the different tissues. These 
negative transcription sites in the galanin promoter might be of importance for down 
regulating the gene during development. 
The functional role of galanin remains largely unknown, as is the case for most other 
neuropeptides; however, Galanin has been implicated in many biologically diverse 
functions, including nociception, waking and sleep regulation, cognition, feeding, regulation 
of mood and regulation of blood pressure. It also has roles in development and can act as a 
trophic factor. Galanin has been linked to a number of diseases, including Alzheimer’s 
disease, epilepsy, depression and eating disorders. Galanin appears to have neuroprotective 
activity, as its biosynthesis is increased 10- to 100-fold upon axotomy in the peripheral 
nervous system (whereas most neuropeptides are induced only 1.5- to 2-fold) or when 
seizure activity occurs in the brain. It may also promote neurogenesis (Mitsukawa, Lu et al. 
2008). Galanin frequently co-localizes with classical neurotransmitters such as acetylcholine, 
serotonin and norepinephrine as well as with other neuromodulators such as Neuropeptide 
Y, Substance P and Vasoactive peptide (Lang, Gundlach et al. 2007). Expression of galanin at 
the mRNA and peptide levels is elevated following estrogen administration, neuronal 
activation, denervation and/or nerve injury as well as during development. The wide 
spectrum of galanin's activities indicates that galanin is an important messenger for 
intercellular communication within the nervous system and the neuroendocrine axis. 
Galanin acts at specific membrane receptors to exert its effects. To date, three human and 
rodent galanin receptor subtypes have been cloned, namely, GalR1, GalR2 and GalR3 
(Branchek, Smith et al. 2000). High conservation between species exists among receptors of a 
given subtype but not between subtypes in an individual species (Howard, Tan et al. 1997; 
Iismaa, Fathi et al. 1998; Kolakowski, O'Neill et al. 1998). All three galanin receptor subtypes 
are members of the G protein-coupled receptor superfamily, but the subtypes show 
substantial differences in their functional coupling and subsequent signaling activities, 
contributing to the diversity of the possible physiological effects of galanin (Fig. 2). GalR1, 
the most abundant receptor subtype in adult tissues, is associated with the Gi family, which 
mediates the inhibition of cAMP synthesis by adenylate cyclase. Furthermore, it opens G-
protein-regulated inwardly rectifying potassium channels and stimulates mitogen-activated 
protein kinase (MAPK) activity. GalR2 acts through Gq/11 to regulate phospholipase C-
mediated events. GalR3 couples to Gi/Go and mediates the opening of G protein-coupled 
inwardly rectifying potassium channels (Lang, Gundlach et al. 2007). Since  the three 
galanin receptors exhibit distinct but overlapping patterns of expression in the central and 
peripheral nervous systems, a variety of ligands have been developed in an effort to 
elucidate the specific roles of each receptor (Langel and Bartfai 1998; Pooga, Jureus et al. 
1998; Lu, Lundstrom et al. 2005). Galanin agonists have been shown to have therapeutic 
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factors. Up streamed of the modified TATA box, there is a conserved half-element (TGACG) 
for the protein CREB, which typically mediates gene expression by binding to the cyclic 
AMP response element (CRE).  In the rat galanin promoter region, there are also several AP-
1 binding sequences for the Jun/Fos protein families. Upstream of the CREB binding site 
there is a c-Ets element for the Ets factors. Furthermore, both negative and positive 
regulatory elements exist in the rat galanin gene. The negative regulatory elements 
appeared to be tissue specific since they are located differently in the different tissues. These 
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intercellular communication within the nervous system and the neuroendocrine axis. 
Galanin acts at specific membrane receptors to exert its effects. To date, three human and 
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(Branchek, Smith et al. 2000). High conservation between species exists among receptors of a 
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Iismaa, Fathi et al. 1998; Kolakowski, O'Neill et al. 1998). All three galanin receptor subtypes 
are members of the G protein-coupled receptor superfamily, but the subtypes show 
substantial differences in their functional coupling and subsequent signaling activities, 
contributing to the diversity of the possible physiological effects of galanin (Fig. 2). GalR1, 
the most abundant receptor subtype in adult tissues, is associated with the Gi family, which 
mediates the inhibition of cAMP synthesis by adenylate cyclase. Furthermore, it opens G-
protein-regulated inwardly rectifying potassium channels and stimulates mitogen-activated 
protein kinase (MAPK) activity. GalR2 acts through Gq/11 to regulate phospholipase C-
mediated events. GalR3 couples to Gi/Go and mediates the opening of G protein-coupled 
inwardly rectifying potassium channels (Lang, Gundlach et al. 2007). Since  the three 
galanin receptors exhibit distinct but overlapping patterns of expression in the central and 
peripheral nervous systems, a variety of ligands have been developed in an effort to 
elucidate the specific roles of each receptor (Langel and Bartfai 1998; Pooga, Jureus et al. 
1998; Lu, Lundstrom et al. 2005). Galanin agonists have been shown to have therapeutic 
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applications in the treatment of chronic pain. Conversely, galanin antagonists have 




Fig. 2. Schematic illustration of the three galanin receptor subtypes and their intracellular 
transduction mechanisms. AC-adenyl cyclase , ATP-adenosine triphosphate, cAMP- cyclic 
adenosine monophosphate, DAG-diacyglycerol, IP3-inositol triphosphate, MAPK-mitogen 
activated protein kinase, PIP2-phosphatidyl 4,5-biposphate, PKC- protein kinase, PLC- 
phospholipase C. 
2.1 Galanin in the early embryo 
Galanin is one of the earliest neuropeptides to be expressed in the embryo. In the chicken 
embryo, galanin immunoreactive cells were first detected at E3.5 within the pharyngeal 
pouch region, the nodose ganglion, the primary sympathetic chain, the primitive splanchnic 
branches and the caudal portion of the Remark ganglion. These cells are derived from the 
neural crest. Indeed, galanin immunostaining appears at the same time as markers of neural 
crest cells. Transient galanin immunostaining was detected during the first week of 
development in cells displaying morphological features of migrating neuroblasts, but this 
expression domain had disappeared by E18 (Salvi, Vaccaro et al. 2001). At E4, galanin 
immunoreactivity was found in the spinal cord, medially in the motor column and in the 
intermediate zone. Neuroblasts appear coincident with galanin staining in the mesenchyme 
of the proventriculus/gizzard primordium (Salvi, Vaccaro et al. 1999; Salvi, Vaccaro et al. 
2001). The precise role of galanin during chicken development remains unclear. The fact that 
in these experiments, galanin was present in undifferentiated or partially differentiated cells 
and the primitive sympathetic system well before these neurons reach their peripheral 
targets suggests that galanin has a developmental role in proliferation and migration. 
Similar to the chicken, galanin-like immunoreactivity was detected in the mesenchyme and 
neural crest tissues of the early mouse embryo. At E10, we found that galanin-like 
immunoreactivity was readily detectable in the undifferentiated head and trunk 
mesenchyme (fig. 3) of mesenchymal or neural crest origin (Jones, Perumal et al. 2009), 
including the mesenchymal spiral ridges of the outflow tract of the heart and the 
endocardial cushions. The presence of galanin during these periods of morphogenesis 
 
 




Fig. 3. Histochemistry profile of galanin like immunoreactivity in embryonic day 10 mouse 
embryo.  A; sagittal and B; parasagittal section. Srong immonostaining for galanin is 
detected in the cephalic mesenchyme, trunk mesenchyme/somites, brachial arches, dorsal 
aorta and heart. 
indicates a developmental role for this peptide in tissues of mesenchymal and neural crest 
origin in the early embryo. Galanin expression in mesenchymal cells during organogenesis 
was greater in tissues that depend on mesenchymal-epithelial interactions for their 
coordinated morphogenesis. Indeed, galanin staining is apparent during many instances of 
mesenchymal remodeling, e.g., during the formation of digits from limb buds, the formation 
of cartilage primordia in vertebrae and ribs, the formation of bones, the formation of the 
heart and in the mesenchyme of the kidney and genital organs (Jones, Perumal et al. 2009). It 
is surprising that at this early stage of development, galanin expression is largely outside the 
developing central nervous system. Thus, galanin might have different functions in the 
embryo and the adult. Although the functional significance of galanin expression in 
mesenchymal and neural crest cells is currently unclear, these data suggest a possible role 
for galanin in regulating stem/progenitor cell proliferation, migration and/or 
differentiation. This possibility is supported by our observation that galanin and its 
receptors are highly expressed in bone marrow mesenchymal stem cells (fig. 4) and facilitate 
cell migration both in vitro and in vivo (Louridas, Letourneau et al. 2009). Furthermore, the 
expression of galanin in neural crest cells may be relevant to our understanding of the 
molecular genetics of neuronal tumors. It has been shown that galanin and galanin receptors 
are expressed in cells of peripheral embryonic neuroectodermal tumors, such as 
glioblastomas and neuroblastomas (Berger, Tuechler et al. 2002; Berger, Santic et al. 2003; 
Berger, Santic et al. 2005). Perel et al. has suggested that galanin influences neuroblastoma 
development and tumor growth, counteracting differentiation as an autocrine/paracrine 
modulator (Perel, Amrein et al. 2002). 
Galanin expression is also present in the mouse embryo at E7.5, during the late gastrulation 
stage. Here, galanin is abundantly expressed in the node (fig. 5) and primitive streak (Blum,  
 
 
Embryonic Stem Cells – Basic Biology to Bioengineering  
 
324 
applications in the treatment of chronic pain. Conversely, galanin antagonists have 




Fig. 2. Schematic illustration of the three galanin receptor subtypes and their intracellular 
transduction mechanisms. AC-adenyl cyclase , ATP-adenosine triphosphate, cAMP- cyclic 
adenosine monophosphate, DAG-diacyglycerol, IP3-inositol triphosphate, MAPK-mitogen 
activated protein kinase, PIP2-phosphatidyl 4,5-biposphate, PKC- protein kinase, PLC- 
phospholipase C. 
2.1 Galanin in the early embryo 
Galanin is one of the earliest neuropeptides to be expressed in the embryo. In the chicken 
embryo, galanin immunoreactive cells were first detected at E3.5 within the pharyngeal 
pouch region, the nodose ganglion, the primary sympathetic chain, the primitive splanchnic 
branches and the caudal portion of the Remark ganglion. These cells are derived from the 
neural crest. Indeed, galanin immunostaining appears at the same time as markers of neural 
crest cells. Transient galanin immunostaining was detected during the first week of 
development in cells displaying morphological features of migrating neuroblasts, but this 
expression domain had disappeared by E18 (Salvi, Vaccaro et al. 2001). At E4, galanin 
immunoreactivity was found in the spinal cord, medially in the motor column and in the 
intermediate zone. Neuroblasts appear coincident with galanin staining in the mesenchyme 
of the proventriculus/gizzard primordium (Salvi, Vaccaro et al. 1999; Salvi, Vaccaro et al. 
2001). The precise role of galanin during chicken development remains unclear. The fact that 
in these experiments, galanin was present in undifferentiated or partially differentiated cells 
and the primitive sympathetic system well before these neurons reach their peripheral 
targets suggests that galanin has a developmental role in proliferation and migration. 
Similar to the chicken, galanin-like immunoreactivity was detected in the mesenchyme and 
neural crest tissues of the early mouse embryo. At E10, we found that galanin-like 
immunoreactivity was readily detectable in the undifferentiated head and trunk 
mesenchyme (fig. 3) of mesenchymal or neural crest origin (Jones, Perumal et al. 2009), 
including the mesenchymal spiral ridges of the outflow tract of the heart and the 
endocardial cushions. The presence of galanin during these periods of morphogenesis 
 
 




Fig. 3. Histochemistry profile of galanin like immunoreactivity in embryonic day 10 mouse 
embryo.  A; sagittal and B; parasagittal section. Srong immonostaining for galanin is 
detected in the cephalic mesenchyme, trunk mesenchyme/somites, brachial arches, dorsal 
aorta and heart. 
indicates a developmental role for this peptide in tissues of mesenchymal and neural crest 
origin in the early embryo. Galanin expression in mesenchymal cells during organogenesis 
was greater in tissues that depend on mesenchymal-epithelial interactions for their 
coordinated morphogenesis. Indeed, galanin staining is apparent during many instances of 
mesenchymal remodeling, e.g., during the formation of digits from limb buds, the formation 
of cartilage primordia in vertebrae and ribs, the formation of bones, the formation of the 
heart and in the mesenchyme of the kidney and genital organs (Jones, Perumal et al. 2009). It 
is surprising that at this early stage of development, galanin expression is largely outside the 
developing central nervous system. Thus, galanin might have different functions in the 
embryo and the adult. Although the functional significance of galanin expression in 
mesenchymal and neural crest cells is currently unclear, these data suggest a possible role 
for galanin in regulating stem/progenitor cell proliferation, migration and/or 
differentiation. This possibility is supported by our observation that galanin and its 
receptors are highly expressed in bone marrow mesenchymal stem cells (fig. 4) and facilitate 
cell migration both in vitro and in vivo (Louridas, Letourneau et al. 2009). Furthermore, the 
expression of galanin in neural crest cells may be relevant to our understanding of the 
molecular genetics of neuronal tumors. It has been shown that galanin and galanin receptors 
are expressed in cells of peripheral embryonic neuroectodermal tumors, such as 
glioblastomas and neuroblastomas (Berger, Tuechler et al. 2002; Berger, Santic et al. 2003; 
Berger, Santic et al. 2005). Perel et al. has suggested that galanin influences neuroblastoma 
development and tumor growth, counteracting differentiation as an autocrine/paracrine 
modulator (Perel, Amrein et al. 2002). 
Galanin expression is also present in the mouse embryo at E7.5, during the late gastrulation 
stage. Here, galanin is abundantly expressed in the node (fig. 5) and primitive streak (Blum,  
 
 




Fig. 4. Immunohistochemistry of bone marrow mesenchymal stem cells stained with a 
polyclonal galanin antibody. Strong staining is observed in both the cytoplasm and the 
nucleus of the cells. 
 
 
Fig. 5. E7.5 Galanin RNA in situ. A; is a lateral view of the embryo. B; is a distal view of the 
embryo. Copyright: This image is from Tamplin OJ, BMC Genomics 2008; 9(1):511, an open-
access article, licensee BioMed Central Ltd 
Andre et al. 2007) and thus represents a marker for the node and the notochord 
(Schweickert, Deissler et al. 2008; Tamplin, Kinzel et al. 2008). Shortly thereafter, at E8, 
expression in the primitive streak disappears. Nevertheless, the expression of a 
neuropeptide in the gastrula, that is, in the absence of any neural tissue, is quite surprising. 
In their studies, Tamplin et al. used Foxa2 mutant mice to identify novel marker genes for 
the node. Foxa2 is a forkhead transcription factor that is absolutely required for the 
formation of the node and the development of the three germ layers. Galanin expression 
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was completely absent in the Foxa2 mutant embryos, indicating that galanin is a target of 
the Foxa2 gene as well as a regulatory factor involved in patterning. 
There are also reports of galanin mRNA expression in preimplantation embryos (Kang, Yeo 
et al. 2003; Kimber, Sneddon et al. 2008). In the first report (Kang, Yeo et al. 2003), the 
galanin gene sequence was examined for methylation changes in bovine embryos derived 
by in vitro fertilization (IVF). The authors observed that the galanin sequence maintained an 
undermethylated status until the morula stage. By the blastocyst stage, certain CpG sites 
became specifically methylated, which may be an epigenetic sign for the galanin gene to 
initiate a differentiation program. Such changes in DNA methylation status are very 
unusual in pre-implantation mouse development. Shortly after fertilization, the paternal 
pronucleus is subjected to active demethylation (Mayer, Niveleau et al. 2000), whereas the 
maternal genome simultaneously undergoes de novo methylation. Afterward, a passive 
replication-coupled demethylation process occurs in successive cleavage stages up to the 
blastocyst stage (Dean, Santos et al. 2001). This methylation reprogramming process allows 
the mouse zygote to gain totipotency and commence the formation of a new individual. In 
mammals, there are several periods of genome-wide reprogramming of methylation 
patterns during in vivo development. Typically, a substantial part of the genome is 
demethylated and then, after some time, remethylated in a cell- or tissue-specific pattern. 
Thus, galanin methylation appears to play a critical role in cell fate determination and 
differentiation during development. The study of epigenetic mechanisms underlying the 
establishment and maintenance of the pluripotent state as well as the differentiation process 
is an area of intense investigation in ESC biology.  
In the second study mentioned above (Kimber, Sneddon et al. 2008), Kimber et al. examined 
the expression of a number of genes known to be critical for early mouse development in 
human pre-implantation embryos. Developmental expression of a number of these genes 
(e.g., galanin, OCT3/4, CDX2, NANOG) was similar to that seen in murine embryos. 
Galanin mRNA was expressed in the cleavage stages (8-cell stage onward), suggesting a role 
for galanin in early cell fate decision in human embryos, which may have important 
implications for IVF treatment and the derivation of human ESCs (hESCs). Indeed, the same 
group reported that galanin mRNA and protein were both expressed in undifferentiated 
hESCs and human embryonal carcinoma cells but down regulated upon differentiation, 
shortly after the down regulation of OCT3/4, Nanog and FoxD3 (El-Bareg et al. 2007), 
implicating communication between these pluripotent genes in the pre-implantation human 
embryo and hESCs.  
2.2 Galanin in ESCs  
ESCs derived from the blastocysts of pre-implantation embryos are pluripotent and have the 
capability to generate all of the differentiated cell types present in the embryo. The 
mechanisms regulating self-renewal and cell fate decisions in mammalian stem cells are 
poorly understood. As compared with differentiated cells, stem cells express a significantly 
higher number of genes (represented by expressed sequence tags) of unknown function. The 
properties that distinguish stem cells from other cell types are largely unknown, and the 
identification of signals that regulate stem cell differentiation remains fundamental to our 
understanding of cellular diversity. Thus, an important step in the characterization of ESCs 
will involve the identification of a set of ESC-specific genes that function as markers or 
contribute to unique regulatory pathways. One approach to identify these signals is to 
generate stem cell gene expression profiles. Anisimov et al. used the genomic technique of 
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serial analysis of gene expression (SAGE) to define the molecular bases of pluripotency and 
self-renewal (Anisimov, Tarasov et al. 2002). SAGE is a prominent technique for the 
quantitative and qualitative characterization of a cell’s complete transcriptome (Velculescu, 
Madden et al. 1999). In their study, the authors performed SAGE on pluripotent mouse 
R1embryonic stem cells, sequencing a total of 140,313 SAGE tags. Because of the sensitivity 
of SAGE and the potential quantification of tags from contaminating cells, they cultivated 
ESCs without feeder layers in the presence of conditioned medium and leukemia inhibitory 
factor (LIF). After five passages, R1 ESCs maintained pluripotency and the ability to 
differentiate into cardiac myocytes, hematopoietic and neuron-like cells. One of the most 
abundant sequences in this SAGE catalogue was galanin. To determine whether the 
abundance of galanin was a characteristic of ES cells in general or possibly a feature limited 
to R1 ESCs cultivated under these defined conditions, they constructed other SAGE libraries 
from embryonal carcinoma (EC) P19 cells, embryonic germ (EG) cells and embryonic stem 
(ES) cells under different cultivation conditions. Galanin was highly expressed in each of 
these lines, indicating that high galanin expression is a distinguishing molecular feature of 
ESCs (Tarasov, Tarasova et al. 2002).  
In addition to galanin, all three galanin receptors (GalR1, GalR2 and GalR3) are expressed in 
mouse R1 ESCs. Quantification of their relative abundances showed that GalR1 is barely 
detectable in R1 ESCs, while GalR2 and GalR3 are relatively abundant (GalR2 & GalR3 >> 
GalR1). Similarly, GalR1 is almost undetectable in P19 EC cells but highly abundant in fetal 
tissues (E16). GalR2 and GalR3 have similar levels of expression in P19 EC and R1 ESCs, and 
both receptors are widely distributed among fetal tissues (Tarasov, Tarasova et al. 2002). 
Unlike GalR1 and GalR3, the biological activity of GalR2 is exerted through activation of Gq 
and phospholipase C. It has also been suggested to play a prominent role during nervous 
system development (Burazin, Larm et al. 2000). Thus, the presence of galanin transcripts 
and the relative abundance of GalR2 and GalR3 in ES and EC cells suggest that galanin may 
be biologically active in ESCs. 
Galanin function has been associated with LIF signaling. Addition of LIF into primary 
dorsal root ganglia (DRG) cultures significantly upregulated galanin expression (Ozturk and 
Tonge 2001). Similarly, LIF knockout mice have significantly lower levels of galanin (Sun 
and Zigmond 1996; Sun and Zigmond 1996). To determine whether the prominence of 
galanin in ESCs is mediated through an interaction with LIF, a series of further experiments 
were performed in which the medium containing LIF was substituted with non-conditioned 
maintenance medium without LIF. The absence of LIF actually increased galanin expression 
in R1 cells. Similarly, removing LIF had no effect on galanin expression in cultured hESCs 
(El-Bareg et al. 2007; Kimber, Sneddon et al. 2008), indicating that the abundance of galanin 
transcripts in ESCs is not regulated by LIF.  
Several differences between human and mouse ESCs have been identified, including an 
inactive LIF pathway in human ESCs. Similar to the mouse, the transcriptome profile of 
hESCs was obtained using SAGE (Richards, Tan et al. 2004). A list of candidate marker 
genes responsible for stemness in human ESCs has also been created, with galanin 
highlighted as one of the most abundant genes (Richards, Tan et al. 2004). Transcription 
factors with a defined role in the maintenance of pluripotency and whose expression is 
downregulated upon differentiation, including POU5F1 (Oct3/4), SOX2, Galanin, REX1, 
NANOG, and FLJ10713, were previously identified in mouse ESCs (Anisimov, Tarasov et al. 
2002; Ramalho-Santos, Yoon et al. 2002; Mitsui, Tokuzawa et al. 2003). 
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Using a large-scale oligonucleotide microarray, the profiles of 6 available human ESC lines 
were analyzed. The expression of defined genes was confirmed by reverse transcriptase 
polymerase chain reaction (RT-PCR), immunohistochemistry, focused microarrays and 
comparison to various databases maintained at the National Cancer Institute (Bhattacharya, 
Miura et al. 2004; (Zeng, Miura et al. 2004). A comparison of overexpressed genes identified 
92 genes common to all six lines. These 92 genes constitute a molecular signature of 
“stemness” in human ESCs. Galanin was the most abundant, along with Oct3/4, Nanog, 
Sox2 and FOXD3. However, the exact molecular mechanisms involved in self-renewal and 
pluripotency are still not very clear. 
In many respects, germ cell tumorigenesis resembles early embryogenesis. Embryonal 
carcinomas represent a histologic subgroup of testicular germ cell tumors, and EC cells may 
follow a differentiation trajectory in a manner similar to early embryogenesis. Using 
microarray analysis, the transcriptome of neoplastic tissues from the human testis was 
analyzed by Skotheim et al. (Skotheim, Lind et al. 2005). Selection for genes highly expressed 
in the undifferentiated, pluripotent embryonal carcinomas identified the major pluripotency 
markers, including Galanin, POU5F1(Oct3/4), NANOG, DPPA4. Again, Galanin was the most 
highly expressed gene. Galanin and POU5F1 were both up regulated at the protein level and 
thereby validated as diagnostic markers for undifferentiated tumor cells.  
Preliminary data support the hypothesis that galanin exerts an effect on self-renewal and 
pluripotency of ESCs along with POU5FI, NANOG and DPPA4 because it is temporarily 
down regulated upon ESC differentiation and is also more abundant in undifferentiated 
embryonal carcinomas relative to differentiated carcinomas. Differential DNA methylation 
of specific sites in the galanin gene might represent an epigenetic signal for the galanin gene 
to initiate a differentiation program. This occurrence may explain why galanin continues to 
be expressed in somatic cells of neural crest and mesenchymal origin in the early embryo. 
Both de novo methylation and maintenance DNA methylation are critical for early 
development, but they are required for differentiation rather than maintenance of the 
undifferentiated state. Human ESCs have been shown to possess a unique DNA methylation 
signature as compared with differentiated cells and cancer cells (Bibikova, Chudin et al. 
2006; Meissner, Mikkelsen et al. 2008; Amabile and Meissner 2009; Ball, Li et al. 2009; 
Meissner 2010), which supports the concept that a specific DNA methylation pattern may 
contribute to the pluripotent state. In particular, the pluripotency-associated genes Galanin, 
POU5F1(Oct3/4), NANOG and DPPA4 are largely unmethylated in ESCs and methylated in 
differentiated cells. 
Understanding the epigenetic regulation of ESCs will help to shed light on the molecular 
basis of normal development as well as the abnormal processes that underlie cancer.      
3. Conclusion  
In conclusion, the neuroendocrine peptide galanin is one of the most highly expressed genes 
in both human and mouse ESCs and the embryonic tissues of many species. Galanin is thus 
considered a marker of “stemness” and pluripotency. All three galanin receptors are present 
in ESCs, suggesting that the peptide may be biologically active. There are enough 
indications  to suggest a highly dynamic role of galanin in ESCs and in committing the fate 
of ES cells. The variety of cellular effect of galanin may depend on the environment 
surrounding the cells and possibly differential activation of its receptors. The switch from 
self-renewal to differentiation of ESCs might be triggered by a combination of other signals 
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abundance of galanin was a characteristic of ES cells in general or possibly a feature limited 
to R1 ESCs cultivated under these defined conditions, they constructed other SAGE libraries 
from embryonal carcinoma (EC) P19 cells, embryonic germ (EG) cells and embryonic stem 
(ES) cells under different cultivation conditions. Galanin was highly expressed in each of 
these lines, indicating that high galanin expression is a distinguishing molecular feature of 
ESCs (Tarasov, Tarasova et al. 2002).  
In addition to galanin, all three galanin receptors (GalR1, GalR2 and GalR3) are expressed in 
mouse R1 ESCs. Quantification of their relative abundances showed that GalR1 is barely 
detectable in R1 ESCs, while GalR2 and GalR3 are relatively abundant (GalR2 & GalR3 >> 
GalR1). Similarly, GalR1 is almost undetectable in P19 EC cells but highly abundant in fetal 
tissues (E16). GalR2 and GalR3 have similar levels of expression in P19 EC and R1 ESCs, and 
both receptors are widely distributed among fetal tissues (Tarasov, Tarasova et al. 2002). 
Unlike GalR1 and GalR3, the biological activity of GalR2 is exerted through activation of Gq 
and phospholipase C. It has also been suggested to play a prominent role during nervous 
system development (Burazin, Larm et al. 2000). Thus, the presence of galanin transcripts 
and the relative abundance of GalR2 and GalR3 in ES and EC cells suggest that galanin may 
be biologically active in ESCs. 
Galanin function has been associated with LIF signaling. Addition of LIF into primary 
dorsal root ganglia (DRG) cultures significantly upregulated galanin expression (Ozturk and 
Tonge 2001). Similarly, LIF knockout mice have significantly lower levels of galanin (Sun 
and Zigmond 1996; Sun and Zigmond 1996). To determine whether the prominence of 
galanin in ESCs is mediated through an interaction with LIF, a series of further experiments 
were performed in which the medium containing LIF was substituted with non-conditioned 
maintenance medium without LIF. The absence of LIF actually increased galanin expression 
in R1 cells. Similarly, removing LIF had no effect on galanin expression in cultured hESCs 
(El-Bareg et al. 2007; Kimber, Sneddon et al. 2008), indicating that the abundance of galanin 
transcripts in ESCs is not regulated by LIF.  
Several differences between human and mouse ESCs have been identified, including an 
inactive LIF pathway in human ESCs. Similar to the mouse, the transcriptome profile of 
hESCs was obtained using SAGE (Richards, Tan et al. 2004). A list of candidate marker 
genes responsible for stemness in human ESCs has also been created, with galanin 
highlighted as one of the most abundant genes (Richards, Tan et al. 2004). Transcription 
factors with a defined role in the maintenance of pluripotency and whose expression is 
downregulated upon differentiation, including POU5F1 (Oct3/4), SOX2, Galanin, REX1, 
NANOG, and FLJ10713, were previously identified in mouse ESCs (Anisimov, Tarasov et al. 
2002; Ramalho-Santos, Yoon et al. 2002; Mitsui, Tokuzawa et al. 2003). 
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Using a large-scale oligonucleotide microarray, the profiles of 6 available human ESC lines 
were analyzed. The expression of defined genes was confirmed by reverse transcriptase 
polymerase chain reaction (RT-PCR), immunohistochemistry, focused microarrays and 
comparison to various databases maintained at the National Cancer Institute (Bhattacharya, 
Miura et al. 2004; (Zeng, Miura et al. 2004). A comparison of overexpressed genes identified 
92 genes common to all six lines. These 92 genes constitute a molecular signature of 
“stemness” in human ESCs. Galanin was the most abundant, along with Oct3/4, Nanog, 
Sox2 and FOXD3. However, the exact molecular mechanisms involved in self-renewal and 
pluripotency are still not very clear. 
In many respects, germ cell tumorigenesis resembles early embryogenesis. Embryonal 
carcinomas represent a histologic subgroup of testicular germ cell tumors, and EC cells may 
follow a differentiation trajectory in a manner similar to early embryogenesis. Using 
microarray analysis, the transcriptome of neoplastic tissues from the human testis was 
analyzed by Skotheim et al. (Skotheim, Lind et al. 2005). Selection for genes highly expressed 
in the undifferentiated, pluripotent embryonal carcinomas identified the major pluripotency 
markers, including Galanin, POU5F1(Oct3/4), NANOG, DPPA4. Again, Galanin was the most 
highly expressed gene. Galanin and POU5F1 were both up regulated at the protein level and 
thereby validated as diagnostic markers for undifferentiated tumor cells.  
Preliminary data support the hypothesis that galanin exerts an effect on self-renewal and 
pluripotency of ESCs along with POU5FI, NANOG and DPPA4 because it is temporarily 
down regulated upon ESC differentiation and is also more abundant in undifferentiated 
embryonal carcinomas relative to differentiated carcinomas. Differential DNA methylation 
of specific sites in the galanin gene might represent an epigenetic signal for the galanin gene 
to initiate a differentiation program. This occurrence may explain why galanin continues to 
be expressed in somatic cells of neural crest and mesenchymal origin in the early embryo. 
Both de novo methylation and maintenance DNA methylation are critical for early 
development, but they are required for differentiation rather than maintenance of the 
undifferentiated state. Human ESCs have been shown to possess a unique DNA methylation 
signature as compared with differentiated cells and cancer cells (Bibikova, Chudin et al. 
2006; Meissner, Mikkelsen et al. 2008; Amabile and Meissner 2009; Ball, Li et al. 2009; 
Meissner 2010), which supports the concept that a specific DNA methylation pattern may 
contribute to the pluripotent state. In particular, the pluripotency-associated genes Galanin, 
POU5F1(Oct3/4), NANOG and DPPA4 are largely unmethylated in ESCs and methylated in 
differentiated cells. 
Understanding the epigenetic regulation of ESCs will help to shed light on the molecular 
basis of normal development as well as the abnormal processes that underlie cancer.      
3. Conclusion  
In conclusion, the neuroendocrine peptide galanin is one of the most highly expressed genes 
in both human and mouse ESCs and the embryonic tissues of many species. Galanin is thus 
considered a marker of “stemness” and pluripotency. All three galanin receptors are present 
in ESCs, suggesting that the peptide may be biologically active. There are enough 
indications  to suggest a highly dynamic role of galanin in ESCs and in committing the fate 
of ES cells. The variety of cellular effect of galanin may depend on the environment 
surrounding the cells and possibly differential activation of its receptors. The switch from 
self-renewal to differentiation of ESCs might be triggered by a combination of other signals 
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and coordinated changes in recruitment of epigenetic modulators and transcription factors 
to the promoter region. The strength of the intracellular signaling may affect the negative or 
positive regulatory elements of the galanin gene to use different intracellular pathways to 
mediate different cell function in ES cells. 
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The Rho family of small GTP-binding proteins is comprised of 22 members, including the 
most well characterized members RhoA, Rac1 and Cdc42 (Jaffe and Hall 2005). The Rho 
family proteins share a high degree of homology with the Ras proto-oncogene, and indeed 
were first identified as a result of this similarity (Ras homologue). Activity of these proteins 
is dependent upon their nucleotide binding state; inactive when associated with GDP but 
active following exchange of GDP for GTP, which induces conformational changes that 
promote association/activation of downstream effector proteins. The GDP/GTP cycle is 
regulated by GAPs that accelerate GTP hydrolysis by providing a critical catalytic amino 
acid leading to a return to the inactive state (Bernards and Settleman 2005), and GEFs that 
promote guanine nucleotide exchange and consequent Rho activation (Rossman et al. 2005). 
The number of GAPs and GEFs far exceeds the number of Rho proteins, and the roles of 
individual GAPs and GEFs in specific cell types and biological processes is currently an 
intensively studied field. 
Although united by homology and function as regulators of the actin cytoskeleton, each of 
RhoA, Rac1 and Cdc42 has a distinct role in the organization of actin structures (Figure 1). 
RhoA is principally involved with the production of actin-myosin bundles and the 
generation of actomyosin contractile force. Rac1 contributes to the formation of actin 
meshworks that result in the emergence of large protrusive structures that lead to spreading 
or, if occurring in a polarized manner, will contribute to motility. Cdc42 promotes the 
formation of actin-rich filopodia. Together, coordinated programs of RhoA, Rac1 and Cdc42 
activation/inactivation play prominent roles in processes such as endocytosis/exocytosis, 
adhesion and motility, which may subsequently impact upon proliferation and 
death/survival. Recent advances in the development of activation-state sensitive fluorescent 
probes have allowed temporal and spatial analysis of Rho protein activation, which has 
added significantly to our appreciation of Rho regulation and function (Hodgson et al. 
2010). Much of the early research on Rho protein function relied upon over-expression of 
dominant-negative mutants that reduced affinity for GTP and constitutively-active mutants 
that reduced GTP hydrolysis; however, more refined analysis has become possible with the 
rise of RNAi and knockout methodologies (Heasman and Ridley 2008). 
The study of Rho family proteins has historically focused on their roles as molecular 
switches acting downstream of cell surface receptors to regulate the actin cytoskeleton (Jaffe 
and Hall 2005). Significant effort has gone into classifying signaling from Rho proteins into  
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The Rho family of small GTP-binding proteins is comprised of 22 members, including the 
most well characterized members RhoA, Rac1 and Cdc42 (Jaffe and Hall 2005). The Rho 
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Fig. 1. Diagram of actin structures regulated by RhoA, Rac1 and Cdc42. 
linear cascades, similarly to the classical Ras/Raf/MEK/ERK kinase cascade. However, 
recently a greater appreciation of the role of mechanical forces as fundamental influences in 
biology has emerged (Puceat et al. 2003). As central regulators of the actin-myosin 
cytoskeleton, an emerging concept is that many of the activities of Rho proteins may not be 
attributable to simple linear pathways, but instead are the product of modulating 
contraction and relaxation at the cellular and subcellular levels, with consequent effects on 
development and function at the tissue and organismal levels. 
2. Embryonic Stem Cells 
Pluripotent stem cells were first isolated from testicular teratocarcinoma (Pierce and Dixon 
1959), a germ cell tumor type containing a population of pluripotent stem cells together with 
embryonic and extra-embryonic tissues that arise from these stem cells. Pluripotent stem 
cells of testicular teratocarcinomas are termed Embryonal Carcinoma (EC) cells and can give 
rise to collections of tumor cells having morphological characteristics of each of the three 
embryonic germ layers. In mice, EC cells have been demonstrated to be capable of 
contributing to every germ layer including the germ-line when injected into host blastocysts 
(Brinster 1974; Mintz and Illmensee 1975; Illmensee and Mintz 1976). Interestingly, under 
these conditions, EC cells are non-malignant, and chimeric mice containing tissues 
differentiated from EC cells are generally healthy. These observations formed the basis for 
the isolation of Embryonic Stem (ES) cells, which were derived from the pre-implantation 
embryo, arising when cells constituting the inner cell mass (ICM) of the pre-implantation 
blastocyst or the epiblast of the post-implantation blastocyst were placed in 2D-culture 
(Evans and Kaufman 1981; Martin 1981). Like EC cells, ES cells are pluripotent, being 
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capable of giving rise to all tissues of the adult organism originating from the three germ 
layers, upon injection into a host blastocyst (Bradley et al. 1984). The great similarities 
observed between EC cells and ES cells led to an appreciation of the importance of the tissue 
microenvironment in informing cell behavior and fate. 
A major attraction of murine ESC (mESC) research stemmed from the realization that 
mutations introduced into the mESC genome would be readily transmitted through the germ-
line, enabling the establishment of strains of mice harboring specific genetic mutations 
(Capecchi 1989), thereby facilitating the elegant functional characterization of virtually any 
gene of interest. The first gene to be targeted and inactivated in mES cells was the X-linked 
gene Hprt, which encodes hypoxanthine guanine phosphoribosyltransferase, an enzyme 
involved in purine metabolism (Thomas and Capecchi 1987). In turn, an Hprt-deficient ES cell 
line was engineered to re-introduce the Hprt coding sequence and used to produce knock-in 
gene-targeted mice for the first time, which faithfully recapitulated the wild-type Hprt 
expression pattern (Thompson et al. 1989). Following on from these pioneering studies, 
techniques for establishing gene-targeted mice have been considerably improved and refined. 
Gene targeting in mES cells to generate loss of function or gain of function mutations with an 
exquisite degree of subtlety and control is now an established tool in biological research. 
2.1 Maintenance of pluripotency 
ES cells express markers of their undifferentiated state such as the octamer binding protein 4 
(Oct4) (Rosner et al. 1990; Scholer et al. 1990), the SRY-related HMG-box gene 2 (Sox2) (Yuan 
et al. 1995), signal transducer and activator of transcription 3 (Stat3) (Niwa et al. 1998), the 
homeobox protein Nanog (Chambers et al. 2003; Mitsui et al. 2003) and alkaline phosphatase 
(AP) (Hahnel et al. 1990) that denote their capacity for both self-renewal and pluripotency. 
Of these, Oct4 and Sox2 have key roles in the maintenance of ES cell self-renewing capacity 
such that their expression is essential for the maintenance of pluripotency and their ectopic 
expression in somatic cells contributes to the generation of induced pluripotent (iPS) cells 
(Takahashi and Yamanaka 2006; Yu et al. 2007; Nakagawa et al. 2008).  
Oct4 is a POU-domain transcription factor also termed POU5F1 and is indispensable for 
plutipotency. Oct4 deficient embryos develop to the morula stage, but are unable to form an 
ICM (Nichols et al. 1998) and in vitro culture of Oct4 deficient embryos failed to yield ES 
cells (Nichols et al. 1998). These observations are further elaborated by more recent work 
showing that selective deletion of the Oct4 gene in primordial germ cells (PGC) results in 
their death by apoptosis (Kehler et al. 2004). Oct4 expression is very tightly regulated and its 
transient increase and decrease during early stages of embryonic development have been 
termed the totipotent cycle (Yeom et al. 1996). While evidence for the absolute requirement 
for Oct4 in the maintenance of ES cells is very strong, there is controversy on whether it is 
required for the maintenance of adult stem cells. Although there are numerous reports of 
Oct4 expression in adult stem cells including in hematopoietic and mesenchymal stem cells 
and stem cells of epithelial tissues such as the pancreas, kidney, breast, uterus, lung and 
skin, a recent study in which its expression was systematically abrogated in several of these 
tissues has revealed that Oct4 is required for neither the maintenance of adult stem cells nor 
for wound healing (Lengner et al. 2007). 
Sox2 is a HMG-box containing transcription factor closely related to the Y-chromosome 
located sex determining gene SRY. Its main role in the maintenance of pluripotency is 
thought to be closely related to the regulation of Oct4 transcription. Indeed Sox2 and Oct4 
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can jointly bind regulatory chromosomal regions associated with both the Oct4 and Sox2 
genes (Chew et al. 2005; Masui et al. 2007) as well as regulating Nanog expression (Kuroda 
et al. 2005; Rodda et al. 2005). 
2.2 Culturing ES cells 
Since the initial isolation of ICM-derived mESCs in the early 1980s (Evans and Kaufman 
1981; Martin 1981), conditions for the culture of ESCs have been developed and 
progressively refined. mESCs are propagated on a feeder layer of murine embryonic 
fibroblasts (MEFs) or in media containing leukemia inhibitory factor (LIF), under which 
conditions they maintain a pluripotent state (Williams et al. 1988). Withdrawal of LIF or 
culture in the absence of fibroblasts results in spontaneous differentiation of mESCs into a 
variety of lineages (Evans and Kaufman 1981; Martin 1981; Williams et al. 1988). The 
dependence of mES cells on LIF is thought to be related to LIF mediated activation of STAT3 
signaling (Smith et al. 1988) which together with Oct4/Sox2, has a possible role in the 
regulation of Nanog expression.  
Human ESCs (hESCs), which have been isolated from the epiblasts of human blastocysts 
(Thomson et al. 1998; Reubinoff et al. 2000) are also propagated on a feeder layer of MEFs, 
but LIF has no role in maintaining their pluripotency (Thomson et al. 1998; Reubinoff et al. 
2000). Instead, a balance between Tgfβ/activin/nodal signaling and suppression of BMP 
signaling together with the FGF signaling pathway are important for self-renewal and the 
maintenance of pluripotency in this system (James et al. 2005; Vallier et al. 2005; Xu et al. 
2005). However, as yet no reliable defined medium has been developed to enable the culture 
of hES cells in the absence of feeder cells. Like mESCs, hESCs spontaneously differentiate if 
cultured in the absence of a feeder layer, but unlike mESCs they undergo blebbing and 
apoptosis when maintained in a dissociated state (Watanabe et al. 2007).  
hESCs are not only a valuable tool for the study of human development, but also have 
applications in regenerative medicine, toxicology and the development of new drugs to 
target human disease (Murry and Keller 2008). mESCs and hESCs are thus examples of the 
two major types of pluripotent stem cells, derived as they are from the ICM and the epiblast 
respectively. 
3. Rho family GTPases in embryonic stem cells 
One of the most interesting recent developments in ES research is the revelation that signaling 
through RhoA plays a key role in the survival of human embryonic stem cells. This was first 
appreciated in 2007, following a cell-based screen of biologically active compounds that 
promoted survival and proliferation of dissociated hESCs that identified Y27632, a selective 
inhibitor of the Rho-effector protein ROCK (Watanabe et al. 2007). The ROCK1 and ROCK2 
serine/threonine kinases are central and critical regulators of actomyosin contractility 
(Coleman et al. 2001). Typically, these kinases are activated by association with active GTP-
bound Rho proteins. Active ROCK promotes actomyosin contractility through a dual 
mechanism of simultaneously phosphorylating and activating the contractile force-generating 
regulatory myosin light chain (MLC) and the LIM kinases (Sugihara et al. 1998), which 
modulate filamentous actin stability. In contrast to hESC, mES cells do not require ROCK 
inhibition for survival even when disaggregated to a single cell suspension. Since that initial 
study, subsequent screens have identified additional ROCK selective inhibitors that promote 
the survival of hESC (Andrews et al. 2010; Pakzad et al. 2010) and neural stem cells (Xu et al. 
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2010), thereby independently validating the role of ROCK as a key regulator of ESC survival. 
The addition of Y27632 to the culture media is now standard practice and has greatly 
improved the reliability of hES cell survival (Olson 2008; Krawetz et al. 2009). The addition of 
Y-27632 can be directly to the cell culture medium or into the extracellular matrix upon which 
the hESCs are plated (Danovi et al. 2010). ROCK inhibitors have also been shown to improve 
recovery of cryopreserved ESC  (Scott and Olson 2007; Wickman et al. 2010) and increase the 
efficiency of adenovirus-mediated gene transfer (Patwari and Lee 2008).  
3.1 Rho signaling in ES cells 
Recently, it has become clear that the actomyosin machinery downstream of Rho activation is 
essential for the blebbing and apoptosis that follow dissociation of hESCs (Martin 1981; Chen 
et al. 2010; Ohgushi et al. 2010), as inhibition of the myosin heavy chain ATPase with 
Blebbistatin, the use of actin disruption drugs or selective knock-down of ROCK1, ROCK2 or 
the myosin heavy and light chains all prolong survival of dissociated hESCs. Rho activation, 
coupled with Rac inhibition, was determined to be the driver of dissociation-induced hESC 
apoptosis via ROCK-mediated myosin light chain phosphorylation (Ohgushi et al. 2010). 
Activation of ROCK1 by caspase-mediated cleavage (Buecker et al. 2010) does not appear to 
contribute to apoptosis induced in this manner (Ohgushi et al. 2010). Overexpression of an 
active form of Ezrin, which strengthens the physical coupling between the plasma membrane 
and cortical actin cytoskeleton, was sufficient to block blebbing but not the dissociation-
induced cell death, indicating that apoptosis was not caused by blebbing itself but the result of 
actomyosin contraction (Ohgushi et al. 2010). Although the dissociation-induced cell death 
was linked back to mitochondrial depolarization and cytochrome c release, further study will 
be required to determine how actomyosin contractility is coupled to the mitochondrial 
pathway of apoptosis (Ohgushi et al. 2010). It is also becoming clear that the particular sub-
embryonic origin of the embryonic stem cell line determines whether Rho signaling is 
detrimental to survival on dissociation. While epiblast-derived hESCs are acutely sensitive to 
Rho signaling following dissociation, ICM-derived mESC have the capacity to survive 
dissociation without the need for inhibition of the actomyosin machinery (Ohgushi et al. 2010), 
a characteristic they share with human induced pluripotent stem cells (hiPSC), which display 
mESC-like morphological features (Evans and Kaufman 1981). On the other hand, epiblast-
derived murine epiblast stem cells (mEpiSC) or mESCs differentiated into epiblast-like cells 
acquire a dependence on ROCK-inhibition in order to survive dissociation (Ohgushi et al. 
2010). One theoretical possibility to account for these observations is that external pulling 
forces from adjacent cells in an epithelial sheet counteract the internal actomyosin contractile 
forces within individual cells such that the internal and external mechanical forces become 
balanced in all directions along the epithelial plane, thereby limiting their pro-apoptotic 
effects. Since mESCs are derived from the ICM prior to differentiation into epithelial-type cells 
and grow in disorganized three-dimensional cell collectives similar to the bona fide  inner cell 
mass, they may not be dependent on external tension derived from cell-cell adhesions, such as 
those that occur in an epithelial sheet, for survival. In contrast, hESCs grow as tightly adherent 
two-dimensional sheets similar to the epiblast where pulling forces from adjacent cells would 
be sensed. In agreement with this model, when human induced pluriopotent stem cells 
(hiPSCs) were reprogrammed from fibroblasts through the expression of five reprogramming 
factors plus LIF, they acquired the ability to grow at low density or in suspension in parallel 
with changed in vitro growth characteristics to mESC-like disorganized three-dimensional 
structures (Tashiro et al. 2010). This exquisite sensitivity of epiblast and epiblast-like stem cells 
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forces within individual cells such that the internal and external mechanical forces become 
balanced in all directions along the epithelial plane, thereby limiting their pro-apoptotic 
effects. Since mESCs are derived from the ICM prior to differentiation into epithelial-type cells 
and grow in disorganized three-dimensional cell collectives similar to the bona fide  inner cell 
mass, they may not be dependent on external tension derived from cell-cell adhesions, such as 
those that occur in an epithelial sheet, for survival. In contrast, hESCs grow as tightly adherent 
two-dimensional sheets similar to the epiblast where pulling forces from adjacent cells would 
be sensed. In agreement with this model, when human induced pluriopotent stem cells 
(hiPSCs) were reprogrammed from fibroblasts through the expression of five reprogramming 
factors plus LIF, they acquired the ability to grow at low density or in suspension in parallel 
with changed in vitro growth characteristics to mESC-like disorganized three-dimensional 
structures (Tashiro et al. 2010). This exquisite sensitivity of epiblast and epiblast-like stem cells 
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may reflect the critical importance of proper differentiation and spatial organization of the 
epiblast stage during embryonic development. If any individual cell in the epiblast layer were 
improperly positioned in the epithelial sheet, the potential consequences to the subsequent 
developmental stages and ultimately to the organism as a whole could be catastrophic. 
3.2 Rac signaling in ES cells 
The pro-apoptotic effect of Rho signaling in dissociated hESC is strongly counteracted by 
signaling through Rac. Indeed it has been shown that Rac1 is required for the survival of 
epiblast cells within the blastocyst during morphogenesis of the murine peri-implantation egg 
cylinder (He et al. 2010). During this process, the apoptosis mediated clearance of cells that are 
not in contact with the basement membrane (known as cavitation) is counteracted by signaling 
through Rac in those cells that remain apposed to the basement membrane (BM). In the 
absence of Rac1, cells in contact with the BM undergo apoptosis despite the survival signals 
that it normally provides (Kim et al. 2011). It is these BM-associated cells that give rise to the 
epiblast (He et al. 2010). Activation of Rac in the epiblast is mediated by the recruitment of the 
Crk adaptor protein and DOCK180 GEF (He et al. 2010). In turn, active Rac signals via PI3K 
and Akt to promote survival (He et al. 2010). Interestingly, a single dual-function protein, Abr, 
acts as Rho-GEF and Rac-GAP within dissociated hES cells in culture, simultaneously 
activating Rho and inactivating Rac upon cell dissociation, in a manner dependent on cell-cell 
interactions involving E-cadherin (Martin 1981; Ohgushi et al. 2010). The role of E-cadherin in 
hESC survival was also revealed in a chemical biology screen for small molecules that affected 
survival (Pakzad et al. 2010). One compound increased the survival of dissociated cells by 
reducing E-cadherin endocytosis, thus increasing the levels of cell-surface E-cadherin and 
consequently promoting cell-cell adhesions. In agreement with these observations, ectopic 
over-expression of E-cadherin was also sufficient to increase survival of dissociated hESCs 
(Rizzino 2010). However, when dissociated hESCs were grown on E-cadherin coated plates, 
they still underwent membrane blebbing and had significantly lower survival, indicating that 
homotypic E-cadherin interactions alone were not sufficient to promote survival (Ohgushi et 
al. 2010). These observations suggest the existence of a yet uncharacterized sensor that 
transmits a complementary signal derived from cell-cell adhesion that acts in concert with, or 
in parallel to, E-cadherin activation to repress actomyosin contractility and consequent cell 
death. Although mESCs are not sensitive to the same sort of dissociation-induced cell death, 
constitutive Rac1 deletion was found to induce membrane blebbing and eventual apoptosis of 
epiblast derived stem cells, possibly due to the lack of Rac1 activity to counter-balance the 
effect of RhoA activation (Kim et al. 2011). These Rac1 deleted cells also were defective in the 
formation of actin cytoskeleton structures such as lamellipodia and were significantly slower 
in migrating on collagen I coated dishes, revealing the critical role played by Rac1 in these 
biological activities. Similarly, Rac1 was found to be an important contributor to mESC 
migration on laminin (Li et al. 2010).  
3.3 Cdc42 signaling in ES cells 
Also implicated in murine peri-implantation development is the Cdc42 GTP-binding 
protein. Mouse embryoid bodies deficient for Cdc42 exhibited polarization defects 
characterized by aberrant adherens and tight cell-cell junction formation and failure of 
cavitation (Wu et al. 2007), in a process mediated by the atypical protein kinase C (aPKC) 
family of kinases. Despite the polarization defects, basement membrane formation, which 
requires polarized deposition and assembly of basement membrane components at the basal 
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side of a cell layer, was unaffected by deletion of Cdc42 (Wu et al. 2007). Interestingly mES 
cells lacking Cdc42 had lower levels of active Rac1 although total Rac1 protein levels were 
unaffected (Wu et al. 2007), suggesting that some of the observed defects could be the result 
of reduced Rac1 activity. However, unlike Rac1 deficient mES cells that would undergo 
apoptosis while in contact with the basement membrane (Kim et al. 2011), deletion of Cdc42 
still allowed survival of cells in contact with the BM (Wu et al. 2007). Additional defects in 
PIP2-induced actin polymerization and cytoskeletal organization were likely to also 
contribute to defective adhesion and migration of mESC deleted of Cdc42 (Chambers et al. 
2003; Wu et al. 2007). The motility of mESC plated on plated on laminin also were 
dependent on Cdc42 as revealed by siRNA-mediated knockdown (Li et al. 2010). These 
morphological, polarization and motility defects almost certainly contributed to early 
embryonic lethality in Cdc42 deficient mice (Chambers et al. 2003). These tantalizing 
observations point to complementary functions for Rho, Rac and Cdc42 during the 
processes of cavitation and the appearance of the epiblast, and underscore the importance of 
these proteins in appropriately mediating the survival or apoptotic clearance of cells during 
early morphogenesis. It therefore appears that the activity of the Rho family GTPases 
crucially determines the fate of pluripotent stem cells within the early developing embryo. 
4. Additional functions of Rho proteins in ES cells 
An interesting aspect of ESC is that under the right conditions, such as hanging drop 
suspension leading to the formation of embryoid bodies (Kurosawa 2007) , differentiation 
results in the production of cardiomyocytes that spontaneously contact and relax (beating) as 
they would in an intact heart (Wobus et al. 1991). Human ESC can also be differentiated into 
cardiomyocytes, which has generated considerable excitement in the field because of their 
value in examining the role of specific proteins in cardiac disease phenotypes, and also due to 
the eventual possibility that they might have therapeutic utility (Brinster 1974). To examine the 
role of Rac1 in the differentiation of mESC into cardiomyocytes, ectopic expression of 
constitutively-active Rac 1 deficient in GTPase activity (Rac1V12) or dominant-negative Rac1 
with reduced affinity for GTP (Rac1N17 was used to elucidate the consequences of Rac1 gain-
of-function and loss-of-function, respectively (Puceat et al. 2003). Expression of active Rac1V12 
blocked the characteristic beating of embryoid bodies, due to a differentiation defect as 
indicated by reduced expression of cardiomyocyte differentiation markers such as MEF2C and 
ventricular myosin light chain 2 (MLCv2). In contrast, expression of a constitutively active 
form of RhoA did not block cardiomyocyte differentiation. Previous research had revealed 
that Rac1 regulates the activity of the NADPH oxidase that generates reactive oxygen species 
(ROS) (Di-Poi et al. 2001) , and when H2O2 was added to embryoid bodies for up to 7 days the 
effect on blocking cardiomyocyte differentiation by active Rac1V12 was mimicked, while the 
ROS scavenger catalase reduced the differentiation block induced by active Rac1V12 (Puceat et 
al. 2003). Consistent with this conclusion, expression of a point-mutant form of Rac1 that does 
not activate the NADPH oxidase (Rac1V12D38) did not block cardiomyocyte differentiation. 
Expression of the dominant-negative Rac1N17 to examine loss-of-function did not affect 
differentiation but did impair beating by interfering with the organization of sarcomeric units 
required for contraction (Puceat et al. 2003). In contrast to what occurred when Rac1 was 
expressed early, when the MLCv2 promoter was used to express active Rac1 in differentiated 
cardiomyocytes, increased beating was observed due to a facilitation of differentiation and 
prolonged proliferation (Puceat et al. 2003). Expression of dominant-negative Rac1N17 from 
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may reflect the critical importance of proper differentiation and spatial organization of the 
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in parallel to, E-cadherin activation to repress actomyosin contractility and consequent cell 
death. Although mESCs are not sensitive to the same sort of dissociation-induced cell death, 
constitutive Rac1 deletion was found to induce membrane blebbing and eventual apoptosis of 
epiblast derived stem cells, possibly due to the lack of Rac1 activity to counter-balance the 
effect of RhoA activation (Kim et al. 2011). These Rac1 deleted cells also were defective in the 
formation of actin cytoskeleton structures such as lamellipodia and were significantly slower 
in migrating on collagen I coated dishes, revealing the critical role played by Rac1 in these 
biological activities. Similarly, Rac1 was found to be an important contributor to mESC 
migration on laminin (Li et al. 2010).  
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protein. Mouse embryoid bodies deficient for Cdc42 exhibited polarization defects 
characterized by aberrant adherens and tight cell-cell junction formation and failure of 
cavitation (Wu et al. 2007), in a process mediated by the atypical protein kinase C (aPKC) 
family of kinases. Despite the polarization defects, basement membrane formation, which 
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side of a cell layer, was unaffected by deletion of Cdc42 (Wu et al. 2007). Interestingly mES 
cells lacking Cdc42 had lower levels of active Rac1 although total Rac1 protein levels were 
unaffected (Wu et al. 2007), suggesting that some of the observed defects could be the result 
of reduced Rac1 activity. However, unlike Rac1 deficient mES cells that would undergo 
apoptosis while in contact with the basement membrane (Kim et al. 2011), deletion of Cdc42 
still allowed survival of cells in contact with the BM (Wu et al. 2007). Additional defects in 
PIP2-induced actin polymerization and cytoskeletal organization were likely to also 
contribute to defective adhesion and migration of mESC deleted of Cdc42 (Chambers et al. 
2003; Wu et al. 2007). The motility of mESC plated on plated on laminin also were 
dependent on Cdc42 as revealed by siRNA-mediated knockdown (Li et al. 2010). These 
morphological, polarization and motility defects almost certainly contributed to early 
embryonic lethality in Cdc42 deficient mice (Chambers et al. 2003). These tantalizing 
observations point to complementary functions for Rho, Rac and Cdc42 during the 
processes of cavitation and the appearance of the epiblast, and underscore the importance of 
these proteins in appropriately mediating the survival or apoptotic clearance of cells during 
early morphogenesis. It therefore appears that the activity of the Rho family GTPases 
crucially determines the fate of pluripotent stem cells within the early developing embryo. 
4. Additional functions of Rho proteins in ES cells 
An interesting aspect of ESC is that under the right conditions, such as hanging drop 
suspension leading to the formation of embryoid bodies (Kurosawa 2007) , differentiation 
results in the production of cardiomyocytes that spontaneously contact and relax (beating) as 
they would in an intact heart (Wobus et al. 1991). Human ESC can also be differentiated into 
cardiomyocytes, which has generated considerable excitement in the field because of their 
value in examining the role of specific proteins in cardiac disease phenotypes, and also due to 
the eventual possibility that they might have therapeutic utility (Brinster 1974). To examine the 
role of Rac1 in the differentiation of mESC into cardiomyocytes, ectopic expression of 
constitutively-active Rac 1 deficient in GTPase activity (Rac1V12) or dominant-negative Rac1 
with reduced affinity for GTP (Rac1N17 was used to elucidate the consequences of Rac1 gain-
of-function and loss-of-function, respectively (Puceat et al. 2003). Expression of active Rac1V12 
blocked the characteristic beating of embryoid bodies, due to a differentiation defect as 
indicated by reduced expression of cardiomyocyte differentiation markers such as MEF2C and 
ventricular myosin light chain 2 (MLCv2). In contrast, expression of a constitutively active 
form of RhoA did not block cardiomyocyte differentiation. Previous research had revealed 
that Rac1 regulates the activity of the NADPH oxidase that generates reactive oxygen species 
(ROS) (Di-Poi et al. 2001) , and when H2O2 was added to embryoid bodies for up to 7 days the 
effect on blocking cardiomyocyte differentiation by active Rac1V12 was mimicked, while the 
ROS scavenger catalase reduced the differentiation block induced by active Rac1V12 (Puceat et 
al. 2003). Consistent with this conclusion, expression of a point-mutant form of Rac1 that does 
not activate the NADPH oxidase (Rac1V12D38) did not block cardiomyocyte differentiation. 
Expression of the dominant-negative Rac1N17 to examine loss-of-function did not affect 
differentiation but did impair beating by interfering with the organization of sarcomeric units 
required for contraction (Puceat et al. 2003). In contrast to what occurred when Rac1 was 
expressed early, when the MLCv2 promoter was used to express active Rac1 in differentiated 
cardiomyocytes, increased beating was observed due to a facilitation of differentiation and 
prolonged proliferation (Puceat et al. 2003). Expression of dominant-negative Rac1N17 from 
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the MLCv2 promoter had a similar effect as early expression on the organization of sarcomeric 
units. These results revealed that the role of Rac1 in cardiac differentiation is likely dependent 
on the developmental stage. Given the availability of mESC in which Rac1 can be conditionally 
deleted (Yuan et al. 1995), more refined analysis of the role of Rac1 in cardiac differentiation 
and disease should be possible.  
5. Activating ROCK in mouse ICM-derived ES cells 
Mechanical forces are increasingly appreciated as major influences in embryonic 
development. External mechanical forces can be produced by physical alterations to the 
microenvironment. These external forces are sensed by cells, leading to responses that allow 
the cell to adapt to the changed environmental circumstances. One way that cells respond to 
mechanical force is via integrin-mediated activation of Rho and ROCK resulting in increased 
cellular stiffness via increased actomyosin contracility, which is also known as 
reinforcement (Guilluy et al. 2011). There is considerable evidence that suppression of  
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Fig. 2. Mechanism of conditional activation of ROCK. 1: Diagram of ROCK domains, RBD = 
Rho Binding Domain, PH = Pleckstrin Homology domain, CRD = Cysteine-Rich Domain. 2: 
Kinase domain of ROCK2 was fused to Enhanced Green Fluorescent Protein (EGFP) and the 
hormone-binding domain of Estrogen Receptor (ER) to create conditionally regulated 
ROCK:ER. 3: In the absence of ligand, Heat Shock Protein 90 (Hsp90) binds to the ER domain 
and represses catalytic activity. 4: Upon binding of estrogen analogues such as 4-
hydroxytamoxifen (4HT), 5: Hsp90 is displaced thereby allowing for ROCK catalytic activity.  
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actomyosin contractility by inhibition of ROCK promotes the survival and continued 
proliferation of epiblast-derived hES cells. It is suggested, however, that this signaling axis is 
less important in ICM-derived mES cells. We therefore decided to take advantage of a 
system to conditionally activate ROCK within mES cells to determine whether ROCK 
activation and consequent actomyosin contractility had a role in their proliferation, survival 
and/or maintenance of pluripotency. Accordingly, we transduced G4 mES cells (George et 
al. 2007) with a pBabe-Puro retroviral vector (Morgenstern and Land 1990) encoding a 
conditionally-active version of ROCK fused to the hormone-binding domain of the estrogen 
receptor (Figure 2) (Croft and Olson 2006) to establish the pBabe-Puro-ROCK:ER mES cell 
line in which ROCK activity could be elicited by treatment with the estrogen analog 4-
hydroxytamoxifen (4HT). As a negative control, cells were transduced with pBabe-Puro 
encoding a kinase-dead counterpart (KD:ER) to produce control pBabe-Puro-KD:ER mES 
cells that express of  catalytically inactive control ROCK protein. 
When maintained in 4HT, pBabe-Puro-ROCK:ER mES cells exhibited robust growth and a 
large number of colonies exhibiting a refractive colony morphology under transmitted light 
and fewer colonies exhibiting a differentiated morphology, consistent with a high degree of 
pluripotency (Figure 3). Consistent with this observation, 4HT treated pBabe-Puro-ROCK:ER 
mES cells express significantly higher levels of the pluripotency marker alkaline phosphatase 















Fig. 3. Conditional ROCK activation in mES cells elicits a highly refractive colony 
morphology. Panels show brightfield images of pBabe-Puro-ROCK:ER and pBabe-Puro-
KD:ER mES cells treated with Vehicle or 4HT. Flat colonies containing mainly differentiated 
cells (purple arrows) and raised colonies containing mainly undifferentiated cells (white 
arrows) are indicated. Scale bar denotes 500µm.  
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activation and consequent actomyosin contractility had a role in their proliferation, survival 
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encoding a kinase-dead counterpart (KD:ER) to produce control pBabe-Puro-KD:ER mES 
cells that express of  catalytically inactive control ROCK protein. 
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and pBabe-Puro-KD:ER mES cells (Figure 4A). To determine whether the increased ALP 
activity observed upon ROCK activation correlated with an increase in stemness, we then 
assessed the expression of two classical markers of pluripotency, Oct4 and Nanog. 4HT treated 
pBabe-Puro-ROCK:ER mES cells express significantly higher levels of Oct4 and Nanog than 
4HT treated pBabe-Puro-KD:ER mES cells or vehicle treated pBabe-Puro-ROCK:ER and 
pBabe-Puro-KD:ER mES cells (Figure 4B). Consistent with this effect being mediated by the 
activity of ROCK, co-treatment of pBabe-Puro-ROCK:ER mES cells with 4HT and the selective 
ROCK inhibitor Y-27632 failed to induce Oct4 or Nanog expression (Figure 4B).  
Taken together, these results strongly suggest that ROCK activation in mES cells promotes 
stemness and facilitates proliferation and survival. These observations are consistent with a 
previous report that inhibition of ROCK activity or silencing of ROCK expression in mESC 
causes a reduction in stem like properties including alkaline phosphatase activity and 
Oct3/4 expression, and increased expression of differentiation markers SOX-1, nestin and 
MAP2c when grown at high seeding densities (Chang et al. 2010). Interestingly, the effects 




























































Fig. 4. Conditional ROCK activation in mES cells increases stemness. (A) Histogram shows 
alkaline phosphatase activity in pBabe-Puro-ROCK:ER and pBabe-Puro-KD:ER mES cells 
treated with Vehicle or 4HT. (B) Histograms show expression at the mRNA level of the stem 
cell markers Oct4 and Nanog in pBabe-Puro-ROCK:ER and pBabe-Puro-KD:ER mES cells 
treated with Vehicle or 4HT. All values are expressed as mean ± SD. P values were 
calculated using the Student’s t-test. 
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grown at low initial densities where the reduction in stem like properties were not observed. 
However, at high cell densities where ROCK inhibition had repressed stem cell properties 
the effects were not reversible, suggesting that epigenetic reprogramming had occurred. It 
would be very interesting to determine whether the effects of ROCK activation on the 
maintenance of stemness would persist upon removal of tamoxifen and return of 
actomyosin contractility to basal levels. 
6. Rho signalling in ES cell maintenance, proliferation, survival 
There have been significant recent advances in our understanding of the requirement for 
specific Rho GTPases and downstream signaling pathways in ES cells from gene knockouts, 
RNAi and small molecule inhibitors. However, what has been missing is an understanding 
of where and when Rho proteins are activated and inactivated, for example during adhesion 
or differentiation. Activation-state sensitive fluorescent probes have been developed and 
used to characterize the temporal and spatial patterns of Rho activation during tumor cell 
migration and invasion (Vega et al. 2011). One exciting complementary area of research will 
be the determination of Rho protein activation with spatial and temporal resolution during 
ES cell growth and differentiation, ultimately through progressive developmental stages 
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RNAi and small molecule inhibitors. However, what has been missing is an understanding 
of where and when Rho proteins are activated and inactivated, for example during adhesion 
or differentiation. Activation-state sensitive fluorescent probes have been developed and 
used to characterize the temporal and spatial patterns of Rho activation during tumor cell 
migration and invasion (Vega et al. 2011). One exciting complementary area of research will 
be the determination of Rho protein activation with spatial and temporal resolution during 
ES cell growth and differentiation, ultimately through progressive developmental stages 
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1. Introduction 
Human Cripto-1 is a member of the Epidermal Growth Factor-Cripto-FRL-1-cryptic (EGF-
CFC) family of peptides (Bianco et al., 2010; de Castro et al., 2010). During early vertebrate 
development, Cripto-1 functions as a co-receptor for transforming growth factor  (TGF-) 
ligands, such as Nodal and growth and differentiation factor-1 and -3 (GDF-1 and GDF-3), 
through an heteromeric complex composed of Activin type II and type I (ALK4) serine 
threonine kinase receptors in the plasma membrane. Genetic studies in zebrafish and mice 
have demonstrated that Cripto-1/Nodal signaling is essential for the formation of the 
primitive streak, patterning of the anterior/posterior (A/P) axis, specification of mesoderm 
and endoderm and establishment of left/right (L/R) asymmetry (Bianco et al., 2010; de 
Castro et al., 2010). In adult tissues, Cripto-1 is expressed at low levels in all stages of 
mammary gland development and its expression increases during pregnancy and lactation. 
Overexpression of Cripto-1 in mouse mammary epithelial cells leads to their transformation 
in vitro and can enhance migration, invasion, branching morphogenesis and epithelial to 
mesenchymal transition (EMT) (Bianco et al., 2010; de Castro et al., 2010). Furthermore, 
transgenic mouse studies have shown that overexpression of a human Cripto-1 transgene in 
the mouse mammary gland under the transcriptional control of the mouse mammary tumor 
virus (MMTV) promoter results in mammary hyperplasias and papillary adenocarcinomas 
(Wechselberger et al., 2005). Cripto-1 is also expressed at high levels in approximately 50-
80% of different types of human carcinomas, including breast, colon, pancreas, lung and 
ovary (Bianco et al., 2010; de Castro et al., 2010). Cripto-1 is therefore an example of an 
embryonic gene that plays an important role not only during embryogenesis, but is also 
implicated in malignant progression. Furthermore, Cripto-1 signaling might represent a 
common signaling pathway shared by embryonic stem cells and cancer cells. Recent studies 
have shown that Cripto-1 is an important component of critical core pathways that regulate 
stem cell self-renewal and differentiation (Hough et al., 2009). Chromatin 
immunoprecipitation  (ChiP) analysis has revealed the presence of Oct-4 and Nanog binding 
sites in the Cripto-1 promoter region, suggesting that Cripto-1 is a direct transcriptional 
target of Oct-4 and Nanog transcription factors (Loh et al., 2006). More importantly, several 
signaling pathways that are critical for early embryonic development and regulate stem cell 
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(Wechselberger et al., 2005). Cripto-1 is also expressed at high levels in approximately 50-
80% of different types of human carcinomas, including breast, colon, pancreas, lung and 
ovary (Bianco et al., 2010; de Castro et al., 2010). Cripto-1 is therefore an example of an 
embryonic gene that plays an important role not only during embryogenesis, but is also 
implicated in malignant progression. Furthermore, Cripto-1 signaling might represent a 
common signaling pathway shared by embryonic stem cells and cancer cells. Recent studies 
have shown that Cripto-1 is an important component of critical core pathways that regulate 
stem cell self-renewal and differentiation (Hough et al., 2009). Chromatin 
immunoprecipitation  (ChiP) analysis has revealed the presence of Oct-4 and Nanog binding 
sites in the Cripto-1 promoter region, suggesting that Cripto-1 is a direct transcriptional 
target of Oct-4 and Nanog transcription factors (Loh et al., 2006). More importantly, several 
signaling pathways that are critical for early embryonic development and regulate stem cell 
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proliferation and differentiation have been shown to cross-talk with Cripto-1 (Bianco et al., 
2010). Examples of embryonic signaling pathways that interact with Cripto-1 are the Wnt-
/catenin, the Notch, hypoxia and TGF- signaling pathways.  Interestingly, Cripto-1 and 
other embryonic genes that regulate stem cell function are also overexpressed in human 
tumors, confirming this connection between stem cells and cancer. Recently, Cripto-1 has 
been shown to be highly expressed in a small subset of stem-like cells in human embryonal 
carcinoma cells, in human malignant melanomas and in androgen-responsive and refractory 
human prostate cancer cells (Cocciadiferro et al., 2009; Strizzi et al., 2008; Watanabe et al., 
2010). Therefore, Cripto-1 signaling pathway may represent an attractive target for 
treatment in cancer, because Cripto-1 targeting will eliminate not only differentiated cancer 
cells but also might target an undifferentiated subpopulation of tumor cells that exhibit 
stem-like characteristics, thereby leading to eradication of the tumor. In this review we will 
discuss the dual role of Cripto-1 as embryonic gene in the regulation of stem cell self-
renewal and differentiation and as oncogene with re-expression in human cancers.  
2. The EGF-CFC family  
Human Cripto-1 is a member of the EGF-CFC family of peptides identified only in 
vertebrates, and plays an important role in embryonic development and in tumor 
progression. The EGF-CFC family includes monkey Cripto-1, mouse Cripto-1 (Cr-1=cfc2), 
chicken Cripto-1, zebrafish one-eyed pinhead (oep), Xenopus XCR1/FRL-1, XCR2 and XCR3, 
mouse cryptic (Cfc1) and human Cryptic (CFC1) (Bianco et al., 2005b). Structurally, these 
proteins contain an NH2-terminal signal peptide, a modified EGF-like domain, a CFC 
cysteine-rich domain and a short hydrophobic COOH-terminus containing short sequences 
for glycosylphosphatidylinositol (GPI) cleavage and attachment (Figure 1).  
 
 
Fig. 1. Structure of the human Cripto-1 protein.  
Cripto-1 contains several glycosylation sites and the residue Threonin 88 within the EGF-
like domain modulates Cripto-1 ability to activate a Nodal-dependent signaling pathway. 
Cripto-1 can be cleaved from the cell membrane and can be released in the supernatant of 
cells by activity of the enzyme GPI-phospholipase D (GPI-PLD). EGF: epidermal growth 
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factor, CFC: Cripto-FRL-1-Cryptic, GPI: glycosylphosphatidylinositol, Ser: Serine, Asn: 
Asparagine, Thr: Threonine. 
GPI anchoring determines membrane localization of Cripto-1 within lipid rafts 
microdomains and is required for the paracrine activity of Cripto-1 as a Nodal co-receptor 
(Bianco et al., 2008; Watanabe et al., 2007b). Removal of the GPI anchor by GPI-PLD 
generates a soluble form of Cripto-1, which can therefore function both as a cell membrane 
anchored protein or as a soluble protein (Watanabe et al., 2007a; Watanabe et al., 2007b). In 
fact, soluble forms of Cripto-1 are biologically active in a number of different in vitro and in 
vivo assays (Minchiotti et al., 2001; Xu et al., 1999; Yan et al., 2002). Furthermore, Cripto-1 
protein has several glycosyl modification sites, including O-linked glycosylation at Ser40 
and Ser161 (-site for GPI-attachment), N-linked glycosylation at Asn79 and O-linked 
fucosylation at Thr88 (Figure 1) (Minchiotti et al., 2000; Schiffer et al., 2001; Shi et al., 2007; 
Watanabe et al., 2007a; Watanabe et al., 2007b). Among them, O-linked fucosylation of EGF-
CFC proteins is required for their ability to function as co-receptors for the TGF--related 
protein Nodal (Schiffer et al., 2001). However, Cripto-1 O-fucosylation mutants are fully 
functional with regard to activation of Nodal independent signaling pathways (Bianco et al., 
2008). Another study has demonstrated that is the Thr88 residue and not fucosylation of this 
residue that is necessary for Cripto-1 to function as a Nodal co-receptor (Schiffer et al., 2001; 
Shi et al., 2007). 
3. Cripto-1 during embryonic development  
In the embryonic development EGF-CFC proteins function as co-receptors for the TGF- 
ligands Nodal, GDF-1 and GDF-3 (Bianco et al., 2010; de Castro et al., 2010 as cited in Yeo et 
al. 2001; Andersson at al. 2007). Genetic studies in zebrafish and mice have defined an 
essential role for Nodal that functions through oep/Cripto-1 in the formation of the 
primitive streak, patterning of the A/P axis, and specification of mesoderm and endoderm 
(mesoendoderm) (Bianco et al., 2010; de Castro et al., 2010 as cited in Chu et al. 2005). In 
later stages of embryonic development the EGF-CFC ortholog of Cripto-1, Cryptic, regulates 
the establishment of L/R axis, allowing asymmetric development of visceral organs (Bianco 
et al., 2010 as cited in Yan et al., 1999). Biochemical studies have demonstrated that EGF-
CFC proteins bind directly to Nodal, GDF-1 or GDF-3 and the Activin type I receptor ALK4 
(ActRIB), recruiting the Activin type II receptor and inducing activation and 
phosphorylation of Smad-2/Smad-3 signaling pathway (Bianco et al., 2010) (Figure 2). 
However, Cripto-1 can also regulate A/P axis specification independently of Nodal 
signaling (D'Andrea et al., 2008). In fact, Cripto-1F78A/F78A mouse embryos carrying the 
amino acid substitution F78A are unable to activate a Nodal signaling pathway but clearly 
establish an A/P axis and initiate germ layer formation and gastrulation movements 
(D'Andrea et al., 2008). During early mouse embryogenesis, Cripto-1 cannot be detected 
until prior to the gastrulation stage in the inner cell mass and in extra-embryonic 
trophoblast cells at day 4 of development. Increase in Cripto-1 expression is observed on 
day 6.5 of embryonic development when Cripto-1 is found in the primitive streak within 
epiblast cells undergoing EMT, which eventually give rise to mesoderm and endoderm 
(Bianco et al., 2010; de Castro et al., 2010). Cripto-1 is also detected in the ectoplacental cone 
at this stage. Cripto-1 expression then decreases on day 7 when it is detected mostly in the 
truncus arterious of the developing heart. 
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proliferation and differentiation have been shown to cross-talk with Cripto-1 (Bianco et al., 
2010). Examples of embryonic signaling pathways that interact with Cripto-1 are the Wnt-
/catenin, the Notch, hypoxia and TGF- signaling pathways.  Interestingly, Cripto-1 and 
other embryonic genes that regulate stem cell function are also overexpressed in human 
tumors, confirming this connection between stem cells and cancer. Recently, Cripto-1 has 
been shown to be highly expressed in a small subset of stem-like cells in human embryonal 
carcinoma cells, in human malignant melanomas and in androgen-responsive and refractory 
human prostate cancer cells (Cocciadiferro et al., 2009; Strizzi et al., 2008; Watanabe et al., 
2010). Therefore, Cripto-1 signaling pathway may represent an attractive target for 
treatment in cancer, because Cripto-1 targeting will eliminate not only differentiated cancer 
cells but also might target an undifferentiated subpopulation of tumor cells that exhibit 
stem-like characteristics, thereby leading to eradication of the tumor. In this review we will 
discuss the dual role of Cripto-1 as embryonic gene in the regulation of stem cell self-
renewal and differentiation and as oncogene with re-expression in human cancers.  
2. The EGF-CFC family  
Human Cripto-1 is a member of the EGF-CFC family of peptides identified only in 
vertebrates, and plays an important role in embryonic development and in tumor 
progression. The EGF-CFC family includes monkey Cripto-1, mouse Cripto-1 (Cr-1=cfc2), 
chicken Cripto-1, zebrafish one-eyed pinhead (oep), Xenopus XCR1/FRL-1, XCR2 and XCR3, 
mouse cryptic (Cfc1) and human Cryptic (CFC1) (Bianco et al., 2005b). Structurally, these 
proteins contain an NH2-terminal signal peptide, a modified EGF-like domain, a CFC 
cysteine-rich domain and a short hydrophobic COOH-terminus containing short sequences 
for glycosylphosphatidylinositol (GPI) cleavage and attachment (Figure 1).  
 
 
Fig. 1. Structure of the human Cripto-1 protein.  
Cripto-1 contains several glycosylation sites and the residue Threonin 88 within the EGF-
like domain modulates Cripto-1 ability to activate a Nodal-dependent signaling pathway. 
Cripto-1 can be cleaved from the cell membrane and can be released in the supernatant of 
cells by activity of the enzyme GPI-phospholipase D (GPI-PLD). EGF: epidermal growth 
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factor, CFC: Cripto-FRL-1-Cryptic, GPI: glycosylphosphatidylinositol, Ser: Serine, Asn: 
Asparagine, Thr: Threonine. 
GPI anchoring determines membrane localization of Cripto-1 within lipid rafts 
microdomains and is required for the paracrine activity of Cripto-1 as a Nodal co-receptor 
(Bianco et al., 2008; Watanabe et al., 2007b). Removal of the GPI anchor by GPI-PLD 
generates a soluble form of Cripto-1, which can therefore function both as a cell membrane 
anchored protein or as a soluble protein (Watanabe et al., 2007a; Watanabe et al., 2007b). In 
fact, soluble forms of Cripto-1 are biologically active in a number of different in vitro and in 
vivo assays (Minchiotti et al., 2001; Xu et al., 1999; Yan et al., 2002). Furthermore, Cripto-1 
protein has several glycosyl modification sites, including O-linked glycosylation at Ser40 
and Ser161 (-site for GPI-attachment), N-linked glycosylation at Asn79 and O-linked 
fucosylation at Thr88 (Figure 1) (Minchiotti et al., 2000; Schiffer et al., 2001; Shi et al., 2007; 
Watanabe et al., 2007a; Watanabe et al., 2007b). Among them, O-linked fucosylation of EGF-
CFC proteins is required for their ability to function as co-receptors for the TGF--related 
protein Nodal (Schiffer et al., 2001). However, Cripto-1 O-fucosylation mutants are fully 
functional with regard to activation of Nodal independent signaling pathways (Bianco et al., 
2008). Another study has demonstrated that is the Thr88 residue and not fucosylation of this 
residue that is necessary for Cripto-1 to function as a Nodal co-receptor (Schiffer et al., 2001; 
Shi et al., 2007). 
3. Cripto-1 during embryonic development  
In the embryonic development EGF-CFC proteins function as co-receptors for the TGF- 
ligands Nodal, GDF-1 and GDF-3 (Bianco et al., 2010; de Castro et al., 2010 as cited in Yeo et 
al. 2001; Andersson at al. 2007). Genetic studies in zebrafish and mice have defined an 
essential role for Nodal that functions through oep/Cripto-1 in the formation of the 
primitive streak, patterning of the A/P axis, and specification of mesoderm and endoderm 
(mesoendoderm) (Bianco et al., 2010; de Castro et al., 2010 as cited in Chu et al. 2005). In 
later stages of embryonic development the EGF-CFC ortholog of Cripto-1, Cryptic, regulates 
the establishment of L/R axis, allowing asymmetric development of visceral organs (Bianco 
et al., 2010 as cited in Yan et al., 1999). Biochemical studies have demonstrated that EGF-
CFC proteins bind directly to Nodal, GDF-1 or GDF-3 and the Activin type I receptor ALK4 
(ActRIB), recruiting the Activin type II receptor and inducing activation and 
phosphorylation of Smad-2/Smad-3 signaling pathway (Bianco et al., 2010) (Figure 2). 
However, Cripto-1 can also regulate A/P axis specification independently of Nodal 
signaling (D'Andrea et al., 2008). In fact, Cripto-1F78A/F78A mouse embryos carrying the 
amino acid substitution F78A are unable to activate a Nodal signaling pathway but clearly 
establish an A/P axis and initiate germ layer formation and gastrulation movements 
(D'Andrea et al., 2008). During early mouse embryogenesis, Cripto-1 cannot be detected 
until prior to the gastrulation stage in the inner cell mass and in extra-embryonic 
trophoblast cells at day 4 of development. Increase in Cripto-1 expression is observed on 
day 6.5 of embryonic development when Cripto-1 is found in the primitive streak within 
epiblast cells undergoing EMT, which eventually give rise to mesoderm and endoderm 
(Bianco et al., 2010; de Castro et al., 2010). Cripto-1 is also detected in the ectoplacental cone 
at this stage. Cripto-1 expression then decreases on day 7 when it is detected mostly in the 
truncus arterious of the developing heart. 
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Fig. 2. Cripto-1/Nodal dependent signaling pathway. 
Cripto-1 is a co-receptor for Nodal, GDF-1 and GDF-3, allowing them to interact with ALK4 
(ActRIB). The Cripto-1/Nodal/ALK4/ActRII receptor complex triggers activation and 
phosphorylation of Smad-2 and Smad-3. Phosphorylated Smad-2 and Smad-3 form a 
complex with Smad-4 and they translocate into the nucleus. In the nucleus, Smad-2/-3/-4 
complex interacts with CREB binding protein (CBP)/p300 and activates transcription of 
specific target genes. The heat shock protein GRP78 can also enhance Cripto-1/Nodal-
dependent signaling pathway, as discussed later in the text. GDF-1/-3: growth and 
differentiation factor-1/3, GRP78: glucose-regulated protein 78. 
With the exception of the developing heart, little if any expression of Cripto-1 can be 
detected in the embryo after day 8 (Bianco et al., 2010; de Castro et al., 2010 as cited in Dono 
et al., 1993; Minchiotti et al., 2000). Disruption of Cripto-1 in Cripto-1 -/- embryos is 
embryonically lethal and results in the formation of embryos that possess a head without a 
trunk, demonstrating that there is a severe deficiency in embryonic mesoderm and 
endoderm without a loss of anterior neuroectoderm formation (de Castro et al., 2010 as cited 
in Ding et al. 1998). Initiation of the primitive heart tube in Cripto-1 -/- mice is severely 
inhibited due to failure in the development of functional beating cardiomyocytes, as 
demonstrated by the absence of expression of terminal myocardial differentiation genes (de 
Castro et al., 2010 as cited in Xu et al., 1998). Cripto-1 -/- embryonic bodies (EB) derived from 
Cripto-1 -/- embryonic stem (ES) cells fail to form beating cardiomyocytes, while they 
differentiate into neuronal cells. Addition of a Cripto-1 recombinant protein to Cripto-1 -/- 
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EBs during early time points (0–2 days) of differentiation is able to rescue cardiomyocyte 
differentiation. However, addition of Cripto-1 recombinant protein during later stages of 
differentiation fails to rescue cardiamyocyte differentiation, suggesting that Cripto-1 ability 
to promote cardiac differentiation of EB is restricted to an early window of this 
differentiation program (Minchiotti, 2005, as cited in Parisi et al., 2003). Interestingly, a 
microarray study revealed that Cripto-1 -/- ES cells had a reduced mRNA expression of the 
G protein coupled receptor APJ (also known as angiotensin type I-like receptor) and its 
ligand Apelin, as compared to control wild type ES cells. Gain of function experiments 
showed that APJ redirects the neural fate of Cripto-1 -/- ES cells and restores the cardiogenic 
program. Furthermore, comparison of Cripto-1, APJ and Apelin expression profile in mouse 
embryo by in situ hybridization revealed that expression of Apelin and APJ correlates with 
Cripto-1 expression. In fact, Apelin mRNA was clearly expressed in the developing 
primitive streak, whereas APJ was expressed in the primitive streak and adjacent 
mesoderm, resembling Cripto-1 expression pattern (D'Aniello et al., 2009). Therefore, APJ 
and Apelin are downstream targets of Cripto-1 signaling pathway and together with Cripto-
1 they drive ES cells toward a cardiac lineage. 
3.1 Cripto-1 in embryonic stem cells 
Stem cells have the capacity to divide for an undetermined period of time and a potential to 
develop into many different cell types throughout early life and growth. Stem cells are 
distinguished from other cell types by two important characteristics. First, they possess the 
capability to differentiate into mature cells of any particular tissue (pluripotency). Second, 
they can undergo through numerous cell cycle divisions while maintaining their 
undifferentiated state (self-renewal). ES cells can be isolated from a 3- to 5-day-old embryo, 
called blastocyst, and have the potential to give rise to all specialized tissues and organs of a 
mature organism. Adult stem cells are found in various adult tissues, and function as a 
reservoir for cells that are lost during injury or disease (Bendall et al., 2008). Mouse 
embryonic stem cells (mES) or human embryonic stem cells (hES) have been very useful in 
the field of stem cell research. Comparison of gene expression profiles across species has 
shown that mouse and human ES cells share common highly conserved signaling pathways 
that regulate self-renewal and pluripotency, including the Cripto-1/Nodal signaling 
pathway. For example, in addition to Cripto-1, genes such as Oct-4, Lefty, Nodal, Sox-2, Utf-
1 (undifferentiated embryonic cell transcription factor-1) and Tert (telomerase reverse 
transcriptase) are highly enriched in both mouse and human ES cells (Wei et al., 2005). 
Additionally, Cripto-1 has been identified as a pluripotency marker also in primate ES cells 
together with Oct-4, Nanog, Sox-2, Tert, LeftyA, and Rex-1 (Chang et al., 2010). In 2007 a 
comparative study of a large and diverse set of hES cell lines assessed the expression pattern 
of commonly used stem cell markers. All the hES cells analyzed exhibited similar expression 
profile for several stem cell markers, including the glycolipid stage specific embryonic 
antigens SSEA3 and SSEA4, the keratan sulfate antigens TRA-1-60, TRA-1-81, and the 
developmentally regulated genes including Nanog, Oct-4, Dnmt3b, Gabrb3, GDF-3 and 
Cripto-1 (Adewumi et al., 2007; Bianco et al., 2010; de Castro et al., 2010). Finally, Cripto-1 
has been reported as a direct target gene of stem cell transcription factors (Bianco et al., 2010; 
de Castro et al., 2010; Hough et al., 2009). For instance, using the ChIP paired-end ditags 
method, Loh and collaborators mapped the binding sites of the transcription factors Oct-4 
and Nanog in the mouse ES cell genome. Cripto-1 promoter was found to include Oct-4 and 
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Fig. 2. Cripto-1/Nodal dependent signaling pathway. 
Cripto-1 is a co-receptor for Nodal, GDF-1 and GDF-3, allowing them to interact with ALK4 
(ActRIB). The Cripto-1/Nodal/ALK4/ActRII receptor complex triggers activation and 
phosphorylation of Smad-2 and Smad-3. Phosphorylated Smad-2 and Smad-3 form a 
complex with Smad-4 and they translocate into the nucleus. In the nucleus, Smad-2/-3/-4 
complex interacts with CREB binding protein (CBP)/p300 and activates transcription of 
specific target genes. The heat shock protein GRP78 can also enhance Cripto-1/Nodal-
dependent signaling pathway, as discussed later in the text. GDF-1/-3: growth and 
differentiation factor-1/3, GRP78: glucose-regulated protein 78. 
With the exception of the developing heart, little if any expression of Cripto-1 can be 
detected in the embryo after day 8 (Bianco et al., 2010; de Castro et al., 2010 as cited in Dono 
et al., 1993; Minchiotti et al., 2000). Disruption of Cripto-1 in Cripto-1 -/- embryos is 
embryonically lethal and results in the formation of embryos that possess a head without a 
trunk, demonstrating that there is a severe deficiency in embryonic mesoderm and 
endoderm without a loss of anterior neuroectoderm formation (de Castro et al., 2010 as cited 
in Ding et al. 1998). Initiation of the primitive heart tube in Cripto-1 -/- mice is severely 
inhibited due to failure in the development of functional beating cardiomyocytes, as 
demonstrated by the absence of expression of terminal myocardial differentiation genes (de 
Castro et al., 2010 as cited in Xu et al., 1998). Cripto-1 -/- embryonic bodies (EB) derived from 
Cripto-1 -/- embryonic stem (ES) cells fail to form beating cardiomyocytes, while they 
differentiate into neuronal cells. Addition of a Cripto-1 recombinant protein to Cripto-1 -/- 
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EBs during early time points (0–2 days) of differentiation is able to rescue cardiomyocyte 
differentiation. However, addition of Cripto-1 recombinant protein during later stages of 
differentiation fails to rescue cardiamyocyte differentiation, suggesting that Cripto-1 ability 
to promote cardiac differentiation of EB is restricted to an early window of this 
differentiation program (Minchiotti, 2005, as cited in Parisi et al., 2003). Interestingly, a 
microarray study revealed that Cripto-1 -/- ES cells had a reduced mRNA expression of the 
G protein coupled receptor APJ (also known as angiotensin type I-like receptor) and its 
ligand Apelin, as compared to control wild type ES cells. Gain of function experiments 
showed that APJ redirects the neural fate of Cripto-1 -/- ES cells and restores the cardiogenic 
program. Furthermore, comparison of Cripto-1, APJ and Apelin expression profile in mouse 
embryo by in situ hybridization revealed that expression of Apelin and APJ correlates with 
Cripto-1 expression. In fact, Apelin mRNA was clearly expressed in the developing 
primitive streak, whereas APJ was expressed in the primitive streak and adjacent 
mesoderm, resembling Cripto-1 expression pattern (D'Aniello et al., 2009). Therefore, APJ 
and Apelin are downstream targets of Cripto-1 signaling pathway and together with Cripto-
1 they drive ES cells toward a cardiac lineage. 
3.1 Cripto-1 in embryonic stem cells 
Stem cells have the capacity to divide for an undetermined period of time and a potential to 
develop into many different cell types throughout early life and growth. Stem cells are 
distinguished from other cell types by two important characteristics. First, they possess the 
capability to differentiate into mature cells of any particular tissue (pluripotency). Second, 
they can undergo through numerous cell cycle divisions while maintaining their 
undifferentiated state (self-renewal). ES cells can be isolated from a 3- to 5-day-old embryo, 
called blastocyst, and have the potential to give rise to all specialized tissues and organs of a 
mature organism. Adult stem cells are found in various adult tissues, and function as a 
reservoir for cells that are lost during injury or disease (Bendall et al., 2008). Mouse 
embryonic stem cells (mES) or human embryonic stem cells (hES) have been very useful in 
the field of stem cell research. Comparison of gene expression profiles across species has 
shown that mouse and human ES cells share common highly conserved signaling pathways 
that regulate self-renewal and pluripotency, including the Cripto-1/Nodal signaling 
pathway. For example, in addition to Cripto-1, genes such as Oct-4, Lefty, Nodal, Sox-2, Utf-
1 (undifferentiated embryonic cell transcription factor-1) and Tert (telomerase reverse 
transcriptase) are highly enriched in both mouse and human ES cells (Wei et al., 2005). 
Additionally, Cripto-1 has been identified as a pluripotency marker also in primate ES cells 
together with Oct-4, Nanog, Sox-2, Tert, LeftyA, and Rex-1 (Chang et al., 2010). In 2007 a 
comparative study of a large and diverse set of hES cell lines assessed the expression pattern 
of commonly used stem cell markers. All the hES cells analyzed exhibited similar expression 
profile for several stem cell markers, including the glycolipid stage specific embryonic 
antigens SSEA3 and SSEA4, the keratan sulfate antigens TRA-1-60, TRA-1-81, and the 
developmentally regulated genes including Nanog, Oct-4, Dnmt3b, Gabrb3, GDF-3 and 
Cripto-1 (Adewumi et al., 2007; Bianco et al., 2010; de Castro et al., 2010). Finally, Cripto-1 
has been reported as a direct target gene of stem cell transcription factors (Bianco et al., 2010; 
de Castro et al., 2010; Hough et al., 2009). For instance, using the ChIP paired-end ditags 
method, Loh and collaborators mapped the binding sites of the transcription factors Oct-4 
and Nanog in the mouse ES cell genome. Cripto-1 promoter was found to include Oct-4 and 
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Nanog binding sites, suggesting that key modulators of stem cell self-renewal and 
pluripotentiality directly regulate Cripto-1 expression in ES cells (Bianco et al., 2010; de 
Castro et al., 2010; Loh et al., 2006). 
3.1.1 Cross-talk of Cripto-1 with stem cell signature pathways 
Several signaling pathways regulate in a coordinate fashion early embryonic development 
and stem cell proliferation, maintenance and differentiation. Some of these signaling 
cascades have been shown to cross-talk with Cripto-1 signaling, suggesting a pivotal role 
played by Cripto-1 in stem cell self-renewal and maintenance. Among these signaling 
pathways are genes in the Wnt/-catenin signaling pathway, TGF- family members, the 
Notch pathway, and hypoxia inducible factor-1 alpha (HIF-1) (Bianco et al., 2010; de Castro 
et al., 2010). A schematic diagram of the cross-talk of Cripto-1/Nodal signaling with other 
stem cell signature signaling pathways is shown in figure 3. 
 
 
Fig. 3. Interplay of Cripto-1/Nodal signaling with other embryonic stem cell signaling 
pathways. 
Cripto-1 signaling is a downstream target of Oct-4, Nanog, Wnt/-catenin, Notch and 
Hypoxia/HIF-1 pathways. Cripto-1 also mediates signaling of TGF- family members and 
enhances Notch signaling by facilitation of Notch receptor maturation. TGF-: transforming 
growth factor-, HIF-1: hypoxia inducible factor-1, GDF-1/-3: growth and differentiation 
factor-1/-3, BMP-4: bone morphogenetic protein-4, ES cells: embryonic stem cells, mES cells: 
mouse embryonic stem cells. 
Activation of the canonical Wnt/-catenin pathway has been reported to sustain the 
undifferentiated state of ES cells by triggering transcription of genes that regulate ES cell 
pluripotency and self-renewal, such as Oct-4, Nanog, Sox-2 and Cripto-1. For instance, 
Cripto-1 has been identified as a direct target gene in the canonical Wnt/-catenin signaling 
pathway during embryonic development and in colon carcinoma cell lines and tissues 
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(Morkel et al., 2003). Remarkably, in -catenin -/- or Wnt3 -/- mutant mouse embryos, Cripto-
1 expression was found to be dramatically downregulated, suggesting that the Wnt/-
catenin signaling pathway is a positive regulator of Cripto-1 expression during embryonic 
development (Bianco et al., 2010). In addition, in Xenopus, the Cripto-1 ortholog XCR1/FRL-
1 functions as a co-receptor for Wnt11 and together with frizzled receptor 7 and Glypican-4 
mediates stabilization and activation of -catenin (Bianco et al., 2010). Several studies have 
clearly implicated Wnt/-catenin signaling pathway in initiation and maintenance of 
carcinomas of the skin, intestine, liver, and brain (Bianco et al., 2010; de Castro et al., 2010). 
Hence, the interaction between the Wnt/-catenin and Cripto-1 signaling pathways might 
be significant also in cancer initiation and progression. Activation of TGF-/Activin/Nodal 
signaling has also been reported to be required for the maintenance of undifferentiated state 
in human ES cells (James et al., 2005; Vallier et al., 2009). Some TGF- family members, 
including Nodal, GDF-1 and GDF-3, require Cripto-1 for signaling and they are critical for 
ES cell maintenance and self-renewal (Bianco et al., 2010). Furthermore, Activin, TGF- and 
bone morphogenetic protein (BMP)-4 can directly regulate Cripto-1 expression by binding to 
smad binding elements (SBE) within the Cripto-1 promoter in human embryonal carcinoma 
cells and in human colon cancer cells (Mancino et al., 2008). GDF-3 and Cripto-1 have also 
been identified as ES cell markers that are enriched in a population of ES cells which are 
uncommitted and have high self-renewal capacity (Hough et al., 2009). Finally, 
Activin/TGF- signaling activity is required for Nanog expression in epiblast cells, 
suggesting a key role played by TGF- family members in maintaining ES pluripotency and 
self-renewal (Shin et al., 2011; Wang et al., 2009). The Notch pathway is a key regulator of 
many developmental processes during fetal and adult differentiation. Studies have reported 
that inappropriate activation of Notch signaling cascade contributes to tumorigenesis 
(Wilson & Radtke, 2006; Wang et al., 2009). Interaction between Notch and Cripto-1/Nodal 
signaling pathways has also been described. Analysis of the transcriptional regulatory 
regions within the mouse Nodal promoter has identified the presence of CBF1 binding 
elements, suggesting a direct regulation of Nodal expression by Notch signaling (Bianco et 
al., 2010; as cited in Raya et al., 2003; Krebs et al 2003). In this regard, mouse embryo double 
mutants for Notch1 and Notch2 exhibit multiple defects in L/R asymmetry, which is 
regulated by Nodal. Moreover, a new insight into Notch and Cripto-1/Nodal signaling 
pathways has been reported. Watanabe and colleagues (2009) using a yeast two-hybrid 
system screened a mouse embryo or human colon cDNA prey library for potential Cripto-1 
binding partners. Six candidate genes were isolated, including the mouse Notch3. By 
coimmunoprecipitation analysis Cripto-1 was found to directly bind to all four mammalian 
Notch receptors. Surprisingly, binding of Cripto-1 to Notch1 occurred mainly inside the 
cells in the endoplasmic reticulum/Golgi complex, where Cripto-1 enhanced cleavage of the 
Notch1 extracellular domain through a furin-like convertase. Enhanced cleavage of Notch1 
receptor by Cripto-1 potentiates Notch signaling as demonstrated by enhanced ligand-
induced activation of Notch signaling in Chinese hamster ovary cells expressing a CBF1-
dependent Notch reporter assay (Watanabe et al., 2009). Hypoxia is an important regulator 
of stem cell proliferation and differentiation (Yeung et al., 2011). In fact, tissue stem cells 
reside within niches that are naturally hypoxic and low oxygen levels prevent their 
differentiation toward specific fates. Moreover, HIF-2 can directly regulate Oct-4 
expression in ES cells by binding to hypoxia-responsive elements (HREs) within the 
promoter of mouse Oct-4. HIF-1 interacts with Notch signaling by binding to Notch 
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Nanog binding sites, suggesting that key modulators of stem cell self-renewal and 
pluripotentiality directly regulate Cripto-1 expression in ES cells (Bianco et al., 2010; de 
Castro et al., 2010; Loh et al., 2006). 
3.1.1 Cross-talk of Cripto-1 with stem cell signature pathways 
Several signaling pathways regulate in a coordinate fashion early embryonic development 
and stem cell proliferation, maintenance and differentiation. Some of these signaling 
cascades have been shown to cross-talk with Cripto-1 signaling, suggesting a pivotal role 
played by Cripto-1 in stem cell self-renewal and maintenance. Among these signaling 
pathways are genes in the Wnt/-catenin signaling pathway, TGF- family members, the 
Notch pathway, and hypoxia inducible factor-1 alpha (HIF-1) (Bianco et al., 2010; de Castro 
et al., 2010). A schematic diagram of the cross-talk of Cripto-1/Nodal signaling with other 
stem cell signature signaling pathways is shown in figure 3. 
 
 
Fig. 3. Interplay of Cripto-1/Nodal signaling with other embryonic stem cell signaling 
pathways. 
Cripto-1 signaling is a downstream target of Oct-4, Nanog, Wnt/-catenin, Notch and 
Hypoxia/HIF-1 pathways. Cripto-1 also mediates signaling of TGF- family members and 
enhances Notch signaling by facilitation of Notch receptor maturation. TGF-: transforming 
growth factor-, HIF-1: hypoxia inducible factor-1, GDF-1/-3: growth and differentiation 
factor-1/-3, BMP-4: bone morphogenetic protein-4, ES cells: embryonic stem cells, mES cells: 
mouse embryonic stem cells. 
Activation of the canonical Wnt/-catenin pathway has been reported to sustain the 
undifferentiated state of ES cells by triggering transcription of genes that regulate ES cell 
pluripotency and self-renewal, such as Oct-4, Nanog, Sox-2 and Cripto-1. For instance, 
Cripto-1 has been identified as a direct target gene in the canonical Wnt/-catenin signaling 
pathway during embryonic development and in colon carcinoma cell lines and tissues 
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(Morkel et al., 2003). Remarkably, in -catenin -/- or Wnt3 -/- mutant mouse embryos, Cripto-
1 expression was found to be dramatically downregulated, suggesting that the Wnt/-
catenin signaling pathway is a positive regulator of Cripto-1 expression during embryonic 
development (Bianco et al., 2010). In addition, in Xenopus, the Cripto-1 ortholog XCR1/FRL-
1 functions as a co-receptor for Wnt11 and together with frizzled receptor 7 and Glypican-4 
mediates stabilization and activation of -catenin (Bianco et al., 2010). Several studies have 
clearly implicated Wnt/-catenin signaling pathway in initiation and maintenance of 
carcinomas of the skin, intestine, liver, and brain (Bianco et al., 2010; de Castro et al., 2010). 
Hence, the interaction between the Wnt/-catenin and Cripto-1 signaling pathways might 
be significant also in cancer initiation and progression. Activation of TGF-/Activin/Nodal 
signaling has also been reported to be required for the maintenance of undifferentiated state 
in human ES cells (James et al., 2005; Vallier et al., 2009). Some TGF- family members, 
including Nodal, GDF-1 and GDF-3, require Cripto-1 for signaling and they are critical for 
ES cell maintenance and self-renewal (Bianco et al., 2010). Furthermore, Activin, TGF- and 
bone morphogenetic protein (BMP)-4 can directly regulate Cripto-1 expression by binding to 
smad binding elements (SBE) within the Cripto-1 promoter in human embryonal carcinoma 
cells and in human colon cancer cells (Mancino et al., 2008). GDF-3 and Cripto-1 have also 
been identified as ES cell markers that are enriched in a population of ES cells which are 
uncommitted and have high self-renewal capacity (Hough et al., 2009). Finally, 
Activin/TGF- signaling activity is required for Nanog expression in epiblast cells, 
suggesting a key role played by TGF- family members in maintaining ES pluripotency and 
self-renewal (Shin et al., 2011; Wang et al., 2009). The Notch pathway is a key regulator of 
many developmental processes during fetal and adult differentiation. Studies have reported 
that inappropriate activation of Notch signaling cascade contributes to tumorigenesis 
(Wilson & Radtke, 2006; Wang et al., 2009). Interaction between Notch and Cripto-1/Nodal 
signaling pathways has also been described. Analysis of the transcriptional regulatory 
regions within the mouse Nodal promoter has identified the presence of CBF1 binding 
elements, suggesting a direct regulation of Nodal expression by Notch signaling (Bianco et 
al., 2010; as cited in Raya et al., 2003; Krebs et al 2003). In this regard, mouse embryo double 
mutants for Notch1 and Notch2 exhibit multiple defects in L/R asymmetry, which is 
regulated by Nodal. Moreover, a new insight into Notch and Cripto-1/Nodal signaling 
pathways has been reported. Watanabe and colleagues (2009) using a yeast two-hybrid 
system screened a mouse embryo or human colon cDNA prey library for potential Cripto-1 
binding partners. Six candidate genes were isolated, including the mouse Notch3. By 
coimmunoprecipitation analysis Cripto-1 was found to directly bind to all four mammalian 
Notch receptors. Surprisingly, binding of Cripto-1 to Notch1 occurred mainly inside the 
cells in the endoplasmic reticulum/Golgi complex, where Cripto-1 enhanced cleavage of the 
Notch1 extracellular domain through a furin-like convertase. Enhanced cleavage of Notch1 
receptor by Cripto-1 potentiates Notch signaling as demonstrated by enhanced ligand-
induced activation of Notch signaling in Chinese hamster ovary cells expressing a CBF1-
dependent Notch reporter assay (Watanabe et al., 2009). Hypoxia is an important regulator 
of stem cell proliferation and differentiation (Yeung et al., 2011). In fact, tissue stem cells 
reside within niches that are naturally hypoxic and low oxygen levels prevent their 
differentiation toward specific fates. Moreover, HIF-2 can directly regulate Oct-4 
expression in ES cells by binding to hypoxia-responsive elements (HREs) within the 
promoter of mouse Oct-4. HIF-1 interacts with Notch signaling by binding to Notch 
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intracellular domain and enhancing transcription of Notch downstream target genes Hes-1 
and Hey-2. HIF-1, in addition to regulating Notch1 signaling, can also regulate Cripto-1 
expression by binding to HREs within the promoter region of mouse and human Cripto-1 
gene in mouse ES cells and in human embryonal carcinoma cells (Bianco et al., 2009). In 
addition, hypoxic conditions enhanced differentiation of mES cells into beating 
cardiomyocytes when compared with mES cells grown under normoxic conditions. 
However, expression of Cripto-1 in mES was critical, because hypoxia was unable to induce 
differentiation of mES cells into cardiomyocytes in the absence of Cripto-1 expression.  
4. Cripto-1 in cancer 
Similarities between embryonic development and cellular transformation during 
oncogenesis have led to the identification of common signaling pathways, suggesting that 
reactivation of developmental signaling pathways might drive cell transformation and 
tumor progression in adult tissues (Bianco et al., 2010). Cripto-1 is a typical example of an 
embryonic gene that is re-expressed in human tumors, promoting cellular proliferation, 
migration, and tumor angiogenesis (Figure 4).  
 
 
Fig. 4. Expression of Cripto-1 during embryogenesis and tumorigenesis. 
Cripto-1 is highly expressed in undifferentiated embryonic stem cells and germ cells. Cripto-
1 is important for mesoendoderm differentiation of ES cells and its expression is lost upon 
differentiation of ES cells toward the three germ cell layers. In the adult, Cripto-1 is re-
expressed by tumor cells. Green color: no Cripto-1 expression, red color: Cripto-1 
expression. ICM: Inner cell mass, ES: embryonic stem cells. 
4.1 Cripto-1 oncogenic activities in vitro and in vivo 
The first evidence of Cripto-1 oncogenic activity derives from studies demonstrating that 
Cripto-1 overexpression can induce in vitro transformation of a variety of cells, including 
NIH-3T3 fibroblasts and NOG-8 or CID9 mouse mammary epithelial cells (Ciardiello et al., 
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1991; Ciccodicola et al., 1989; Niemeyer et al., 1998). Furthermore, Cripto-1 can enhance 
migration and invasion of a variety of normal mammary epithelial cells and human breast 
and cervical carcinoma cells, suggesting the involvement of Cripto-1 in tumor progression 
(Ebert et al., 2000; Normanno et al., 2004a; Wechselberger et al., 2001). Cripto-1 can also 
function as a potent angiogenic protein both in vitro and in vivo, enhancing the proliferation, 
migration and invasion of human umbilical vascular endothelial cells and stimulating their 
differentiation into vascular-like structures in matrigel. Likewise, overexpression of Cripto-1 
promotes in vivo neovascularization of MCF-7 xenografts, supporting a role for Cripto-1 in 
modulating tumor angiogenesis (Bianco et al., 2005a). Since HIF-1 can enhance Cripto-1 
expression by directly binding to the Cripto-1 promoter, it is possible that the hypoxic 
microenvironment within the growing tumor might enhance Cripto-1 expression, which in 
turn induces new vessel formation to sustain tumor growth (Bianco et al., 2009). Cripto-1 
has also been directly implicated in mouse mammary tumor development (Sun et al., 2005; 
Wechselberger et al., 2005), as demonstrated by transgenic mouse models overexpressing 
the human Cripto-1 transgene in mouse mammary glands under the control of the MMTV 
or whey acidic protein (WAP) promoter (Sun et al., 2005; Wechselberger et al., 2005). The 
majority of nulliparous MMTV-Cripto-1 transgenic mice exhibited enhanced ductal 
branching, intraductal hyperplasias and hyperplastic alveolar nodules, and about 30-40% of 
aged multiparous female mice developed multifocal hyperplasias and papillary 
adenocarcinomas (Wechselberger et al., 2005). Interestingly, under a 2 years observation 
period, approximately 20% of female nulliparous or multiparous MMTV-Cripto-1 
transgenic mice developed uterine leiomyosarcomas as compared to control mice. High 
levels of Cripto-1 transgene, phosphorylated forms of c-Src, AKT, glycogen synthase kinase-
3 (GSK-3) and dephosphorylated active--catenin were detected in the uterine tumors 
collected from MMTV-Cripto-1 transgenic mice (Strizzi et al., 2007), suggesting a role for 
Cripto-1 during uterine tumorigenesis either by activation of c-Src and Akt and/or via 
cross-talk with the canonical Wnt/-catenin signaling pathway. Unlike the MMTV 
promoter, the WAP promoter is maximally active during mid-pregnancy and lactation. 
Approximately 50% of old nulliparous WAP-Cripto-1 mice developed multifocal intraductal 
hyperplasias, and more than 50% of multiparous WAP-Cripto-1 female mice developed 
multifocal mammary tumors of mixed histological subtypes (Sun et al., 2005). Histological 
analysis of the WAP-Cripto-1 mammary tumors revealed the presence of tumors containing 
glandular, papillary and undifferentiated carcinoma, as well as myoepithelioma and adeno-
squamous carcinoma. Mammary tumors with mixed histology have also been described in 
MMTV-Wnt-1 transgenic mice, which have alterations in the canonical Wnt/-catenin 
pathway. Interestingly, hyperactivation of a canonical Wnt/-catenin pathway was detected 
in WAP-Cripto-1 mammary tumors, suggesting that the canonical Wnt/-catenin pathway 
together with Cripto-1 might play an important role during mammary transformation in 
vivo (Miyoshi et al., 2002a; Miyoshi et al., 2002b; Sun et al., 2005). Finally, several studies 
have demonstrated that Cripto-1, in addition to function as an oncogene in vitro and in 
animal models, is overexpressed at the mRNA and protein level in a wide variety of human 
tumors, including colorectal, breast, gastric, pancreatic, ovarian, endometrium, nasopharynx 
and lung carcinomas, while very little or no expression is detected in normal adult tissues. 
Therefore, the selective expression of Cripto-1 in cancer cells suggests that it represents a 
promising target in cancer therapy. For an extensive review on Cripto-1 expression in 
human tumors see de Castro et al., 2010. 
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intracellular domain and enhancing transcription of Notch downstream target genes Hes-1 
and Hey-2. HIF-1, in addition to regulating Notch1 signaling, can also regulate Cripto-1 
expression by binding to HREs within the promoter region of mouse and human Cripto-1 
gene in mouse ES cells and in human embryonal carcinoma cells (Bianco et al., 2009). In 
addition, hypoxic conditions enhanced differentiation of mES cells into beating 
cardiomyocytes when compared with mES cells grown under normoxic conditions. 
However, expression of Cripto-1 in mES was critical, because hypoxia was unable to induce 
differentiation of mES cells into cardiomyocytes in the absence of Cripto-1 expression.  
4. Cripto-1 in cancer 
Similarities between embryonic development and cellular transformation during 
oncogenesis have led to the identification of common signaling pathways, suggesting that 
reactivation of developmental signaling pathways might drive cell transformation and 
tumor progression in adult tissues (Bianco et al., 2010). Cripto-1 is a typical example of an 
embryonic gene that is re-expressed in human tumors, promoting cellular proliferation, 
migration, and tumor angiogenesis (Figure 4).  
 
 
Fig. 4. Expression of Cripto-1 during embryogenesis and tumorigenesis. 
Cripto-1 is highly expressed in undifferentiated embryonic stem cells and germ cells. Cripto-
1 is important for mesoendoderm differentiation of ES cells and its expression is lost upon 
differentiation of ES cells toward the three germ cell layers. In the adult, Cripto-1 is re-
expressed by tumor cells. Green color: no Cripto-1 expression, red color: Cripto-1 
expression. ICM: Inner cell mass, ES: embryonic stem cells. 
4.1 Cripto-1 oncogenic activities in vitro and in vivo 
The first evidence of Cripto-1 oncogenic activity derives from studies demonstrating that 
Cripto-1 overexpression can induce in vitro transformation of a variety of cells, including 
NIH-3T3 fibroblasts and NOG-8 or CID9 mouse mammary epithelial cells (Ciardiello et al., 
 
Cripto-1: At the Crossroads of Embryonic Stem Cells and Cancer 355 
1991; Ciccodicola et al., 1989; Niemeyer et al., 1998). Furthermore, Cripto-1 can enhance 
migration and invasion of a variety of normal mammary epithelial cells and human breast 
and cervical carcinoma cells, suggesting the involvement of Cripto-1 in tumor progression 
(Ebert et al., 2000; Normanno et al., 2004a; Wechselberger et al., 2001). Cripto-1 can also 
function as a potent angiogenic protein both in vitro and in vivo, enhancing the proliferation, 
migration and invasion of human umbilical vascular endothelial cells and stimulating their 
differentiation into vascular-like structures in matrigel. Likewise, overexpression of Cripto-1 
promotes in vivo neovascularization of MCF-7 xenografts, supporting a role for Cripto-1 in 
modulating tumor angiogenesis (Bianco et al., 2005a). Since HIF-1 can enhance Cripto-1 
expression by directly binding to the Cripto-1 promoter, it is possible that the hypoxic 
microenvironment within the growing tumor might enhance Cripto-1 expression, which in 
turn induces new vessel formation to sustain tumor growth (Bianco et al., 2009). Cripto-1 
has also been directly implicated in mouse mammary tumor development (Sun et al., 2005; 
Wechselberger et al., 2005), as demonstrated by transgenic mouse models overexpressing 
the human Cripto-1 transgene in mouse mammary glands under the control of the MMTV 
or whey acidic protein (WAP) promoter (Sun et al., 2005; Wechselberger et al., 2005). The 
majority of nulliparous MMTV-Cripto-1 transgenic mice exhibited enhanced ductal 
branching, intraductal hyperplasias and hyperplastic alveolar nodules, and about 30-40% of 
aged multiparous female mice developed multifocal hyperplasias and papillary 
adenocarcinomas (Wechselberger et al., 2005). Interestingly, under a 2 years observation 
period, approximately 20% of female nulliparous or multiparous MMTV-Cripto-1 
transgenic mice developed uterine leiomyosarcomas as compared to control mice. High 
levels of Cripto-1 transgene, phosphorylated forms of c-Src, AKT, glycogen synthase kinase-
3 (GSK-3) and dephosphorylated active--catenin were detected in the uterine tumors 
collected from MMTV-Cripto-1 transgenic mice (Strizzi et al., 2007), suggesting a role for 
Cripto-1 during uterine tumorigenesis either by activation of c-Src and Akt and/or via 
cross-talk with the canonical Wnt/-catenin signaling pathway. Unlike the MMTV 
promoter, the WAP promoter is maximally active during mid-pregnancy and lactation. 
Approximately 50% of old nulliparous WAP-Cripto-1 mice developed multifocal intraductal 
hyperplasias, and more than 50% of multiparous WAP-Cripto-1 female mice developed 
multifocal mammary tumors of mixed histological subtypes (Sun et al., 2005). Histological 
analysis of the WAP-Cripto-1 mammary tumors revealed the presence of tumors containing 
glandular, papillary and undifferentiated carcinoma, as well as myoepithelioma and adeno-
squamous carcinoma. Mammary tumors with mixed histology have also been described in 
MMTV-Wnt-1 transgenic mice, which have alterations in the canonical Wnt/-catenin 
pathway. Interestingly, hyperactivation of a canonical Wnt/-catenin pathway was detected 
in WAP-Cripto-1 mammary tumors, suggesting that the canonical Wnt/-catenin pathway 
together with Cripto-1 might play an important role during mammary transformation in 
vivo (Miyoshi et al., 2002a; Miyoshi et al., 2002b; Sun et al., 2005). Finally, several studies 
have demonstrated that Cripto-1, in addition to function as an oncogene in vitro and in 
animal models, is overexpressed at the mRNA and protein level in a wide variety of human 
tumors, including colorectal, breast, gastric, pancreatic, ovarian, endometrium, nasopharynx 
and lung carcinomas, while very little or no expression is detected in normal adult tissues. 
Therefore, the selective expression of Cripto-1 in cancer cells suggests that it represents a 
promising target in cancer therapy. For an extensive review on Cripto-1 expression in 
human tumors see de Castro et al., 2010. 
 
Embryonic Stem Cells – Basic Biology to Bioengineering 356 
4.1.1 Intracellular signaling pathways activated by Cripto-1 during oncogenic 
transformation 
While Cripto-1 functions mostly in a Nodal-dependent manner during embryogenesis, 
several studies have demonstrated that Cripto-1 induces cellular proliferation, motility, 
survival and EMT in a Nodal-independent fashion. Following binding to the GPI-linked 
heparan sulphate proteoglycan Glypican-1, Cripto-1 induces activation and phosphorylation 
of the cytoplasmic tyrosine kinase c-Src, which in turn activates mitogen-activated protein 
kinase (MAPK)/Phosphatydil inositol 3’ kinase (PI3K)/Akt signaling pathways (Figure 5) 
(Bianco et al., 2005b).  
 
 
Fig. 5. Nodal-independent Cripto-1 signaling pathway. 
Cripto-1 upon binding to Glypican-1 activates MAPK and Akt signaling pathways during 
tumor progression, enhancing cell proliferation and survival. MAPK and PI3K/Akt pathways 
can also inhibit GSK-3 leading to activation and stabilization of -catenin. GRP78 can also 
enhance Cripto-1 activation of the MAPK/Akt signaling pathways. GRP78: glucose-regulated 
protein 78, MAPK: mitogen-activated protein kinase, PI3K: phosphatydil inositol 3’ kinase, 
GSK3 : glycogen synthase kinase 3, TCF/LEF: T-cell factor/lymphoid enhancer factor, RSK: 
Ribosomal s6 kinase, STAT: signal transducers and activators of transcription. 
Activation of the MAPK and PI3K/Akt signaling pathways by Cripto-1 is independent of 
Nodal and ALK4, since Cripto-1 can enhance phosphorylation of MAPK and Akt in cells 
lacking ALK4 and/or Nodal expression (Bianco et al., 2002). Furthermore, the tyrosine 
kinase c-Src is required by Cripto-1 to induce in vitro transformation of mouse mammary 
epithelial cells, indicating that inappropriate activation of c-Src by Cripto-1 in a Nodal- and 
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ALK4-independent manner might play a key role in Cripto-1 tumorigenic activity (Bianco et 
al., 2003). The interaction between Cripto-1 and Gypican-1 occurs within lipid raft 
microdomains, regions of the cell membrane that are enriched in GPI-linked proteins 
(Bianco et al., 2003). Cripto-1 mitogenic signaling is also dependent upon binding to GRP78, 
an endoplasmic reticulum (ER) heat shock chaperone protein that is expressed on the cell 
surface of tumor cells (Shani et al., 2008). Indeed, disruption of the Cripto-1/GRP78 complex 
at the cell membrane interferes with Cripto-1 oncogenic activity in vitro, preventing Cripto-1 
activation of MAPK/Akt signaling pathway (Figure 5). Interestingly, unlike Glypican-1, 
GRP78 is also important for Nodal-dependent Cripto-1 signaling, enhancing activation of 
the Smad-2/Smad-3 signaling pathway (Kelber et al., 2009). Furthermore, GRP78 enhanced 
Cripto-1-dependent activation of the c-Src/MAPK/Akt signaling pathways, increased 
cellular proliferation and reduced cell adhesion, as evidenced by a decrease in E-cadherin 
expression in breast cancer cells (Kelber et al., 2009). 
5. Cripto-1 and Cancer Stem Cells 
Cancer stem cells (CSCs), also known as tumor initiating cells, share characteristics 
associated with embryonic stem cells, specifically the ability to give rise to all cell types 
within a particular tumor tissue. CSCs were first identified in the hematopoietic system and 
later they have also been reported in solid cancers, including cancers of the breast, lung, 
prostate, colon, brain, head and neck, and pancreas (Bianco et al., 2010; de Castro et al., 
2010). CSCs represent a distinct population of cancer cells with innate chemo- and radio-
resistance and therefore are responsible of tumor relapse (Bianco et al., 2010; de Castro et al., 
2010 as cited in Huntly and Gilliland 2010). Moreover, CSCs are capable to self-renew and 
regenerate the original phenotype of the tumor when implanted into immunodeficient mice 
(Visvader & Lindeman, 2008). Similarities between embryonic development and cell 
transformation during oncogenesis have led to the identification of common contributing 
pathways, suggesting that reactivation of developmental signaling pathways might drive 
cell transformation and tumor progression in adult tissues (Bianco et al., 2010). Cripto-1 is a 
typical example of a common gene shared by embryonic cells and cancer cells contributing 
to early embryogenesis and cancer progression. More importantly, Cripto-1 is enriched in a 
subpopulation of cancer cells with stem-like characteristics. For instance, Watanabe and 
collaborators (2010) described a heterogeneous Cripto-1 expression pattern in human 
embryonal carcinoma (EC) with segregation of these cells into two distinct populations 
portraying high and low Cripto-1 expression. EC cells are pluripotent stem cells derived 
from germ cell teratocarcinomas and they represent the malignant counterparts of human 
ES cells. Interestingly, these two subpopulations showed different gene expression profiles 
and different in vitro and in vivo tumorigenic capability. The Cripto-1 high subpopulation of 
EC cells formed tumor spheres in a serum-free suspension culture with an efficiency 
significantly higher than the Cripto-1 low expressing EC cells. Furthermore, the Cripto-1 
high expressing EC cells were able to generate tumors larger in size and with a shorter 
tumor latency period compared with tumors derived from Cripto-1 low expressing EC cells 
when injected subcutaneously into nude mice. Finally, regulators of pluripotent ES cells, 
such as Activin/Nodal signaling and the transcription factors Nanog and Oct-4, positively 
regulated Cripto-1 expression in Cripto-1 high expressing EC cells, suggesting the existence 
of a core transcriptional regulatory network of pluripotent stem cell transcription factors 
that cross-regulate each other expression (Loh et al., 2006). However, Cripto-1 expression is 
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transformation 
While Cripto-1 functions mostly in a Nodal-dependent manner during embryogenesis, 
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survival and EMT in a Nodal-independent fashion. Following binding to the GPI-linked 
heparan sulphate proteoglycan Glypican-1, Cripto-1 induces activation and phosphorylation 
of the cytoplasmic tyrosine kinase c-Src, which in turn activates mitogen-activated protein 
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can also inhibit GSK-3 leading to activation and stabilization of -catenin. GRP78 can also 
enhance Cripto-1 activation of the MAPK/Akt signaling pathways. GRP78: glucose-regulated 
protein 78, MAPK: mitogen-activated protein kinase, PI3K: phosphatydil inositol 3’ kinase, 
GSK3 : glycogen synthase kinase 3, TCF/LEF: T-cell factor/lymphoid enhancer factor, RSK: 
Ribosomal s6 kinase, STAT: signal transducers and activators of transcription. 
Activation of the MAPK and PI3K/Akt signaling pathways by Cripto-1 is independent of 
Nodal and ALK4, since Cripto-1 can enhance phosphorylation of MAPK and Akt in cells 
lacking ALK4 and/or Nodal expression (Bianco et al., 2002). Furthermore, the tyrosine 
kinase c-Src is required by Cripto-1 to induce in vitro transformation of mouse mammary 
epithelial cells, indicating that inappropriate activation of c-Src by Cripto-1 in a Nodal- and 
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ALK4-independent manner might play a key role in Cripto-1 tumorigenic activity (Bianco et 
al., 2003). The interaction between Cripto-1 and Gypican-1 occurs within lipid raft 
microdomains, regions of the cell membrane that are enriched in GPI-linked proteins 
(Bianco et al., 2003). Cripto-1 mitogenic signaling is also dependent upon binding to GRP78, 
an endoplasmic reticulum (ER) heat shock chaperone protein that is expressed on the cell 
surface of tumor cells (Shani et al., 2008). Indeed, disruption of the Cripto-1/GRP78 complex 
at the cell membrane interferes with Cripto-1 oncogenic activity in vitro, preventing Cripto-1 
activation of MAPK/Akt signaling pathway (Figure 5). Interestingly, unlike Glypican-1, 
GRP78 is also important for Nodal-dependent Cripto-1 signaling, enhancing activation of 
the Smad-2/Smad-3 signaling pathway (Kelber et al., 2009). Furthermore, GRP78 enhanced 
Cripto-1-dependent activation of the c-Src/MAPK/Akt signaling pathways, increased 
cellular proliferation and reduced cell adhesion, as evidenced by a decrease in E-cadherin 
expression in breast cancer cells (Kelber et al., 2009). 
5. Cripto-1 and Cancer Stem Cells 
Cancer stem cells (CSCs), also known as tumor initiating cells, share characteristics 
associated with embryonic stem cells, specifically the ability to give rise to all cell types 
within a particular tumor tissue. CSCs were first identified in the hematopoietic system and 
later they have also been reported in solid cancers, including cancers of the breast, lung, 
prostate, colon, brain, head and neck, and pancreas (Bianco et al., 2010; de Castro et al., 
2010). CSCs represent a distinct population of cancer cells with innate chemo- and radio-
resistance and therefore are responsible of tumor relapse (Bianco et al., 2010; de Castro et al., 
2010 as cited in Huntly and Gilliland 2010). Moreover, CSCs are capable to self-renew and 
regenerate the original phenotype of the tumor when implanted into immunodeficient mice 
(Visvader & Lindeman, 2008). Similarities between embryonic development and cell 
transformation during oncogenesis have led to the identification of common contributing 
pathways, suggesting that reactivation of developmental signaling pathways might drive 
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to early embryogenesis and cancer progression. More importantly, Cripto-1 is enriched in a 
subpopulation of cancer cells with stem-like characteristics. For instance, Watanabe and 
collaborators (2010) described a heterogeneous Cripto-1 expression pattern in human 
embryonal carcinoma (EC) with segregation of these cells into two distinct populations 
portraying high and low Cripto-1 expression. EC cells are pluripotent stem cells derived 
from germ cell teratocarcinomas and they represent the malignant counterparts of human 
ES cells. Interestingly, these two subpopulations showed different gene expression profiles 
and different in vitro and in vivo tumorigenic capability. The Cripto-1 high subpopulation of 
EC cells formed tumor spheres in a serum-free suspension culture with an efficiency 
significantly higher than the Cripto-1 low expressing EC cells. Furthermore, the Cripto-1 
high expressing EC cells were able to generate tumors larger in size and with a shorter 
tumor latency period compared with tumors derived from Cripto-1 low expressing EC cells 
when injected subcutaneously into nude mice. Finally, regulators of pluripotent ES cells, 
such as Activin/Nodal signaling and the transcription factors Nanog and Oct-4, positively 
regulated Cripto-1 expression in Cripto-1 high expressing EC cells, suggesting the existence 
of a core transcriptional regulatory network of pluripotent stem cell transcription factors 
that cross-regulate each other expression (Loh et al., 2006). However, Cripto-1 expression is 
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dispensable for pluripotent stem cell gene expression in EC cells, since siRNA-mediated 
knockdown of Cripto-1 has no effect on the expression of ES-related genes including Oct-4, 
Nanog, Sox-2 and Lefty. In another study, Cripto-1 has been exploited as a potential 
melanoma stem cells candidate marker in human malignant melanomas (Strizzi et al., 2008). 
Strizzi and colleagues, by FACS cell sorting based on Cripto-1 expression, isolated from a 
human melanoma cell line a subpopulation with stem-like characteristics. The Cripto-1 
positive subpopulation of melanoma cells represented a relatively smaller size population 
with a more spindle-shaped morphology, and showed increased expression of the stem cell 
associated transcription factors, Oct-4 and Nanog, as compared to the parental melanoma 
cells. Finally, Cripto-1 and the stem cell markers Oct-4 and SUZ-12 were identified in a small 
subpopulation of stem-like cells in hormone-responsive and nonresponsive prostate tumor 
cell (Cocciadiferro et al., 2009). Altogether, these findings suggest that Cripto-1 might be 
useful in the identification of a subpopulation of cancer cells with stem like behavior that are 
resistant to conventional therapy and are therefore a major obstacle in the clinical treatment 
of cancer patients.  
5.1 Cancer stem cells and EMT 
During embryogenesis, tumor progression and metastasis, epithelial cells undergo dramatic 
morphological changes, acquiring mesenchymal properties in a process known as EMT. In 
the embryo, Cripto-1 is detected at high levels in epiblast cells undergoing EMT, which 
migrate through the primitive streak, eventually giving rise to the mesoderm and endoderm 
(Bianco et al., 2005b; Strizzi et al., 2005). In the tumor, the expression of EMT regulators at 
the tumor periphery is critical for tumor cells to acquire a mesenchymal phenotype that 
allow them to locally invade and escape from the primary tumor site, leading to the 
establishment of metastatic lesions (Micalizzi et al., 2010a). Cripto-1 is involved in tumor 
epithelial cells plasticity and may be an important EMT regulator together with Snail, Slug, 
Twist, and Six1 (Micalizzi et al., 2010b). It has been shown that mammary gland 
hyperplasias and tumors derived from MMTV-Cripto-1 transgenic mice express molecular 
markers and signaling molecules characteristics of EMT, suggesting that Cripto-1 might 
play an important role in facilitating migration and invasion of tumor cells (Strizzi et al., 
2004). These findings might be significant since emerging evidence has suggested a link 
between stem cells and EMT (Hollier et al., 2009). In fact, EMT induction in immortalized 
human mammary epithelial cells resulted in the expression of stem cell markers and 
increased ability to form mammospheres in vitro, suggesting an important role for EMT in 
generating cancer stem-like cells in human breast tumors (Mani et al., 2008). Since Cripto-1 
has been found to promote EMT in mouse mammary epithelial cells and mouse mammary 
tumors, contributing to a more aggressive mesenchymal phenotype, it is possible that 
Cripto-1 might support self-renewal, invasiveness and metastatic abilities of breast cancer 
stem-like cells through induction of an EMT program (Strizzi et al., 2004).  
6. Cripto-1 as target for cancer therapy 
High expression of Cripto-1 in human carcinomas and its enrichment in a stem-like cancer 
cell subpopulation strongly support Cripto-1 as a promising candidate for therapeutic 
intervention in cancer. Two different therapeutic approaches have been successfully used to 
impair Cripto-1 activity in cancer cells, including anti-Cripto-1 antisense (AS) 
oligonucleotides and neutralizing monoclonal antibodies (Adkins et al., 2003; Hu et al., 2007; 
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Normanno et al., 1996; Normanno et al., 2004b). For instance, a significant growth inhibition 
in vitro has been observed in ovarian, breast and colon cancer cells treated with anti-Cripto-1 
AS oligonucleotides. A synergistic growth inhibitory effect was detected when anti-Cripto-1 
AS oligonucleotides were combined together with oligonucleotides against TGF- and 
amphiregulin (AREG), indicating that a variety of growth factors might cooperate in 
stimulating cancer cell proliferation (Casamassimi et al., 2000; De Luca et al., 2000; De Luca 
et al., 1999; Normanno et al., 2004b). Additionally, combination of anti-Cripto-1 AS 
oligonucleotides with anti-TGF- and anti-AREG AS oligonucleotides was more effective in 
vivo as compared to single AS oligonucleotide administration, inhibiting the growth of colon 
cancer tumor xenografts in nude mice in a dose dependent manner (De Luca et al. 2000). 
Neutralizing antibodies that bind Cripto-1 have also been generated (Adkins et al., 2003; Hu 
& Xing, 2005). In particular, Adkins and colleagues of Biogen-Idec have generated a panel of 
monoclonal antibodies (mAbs) directed against a human recombinant Cripto-1 protein 
expressed as a human IgG1 Fc fusion protein (Adkins et al. 2003). The mAbs are capable to 
recognize different domains of the Cripto-1 protein, detecting its expression in human breast 
and colon tumor tissue samples and in human cancer cell lines. Among these anti-Cripto-1 
mAbs, anti-CFC mAbs showed blocking activities in vitro and in vivo by interfering with the 
binding of Cripto-1 with ALK4 through the CFC domain. The anti-CFC blocking antibodies 
also blocked the interaction of Cripto-1 with Activin B (Adkins et al. 2003), restoring the 
growth inhibitory function of Activin B in tumor cells. Recently, among these anti-Cripto-1 
mAbs, an N-terminal anti-Cripto-1 antibody has been selected to target Cripto-1 in human 
tumors, due to the higher binding affinity and range of reactivity of this antibody with 
tumor-derived Cripto-1 (Kelly et al., 2011). A humanized form of the anti-Cripto-1 N-
terminal monoclonal antibody-conjugated to a DM4 toxin is currently been evaluated in 
phase I clinical trials for treatment of patients with refractory or relapsed Cripto-1 positive 
solid tumors (A phase I study of BIIB015 in relapsed/refractory solid tumors, protocol ID 
207ST101/NCT00674947) (Bianco & Salomon, 2010). BIIB015 showed specicity for Cripto-1 
in vitro and in vivo with a clinical response ranging between 50% of tumor inhibition to 
complete tumor regression in xenograft mouse models inoculated with lung (Calu-6), colon 
(CT-3), testicular (NCCIT) or breast (MDA-MB-231) human tumor cell lines (Kelly et al., 
2011). In addition to mouse monoclonal antibodies against Cripto-1, anti-Cripto-1 rat 
monoclonal antibodies have also been generated. Rat anti-Cripto-1 monoclonal antibodies 
inhibited tumor cell growth and increased sensitivity of LS174T human colon cancer cells 
and MCF-7 human breast cancer cells to the cytotoxic effects of chemotherapeutic agents 
such as cisplatin, 5-Fluorouracil, carboplatin and epirubicin (Xing et al., 2004). Furthermore, 
a C13 rat monoclonal antibody inhibited cancer cell growth in vivo in LS174T tumor 
xenografts in SCID mice, inducing up to 80% growth inhibition of established tumors as 
compared to an untreated control groups. Interestingly, C4 and C13 rat monoclonal 
antibodies were also highly effective in reducing tumor growth of a human leukemia 
multidrug resistant (MDR) cell line (CEM/A7R) both in vitro and in vivo in an established 
xenograft tumor model (Hu et al., 2007).  
6.1 Cripto-1 as a target for therapy in neurodegenerative and muscle degenerative 
diseases 
Recent findings have demonstrated that Cripto-1 is a key player in the signaling pathway 
controlling neural induction in ES cells. Parisi and collaborators showed that Cripto-1 
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markers and signaling molecules characteristics of EMT, suggesting that Cripto-1 might 
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2004). These findings might be significant since emerging evidence has suggested a link 
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increased ability to form mammospheres in vitro, suggesting an important role for EMT in 
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binding of Cripto-1 with ALK4 through the CFC domain. The anti-CFC blocking antibodies 
also blocked the interaction of Cripto-1 with Activin B (Adkins et al. 2003), restoring the 
growth inhibitory function of Activin B in tumor cells. Recently, among these anti-Cripto-1 
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terminal monoclonal antibody-conjugated to a DM4 toxin is currently been evaluated in 
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inhibited tumor cell growth and increased sensitivity of LS174T human colon cancer cells 
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such as cisplatin, 5-Fluorouracil, carboplatin and epirubicin (Xing et al., 2004). Furthermore, 
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xenografts in SCID mice, inducing up to 80% growth inhibition of established tumors as 
compared to an untreated control groups. Interestingly, C4 and C13 rat monoclonal 
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Recent findings have demonstrated that Cripto-1 is a key player in the signaling pathway 
controlling neural induction in ES cells. Parisi and collaborators showed that Cripto-1 
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negatively regulated neuronal differentiation of ES cells (Parisi et al., 2003). Furthermore, 
disruption of Cripto-1 expression in mouse ES cells enhances neurogenesis and midbrain 
dopaminergic differentiation in vitro (Parish et al., 2005; Sonntag et al., 2005). These results 
suggest that blocking Cripto-1 expression and activity may provide a novel insight into the 
treatment of neurodegenerative diseases. Parkinson’s disease is a progressive 
neurodegenerative disorder characterized by degeneration of dopaminergic neurons of the 
substantia nigra. Therefore methods that channel undifferentiated ES cells into 
dopaminergic neurons are under extensive evaluation, aiming to improve the safety of ES 
cells grafting that often results in uncontrolled proliferation and teratoma formation (Parish 
& Arenas, 2007). In a rat animal model of Parkinson’s disease, mouse ES cells that are null 
for Cripto-1 expression (Cripto-1-/- ES cells), when grafted at low density into rats, 
differentiated into neuronal cells in the brain and were able to restore normal behavior 
without producing teratomas (Parish et al., 2005). Recently, a tetrameric tripeptide, which 
prevents Cripto-1/ALK4 interaction and interferes with Cripto-1 signaling was identified 
(Lonardo et al., 2010). The Cripto-1 blocking peptide was able to induce formation of 
neuroectoderm and increased midbrain dopaminergic neuron differentiation of mouse ES 
cells in vitro and in vivo (Lonardo et al., 2010). Moreover, mouse ES cells treated with Cripto-
1 blocking peptide enhanced functional recovery and reduced tumor formation in 
Parkinsonian rats (Lonardo et al., 2010). Overexpression of Cripto-1 has also been observed 
in the cerebral cortical tissues of macaques that had been infected with a chimeric simian 
human immunodeficiency virus (SHIV) by cDNA array analysis (Stephens et al., 2006). 
SHIV enters the central nervous system (CNS) early after inoculation and cause encephalitis, 
characterized by transient meningitis and astrocytosis. Immunohistochemical analysis and 
RT-PCR confirmed widespread expression of Cripto-1 in the brains of SHIV-infected 
macaques. Although the functions of Cripto-1 in the neurons of the adult brain and the 
overexpression in the brains of SHIV-infected macaques are unclear, Cripto-1 may play a 
neuroinflammatory role and targeting Cripto-1 with various approaches, such as the 
tetrameric tripeptide described by Lonardo and colleagues, might inhibit progression of 
neurodegenerative disease in mammals. Cripto-1 may also be involved in degenerative 
muscle diseases, such as muscular dystrophy and spinal muscular atrophy. These diseases 
are characterized by skeletal muscle loss and few therapeutic approaches are available to 
restore the function of the lost muscle tissue (Tedesco et al., 2010). Cripto-1 is highly 
expressed in myoblast cells of regenerative muscles, whereas no expression of Cripto-1 is 
detected in normal muscle fibers. Furthermore, Cripto-1 induced a dose-dependent increase 
in proliferation and migration of myogenic precursor cells in vitro and enhanced skeletal 
muscle regeneration and angiogenesis after injury in vivo (Bianco & Salomon, 2010). These 
studies clearly suggest an involvement of Cripto-1 in neurodegenerative and muscle 
degenerative disease. Therefore, approaches that have been developed to target Cripto-1 in 
cancer might benefit also different diseases.  
7. Conclusions 
Critical signaling pathways are involved in modulating embryonic stem cell fate and 
behavior, maintaining a delicate balance between survival and self-renewal signals. Among 
these ES cell “signature” pathways, Cripto-1 is a critical gene that is used by ES cells. For 
instance, Cripto-1 is either a downstream target of ES transcription factors and/or signaling 
pathways or can modulate other ES cell signaling cascades (Fig. 3). Further, deregulation of 
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stem cell self-renewal is probably a requirement for the initiation and formation of CSCs and 
therefore embryonic stem cell signature genes are also involved in cancer formation. Cripto-
1 is indeed an embryonic gene that is re-expressed in an aberrant spatial and temporal 
manner in a variety of human tumors. Recent evidence has clearly demonstrated that 
Cripto-1 is expressed by a subset of cancer cells with stem-like characteristics (Watanabe et 
al., 2010). CSCs are considered to be a major obstacle in the complete eradication of tumors 
due their innate resistance to conventional therapy and therefore identification of surface 
markers that might discriminate CSCs from the bulk population of tumor cells is under 
active investigation. Therefore, Cripto-1 targeting in human tumors might have a major 
breakthrough in cancer therapy. Several approaches have been used to target Cripto-1 in 
cancer cells in vitro and in vivo, from antisense oligonucleotides to blocking monoclonal 
antibodies (Bianco & Salomon, 2010). Translation of Cripto-1 research to a clinical setting 
has been recently achieved. In fact, a humanized anti-Cripto-1 antibody conjugated with a 
potent cytotoxin is currently being evaluated in a Phase I clinical study in cancer patients. In 
conclusion, a complete understanding of Cripto-1 signaling in stem cell biology offers a 
great promise for improving stem cell mediated regenerative therapy as well as cancer 
therapy.  
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negatively regulated neuronal differentiation of ES cells (Parisi et al., 2003). Furthermore, 
disruption of Cripto-1 expression in mouse ES cells enhances neurogenesis and midbrain 
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suggest that blocking Cripto-1 expression and activity may provide a novel insight into the 
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neurodegenerative disorder characterized by degeneration of dopaminergic neurons of the 
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dopaminergic neurons are under extensive evaluation, aiming to improve the safety of ES 
cells grafting that often results in uncontrolled proliferation and teratoma formation (Parish 
& Arenas, 2007). In a rat animal model of Parkinson’s disease, mouse ES cells that are null 
for Cripto-1 expression (Cripto-1-/- ES cells), when grafted at low density into rats, 
differentiated into neuronal cells in the brain and were able to restore normal behavior 
without producing teratomas (Parish et al., 2005). Recently, a tetrameric tripeptide, which 
prevents Cripto-1/ALK4 interaction and interferes with Cripto-1 signaling was identified 
(Lonardo et al., 2010). The Cripto-1 blocking peptide was able to induce formation of 
neuroectoderm and increased midbrain dopaminergic neuron differentiation of mouse ES 
cells in vitro and in vivo (Lonardo et al., 2010). Moreover, mouse ES cells treated with Cripto-
1 blocking peptide enhanced functional recovery and reduced tumor formation in 
Parkinsonian rats (Lonardo et al., 2010). Overexpression of Cripto-1 has also been observed 
in the cerebral cortical tissues of macaques that had been infected with a chimeric simian 
human immunodeficiency virus (SHIV) by cDNA array analysis (Stephens et al., 2006). 
SHIV enters the central nervous system (CNS) early after inoculation and cause encephalitis, 
characterized by transient meningitis and astrocytosis. Immunohistochemical analysis and 
RT-PCR confirmed widespread expression of Cripto-1 in the brains of SHIV-infected 
macaques. Although the functions of Cripto-1 in the neurons of the adult brain and the 
overexpression in the brains of SHIV-infected macaques are unclear, Cripto-1 may play a 
neuroinflammatory role and targeting Cripto-1 with various approaches, such as the 
tetrameric tripeptide described by Lonardo and colleagues, might inhibit progression of 
neurodegenerative disease in mammals. Cripto-1 may also be involved in degenerative 
muscle diseases, such as muscular dystrophy and spinal muscular atrophy. These diseases 
are characterized by skeletal muscle loss and few therapeutic approaches are available to 
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in proliferation and migration of myogenic precursor cells in vitro and enhanced skeletal 
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1. Introduction 
The highly related serine/threonine kinases GSK3α and GSK3β are transducers of Wnt/β-
catenin, PI-3K, Notch and Hedgehog signalling pathways, placing them at the hub of key 
developmental and metabolic processes. There is accumulating evidence suggesting that 
GSK-3 inhibitors aid in the acquisition or sustenance of pluripotency in embryonic stem cells 
of mouse, rat and human origin.  However, the mechanism through which GSK-3 inhibitors 
impart their effects is unclear due to the myriad cellular processes in which GSK-3 plays a 
role. Here, we review the studies that have examined the consequences of GSK-3 inhibition 
in pluripotent stem cells with a focus on key signalling pathways, which have been 
implicated in GSK-3 inhibitor-mediated effects. 
2. Overview of GSK-3 and GSK-3β structure and function  
Glycogen synthase kinase-3 is a serine/threonine protein kinase, which was named based 
on its ability to phosphorylate and inhibit glycogen synthase, the rate-limiting enzyme of 
glycogen synthesis (Embi et al., 1980; Woodgett et al., 1983). Mammals express two 
homologues of GSK-3, GSK-3α and GSK-3β, which are encoded by separate genes 
(Woodgett, 1990). Throughout this chapter we will use “GSK-3” to refer to both GSK-3 and 
GSK-3β. The two GSK-3 gene products share almost identical kinase domains, but differ 
substantially at their amino and carboxy termini. Notably, GSK-3α has a glycine-rich N-
terminal extension, which is not present in GSK-3β. This is reflected in the relative molecular 
masses of GSK-3α and GSK-3β, with GSK-3α having a predicted MW of 51 kDa, and GSK-3β 
having a slightly lower MW of 47 kDa (see Fig. 1).  
Both enzymes retain activity when their non-catalytic N-terminal extensions are deleted, 
whereas truncation mutants of their disparate non-catalytic C-terminal sequences display 
reduced activity, in part due to improper folding (Buescher and Phiel, 2010). There is a 
splice variant of GSK-3β (GSK-3β2), which has a 13 amino acid insert in the kinase domain 
(Mukai et al., 2002; Schaffer et al., 2003). The GSK-3β2 variant is less abundant than the GSK-
3β1 variant. Even in the brain, where it is most enriched, GSK-3β2 protein levels are still 
approximately 2- to 3-fold less than those of GSK-3β1. GSK-3β2 displays reduced activity 
towards some substrates (e.g. Tau, CRMP2, CRMP4, phospho-GS2, Inhibitor-2) when 
compared to the GSK-3β1 variant, although some substrates (e.g. c-Myc and c-Jun) appear to 
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Fig. 1. Schematic depiction of GSK-3 and GSK-3β proteins. Red shaded triangles indicate 
the sites of tyrosine phosphorylation required for maximal catalytic activity. Blue shaded 
triangles point to sites of inhibitory phosphorylation. 
GSK-3 is unusual in that it exhibits a preference for substrates that are pre-phosphorylated 
by another kinase at a position located four residues C-terminal to the GSK-3 target site (Fiol 
et al., 1987). Thus, the consensus sequence for a GSK-3 substrate is S/T-X-X-X-S-P/T-P, 
where the first serine or threonine (S/T) is the GSK-3 target site, X is any amino acid, and 
the final S/T residue is the site that is phosphorylated by a priming kinase. The GSK-3 
substrates CRMP2 and CRMP4 deviate from the usual consensus sequence in that the 
number of residues between the priming site and the GSK-3 target site is four, instead of the 
usual three (Cole et al., 2004). Thus, the GSK-3 substrate consensus sequence is not 
invariant. Frequently, GSK-3 substrates contain several tandem target residues, spaced such 
that after an initial priming phosphorylation, GSK-3 will phosphorylate multiple 
consecutive target sites located N-terminal to the priming site, with GSK-3 acting as the 
priming kinase for each subsequent phosphorylation event. There are hundreds of potential 
GSK-3 substrates with properly spaced tandem GSK-3 target sites, based on bioinformatics 
analyses (Taelman et al., 2010), although less than 100 GSK-3 substrates have been reported 
in the literature and only a subset of these has been thoroughly validated. 
Nascent GSK-3 and GSK-3β enzymes, as they fold into their final conformation, undergo a 
transient state in which they act as tyrosine kinases, serving to autophosphorylate 
themselves on a key tyrosine residue (Lochhead et al., 2006). The resultant phosphorylation 
on tyrosine 216 of GSK-3β or the equivalent tyrosine 279 of GSK-3 is required for full 
serine/threonine kinase activity of the fully mature enzymes. Subsequent kinase activity is 
specific for serine/threonine phosphorylation. In the absence of signals, that is, resting 
conditions, GSK-3 exhibits a high degree of activity. The primary mode of regulating GSK-3 
is via inactivation, which can be accomplished through phosphorylation, protein-protein 
interactions or sequestration. 
2.1 Regulation of GSK-3 activity through phosphorylation by upstream kinases. 
2.1.1 Inhibitory N-terminal phosphorylation  
When serine 9 of GSK-3β (or serine 21 of GSK-3) is phosphorylated, it mimicks a primed, 
intramolecular pseudosubstrate that acts in cis as a competitive inhibitor of GSK-3 activity 
(Cross et al., 1995). The crystal structure of GSK-3β revealed that the negatively charged 
phosphate on primed substrates fits into a pocket of positively charged residues in the 
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substrate binding cleft of the kinase, thereby placing the substrate into the proper 
orientation for GSK-3-mediated phosphorylation (Bax et al., 2001; Dajani et al., 2001; ter 
Haar et al., 2001). This pocket also binds the phosphorylated N-terminal peptide of GSK-3 
when it is phosphorylated at S9/S21 – competing out exogenous substrates and hence, 
interfering with activity. There are several kinases capable of inhibiting GSK-3 through 
S9/S21 phosphorylation, including PKB/Akt, p70 ribosomal S6 kinase, p90 ribosomal S6 
kinase, protein kinase A and certain protein kinase Cs (Cross et al., 1995; Fang et al., 2000; 
Goode et al., 1992; Sutherland and Cohen, 1994; Torres et al., 1999). 
2.1.2 Inhibitory C-terminal phosphorylation (GSK-3β-specific) 
Phosphorylation of serine 389 (S389), which is located near the carboxy terminus of mouse 
GSK-3β (threonine 390 is the equivalent residue in human GSK-3β), is also capable of 
generating a pseudosubstrate inhibitor of GSK-3β activity in a manner analogous to that 
obtained through phosphorylation of S9 (Thornton et al., 2008). There is no equivalent 
residue to S389 found in the sequence of GSK-3, thus, S389 phosphorylation provides a 
mechanism through which GSK-3β activity may be differentially regulated from GSK3- 
activity. The only kinase that has been linked to S389 phosphorylation to date is p38 MAPK, 
which appears to phosphorylate S389 in brain and thymocytes (Thornton et al., 2008). 
2.2 Regulation through multi-protein complexes  
GSK-3 can also be regulated through interactions with other proteins. This is most clearly 
demonstrated in the canonical Wnt/β-catenin signaling pathway where GSK-3 binds several  
proteins with distinct functional consequences. Details of this signalling pathway are 
discussed in section 4.1. In a multi-protein assembly known as the β-catenin destruction 
complex, a high-affinity interaction between GSK-3 and the scaffolding protein Axin or 
Axin2/Conductin is required for GSK-3 to efficiently phosphorylate the substrate β-catenin 
(Behrens et al., 1998; Hart et al., 1998; Ikeda et al., 1998a). GSK-3 interacts strongly with 
members of the GSK-3 binding protein (GBP)/FRAT family of proteins and these 
interactions were thought to compete with Axin/Axin2 interactions with GSK-3 as part of 
the mechanism of Wnt/β-catenin signalling [reviewed in: (van Amerongen and Berns, 
2005)]. However, loss-of-function studies in mice indicate that the FRAT proteins are 
dispensable for Wnt/β-catenin signalling in mammals, given the lack of any obvious 
phenotype in triple knockout FRAT1,2,3-null mice (Van Amerongen, 2005). GSK-3 also 
interacts with the intracellular domain of LRP6, a co-receptor for Wnt/β-catenin signalling 
(Beagle et al., 2009; Mi et al., 2006; Piao et al., 2008; Wu et al., 2009). A model has been 
proposed in which Wnt ligand-induced phosphorylation of the intracellular domain of LRP6 
results in GSK-3 binding and inactivation, thereby inhibiting GSK-3-mediated β-catenin 
phosphorylation (Wu et al., 2009).  
2.3 Functional redundancy of GSK-3α and GSK-3β 
As described above, the kinase domains of GSK-3α and GSK-3β are virtually identical, 
resulting in a high degree of functional overlap between the two proteins. For instance, with 
respect to the role of GSK-3 in Wnt/β-catenin signalling, there is clear functional 
redundancy between GSK-3 and GSK-3β, based on genetic studies in mouse embryonic 
stem cells (Doble et al., 2007). Still, there are striking differences in the phenotypes of mice 
lacking GSK-3α or GSK-3β. GSK-3α knockout mice are viable but insulin-sensitized 
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(MacAulay et al., 2007) and they display abnormal brain structure and behaviour 
(Kaidanovich-Beilin et al., 2009) as well as progressive cardiac hypertrophy and contractile 
dysfunction (Zhou et al., 2010). By contrast, GSK-3β knockout mice are inviable (Hoeflich et 
al., 2000). These animals die either prior to, or immediately after, birth and display 
cardiovascular developmental defects and liver degeneration (Hoeflich et al., 2000; Kerkela 
et al., 2008). It is currently unclear whether the different phenotypes arise due to different 
expression patterns of GSK-3α and GSK-3β (both isoforms are expressed in most tissues 
examined) or distinct subsets of substrates (although few, if any, substrates have been 
shown to be targeted by only one of the two isoforms).  
3. Pathways and transcription factors that regulate pluripotency in mouse 
and human pluripotent stem cells 
Stems cells are defined by their ability to self-renew (i.e. to make more stem cells) while 
retaining the ability to differentiate into one or more specialized cell types. Embryonic stem 
cells (ESCs) have the ability to differentiate into all cell types of the embryo proper (Evans 
and Kaufman, 1981; Rossant, 2001). In other words, they are pluripotent, a remarkable 
property that has obvious implications for tissue replacement therapies targetting diseased 
or damaged tissues. To retain their stem cell identity, both embryonic and adult stem cells 
(such as hematopoietic stem cells) have active signalling pathways that regulate their 
proliferation and pluripotency (reviewed in: (Molofsky et al., 2004)). In ESCs, self-renewal 
depends on the maintenance of a transcriptional program regulated, minimally, by a set of 
three transcription factors. These factors comprise the core transcriptional program 
responsible for the maintenance of mouse ES cell pluripotency and include; Oct-4, Sox-2 and 
Nanog (Boyer et al., 2005; Chew et al., 2005; Loh et al., 2006; Rodda et al., 2005).  
The most commonly used  media for maintaining mouse ESCs under serum-free conditions 
require supplementation with leukemia inhibitory factor (LIF) and bone morphogenetic 
protein-4 (BMP4), which initiate signalling through gp130/STAT- and Smad-mediated 
pathways, respectively (Niwa et al., 1998; Ying et al., 2003; Ying and Smith, 2003). Notably, 
these signalling molecules/pathways are incapable of maintaining undifferentiated human 
ESCs in vitro (Daheron et al., 2004; Humphrey et al., 2004; Xu et al., 2002). Feeder-free 
culture of human ESCs requires Activin/Nodal and FGF-2 supplementation instead (Beattie 
et al., 2005; James et al., 2005; Levenstein et al., 2006; Ludwig et al., 2006; Vallier et al., 2005). 
Despite a requirement for activation of ostensibly different signalling pathways, the 
transcriptional mediators of pluripotency appear to be similar in both human and mouse 
ESCs (Boyer et al., 2005; Chew et al., 2005; Loh et al., 2006; Rodda et al., 2005) with Nanog 
playing a central role (Pan and Thomson, 2007). 
The difference in the medium requirements for mouse versus human ESCs (mESCs vs 
hESCs) likely reflects dissimilar developmental origins. There are two primary lines of 
evidence supporting the notion that hESCs represent a more advanced stage of 
development than the early blastocysts from which mESCs are obtained: i. Pluripotent 
mouse epiblast stem cells (EpiSCs), derived from an embryo at a later developmental stage 
than that typically used to obtain mESCs, have the same growth factor requirements 
(Activin/Nodal and FGF-2) as human “ESCs” (Brons et al., 2007; Tesar et al., 2007). 
ii. Human ESCs or induced pluripotent stem cells can attain a mESC-like, LIF-dependent 
state, if they are reprogrammed with pluripotency-inducing transcription factors in the 
presence of LIF (Buecker et al., 2010; Hanna et al., 2010). The pluripotent state of rodent 
Molecular Mechanisms Underlying 
Pluripotency and Lineage Commitment – The Role of GSK-3 
 
373 
EpiSCs (and primate “ESCs”) differs biochemically and epigenetically from that of true 
rodent ESCs; the two conditions have been termed primed and naïve pluripotent states, 
respectively (Nichols and Smith, 2009). 
Of note, inactivation of GSK-3 through the use of small molecule inhibitors enhanced the 
maintenance of human pluripotent stem cells or pluripotent stem cells derived from the 
NOD strain of mouse in a naïve pluripotent state (Hanna et al., 2010; Hanna et al., 2009). 
Furthermore, the “ground state” of naïve pluripotency in mESCs can be maintained with 
fully defined serum-free medium by adding a combination of three small-molecule 
inhibitors (3i): SU5402 and PD184352, which serve to inhibit mitogen-activated protein 
kinase (MAPK) signaling; and CHIR99021, a high-specificity GSK-3 inhibitor (Ying et al., 
2008). A proposed mechanism of the 3i cocktail is that inhibition of MAPK signalling blocks 
autoinductive FGF4 signalling required for mESC differentiation, while GSK-3 inhibition 
may play a role in allowing undifferentiated mESCs to survive and proliferate.  
4. Effects of GSK-3 inhibition/ablation on pluripotent stem cells 
There are now several reports in which inhibition of GSK-3 through the use of small 
molecules (e.g. CHIR99021 or BIO) has been shown to enhance the maintenance and 
derivation of embryonic stem cells obtained from mice, including the problematic C57BL/6 
strain, from which de novo mESC cell line generation had been very difficult (Gertsenstein et 
al., 2010; Kiyonari et al., 2010; Sato et al., 2009). Furthermore, inhibition of GSK-3 has 
facilitated the isolation of rat ESCs, which had also been technically challenging (Buehr et 
al., 2008; Li et al., 2009). In the following sections, we provide an overview of the potential 
mechanisms through which GSK-3 inhibition imparts its effects on pluripotency. 
4.1 The central role of GSK-3 in Wnt/β-catenin signalling 
The Wnt family of secreted glycoproteins regulates cellular interactions during Wnt 
signalling and is involved in the genesis of a variety of human cancers, including those of 
the colon, liver and breast (Giles et al., 2003; Morin and Weeraratna, 2003). In the canonical 
Wnt/β-catenin pathway, the ultimate outcome of ligand-initiated signal transduction is 
largely dependent on the activation of genes regulated by T-cell factor (TCF) / lymphoid 
enhancer factor (LEF) transcription factors (Arce et al., 2006; Brantjes et al., 2002). TCF/LEF 
proteins, in the absence of a Wnt signal, repress transcription in conjunction with co-
repressors such as members of the Groucho/TLE (Transducin-like Enhancer of split) family 
(Chen and Courey, 2000; Hurlstone and Clevers, 2002). In response to Wnt, newly 
accumulated  β-catenin displaces Groucho/TLE from TCF/LEF and acts as a co-activator of 
TCF/LEF to initiate transcription (Brantjes et al., 2002; Chen and Courey, 2000; Daniels and 
Weis, 2005). There are four mammalian TCF/LEF family members: TCF1, LEF1, TCF3 and 
TCF4 (Arce et al., 2006). In mESCs, transcripts from all of the TCF/LEF genes are readily 
detected, but those encoding TCF3 predominate at steady state (Anton et al., 2007; Pereira et 
al., 2006). At the protein level, all TCF/LEF family members are readily detected by western 
blot analyses of mESC lysates (Kelly et al., 2011). TCF3 has been shown to negatively 
regulate the transcription of Nanog (Pereira et al., 2006; Yi et al., 2008) and to co-occupy 
promoters with Nanog and Oct-4 in mESCs (Cole et al., 2008). 
GSK-3 plays a central role in the canonical Wnt/β-catenin signalling pathway (see Fig. 2), 
serving to keep steady state levels of the cytoplasmic, signalling pool of β-catenin low in the 
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(MacAulay et al., 2007) and they display abnormal brain structure and behaviour 
(Kaidanovich-Beilin et al., 2009) as well as progressive cardiac hypertrophy and contractile 
dysfunction (Zhou et al., 2010). By contrast, GSK-3β knockout mice are inviable (Hoeflich et 
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EpiSCs (and primate “ESCs”) differs biochemically and epigenetically from that of true 
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proteins, in the absence of a Wnt signal, repress transcription in conjunction with co-
repressors such as members of the Groucho/TLE (Transducin-like Enhancer of split) family 
(Chen and Courey, 2000; Hurlstone and Clevers, 2002). In response to Wnt, newly 
accumulated  β-catenin displaces Groucho/TLE from TCF/LEF and acts as a co-activator of 
TCF/LEF to initiate transcription (Brantjes et al., 2002; Chen and Courey, 2000; Daniels and 
Weis, 2005). There are four mammalian TCF/LEF family members: TCF1, LEF1, TCF3 and 
TCF4 (Arce et al., 2006). In mESCs, transcripts from all of the TCF/LEF genes are readily 
detected, but those encoding TCF3 predominate at steady state (Anton et al., 2007; Pereira et 
al., 2006). At the protein level, all TCF/LEF family members are readily detected by western 
blot analyses of mESC lysates (Kelly et al., 2011). TCF3 has been shown to negatively 
regulate the transcription of Nanog (Pereira et al., 2006; Yi et al., 2008) and to co-occupy 
promoters with Nanog and Oct-4 in mESCs (Cole et al., 2008). 
GSK-3 plays a central role in the canonical Wnt/β-catenin signalling pathway (see Fig. 2), 
serving to keep steady state levels of the cytoplasmic, signalling pool of β-catenin low in the 
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absence of Wnt ligands (Dominguez et al., 1995; He et al., 1995; Peifer et al., 1994). A fraction 
of GSK-3 is complexed with the scaffolding proteins adenomatous polyposis coli (APC) and 
Axin1 (or Axin2), and efficiently phosphorylates β-catenin [“primed” by casein kinase-1 
(CK1)] on a series of N-terminal domain residues earmarking it for polyubiquitination and 
proteasomal degradation (Doble and Woodgett, 2003). GSK-3 also phosphorylates APC and 
Axin, increasing their affinities for β-catenin (Hoeflich et al., 2000; Ikeda et al., 1998b; Jho et 
al., 1999; Yamamoto et al., 1999).  
Activation of Wnt/β-catenin signalling requires two types of receptors. The first class belongs 
to a sub-family of single-pass transmembrane receptors, the low-density lipoprotein receptor 
related proteins (LRPs), LRP5 and LRP6 (He et al., 2004; Schweizer and Varmus, 2003; Tamai 
et al., 2000; Wehrli et al., 2000). The second type of receptor comprises a family of serpentine 7-
pass transmembrane receptors known as Frizzleds (Fz)(Logan and Nusse, 2004; Orsulic and 
Peifer, 1996), which appear to function as G protein-coupled receptors (Katanaev et al., 2005; 
Liu et al., 2005; Schulte and Bryja, 2007). The binding of Wnt to Fz/LRP6 results in the 
recruitment of a trimolecular complex of Dishevelled, Axin and GSK-3 to the Fz/LRP6 
heterodimer (Bilic et al., 2007; Zeng et al., 2008; Zeng et al., 2005)GSK-3 and CKI then 
phosphorylate residues of LRP6 to create an Axin docking site which enhances Axin’s affinity 
for LRP6 and results in inhibition of the β-catenin destruction complex in an unclear manner, 
possibly involving direct GSK-3 inhibition through Axin-binding (Zeng et al., 2008; Zeng et al., 
2005) and/or interactions with phospho-LRP6 (Wu et al., 2009). The reorganization of Axin 
upon LRP5/6 binding may also trigger sequestration of Axin-associated GSK-3 into multi-
vesicular endosomes – preventing direct access to β-catenin (Taelman et al., 2010). 
4.1.1 Wnt/-catenin signalling reinforces the pluripotent state of mESCs 
The first study to directly implicate GSK-3 and Wnt/-catenin signalling in the regulation of 
ESC pluripotency suggested that human and mouse ESCs respond similarly to activation of 
Wnt/β-catenin signalling (Sato et al., 2004). By using a reporter construct harbouring TCF 
binding sites driving yellow fluorescent protein (YFP) expression, pathway activation was 
found to be highest in undifferentiated mESCs and was gradually lost as the cells 
differentiated, suggesting that endogenous -catenin/TCF signalling supported the 
maintenance of pluripotency. Activation of the Wnt pathway in mESCs or hESCs, by 
treatment with either Wnt3a or the GSK-3 inhibitor BIO, prolonged the retention of 
pluripotency markers, although one caveat of this study is that these cells were not 
examined for more than 5-7 days, over multiple passages (Sato et al., 2004).  Similar 
observations were made in mESCs treated with the GSK-3 inhibitor, LiCl (Anton et al., 
2007), as well as Wnt-conditioned medium (Hao et al., 2006; Ogawa et al., 2006; Singla et al., 
2006). As an aside, there is a fundamental difference between treatment with GSK-3 
inhibitors and treatment with Wnt due to the inherent feedback control circuitry of Wnt 
signalling. Hence, the target genes of β-catenin include Axin2 and DKK1 which both act to 
reduce Wnt signalling. However, inhibition of GSK-3 short-circuits these controls leading to 
chronic activation of β-catenin signalling that is more reminiscent of tumours that harbour 
APC deletions or β-catenin mutations. 
Some of the conclusions reached by Sato et al. conflict with an independent study 
investigating the effects of Wnt pathway manipulation in hESCs over multiple weeks 
(Dravid et al., 2005). In this study, addition of the Wnt antagonists Dkk1 or sFRP2 did not 
compromise the self-renewal ability of hESCs when cultured on a feeder layer, nor did the 
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inclusion of recombinant Wnt3a support hESC propagation in the undifferentiated state in 
the absence of feeders. -catenin/TCF activity increased significantly after BMP-4- or 
retinoic acid-induced hESC differentiation, supporting a pro-differentiation role for the Wnt 
pathway in hESCs (Dravid et al., 2005). Indeed, sustained Wnt pathway activation or GSK-3 
inhibition in monolayer culture promotes hESC and mESC differentiation into 
mesoendodermal progenitors, which are capable of enhanced endothelial and cardiac 
specification (Bakre 2007). A bisindoylmaleimide GSK-3 inhibitor, designated 1m, which 
was shown to sustain pluripotency of mESCs (Bone et al., 2009), by contrast, has been shown 
to be effective in differentiating hESCs into definitive endoderm (Bone et al., 2011). These 
divergent effects of 1m-mediated GSK-3 inhibition are likely due to the caveats associated 
with the developmental origins of human and mouse ESCs, discussed in section 3 above. 
4.1.2 Genetic Gain- and Loss-of-function studies of Wnt pathway regulators in ESCs 
4.1.2.1 mESCS with mutant Adenomatous polyposis coli (Apc) display impaired 
differentiation  
The scaffolding protein Adenomatous polyposis coli (Apc) is a key negative regulator of the 
Wnt/-catenin pathway that is frequently mutated in human cancers, particularly those of 
the colon (Kwong and Dove, 2009). Kielman et al. used teratoma assays in syngeneic mice to 
evaluate the differentiation capacities of mESCs harbouring a spectrum of mutant forms of 
Apc (Kielman et al., 2002). These mutants exhibit varying abilities to regulate -catenin 
levels, with some (i.e. ApcMIN/MIN) being completely deficient in this regard, while others 
(i.e. Apc1638N/1638N) retaining about 50% activity (Kielman et al., 2002). Interestingly, these 
cells exhibit a range of differentiation defects, with those harbouring the most disruptive 
Apc mutations having the most profound deficiencies. Although ApcMIN/MIN mESCs fail to 
form teratomas, Apc1638N/1638N teratomas fail to generate detectable neural tissue, cartilage 
and bone. These observations carried over to in vitro analyses: upon LIF withdrawal, only 
the most severe Apc mutant lines retained an undifferentiated morphology. Dysregulation 
of -catenin levels was implicated as the mechanism underlying the differentiation 
blockade, since mESCs with a targeted deletion of -catenin exon 3, which encodes the GSK-
3 phosphorylation sites and so generates a stabilized form of the protein, also failed to 
differentiate (Kielman et al., 2002).  
4.1.2.2 Ectopic expression of -catenin reinforces pluripotency 
A caveat of studies relying solely on GSK-3 inhibitors and/or Wnt stimulation is that such 
treatments can have pleiotropic effects that are not limited to -catenin stabilization due to 
the many other targets of GSK-3. To directly examine whether increased -catenin levels are 
sufficient to reinforce pluripotency, the effects of wild type and stabilized -catenin 
overexpression were examined using an inducible system in mESCs (Ogawa et al., 2006).  In 
this system, the expression of stabilized -catenin, and to a lesser extent wild type -catenin, 
prolonged the retention of an undifferentiated ESC morphology after LIF removal. This 
effect may be attributable, at least in part, to crosstalk between -catenin and LIF/Stat3 
signalling, since GSK-3 inhibition using BIO activated a Stat3 reporter construct (Ogawa et 
al., 2006). Takao et al. (2007) obtained similar results by expressing stabilized (S33A) -
catenin in mESCs, transiently selecting the cells for expression of puromycin resistance, and 
assaying for the retention of pluripotency markers after LIF withdrawal (Takao et al., 2007).  
Finally, our group demonstrated that mESCs stably expressing the S33A form of -catenin 
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absence of Wnt ligands (Dominguez et al., 1995; He et al., 1995; Peifer et al., 1994). A fraction 
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to a sub-family of single-pass transmembrane receptors, the low-density lipoprotein receptor 
related proteins (LRPs), LRP5 and LRP6 (He et al., 2004; Schweizer and Varmus, 2003; Tamai 
et al., 2000; Wehrli et al., 2000). The second type of receptor comprises a family of serpentine 7-
pass transmembrane receptors known as Frizzleds (Fz)(Logan and Nusse, 2004; Orsulic and 
Peifer, 1996), which appear to function as G protein-coupled receptors (Katanaev et al., 2005; 
Liu et al., 2005; Schulte and Bryja, 2007). The binding of Wnt to Fz/LRP6 results in the 
recruitment of a trimolecular complex of Dishevelled, Axin and GSK-3 to the Fz/LRP6 
heterodimer (Bilic et al., 2007; Zeng et al., 2008; Zeng et al., 2005)GSK-3 and CKI then 
phosphorylate residues of LRP6 to create an Axin docking site which enhances Axin’s affinity 
for LRP6 and results in inhibition of the β-catenin destruction complex in an unclear manner, 
possibly involving direct GSK-3 inhibition through Axin-binding (Zeng et al., 2008; Zeng et al., 
2005) and/or interactions with phospho-LRP6 (Wu et al., 2009). The reorganization of Axin 
upon LRP5/6 binding may also trigger sequestration of Axin-associated GSK-3 into multi-
vesicular endosomes – preventing direct access to β-catenin (Taelman et al., 2010). 
4.1.1 Wnt/-catenin signalling reinforces the pluripotent state of mESCs 
The first study to directly implicate GSK-3 and Wnt/-catenin signalling in the regulation of 
ESC pluripotency suggested that human and mouse ESCs respond similarly to activation of 
Wnt/β-catenin signalling (Sato et al., 2004). By using a reporter construct harbouring TCF 
binding sites driving yellow fluorescent protein (YFP) expression, pathway activation was 
found to be highest in undifferentiated mESCs and was gradually lost as the cells 
differentiated, suggesting that endogenous -catenin/TCF signalling supported the 
maintenance of pluripotency. Activation of the Wnt pathway in mESCs or hESCs, by 
treatment with either Wnt3a or the GSK-3 inhibitor BIO, prolonged the retention of 
pluripotency markers, although one caveat of this study is that these cells were not 
examined for more than 5-7 days, over multiple passages (Sato et al., 2004).  Similar 
observations were made in mESCs treated with the GSK-3 inhibitor, LiCl (Anton et al., 
2007), as well as Wnt-conditioned medium (Hao et al., 2006; Ogawa et al., 2006; Singla et al., 
2006). As an aside, there is a fundamental difference between treatment with GSK-3 
inhibitors and treatment with Wnt due to the inherent feedback control circuitry of Wnt 
signalling. Hence, the target genes of β-catenin include Axin2 and DKK1 which both act to 
reduce Wnt signalling. However, inhibition of GSK-3 short-circuits these controls leading to 
chronic activation of β-catenin signalling that is more reminiscent of tumours that harbour 
APC deletions or β-catenin mutations. 
Some of the conclusions reached by Sato et al. conflict with an independent study 
investigating the effects of Wnt pathway manipulation in hESCs over multiple weeks 
(Dravid et al., 2005). In this study, addition of the Wnt antagonists Dkk1 or sFRP2 did not 
compromise the self-renewal ability of hESCs when cultured on a feeder layer, nor did the 
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inclusion of recombinant Wnt3a support hESC propagation in the undifferentiated state in 
the absence of feeders. -catenin/TCF activity increased significantly after BMP-4- or 
retinoic acid-induced hESC differentiation, supporting a pro-differentiation role for the Wnt 
pathway in hESCs (Dravid et al., 2005). Indeed, sustained Wnt pathway activation or GSK-3 
inhibition in monolayer culture promotes hESC and mESC differentiation into 
mesoendodermal progenitors, which are capable of enhanced endothelial and cardiac 
specification (Bakre 2007). A bisindoylmaleimide GSK-3 inhibitor, designated 1m, which 
was shown to sustain pluripotency of mESCs (Bone et al., 2009), by contrast, has been shown 
to be effective in differentiating hESCs into definitive endoderm (Bone et al., 2011). These 
divergent effects of 1m-mediated GSK-3 inhibition are likely due to the caveats associated 
with the developmental origins of human and mouse ESCs, discussed in section 3 above. 
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4.1.2.1 mESCS with mutant Adenomatous polyposis coli (Apc) display impaired 
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The scaffolding protein Adenomatous polyposis coli (Apc) is a key negative regulator of the 
Wnt/-catenin pathway that is frequently mutated in human cancers, particularly those of 
the colon (Kwong and Dove, 2009). Kielman et al. used teratoma assays in syngeneic mice to 
evaluate the differentiation capacities of mESCs harbouring a spectrum of mutant forms of 
Apc (Kielman et al., 2002). These mutants exhibit varying abilities to regulate -catenin 
levels, with some (i.e. ApcMIN/MIN) being completely deficient in this regard, while others 
(i.e. Apc1638N/1638N) retaining about 50% activity (Kielman et al., 2002). Interestingly, these 
cells exhibit a range of differentiation defects, with those harbouring the most disruptive 
Apc mutations having the most profound deficiencies. Although ApcMIN/MIN mESCs fail to 
form teratomas, Apc1638N/1638N teratomas fail to generate detectable neural tissue, cartilage 
and bone. These observations carried over to in vitro analyses: upon LIF withdrawal, only 
the most severe Apc mutant lines retained an undifferentiated morphology. Dysregulation 
of -catenin levels was implicated as the mechanism underlying the differentiation 
blockade, since mESCs with a targeted deletion of -catenin exon 3, which encodes the GSK-
3 phosphorylation sites and so generates a stabilized form of the protein, also failed to 
differentiate (Kielman et al., 2002).  
4.1.2.2 Ectopic expression of -catenin reinforces pluripotency 
A caveat of studies relying solely on GSK-3 inhibitors and/or Wnt stimulation is that such 
treatments can have pleiotropic effects that are not limited to -catenin stabilization due to 
the many other targets of GSK-3. To directly examine whether increased -catenin levels are 
sufficient to reinforce pluripotency, the effects of wild type and stabilized -catenin 
overexpression were examined using an inducible system in mESCs (Ogawa et al., 2006).  In 
this system, the expression of stabilized -catenin, and to a lesser extent wild type -catenin, 
prolonged the retention of an undifferentiated ESC morphology after LIF removal. This 
effect may be attributable, at least in part, to crosstalk between -catenin and LIF/Stat3 
signalling, since GSK-3 inhibition using BIO activated a Stat3 reporter construct (Ogawa et 
al., 2006). Takao et al. (2007) obtained similar results by expressing stabilized (S33A) -
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exhibits enhanced self-renewal and delayed loss of pluripotency (Kelly et al., 2011).  
Intriguingly, similar results were observed using a deletion mutant of -catenin lacking its 
C-terminal transactivation domain, which transactivates -catenin/TCF target genes with 
~10% the efficiency of the full length form, suggesting that sustenance of pluripotency by -
catenin occurs independently of TCF proteins.  
One possible mechanism through which stabilized -catenin could restrict exit from 
pluripotent state is through the direct modulation of the pluripotency regulators. In support 
of such a mechanism, the formation of -catenin/Oct-4 complexes was implicated in the 
regulation of Nanog expression (Takao et al., 2007).  Indeed, -catenin/Oct-4 complexes 
were detected by co-immunoprecipitation using DKO mESC lysates, or wild type mESCs 
lysates after stimulation of the Wnt--catenin pathway using Wnt3a or GSK-3 inhibition.  
Furthermore, an established Oct reporter [PORE; (Botquin et al., 1998)] and specific Oct-4 
target genes were induced after pathway stimulation, supporting a mechanism whereby -
catenin enhances Oct-4-mediated transcriptional activation (Kelly et al., 2011). 
-catenin also exerts some of its effects on ESCs through its function as a structural protein 
(see Fig. 2). The role of -catenin in the cadherin/catenin complex has historically been a 
structural one, to “hardwire” the cadherin complex to the actin cytoskeleton (Nelson, 2008). 
More recently, this view has been called into question, owing to controversial studies 
proposing that a tripartite cadherin/-catenin/actin complex does not form in vivo (Drees et 
al., 2005; Yamada et al., 2005). Nonetheless, analyses of -catenin knockout mice strongly 
support its role as a key regulator of cadherin-mediated cell-cell adhesion (Haegel et al., 
1995; Huelsken et al., 2000). Ablation of -catenin causes embryonic lethality at ~d6.5, with 
the mutant embryos exhibiting defects in formation of embryonic ectoderm (Haegel et al., 
1995), as well as anterior-posterior axis formation (Huelsken et al., 2000). Interestingly, 
expression levels and adherens junction localization of the -catenin-related protein 
plakoglobin appear increased in -catenin(-/-) embryos, suggesting that plakoglobin at least 
partly rescues adhesion defects caused by -catenin deficiency (Huelsken et al., 2000). -
catenin(-/-) mESCs cultured in LIF-containing medium express markedly lower levels of Rex-
1 transcript when compared to wild type mESCs, suggesting that these cells are prone to 
spontaneous differentiation (Anton et al., 2007). In support of this possibility, the expression 
of pluripotency markers is more rapidly lost in these cells after retinoic acid-induced 
differentiation (Wagner et al., 2010).   
The dual roles of β-catenin have been re-examined recently by using genetic "rescue" 
experiments in Ctnnb1-deficient mESCs with a deletion of exons 3-6 (β-catenin∆/∆) 
(Lyashenko et al., 2011). In mESCs lacking endogenous full-length β-catenin, plakoglobin 
partially compensates for the loss of β-catenin with respect to its cell adhesion functions in 
undifferentiated mESCs. Under standard mESC culture conditions, global gene transcript 
expression profiles of wild-type and β-catenin knockout mESCs were almost identical, with 
no observed differences in the transcript levels of the pluripotency factors: Nanog, Oct4, 
Sox2 or Rex1. Despite their normal appearance, β-catenin∆/∆ mESCs were impaired in their 
ability to differentiate into mesendoderm and neuronal cell types. Stable re-expression of 
full-length or truncated β-catenin lacking its transactivation domain, in β-catenin∆/∆ mESCs, 
was able to rescue their ability to differentiate into definitive endoderm and neuronal cells.  
4.1.2.3 Generation and analysis of mouse embryonic stem cells lacking GSK-3  
Although GSK-3 inhibition is strongly implicated in the sustenance of pluripotency through 
the use of small molecular inhibitors, some of these inhibitors are known to elicit off-target 
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Fig. 2. Model illustrating the central role of β-catenin in mediating the pluripotency-
enhancing effects of Wnt signaling (or GSK-3 inhibition/ablation) in mESCs. A. In the 
absence of Wnt, β-catenin is phosphorylated by GSK-3 in a "destruction complex", which 
tags it for proteosomal degradation. Levels of cytosolic and nuclear β-catenin are very low 
and canonical target genes are repressed via TCF/LEF factor interactions with TLE 
repressors. TCF3 exerts a weak repressive effect on Nanog gene expression but LIF and BMP 
supplementation are sufficient to prevent differentiation and ensure that the network of 
pluripotent transcription factors (Oct4, Sox2 and Nanog) supports pluripotency. B) In the 
presence of Wnt, β-catenin is no longer targeted for degradation as the destruction complex 
is disrupted and GSK-3 is sequestered in multivesicular endosomes (see text for details). β-
catenin accumulates in the cytosol and translocates to the nucleus where it activates 
canonical Wnt/β-catenin target genes and associates with Oct-4 complexes. β-catenin also 
de-represses TCF3 targets such as Nanog through a mechanism that does not require its 
transactivation domain. Inhibition of Mek signal transduction, together with Wnt treatment 
(or GSK-3 inhibition) are sufficient to maintain mESCs in a pluripotent ground state.  
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exhibits enhanced self-renewal and delayed loss of pluripotency (Kelly et al., 2011).  
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Fig. 2. Model illustrating the central role of β-catenin in mediating the pluripotency-
enhancing effects of Wnt signaling (or GSK-3 inhibition/ablation) in mESCs. A. In the 
absence of Wnt, β-catenin is phosphorylated by GSK-3 in a "destruction complex", which 
tags it for proteosomal degradation. Levels of cytosolic and nuclear β-catenin are very low 
and canonical target genes are repressed via TCF/LEF factor interactions with TLE 
repressors. TCF3 exerts a weak repressive effect on Nanog gene expression but LIF and BMP 
supplementation are sufficient to prevent differentiation and ensure that the network of 
pluripotent transcription factors (Oct4, Sox2 and Nanog) supports pluripotency. B) In the 
presence of Wnt, β-catenin is no longer targeted for degradation as the destruction complex 
is disrupted and GSK-3 is sequestered in multivesicular endosomes (see text for details). β-
catenin accumulates in the cytosol and translocates to the nucleus where it activates 
canonical Wnt/β-catenin target genes and associates with Oct-4 complexes. β-catenin also 
de-represses TCF3 targets such as Nanog through a mechanism that does not require its 
transactivation domain. Inhibition of Mek signal transduction, together with Wnt treatment 
(or GSK-3 inhibition) are sufficient to maintain mESCs in a pluripotent ground state.  
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effects, which could confound the interpretation of results (Bain et al., 2007). To circumvent 
such limitations, mouse embryonic stem cells lacking both alleles of GSK3 and GSK-3 
(double knockout; DKO) were generated and characterized (Doble et al., 2007). The 
morphology of DKO mESCs is altered dramatically relative to the wild type line, as colonies 
closely resemble the compact, highly refractile morphology of mESCs treated with 
CHIR99021 (Kelly et al., 2011). These cells exhibit highly elevated levels of cytoplasmic and 
nuclear -catenin and expression of several prototypical targets of the Wnt/-catenin 
pathway (axin2, brachyury and cdx1) is strongly upregulated (Doble et al., 2007).   One of the 
most striking consequences of GSK-3 ablation in mESCs is their profound inability to 
differentiate efficiently, particularly to the neurectoderm lineage.  Using established 
differentiation assays such as embryoid bodies or teratomas, in striking contrast to wild type 
mESCs, DKO mESCs retain the expression of pluripotency markers (Oct-4, Nanog) and fail 
to express detectable amounts of neural markers, such as -III-tubulin.  
To determine whether this differentiation blockade was due to the hyperactivation of -
catenin/TCF target genes, the original DKO line was modified to allow for the site-specific 
integration of transgenes at the endogenous GSK-3 locus; thereafter, a dominant negative 
form of TCF4 (TCF4DN) was constitutively expressed from this locus under the control of 
the EF1 promoter (Kelly et al., 2011). Surprisingly, although the expression of TCF4DN 
efficiently attenuated the activation of -catenin/TCF target genes, these cells were not 
rescued with regard to their impaired neurectoderm differentiation.  However, after 
normalization of -catenin levels through the stable expression of -catenin-specific 
shRNAs, these cells were capable of neurectoderm differentiation in teratoma assays. These 
findings  suggested that -catenin, independent of its role as a transactivator of TCF target 
genes, regulates the acquisition and maintenance of the pluripotent state (Kelly et al., 2011).   
Recent studies by two groups have revealed that TCF3 is regulated by β-catenin in a 
somewhat atypical manner (Wray et al., 2011; Yi et al., 2011). Of the four TCF/LEF family 
members, TCF3 is unusual in that there is little evidence that β-catenin directly activates 
TCF3 target genes. In most contexts, the other TCF/LEF family members, upon binding β-
catenin, recruit transcriptional activators to increase target gene transcription. In mESCs, β-
catenin appears to alleviate the repression of Tcf3 on genes such as Nanog, without 
recruiting transactivating factors (Wray et al., 2011). Derepression of TCF3 by β-catenin 
appears to be a significant part of the mechanism through which GSK-3 inhibition exerts its 
effects on mESC pluripotency (see Fig. 2). 
4.2 PI3K signalling and GSK-3 inhibition 
4.2.1 Signalling through PI3K and the sustenance of pluripotency 
The PI3K pathway regulates various cellular processes, ranging from cell motility to growth, 
proliferation, survival and metabolism [reviewed in: (Cully et al., 2006; Yuan and Cantley, 
2008)]. PI3Ks comprise a family of lipid kinases that phosphorylate the 3’ hydroxyl group of 
phosphoinositide lipids within membranes. After activation by upstream growth factors, 
cytokines and receptor tyrosine kinases (RTKs), PI3K phosphorylates PIP2, to form PIP3. 
This process is reversed by the tumour suppressor phosphatase and tensin homolog deleted 
on chromosome ten (PTEN), which dephosphorylates PIP3 back to PIP2, thus terminating the 
pathway. Upon generation, PIP3 propagates the signal by binding to the pleckstrin 
homology (PH) domain of several downstream effector proteins, including the key effector 
protein kinase phosphoinositide-dependent kinase 1 (PDK1) which targets a variety of 
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members of the AGC family of protein-serine kinases including Protein Kinase B (PKB; also 
known as Akt), resulting in the activation of PKB through its phosphorylation on T308. PKB 
elicits diverse effects through its phosphorylation of many signalling intermediates, 
including GSK-3, the Foxo transcriptional regulators and modulators of apoptotic signalling 
pathways. Aberrant activation of the PI3K pathway is thought to be a key event in the 
genesis and maintenance of several types of human cancers and various components of this 
system are frequently mutated in tumours (Luo et al., 2003; Cully et al., 2006; Yuan and 
Cantley, 2008).  
The first indications that PI3K signalling may regulate self-renewal arose from the 
realization that signalling through the LIF receptor subunit, gp130, elicits pleiotropic effects 
through modulation of various signalling pathways, including the Ras/MAPK, JAK/STAT 
and PI3K pathways (Boeuf et al., 1997; Boeuf et al., 2001; Ernst et al., 1996; Takahashi-Tezuka 
et al., 1998). Indeed, direct stimulation of mESCs with LIF induces robust PI3K pathway 
activation (as assessed through the phosphorylation of Akt/PKB on S473, GSK3/ on S21 
and S9, respectively, and a downstream pathway target, ribosomal S6 kinase) (Paling et al., 
2004). This effect is blocked by treatment with the PI3K inhibitor, LY294002, or after the 
expression of a dominant negative form of p85, the regulatory subunit of Class IA PI3Ks 
(Paling et al., 2004). Inhibition of PI3K activity by these means results in substantially 
reduced self-renewal of mESCs (Paling et al., 2004), by a mechanism that involves the 
regulation of Nanog expression (Kingham and Welham, 2009; Storm et al., 2007).  
Importantly, while treatment of mESCs with LY294002 blocks PI3K-mediated induction of 
Nanog expression, this effect is reversed by treatment with GSK-3 inhibitors, implicating 
GSK-3 in the regulation of self-renewal through the modulation of Nanog levels (Storm et 
al., 2007). More recently, by performing gene expression analyses on mESCs cultured in LIF-
containing media with and without PI3K pathway inhibition, Storm et al. identified putative 
target genes of PI3K signalling (Storm et al., 2009). The majority of identified gene changers 
(~73%) were downregulated after PI3K inhibition, indicating that they are normally 
transcriptionally increased downstream of PI3K signalling. As was observed for Nanog (Storm 
et al., 2007), GSK-3 inhibition using BIO de-repressed the expression of some PI3K targets 
(Shp-1 and 1700061G19Rik), though many appeared to be regulated in a GSK-3-independent 
manner (Storm et al., 2009). Interestingly, knockdown of one of the GSK-3 targets, the tyrosine 
phosphatase Shp-1, compromised ESC self-renewal capacity, an effect that may involve its 
desphosphorylation of Stat3 (Storm et al., 2009). The identification of additional Shp-1 
substrates will help clarify its mechanism of action in ESCs. 
To determine whether constitutive activation of PI3K signalling was sufficient to support 
ESC self-renewal in the absence of LIF, the effects of stably expressing a constitutively  
active form of PKB (myr-PKB) in ESCs were examined (Watanabe et al., 2006).  Both mouse 
and monkey ESCs expressing myr-PKB retained expression of pluripotency markers (Oct-4, 
Nanog, Rex-1) after LIF withdrawal, indicating that PI3K activation can reinforce 
pluripotency under conditions permissive of differentiation (Watanabe et al., 2006). We have 
confirmed these findings using stable ESC lines expressing activated alleles of PKB and 
PDK1 (Ling et al. unpublished). 
4.2.2 Does PI3K signalling through GSK-3 modulate c-Myc stability to reinforce self-
renewal? 
PI3K induced phosphorylation and inhibition of GSK-3 does not lead to increased 
stabilization of β-catenin (likely due to insulation of the relatively small fraction of GSK-3 
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morphology of DKO mESCs is altered dramatically relative to the wild type line, as colonies 
closely resemble the compact, highly refractile morphology of mESCs treated with 
CHIR99021 (Kelly et al., 2011). These cells exhibit highly elevated levels of cytoplasmic and 
nuclear -catenin and expression of several prototypical targets of the Wnt/-catenin 
pathway (axin2, brachyury and cdx1) is strongly upregulated (Doble et al., 2007).   One of the 
most striking consequences of GSK-3 ablation in mESCs is their profound inability to 
differentiate efficiently, particularly to the neurectoderm lineage.  Using established 
differentiation assays such as embryoid bodies or teratomas, in striking contrast to wild type 
mESCs, DKO mESCs retain the expression of pluripotency markers (Oct-4, Nanog) and fail 
to express detectable amounts of neural markers, such as -III-tubulin.  
To determine whether this differentiation blockade was due to the hyperactivation of -
catenin/TCF target genes, the original DKO line was modified to allow for the site-specific 
integration of transgenes at the endogenous GSK-3 locus; thereafter, a dominant negative 
form of TCF4 (TCF4DN) was constitutively expressed from this locus under the control of 
the EF1 promoter (Kelly et al., 2011). Surprisingly, although the expression of TCF4DN 
efficiently attenuated the activation of -catenin/TCF target genes, these cells were not 
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catenin appears to alleviate the repression of Tcf3 on genes such as Nanog, without 
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appears to be a significant part of the mechanism through which GSK-3 inhibition exerts its 
effects on mESC pluripotency (see Fig. 2). 
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The PI3K pathway regulates various cellular processes, ranging from cell motility to growth, 
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2008)]. PI3Ks comprise a family of lipid kinases that phosphorylate the 3’ hydroxyl group of 
phosphoinositide lipids within membranes. After activation by upstream growth factors, 
cytokines and receptor tyrosine kinases (RTKs), PI3K phosphorylates PIP2, to form PIP3. 
This process is reversed by the tumour suppressor phosphatase and tensin homolog deleted 
on chromosome ten (PTEN), which dephosphorylates PIP3 back to PIP2, thus terminating the 
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desphosphorylation of Stat3 (Storm et al., 2009). The identification of additional Shp-1 
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Nanog, Rex-1) after LIF withdrawal, indicating that PI3K activation can reinforce 
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confirmed these findings using stable ESC lines expressing activated alleles of PKB and 
PDK1 (Ling et al. unpublished). 
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PI3K induced phosphorylation and inhibition of GSK-3 does not lead to increased 
stabilization of β-catenin (likely due to insulation of the relatively small fraction of GSK-3 
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molecules associated with the Axin/APC destruction complex) (Ng et al., 2009). A possible 
mechanism through which PI3K/GSK-3 signalling may regulate ESC self-renewal is through 
the regulation of c-Myc stability. As a target of LIF/Stat3 signalling, maintenance of c-Myc 
expression reinforces the pluripotent state of mESCs by suppressing differentiation 
(Cartwright et al., 2005). Upon LIF withdrawal, c-Myc transcript and protein levels in mESCs 
are sharply reduced, through a mechanism involving both its transcriptional repression and 
increased targeting for proteasomal degradation. However, ectopic expression of c-Myc 
harbouring the T58A mutation, abrogating a target site for GSK-3 phosphorylation that 
promotes ubiquitation and turnover, sustains pluripotency in the absence of LIF (Cartwright et 
al., 2005). In a follow-up study from the same group, it was suggested that GSK-3’s ability to 
phosphorylate c-Myc relies upon its nuclear translocation. Upon LIF withdrawal of mESCs, 
GSK-3 localization shifts from the cytoplasm to the nucleus, thereby gaining access to c-Myc, 
and destabilizing it through phosphorylation on T58. Moreover, expression of activated PKB 
(myr-PKB), triggering GSK-3 inactivation through its phosphorylation at S21/S9, blocks GSK-3 
nuclear translocation and c-Myc T58 phosphorylation/degradation (Bechard and Dalton, 
2009). Taken together, downstream LIF signalling involving GSK-3-mediated stabilization of c-
Myc, may have a role in the regulation of ESC self-renewal.   
5. Conclusions/Future studies  
It is clear that in both human and mouse ESCs, inhibition of GSK-3 exerts strong effects on 
the biology of these unique cells. Whereas, in some contexts, GSK-3 inhibition promotes 
retention of naïve pluripotency, there are signalling environments in which GSK-3 inhibition 
promotes lineage-specific (mesendoderm) differentiation. Although we have focused on 
Wnt/β-catenin and PI3K signalling, GSK-3 also plays a role in other developmentally 
important signalling pathways, such as the Hedgehog pathway [reviewed in: (Jiang and 
Hui, 2008)]. How GSK-3-mediated regulation of substrates beyond those in the Wnt and PI-
3K signalling pathways modulates ESC properties remains to be thoroughly investigated. 
Intriguingly, GSK-3 also appears to play a role in directing the expression of the de novo 
DNA methyltransferase Dnmt3a2, suggesting that GSK-3 may play a role in the regulation 
of the epigenome (Popkie et al., 2010). The role of GSK-3 in the epigenetic regulation of 
genes important for pluripotent stem cell self-renewal and differentiation is an exciting new 
direction for future studies. 
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promotes ubiquitation and turnover, sustains pluripotency in the absence of LIF (Cartwright et 
al., 2005). In a follow-up study from the same group, it was suggested that GSK-3’s ability to 
phosphorylate c-Myc relies upon its nuclear translocation. Upon LIF withdrawal of mESCs, 
GSK-3 localization shifts from the cytoplasm to the nucleus, thereby gaining access to c-Myc, 
and destabilizing it through phosphorylation on T58. Moreover, expression of activated PKB 
(myr-PKB), triggering GSK-3 inactivation through its phosphorylation at S21/S9, blocks GSK-3 
nuclear translocation and c-Myc T58 phosphorylation/degradation (Bechard and Dalton, 
2009). Taken together, downstream LIF signalling involving GSK-3-mediated stabilization of c-
Myc, may have a role in the regulation of ESC self-renewal.   
5. Conclusions/Future studies  
It is clear that in both human and mouse ESCs, inhibition of GSK-3 exerts strong effects on 
the biology of these unique cells. Whereas, in some contexts, GSK-3 inhibition promotes 
retention of naïve pluripotency, there are signalling environments in which GSK-3 inhibition 
promotes lineage-specific (mesendoderm) differentiation. Although we have focused on 
Wnt/β-catenin and PI3K signalling, GSK-3 also plays a role in other developmentally 
important signalling pathways, such as the Hedgehog pathway [reviewed in: (Jiang and 
Hui, 2008)]. How GSK-3-mediated regulation of substrates beyond those in the Wnt and PI-
3K signalling pathways modulates ESC properties remains to be thoroughly investigated. 
Intriguingly, GSK-3 also appears to play a role in directing the expression of the de novo 
DNA methyltransferase Dnmt3a2, suggesting that GSK-3 may play a role in the regulation 
of the epigenome (Popkie et al., 2010). The role of GSK-3 in the epigenetic regulation of 
genes important for pluripotent stem cell self-renewal and differentiation is an exciting new 
direction for future studies. 
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1. Introduction 
Stem cells possess the unique ability to either propagate by self-renewal or to differentiate to 
mature tissues under the influence of appropriate molecular cues. This remarkable feature, 
also termed “stem cell potency” has been the focus of both a historical and current research 
spotlight on stem cells, and particularly the potential for human stem cells in regenerative 
medicine and organ transplantation. There are several classes of stem cells, all varying in 
degrees of pluripotency. Depending on the developmental stage from where they originate, 
stem cell potencies range from totipotency (ability to transform into all cell types), 
pluripotency (most cell types), multipotency (many cell types), oligopotency (few cell types) 
to unipotency (one cell type) (Smith, 2001). Among these, embryonic stem cells (ESCs) 
represent the prototypical pluripotent stem cells.  
Embryonic stem cells are localized to the inner cell mass of the developing mammalian 
blastocyst and can give rise to all future cell types and tissues of the organism. Additionally, 
a small population of embryonic stem cells is allocated to the germline (primordial germ 
cells). The evolution of these germline stem cells is different from the remaining cells which 
undergo gastrulation and give rise to the three germ layers (endoderm, mesoderm and 
ectoderm) during development (Ewen & Koopman, 2010). The survival, gonadal migration 
and proper epigenetic programming of primordial germ cells (PGCs) are major, distinct and 
early events that have an impact on future fertility and the successful transmission of 
genetic information from parent to offspring.  
Finally, stem cells found in neonatal tissues, amniotic fluid, cord blood, and adult tissues are 
categorized as adult stem cells and are usually multipotent, oligopotent or unipotent. Adult 
stem cells are clinically important due to the absence of ethical and federal restrictions on 
their use. Furthermore, they are valued for their relative abundance and accessibility in 
somatic tissues. In contrast, human embryonic stem cells have been the focus of substantial 
research and discussion because of their unique potential to differentiate into almost all 
body cell types and tissues and the relative ease with which they are propagated in cell 
culture. The search for an alternative source of pluripotent stem cells other than from 
human embryos is a much sought after goal in the stem cell research community for several 
reasons. First, diversity in stem cells sources should be explored to better understand and 
evaluate their various clinical utilities. Second, immunological matching of stem cells to 
recipients is necessary to avoid rejection in stem cell-based regenerative therapies. Hence, 
the advent of induced pluripotency and nuclear reprogramming strategies have been well 
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received as alternatives to derive human stem cells (Yamanaka & Blau, 2010). Finally, the 
derivation and use of stem cells require adherence to moral, ethical and political guidelines 
that are constantly changing. This chapter will review the formation of the human germline 
from embryonic stem cells and the subsequent derivation of gametes from mouse and 
human pluripotent stem cells, with an emphasis on the male germline.  
1.1 Mouse and human embryonic stem cells 
The first forays into understanding pluripotency in the mammalian embryo began with rather 
simple experiments in which pieces of mouse germ cell tumors known as teratocarcinomas 
were grown in culture and a variety of pluripotent cell types emerged (Solder, 2006). One cell 
type, termed Embryonal Carcinoma Cells (ECCs), produced all three germ layers as well as the 
original tumorigenic cells when isolated and transplanted into host mice. This established for 
the first time the pluripotent nature of embryonic cells. In the mouse pre-implantation embryo, 
embryonic stem cells (mESCs) first form within the inner cell mass (ICM). In studies by Evans 
and Kauffman and others, cells of the ICM were isolated from late blastocysts and grown in 
culture (Evans & Kaufman, 1981; Martin, 1981). These cells proliferated and demonstrated the 
capacity of self-renewal. The subsequent addition of Leukemia Inhibitory Factor (LIF) 
promoted the self-renewal of mESCs in culture by acting through the Stat3 pathway (Ying et 
al., 2008). Further studies showed that the ICM-derived cells could, if reintroduced into an 
embryo lacking an ICM, recolonize and form all three germ layers of the embryo, including the 
germline (Bradley et al., 1984). MESCs are characterized by the strong and persistent 
expression of important pluripotency genes such as Oct4, Sox2, Nanog and Tcf, among others. 
Thus, in mice, the pluripotent nature of cells derived from the inner cells mass was established 
relatively rapidly and easily than in the human. 
In the human, embryonic stem cells (hESCs) are derived in a very similar manner to mouse 
ESCs from explants of the Inner Cell Mass (ICM) of in vitro fertilized blastocysts. Thomson et 
al. first isolated hESCs from pre-implantation human blastocysts and analyzed their 
morphology and expression of pluripotency genes (Thomson et al., 1998). Although they 
express high levels of pluripotency genes, hESCs share a morphology that is more consistent 
with that of early epiblast stem cells of the mouse (mEpiSCs). Specifically, they are “flattened.“ 
In addition, they depend on basic FGF and Activin signaling for self-renewal, possess large 
nuclear to cytoplasmic ratios, and respond less favorably to single cell clonability in contrast to 
mESCs (Vallier et al., 2005, 2009). While the TGFβ/Activin/Nodal signaling pathways are 
undoubtedly important for hESC pluripotency, the molecular mechanisms underlying these 
observations have yet to be explained. Meanwhile, the transcription factors Oct4, Nanog and 
Sox2 are clearly all involved in hESC pluripotency and newer molecules such as the WNTs 
(Wingless-Type MMTV Integration Site Family Members) have been implicated to drive hESC 
self-renewal through canonical signaling pathways (Sato et al., 2004). The functions of Oct4, 
Sox2 and Nanog are regarded as indispensable for hESC self-renewal as their expression 
typically reduces when hESCs differentiate. Finally, hESCs and mESCs are similar in that they 
both express a reportoire of cell surface proteins that distinguish them from other cell types, 
including SSEA-3, SSEA-4, Tra1-60 and Tra1-81, markers that are routinely used for 
characterization of ES and iPS cell lines. 
Despite the fact that mESCs and hESCs are derived from seemingly equivalent epiblast cells 
in the blastocyst, there remains the question of whether hESCs possess as ‘naïve’ a state of 
pluripotency as do mESCs. This is because mESCs in culture behave more like the early 
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mouse epiblast and demonstrate unrestricted potential for differentiation (Hanna & 
Jaenisch, 2010). Meanwhile, hESCs share some properties with mouse epiblast stem cells 
(pluripotency) but may be more restricted than mESCs (Vallier & Pedersen, 2009). This may 
be the case because current hESC derivation methods from ICM could actually select for 
cells in a different developmental stage than that from the mouse ICM (Nichols & Smith, 
2011). Additionally, it has been observed that ESCS and embryonic germ cells (EGCs) share 
several biomarkers making it difficult to distinguish between the embryonic, pluripotent 
cells and primitive germ cells. The intimate relationship that exists between germline and 
embryonic stem cells in mice and humans is critically important to understand in the future, 
and will vastly improve current and future efforts to derive ‘artificial’ gametes.  
1.2 Nuclear reprogramming and induced pluripotency 
A set of landmark studies conducted by Yamanaka and others recently revealed that just 
four factors normally produced in the embryo are sufficient to reprogram differentiated, 
non-embryonic cells into pluripotent stem cells. This important finding bypasses many of 
the ethical issues associated with the use of human embryos, and also evades potential 
problems with immune rejection that might affect patients upon stem cells transplantation. 
The four Yamanaka reprogramming factors, Oct4, Sox2, Klf4 and c-Myc, when introduced 
into differentiated cells in excess amounts, reverses cell fate and by inducing these cells to 
revert back to a progenitor-like or ESC-like state. It is believed that this is a stochastic 
process whose mechanisms lie in the ability of these four transcription factors to induce 
epigenetic restructuring of the genome, thereby enabling expression of previously silenced 
genes (Hanna & Jaenisch, 2010). These artificially created pluripotent stem cells are termed 
induced pluripotent stem cells (iPSCs) and were first described by Takashaki and Yamanaka 
in rats in 2006 (Takahashi & Yamanaka, 2006). The same researchers also demonstrated that 
they could derive iPSCs from adult human cells, a finding subsequently confirmed by others 
(Nakagawa et al., 2008; Park et al., 2008; Takahashi et al., 2007; Yu et al., 2007).   
A major concern with iPS cells is the level of genomic disruption that occurs with viral 
delivery of the reprogramming factors using retroviral or lentiviral vectors.  Theoretically, 
these viral vectors, by integrating randomly into the host genome, may cause chromosomal 
translocations or transform reprogrammed cells into malignant cells. There are now several 
initiatives underway that seek to understand the degree of genome-wide mutations and 
changes in gene function that occur in iPSCs (Panopoulos et al., 2011). The art of generating 
pluripotent cells now involves making iPSCs with reprogramming proteins using 
techniques that both avoid the use of embryos and the downstream hazards of viral vectors. 
Additionally, it is now possible to employ just the reprogramming proteins of these factors 
without the use of viral vectors to create iPSCs (Zhou et al., 2009). Several gene delivery 
systems that have been described include employing excisable polycistronic cassettes 
(Sommer et al., 2010; Somers et al., 2010), piggyBAC introduction (Yusa et al., 2009), 
transfection and/or nucleofection of plasmids (Okita et al., 2008) and most recently, mRNA 
and miRNA delivery (Warren et al., 2010). There is also evidence that small chemicals can be 
used as agents to induce reprogramming in somatic cells (Zhu et al., 2010). Finally, direct 
reprogramming methods wherein cells from one lineage are directly trans-differentiated to 
another lineage (e.g. fibroblast to neural-like lineage) are gaining in popularity. Specifically, 
terminally differentiated cells like skin fibroblasts can be exposed to a cocktail of factors that 
simultaneously enable reversal of cell fate and induce differentiation to the second lineage 
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without the use of viral vectors to create iPSCs (Zhou et al., 2009). Several gene delivery 
systems that have been described include employing excisable polycistronic cassettes 
(Sommer et al., 2010; Somers et al., 2010), piggyBAC introduction (Yusa et al., 2009), 
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used as agents to induce reprogramming in somatic cells (Zhu et al., 2010). Finally, direct 
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(Ieda et al., 2009; Uhlenhaut et al., 2009; Vierbuchen et al., 2010). The use of human, patient-
specific iPSCs in regenerative medicine represents an exciting clinical avenue for the future, 
and will likely find application to human germ cell development. 
1.3 Ethical and technical concerns in the use of stem cells 
Among of the many ethical, technical, and safety concerns associated with the clinical 
application of stem cells, the primary concern surrounds the stem cell source. Human 
embryonic stem cells have generated the most controversy because the procedure of deriving a 
hESC line involves the sacrifice of a donated human embryo, even though the donated 
embryos most likely will be discarded (reviewed in Greely, 2006; Scott & Reijo Pera, 2008). 
Therefore, alternative sources of stem cells, such as iPSCs, which might achieve similar 
therapeutic goals, could be very valuable and bear fewer ethical issues than embryonic stem 
cells. Since one of the standard measures of a pluripotent stem cell is that it reliably forms 
teratomas when transplanted into animal models, careful long-term analysis and follow-up 
after transplantation will be needed in animal models before stem cells or directed 
differentiated cells are applied to humans. Yet, hESCs still represent the best model system 
with which to study early human development because of their differentiation potential and 
epigenetic programming and therefore remain the standard for studying stem cells properties. 
However, their suitability for transplantation studies is questionable mainly because of the risk 
of immune rejection from host human tissues (Swijnenburg et al., 2008). In contrast, patient-
autologous iPSCs are considered more suitable for clinical transplantation due to better 
immunological suitability, but their differentiation profiles, epigenetic status, and potential for 
tumor formation are far less well characterized than are hESCs (Hyun et al., 2007). Therefore, it 
is imperative that studies with hESCs continue to allow better definition of the true potential of 
all other stem cell sources, including human iPSCs. Fortunately, there is currently considerable 
research devoted to deciphering the molecular mechanisms that underlie the cell fate 
reprogramming process. In parallel, many laboratories are now developing iPSC-based 
disease models for human degenerative diseases and cancers. These in vitro studies should 
provide the research community with insight into the mechanisms of disease progression and 
illuminate avenues of therapeutic potential.  Consequently, hESCs will likely remain the “gold 
standard” stem cell type for developing basic scientific and clinical therapeutic protocols, and 
to which iPSCs and adult stem cells will be carefully compared for their therapeutic potential.   
2. Mammalian germline formation  
2.1 Primordial germ cell specification and candidate genes controlling germline 
establishment 
The establishment of early germ cells and their successful maturation are complex processes, 
and require frequent changes in physiology, location and transcriptional profile of involved 
cells. Germline establishment in mammals occurs via “inductive” signaling, in contrast to 
lower organisms such as flies and worms where the germ cell identity is transmitted via the 
inheritance of germ “plasm” (McLaren, 1999, 2000; Saitou et al., 2002). In rodents and 
humans, the first glimpses of primordial germ cell (PGC) formation are observed in the 
embryo after implantation and gastrulation, when the epiblast, endoderm, mesoderm and 
ectoderm are first established (Matsui & Okamura, 2005). At this time, in response to 
molecular cues including Bone Morphogenetic Proteins (BMP4 and BMP8a) from the yolk 
sac, a population of pluripotent stem cells is segregated from the ICM and set physically 
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apart from the extra-embryonic ectoderm or yolk sac of the embryo (Figure 1)  (Lawson et 
al., 1999; Ying 2000, 2001). While BMPs provide the inductive signal to epiblast stem cells to 
supply PGCs, it is not clear what signals control the size of the PGC founder population or 
what molecules signal the termination of PGC specification. BMPs are crucial to 
specification of PGCs due to their activation of the ALK2 receptor and Smad-1/5 signaling 
pathways, as evidenced in mice (Hayashi et al., 2002). In the human embryo, the effects of 
BMPs on germline specification are unclear because there is very limited access to early 
embryonic samples. From work in our laboratory, it appears that similar BMP protein 
pathways are activated in the human embryo during gastrulation that direct PGC 
specification (Clark & Reijo Pera, 2006, Kee et al, 2006).  
Additional mechanisms that may assist germline specification are the activation of 
pathways that either promote PGC survival and/or inhibit molecules that promote somatic 
differentiation of PGCs (Ewen & Koopman, 2010). As such, mouse and human PGCs retain 
expression of several biomarkers of pluripotency, including Oct4, Nanog and Sox2 which 
underlies their close resemblance to other pluripotent stem cells  (Clark & Reijo Pera, 2006; 
Medrano et al., 2010; Nicholas et al., 2009). Interestingly, the transcription factor Sox2 is 
expressed on both mouse and human embryonic stem cells but unlike in the mouse, human 
Sox2 expression is diminished when PGCs migrate to the fetal gonad (Perrett et al., 2008). 
Coincident with the timing of germline specification in the mouse (E7.5), PGCs near the 
extraembryonic ectoderm begin to express germ-cell specific markers such as Blimp-1 
(Prdm1 in human), Stella (Dppa3 in human), E-Cadherin, and Dazl and harbor alkaline 
phosphatase activity. Blimp-1/Prdm-1 is a transcriptional repressor whose activity is 
restricted to the germ lineage and appears to be critical for maintaining a PGC fate. There is 
strong evidence to suggest that in the mouse, Blimp-1 actively represses the somatic fate of 
PGCs by inhibiting expression of key somatic regulators during development (Ohinata et 
al., 2005; Hayashi et al., 2007). It is unclear whether Prdm-1 carries out a similar function in 
human germline formation. Once cell-cell communication has been established, the Fragilis 
(IFITIM-1 in human) and Stella/ Dppa3 genes promote further development of PGCs and 
may do so in a similar fashion as Blimp-1 in mice (Saitou et al., 2002).  
Migration of germ cells to the gonad begins at E8.5 in the mouse and during weeks 4 to 6 of 
human gestation (first trimester). At this stage, PGCs accumulating at the base of the 
allantois exit the extraembryonic ectoderm and begin migration to the developing gonads, 
also known as the genital ridge. During migration, PGCs also proliferate by undergoing 
mitosis and express a new set of biomarkers, including the CXCR4 receptor in mice and the 
proto-oncogene c-KIT and its ligand, KIT in both mice and humans (Molyneaux & Wylie, 
2004; Gomperts et al., 1994). The DAZ gene homologue, DAZL is also expressed on 
migrating PGCs. In the mouse, migratory PGCs display pseudopodia that may assist in 
movement through the hindgut and it is plausible that human germ cells behave similarly 
since they are also observed in the hindgut during migration. Various somatic tissues 
interact with PGCs during the migratory path to the gonad. It is likely therefore, that these 
tissues express molecules and factors that guide or “cue” the PGCs and help maintain their 
survival. In the mouse, several candidate molecules have been identified, including 
receptors such as β-1 Integrin and extracellular matrix components such as Collagen I 
(Chuva de Sousa Lopes et al., 2005; De Felici et al., 2005). Although migration of PGCs is less 
well understood in human development, germ cells have been histologically observed 
during the late first trimester, when they undergo migration to the hindgut (Fujimoto et al., 
1977; Gaskell et al., 2004; Goto et al., 2004). Male and female PGCs have been isolated from 
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specification of PGCs due to their activation of the ALK2 receptor and Smad-1/5 signaling 
pathways, as evidenced in mice (Hayashi et al., 2002). In the human embryo, the effects of 
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restricted to the germ lineage and appears to be critical for maintaining a PGC fate. There is 
strong evidence to suggest that in the mouse, Blimp-1 actively represses the somatic fate of 
PGCs by inhibiting expression of key somatic regulators during development (Ohinata et 
al., 2005; Hayashi et al., 2007). It is unclear whether Prdm-1 carries out a similar function in 
human germline formation. Once cell-cell communication has been established, the Fragilis 
(IFITIM-1 in human) and Stella/ Dppa3 genes promote further development of PGCs and 
may do so in a similar fashion as Blimp-1 in mice (Saitou et al., 2002).  
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Fig. 1. Developmental Cycle of Mammalian Germ Cells.  
Life cycle of the mouse and human embryo following fertilization, progressing through 
gastrulation and producing the germline. The germline develops in the gonads and 
transmits genetic information to the next generation, thus completing the cycle. Fertilization 
of oocytes by sperm promotes the formation of a 1-cell zygote that undergoes cell division 
and cleavage to form a blastocyst. The outer layer of blastocyst gives rise to the 
trophectoderm while the inner cell mass (ICM) contains embryonic stem cells (ESCs). 
During gastrulation (E7.5 in mouse; Day 15+ in human), the blastocyst cavitates and 
develops the three germ layers and the epiblast. The primordial germ cells (PGCs) are 
specified and localize near the extra-embryonic ectoderm, at the base of the allantois. Once 
PGCs are specified, they migrate to the fetal gonads and undergo sex-specific 
developmental to male and female gonocytes. Subsequently, male gonocytes undergo 
spermatogenesis while female gonocytes enter meiotic prophase I and begin oogenesis. 
Adapted from Schuh-Huerta et al., 2011. 
10-week old fetuses and were observed to express Alkaline Phosphatase (AP), a marker of 
PGCs (Goto et al., 2004). The morphology of human PGCs also resemble the rounded shape 
of mouse PGCs. Female-specific germ cells have also been visualized at the ultrastructural 
level during gonadal development in human fetuses (Motta et al., 1997). Finally, recent 
studies by Kerr et al. with human fetal gonads (testis and ovary) provide a detailed analysis 
of pluripotency and germ cell-specific markers. The germ cells of the fetal testis are Oct4 
+/Nanog +/ c-Kit+ from week 7 to 15 after which these cells become localized to the testis 
periphery. Meanwhile, the presumptive gonocytes in the week 15 testis show strong 
expression of Pumilio2 (PUM2), VASA and DAZL and express low to no pluripotency 
markers (Oct4, Nanog, c-Kit, Tra1-60, Tra1-81) (Kerr et al., 2007). In the human fetal ovary, 
as in the testis, the expression of pluripotency markers peaks by week 8 and then declines 
after week 9, as oocytes enter meiosis (Kerr et al., 2008). Interestingly, the cell surface 
markers SSEA-1 and SSEA-4 are co-expressed on the female germ cells from week 5 
onwards although only SSEA-1 is restricted to the germ cell lineage.  
Upon arrival at the genital ridge, germ cells express another germ-cell specific marker, 
VASA, a cytoplasmic protein that is implicated in translational regulation. The gene 
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encoding VASA expression, DDX4 (Mvh in mouse) is highly conserved among species and 
is expressed exclusively in both male and female pre-meiotic germ cells (Gustafson & 
Wessel, 2010). This finding underlines the importance of the VASA protein in germline 
function and makes it an attractive candidate for further study. Along with VASA, other 
factors produced are germ cell nuclear antigen-1 (GCNA-1) and E-cadherin. The sex-specific 
character of the developing gonad is controlled by the chromosomal constitution of gonadal 
somatic cells. In particular, the SRY gene expressed on the Y chromosome in mammals is 
thought to be an essential regulator of various downstream targets including the Sox9 gene 
that controls male gonadal development (McLaren, 1995, 2003). Once within the gonad, 
germ cells associate with Sertoli cells to form testis cords and this interaction induces the 
expression of VASA in post-migratory PGCs. VASA expression is induced in both male and 
female PGCs and persists until these cells enter meiosis and after which its levels diminish 
(Castrillon et al., 2000; Toyooka et al., 2000).  
During germline development, an extensive remodeling of the epigenetic landscape occurs. 
This takes place during embryogenesis and during PGC migration to the gonad (Nicholas et 
al, 2009). The first wave of epigenetic remodeling occurs during implantation of the 
blastocyst and involves the erasure of all DNA methylation at CpG islands except those at 
imprinted gene loci. This transition is observed in all cells of the embryo, including the 
primitive germline. In female PGCs, there is another level of epigenetic change in the form 
of random X inactivation wherein one copy of the X chromosome pair is silenced. The 
second wave of epigenetic remodeling occurs when PGCs migrate to the primitive gonads 
and their paternal or maternal imprinted loci undergo a gradual process of erasure (Hajkova 
et al., 2002; Yamazaki et al., 2003). This phase occurs only in germ cells and may help to 
prime them for sex-specific DNA remethylation, when their developmental programs are 
established (Durcova-Hills et al., 2006). In the mouse, the re-establishment of imprints takes 
place prior to birth in the male prospermatogonia (E15) and only after birth in oocytes 
(Lucifero et al., 2002). In addition to DNA methylation changes, male and female germ cells 
also undergo post-translational histone modifications and RNA-mediated silencing 
(Reviewed in Tasler, 2009 & Nicolas et al., 2009).  
The successful passage of germ cells through meiosis is a unique and highly rigorous 
process. However, between male and female embryos, the timing of meiosis is different. 
Male germ cells are restricted from entering meiosis while female germ cells enter meiosis 
within the embryo. Although the mechanisms for these contrasting behaviors are unclear, it 
appears that the gonadal cells provide the signal for (or against) meiotic entry (Brennan & 
Capel, 2004; Ewen & Koopman, 2010). One signal could be retinoic acid (RA) produced in 
the fetal ovary, which in turn induces Stra8, a key regulator of meiotic entry. In female germ 
cells destined to become oocytes, mitotic divisions cease and meiotic prophase begins with 
the correct stimuli (Borum, 1961); eventually oocytes arrest during Meiosis I prior to fetal 
birth and will only resume meiosis upon receiving hormonal signals during adulthood 
(Peters, 1970). Meanwhile, male germ cells transition from primordial status to the gonocyte 
stage, stop proliferating and remain quiescent in the fetal seminiferous tubules until after 
birth. The post-natal gonocytes then commit to a spermatogonial stem cell (SSC) fate and 
amplify through self-renewal or enter meiosis to initiate spermatogenesis. In both male and 
female germ cells, the synaptonemal complex proteins (SCPs) SCP-1, SCP-2 and SCP-3 are 
critical components of the meiotic machinery during chromosomal segregation (Chuma et 
al., 2001; Parra et al., 2004; Yuan et al., 2000). The completion of meiosis signals that germ 
cells have matured into haploid male and female gametes. At this stage, oocytes exclusively 
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encoding VASA expression, DDX4 (Mvh in mouse) is highly conserved among species and 
is expressed exclusively in both male and female pre-meiotic germ cells (Gustafson & 
Wessel, 2010). This finding underlines the importance of the VASA protein in germline 
function and makes it an attractive candidate for further study. Along with VASA, other 
factors produced are germ cell nuclear antigen-1 (GCNA-1) and E-cadherin. The sex-specific 
character of the developing gonad is controlled by the chromosomal constitution of gonadal 
somatic cells. In particular, the SRY gene expressed on the Y chromosome in mammals is 
thought to be an essential regulator of various downstream targets including the Sox9 gene 
that controls male gonadal development (McLaren, 1995, 2003). Once within the gonad, 
germ cells associate with Sertoli cells to form testis cords and this interaction induces the 
expression of VASA in post-migratory PGCs. VASA expression is induced in both male and 
female PGCs and persists until these cells enter meiosis and after which its levels diminish 
(Castrillon et al., 2000; Toyooka et al., 2000).  
During germline development, an extensive remodeling of the epigenetic landscape occurs. 
This takes place during embryogenesis and during PGC migration to the gonad (Nicholas et 
al, 2009). The first wave of epigenetic remodeling occurs during implantation of the 
blastocyst and involves the erasure of all DNA methylation at CpG islands except those at 
imprinted gene loci. This transition is observed in all cells of the embryo, including the 
primitive germline. In female PGCs, there is another level of epigenetic change in the form 
of random X inactivation wherein one copy of the X chromosome pair is silenced. The 
second wave of epigenetic remodeling occurs when PGCs migrate to the primitive gonads 
and their paternal or maternal imprinted loci undergo a gradual process of erasure (Hajkova 
et al., 2002; Yamazaki et al., 2003). This phase occurs only in germ cells and may help to 
prime them for sex-specific DNA remethylation, when their developmental programs are 
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place prior to birth in the male prospermatogonia (E15) and only after birth in oocytes 
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Male germ cells are restricted from entering meiosis while female germ cells enter meiosis 
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appears that the gonadal cells provide the signal for (or against) meiotic entry (Brennan & 
Capel, 2004; Ewen & Koopman, 2010). One signal could be retinoic acid (RA) produced in 
the fetal ovary, which in turn induces Stra8, a key regulator of meiotic entry. In female germ 
cells destined to become oocytes, mitotic divisions cease and meiotic prophase begins with 
the correct stimuli (Borum, 1961); eventually oocytes arrest during Meiosis I prior to fetal 
birth and will only resume meiosis upon receiving hormonal signals during adulthood 
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stage, stop proliferating and remain quiescent in the fetal seminiferous tubules until after 
birth. The post-natal gonocytes then commit to a spermatogonial stem cell (SSC) fate and 
amplify through self-renewal or enter meiosis to initiate spermatogenesis. In both male and 
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express GDF9 and spermatocytes express TEKT1. However, one feature that distinguishes 
human and mouse germline differentiation is the synchronization of meiotic entry, as in 
human fetal gonads, one can observe both pre-meiotic and meiotic germ cells in close 
proximity (Anderson, 2007).     
Significant efforts have been made to culture mouse and human PGCs and gonocyes in vitro. 
In the case of mouse germ cells, the addition of endogenous factors known to affect germ 
cell development such as BMPs, RA, LIF and Forskolin have produced mixed results in 
maintaining PGCs in culture. For example, adding LIF enhanced PGC survival but the 
observations with the use of other factors not as clear. PGCs may also behave erratically in 
culture (showing low survival rates and non sex-specific behavior) because of the lack of a 
normal somatic environment (Childs et al., 2008). Studies of PGCs by Shamblott et al., 
Turnpenny et al. and Tu et al. with fetal human gonocytes resulted in a mixture of cellular 
phenotypes. Some gonocytes appeared rounded while others took on an elongated or 
‘spindly’ appearance. In addition, they appeared to have different proliferation rates 
(Shamblott et al., 1998; Turnpenny et al., 2003; Tu et al., 2007). Currently, it is not at all clear 
that these cells resemble their germ cell counterparts in vivo, but improvements in culture 
conditions and the cellular microenvironment will certainly help in this regard. 
2.2 Spermatogenesis and early oogenesis 
As delineated earlier, mammalian germ cells populate the testis and ovary during 
development in a incredibly dynamic manner. During early prenatal mice and human embryo 
development, PGCs migrate to the primitive gonad (gonadal ridge) and associate with Sertoli 
cells to form primitive testicular cords (Brennan et al., 2004). Within the testicular cords, the 
primitive germline stem cells (now termed gonocytes) remain in the testis as the gonad 
differentiates. Eventually, Sertoli cells, peritubular myoid cells and gonocytes form more 
compact structures known as the seminiferous tubules. When the gonocytes migrate to the 
periphery of the tubules, they transform into prospermatogonia and then into spermatogonia 
(Gondos & Hobel, 1971). In the fetal testis, prospermatogonia enter mitotic arrest, a feature 
observed at E12.5 to E14.5 in the mouse. At the molecular level, during entry into meiosis, both 
male and female human gonocytes express DAZL proteins and Vasa transcripts and 
downregulate OCT3/4 expression (Anderson et al., 2007). Interestingly, it is the early 
migrating germ cells that share similar properties with embryonic stem cells and testicular 
germ cell tumors (Ezeh et al., 2005). From what is known, the development of gonocytes in the 
fetal ovary follows a similar path in that OCT3/4 expression is reduced while VASA, Germ 
Cell Nuclear Antigen (GCNA) and DAZL are expressed (McLaren, 2003). In contrast to the 
male gonocytes, the female gonocytes receive sex-specific signals from the fetal gonad to enter 
meiotic prophase. After initiating meiosis, the female gonocytes will develop into primordial 
follicles and subsequently into primary follicles at puberty. A key difference between mouse 
and human systems is the timing of primary follicle formation: the mouse achieves this stage 
at birth while in the human ovary, this occurs at puberty (Bukovsky et al., 2005). There is some 
speculation whether this difference in follicle development is due to autocrine signals 
produced from the oocyte itself or from the ovarian environment (Hutt & Albertini, 2007). A 
plausible hypothesis is that the immediate environment of early germ cells determines 
whether they are commit to spermatogenesis or oogenesis. The most obvious source of signals 
are the mesonephros, primitive Sertoli cells in the testis, and primitive Granulosa cells in the 
ovary.     
 




Fig. 2. Timeline of Germline Specification and Germ Cell Marker Expression. A temporal 
representation of the stages of human and mouse germline differentiation in vivo. At each 
cellular stage, important molecular and somatic signals controlling that stage are indicated 
above the diagram. Specific germ cell molecular markers are indicated on left with arrows 
depicting the duration of development during which they expression has been observed. 
Genes that are italicized are present in both mouse and human germ cells. At the bottom, an 
approximate timing of each stage during mouse or human germline development is 
indicated. Adapted from Schuh-Huerta & Reijo Pera, 2011. 
 The seminiferous tubule serves as the sperm production center, where approximately 123 x 
106 spermatozoa are produced from germ cells daily, or about 1000 sperm/second (Amann 
et al., 1980; Rooij, 2009). Developing germ cells are arranged along the basement membrane 
in a highly ordered sequence and extend into the lumen of the tubule. At the most basal 
portion of the tubules lies the spermatogonial stem cell (SSC) population, closely associated 
with the adjacent Sertoli cells. Morphologic analysis of the various germ cells reveals at least 
13 recognizable germ cell types in the human testis (Heller & Clermont, 1963, 1964). Each 
cell type is thought to represent a different step in spermatogenesis. From the least to the 
most differentiated, they have been named dark type A spermatogonia (Ad); pale type A 
spermatogonia (Ap); type B spermatogonia (B); preleptotene (R), leptotene (L), zygotene (z) 
and pachytene primary spermatocytes (p); secondary spermatocytes (II); and Sa, Sb, Sc, Sd1, 
and Sd2 spermatids (Figure 3). The early, type A spermatogonia are the most interesting 
germ cell type from a stem cell point of view (Rooij, 2009). In fact, time-course studies using 
GFP-based reporters with early type A, type Ad and type Ap spermatogonia in the mouse 
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revealed that the early type A cell has the ability to divide, self-renew, and give rise to the 
Ad and Ap sun-populations (Nakagawa T. et al., 2007). These observations provide 
evidence for the existence of SSCs in the testis and their clonal behavior is protypical of 
other adult stem cells. 
It is currently thought that pale type A (Ap) spermatogonia in the basal, stem cell niche of 
the seminiferous tubule divide at 16-day intervals and differentiate to type B spermatogonia, 
which then become spermatocytes (Clermont, 1972). The ability of SSCs within the testis 
stem cell niche to undergo stem cell renewal is governed by several known factors. The 
growth factor-receptor kit ligand/c-kit receptor system and the niche factor glial cell line-
derived neurotrophic factor (GDNF) are important in this process (Oatley & Brinster, 2008). 
In fact, spermatogenesis in the rat is dependent on c-Kit receptor activity, whereas 
spermatogonial stem cell renewal may be c-kit independent (Dym, 1994). GDNF appears to 
provide a significant stimulus to self-renewal of SSCs through receptors for GDNF on SSCs 
such as c-Ret and GFR-1(Meng et al., 2000). Despite this, our knowledge of other receptor-
ligand systems that control human SSC renewal is limited at this point. During 
spermatogenesis, the cytoplasm between spermatogonial daughter cells remains conjoined 
after mitosis, forming cytoplasmic bridges between adjacent cells (Ewing et al., 1980). 
Cytoplasmic bridges are thought to be important for synchronized cellular proliferation, 
differentiation, and possibly regulation of gene expression. Thus, SSCs and early 
spermatogonia in the adult testis are critical for germ cell renewal and differentiation into 
sperm and raise important questions about the source of proliferative and differentiation 
signals for spermatogenesis. The majority of stages in mouse spermatogenesis delineated 
above are translatable to the human germ cell development pathway except for differences 
in the timing of each stage during development.   
                   
 
Fig. 3. Cells of the Human Germ Line Sequence. See text for details. With permission from 
Kee et al, 2009. 
3. Germline stem cells 
Under the premise that male and female gametes must be replenished, several investigators 
have queried the existence of elusive germline stem cells. Additionally, the pluripotency 
potential of embryonic germ cells and their similarity to mESCs has fueled the speculation 
about the existence of spermatogonial stem cells and their true differentiation potential both 
in vivo and in vitro. There is compelling data proving the existence and plasticity of testicular 
germline stem cells in the mouse and more recently the human testis. The exploration of 
germline stem cells in the human ovary has been confusing because of findings that 
challenged the long-held notion that females are endowed with a finite supply of oocytes. 
For instance, Johnson and colleagues observed that a small population of germline stem 
cells (GSCs) reside in the ovarian surface epithelium in the mouse and can undergo self 
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renewal of the follicular pool within 24 hours (Johnson et al., 2004). However, these results 
have not been corroborated (Telfer et al., 2005). Johnson et al. reported that bone marrow 
stem cells enter the ovarian follicular pool through the vasculature and could provide a 
source for ovarian stem cells (Johnson et al., 2005). Despite the proof of successful 
transplantation in this study, they failed to demonstrate meiosis in the oocytes generated 
from ovarian stem cells or bone marrow-derived stem cells (Telfer et al., 2005). Furthermore, 
it was not clear whether these ovarian stem cell-derived oocytes could be artificially 
fertilized. Based on these findings, the existence of germline stem cells in the adult ovary 
remains unknown.   
3.1 Testicular stem cells in animal models 
Evidence for stem cells in the adult testis was first provided by Brinster and colleagues in 
1994 when they transplanted a putative SSC population into mice and observed complete 
spermatogenesis with transplanted cells (Brinster RL & Zimmermann JW, 1994). Recent 
research has sought to characterize the true stem cell potential of early spermatogonia 
within the seminiferous tubule. Kanatsu-Shinohara et al first reported the generation of 
pluripotent stem cells from the mouse testis (Kanatsu-Shinohara et al., 2004). In their study, 
a population of cells termed germ line stem cells (GSCs) were isolated from neonatal mouse 
testis and propagated in culture (Kanatsu-Shinohara et al., 2003). Subsequently, they found 
that cell colonies with morphology quite distinct from GSCs, termed ESC-like cells, also 
appeared in culture. The formation of both GSCs and ESC-like cells depended on a GDNF 
signal and only ES-like cells expanded in regular mESC media. The expression profile and 
imprinting profiles indicated that the ES-like cells were more like ESC than GSCs. The 
definitive test of pluripotency or multipotency in stem cells is to transplant them and assess 
their ability to form all three germinal layers. In the case of spermatogonial stem cells or 
their transformed cell types, the ability to form germinal layers and sperm was tested 
following transplantation. Interestingly, transplantation of ESC-like cells into seminiferous 
tubules gave rise to teratomas while GSC transplants led to spermatogenesis without 
teratomas. When ESC-like cells were transplanted via subcutaneous delivery, teratomas 
containing all three germ layers formed. These ESC-like cells also had the potential to 
develop into various other cell types, including mature germ cells, showed chimera 
formation and germ line transmission. More recently, a study by Simon et al. revealed that 
when putative mouse SSCs were recombined with organs of fetal or neonatal origin, these 
cells had the ability to transdifferentiate into cells of all three germ layers as well as uterine, 
prostatic and skin epithelia (Simon et al., 2009). Thus, these experiments in rodents reveal 
that GSCs and ESC-like cells have very different stem cell characteristics. Unlike with 
neonatal testis, the authors were unable to generate ESC-like cells from adult mouse adult 
testis.  
A major finding was reported in 2006 by Guan et al. wherein they successfully derived 
pluripotent stem cells from the adult mouse testis (Guan et al., 2006). With the introduction 
of a Stra8-eGFP reporter in which GFP expression was regulated by Stra8 promoter activity, 
ES-like cells were separated from a heterogenous population of testicular cells. When these 
isolated ES-like cells were grown on mouse embryonic fibroblasts or cultured in medium 
containing LIF, they evolved into a subpopulation of cells that the authors termed 
multipotent adult germline stem cells (maGSCs). The pluripotency potential of maGSCs was 
verified by RT-PCR, in vitro differentiation to all three somatic germ layers, and by 
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revealed that the early type A cell has the ability to divide, self-renew, and give rise to the 
Ad and Ap sun-populations (Nakagawa T. et al., 2007). These observations provide 
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renewal of the follicular pool within 24 hours (Johnson et al., 2004). However, these results 
have not been corroborated (Telfer et al., 2005). Johnson et al. reported that bone marrow 
stem cells enter the ovarian follicular pool through the vasculature and could provide a 
source for ovarian stem cells (Johnson et al., 2005). Despite the proof of successful 
transplantation in this study, they failed to demonstrate meiosis in the oocytes generated 
from ovarian stem cells or bone marrow-derived stem cells (Telfer et al., 2005). Furthermore, 
it was not clear whether these ovarian stem cell-derived oocytes could be artificially 
fertilized. Based on these findings, the existence of germline stem cells in the adult ovary 
remains unknown.   
3.1 Testicular stem cells in animal models 
Evidence for stem cells in the adult testis was first provided by Brinster and colleagues in 
1994 when they transplanted a putative SSC population into mice and observed complete 
spermatogenesis with transplanted cells (Brinster RL & Zimmermann JW, 1994). Recent 
research has sought to characterize the true stem cell potential of early spermatogonia 
within the seminiferous tubule. Kanatsu-Shinohara et al first reported the generation of 
pluripotent stem cells from the mouse testis (Kanatsu-Shinohara et al., 2004). In their study, 
a population of cells termed germ line stem cells (GSCs) were isolated from neonatal mouse 
testis and propagated in culture (Kanatsu-Shinohara et al., 2003). Subsequently, they found 
that cell colonies with morphology quite distinct from GSCs, termed ESC-like cells, also 
appeared in culture. The formation of both GSCs and ESC-like cells depended on a GDNF 
signal and only ES-like cells expanded in regular mESC media. The expression profile and 
imprinting profiles indicated that the ES-like cells were more like ESC than GSCs. The 
definitive test of pluripotency or multipotency in stem cells is to transplant them and assess 
their ability to form all three germinal layers. In the case of spermatogonial stem cells or 
their transformed cell types, the ability to form germinal layers and sperm was tested 
following transplantation. Interestingly, transplantation of ESC-like cells into seminiferous 
tubules gave rise to teratomas while GSC transplants led to spermatogenesis without 
teratomas. When ESC-like cells were transplanted via subcutaneous delivery, teratomas 
containing all three germ layers formed. These ESC-like cells also had the potential to 
develop into various other cell types, including mature germ cells, showed chimera 
formation and germ line transmission. More recently, a study by Simon et al. revealed that 
when putative mouse SSCs were recombined with organs of fetal or neonatal origin, these 
cells had the ability to transdifferentiate into cells of all three germ layers as well as uterine, 
prostatic and skin epithelia (Simon et al., 2009). Thus, these experiments in rodents reveal 
that GSCs and ESC-like cells have very different stem cell characteristics. Unlike with 
neonatal testis, the authors were unable to generate ESC-like cells from adult mouse adult 
testis.  
A major finding was reported in 2006 by Guan et al. wherein they successfully derived 
pluripotent stem cells from the adult mouse testis (Guan et al., 2006). With the introduction 
of a Stra8-eGFP reporter in which GFP expression was regulated by Stra8 promoter activity, 
ES-like cells were separated from a heterogenous population of testicular cells. When these 
isolated ES-like cells were grown on mouse embryonic fibroblasts or cultured in medium 
containing LIF, they evolved into a subpopulation of cells that the authors termed 
multipotent adult germline stem cells (maGSCs). The pluripotency potential of maGSCs was 
verified by RT-PCR, in vitro differentiation to all three somatic germ layers, and by 
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successful teratoma formation in vivo. Another transplantation study by Nakagawa et al. in 
2007 employed the Neurog3 (Ngn3) promoter to induce GFP expression and thereby enrich 
for two populations of undifferentiated spermatogonia (Nakagawa T. et al., 2007). The 
researchers took advantage of the expression of NGN3 on undifferentiated spermatogonia 
and, from their sorting studies, the first population of cells maintained the SSC progenitor 
pool through self-renewal while the second population revealed a pool of SSCs that 
diminished with age. More importantly, the study by Nakagawa and colleagues suggested 
that the population of SSCs in mice testes is ~2000 cells, substantially less than previous 
estimates of ~35000 cells (Nakagawa T. et al., 2007). A population of pluripotent stem cells in 
the adult mouse testis was again confirmed by Ko et al. in 2009. The authors showed that 
GSCs obtained from the adult mouse testis traverse through unipotency before conversion 
into multipotent ESC-like cells (Ko et al., 2009). They concluded that that the number of 
GSCs and culture duration are defining factors in deriving pluripotent stem cells from the 
germline: they termed these cells germline-derived pluripotent stem cells (gPSCs). In 
characteristic fashion of ESC-like cells, gPSCs demonstrated in vitro differentiation to all 
three somatic cell layers, teratoma formation and germ line transmission. Thus, several 
reports have documented the production of multi- or pluripotency germline stem cells in 
the mouse. 
In parallel to these studies of mice multipotent germline stem cells, several groups have 
reported a collection of genes and biomarkers that are non-exclusively expressed by mouse 
SSCs (Reviewed in Caires et al., 2010). These include receptors and downstream facilitators 
of GDNF action such as GFR1 and RET proteins (Naughton et al., 2006). The gene Ngn3 is 
also highly expressed on undifferentiated spermatogonial stem cells (Yoshida et al., 2004).  
The signaling activities of the PI3 Kinase family acting through AKT proteins are also 
important for SSC self-renewal because blocking these pathways suppresses GDNF activity 
and reduces spermatogenesis in mice (Oatley et al., 2006). Other molecules expressed on 
SSCs are Oct4, Bclb6, Etv5, Lhx1 and Nanos2 (Caires et al., 2010). In the future, we hope to 
employ these markers to more accurately isolate and definitively characterize putative SSC-
like cells.  
3.2 Testicular stem cells in the human 
Based on the success in the adult rodent testes, several investigators have attempted the 
same types of studies in the human. In a landmark study, Conrad and colleagues devised a 
method by which they could harvest adult spermatogonial stem cells and subsequently 
reprogram them into pluripotent cells (Conrad et al., 2008). They employed the use of adult 
testis tissue from which they harvested a mixed cell population. The single cell suspension 
was then cultured in vitro in the presence of GDNF, as mouse studies have shown this 
growth factor to be critical for self-renewal of SSCs. They then purified SSCs by magnetic-
activated cell separation (MACS) with CD49f bound beads. Further selection on collagen 
and laminin plates led to a highly enriched population of spermatogonial cells. When 
cultured in the same media used for hESCs and supplemented with LIF, the spermatogonial 
cells gradually arranged in multilayered, clustered colonies and displayed features 
consistent with pluripotent stem cells. The researchers termed these cells human adult 
germline stem cell (haGSC). Extensive characterization of haGSCs was then carried out by 
analyzing gene and protein expression and conducting microarray analysis for genome-
wide changes in expression. Epigenetic reprogramming was assessed and various 
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pluripotency markers were measured. Finally, the cells were karyotyped and a teratoma 
formation assay was successful in immunodeficient mice (Conrad et al., 2008). Overall, the 
authors observed significantly different expression profiles in haGCSs compared to the 
parent spermatogonial cells, and haGSCs acquired expression profiles similar to hESCs. 
Although a complete analysis of a novel cell population in the human testis, several caveats 
to this research exist. Entire testicles were used to derive spermatogonial cells, bringing into 
question the feasibility of this approach for clinical use (Kee et al., 2010). In addition, the 
global gene expression patterns of plurpotency markers obtained from these haGSCs have 
been challenged as being more closely associated with fibroblasts than hESCs (Ko et al, 
2010). Nevertheless, the above experiments underline the concept that adult germline stem 
cells and by extension PGCs may share basic properties with hESCs. 
To address the issue of limited availability of starting material, an alternative protocol for 
generating human pluripotent stem cells was reported by Kossack et al., 2009. Their 
approach required only a testis biopsy as starting substrate. The biopsies were 
enzymatically digested and testicular cells released in suspension were grown in basic 
media until small colonies of cells began to form. Selection for cells in colonies was 
performed by manually dissecting out colonies and then propagation on mouse embryonic 
fibroblasts (MEFs) in hESC culture conditions, supplemented with bFGF. Under these 
conditions, the spermatogonial cells acquired a hESC-like morphology and physical 
characteristics, and were termed human multipotent adult germline stem cells (hMGSCs). 
Careful analysis revealed that hMGSCs were karyotypically nomal, expressed both 
pluripotency and early germ cell markers and contained a generally hypomethylated DNA 
pattern consistent with hESCs rather than somatic cells. Albeit spontaneously differentiating 
to cells of endodermal, mesodermal, and ectodermal lineages, hMGSCs did not successfully 
form teratomas in vivo. Therefore, despite a simpler methodology using limited substrate, 
this study suggested that hMGSCs, unlike true hESCs, might be only multipotent and not 
fully pluripotent. A third study also used testicular tissue fragments as a cell source from 
which to separate spermatogonial stem cells (Golestaneh et al., 2009). Using 1g of testicular 
tissue, much larger than routine testis biopsy, they also derived pluripotent stem cells after 
isolated seminiferous tubules were enzymatically digested and grown in hESC media 
(supplemented with bFGF and TGF-β but not grown on MEF feeders). After several 
passages, they observed medium-sized colonies of ~500 cells which were termed ESC-like 
cells. As expected, these cells expressed pluripotency markers and they were able to 
differentiate to endoderm, mesoderm, and ectoderm. Similar to the finding of Kossack et al, 
only small teratomas formed from the transplanted ES-like cells, and only when large cell 
numbers (~2x106) were used. Thus, this study also suggests that the pluripotency of these 
ES-like cells may not be identical to true hESCs.  
As eluded to above, a major limitation of deriving SSCs is the requirement for generous 
amounts of human testicular tissue as starting substrate. Protocols need to be refined to 
allow pluripotent stem cell generation from the smallest amount of testis tissue substrate to 
make this technology feasible for clinical use. Another limitation is the low efficiency of 
isolating SSCs from testis tissue and of generating pluripotent stem cells from SSCs. 
Optimization of culture conditions may reduce these inefficiencies in the future. Despite 
this, research over the last decade has uniquely highlighted the stem cell potential of SSCs 
derived from the human testis and their remarkable similarity to the differentiation 
potential of ESCs. A major drawback has been the inability of the SSCs to consistently 
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successful teratoma formation in vivo. Another transplantation study by Nakagawa et al. in 
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pluripotency markers were measured. Finally, the cells were karyotyped and a teratoma 
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passages, they observed medium-sized colonies of ~500 cells which were termed ESC-like 
cells. As expected, these cells expressed pluripotency markers and they were able to 
differentiate to endoderm, mesoderm, and ectoderm. Similar to the finding of Kossack et al, 
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make this technology feasible for clinical use. Another limitation is the low efficiency of 
isolating SSCs from testis tissue and of generating pluripotent stem cells from SSCs. 
Optimization of culture conditions may reduce these inefficiencies in the future. Despite 
this, research over the last decade has uniquely highlighted the stem cell potential of SSCs 
derived from the human testis and their remarkable similarity to the differentiation 
potential of ESCs. A major drawback has been the inability of the SSCs to consistently 
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produce large teratomas. This likely indicates that SSCs are only multipotent and not 
pluripotent (Kee et al., 2009), a distinction that has implications for the therapeutic potential 
of SSCs. Will they only be useful for obtaining sperm or will they have a broader potential 
for cell-based therapies in unrelated target tissues? Finally, the relatively invasive procedure 
for isolation of adult human germline stem cells from the testis compared to derivation of 
iPSCs may favor the latter approach as a preferred methodology for clinical use.    
3.3 Azoospermia and genetic control of spermatogenesis 
Human infertility is remarkably common, affecting 10-15% of couples. Most commonly, 
infertility is caused by defects in germ cell development (de Kretser, 1997; Skakkebaek et 
al., 1994). Microdeletions in the AZF (Azoospermia Factor) region of the human Y 
chromosome are the most common cause of human infertility and Non-Obstructive 
Azoospermia (NOA) in men. The associated clinical phenotypes are typically 
azoospermia or severe oligospermia, and on diagnostic testis biopsy reveal the complete 
absence of the germ cell lineage, to maturation arrest of spermatogenesis, to the 
production of a small number of germ cells (Gonzalves et al., 2005). The AZF region is 
highly repetitive and consists of numerous palindromic regions thought to have arisen 
out of repeated rounds of gene duplication and inversion (Kuroda-Kawaguchi et al., 2001; 
Skaletsky et al., 2003). The highly repetitive nature of the AZF region makes it particularly 
prone to homologous recombination between direct repeats and resulting in deletions. 
There is now a fairly comprehensive chromosomal map of the AZF regions with three 
specific regions currently identified, AZFa, AZFb and AZFc, that represent multi-gene 
segments on the Y chromosome (Kuroda-Kawaguchi et al., 2001).  The most commonly 
deleted of these three is the AZFc region, resulting in phenotypes that range from 
complete absence of the germ cell lineage (termed Sertoli Cell Only [SCO] syndrome) to 
oligospermia (Reijo Pera, 1995, 1996). In spite of their deletion frequency, the function of 
genes that map to the Y chromosome AZFc are still poorly understood. This region 
harbors six multi-gene families including the RBMY, PRY, VCY2, CDY1 and DAZ genes 
(Kuroda-Kawaguchi et al., 2001). Intriguingly, all of the protein-coding AZF genes are 
expressed exclusively in germ cells and some testicular cells, suggesting their importance 
in germ cell development (Navarro-Costa et al., 2010). Although precise functions have 
not been pinpointed, the predicted sequences and protein structures encoded by these 
genes provide a glimpse into their potential function. For instance, DAZ and RBMY genes 
are thought to be involved in RNA binding and transport, thereby positioning them as 
regulators of mRNA translation during spermatogenesis (Collier et al., 2005; Kee et al., 
2009; Lee et al., 2006). Meanwhile, CDY and BPY2 genes are likely regulators of chromatin 
and genome organization (Caron et al., 2003; Lahn et al., 2002). Our overall understanding 
of infertility genetics will be greatly advanced by studying the molecular contribution of 
genes such as DAZ to meiotic recombination, DNA repair, epigenetic reprogramming and 
the development of cancer and other clinical aberrations.  
4. From embryonic stem cells to germ cells 
Our knowledge about mouse embryo and germline development from mESCs has allowed 
for in vivo and in vitro modeling of germline development. However,  very limited access to 
early-stage human embryos and especially primordial human germ cells has greatly 
reduced the ability to conduct similar investigations into human germline development, let 
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alone modelling it in vitro. This section reviews the highlights of experiments conducted 
during the last decade using in vitro model systems of mouse and human germline 
development from mESCs and hESCs (Table 1).  
 
 
Table 1. A Summary of the Recent Efforts to Derive Gametes from ESCs and iPSCs. Note: 
mESC – mouse embryonic stem cells; hESC – human embryonic stem cells; EB – embryoid 
body; BMP – bone morphogenetic protein; Mvh – mouse Vasa homolog; RA – retinoic acid; 
ICSI – intracytoplasmic sperm injection; MEF – mouse embryonic feeders. 
4.1 Derivation of germ cells from mouse and human embryonic stem cells 
The mouse has proven to be a robust and dependable system for analysis of germline 
development. Studies conducted in vivo during mouse early development have greatly 
informed in vitro investigations and have generated promising prospects for creating 
gametes from stem cells. The earliest in vivo evidence for embryonic stem cell-derived germ 
cells was suggested from experiments performed by Bradley et al. in 1984. They generated 
germline chimeras after injecting mESCs into blastocysts (Bradley et al., 1984). This work 
suggests that mESCs, if cultured under the right conditions, could be differentiated to PGCs. 
We now know that mESC share many developmental features and markers with PGCs 
which further supports the use of mESCs as a starting point. This is most convenient as 
mouse PGCs are difficult to grow and differentiate in vitro due to limited viability in culture 
(Resnick et al., 1992; Farini et al., 2005). Thus, we have learned a lot over the two decades 
about mouse embryonic and germ cell development to guide us as we more forward. 
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The first report on the creation of putative germ cells in vitro was reported in 2003. In this 
study, mESCs were transfected with a reporter Green Fluorescent Protein (GFP) under the 
control of an Oct4 enhancer sequence (Hubner et al., 2003). The withdrawal of LIF, a factor 
that promotes self-renewal in mESCs, promoted PGC development and resulted in an 
increase in GFP-positive cells. More importantly, the GFP-positive cells assumed a follicle-
like appearance and showed overall structural and molecular similarities to oocytes. 
Tooyaka et al. used a similar, reporter-based approach to derive male germ cells that 
resembled mouse spermatozoa (Tooyaka et al., 2003). They utilized the mouse VASA 
homologous gene promoter Mvh to drive GFP expression in mESC, which then 
spontaneously differentiated to embryoid bodies (EBs) in the absence of LIF. The putative 
PGC population when transplanted into a mouse neonatal testis, differentiated to give rise 
to spermatozoa.  These two landmark studies set the stage for further investigation of 
deriving gametogenesis from mESC.  
In 2004, Geijsen et al. derived male gametes from EBs after culture in the presence of retinoic 
acid (RA), a key paracrine factor produced in the testis (Geijsen et al., 2004). Additionally, by 
selecting cells that only expressed SSEA-1 and Oct4, the authors were able to enrich for 
mature, post-meiotic germ cells that were then capable of forming blastocytes after injection 
into oocytes. It was later shown by Kerkis et al. that the divergence of male and female germ 
cell programs during spontaneous differentiation of EBs in vitro was dependent on the 
length of culture time (Kerkis et al., 2007).   Several attempts at oocyte or follicle derivation 
from mESC have been made using the EB-based approach with various culture  and 
attachment conditions all of which yielded oocyte-like cells that lacked critical structural 
features such as the zona pellucida or expression of meiotic molecular machinery (Lacham-
Kaplan et al., 2006; Novak et al., 2006). Other studies have employed slightly different 
approaches to derive putative oocytes from mESCs. Qing et al. obtained PGCs from cultured 
EBs and then co-cultured them on a layer of fetal ovarian granulosa cells and observed an 
increase in the meiotic marker SCP3 and upregulation of oocyte-specific genes such as Gdf9. 
The GDF9 positive cells probably resembled an immature oocyte as they lacked a zona 
pellucida and did not express mature oocyte proteins such as ZP4 (Qing et al., 2007). In an 
alternative approach developed by Salvador et al., a Gdf9-driven GFP reporter assay was 
introduced into mESC. The mESCs were then differentiated to EBs and GFP-positive cells 
were isolated from the EBs to isolate PGCs (Salvador et al., 2007). In summary, these studies 
may have derived primitive oocytes from mESCs, but failed to accomplish meiotic entry in 
the final cell products.  
An alternative approach to deriving female germ cells was employed by Nicholas et al. by 
using a germ cell-specific reporter, ΔPE:Oct4: GFP. This reporting system was previously 
employed by Hubner et al. to separate GFP-expressing ESCs, PGCs and primary 
spermatogonia in the mouse (Nicholas et al., 2009). After verifying the expression of GFP on 
these subsets of cells, the authors spontaneously differentiated mESCs carrying this reporter 
to EBs, then FACS-sorted GFP positive cells, and observed a higher expression of germ cell 
and oocyte markers in the selected cells. They then assessed whether ESCs could give rise to 
mature oocytes in vivo by first forming aggregates of the GFP-positive cells with fetal 
ovarian tissue and then transplanting them to the kidney capsule. In doing so, they 
observed mature oocytes of confirmed ESC origin, some of which resembled primordial 
follicles with a surrounding layer of granulosa cells. An important insight from this work 
was that the timing of germline development, particularly with oocyte maturation, is a 
major parameter in deriving gametes. Furthermore, it highlights that the use of 
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transplantation in combination with in vitro culturing may greatly improve the success of 
gamete production from mESCs.             
The first study to show virtually complete gametogenesis in vitro was conducted by 
Nayernia et al. in 2006. A two-stage approach was employed to first derive pre-meiotic 
PGCs from mESCs with a Stra8 driven GFP reporter induced with RA addition (Nayernia et 
al., 2006). GFP-positive cells were then separated by Fluorescence Activated Cell Sorting 
(FACS), grown in RA-supplemented medium and transfected with a second reporter, Prm1-
dsred. The second reporter enriched for PGCs that had undergone meiosis and formed red-
fluorescing, haploid cells. After further RA treatment, the haploid sperm-like cells were then 
injected into mouse oocytes by Intra-Cytoplasmic Sperm Injection (ICSI) to test the 
functionality of the derived germ cells. Indeed, blastocysts formed and viable offspring born 
that eventually succumbed to developmental complications and died prematurely. 
Potentially, the epigenetic reprogramming of the derived germ cells may not have been 
complete. Nevertheless, these efforts provided functional proof of gametogenesis in vitro.  
Additional studies demonstrating in vitro spermatogenesis have employed organ culture 
systems as far back as 1960. Since then, there has been tremendous progress in the study of 
germ cell development, particularly in the mouse. This is best exemplified by a very recent 
study by Sato et al. in which functional mouse sperm were generated in vitro by employing 
a novel organ culture method. Specifically, they improved on existing organ culture 
methods by placing neonatal (mouse pup) testis fragments in FBS-soaked agar plugs in 
culture (Sato et al., 2011). With these plugs, they controlled the gas:liquid interface and also 
added exogenous factors. Their study conclusively showed through an analysis of reporter 
expression before and after meiosis, that functional, haploid spermatozoa were generated 
that could fertilize oocytes and give rise to viable, healthy pups. In addition, the generated 
pups were also shown to be naturally fertile as adults. In summary, attempts to generate 
germ cells from mESCs have yielded cells that resemble sperm or oocytes in gene 
expression, ploidy, epigenetic reprogramming and fertilization ability. However, these 
studies have also revealed inregularities in the duration of meiosis in culture, in the 
morphological features of oocytes, in the viability of offspring generated and in the germline 
transmission of exogenous genes to the offspring (Chuva de Sousa Lopes et al., 2010).    
The evidence for germline differentiation from hESCs is more complex; as such literature is 
more preliminary than that from the mouse. Furthermore, doubts regarding the extent of 
pluripotency in hESCs vs. mESCs and the ethical constraints of testing the functionality of 
human germ cells are legitimate considerations with this research. Despite this, there is a 
tremendous need to understand human germline formation, the genes that control 
spermatogenesis and oogenesis and from a clinical standpoint, a need for in vitro derived 
functional gametes. Efforts to derive human germ cells began with a study by Clark et al. in 
2004 in which spontaneously differentiated hESCs were used to create embryoid bodies 
(EBs) (Clark et al., 2004). Within the EB mixed cell population, they identified the levels of 
several known germ cell markers such as DAZL, STELLAR and c-KIT. Additionally, they 
observed that VASA levels were induced within a putative PGC population and other 
markers of meiosis were also upregulated. Collectively, their data indicated that PGCs had 
formed but had not entered meiosis. An important facet of their study was the identification 
of germline-associated genes such as DAZL and c-KIT as expressed in undifferentiated 
hESCs, which reminds us that hESCs may not be truly equivalent to cells of the ICM (Clark 
et al., 2006). The methods of Clark et al. were optimized in a follow-up study in which BMP-
4, -7 and -8 were added exogenously during EB formation from hESCs and higher VASA 
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expression was observed in the putative PGC population (Kee et al., 2006). Therefore, 
similar to the mouse model, the role of BMPs in human germline specification may be 
important. More recent studies using mESCs in vitro by Young et al. have illustrated how 
BMP2 and BMP4 but not BMP8b are important inductive agents for specifying the germ cell 
lineage in EBs (Young et al., 2010). These results help to clarify our understanding of BMP 
action in the germline as the goal of deriving haploid germ cells is pursued. 
Chen et al. and Tilgner et al. also derived human PGCs from substrate EBs in independent 
studies. They observed that their EBs contained small structures that resembled ovarian 
follicles and that tested positive for c-KIT and low amounts of VASA protein (Chen et al., 
2007). They also observed these structures in hESCs that were spontaneously differentiated 
in adherent cultures, suggesting that EBs are not essential for germ cell differentiation, at 
least in the female lineage. Meanwhile, Tilgner et al. used a more sophisticated strategy to 
separate germ cells from EBs and adherent cultures through FACs sorting for cells 
expressing the surface marker SSEA-1, a protein associated with very early germ cells 
(Tilgner et al., 2008). Despite evidence of complete epigenetic reprogramming in these early 
germ cells, the authors did not observe meiosis. In 2009, Park et al. built upon the findings of 
Tilgner et al. by isolating differentiated cells enriched in SSEA-1 as well as c-KIT expression. 
However, they used an interesting differentiation strategy and co-cultured hESC colonies 
with stromal cells from the human fetal gonad (Park et al., 2009).  In this model, the 
paracrine factors produced from fetal stromal cells would ideally resemble those made in 
vivo, thereby theoretically inducing primitive germ cells to differentiate into PGCs. Their 
efforts were successful, yielding SSEA-1 /c-KIT positive PGCs that expressed numerous 
germ cell markers such as VASA, PRDM1 and DAZL and revealed evidence of partial 
epigenetic reprogramming. 
Based on the findings of spontaneous differentiation of hESCs to PGCs, researchers have 
entertained the possibility that a small population of cells within a typical hESC population 
is pre-destined to become germ cells. Based on this hypothesis, several groups have 
explored whether simply optimizing culture conditions of hESCs can promote or induce 
germline differentiation. Stice and colleagues first reported that by the simple addition of 
basic FGF (bFGF) to hESCs growing on inactivated MEF feeder cells, they could produce 
approximately 69% VASA-positive cells with increases in expression of germline and 
meiotic markers (West et al., 2008). These data seem rather optimistic given that most other 
groups have reported much lower germ cell numbers under similar culture conditions. 
Concurrently, Bucay et al. modified their culture conditions by lowering the confluency of 
hESC colonies and observed a subpopulation of cells expressing CXCR4, a membrane 
receptor implicated in PGC migration (Bucay et al., 2009). Upon purification, the CXCR4-
expressing cells could be grown on a laminin substrate and gave rise to putative PGCs and 
Sertoli cells. In recent studies, West et al. explore the effect of modulating KIT ligand (KIT-L) 
and BMP4 activities in culture of hESCs and observed that these are required for early germ-
like cell (GLC) derivation (West et al., 2010a).  
A major milestone in germline differentiation of both male and female human PGCs is the 
initiation and completion of meiosis. Deriving haploid gametes in vitro is a significant feat 
and one that researchers have struggled with for years in human germline differentiation. 
Kee and colleagues derived human haploid gametes for the first time in 2009 by introducing 
three major genes of the Deleted-in-Azoospermia (DAZ) family, DAZ, DAZL, and BOULE 
in hESCs and then differentiating the cells spontaneously in adherent culture conditions 
(Kee et al., 2009). Although a low number of haploid (1n) cells were observed (~2%) seven 
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days after differentiation, they expressed numerous germ cell-specific markers and meiotic 
spreads indicated the presence of SCP3, a key member of the synaptonemal complex that 
forms during meiosis. These data also reinforce the importance of the DAZ family of genes 
for early (DAZL) and late (BOULE, DAZ) primordial germ cell formation. Since this work 
was published, another group has demonstrated meiosis in in vitro derived PGCs: West et 
al. had previously shown that they could isolate early VASA-positive germ-like cells (GLCs) 
and were able to subclone at least three populations of these cells from their mixed cultures 
and propagate them through at least 50 serial passages (West et al., 2010b). These cells were 
then be differentiated with FBS into a more homogenous population and the majority of 
cells entered meiosis (~71%) while also expressing germline and meiotic markers (West et 
al., 2010b). Taken together, these studies offer alternative and compelling strategies for 
derivation of PGCs from hESCs. While one (West et al., 2010b) suggests that GLCs are a 
natural clonal subpopulation of hESCs that can be propagated in vitro, the other (Kee et al., 
2009) argues in favor of an active, gene-driven induction of germline differentiation.  
4.2 Germline differentiation from human induced pluripotent stem cells  
Ongoing advances in reprogramming of human somatic cell to pluripotent stem cells 
(iPSCs) or direct reprogramming of somatic cells to specific cell lineages, are a legitimate 
avenue for autologous, patient-derived stem cell therapies. By applying similar genetic 
approaches used for human ESCs, iPSCs can now be directed to give rise to cells of the germ 
cell lineage. We summarize here some of the recent efforts in this area. The use of human 
iPSCs (hiPSCs) to derive gametes was first shown by Park et al. in a study that also 
compared the derivation efficiency to hESCs (Park et al., 2009). In short, they grew hiPSCs 
on a feeder layer of fetal gonad stromal cells and subsequently isolated SSEA-1 + / c-KIT + 
cells which they characterized as a putative PGC population. These human induced PGCs 
(hiPGCs) expressed several germline markers but did not show evidence of imprinting 
erasure, a key feature of early PGCs. Further evidence for the creation of haploid hiPGCs 
from male and female hiPSCs was provided by Panula et al. recently wherein they used a 
GFP reporter under the control of the Vasa promoter to select for putative germ cells from 
spontaneously differentiated cultures (Panula et al., 2010). The Vasa-GFP transduced hiPSCs 
were differentiated adherently in feeder-free conditions in the presence of BMPs, giving rise 
to approximately 5% GFP-positive PGCs. These PGCs expressed a number of germ cell 
markers such as Prdm1A, ACTC, Gata6, Pelota and IFITM1. More importantly, the GFP-
positive hiPGCs expressed the meiotic marker SCP3 in both punctate and elongated 
patterns, indicative of early and late meiosis, respectively. Interestingly, when compared to 
PGCs derived from both male or female hESCs, the efficiency of hiPGC derivation appears 
higher, suggesting that hiPSCs may be a better starting substrate for germline 
differentiation. In summary, these two investigations provide encouraging results about the 
ability to use hiPSCs to derive gametes in vitro. Although the differentiation potential of 
hiPSCs may vary greatly from one cell line to another, they appear to have strong potential 
as a genetic model system to study human germ cell development. 
4.3 Clinical need and applications for in vitro-derived gametes 
Currently many men suffer from non-obstructive azoospermia as described earlier that 
results in complete sterility. In addition, in the U.S. alone there are 55,000 childhood cancer 
survivors annually, many of whom were unable to bank sperm before receiving sterilizing 
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treatments. Similarly, women have a finite supply of reproductively competent oocytes 
while others undergo premature ovarian failure, making childbearing difficult or 
impossible. Alternative options for parenthood in these cases are not always simple or 
inexpensive. Although sperm donation is economical, oocyte donation is quite expensive 




Fig. 4. Comparison of in vivo Germline Development and in vitro Germ Cell Derivation from 
ESCs and iPSCs.A depiction of in vivo development of germ cells and gametes from the 
mammalian embryo showing that embryonic stem cells (ESCs) originate from primitive 
ectoderm, by way of the inner cell mass (ICM). Primordial germ cells then migrate to gonads 
where they undergo self-renewal in the form of spermatogonial stem cells (SSCs) in the 
testis and oocytes in the ovary. On the right is a schematic of the cell lineages derived in 
vitro. ESCs cultured in dishes can be differentiated to PGCs via methods summarized in 
Table 1. PGCs cultured in vitro, at least in the mouse, can transform to embryonic germ (EG) 
cells. There is also evidence a subpopulation of hESCs cultured in vitro behave like EG cells. 
Finally, somatic cells can be reprogrammed with addition of Oct4, Sox2, Klf4 and c-Myc 
transcription factors to induce a stem cell-like fate. iPSCs can then be induced to form PGC-
like cells or EG-like cells. Finally, ESCs, PGCs and iPSCs can all form teratomas when 
injected in vivo demonstrating their pluripotency. 
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such as extracting low numbers of testis sperm after prior localization with Fine Needle 
Aspiration (FNA) mapping, offer the hope of fatherhood for some candidates (Beliveau et 
al., 2011; Natali et al., 2011). 
Although such strategies are gaining in popularity, the pregnancy success rates remains at 
about 30-40% using sophisticated in vitro fertilization (IVF) techniques (Centers for 
Disease Control [CDC], 2008). In addition, with these reproductive technologies, there 
remain important safety concerns about de novo sex chromosomal disorders, birth defects 
and imprinting-related disorders such as Beckwith-Wiedeman syndrome in offspring 
(Childs et al., 2008). Therefore, there is an obvious clinical need for high quality, in vitro-
derived gametes. However, the prospect of employing current protocols and reagents to 
derive human gametes from hESCs appears unlikely at this time. On the other hand, the 
use of iPSCs and alternative stem cell sources such as adult stem cells, hold great promise 
in thisregard. In the foreseeable future, patients with genetic disorders affecting fertility 
could theorectially donate somatic cell biopsies that could then be reprogrammed into 
iPSCs and genetically modified to normal and subsequently utilized for gametogenesis in 
vitro. 
However, there are numerous challenges to the application of iPSCs for clinical use (Hanna 
et al., 2010). For one, the exact level of authenticity and experimental proof required for the 
safe use of iPSC and hESC derived gametes in the clinic is entirely unknown. To address this 
issue, there are at least three major areas that the research community can and should 
address before taking in vitro-derived gametes to the clinic. Firstly, the chromosomal 
composition of the iPSCs must be identical to the original patient from where they were 
derived. There is now sufficient data detailing the gene mutations and copy number 
variations arising in iPSCs during reprogramming and clonal expansion. It would be wise to 
carefully screen for these variation in patient-derived samples (Reviewed in Panopoulos et 
al., 2011). Moreover, frequent chromosomal aberrations arise during meiotic recombination 
so it would be necessary to examine the fidelity of meiosis in gametes in vitro. Secondly, it is 
important to check for the proper erasure and subsequent re-establishment of maternal and 
paternal imprints in PGCs derived from both iPSCs and hESCs. There is published work 
with hESCs and iPSCs that has attempted to characterize imprinting status and DNA 
methylation patterns in these derived cells; the preliminary evidence seems to indicate that 
in vitro derived hiPGCs appear to undergo partial to full imprinting erasure (Kee et al., 2009; 
Panula et al., 2010). Whether the correct imprints are restored later on during germ cell 
development remains unknown. Thirdly, the most infallible method to test full functionality 
of in vitro-derived gametes is to test their ability to fertilize, form a blastocyst and viable 
offspring. In the mouse, this has been tested despite the premature death of offspring 
(Nayernia et al., 2006). One obstacle is how can we overcome ethical boundaries and 
challenges to do similar tests with human gametes? Perhaps for now, the primary medical 
application of human stem cell-derived gametes would be to use them as a reproductive 
toxicological screen for pharmaceutical compounds and other chemicals.  
5. Conclusions 
In the last decade, much progress has been made in our understanding of mouse and 
human embryology and embryonic stem cells. We have learned that complex genetic 
pathways that underlie the pluripotency aspects of hESCs and mESCs also underline our 
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inability to easily control and direct these cells toward a specific lineage. In addition, the 
advent of diverse strategies to ‘reprogram’ somatic cells has opened up an almost limitless 
access to patient-specific stem cells that if used correctly, could provide very powerful cell-
based therapies. Scientifically, the biology of germline development has always been an 
popular area of exploration for embryologists and stem cell biologists, especially because 
germ cells are unique in their ability to transmit genetic information from one generation to 
the next. If we can understand how germ cells develop from ESCs at the cellular and 
molecular level, we can apply this information to the derivation of male and female 
gametes. The goals of gamete formation include: 1) to address immediate health issues such 
as infertility in men and women due to sperm and egg dysfunction or absence; 2) to produce 
gametes that can be fertilized and produce an almost limitless source of mammalian 
embryos and ESCs for the study of specific diseases; 3) to devise methods with which to 
target hereditary and non-hereditary germline mutations or chromosomal abnormalities 
during the earliest stages of germ cell production.  
The studies summarized in this review have shown that multipotent ES-like SSCs can 
develop into somatic cells of all three germ layers, but their ability to differentiate to the 
germline remains unclear or untested. In addition, it is believed that SSCs may only be 
multipotent and will be useful only for autologous transplantation and maybe for only a few 
tissue types. In this regard, one promising avenue for SSCs is differentiation down the 
spermatogenic pathway. Finally, there is a limited expansion potential of SSCs compared to 
iPSCs or hESCs and the imprinting status of these cells is less well defined than that of 
hESCs. A similar approach as used by Kee et al. in 2009 to overexpresss DAZ genes in 
hESCs could potentially be applied to differentiate SSC’s to spermatids or sperm in vitro. 
Alternatively, one could envision that the research on in vitro-derived human oocytes could 
be similarly advanced and lead to a better understanding of the concept that there are 
renewable ovarian stem cells in humans. In conclusion, the potential of ESCs and iPSCs to 
be used for cell-based therapy is now being realized. Major challenges, both scientific and 
clinical, still exist in deriving germline cells that look and behave as reliably as their natural 
counterparts. With further advances in technology and the elucidation of new pathways in 
gerrmline function in the mouse and human systems, we predict that these challenges can 
be met and overcome in the future. 
Keypoints: 
 Mouse and human embryonic stem cells provide the ideal substrate for germline 
differentiation, both in vivo and in vitro. 
 The mammalian germline is established as primordial germ cells immediately prior to 
gastrulation in mice and humans, and undergo similar physiological and molecular 
events. 
 Induced pluripotent stem cells (iPSCs) and adult stem cells may provide alternative 
sources of pluripotent and multipotent stem cells with less potential for host rejection 
and decreased tumorigenicity.  
 Testicular stem cells with multipotent and even pluripotent potential have been isolated 
in mouse models and, more recently, in humans. 
 The in vitro derivation of early male and female germ cells is now achievable from 
mESCs, hESCs and human iPSCs with the application of various reporter systems and 
through embryoid body (EB) formation.  
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inability to easily control and direct these cells toward a specific lineage. In addition, the 
advent of diverse strategies to ‘reprogram’ somatic cells has opened up an almost limitless 
access to patient-specific stem cells that if used correctly, could provide very powerful cell-
based therapies. Scientifically, the biology of germline development has always been an 
popular area of exploration for embryologists and stem cell biologists, especially because 
germ cells are unique in their ability to transmit genetic information from one generation to 
the next. If we can understand how germ cells develop from ESCs at the cellular and 
molecular level, we can apply this information to the derivation of male and female 
gametes. The goals of gamete formation include: 1) to address immediate health issues such 
as infertility in men and women due to sperm and egg dysfunction or absence; 2) to produce 
gametes that can be fertilized and produce an almost limitless source of mammalian 
embryos and ESCs for the study of specific diseases; 3) to devise methods with which to 
target hereditary and non-hereditary germline mutations or chromosomal abnormalities 
during the earliest stages of germ cell production.  
The studies summarized in this review have shown that multipotent ES-like SSCs can 
develop into somatic cells of all three germ layers, but their ability to differentiate to the 
germline remains unclear or untested. In addition, it is believed that SSCs may only be 
multipotent and will be useful only for autologous transplantation and maybe for only a few 
tissue types. In this regard, one promising avenue for SSCs is differentiation down the 
spermatogenic pathway. Finally, there is a limited expansion potential of SSCs compared to 
iPSCs or hESCs and the imprinting status of these cells is less well defined than that of 
hESCs. A similar approach as used by Kee et al. in 2009 to overexpresss DAZ genes in 
hESCs could potentially be applied to differentiate SSC’s to spermatids or sperm in vitro. 
Alternatively, one could envision that the research on in vitro-derived human oocytes could 
be similarly advanced and lead to a better understanding of the concept that there are 
renewable ovarian stem cells in humans. In conclusion, the potential of ESCs and iPSCs to 
be used for cell-based therapy is now being realized. Major challenges, both scientific and 
clinical, still exist in deriving germline cells that look and behave as reliably as their natural 
counterparts. With further advances in technology and the elucidation of new pathways in 
gerrmline function in the mouse and human systems, we predict that these challenges can 
be met and overcome in the future. 
Keypoints: 
 Mouse and human embryonic stem cells provide the ideal substrate for germline 
differentiation, both in vivo and in vitro. 
 The mammalian germline is established as primordial germ cells immediately prior to 
gastrulation in mice and humans, and undergo similar physiological and molecular 
events. 
 Induced pluripotent stem cells (iPSCs) and adult stem cells may provide alternative 
sources of pluripotent and multipotent stem cells with less potential for host rejection 
and decreased tumorigenicity.  
 Testicular stem cells with multipotent and even pluripotent potential have been isolated 
in mouse models and, more recently, in humans. 
 The in vitro derivation of early male and female germ cells is now achievable from 
mESCs, hESCs and human iPSCs with the application of various reporter systems and 
through embryoid body (EB) formation.  
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Embryonic germ cells (EGCs) are pluripotent stem cells derived from primordial germ cells 
(PGCs), which are unipotent cells that in vivo give rise to the gametes (McLaren, 2003).  
Specification of PGCs takes place in the proximal posterior part of the epiblast shortly before 
gastrulation, when the epiblast is about to give rise to the three germ layers ectoderm, 
mesoderm, and endoderm. PGCs can be identified by expression of tissue non-specific 
alkaline phosphatase (TNAP) activity, various surface antigens stage specific embryonic 
antigen (SSEA1,3,4), mouse vasa homolog (Mvh) and intracellular proteins (Stella, Fragilis, 
Oct-4, Nanog and Blimp1 among others). From the proximal epiblast, PGCs migrate along 
the extraembryonic mesoderm at the base of the allantois, and then move into the 
epithelium of the hindgut. Later, PGCs start to move through the dorsal mesentery reaching 
the aorta-gonad-mesonephros (AGM) region and finish their migration at the developing 
genital ridges. When in gonads, PGC proliferate by mitosis until males enter in mitotic 
quiescence and in females enter into meiosis (De Felici, 2009).  
Under special conditions, PGCs become pluripotent stem cells. In vivo PGCs can generate 
embryonal carcinoma cells (ECC), the pluripotent stem cells of testicular tumors (Stevens, 
1967; Oosterhuis& Looijenga, 2005), while in vitro they can generate EGCs (Matsui et al., 
1992; Resnick et al., 1992; Surani, 2007; De Felici et al., 2009; De Miguel et al., 2010). PGCs 
could be isolated and cultured as such during short periods (up to 10 days) maintaining 
their phenotype, until they undergo apoptosis. When exposed to a specific mixture of 
growth factors, PGCs generate EGC colonies. EGCs could be an important source of cells for 
germ cell or stem cell therapy and a valuable model for understanding development 
processes involved in reprogramming such as the acquisition of pluripotency. 
EGCs were first derived in mice (Matsui et al., 1992; Resnick et al., 1992), and afterwards in a 
wide variety of mammals like cow (Cherny et al., 1994), goat (Jia et al., 2008), pig (Shim et 
al., 1997), and sheep (Ledda et al., 2010) among others. Importantly, in 1998 Shamblott et al. 
derived the first human EGC line, providing a potential source of pluripotent stem cells for 
therapy.  
In this chapter, differences and similarities of EGC derivation and culture of different 
species are discussed, including species in which long term EGC lines derivation has not yet 
been achieved. 
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2. Mouse embryonic germ cells 
PGCs in mouse arise at the epiblast adjacent to the extra-embryonic ectoderm around 6.5 
days post coitum (dpc) (Lawson et al., 1999). At this stage mouse PGCs constitute a small 
cluster of TNAP positive cells which also express the POU domain transcription factor Oct-
4, both of which are pluripotent markers of the inner cell mass (ICM) of the blastocyst and 
embryonic stem cells (ES). At 8-8.5 dpc, PGCs migrate and are found in the hindgut 
endoderm and at the base of the allantois. From there they migrate along the hindgut 
mesentery and begin to colonize the developing genital ridges at 10.5 dpc. At 13.5 dpc, an 
established population of 25,000-35,000 PGCs in the gonad will form the future gametes 
(Tam & Snow, 1981; Ginsburg et al., 1990). 
PGCs from embryonic days 8.5 to 12.5 dpc are prevalently used for EGC derivation. They 
express the pluripotent markers Oct-3/4, Sox-2 and Nanog. However, in culture, PGCs 
proliferate for 7-10 days and then disappear either because they differentiate or die (De Miguel 
& Donovan, 2003).  In vitro culture of mouse PGCs has identified many growth factors that 
affect their survival and/or proliferation. When PGCs in culture are exposed to leukemia 
inhibitory factor (LIF), basic fibroblast growth factor (bFGF), stem cell factor (SCF) and serum 
(Matsui et al., 1992; Resnick et al., 1992; Durcova-Hills et al., 2001) they become immortalized. 
In addition, unipotent PGCs turn into pluripotent cells called embryonic germ cells through a 
molecular reprogramming event. These cells are similar to embryonic stem (ES) cells derived 
from the early embryo or induced pluripotent stem cells (iPS) generated from differentiated 
tissue in terms of cell morphology and gene expression profile (Sharova et al., 2007; Durcova-
Hills et al., 2008). Mouse EG cells also share many features that define pluripotency including 
the ability to differentiate into a variety of cell types in vitro, contribution to germline-
competent chimaeras when introduced into blastocysts and the capacity to form spontaneous 
teratomas (Matsui et al., 1992; Labosky et al., 1994; Stewart et al., 1994). 
However, EG cells differ from iPS and ES cells in some properties. EG cells have a different 
epigenetic state demonstrated by the erasure of genomic imprints and chromatin 
remodeling from certain imprinted genes like Igf2, Igf2rr, Dlk1 and H19, a process that 
occurs after specification of PGCs (Lee et al., 2002).  Therefore, the pluripotency state from 
EG cells is somewhat distinct from the naïve pluripotency state of mouse ES cells (Gillich & 
Hayashi, 2011). 
Although the findings in this respect are increasing, the molecular and epigenetic 
mechanisms that control the reprogramming conversion from PGCs into pluripotent EGCs 
are not fully understood. However, the signaling pathways and genes that control several 
processes like proliferation and specification of PGCs and the epigenetic restriction that 
separate PGCs from pluripotency have been identified. Several lines of evidence highlight 
key molecules involved in the pluripotency acquirement of PGCs. It has been proposed that 
downregulation of Prdm1/Blimp1 is a prerequisite for EG cell derivation (Durcova-Hills et 
al., 2008) and PGC-specific inactivation of the tumor suppressor PTEN enhances both EG 
cell production and testicular teratoma formation (Kimura et al., 2003). Also, an enforced 
activation of Akt, one of the major downstream effectors of PI3K, augments the efficiency of 
EG cell establishment and enables derivation of EG cells from late PGCs, such as from 14.5 
dpc embryos (Kimura et al., 2008; Gillich & Hayashi, 2011).  
2.1 Isolation and culture of mouse embryonic germ cells 
Several protocols have been described for culturing mouse PGCs, their posterior conversion 
into EG cells as well as derivation of mouse EG cell lines. This part describes the basic 
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protocol developed by the Donovan´s lab (Resnick et al., 1992; De Miguel & Donovan, 2003) 
for the derivation and establishment of mouse embryonic germ cells lines from mouse PGCs 
isolated from both 8.5 and 10.5 dpc embryos and some differences with protocols described 
by Matsui and Durcova-Hills & Surani (Matsui et al., 1992; Durcova–Hills & Surani, 2008). 
2.1.1 Buffers and solutions 
PBS: Phosphate buffered saline, without Ca+2 and Mg+2, pH 7.0 (Gibco/Invitrogen). 
Trypsin/EDTA: HBSS containing 0.05% trypsin and 0.53 mM EDTA (Sigma). 
Fast Red/Naphtol phosphate solution (Alkaline phosphatase staining solution): a 1 mg/ml 
solution of Fast red TR salt (Sigma, stored at -20ºC) is made up in  dH2O.  40 µl/ml Naphtol 
AS-MX phosphate is then added (Sigma, stored at 4ºC). Used immediately. 
2.1.2 Culture media 
Basic culture medium for PGCs: DMEM (Dulbecco’s modified Eagle’s medium) high 
glucose, supplemented with 15% Fetal Bovine Serum (Gibco/Invitrogen) (we recommend to 
test different batches of Fetal Bovine Serum before purchasing since serum batch used for 
culture may be especially critical for the growth of PGCs and derivation of EG cells), 2 mM 
glutamine (Gibco/Invitrogen), 5 U/ml penicillin–streptomycin (Invitrogen), and 1 mM Na+ 
pyruvate (Sigma). 
Growth factors for EG cell derivation and culture: mSCF (R&D Systems) 10 ng/ml, mLIF 
(Millipore) 1000 U/ml, hbFGF (Gibco/Invitrogen) 1 ng/ml and Forskolin (Sigma) 100mM. 
Basic culture medium for STO: (Sandoz Thioguanine- and Ouabain-resistant cell line, a 
transformed mouse embryonic fibroblast line): DMEM high glucose, supplemented with 
10% Fetal Bovine Serum (Gibco/Invitrogen), 2 mM glutamine (Gibco/Invitrogen), 5 U/ml 
penicillin–streptomycin (Gibco/Invitrogen), 1 mM Na+ pyruvate (Sigma). Protocol down 
below can be used with primary MEFs instead of STO cell line; in that case add 0.1mM non-
essential amino acids (Gibco/ Invitrogen) to the medium.  
Freezing medium: 9 ml of basic culture medium for PGCs (see above) plus 1 ml of dimethyl 
sulfoxide (DMSO). Mix thoroughly and keep on ice. 
2.1.3 Fixatives 
4% Paraformaldehyde: 4g paraformaldehyde in 100 ml PBS. To dissolve the 
paraformaldehyde,  PBS is preheated  at 90°C, and NaOH is added drop-wise until the 
solution turns clear. Solution is  cooled  down before use.  
acid–ethanol: 1 ml acetic acid and 19 ml ethanol precooled at -20ºC. 
2.1.4 PGCs Isolation and culture 
8.5 days post coitum Embryo Dissection: C57BL/6J inbred mouse line is used to collect tissues 
containing PGCs (available from Jackson Labs). 8.5 day pregnant females are sacrificed by 
cervical dislocation. The day on which a vaginal plug is found is designated 0.5 dpc (coitus 
is assumed to take place at midnight). The abdomen is dissected using scissors and the uteri 
is removed. Using forceps, each implantation site is separated by cutting the uterus between 
them, very near to each embryo to allow the deciduum to project. The dissected 
implantation sites are placed  in a Petri dish with ice cold PBS. The decidua is cut across 
with a pair of fine forceps (Dumont #55). Pressure is applied with fine forceps to the other 
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2. Mouse embryonic germ cells 
PGCs in mouse arise at the epiblast adjacent to the extra-embryonic ectoderm around 6.5 
days post coitum (dpc) (Lawson et al., 1999). At this stage mouse PGCs constitute a small 
cluster of TNAP positive cells which also express the POU domain transcription factor Oct-
4, both of which are pluripotent markers of the inner cell mass (ICM) of the blastocyst and 
embryonic stem cells (ES). At 8-8.5 dpc, PGCs migrate and are found in the hindgut 
endoderm and at the base of the allantois. From there they migrate along the hindgut 
mesentery and begin to colonize the developing genital ridges at 10.5 dpc. At 13.5 dpc, an 
established population of 25,000-35,000 PGCs in the gonad will form the future gametes 
(Tam & Snow, 1981; Ginsburg et al., 1990). 
PGCs from embryonic days 8.5 to 12.5 dpc are prevalently used for EGC derivation. They 
express the pluripotent markers Oct-3/4, Sox-2 and Nanog. However, in culture, PGCs 
proliferate for 7-10 days and then disappear either because they differentiate or die (De Miguel 
& Donovan, 2003).  In vitro culture of mouse PGCs has identified many growth factors that 
affect their survival and/or proliferation. When PGCs in culture are exposed to leukemia 
inhibitory factor (LIF), basic fibroblast growth factor (bFGF), stem cell factor (SCF) and serum 
(Matsui et al., 1992; Resnick et al., 1992; Durcova-Hills et al., 2001) they become immortalized. 
In addition, unipotent PGCs turn into pluripotent cells called embryonic germ cells through a 
molecular reprogramming event. These cells are similar to embryonic stem (ES) cells derived 
from the early embryo or induced pluripotent stem cells (iPS) generated from differentiated 
tissue in terms of cell morphology and gene expression profile (Sharova et al., 2007; Durcova-
Hills et al., 2008). Mouse EG cells also share many features that define pluripotency including 
the ability to differentiate into a variety of cell types in vitro, contribution to germline-
competent chimaeras when introduced into blastocysts and the capacity to form spontaneous 
teratomas (Matsui et al., 1992; Labosky et al., 1994; Stewart et al., 1994). 
However, EG cells differ from iPS and ES cells in some properties. EG cells have a different 
epigenetic state demonstrated by the erasure of genomic imprints and chromatin 
remodeling from certain imprinted genes like Igf2, Igf2rr, Dlk1 and H19, a process that 
occurs after specification of PGCs (Lee et al., 2002).  Therefore, the pluripotency state from 
EG cells is somewhat distinct from the naïve pluripotency state of mouse ES cells (Gillich & 
Hayashi, 2011). 
Although the findings in this respect are increasing, the molecular and epigenetic 
mechanisms that control the reprogramming conversion from PGCs into pluripotent EGCs 
are not fully understood. However, the signaling pathways and genes that control several 
processes like proliferation and specification of PGCs and the epigenetic restriction that 
separate PGCs from pluripotency have been identified. Several lines of evidence highlight 
key molecules involved in the pluripotency acquirement of PGCs. It has been proposed that 
downregulation of Prdm1/Blimp1 is a prerequisite for EG cell derivation (Durcova-Hills et 
al., 2008) and PGC-specific inactivation of the tumor suppressor PTEN enhances both EG 
cell production and testicular teratoma formation (Kimura et al., 2003). Also, an enforced 
activation of Akt, one of the major downstream effectors of PI3K, augments the efficiency of 
EG cell establishment and enables derivation of EG cells from late PGCs, such as from 14.5 
dpc embryos (Kimura et al., 2008; Gillich & Hayashi, 2011).  
2.1 Isolation and culture of mouse embryonic germ cells 
Several protocols have been described for culturing mouse PGCs, their posterior conversion 
into EG cells as well as derivation of mouse EG cell lines. This part describes the basic 
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protocol developed by the Donovan´s lab (Resnick et al., 1992; De Miguel & Donovan, 2003) 
for the derivation and establishment of mouse embryonic germ cells lines from mouse PGCs 
isolated from both 8.5 and 10.5 dpc embryos and some differences with protocols described 
by Matsui and Durcova-Hills & Surani (Matsui et al., 1992; Durcova–Hills & Surani, 2008). 
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PBS: Phosphate buffered saline, without Ca+2 and Mg+2, pH 7.0 (Gibco/Invitrogen). 
Trypsin/EDTA: HBSS containing 0.05% trypsin and 0.53 mM EDTA (Sigma). 
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solution of Fast red TR salt (Sigma, stored at -20ºC) is made up in  dH2O.  40 µl/ml Naphtol 
AS-MX phosphate is then added (Sigma, stored at 4ºC). Used immediately. 
2.1.2 Culture media 
Basic culture medium for PGCs: DMEM (Dulbecco’s modified Eagle’s medium) high 
glucose, supplemented with 15% Fetal Bovine Serum (Gibco/Invitrogen) (we recommend to 
test different batches of Fetal Bovine Serum before purchasing since serum batch used for 
culture may be especially critical for the growth of PGCs and derivation of EG cells), 2 mM 
glutamine (Gibco/Invitrogen), 5 U/ml penicillin–streptomycin (Invitrogen), and 1 mM Na+ 
pyruvate (Sigma). 
Growth factors for EG cell derivation and culture: mSCF (R&D Systems) 10 ng/ml, mLIF 
(Millipore) 1000 U/ml, hbFGF (Gibco/Invitrogen) 1 ng/ml and Forskolin (Sigma) 100mM. 
Basic culture medium for STO: (Sandoz Thioguanine- and Ouabain-resistant cell line, a 
transformed mouse embryonic fibroblast line): DMEM high glucose, supplemented with 
10% Fetal Bovine Serum (Gibco/Invitrogen), 2 mM glutamine (Gibco/Invitrogen), 5 U/ml 
penicillin–streptomycin (Gibco/Invitrogen), 1 mM Na+ pyruvate (Sigma). Protocol down 
below can be used with primary MEFs instead of STO cell line; in that case add 0.1mM non-
essential amino acids (Gibco/ Invitrogen) to the medium.  
Freezing medium: 9 ml of basic culture medium for PGCs (see above) plus 1 ml of dimethyl 
sulfoxide (DMSO). Mix thoroughly and keep on ice. 
2.1.3 Fixatives 
4% Paraformaldehyde: 4g paraformaldehyde in 100 ml PBS. To dissolve the 
paraformaldehyde,  PBS is preheated  at 90°C, and NaOH is added drop-wise until the 
solution turns clear. Solution is  cooled  down before use.  
acid–ethanol: 1 ml acetic acid and 19 ml ethanol precooled at -20ºC. 
2.1.4 PGCs Isolation and culture 
8.5 days post coitum Embryo Dissection: C57BL/6J inbred mouse line is used to collect tissues 
containing PGCs (available from Jackson Labs). 8.5 day pregnant females are sacrificed by 
cervical dislocation. The day on which a vaginal plug is found is designated 0.5 dpc (coitus 
is assumed to take place at midnight). The abdomen is dissected using scissors and the uteri 
is removed. Using forceps, each implantation site is separated by cutting the uterus between 
them, very near to each embryo to allow the deciduum to project. The dissected 
implantation sites are placed  in a Petri dish with ice cold PBS. The decidua is cut across 
with a pair of fine forceps (Dumont #55). Pressure is applied with fine forceps to the other 
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side and base of the decidua to pop the embryo  out of the slit in the deciduum. The 
extraembryonic membranes are dissected away and the posterior third of the embryo is 
removed, including the caudal end of the primitive streak and allantois. 50-100 PGCs are 
localized at the junction of the primitive streak and the base of allantois at this embryonic 
stage. The embryo fragments are collected  in PBS and kept on ice until trypsinization. 
10.5 days post coitum Embryo Dissection: At this stage most PGCs are in the developing genital 
ridges and the wall of the hindgut of the embryo. The embryos are removed from the 
implantation site and dissected out from the uterus and extraembryonic tissues. The embryo 
is cut in half, below the forelimbs. The caudal half of the embryo is kept and the anterior 
portion is discarded. A cut down is made at the midline of the embryo. The genital ridges 
lay on the dorsal body wall either side of the hindgut mesentery. The skin is opened out on 
either side of genital ridges and the forceps lifted upwards and towards the tail of the 
embryo. The two genital ridges, the dorsal aorta that is between them and hindgut are close 
to the dorsal body wall. The genital ridges are separated from the anterior end and pulled 
out and replaced in the PBS to squeeze the blood out from the aorta to reduce the number of 
contaminating cells. The genital ridge/aorta/dorsal mesentery PGC-containing portions are 
collected. The estimated number of PGCs per embryo is 1x103 at 10.5 dpc. 
12.5 days post coitum Embryo Dissection: The dissection of 12.5 dpc embryos is similar to that 
for the 10.5 dpc embryos. All the PGCs are in the genital ridge. At this stage in 
embryogenesis it is  preferable to dissect the genital ridges away from the adhering tissue 
with fine forceps. The expected increase in embryo size is associated with a higher yield of 
PGCs isolation. The estimated number of PGCs per embryo is 10x103 PGCs at 12.5 dpc. 
PGCs from older embryos than 10.5 dpc are not routinely isolated in our labs because the 
efficiency of EG cells derivation in culture is lower due to reduced cell proliferation in PGCs 
of male embryos and the entry into meiosis of PGCs in female embryos. 
Enzymatic treatment: The PBS is eliminated and trypsin/EDTA is added to the tube. The 
embryo fragments are incubated in the solution for 8 min at 37ºC in a water bath and the 
trypsin/EDTA solution is removed as much as possible being careful not to aspirate the 
tissue fragments. An appropriate volume of PGC basic culture medium is added to break up 
the tissue fragments by pipetting slowly up and down with a micropipette tip to obtain a 
single cell suspension. The cells are diluted into the required volume of basic culture 
medium for PGCs supplemented with growth factors.  
PGC Culture: PGCs are cultured using a transformed mouse embryonic fibroblast line as 
feeder layer, the Sandoz Thioguanine- and Ouabain-resistant  cell line (STO). STO cells are 
commercially available from the American Type Culture Collection (CRL-1503™). PGCs are 
plated onto confluent mitotically inactivated STO feeder cells and cultured in incubator at 
37ºC in an atmosphere of 95% air and 5% CO2.  Although soluble form of recombinant SCF 
is further added to the basic culture medium, both the transmembrane and the soluble form 
of SCF produced by STO cells is required for enhancing proliferation and long-term survival 
of cultured PGCs (Resnick et al., 1992). Notably, Sl4m220 feeder cell line is also used by other 
investigators to culture PGCs and derive EG cell lines. Sl4m220 cells are derived from a 
homozygous null (Sl/Sl) murine embryo which contains a deletion of the gene coding SCF 
(Sl gene) and have been stably transfected with the membrane bound murine form of SCF 
(Matsui et al., 1991; Toksoz et al., 1992).  
STO cells are maintained in basic culture medium for STO cells. For convenience these 
feeder cells should be prepared the day before the dissection.  The STO cells are plated  at a 
density of 10x104 cells/cm2 onto 0.1% w/v pregelatinized coated culture dishes. Next 
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morning, STO cells are γ-irradiated with a dose of 50 Gy (5000 rads) to induce cell cycle 
arrest. After irradiation, the STO cells culture medium is removed and PGC basic culture 
medium supplemented with growth factors is added (STO cells can also be mitotically 
inactivated by treatment with mitomycin C (Sigma) at a concentration of 10µg/ml for 4 
hours at 37ºC). PGCs are plated on top of the STO feeder layer. The final dilution volume of 
basic culture PGC medium is calculated to plate approximately two 8.5-dpc embryos or 0.5 
of one 11.5-dpc embryo per well of a 24-well culture plate. The number of PGCs isolated is 
estimated from the known numbers of PGCs present in each embryonic stage of the embryo. 
The medium is replaced every day by gentle aspiration of 2/3 of medium and fresh medium 
supplemented with growth factors is added. 
2.1.5 Identification of PGCs and EG cells 
Alkaline phosphatase staining: PGCs and EGCs colonies are distinguished from accompanying 
somatic and feeder cells by several techniques but the simplest method is alkaline 
phosphatase staining (Ginsburg et al., 1990). Note that this marker is not unique to germ 
cells. In mouse embryos, alkaline phosphatase activity is present also in the developing 
skeletal system (Kaufman, 1992), the developing gut (Merchant-Larios et al., 1985) and the 
neural tube (Kwong & Tam, 1984). Also, note that this marker stains dead cells, to stain live 
and dead cells use SSEA1 (see below). 
The cultures are washed twice in PBS without Ca+2 and Mg+2, and then fixed in 4% 
paraformaldehyde in PBS (see above) for 15 min at room temperature (RT). The cultures are 
washed three times in PBS, once in distilled water, and then are incubated in the dark in 
freshly made alkaline phosphatase staining solution  for 20- 30 min at room temperature. 
After staining, cultures are washed  in distilled water; the color reaction will stain PGCs red. 
The cells must be counted or photographed within a few days of staining, otherwise the cell 




Fig. 1. Mouse primordial germ cells (8.5 dpc) cultured on STO feeder layer and stained for 
alkaline phosphatase activity in red.  
Another way to distinguish between PGCs and EG cells is by their morphological 
characteristics and growth properties; PGCs grow as single cells, are mortal and will survive 
for only about 7-10 days in culture, whereas EG cells are immortal, form colonies and can be 
maintained indefinitely. 
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side and base of the decidua to pop the embryo  out of the slit in the deciduum. The 
extraembryonic membranes are dissected away and the posterior third of the embryo is 
removed, including the caudal end of the primitive streak and allantois. 50-100 PGCs are 
localized at the junction of the primitive streak and the base of allantois at this embryonic 
stage. The embryo fragments are collected  in PBS and kept on ice until trypsinization. 
10.5 days post coitum Embryo Dissection: At this stage most PGCs are in the developing genital 
ridges and the wall of the hindgut of the embryo. The embryos are removed from the 
implantation site and dissected out from the uterus and extraembryonic tissues. The embryo 
is cut in half, below the forelimbs. The caudal half of the embryo is kept and the anterior 
portion is discarded. A cut down is made at the midline of the embryo. The genital ridges 
lay on the dorsal body wall either side of the hindgut mesentery. The skin is opened out on 
either side of genital ridges and the forceps lifted upwards and towards the tail of the 
embryo. The two genital ridges, the dorsal aorta that is between them and hindgut are close 
to the dorsal body wall. The genital ridges are separated from the anterior end and pulled 
out and replaced in the PBS to squeeze the blood out from the aorta to reduce the number of 
contaminating cells. The genital ridge/aorta/dorsal mesentery PGC-containing portions are 
collected. The estimated number of PGCs per embryo is 1x103 at 10.5 dpc. 
12.5 days post coitum Embryo Dissection: The dissection of 12.5 dpc embryos is similar to that 
for the 10.5 dpc embryos. All the PGCs are in the genital ridge. At this stage in 
embryogenesis it is  preferable to dissect the genital ridges away from the adhering tissue 
with fine forceps. The expected increase in embryo size is associated with a higher yield of 
PGCs isolation. The estimated number of PGCs per embryo is 10x103 PGCs at 12.5 dpc. 
PGCs from older embryos than 10.5 dpc are not routinely isolated in our labs because the 
efficiency of EG cells derivation in culture is lower due to reduced cell proliferation in PGCs 
of male embryos and the entry into meiosis of PGCs in female embryos. 
Enzymatic treatment: The PBS is eliminated and trypsin/EDTA is added to the tube. The 
embryo fragments are incubated in the solution for 8 min at 37ºC in a water bath and the 
trypsin/EDTA solution is removed as much as possible being careful not to aspirate the 
tissue fragments. An appropriate volume of PGC basic culture medium is added to break up 
the tissue fragments by pipetting slowly up and down with a micropipette tip to obtain a 
single cell suspension. The cells are diluted into the required volume of basic culture 
medium for PGCs supplemented with growth factors.  
PGC Culture: PGCs are cultured using a transformed mouse embryonic fibroblast line as 
feeder layer, the Sandoz Thioguanine- and Ouabain-resistant  cell line (STO). STO cells are 
commercially available from the American Type Culture Collection (CRL-1503™). PGCs are 
plated onto confluent mitotically inactivated STO feeder cells and cultured in incubator at 
37ºC in an atmosphere of 95% air and 5% CO2.  Although soluble form of recombinant SCF 
is further added to the basic culture medium, both the transmembrane and the soluble form 
of SCF produced by STO cells is required for enhancing proliferation and long-term survival 
of cultured PGCs (Resnick et al., 1992). Notably, Sl4m220 feeder cell line is also used by other 
investigators to culture PGCs and derive EG cell lines. Sl4m220 cells are derived from a 
homozygous null (Sl/Sl) murine embryo which contains a deletion of the gene coding SCF 
(Sl gene) and have been stably transfected with the membrane bound murine form of SCF 
(Matsui et al., 1991; Toksoz et al., 1992).  
STO cells are maintained in basic culture medium for STO cells. For convenience these 
feeder cells should be prepared the day before the dissection.  The STO cells are plated  at a 
density of 10x104 cells/cm2 onto 0.1% w/v pregelatinized coated culture dishes. Next 
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morning, STO cells are γ-irradiated with a dose of 50 Gy (5000 rads) to induce cell cycle 
arrest. After irradiation, the STO cells culture medium is removed and PGC basic culture 
medium supplemented with growth factors is added (STO cells can also be mitotically 
inactivated by treatment with mitomycin C (Sigma) at a concentration of 10µg/ml for 4 
hours at 37ºC). PGCs are plated on top of the STO feeder layer. The final dilution volume of 
basic culture PGC medium is calculated to plate approximately two 8.5-dpc embryos or 0.5 
of one 11.5-dpc embryo per well of a 24-well culture plate. The number of PGCs isolated is 
estimated from the known numbers of PGCs present in each embryonic stage of the embryo. 
The medium is replaced every day by gentle aspiration of 2/3 of medium and fresh medium 
supplemented with growth factors is added. 
2.1.5 Identification of PGCs and EG cells 
Alkaline phosphatase staining: PGCs and EGCs colonies are distinguished from accompanying 
somatic and feeder cells by several techniques but the simplest method is alkaline 
phosphatase staining (Ginsburg et al., 1990). Note that this marker is not unique to germ 
cells. In mouse embryos, alkaline phosphatase activity is present also in the developing 
skeletal system (Kaufman, 1992), the developing gut (Merchant-Larios et al., 1985) and the 
neural tube (Kwong & Tam, 1984). Also, note that this marker stains dead cells, to stain live 
and dead cells use SSEA1 (see below). 
The cultures are washed twice in PBS without Ca+2 and Mg+2, and then fixed in 4% 
paraformaldehyde in PBS (see above) for 15 min at room temperature (RT). The cultures are 
washed three times in PBS, once in distilled water, and then are incubated in the dark in 
freshly made alkaline phosphatase staining solution  for 20- 30 min at room temperature. 
After staining, cultures are washed  in distilled water; the color reaction will stain PGCs red. 
The cells must be counted or photographed within a few days of staining, otherwise the cell 




Fig. 1. Mouse primordial germ cells (8.5 dpc) cultured on STO feeder layer and stained for 
alkaline phosphatase activity in red.  
Another way to distinguish between PGCs and EG cells is by their morphological 
characteristics and growth properties; PGCs grow as single cells, are mortal and will survive 
for only about 7-10 days in culture, whereas EG cells are immortal, form colonies and can be 
maintained indefinitely. 
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Immunofluorescence staining for SSEA-1 or Oct-3/4: PGCs and EG cells can be identified in 
culture using monoclonal antibodies that recognize pluripotency markers, such as SSEA-1 
(anti-SSEA-1 monoclonal antibody can be obtained from the Developmental Studies 
Hybridoma Bank (http:// www.uiowa.edu/dshbwww/info.html) or commercially (R&D 
systems) (Donovan et al., 1986; Fenderson et al., 2006) and Oct-3/4 (BD Transduction 
Laboratories).  Here we present a standard protocol for IF staining for SSEA-1 or Oct-3/4 on 
PGCs and EG cells (Durcova-Hills & Surani, 2008). 
PGCs or EGCs are cultured on the appropriate feeder cells over 0.1% gelatin pre-coated 
microscope glass slides (Fisher) on 24-well culture plates. Cells are washed in PBS and the 
fixative solution is added for 15 minutes at RT. After that the fixative solution is removed 
and cells are washed with PBS. Cells are permeabilized and blocked with PBS solution 
containing 0.1% (w/v) Triton X-100 and bovine serum albumin (BSA; Sigma) at a 
concentration 1% (w/v) in PBS and incubated for 20 minutes at RT. Mouse anti SSEA-1 
(1:200) or mouse anti Oct-3/4 (1:250) antibody diluted in antibody dilution buffer (PBS with 
0.1% (w/v) BSA) are added to the fixed cells and incubated overnight at 4ºC in a humidified 
chamber. Then samples are washed and the appropriate secondary antibody (anti-mouse 
IgM- FITC (1:100; Sigma) for SSEA-1 or Anti-mouse IgG-Alexa (red, 1:500; Molecular 
Probes) for Oct-3/4) diluted in antibody dilution buffer is added and incubated in a 
humidified dark chamber for 60 min at RT. Afterwards cells are washed with PBS and 
nuclei  are counterstained with DAPI solution (Sigma) for 10 min at RT in a humidified 
chamber in the dark.  The DAPI solution is aspirated and a drop of fluorescence mounting 
medium (Vectashield; Vector) is placed on an immunohistochemistry glass slide. The 
microscope glass slide with stained cells is placed onto the drop of mounting medium and 
any excess is removed with paper tissue. The samples should be examined under a 
fluorescence microscope with appropriate filters as soon as possible as the signal diminishes 
over time (Fig 2).  Slides should be  stored at 4ºC (short term storage) or in a freezer at -20ºC 




Fig. 2. Characterization of pluripotent EG cells. Detection of cell surface pluripotent marker 
SSEA-1 performed by immunofluorescence staining (red) in mouse EG cells.  
2.1.6  Derivation of EG cells 
For EG derivation, PGCs 7- 9 days are cultured in basic culture medium supplemented with 
leukemia inhibitory factor (LIF), basic fibroblast growth factor (bFGF) and stem cell factor 
(SCF). The pharmacological agent forskolin is a cAMP agonist, and one of the most potent 
 
Techniques and Conditions for Embryonic Germ Cell Derivation and Culture 
 
431 
PGC mitogens (De Felici et al., 1993). It can also be added to PGC culture to increase 
derivation efficiency, however is not required for mouse EG derivation. By 7–10 days of 
primary culture, large colonies of EG cells resembling ES cell colonies should be growing on 
the STO feeder layer. If the generation of a EG cell line is desired, colonies of EG cells can 
then be subcultured by trypsinization onto fresh, mitotically inactive primary mouse 
embryonic fibroblasts (MEFs) or STO. The CF-1 mouse strain feeder layer MEFs isolated 
from 13.5 dpc embryos (also available at Millipore, PMEF-CFL) is used to subculture EG 
cells since in our hands EG cells grow better on this cell type. However, feeder layer Sl4-
m220 or STO have also been used to derive EG cell lines (Matsui et al., 1992). MEF feeder 
cells are plated the day prior to the EG colonies passage at a density 10 x 104 cells/cm2 and 
irradiated (50 Gy) on the morning of use.  EG tightly packed dome-shaped colonies can be 
visualized by fixing the cultures and staining for alkaline phosphatase or by observing 
living cultures under a microscope equipped with phase contrast or Hoffman modulation 
contrast optics.  
To subculture EG cell colonies, primary cultures are washed twice with PBS and 
trypsin/EDTA solution is added, then the culture is incubated at 37ºC in a humidified CO2 
incubator for 5–10 min. The trypsin/EDTA solution is removed and PGC basic culture 
medium added to neutralize the action of the trypsin. The solution is pipetted up and down 
to obtain a single cell suspension. Importantly, the extent of cell disruption of EGC clumps 
must be controlled to obtain 2 to 5-cell clumps as large clumps of EG colonies will 
differentiate if passaged. The cell suspension is transferred to a centrifuge tube and 
centrifuged 5 min at 400 g at RT, and then the pellet is resuspended in fresh basic culture 
medium supplemented with LIF. The cell suspension is plated onto mitotically inactivated 
MEF containing wells.  To generate a EG cell line, cells can be grown in the same way as 
mouse ES cell lines and cultured on medium with only LIF, since the previously mentioned 
factors are no longer necessary. The medium is replaced every 24 hr by removing as much 
of the existing medium as possible and fresh medium supplemented with LIF. At early 
stages of EG cell derivation it may be difficult to see the small numbers of EG cells present. 
After 3–5 days the EG cell colonies should start growing and must be visible on the culture 




Fig. 3. Phase contrast image of mouse EGC colonies of a mouse EGC cell line cultured on 
MEFS. 
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Immunofluorescence staining for SSEA-1 or Oct-3/4: PGCs and EG cells can be identified in 
culture using monoclonal antibodies that recognize pluripotency markers, such as SSEA-1 
(anti-SSEA-1 monoclonal antibody can be obtained from the Developmental Studies 
Hybridoma Bank (http:// www.uiowa.edu/dshbwww/info.html) or commercially (R&D 
systems) (Donovan et al., 1986; Fenderson et al., 2006) and Oct-3/4 (BD Transduction 
Laboratories).  Here we present a standard protocol for IF staining for SSEA-1 or Oct-3/4 on 
PGCs and EG cells (Durcova-Hills & Surani, 2008). 
PGCs or EGCs are cultured on the appropriate feeder cells over 0.1% gelatin pre-coated 
microscope glass slides (Fisher) on 24-well culture plates. Cells are washed in PBS and the 
fixative solution is added for 15 minutes at RT. After that the fixative solution is removed 
and cells are washed with PBS. Cells are permeabilized and blocked with PBS solution 
containing 0.1% (w/v) Triton X-100 and bovine serum albumin (BSA; Sigma) at a 
concentration 1% (w/v) in PBS and incubated for 20 minutes at RT. Mouse anti SSEA-1 
(1:200) or mouse anti Oct-3/4 (1:250) antibody diluted in antibody dilution buffer (PBS with 
0.1% (w/v) BSA) are added to the fixed cells and incubated overnight at 4ºC in a humidified 
chamber. Then samples are washed and the appropriate secondary antibody (anti-mouse 
IgM- FITC (1:100; Sigma) for SSEA-1 or Anti-mouse IgG-Alexa (red, 1:500; Molecular 
Probes) for Oct-3/4) diluted in antibody dilution buffer is added and incubated in a 
humidified dark chamber for 60 min at RT. Afterwards cells are washed with PBS and 
nuclei  are counterstained with DAPI solution (Sigma) for 10 min at RT in a humidified 
chamber in the dark.  The DAPI solution is aspirated and a drop of fluorescence mounting 
medium (Vectashield; Vector) is placed on an immunohistochemistry glass slide. The 
microscope glass slide with stained cells is placed onto the drop of mounting medium and 
any excess is removed with paper tissue. The samples should be examined under a 
fluorescence microscope with appropriate filters as soon as possible as the signal diminishes 
over time (Fig 2).  Slides should be  stored at 4ºC (short term storage) or in a freezer at -20ºC 




Fig. 2. Characterization of pluripotent EG cells. Detection of cell surface pluripotent marker 
SSEA-1 performed by immunofluorescence staining (red) in mouse EG cells.  
2.1.6  Derivation of EG cells 
For EG derivation, PGCs 7- 9 days are cultured in basic culture medium supplemented with 
leukemia inhibitory factor (LIF), basic fibroblast growth factor (bFGF) and stem cell factor 
(SCF). The pharmacological agent forskolin is a cAMP agonist, and one of the most potent 
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PGC mitogens (De Felici et al., 1993). It can also be added to PGC culture to increase 
derivation efficiency, however is not required for mouse EG derivation. By 7–10 days of 
primary culture, large colonies of EG cells resembling ES cell colonies should be growing on 
the STO feeder layer. If the generation of a EG cell line is desired, colonies of EG cells can 
then be subcultured by trypsinization onto fresh, mitotically inactive primary mouse 
embryonic fibroblasts (MEFs) or STO. The CF-1 mouse strain feeder layer MEFs isolated 
from 13.5 dpc embryos (also available at Millipore, PMEF-CFL) is used to subculture EG 
cells since in our hands EG cells grow better on this cell type. However, feeder layer Sl4-
m220 or STO have also been used to derive EG cell lines (Matsui et al., 1992). MEF feeder 
cells are plated the day prior to the EG colonies passage at a density 10 x 104 cells/cm2 and 
irradiated (50 Gy) on the morning of use.  EG tightly packed dome-shaped colonies can be 
visualized by fixing the cultures and staining for alkaline phosphatase or by observing 
living cultures under a microscope equipped with phase contrast or Hoffman modulation 
contrast optics.  
To subculture EG cell colonies, primary cultures are washed twice with PBS and 
trypsin/EDTA solution is added, then the culture is incubated at 37ºC in a humidified CO2 
incubator for 5–10 min. The trypsin/EDTA solution is removed and PGC basic culture 
medium added to neutralize the action of the trypsin. The solution is pipetted up and down 
to obtain a single cell suspension. Importantly, the extent of cell disruption of EGC clumps 
must be controlled to obtain 2 to 5-cell clumps as large clumps of EG colonies will 
differentiate if passaged. The cell suspension is transferred to a centrifuge tube and 
centrifuged 5 min at 400 g at RT, and then the pellet is resuspended in fresh basic culture 
medium supplemented with LIF. The cell suspension is plated onto mitotically inactivated 
MEF containing wells.  To generate a EG cell line, cells can be grown in the same way as 
mouse ES cell lines and cultured on medium with only LIF, since the previously mentioned 
factors are no longer necessary. The medium is replaced every 24 hr by removing as much 
of the existing medium as possible and fresh medium supplemented with LIF. At early 
stages of EG cell derivation it may be difficult to see the small numbers of EG cells present. 
After 3–5 days the EG cell colonies should start growing and must be visible on the culture 




Fig. 3. Phase contrast image of mouse EGC colonies of a mouse EGC cell line cultured on 
MEFS. 
 







Fig. 4. Alkaline phosphatase staining of a mouse EGC colony.  
Recently mouse EG cells have been derived from PGCs efficiently in similar conditions as 
those used for ES cell derivation from the ICM. By addition of SCF, bFGF, LIF and FBS to 
the primary culture of murine PGCs on Sl4m220 feeders, an efficiency of EGC derivation 
of 1-2% has been reported (Leitch et al., 2010; Gillich & Hayashi, 2011). The addition of 
two inhibitors (MEK and GSK3 inhibitors) and LIF after two days of previous 
culture conditions yielded an efficiency of 2-10% (Leitch et al., 2010; Gillich & Hayashi, 
2011). 
2.1.7 Colony selection and Passaging EGC colonies  
Single colonies of EG cells can be selected and expanded. Mitotically inactivated MEF 
feeder cells must be prepared 24 h before and irradiated  on the morning of use. The 
medium from a culture dish of EG cells is removed and washed with PBS. Using an 
inverted or dissecting microscope, individual colonies are picked with a pipettor and 
transferd to a centrifuge conical tube containing a trypsin/EDTA solution. As many 
colonies as possible should be picked in a short period of time (so as to avoid over 
trypsinization of the colonies because it can affect the viability of cells) and the suspension 
placed into the incubator at 37ºC for 5 to 10 min.  The cell clumps are mixed by pipetting 
up and down  until a single-cell suspension is obtained. To neutralize the effect of trypsin,  
complete medium is added and centrifuged for 5 min at 400 g at RT. The pellet is 
resuspended in complete medium and placed onto mitotically inactivated MEF feeder 
cells plate containing EGC complete medium with LIF. The medium with LIF factor 
should be replaced daily until the cells have expanded sufficiently that they can be 
passaged onto a larger culture dish plate. 
EG colonies also can be picked using a pulled-glass pipette instead of using a pipettor to 
disaggregate cells in a trypsin-EDTA solution. Also picked EGCs colonies can be  
trypsinized in a microdrop under mineral oil before transferred onto feeder layer cells   
(Matsui et al., 1992; Durcova-Hills &  Surani,  2008).  
Once a EG cell line is derived as explained in the above paragraph, growing colonies can be 
picked and expanded on gelatin-coated plates without feeder layers albeit at a lower 
efficiency compared to the traditional method (Leitch et al., 2010). 
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3. Other mammalian EG cells 
3.1. Rat embryonic germ cells 
The first derivation of EG cells from rat has been recently reported (Leitch et al., 2010). 
Leitch and collaborators have efficiently derived and propagated rat EG cell lines with using 
culture conditions previously used for clonogenic expansion of rat pluripotent embryonic 
stem cells (Li et al., 2008). EG cell line generation was obtained adding a MEK inhibitor and 
a GSK3 inhibitor in combination with LIF without SCF or bFGF to the culture of PGCs at the 
first medium change. Rat EG cells express pluripotency markers similar to mouse EG cells 
(Nanog, Oct3/4, Sox2, AP, Klf4 and Rex1) and the EG cell lines derived were competent for 
multilineage colonization of chimaeras and embryoid body formation giving rise to cells of 
the three germ layers thus showing the ability to reprogram rat PGCs to the pluripotent 
state. 
Rat EG cells were derived from rat embryos from embryonic day 10, equivalent to 8.5 dpc in 
the mouse.  The protocol used for derivation of rat EG cell lines follows the same schedule 
as described above for mice (Leitch et al., 2010) but on day 3 of derivation (first medium 
change), the cultures were washed with PBS and the medium was replaced with serum-free 
N2B27 medium supplemented with 1µM PD0325901 MEK inhibitor, and 3 µM CHIR99021 
GSK3 inhibitor and LIF. Cultures were then maintained continuously in these conditions. 
Picked colonies were expanded on gelatin-coated plates with neither feeders nor conditional 
medium. After colony picking, cells were expanded by dissociation with trypsin and 
replating every 2-4 days.  
3.2 Buffalo embryonic germ cells 
Recently, embryonic germ cell like-cells from 30-90 dpc fetuses of the Chinese buffalo have 
been derived. These EG-like cells were cultured for more than two weeks on buffalo 
embryonic fibroblast feeder cells in DMEM containing 20% FBS media and supplemented 
with LIF, bFGF and SCF.  During isolation of EG-like cells, the mechanical method used for 
disaggregating cells was better than the trypsin digestion, enabling cells to reach a higher 
passage in culture.  Buffalo EG-like cells grew in large densely packed colonies resembling 
mouse ES or EG cells colonies and were characterized by their expression of the 
pluripotency markers AP, SSEA-1, SSEA-3, SSEA-4 and Oct-4. EG-like cells were capable to 
differentiate into the three germ layers in vitro, although chimaera formation was not 
determined (Huang et al., 2007). 
3.3 Pig EG cells 
Pig EG cells have been derived from porcine primordial germ cells isolated from the 
gonadal ridges of fetuses on days 24-28 of gestation (approximate to human Carnegie Stages 
18-20) (Piedrahita et al., 1998). Several breeds have been used:  Hampshire X Yorkshire 
(Shim et al., 1997), Duroc and German Landrace (Mueller et al., 1999), and the Chinese mini 
pig (Tsung et al., 2003). Genital ridges are dissected from the embryos, washed with PBS 
and then underwent different enzymatic dissociation treatments depending on the author: 
0.02% EDTA (Sigma) for 20 min at RT (Shim et al., 1997; Mueller et al., 1999), 0.25% trypsin + 
0.02% EDTA or 1mg/ml dispase (Sigma) in PBS for 5 min or up to 15 min at 37ºC (Tsung et 
al., 2003). After incubation, PGCs are mechanically dissociated by gentle disruption of the 
tissues using fine forceps and then centrifuged at 800 x g for 5 min.  Enzymatic treatment 
could be replaced by more roughly mechanically dissociation passing the disrupted tissues 
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EG colonies also can be picked using a pulled-glass pipette instead of using a pipettor to 
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3. Other mammalian EG cells 
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a GSK3 inhibitor in combination with LIF without SCF or bFGF to the culture of PGCs at the 
first medium change. Rat EG cells express pluripotency markers similar to mouse EG cells 
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the three germ layers thus showing the ability to reprogram rat PGCs to the pluripotent 
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change), the cultures were washed with PBS and the medium was replaced with serum-free 
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GSK3 inhibitor and LIF. Cultures were then maintained continuously in these conditions. 
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18-20) (Piedrahita et al., 1998). Several breeds have been used:  Hampshire X Yorkshire 
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pig (Tsung et al., 2003). Genital ridges are dissected from the embryos, washed with PBS 
and then underwent different enzymatic dissociation treatments depending on the author: 
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could be replaced by more roughly mechanically dissociation passing the disrupted tissues 
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several times through a 20-gauge needle, then centrifuged for 3-5 min at 250 g to settle tissue 
fragments, and supernatant containing mostly single cells is collected and centrifuged at 
1000 g for 5 min (Piedrahita et al., 1998). Colonies are disaggregated with 0.25% trypsin-
EDTA for 10-15 min and passaged to fresh feeder layers at 4- to 10-day intervals (Shim et al., 
1997; Piedrahita et al., 1998).  
Similar to other species, feeder cells expressing membrane-bound SCF are required for 
survival and establishment of porcine EG cells (Lee & Piedrahita, 2000). STO cells, 
mitotically inactivated with 10 μg/ml mitomycin C (Sigma) for 2 h, are plated at a density of 
~1.5-3 x 105 cells/cm2 (Shim et al., 1997; Piedrahita et al., 1998). 
The growth medium used to derive and maintain porcine EGCs is DMEM or DMEM:Ham´s 
F10 (1:1) (Piedrahita et al., 1998) containing 15% FBS, 1 mM L-glutamine, 0.1 mM or 0.01 mM 
nonessential amino acids (Gibco) (Piedrahita et al., 1998), 0.1 mM 2-mercaptoethanol (10 μM 
by Shim et al., 1997), penicillin (100 U/ml), and streptomycin (0.5 mg/ml) (Shim et al., 1997). 
FBS can be replaced with knockout serum replacement (KSR) (Petkov & Anderson, 2008) 
and 0.1 M Na+ pyruvate (Gibco) has also added (Mueller et al., 1999). Cultures are 
maintained at 37-39°C in 5% CO2, 95% air, and medium is changed every day. Growth factor 
supplementation is not necessary, but is common to use SCF (40 ng/ml), hbFGF (20-25 
ng/ml), and LIF (10-20 ng/ml) (Piedrahita et al., 1998; Tsung et al., 2003). Lee & Piedrahita 
(2000) reported that even if it is not required for EGCs culture, supplementation with all 
three growth factors increases eight times the number of EGC colonies TNAP positive. In 
addition to AP, pig EGCs are Oct4, SSEA-1 and SSEA-4 and TRA-1-81 positive (Petkov & 
Anderson, 2008). 
3.4 Goat EG cells 
First attempts to generate EGCs from goat resulted in lines that survived briefly and after 3-
4 passages differentiated (Kuhholzer et al., 2000; Lee & Piedrahita, 2000). However, the most 
successful attempt achieved to subculture goat EGC cells over 12 passages before 
spontaneous differentiation. Moreover, two chimeras out of 29 injected blastocysts were 
obtained: one aberrant chimera, showing cells representing the three germ layers and one  
viable chimera, showing chimerism in skin and blood. However, germ line transmission of 
the chimerism could not be confirmed (Jia et al., 2008). 
Goat primordial germ cells were isolated from the gonadal ridges of fetuses from 
slaughterhouse. The fetuses age varied between groups, from 25 (Lee et al., 2000) to 32 dpc 
(Kuhholzer et al., 2000) or 28-42 dpc (Jia et al., 2008).  
Tissues were washed with PBS with 0.02% EDTA, mechanically disaggregated and then 
incubated in 0.25% type IV collagenase (Sigma) for 30 min. To remove most somatic cells, 
cell suspension was filtered through a 100 mesh sterile gauze. After washing again in PBS 
and centrifugation at 1000 g for 5 min, cells were cultured on a goat embryonic fibroblast 
(GEF) feeder layer mitotically inactivated with mitomycin C at 100% density (Jia et al., 2008). 
First attempts used STO cells as feeders and different media, such as DMEM: Ham's F10 
medium (1:1), but colonies differentiated earlier in culture (Kuhholzer et al., 2000; Lee et al., 
2000).  
The growth medium used was DMEM supplemented with 15% KSR (Gibco), 0.1 mM 
nonessential amino acids, 0.1 mM 2-mercaptoethanol, 2 mM L-glutamine, 1 mM Na+ 
pyruvate (Invitrogen), 100 U/ml penicillin and 0.1 mg/ml streptomycin (Sigma), 10 ng/ml 
recombinant human bFGF (Sigma), 10 ng/ml SCF and 1000 IU/ml recombinant murine LIF 
(Chemicon) at 37 °C in a humidified atmosphere with 5% CO2 (Jia et al., 2008). 
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The EGC cells were subsequently passaged to a fresh MEF feeder layer in the same medium 
by picking up colonies after 10 to 12 days (Jia et al., 2008). Long term culture of EGCs was 
difficult because of spontaneous differentiation into epithelial-, neuronal-, and fibroblast-
like cells after few passages (Kuhholzer et al., 2000; Lee et al., 2000). However, goat EGCs 
were positive for AP, SSEA-1, Nanog and c-kit, as their mouse counterparts (Jia et al., 2008). 
4. Human EG cells 
To date, six laboratories have reported successful derivation of human EGC lines (Shamblott 
et al., 1998; Turnpenny et al., 2003; Liu et al., 2004; Park et al., 2004; He et al., 2007; Hua et al., 
2009). This very limited number of groups is due to the difficulties of acquiring human 
PGCs (therapeutic termination of pregnancy and ethical approval is needed), and the 
complexity of the derivation and culture of EGCs (Turnpenny et al., 2006; Kerr et al., 2006; 
Perret et al., 2008). 
4.1 Growth medium  
The methods used for human EGCs derivation are based in part in those described 
previously for mouse. The growth medium used to derive and maintain human EGCs is 
Dulbecco’s modified Eagle’s medium, DMEM-199 or KO-DMEM (Invitrogen) supplemented 
with 15% FBS or 20% Knockout serum (HyClone/Invitrogen), 0.1 mM nonessential amino 
acids (Invitrogen), 0.1 mM 2-mercaptoethanol (Sigma), 2mM glutamine (Invitrogen), 1mM 
Na+ pyruvate (Invitrogen), 100 U/ml penicillin (Invitrogen), and 100 mg/ml streptomycin 
(Invitrogen). For human EGC derivation, 1000 U/ml human recombinant LIF (hLIF, 
Chemicon), 1–2 ng/ml human recombinant bFGF (Genzyme/R&D Systems), and 10 μM 
forskolin (Sigma) is added (Shamblott et al., 1998; Kerr et al., 2006).  bFGF doses vary 
between groups, from 1 ng/ml (Shamblott et al., 1998) to 10 ng/ml (Hua et al., 2009). In 
contrast to mouse EGC derivation, supplementation with soluble SCF is not necessary for 
human EGCs. In agreement with mouse, transmembrane SCF expression of the feeder layer 
promoted human PGC growth (Kerr et al., 2006).  
It is also possible to derive and maintain human EGCs without serum using 15-20% KSR 
(Invitrogen) (Turnpenny et al., 2003; Pan et al., 2005; Hua et al., 2009; Hiller et al., 2011).  
Whereas serum provides essential nutrients also provides some factors that promote 
differentiation of EGCs and make the analysis of the experiments difficult. Thus, it is 
reported that the derivation efficiency increases using KSR instead of FBS (Hua et al., 2009).   
Recently it has been reported that the addition of 5-20 ng/ml recombinant BMP4 (R&D 
Systems) increases, in a dose-responsive manner, the efficiency of EGC derivation and 
maintenance. The results revealed an increase in EGC derivation of 5-fold with 20 ng/ml 
BMP4 and, after 3 weeks the survival efficiency increased by 50-fold in the presence of 
BMP4 (Hiller et al., 2011). Survival appeared to be in part related to the ability of BMP4 to 
inhibit spontaneous differentiation in these cultures, an inherent problem with long-term 
maintenance of human EGC cultures.  
4.2 Feeder layer 
Human EGCs have been mainly derived using the transformed mouse embryonic fibroblast 
line STO (Swelstad & Kerr, 2010). Although it is a clonal cell line, there are several 
phenotypic variations in STO cells from different isolates or even depending on the time in 
culture that affects the human EGC derivation (Kerr et al., 2006). Some groups have also 
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successfully utilized primary MEFs (CF1) as feeder layers for EGC derivation (Liu et al., 
2004; Hua et al., 2009) and even human embryonic fibroblast-like cells derived from gonadal 
ridges and dorsal mesenteries (see below, He et al., 2007). 
The feeder layer can be mitotically inactivated with mitomycin C or by irradiation, either 
before or after plating. The most convenient method is to irradiate the STO cells after 
plating, although a large γ radiation unit is needed (Kerr et al., 2006). STO cells are cultured 
in the EGC growth medium without growth factor and are passaged for short periods, being 
disaggregated with 0.05% trypsin–EDTA. STO cells are plated at 5 x 104 cells per well in 96-
well plates previously coated with 0.1% gelatin for 30 min. It is also possible to culture the 
STO cells in other plate types, maintaining a similar cell density of 1.5 x 105 cells/cm2.  
Feeder cells can be irradiated before plating, which has the advantage of the need of a 
smaller γ radiation unit, but the disadvantage of lower control of feeder cell density. Feeder 
cells are disaggregated as described, resuspended in growth medium and then exposed to 
50 Gy of γ radiation or X rays. Finally, cells are cultured into gelatinized culture plates at 
~1.5 x 105 cells/cm2 and allowed to adhere overnight. Alternatively, feeder layers can be 
mitotically inactivated with 10 μg/ml mitomycin C (Sigma) (Park et al., 2004; Liu et al., 2004; 
Hua et al., 2009).  
When MEFs are used instead of STO cells, these have to be seeded at 7.5 ×104 cells/cm2, half 
the density of STO cells (Pan et al., 2005; Hua et al., 2009). There is not comparison reported 
between human EGCs derivation on MEFs versus STO cells or between irradiation against 
mitomycin C mitotic inactivation. 
Co-culture of human EGCs with mouse feeder cells entails clinical restrictions due to the 
possible contamination by xenogenic proteins or pathogens. As a result, a new method has 
been developed for hEGCs culture using human embryonic fibroblast-like cells derived 
from gonadal ridges and dorsal mesenteries obtained from 5-10 week human embryos. The 
tissues are mechanical and enzymatically (0.25% trypsin 10 min) dissociated and then 
cultured in high glucose (HG)-DMEM, 10% FBS (Gibco), 1 mM Na+ pyruvate, 100 U/ml 
penicillin, and 50 μg/ml streptomycin. These cells are plated at 3 x 105 cells in a 6-well plate 
(~3.2 x 104 cells/cm2), and after 24 h treated with 12.5 mg/l of mitomycin C (Roche) (He et 
al., 2007). 
4.3 PGC isolation  
To derive human EGCs, PGCs are isolated from the fetal gonad between 5 and 11 weeks of 
gestation (Carnegie stage 15 onwards) at termination of pregnancy by using a drug protocol 
or surgically and with local research ethics committee approval with written informed 
consents (Kerr et al., 2006). Hua et al. (2009) used a wider margin with fetuses aged 4-13 
weeks, but is not clear that EGC derivation is possible with PGCs of those younger or older 
ages since the authors did not specify the age of the PGCs that actually originated EGC 
colonies. Human EGC derivation is more difficult to standardize compared to mouse EGCs 
in part because of the age and genetic heterogeneity among the embryonic sources. The 
collection of mesenteries besides the gonadal ridges also varies between different groups. 
Most of them but two groups included mesenteries (Pan et al., 2005; Turnpenny et al., 2006). 
Here we are going to describe the detailed protocol reported by Kerr et al. (2006) pointing 
out the differences with other laboratories. 
Dissected tissues are collected in 1 ml of ice cold growth medium, then soaked in Ca+2 and 
Mg+2 free Dulbecco’s phosphate buffered saline (DPBS) for 5 min and then enzymatically 
disaggregated with 100μl of trypsin–EDTA solution (Invitrogen). The concentration of 
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trypsin and EDTA varies depending on the developmental stages, using 0.05% trypsin–0.5 
mM EDTA solution at earlier stages, and 0.25% trypsin–0.5 mM EDTA at later stages. 
Following that, the tissue is mechanically dissociated, using fine forceps and iris scissors, for 
5–10 min at RT, and then placed at 37ºC for 5–10 min. Growth medium is added to the tube 
to stop the digestion and finally the cell suspension is pipetted  30–50 strokes with a 200 μl 
Pipetman (Gilson) (Kerr et al., 2006). 
Slight variations in these protocols are used by other groups: A previous 0.01% EDTA 
treatment for 10 minutes (Turnpenny et al., 2003), different enzymatic dissociation treatments 
between using only trypsin (without EDTA) (Liu et al., 2004), collagenase IV + DNase I 
(Turnpenny et al., 2003; Park et al., 2004), and even without mechanically dissociation and just 
incubation with 0.125% trypsin and 0.02% EDTA for 10–20 min or with 0.125% collagenase for 
20–40 min at 37°C (Hua et al., 2009). No comparisons between different PGC isolation 
protocols have been reported, so it is unknown which one is the more efficient.   
The cell suspension is plated on the previously prepared feeder layer, culturing each gonad 
on 4–10 wells of a 96 well plate, keeping in mind that derivation efficiency could be affected 
by the plating density (Kerr et al., 2006).  
To get rid of accompanying somatic cells, PGCs could be sorted before plating (Kerr et al., 
2008; Hiller et al., 2011). PGCs are isolated using magnetic cell sorting technology and an 
indirect labeling of cells with magnetically tagged goat anti-mouse IgM antibodies towards 
a mouse-anti-SSEA1 antibody (Miltenyi Biotech). After tissue dissociation, cells are 
incubated with SSEA1 antibody (1:5 dilution) for 15 min on ice, then secondary antibody is 
applied at 1:100 dilution for another 30 min on ice and sorted on magnetic columns. 
Culturing a pure population of PGCs allows ruling out possible effects of the somatic cells of 
the gonads in EGC derivation. When PGCs are counted after sorting, approximately 50 
PGCs are seeded in each well of a 96-well plate (Hiller et al., 2011).  
The plate is incubated at 37ºC in 5% (or 8% (Shamblott et al., 1998) CO2 with 95% humidity 
for 7 days. Growth medium is changed every day, removing 90% of the old medium (Kerr et 
al., 2006). 
4.4 Passage of EGC cultures 
No EGC colonies are normally seen in most human EGC cultures during the first 7 days and 
only solitary PGCs could be observed when staining for TNAP activity. Passages are 
performed after 7 days, subculturing the PGCs onto fresh feeder cells. Compared to other 
pluripotent stem cells, hEGCs are also challenging to maintain due to the difficulty in 
disaggregating colonies, so the passage is a critical step in the EGC culture (Kerr et al., 2006). 
Medium has to be removed and the wells washed with Ca+2 and Mg+2 free DPBS. To 
disaggregate the cells, 40 μl of freshly thawed trypsin-EDTA solution (0.05%-0.25% trypsin 
and 0.5 mM EDTA) is added to each well and incubated for 5 min at 37ºC. Instead of 
trypsin, 0.1% type IV collagenase could be used (He et al., 2007). Then a Pipetman and 200 
μl tip is used to scrape the bottom of the wells and gently pipetting the culture 20–30 times. 
To stop digestion fresh growth medium is added and pipetting another 10–30 times. Cell 
suspension is placed into twice the number of former wells on feeder cells (Kerr et al., 2006). 
Subsequent passages are repeated every 7 days and after 2-3 weeks EGC colonies can be 
seen in some of the wells (Kerr et al., 2006). 
Although initially 50% of the wells on average produce EGC colonies (Kerr et al., 2006), after 
2 to 3 weeks, large and recognizable EGC colonies are seen only at approximately 10 to 20% 
of the wells (Swelstad & Kerr, 2010) (Figs. 5-7). 
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Fig. 7. Characterization of pluripotent human EG cells. Indirect immunofluorescent 
detection of pluripotent marker, Tra-1-81 (red). Dapi (blue) stains nuclei.  
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A relationship between the conversion efficiency and the embryonic stage or sex of the 
embryo has been reported in both male and female gonads to be associated with an increase 
in Oct-4 expressing PGCs which peak around 10 weeks of age for both sexes (Kerr et al., 
2008a,b). 
5. Attempts in challenging species  
Finally, several attempts to derive EG cells from species are ongoing, and the challenges of 
EG derivation of these particular species are examined.  
5.1 Rabbit EG cells 
No stable EGCs lines have been derived yet from rabbit primordial germ cells. Kakegawa et 
al. (2008) reported the obtaining of EGC-like colonies that can form embryonic bodies (EBs) 
and differentiate in several cell types in vitro but did not develop teratomas after 20 days of 
injection of 3 x 106 cells. In addition, EGC-like colonies were lost in culture after 4 passages. 
These cells expressed Oct3/4, Sox2, and SSEA-1 and were AP positive as their mouse 
counterparts.   
Rabbit PGCs were isolated from New Zealand White rabbit’s embryos of 9.5-11.5 days of 
gestation, which resemble 8.5-11.5 dpc mouse embryos. Genital ridges were dissected and 
the dorsal mesentery was removed. Tissues were then washed with PBS and incubated in 
0.04% trypsin, 0.25% EDTA (Sigma) for 5 minutes at RT. After the enzymatic digestion, 
PGCs were dissociated using a glass capillary tube and seeded on mitotically inactivated 
MEF feeder layer. Culture medium was composed of knockout-DMEM (Invitrogen) with 20 
% KRS (Invitrogen), L-glutamine, Na+ pyruvate, MEM nonessential amino acids and 2-
mercaptoethanol. No growth factor addition was necessary for EG-like colonies formation, 
but the number of colonies increased with the addition of LIF (Chemicon), bFGF (Upstate), 
and forskolin (Sigma) at different concentrations. The greatest improvement was seen with 
1000 IU/ml LIF, 20 ng/ml bFGF and 20 μM forskolin. For passaging, cultures were 
dissociated with 0.04% trypsin, 0.25% EDTA, and centrifuged onto fresh feeder cells at 4- to 
7-day intervals (Kakegawa et al., 2008). 
5.2 Sheep EG cells 
Sheep EGC colonies have been derived and maintained over 14 passages. Their 
pluripotency has been proved by in vitro differentiation into a range of tissue types and by 
embryonic body formation. However, attempts to produce teratoma formation or chimaeric 
generation were attempted but without success (Ledda et al., 2010). Sheep EG expressed AP, 
Oct3/4, Sox2, Nanog and SSEA-1 (Ledda et al., 2010). 
Primordial germ cells from sheep were isolated from fetuses of 20–28 days (similar to 
human Carnegie stages 13-19) following protocols similar to those previously described for 
mouse. PGCs were cultured on mitotically inactivated MEF feeder layers at near 100% of 
density on DMEM supplemented with 20% serum, L-glutamine, Na+ pyruvate, MEM 
nonessential aminoacids, 2-mercaptoethanol and 1000 IU/ml LIF. Supplementation with 10-
30 ng/ml bFGF and forskolin improved in vitro proliferation and long term survival of 
PGCs (Ledda et al., 2010). 
5.3 Cow EG cells 
Bovine EG-like cells were derived from 29-35 days of gestation PGCs. Genital ridges from 
the fetuses obtained from slaughterhouses were dissected without mesonephros. Tissues 
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were enzymatically disrupted with trypsin and EDTA and then seeded on a feeder layer of 
neomycin-resistant LIF-producing STO cells which express recombinant human LIF 
(McMahon & Bradley, 1990), or on bovine primary embryonic fibroblasts. Passages were 
performed picking the colonies from the feeder layers and subculturing (Cherny et al., 1994). 
As with sheep and rabbit EGCs, bovine EG-like cells also demonstrated the ability to 
generate embryoid bodies and differentiate to various cell types. Bovine EGCs were 
demonstrated positive for Oct-4, and Hes-1. Pluripotency in vivo was not demonstrated, as 
no teratomas or chimaeras were developed and EGCs only could be maintained in culture 
for up to 10 passages (7 weeks) (Cherny et al., 1994). 
5.4 Non-human primate EG cells 
Non-human primates pose an interesting alternative source for studying the highmarks of 
EGC derivation relevant to human biology and preclinical applications.  While mouse has 
been the most extended animal model for EGCs research, there remain significant 
differences between mouse and human EGCs in terms of growth characteristics, marker 
expression, signaling patterns and imprinting status. Furthermore, human EGC derivation 
is limited to a diverse genetic background and human embryo donations are anonymous it 
is not possible to analyze epigenetic patterns relating them to parental lines. Thus, it seems 
reasonable to suggest that questions regarding the process of reprogramming and 
differentiation via genomic imprints could potentially be more easily and appropriately 
addressed using non-human primate EGCs. 
To date, there are no reports on the isolation of stable long term EGC lines from non-human 
primate PGCs, but short term EGCs have been developed from the groups of Schatten and 
Simerly (Simerly et al., 2010). 
Baboon embryos were collected between days 28-35 post coitum (similar to human Carnegie 
Stages 12-16), dissecting the lower half of the embryo and excising the genital ridge, dorsal 
mesentery and part of the gut. Tissues were dissociated with 0.05% trypsin treatment and cells 
cultured on irradiated STO feeder cells in 96-well plates at a density of ~10x104 cells/cm2. 
The growth medium used was DMEM high glucose with 15% FBS (Hyclone, Fisher), 2mM 
glutamine, 5 U/ml penicillin-streptomycin and 1mM Na+ pyruvate, supplemented with 
various growth factor combinations, similar to both mouse and human protocols. These 
included different concentrations of hbFGF,  20 µM retinoic acid, 1000 U/ml hLIF, 10 ng/ml 
hSCF (Cell Signaling), 100 µM forskolin (Sigma), 20 ng/ml stromal cell-derived factors α & β 
(α,β-SDF), and 50 ng/ml BMP-4. BMP-4 was previously used to improve human EGC culture 
(Hiller et al., 2011) and retinoic acid has been shown to replace bFGF for mEGC derivation 
(Koshimizu et al., 1996). Three different protocols have been tried: 10 ng/ml hbFGF, LIF, hSCF 
and forskolin; 20 ng/ml hbFGF, LIF, hSCF, α,β-SDF and BMP-4; and retinoic acid, LIF, hSCF, 
α,β-SDF and BMP-4. Medium was removed and replenished with fresh growth medium daily 
and passaging onto fresh STO feeders was performed weekly. EGC colonies were established 
using all three protocols, but after 2-3 passages start to differentiate.   
6. Conclusions 
In summary, EGC lines have been derived from a variety of mammals including human and 
are being attempted in many others. Comparison of differences in methodology used as well 
as in pluripotency markers, achieved time of culturing and functional pluripotency 
demonstration, are summarized in Tables 1 and 2. 
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Table 1. Comparison of different methods of EGC lines derivation from different species. 
GF: growth factors. EBs: in vitro embryoid bodies. dpc: days post coitum. FBS: fetal bovine 
serum. KSR: knockout serum replacement. MEFs: mouse embryo fibroblasts. EFs: embryonic 
fibroblasts. KO: knockout. SNL: STO Neomycin-resistant LIF-producing cells. ND: not 
determined. 
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α,β-SDF and BMP-4. Medium was removed and replenished with fresh growth medium daily 
and passaging onto fresh STO feeders was performed weekly. EGC colonies were established 
using all three protocols, but after 2-3 passages start to differentiate.   
6. Conclusions 
In summary, EGC lines have been derived from a variety of mammals including human and 
are being attempted in many others. Comparison of differences in methodology used as well 
as in pluripotency markers, achieved time of culturing and functional pluripotency 
demonstration, are summarized in Tables 1 and 2. 
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Table 1. Comparison of different methods of EGC lines derivation from different species. 
GF: growth factors. EBs: in vitro embryoid bodies. dpc: days post coitum. FBS: fetal bovine 
serum. KSR: knockout serum replacement. MEFs: mouse embryo fibroblasts. EFs: embryonic 
fibroblasts. KO: knockout. SNL: STO Neomycin-resistant LIF-producing cells. ND: not 
determined. 
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Table 2. Comparison of differences in expression of markers in EGCs of different species. 
CC: Cytochemistry. IF: immunofluorescence. ICC: immunocytochemistry. RT: RT-PCR. 
µarry: microarray. ND: Not determined. 
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1. Introduction 
In this review, morphological and some functional properties of stem cells in different 
representatives of animals with asexual reproduction (sponges, hydroids, planaria, colonial 
rhizocephalan crustaceans and colonial ascidia) are considered in comparison with 
metazoan germline cells and in vitro mammalian embryonic stem cells. 
Stem cells are an essential and defining feature developed during evolution of all 
multicellular organisms (Lohman, 2008; Batygina, 2010; Funayama et al., 2010). The study of 
mammalian embryonic stem cells has become a hot, intensely developing field in biology, 
biotechnology, and biomedicine. However, comparative studies of stem cells in various 
multicellular organisms are required to understand molecular mechanisms of maintaining 
pluri/totipotency, “stemness”, which still remain far from clear, as well as mechanisms that 
regulate gametogenesis, reproduction, development and regeneration. 
According to the generally accepted view, stem cells are cells of embryos or adult organisms 
capable of self-renewing by mitotic reproduction and differentiation into specialized cell 
types (Weissman et al., 2001; Cogle et al 2003; Müller, 2006; Lohman 2008; Rinkevich et al., 
2009; Sköld et al., 2009; Funayama et al., 2010). 
Two main types of stem cells should be considered: the cells of the germline and the somatic 
stem cell lineages (Hogan, 2001; Rinkevich, 2009; Srouji & Extavour, 2011). Germ cells are 
the only cell type capable of generating a new whole organism in animals; everlasting 
germline cycle continues from one generation to the next, thus the germline escapes the 
mortality that all somatic cells of an organism ultimately confront (the common view from 
Weismann, 1892, to Cinalli et al., 2008). The true innovation in the evolution was the 
generation of gametogenic germ line, the loss of gametogenic potential from the majority of 
cells of the organism and protection of the germ line throughout development (Extavour, 
2008; Strouji & Extavour, 2011). During development, germ cells are set aside from all 
somatic cells of the embryo (Cinalli et al., 2008). 
E. Davidson and colleagues have developed the “set-aside” hypothesis (Davidson et al., 
1995; Cameron et al., 1998; Jenner, 2000; Collins & Valentine, 2001). Cameron et al. (1998) 
called “set-aside cells” the patches of larval cells that give rise to the adult body plan in 
animals with indirect development while most of the larval cells have a dead-end fate. 
These cells are developmentally set aside from the embryo-larva differentiation process, 
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have an essentially unlimited division capacity, and they produce new populations of cells 
that are organized into the parts of the adult body plan (Cameron et al., 1998). So many 
adult organs are not derived from cells within larval organs, but from pluripotent cells 
sequestered, set aside during larval life as primordia from which adult structures form, such 
as imaginal discs of insects (Collins & Valentine, 2001). 
Generally, we can regard all stem cells as “set-aside cells”, reserve cells. 
The reproductive strategy of multicellular organisms can include sexual and asexual 
reproduction. In organisms with exclusively sexual reproduction, primary germ cells 
become segregated during embryogenesis. Two main types of germline cell specification 
were defined as preformation (early specification of primary germ cells by means of 
asymmetric distribution of maternal cytoplasmic determinants) and epigenesis, i.e. later 
specification of germ lineage cells by inductive signals (Extavour & Akam, 2003; Travis, 
2007; Frank et al., 2009). Recently, Strouji and Extavour (2011) refer to former 
“preformation” as “inheritance mode”, and former “epigenesis” as “inductive mode”. 
Besides, a third variant of germ cell specification, along with preformation and epigenesis, is 
recognized as somatic embryogenesis, in asexually reproducing animals, which have stem 
cells able to differentiate into germ and somatic cells throughout the life of an individual or 
a colony (Buss, 1987, 1999; Blackstone & Jasker, 2003; Frank et al., 2009; Rinckevich et al., 
2009). Pluri/totipotent stem cells of these animals provide a cell source for gametogenesis, 
asexual reproduction and regeneration (Isaeva et al., 2008b, 2009; Frank et al., 2009; Sköld et 
al., 2009). Stem cells that have the potential to become both somatic and primary germ cells 
and are morphologically indistinguishable from the latter were defined as “primary stem 
cells” (Sköld et al., 2009).  
In animals with asexual reproduction by somatic embryogenesis, the germ lineage remains 
non-segregated even in the adult organism, the gametes of which differentiate from stem 
cells (Blackstone & Jasker, 2003; Rinkevich, 2009; Sköld et al., 2009). Examples of such 
reserve stem cells, capable of differentiating both into germ and somatic cells, include 
sponge archaeocytes, cnidarian interstitial cells, planarian neoblasts, and stem cells of 
colonial ascidians (reviews: Isaeva et al., 2008b, 2009; Frank et al., 2009; Rinkevich et al., 
2009; Sköld et al., 2009; Isaeva, 2010; Srouji, Extavour, 2011). These self-renewing stem cells 
maintains continuously throughout the life of an individual or a colony, being predecessors 
of germ cells and all the types (or a wide spectrum) of somatic cells, so ensuring both sexual 
and asexual reproduction. Thus, in invertebrates with asexual reproduction, no early 
segregation of a germ cell lineage takes place, and a self-renewing reserve of stem cells with 
broad or unlimited morphogenetic potential is maintained over the entire lifespan. 
Similarly in plants, floral stem cells arise from stem cells of shoot apical meristema (Verdeil 
et al., 2007; Lohman, 2008; Batygina, 2010). Somatic embryogenesis is viewed as a condition 
characteristic to the lower metazoans; in the course of evolution, metazoans switch from 
somatic embryogenesis to preformation and epigenesis, and a subsequent return to somatic 
embryogenesis is a rare event (Blackstone & Jasker, 2003). If epigenesis was used by 
Urbilateria to specify the germ line, then preformation must have evolved convergently 
several times during the bilaterian radiation (Extavour, 2008).  
In organisms with asexual, agamous development, the organism that has developed from 
the zygote is capable of natural cloning and forming numerous genetically identical 
individuals or modular units of a colony. Clonal morphogenesis, called somatic 
embryogenesis, as applied to animals, was usually termed blastogenesis (Berrill, 1961; 
Ivanova-Kazas, 1996) while in plants it was termed somatic embryogenesis or 
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embryoidogenesis (see Verdeil et al., 2007; Batygina, 2010). In the life cycle of colonial 
animals, one generation of oozooid (individual that has developed from an egg) alternates 
with numerous generations of blastozooids, with respectively alternating morphogenetic 
processes: embryogenesis and blastogenesis (Ivanova-Kazas, 1996). In animal kingdom, 
natural cloning is a widespread phenomenon that includes polyembryony, budding, fission 
(architomy, paratomy, autotomy) etc. 
Both striking similarities and considerable differences in stem cell systems have been 
observed between plants and animals (Lohman, 2008; Batygina, 2010; Sablowski, 2010). 
Lohman (2008) considers as the most important differences the capacity of plants to 
maintain totipotent stem cells throughout their entire lives and the dramatic developmental 
plasticity of plant cells; besides, plant cells are unable to move within the organism by active 
migration. Similarities in the stem cell pools of plants and animals suggest that there might 
have been strong evolutionary constraints that shaped the path for the development of stem 
cell systems (Lohman, 2008; Sablowski, 2010). 
Our study points towards elucidation of the evolutionary conservative cellular, sub-cellular 
and molecular bases of “stemness”, focusing on the comparative investigation of pluripotent 
stem cells in reproducing asexually representatives of five metazoan types: archаeocytes in 
the sponge Oscarella malakhovi (Porifera), interstitial cells in the colonial hydroids Obelia 
longissima and Ectopleura crocea (Cnidaria), neoblasts in the planarian Girardia (Dugesia) 
tigrina (Plathelmintes), stem cells in the colonial parasitic rhizocephalan crustaceans 
Peltogasterella gracilis and Polyascus polygenea (Arthropoda), the colonial ascidian Botryllus 
tuberatus (Chordata), and also mammalian embryonic stem cells as a benchmark, “standard 
reference”, using in vitro culture, electron microscopic, histological, some histochemical, 
immunochemical, and molecular methods. Our hypothesis is the evolutionary conserved 
structural and functional organization of pluri/totipotent cells with gametogenic 
potentiality and of the molecular mechanisms maintaining it, in embryonic stem, reserve 
“primary” stem, and germline cells of different metazoan animals. Germplasm granules (or 
nuage) were studied as an ultrastructural marker and key organelle of germline cells and 
pluripotent stem cells of invertebrates. We have chosen as a molecular marker the 
evolutionarily conserved members of DEAD-box family (vasa and pl10 related genes) whose 
expression was revealed by other researchers in germinal granules of germline cells in 
various metazoan taxa (see below). The reaction revealing the activity of alkaline 
phosphatase, formerly used for the identification of embryonic stem and primary germ cells 
of mammals and other vertebrate animals, was applied as a cytochemical marker of the 
pluripotent cells of invertebrates. The proliferating cell nuclear antigen, PCNA, was used as 
a marker of the proliferation of self-renewing stem cells. 
Sponge archaeocytes, cnidarian interstitial cells, and planarian neoblasts are classical, long-
explored stem cells. Rhizocephalan crustaceans (Arthropoda: Crustacea: Cirripedia: 
Rhizocephala) parasitizing free-living crustaceans, mainly decapods, until now are often 
considered as incapable of asexual reproduction and coloniality (for example, Blackstone & 
Jasker, 2003; Sköld et al., 2009). However, at the parasitic stage of the life cycle, many species 
of rhizocephalan have asexual reproduction without separation of blastozooids, resulting in 
the emergence of colonial organization (Høeg, 1992; Høeg & Lützen, 1995; Isaeva et al., 2003, 
2004; Shukalyuk et al., 2005, 2007, 2011) that is unique among crustaceans, all arthropods, 
and all Ecdysozoa. Direct evidence of colonial organization at the parasitic stage of life cycle 
has been obtained only for a few rhizocephalan species. We visualized asexual 
reproduction, revealed and studied stem cells in the stolons and buds of the colonial 
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the emergence of colonial organization (Høeg, 1992; Høeg & Lützen, 1995; Isaeva et al., 2003, 
2004; Shukalyuk et al., 2005, 2007, 2011) that is unique among crustaceans, all arthropods, 
and all Ecdysozoa. Direct evidence of colonial organization at the parasitic stage of life cycle 
has been obtained only for a few rhizocephalan species. We visualized asexual 
reproduction, revealed and studied stem cells in the stolons and buds of the colonial 
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rhizocephalans Polyascus polygenea and Peltogasterella gracilis (Isaeva et al., 2003, 2004; 
Shukalyuk et al., 2005, 2007). Hemoblasts of the colonial ascidians Botryllus schlosseri, 
Botrylloides leachi and other species are considered as putative totipotent or pluripotent stem 
cells (Pancer et al., 1995; Burighel & Cloney, 1997; Stoner et al., 1999; Cima et al., 2001; Laird 
et al., 2005; Sunanaga et al., 2006), although stem cells have not been morphologically 
identified in the genus Botryllus. We have found stem cells, morphologically similar to 
hemoblasts in B. leachi (Cima et al., 2001) and other studied ascidians (Burighel & Cloney, 
1997), in the early buds and vascular system of the colonial ascidian Botryllus tuberatus 
(Akhmadieva et al., 2007). 
The data of our team showed that studied pluripotent reserve stem cells serve as the 
predecessors of germ and somatic cells and display some evolutionarily conserved features 
of the morphological and functional organization typical also for cells of the germ line and 
embryonic stem cells (Isaeva et al., 2003, 2004, 2005, 2008b, 2009, 2011; Akhmadieva et al., 
2007; Shukalyuk, Isaeva, 2005; Shukalyuk et al., 2005, 2007, 2011; Isaeva, 2010; Isaeva, 
Akhmadieva, 2011).  
2. Stem cells in asexually reproducing animals share common features with 
germ cells and embryonic stem cells  
2.1 Pluri/totipotency  
In animals with asexual reproduction, the differentiation of “primary” stem cells into germ 
and somatic cells is delayed, the germ lineage in these animals is not segregated (Tuzet, 
1964; Buss, 1987, 1999; Sköld et al., 2009); these stem cells serve as the cellular source of 
asexual and sexual reproduction as well as of regeneration (Isaeva et al., 2008b, 2009; Frank 
et al., 2009). Pluripotent stem cells can differentiate into a very wide spectrum of somatic 
cells in adult organisms. 
Depending on the width of the potential range of cell differentiation, totipotent, pluripotent, 
multipotent, oligopotent, and unipotent stem cells are distinguished, but the usage of this 
terminology is not unified (Müller, 2006; Newton, 2006; Isaeva et al., 2008b, 2009; Rinkevich 
et al., 2009; Sköld et al., 2009). Totipotent cells can give rise to all cell types of a developing 
organism; the zygote and the cells of the early mammalian embryo are totipotent. Stem cells 
of invertebrates reproducing asexually are traditionally often but not always referred to as 
totipotent, if their ability to differentiate into gametes and all somatic cells of the organism is 
shown (reviews: Isaeva et al., 2008b, 2009; Rinkevich et al., 2009; Sköld et al., 2009). For 
instance, archaeocytes of sponges are regarded as totipotent (Simpson, 1984; Müller, 2006) or 
pluripotent (Funayama, 2008; Funayama et al., 2010). Funayama believes that both 
archaeocytes and choanocytes of sponges are pluripotent. Neoblasts of planarians are 
considered totipotent (Shibata et al., 1999; Gschwentner et al., 2001; Peter et al., 2001; Sköld 
et al., 2009) or pluripotent (Shibata et al., 2010). Similarly, stem cells of colonial 
rhizocephalan crustaceans can also be considered totipotent (Isaeva et al., 2004, 2008b, 2009; 
Shukalyuk et al., 2005, 2007) or pluripotent. The stem cells in colonial ascidians are named 
both totipotent and pluripotent cells (Stoner et al., 1999; Weissman, 2000; Laird & Weissman, 
2004; Laird et al., 2005; Sunanaga et al., 2006). Stem cells giving rise to germline and many 
but not all somatic cell types are referred to as multipotent. Cnidarian interstitial cells are 
usually believed to be multipotent, especially in the genus Hydra (Bode, 1996; Mochizuki et 
al., 2001; Frank et al., 2009), but the interstitial cells of Hydractinia echinata are recognized as 
totipotent (Frank et al., 2009). 
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Estimations of the potentiality of female germ line cells are also contradictory: such cells can 
be qualified as unipotent, since they produce only one type of differentiated cells, and 
totipotent, taking into account their potential of developing into a whole organism (Hogan, 
2001; Seydoux & Braun, 2006; Strome & Lehman, 2007). Nussbaum (1880) recognized the 
germ line cells as totipotent and principally different from somatic cells with their limited 
potency. Accepting the concept of the maintenance of totipotency by cells of the female 
germ lineage, the author believes that the ability of the stem cells in asexually reproducing 
invertebrates to differentiate into female gametes and potentially to develop into a whole 
organism gives grounds for considering them as totipotent independently of the width of 
their somatic derivates (Isaeva et al., 2008b, 2009). 
If we understand cell totipotency as the ability of a single cell to produce a whole organism, 
only the zygote and the blastomeres of the early embryo of mammals and other animals 
with regulative type of development are totipotent, having the potential to form an entire 
living organism. Mammalian embryonic stem cells derived from inner cell mass of the 
blastocyst have pluripotency: they are able to differentiate into tissues of all three germ 
layers but cannot produce a whole embryo (Cogle et al 2003). On the other hand, 
mammalian embryonic stem cells are able to give oogenic cells and oocytes entering meiosis 
and parthenogenetically producing blastocyst-like cell masses (Hübner et al., 2003; Daley, 
2007; Kerkis et al., 2007). 
In plants, a new individual can develop from one totipotent somatic cell (Verdeil et al., 2007; 
Lohman, 2008; Batygina, 2010; Sablowski, 2010). In the asexual reproduction of plants, for 
instance in polyembryony, a new individual develops from one stem cell, and the pattern of 
the cell divisions is similar to the cleavage of the zygote (Batygina, 2010). Thus, a single 
totipotent stem cell of plants may be similar to zygote. The ability of plants to maintain 
totipotent stem cells over the entire life span of the organism is considered to be their 
fundamental difference from animal stem cells (Lohman, 2008; Verdeil et al., 2007). 
As for the stem cells of invertebrates with asexual reproduction, traditionally named 
totipotent, it is usually not one stem cell, but some kind of a complex, an aggregate of the 
stem cells gives rise to the new organism or zooid in asexual reproduction (Blackstone & 
Jasker, 2003; Rinkevich et al., 2009). It was experimentally shown that one stem cell of a 
trypsinized cysticercus of the parasitic cestode Taenia crassiceps injected into the host 
organism may form a whole cysticercus in the host organism (Toledo et al., 1997), but it is a 
rare exception from the common rule. In rhizocephalan crustaceans, the endoparasitic 
organism develops from a few cells introduced into the host organism by the larva (Høeg & 
Lützen, 1995). The number of stem cells in the earliest bud of the blastozooid of the colonial 
rhizocephalans Peltogasterella gracilis and Polyascus polygenea, according to the author’s data, 
is about 10–15 cells (Isaeva, 2010). The number of stem cells capable of producing the new 
individual in cnidarians, free living flat worms and colonial ascidians is estimated as lying 
between 100 and 300 (Rinkevich et al., 2009). A similar number of archaeocytes is required 
for producing a whole organism of the freshwater sponge Ephydatia fluviatilis, as 
experimentally determined by Nikitin (1977), who showed the necessity of a “critical mass” 
of cell aggregates for the development of a sponge organism. This “mass effect” is explained 
by the formation of sufficient concentrations of required metabolites in cell aggregates. The 
“critical mass” of cells is probably necessary also for the formation of an individual or a 
blastozooid in invertebrates. So, the ability of one cell or a small number of stem cells to 
develop into a whole organism is determined by an adequate environment. 
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To avoid confusion and misunderstanding, the term “pluripotent” is using here according to 
the recent reviews (Seydoux & Braun, 2006; Funayama et al., 2010; Strouji & Extavour, 2011). 
The problem of cell line having unlimited morphogenetic potential stems from A. 
Weismann’ “germ plasm” theory. August Weismann (1834–1914) was the first to discover 
and describe metazoan stem cells (Stammzellen) and primary germ cells (UrKeimzellen) in the 
course of his detailed study of colonial hydroids (Weismann, 1883; see also Frank et al., 
2009). According to Weismann (1892, 1893), stem cells, retaining the “germ plasm” 
(Keimplasma, the nuclear hereditary substance containing the determinants of germ cells), 
are capable of differentiating into gametes, providing for the continuity of the immortal 
germ line, the germline way (Keimbahn) and the continuation of life in the sequence of 
generations. It was Weismann who determined that the germ cells of hydroids originate 
from the embryonic reserve of undifferentiated cells, and he did not associate the concept of 
germ cell line with the early isolation of this line (Weismann, 1892). Weismann has shown 
that the germ cells of hydroids differentiate not during embryonic development, but much 
later, in generations formed by budding (Knospen-Generationen: Weismann, 1883). The idea 
of early germ cell segregation and of the continuity of these cells in the sequence of 
generations was first of all formulated by Nussbaum (1880), who believed that interstitial 
cells of Hydra maintain the germline way. It was later shown that the interstitial cells of 
hydroids, stem cells continuously undergoing the mitotic cycle, produce both germ cells and 
some types of somatic cells (see Bode, 1996; Bosch, 2008; Frank et al., 2009). Thus, hydroids, 
with their late specification of germline cells, differentiating from the interstitial cells during 
the entire lifespan of the colony and producing also somatic derivates, paradoxically became 
the main object of the studies that resulted in the emergence of the idea of early segregation 
of the totipotent germ cell line from somatic cells (Nussbaum, 1880), and to Weismann’s 
“germ plasm” theory (Weismann, 1883, 1892, 1893). Weismann supposed that germ cells 
preserve all the factors of inheritance, whereas each somatic cell loses, in the course of 
differentiation, part of the germ plasm and of the initial potential of the egg (Weissman, 
1892, 1893); Weismann’s concept has been criticized in the light of modern biological data 
(see, e.g., Frank et al., 2009). But Weismann’s views were not as rigid as the views of some 
his followers: “Weismann was not a weismannist” (Winter, 2001, p. 518). 
2.2 Self-renewal of stem cells 
The term “self-renewal” denotes the ability of stem cells to reproduce mitotically during a 
long period, and in the case of the stem cells of adult organisms, during entire life span of 
the organism (Weissman et al., 2001; Lohman 2008; Rinkevich et al., 2009; Sköld et al., 2009). 
Particularly, pluripotent stem, primary germ, and gonial cells have a common property – 
self-renewal through mitotic reproduction over long periods or throughout life span of the 
organism (Houston & King, 2000; Hogan, 2000; Sköld et al., 2009). 
For instance, sponge archaeocytes are self-renewing, mitotically active, telomerase-positive 
and bromodeoxyuridine incorporating cells (Müller, 2006; Funayama et al., 2010). Interstitial 
cells in hydra and other cnidarians can produce both germline cells and some but not all 
somatic cell types, since epidermal and gastrodermal cells are also capable of mitotic 
reproduction; so the stem cell system in hydroids includes interstitial, epidermal and 
gastrodermal stem cells continuously undergoing the mitotic cycle (Campbell, 1974; Thomas 
& Edwards, 1991; Bode, 1996). For the identification of stem cells capable of mitotic 
reproduction, bromodeoxyuridine, a thymidine analogue, was successfully used to reveal 
DNA synthesis in interstitial cells in hydra (Teragawa & Bode, 1990), and neoblasts in 
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flatworms (Gschwentner et al., 2001; Peter et al., 2001). Ethynyl deoxyurudine, another 
thymidine analogue, was employed for the same purpose in the ctenophore Pleurobrachia 
pileus (Alié et al., 2011). High activity of telomerase was shown in cells of the embryos, 
gonads, and early buds in colonial ascidian Botryllus schlosseri (Laird & Weissman, 2004).  
PCNA (proliferating cell nuclear antigen) assay is used to reveal cells that do not cease to 
divide mitotically (Hall & Woods, 1990). The PCNA assay was also used to identify neoblasts 
in planarian; it has been shown that such a test is a reliable tool for neoblast identification in 
Girardia japonica (Orii et al., 2005). We used the immunochemical test PCNA to reveal 
proliferating cells in the colonial rhizocephalan Peltogasterella gracilis and the colonial hydroid 
Obelia longissima. Stem cells in budding stolons proved to be the only PCNA-positive cells in 
the P. gracilis interna while differentiated epithelial cells of the stolon and cells of the trophic 
system of the interna were PCNA-negative (Shukalyuk et al., 2005). Such test in O. longissima 
has revealed a more intense staining of interstitial and gonial cells, although reproducing 
epidermal and gastrodermal cells were also positive; differentiated somatic cells manifested 
poor or negative reaction (Isaeva et al., 2011). 
Mammalian embryonic stem cells express telomerase, the protein associated with a 
pluripotent and immortal phenotype (Cogle et al 2003). 
2.3 Gametogenic potentiality 
The pluripotent stem cells ensure both sexual and asexual reproduction, being predecessors 
of the germ and all the somatic cells. The ability to differentiate into gametogenic and 
somatic cells was shown for archaeocytes and choanocytes in sponges (Simpson, 1984; 
Müller, 2006; Funayama, 2008; Funayama et al., 2010), interstitial cells in hydra and other 
cnidarians (Thomas & Edwards, 1991; Bode, 1996; Isaeva et al., 2011), turbellarian neoblasts 
(Shibata et al., 1999; Peter et al., 2001; Isaeva et al., 2005), stem cells of colonial 
rhizocephalans (Isaeva et al., 2004; Shukalyuk et al., 2005), ascidian stem cells (Pancer et al., 
1995; Stoner & Weissman, 1996; Stoner et al., 1999; Weissman, 2000). So, pluripotent stem 
cells in invertebrates with asexual reproduction are potentially gametogenic cells. 
Particularly, sponges have no permanent germline; archaeocytes and choanocytes are 
gametogenic cells (Tuzet, 1964; Blackstone & Jasker, 2003; Sköld et al., 2009). Sponge 
archaeocytes are considered to be the main cell source in sexual and asexual reproduction 
(Simpson, 1984; Müller, 2006; Funayama, 2008). Probably, the stem system of sponges 
includes two types of pluripotent stem cells: archaeocytes and choanocytes; both cell types 
are able to differentiate into germ and somatic cells; choanocytes can transform to 
archaeocytes, which later produce other cell types (Funayama, 2008; Funayama et al., 2010). 
Cnidarian interstitial cells can produce germline cells (Campbell, 1974; Thomas & Edwards, 
1991; Bode, 1996). The gonial cells and early oocytes developing from interstitial cells are 
distinct from them only by a greater size (Thomas & Edwards, 1991). 
Gametogenic potentiality was most convincingly displayed using planarians (Baguña et al., 
1989; Peter et al., 2001; Shibata et al., 1999). Neoblasts of asexually reproducing planarians 
and other Turbellaria are able to differentiate into germ and somatic cells of all types (Agata 
& Watanabe, 1999; Shibata et al., 1999; Peter et al., 2001; Orii et al., 2005). According to our 
data, neoblasts can become gonial cells: among individuals in asexual race of Girardia tigrina 
that reproduced exclusively by architomy during 40 years, one planaria laid cocoons after 
spontaneous sexualization; histological and ultrastructural study of this planaria 
demonstrated the presence of gonads, gonial cells, and oocytes (Isaeva et al., 2005). 
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Pluripotent stem cells of colonial rhizocephalans are also the predecessors of somatic and 
germ cells, so ensuring the reproductive strategy with alternation of asexual and sexual 
reproduction. In the colonial rhizocephalans Polyascus polygenea and Peltogasterella gracilis 
the stem cells migrated into the developing ovary becoming oogonial cells (Isaeva et al., 
2004; Shukalyuk et al., 2005). 
In colonial ascidians, germline as well as somatic cells differentiate from circulating 
hemoblasts (Pancer et al., 1995; Stoner & Weissman, 1996; Stoner et al., 1999). The 
differentiation of Botryllus primigenus hemoblasts into female germline cells was observed, 
and the primary germ cells are morphologically indistinguishable from hemoblasts 
(Sunanaga et al., 2006). Fusion of the vascular systems of colonies in ascidian B. schlosseri can 
lead to the replacement of germ and somatic cells in one colony with those from another one 
(Pancer et al., 1995; Stoner & Weissman, 1996; Stoner et al., 1999; Weissman, 2000; Laird et 
al., 2005). It remains unclear if the germline and somatic lineages are segregated or they 
descend from the same initial stem cell population in botryllids (Stoner et al., 1999). 
Pluripotent embryonic stem cells of mammals have capability to differentiate in vitro into 
female and male germ cells (Hübner et al., 2003; Geijsen et al., 2003; Toyooka et al., 2003; 
Clark et al., 2004; Daley, 2007; Kerkis et al., 2007). 
2.4 Morphological features of pluripotent stem cells 
Pluripotent stem cells of asexually reproducing invertebrates and germline cells of all 
studied metazoan animals share common morphological and functional features: a high 
nuclear/cytoplasmic ratio, a large rounded nucleus with diffuse chromatin and a prominent 
nucleolus, thin rim of undifferentiated basophilic cytoplasm, including specific electron-
dense cytoplasmic granules or nuage, and a set of specific regulatory molecules (Shukalyuk 
& Isaeva, 2005; Isaeva et al., 2008b, 2009, 2011; Extavour, 2008; Rinkevich et al., 2009; Isaeva, 
2010; Strouji & Extavour, 2011; Shukalyuk et al., 2011). Germ cells can almost always be 
unambiguously distinguished from somatic cells by the same characteristic morphology 
(Extavour, 2008). 
The morphological organization of pluripotent stem and gonial cells in the studied 
representatives of Porifera, Cnidaria, Platyhelminthes, Arthropoda, and Chordata shares 
common features typical for germline cells in other studied Metazoa (Isaeva et al., 2003, 
2004, 2005, 2008b, 2009; Akhmadieva et al., 2007; Shukalyuk & Isaeva, 2005; Shukalyuk et al., 
2005, 2007, 2011; Isaeva et al., 2011). For example, archaeocytes of the sponge Oscarella 
malakhovi, interstitial and gonial cells of the colonial hydroids Obelia longissima and 
Ectopleura crocea as well as neoblasts of the planarian Girardia tigrina have an ultrastructural 
morphology typical for stem and germ cells of all metazoan animals (Isaeva et al., 2005, 
2011; Isaeva & Akhmadieva, 2011). Stem cells in the rhizocephalans Polyascus polygenea 
(Isaeva et al., 2004) and Peltogasterella gracilis (Shukalyuk et al., 2005) similarly demonstrate 
all morphological properties that are common to embryonic, pluripotent stem and germ 
cells of other metazoan animals. 
2.4.1 Germinal granules (nuage) 
Germline cells 
The cells of the germ line can be identified and retraced during development of an organism 
owing to the availability of the “germ plasm” as cytoplasmic markers presented by granular 
or fibrillar material not surrounded by a membrane. “Germ plasm”, Weismann’s famous 
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term (Weismann, 1892, 1893) now is understood metaphorically. According to this modern 
understanding, the “germ plasm” contains electron-dense, RNA-enriched material 
structured as compact germinal granules or a more dispersed “nuage”, a specific 
ultrastructural marker of metazoan germline cells (see Matova & Cooley, 2001; Seydoux & 
Braun, 2006; Strome & Lehman, 2007). The germinal granules or nuage are considered key 
organelles of germline cells (Ikenishi, 1998; Amikura et al., 2001; Matova & Cooley, 2001; 
Chuma et al., 2006; Seydoux & Braun, 2006; Lim & Kai, 2007; Strome & Lehman, 2007). 
The specific electron-dense material of germinal granules was denoted in the early XX 
century by the German terms Keimbahnchromidien and Keimbahnplasma, and this terminology 
was directly related to Weismann’s; later the English terms germ plasm, germ cell 
determinants, polar, perinuclear, chromatoid, germinal, germ granules (bodies), dense bodies, 
ectosomes, the French term nuage, and many others were introduced (see Mahowald, 1971, 
2001; Beams & Kessel, 1974; Eddy, 1975; Ikenishi, 1998;  Houston & King, 2000; Isaeva & 
Reunov, 2001; Matova & Cooley, 2001; Seydoux & Braun, 2006; Lim and Kai, 2007; Strome & 
Lehnam, 2007; Isaeva et al., 2008b, 2009; Frank et al., 2009; Isaeva, 2010). Complex structures, 
including electron-dense material and mitochondria in vitellogenic oocytes, are called also 
the Balbiani body, vitelline (yolk) body, mitochondrial cloud, intermitochondrial cement, yolk 
nucleus: “the chaos in the nomenclature” complicates the comparison of these structures in 
different species (Kloc et al., 2004). 
The presence of germinal (perinuclear) granules is an evolutionary conserved feature of 
germline cells in multicellular animals. These specific organelles have been found in more 
than 80 species of seven animal types (Eddy, 1975). The structure of these organelles is 
similar, but they can be represented in cells of different organisms and at different life cycle 
stages as either a few large granules (bodies) or as a cloud (nuage) of fine-dispersed 
material. In oogenesis, the germinal bodies transform morphologically but do not disappear 
in female germ cells throughout the life cycle: for instance, the polar granules are gradually 
replaced with nuage during polar cell migration in Drosophila (Mahowald, 1971). The 
continuity of the maternally inherited germ plasm material throughout the life cycle has 
been demonstrated in Drosophila, Xenopus, and nematode (Mahowald, 1971, 2001; Ikenishi, 
1998). 
In the plant kingdom, oogonial cells of the brown alga Undaria pinnatifida include electron-
dense bodies similar to the germinal granules of metazoan oogonial cells and oocytes; 
similar bodies were found in the cytoplasm of some other species of higher and lower plants 
(Alexandrova & Reunov, 2008), giving evidence of the common pattern of the 
morphofunctional organization of plant and animal reproductive cells. This similarity 
indicates a very conserved features of reproductive cells in Metazoa and Metaphyta. 
Germlinal granules in pluripotent stem cells 
In some asexually reproducing invertebrates, stem cells capable to differentiate into germ 
and somatic cells can be also identified by the presence of specific electron-dense cytoplasmic 
structures, morphologically similar or identical to germinal granules or nuage in germline 
cells. The “germ plasm,” containing germinal granules or dispersed “nuage” material, 
becomes acceptable as a specific ultrastructural marker and a key organelle in pluripotent, 
potentially gametogenic stem cells of asexually reproducing invertebrates (Shibata et al., 1999; 
Mochizuki et al., 2001; Isaeva et al., 2008b, 2009, 2011; Frank et al., 2009; Strouji & Extavour, 
2011), although the data concerning the structural and molecular organization of germ 
determinants in the cells of various metazoan taxa are rather fragmentary. 
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The germinal granules in stem cells of invertebrates, whose life cycle includes asexual 
reproduction, were earlier have been revealed in the interstitial cells of Pelmatohydra robusta 
(Noda, Kanai, 1977) and the planarian neoblasts (Hori, 1982; Rieger et al., 1991; Auladell et 
al., 1993; Agata & Watanabe, 1999; Shibata et al., 1999). Noda and Kanai (1977) shown that 
not only germline cells but also interstitial cells contain germ plasm with “dense bodies” 
associated with nuclear pores and mitochondria. The number and size of these dense bodies 
in P. robusta decreases as somatic cells (cnidoblasts) differentiate from interstitial cells and 
increases during early oogenesis (Noda & Kanai, 1977). In planarian, the germinal granules 
(chromatoid bodies) were observed both in the germline cells and in the neoblasts, where 
they likewise lie near the nuclear envelope in contact with the mitochondria (Hori, 1982; 
Auladell et al., 1993; Shibata et al., 1999). Chromatoid bodies disappear during neoblast 
differentiation into somatic cells, while in oogenic cells they are present throughout the life 
cycle (Hori, 1982; Auladell et al., 1993; Shibata et al., 1999). These observations led to a 
suggestion that chromatoid bodies have the function related to pluri/totipotency 
maintenance (Shibata et al., 1999). 
Typical electron-dense germinal granules have not been previously described in the 
archaeocytes or any other cells of sponges. Dense fibrillar bodies were found in the oogonia 
and oocytes of different sponges (see Tuzet, 1964; Isaeva, Akhmadieva, 2011). In the 
cytoplasm of archaeocytes in the sponge Oscarella malakhovi we have found germinal 
granules of a typical morphology located near the nuclear envelope (Isaeva & Akhmadieva, 
2011). The electron-dense germinal bodies revealed in interstitial cells of the colonial 
hydroids Obelia longissima and Ectopleura crocea (Akhmadieva et al., 2005; Isaeva et al., 2011) 
were similar in their ultrastructure to the “dense bodies” in interstitial and germ cells of 
Pelmatohydra robusta (Noda & Kanai, 1977) as well as in oocytes of Hydra carnea (Honegger et 
al., 1989) and other cnidarians (Thomas & Edwards, 1991). Such germinal granules are 
common for interstitial cells and oocytes of O. longissima. The germinal granules (usually 
termed chromatoid bodies) have been found near the nuclear envelope (often in contact 
with nuclear pores) surrounded by mitochondria in neoblasts and gonial cells of the 
planarian Girardia tigrina (Isaeva et al., 2005). 
The cytoplasm of embryonic and stem cells in the studied rhizocephalans Peltogasterella 
gracilis and Polyascus polygenea contains germinal granules morphologically similar to those 
in germ cells. In particular, stem cells in rhizocephalan P. gracilis feature the presence of the 
germinal bodies with a typical ultrastructural morphology; all or most blastomeres of 
cleaving Peltogasterella gracilis embryos contain prominent germinal granules (Shukalyuk et 
al., 2005, 2007, 2011). 
In the colonial ascidian Botryllus tuberatus, we observed in the cytoplasm of some stem cells 
in early buds small electron-dense bodies (Akhmadieva et al., 2007), which are similar to the 
nuage material often found in vertebrates. 
So, pluripotent gametogenic stem cells in studied asexually reproducing sponges, 
cnidarians, turbellarians, arthropods, and chordates feature the presence of the germinal 
granules. So germinal granules (or more dispersed nuage material) can be used as a specific 
ultrastructural marker and a key organelle of pluripotent stem cells of asexually 
reproducing invertebrates (Shibata et al., 1999; Mochizuki et al., 2001; Isaeva et al., 2008b, 
2009, 2011; Frank et al., 2009; Isaeva, 2010; Isaeva & Akhmadieva, 2011). 
Electron-dense granular structures were observed also in embryonic stem cells of mouse 
(Shukalyuk et al., 2011). Thus, germinal granules were found not only in cells of the germ 
line but also in pluripotent stem cells of asexually reproducing invertebrates (sponges, 
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hydroids, turbellarians, colonial rhizocephalan crustaceans and ascidians) and pluripotent 
mESC in vitro. 
In some somatic metazoan cells, processing bodies (P-bodies) have been found; their 
function is translation and they are considered as a structural and functional analog of the 
germinal granules (see Seydoux & Braun, 2006; Kotaja et al., 2006). 
2.5 Molecular markers of stem cells 
The ultrastructural and molecular organization of germinal granules of germline cells is 
evolutionarily conserved in all studied representatives of the animal kingdom from sponges 
to mammals (Ding & Lipshitz, 1993; Ikenishi, 1998; Houston & King, 2000; Matova & 
Cooley, 2001; Mochizuki et al., 2001; Extavour & Akam, 2003; Juliano et al., 2006; Seydoux & 
Braun, 2006; Strome & Lehman, 2007; Extavour, 2008; Ewen-Campen et al. 2010; Srouji & 
Extavour, 2011). It has been shown that some molecules localized in germinal granules are 
involved in specification of germline cells, and some genes encoding them are highly 
conserved evolutionary in all studied metazoans (Mahowald, 2001; Matova & Cooley, 2001; 
Mochizuki et al., 2001; Sato et al., 2001; Seydoux & Braun, 2006; Strome & Lehman, 2007). 
Germinal granules components include proteins, mRNAs, and noncoding RNAs; as far as is 
known, RNA-binding proteins are involved in mRNA localization, protection, and 
translation control (Extavour & Akam, 2003; Leatherman & Jongens, 2003; Chuma et al., 
2006; Seydoux & Braun, 2006; Hayashi et al., 2007; Lim & Kai, 2007; Strome & Lehman, 2007; 
Ewen-Camden et al., 2010). The germinal granules are thought to function as a specific 
cytoplasmic regulatory center preventing the expression of somatic differentiation genes, 
maintaining the totipotency in germline cells, necessary for the conception of a new 
organism, preventing somatic gene expression and protecting the cells from somatic 
differentiation, that confirmed by data on the transcription “silence” of germline cells 
(Leatherman & Jongens, 2003; Chuma et al., 2006; Seydoux & Braun, 2006; Strome & 
Lehman, 2007; Cinalli et al., 2008; Extavour, 2008). 
Germline cells can be distinguished from somatic cells by localization of mRNA or protein 
products of germ-cell-specific genes, notably the vasa and nanos gene family products 
(Extavour, 2008). Genes representing the core of the germline program, as vasa, piwi, nanos 
show striking evolutionary conservation (Extavour & Akam, 2003).  
Several conserved molecules are expressed in both germ and pluripotent stem cells; these 
include Piwi family proteins, Tudor family proteins, and PL10 gene products, vasa family 
members, and possibly nanos (Extavour, 2008; Ewen-Camden et al., 2010; Srouji & Extavour, 
2011). Like germline cells, stem cells of asexually reproducing invertebrates are also 
characterized by the expression of protein products of genes related to vasa, piwi, nanos, and 
some other genes (reviews: Rinkevich et al., 2009; Sköld et al., 2009; Funayama et al., 2010). 
Nanos, a CCHC zinc finger RNA-binding protein expressed in germline stem cells in 
planarians (Sato et al., 2006), and in hydra (Mochizuki et al., 2000). 
The piRNA-binding proteins of Argonaute subfamily, coding by piwi-related genes plays a 
central role in RNA silencing in a small RNA-mediated manner or via translational 
regulation; small regulatory RNAs include small interfering RNAs and Piwi-interacting 
RNAs mediating the epigenetic regulation of gene expression; these small RNAs can exert 
regulation at the transcriptional level, by affecting chromatin structure, or post-
transcriptionally, by affecting mRNA stability or translation (Ambrose & Chen 2007). In 
metazoan germ cells, piwi–related genes express, presumably involving in germline and 
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characterized by the expression of protein products of genes related to vasa, piwi, nanos, and 
some other genes (reviews: Rinkevich et al., 2009; Sköld et al., 2009; Funayama et al., 2010). 
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stem cell maintenance; Piwi proteins as well as several microRNAs are highly evolutionary 
conserved within plant and animal kingdoms (Filipowicz et al., 2005; Ambrose & Chen 2007; 
Funayama et al., 2010; Shibata et al. 2010; Alié et al., 2011). Gametogenic pluripotent stem 
cells in sponges (Funayama et al., 2010), cnidarians (Seipel et al., 2004) and flatworms 
(Shibata et al., 2010) express piwi homologs. 
So stem cells of invertebrates with asexual reproduction, as well as cells of the germ lineage, 
also display the expression of proteins related to Piwi, Nanos, and some others (reviews: 
Rinkevich et al., 2009; Sköld et al., 2009; Srouji & Extavour, 2011). In stem cells of the sponge 
Ephydatia fluviatilis, the activity of a gene related to piwi, which is expressed in germ and 
stem cells of other animals and plants and whose function is to maintain the totipotency 
(pluripotency) of these cells, was detected (Funayama, 2008; Funayama et al., 2010). 
Mammalian embryonic stem cells express gene Oct4 coding transcription factor associated 
with a pluripotent and immortal phenotype (Cogle et al., 2003), however, this gene unique 
to deuterostomes (see Srouji & Extavour, 2011). In undifferentiated mouse embryonic and 
induced pluripotent stem cells, which, along with invertebrate stem cells, are potentially 
gametogenic cells retaining pluripotency, expression of Miwi/Piwi, Nanog/Nanos and Oct4 
was found (Shukalyuk et al., 2011). Thus, embryonic stem, germ and pluripotent stem cells 
of various metazoan animals share piwi gene expression. 
2.5.1 Vasa and other members of DEAD-box family 
The first identified component of the granules of germ plasm was the protein product of the 
Drosophila vasa gene (Hay et al., 1988), RNA helicase, belonging to the family of proteins 
containing conserved DEAD-box sequences (Luking et al., 1998; Raz, 2000; Extavour & 
Akam, 2003; Rosak & Linder, 2004). Proteins of the DEAD family are found in all eukaryotes 
(from yeast up to plants and animals) and are involved in splicing, editing, processing, 
nuclear-cytoplasmic traffic, initiation of translation, and degradation of RNA (Raz, 2000; 
Rosak & Linder, 2004). The Vasa family is thought to have evolved from the PL10 family of 
helicases, which share significant structural similarity with vasa gene products (Mochizuki 
et al., 2001). PL10 products are usually localized to both germ cells and pluripotent cell types 
(Extavour, 2008). Germinal granules of germline cells in various animals, from sponges to 
vertebrates, were found to contain a protein product (RNA-helicase) of the vasa gene or 
related genes, a key determinant and a universal marker of germline cells in metazoans, 
which is necessary for the formation and maintenance of the structural organization of 
germinal granules and, presumably, for the maintenance of pluri/totipotency of cells; in 
animals that reproduce only sexually, the expression of vasa-related genes is always 
exclusively confined to the germcell line during the entire course of development, from 
early embryo up to gametogenesis (Ding & Lipshitz, 1993; Ikenishi, 1998; Shibata et al., 1999; 
Castrillon et al., 2000; Raz, 2000; Matova & Cooley, 2001; Mochizuki et al., 2001; Extavour & 
Akam, 2003; Seydoux & Braun, 2006; Sunanaga et al., 2006; Strome & Lehman, 2007; Ewen-
Campen et al. 2010). Antibodies against Vasa protein react with both polar granules and 
nuage in Drosophila (Hay et al., 1988), which confirms the functional identity of these 
structures (Mahowald, 2001). The specifics of the structural organization of the cytoplasm 
and of the functional activity of germline cells has resulted from evolutionarily conserved 
mechanisms common to all studied metazoan animals, and the presence of Vasa-like 
proteins in the germ plasm of different animals indicates the conservation of molecular 
mechanisms underlying the formation and maintenance of the germ plasm (Raz, 2000; 
Extavour & Akam, 2003; Juliano et al., 2006; Extavour, 2008; Ewen-Campen et al., 2010). 
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In the polyembryonic wasp Copidosoma floridanum, the secondary embryos develop either 
into normal larvae and then into fertile insects or into soldier larvae with the defense 
function. During development, at the stage of four blastomeres, one of them is Vasa-
positive, and it gives rise to primary germline cells; embryos containing the Vasa-positive 
blastomere become fertile imagoes while the caste of soldiers without germline cells 
develops from the embryos depleted of the Vasa-positive blastomere, that confirms the 
involvement of Vasa protein in germline and caste determination in C. floridanum (Donnell 
et al., 2004; Corley et al., 2005). 
The presence of a Vasa-like protein was demonstrated not only in germline cells but also in 
large interstitial cells of hydra Pelmatohydra robusta (Mochizuki et al., 2001) and neoblasts of 
planarians (Shibata et al., 1999). Sequences of Vasa homologs have been found in the sponge 
Ephydatia fluviatilis (Mochizuki et al. 2000, 2001). 
We have revealed the evolutionarily conserved sites of genes of the DEAD family, 
particularly vasa and pl10 related genes, in DNA of the rhizocephalan crustaceans Polyascus 
polygenea, Peltogasterella gracilis and Clistosaccus paguri (Shukalyuk et al., 2007). Based on 
deduced sequencing of the protein products of these genes and on data from the genetic 
bank, a phylogenetic tree showing the close relationships of rhizocephalans to other 
arthropods was constructed. Selective expression of RNA of the vasa-related gene in stem 
and germline cells and its localization in the germinal granules of embryonic cells of P. 
polygenea were revealed. So selective expression of the vasa-related genes, the evolutionarily 
conserved markers and determinants of germline cells formerly revealed in germ cells of 
various metazoan animals and in stem cells of cnidarians and planarians, was also observed 
in embryonic, stem and germ cells of rhizocephalans (Shukalyuk et al., 2007). Thus, the 
expression of a gene related to vasa is specific not only to germline cells, but also to 
pluripotent gametogenic stem cells in asexually reproducing invertebrates, and the products 
of vasa-related genes involved in the determination of germ cells and in maintenance of 
cellular pluri/totipotency can be a useful molecular marker of pluripotent stem cells 
(Shibata et al., 1999; Mochizuki et al., 2001; Shukalyuk et al., 2007, 2009; Rinkevich et al., 
2009; Sköld et al., 2009; Srouji & Extavour, 2011). The maintenance of the stem cell 
morphofunctional organization involves evolutionary conserved developmental 
mechanisms common for studied asexually reproducing multicellular animals. 
Recently, Alié et al. (2011) found the expression of piwi, vasa and PL10 in the male and 
female germlines and within pluri/multipotent stem cells in Pleurobrachia pileus 
(Ctenophora) without asexual reproduction. The authors suggest that piwi, vasa and PL10 
belong to a gene network ancestrally acting in two contexts: the germline and stem cells, 
whatever the nature of their progeny (Alié et al., 2011). 
The data on vasa-, PL10- and piwi-related genes in pluripotent stem cells of invertebrates are 
presented in Table 1. 
2.5.2 Mitochondrial components of germinal granules 
The material of germinal granules (nuage) includes products of the nuclear genome; besides, 
there is evidence for the mitochondrial origin of some molecular components of germinal 
granules. The contact with mitochondria is a typical property of structured germinal 
granules in diverse multicellular animals (Isaeva & Reunov, 2001; Matova & Cooley, 2001; 
Carré et al., 2002). Ribosomal RNAs of mitochondrial origin and several other products of 
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stem cell maintenance; Piwi proteins as well as several microRNAs are highly evolutionary 
conserved within plant and animal kingdoms (Filipowicz et al., 2005; Ambrose & Chen 2007; 
Funayama et al., 2010; Shibata et al. 2010; Alié et al., 2011). Gametogenic pluripotent stem 
cells in sponges (Funayama et al., 2010), cnidarians (Seipel et al., 2004) and flatworms 
(Shibata et al., 2010) express piwi homologs. 
So stem cells of invertebrates with asexual reproduction, as well as cells of the germ lineage, 
also display the expression of proteins related to Piwi, Nanos, and some others (reviews: 
Rinkevich et al., 2009; Sköld et al., 2009; Srouji & Extavour, 2011). In stem cells of the sponge 
Ephydatia fluviatilis, the activity of a gene related to piwi, which is expressed in germ and 
stem cells of other animals and plants and whose function is to maintain the totipotency 
(pluripotency) of these cells, was detected (Funayama, 2008; Funayama et al., 2010). 
Mammalian embryonic stem cells express gene Oct4 coding transcription factor associated 
with a pluripotent and immortal phenotype (Cogle et al., 2003), however, this gene unique 
to deuterostomes (see Srouji & Extavour, 2011). In undifferentiated mouse embryonic and 
induced pluripotent stem cells, which, along with invertebrate stem cells, are potentially 
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nuage in Drosophila (Hay et al., 1988), which confirms the functional identity of these 
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 vasa PL10 piwi 
Porifera   Funayama et al., 2010 
Cnidaria Mochizuki et al., 2001; 
Rebscher et al., 2008 
Mochizuki et al., 2001 Seipel et al., 2004 
Ctenophora Alié et al., 2011 Alié et al., 2011 Alié et al., 2011 
Plathelminthes Agata et al., 2006; 
Pfister et al., 2008 
Shibata et al., 1999 Shibata et al. 2010 
Annelida Rebscher et al., 2007 Rebscher et al., 2007 Rebscher et al., 2007 
Arthropoda 
(Rhizocephala) 
Shukalyuk et al., 2007, 
2011 
Shukalyuk et al., 2007, 
2011 
 
Echinodermata Juliano & Wessel, 2009  Juliano et al., 2006 
Chordata 
(Tunicata) 
Rosner et al., 2009 Rosner et al., 2005 Brown et al., 2009 
Table 1. Gene expression in pluripotent stem cells of invertebrates 
the mitochondrial genome were revealed in the germinal granules of Drosophila, planarian 
and the frog Xenopus (Ding & Lipshitz, 1993; Kobayashi et al., 1998, 2005; Kashikawa et al., 
1999; Amikura et al., 2001; Mahowald, 2001; Matova & Cooley, 2001; Leatherman & Jongens, 
2003; Seydoux & Braun, 2006). The germinal granules are commonly surrounded with 
polysomes (Mahowald, 2001); polysomes in Drosophila embryos were shown to contain 
ribosomes similar to mitochondrial ones by size properties (Amikura et al., 2001; Kobayashi 
et al., 2005). In Xenopus 16S rRNA can be found outside of mitochondria only in the germ 
plasm granules (Kobayashi et al., 1998). Mitochondrial (both large and small) ribosomal 
RNA has also been detected in the chromatoid bodies in turbellarian neoblasts (Sato et al., 
2001). 
The presence of mitochondrial rRNAs outside of the mitochondria in association with 
germinal granules has been generally accepted; it becomes apparent that mitochondrial 
rRNAs and other products of the mitochondrial genome are involved in the formation of 
germline cells in diverse multicellular animals (Ikenishi, 1998; Kloc et al., 2000; Mahowald, 
2001; Amikura et al., 2001; Matova & Cooley, 2001; Leatherman & Jongens, 2003; Seydoux & 
Braun, 2006). It has been suggested that products of both the nuclear and mitochondrial 
genomes are essential for the structural organization and functioning of the germinal 
granules of germ plasm (Kobayashi et al., 1998, 2005; Ding & Lipshitz, 1993; Isaeva & 
Reunov, 2001; Isaeva et al., 2005, 2011). 
The export of mitochondrial rRNA from mitochondria to the polar granules in Drosophila 
depends on the activity of nuclear genes oskar, vasa, and tudor (Amikura et al., 2001; Matova 
& Cooley, 2001). Vasa protein or its homolog, a component of the germinal granules in 
different animals, has been found in the mitochondrial matrix of germline cells in Xenopus 
embryos (Watanabe et al., 1992). Similarly, the protein encoded by the nuclear gene tudor is 
present both in the polar granules and inside mitochondria in the early Drosophila embryos 
(see Ding & Lipshitz, 1993). In addition to these proteins, the germ determinants include 
many more components encoded by the nuclear genome. 
The export of the ribosomal RNAs from mitochondria to the germinal granules is no longer 
questioned, but the mechanism underlying a transport is considered unprecedented and 
enigmatic (Kashikawa et al., 1999; Ding & Lipshitz, 1993; Amikura et al., 2001). Our 
ultrastructural data indicating the disruption of the outer mitochondrial membrane and the 
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transformation of the mitochondrial matrix with inner membrane cristae into material of 
germinal granules in representatives of various animal taxa may clarify the mechanism of 
the export of mitochondrial components into germinal granules (Reunov et al., 2000; Reunov 
et al., 2004; Isaeva et al., 2005, 2011; Isaeva & Akhmadieva, 2011). This phenomenon enables 
us to suppose the participation of mitochondria in the biogenesis of the germinal granules 
(Isaeva & Reunov, 2001; Isaeva et al., 2005, 2011). 
Destruction of the outer mitochondrial membrane and transformation of the mitochondrial 
matrix to the material of germinal granules or nuage have been revealed in the gonial cells 
of echinoderms and vertebrates (Reunov et al., 2000, 2004), planarian (Isaeva et al., 2005), 
sponge (Isaeva & Akhmadieva, 2011) and hydroids (Isaeva et al., 2011). The ultrastructural 
evidence of mitochondrial origin of the germinal granules (chromatoid bodies) in gonial 
cells and neoblasts of planarian Girardia tigrina has been obtained: the transformation of 
mitochondrial matrix with inner membrane cristae into the germinal bodies was observed 
(Isaeva et al., 2005). The mitochondrial derivatives devoid of the outer membrane but still 
containing flattened vesicles as remnants of inner membrane cristae is a usual picture 
observed in the germ granules or nuage of stem and gonial cells in the studied 
representatives of diverse taxa including the sponge Oscarella malakhovi and the hydroids 
Obelia longissima and Ectopleura crocea (Isaeva & Akhmadieva, 2011; Isaeva et al., 2011). We 
suggest that the structural frame of germinal granules derives from mitochondria and is 
filled with transcription products of the nuclear genome. The release of the mitochondrial 
matrix material in the germ plasm is the way to incorporate the mitochondrial derivatives 
into germinal granules, mediating the involvement of mitochondrial genome products in the 
biogenesis of the macromolecular complex of germinal determinants (Isaeva & Reunov, 
2001; Isaeva et al., 2005, 2011). We propose also flows of molecular information connecting 
the nucleus, mitochondria, and germinal granules and involving in pluri/totipotency 
maintenance (Isaeva et al., 2005). The maintenance of the preexisted structural and 
functional organization of the germinal granules as cytoplasmic regulatory centers is likely 
controlled by ancient conserved mechanisms common for all multicellular animals (Isaeva & 
Reunov, 2001; Isaeva et al., 2005, 2011). 
2.5.3 Alkaline phosphatase activity in stem cells 
The histochemically detectable high level of alkaline phosphatase activity has become an 
empirical marker of mammalian primary germ and embryonic stem cells in vivo and in vitro 
(Chiquoine, 1954; Mintz, 1959; Talbot et al., 1993; Thompson et al., 1998; Lacham-Kaplan, 
2004). High activity of alkaline phosphatase has been determined in the cultured embryonic 
stem cells, not only of mammals, but also of other vertebrates (for examples, Hong et al., 
1998). Germ cells can be distinguished from somatic cells by high levels of alkaline 
phosphatase activity in vertebrate germline cells (Extavour, 2008). 
No similar research has been carried out on invertebrates until quite recently. We applied 
cytochemical methods to show alkaline phosphatase activity for stem cell identification in 
the rhizocephalans Peltogasterella gracilis and Polyascus polygenea at the colonial parasitic 
stage of their life cycle to reveal the common feature of pluripotent stem cells of vertebrate 
and invertebrate animals. A high level of alkaline phosphatase activity, comparable to that 
of mouse embryonic stem cells in vitro, has been revealed in the cytoplasm of stem cells in 
the studied colonial rhizocephalans (Isaeva et al., 2003; Shukalyuk et al., 2005). The stem 
cells were identified due to their high alkaline phosphatase activity, in contrast with the 
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stage of their life cycle to reveal the common feature of pluripotent stem cells of vertebrate 
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the studied colonial rhizocephalans (Isaeva et al., 2003; Shukalyuk et al., 2005). The stem 
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differentiated somatic cells of the endoparasitic interna characterized by a poor nonspecific 
staining of yellow color (Isaeva et al., 2003; Shukalyuk et al., 2005). In the blastomeres of 
dividing embryos of P. polygenea the alkaline phosphatase activity was confined to germinal 
granules located near the nucleus (Shukalyuk et al., 2005). 
High alkaline phosphatase activity has also been recorded in interstitial and gonial cells of 
the colonial hydroid O. longissima (Isaeva et al., 2011). Histochemical assay for alkaline 
phosphatase revealed intense staining of some hemocytes (apparently, hemoblasts as stem 
cells) and cells of early buds in ascidian Botryllus tuberatus distinguished the stem cells from 
differentiated somatic cells (Akhmadieva et al., 2007). 
Thus, the stem and gonial cells in rhizocephalans, hydroids and ascidians selectively express 
alkaline phosphatase activity. Specific brick red staining of stem cells in the studied 
representatives of colonial cnidarians, arthropods, and chordates was similar in color and 
intensity to that of cultured mouse embryonic stem cells used as “standard reference” 
(Isaeva et al., 2003; Shukalyuk et al., 2005). Our data is the evidence of the common 
functional characteristic of stem cells in such distant taxa as chordates, arthropods and 
cnidarians. We applied this classical histochemical method developed on the mammalian 
embryonic germ and stem cells to identify invertebrate stem cells, that reveals an 
opportunity for the application of this cytochemical reaction to the specific marking of stem 
cells of invertebrates in other taxonomic groups. 
So classical reaction revealing the activity of alkaline phosphatase, earlier used for the 
identification of primary germ cells and embryonic stem cells in vertebrates, became 
applicable as a cytochemical marker of both gametogenic and pluri/totipotent stem cells of 
invertebrates (Isaeva et al., 2003; Laird et al., 2005; Shukalyuk et al., 2005; Akhmadieva et al., 
2007; Rinkevich et al., 2009; Sköld et al., 2009). Among plants, a high alkaline phosphatase 
activity was found in the early gametangia of the brown alga Undaria pinnatifida 
(Alexandrova & Reunov, 2008). 
2.6 Amoeboid cell motility of stem cells 
Archaeocytes of sponges are characterized by amoeboid motility and active migration 
(Simpson, 1984; Müller, 2006; Funayama, 2008; Funayama et al., 2010). Archaeocytes are 
defined as large amoeboid cells actively migrating within the mesohyl (Funayama, 2008; 
Funayama et al., 2010). According to our data, migrating archaeocytes morphologically 
similar to those described previously in other sponge species participate in Oscarella 
malakhovi budding (Isaeva, Akhmadieva, 2011). 
In hydra and other cnidarians, interstitial cells are capable of active migration (Campbell, 
1974; Thomas & Edwards, 1991; Bode, 1996). Migration of numerous interstitial stem and 
oogonial cells inside the stolon and their participation in the formation of medusoid 
generation was also observed in Obelia longissima and Ectopleura crocea (Isaeva et al., 2011). 
Turbellarian neoblasts can migrate to the injured surface and sites of gonad formation 
(Rieger et al., 1991; Auladell et al., 1993; Agata & Watanabe, 1999; Shibata et al., 1999); 
amoeboid neoblasts and gonial cells in planarian Girardia tigrina demonstrated the 
migratory possibility (Isaeva et al., 2005). 
Undifferentiated rhizocephalan stem cells have been found inside each early stolon bud; 
similar cells migrate within the stolons in Peltogasterella gracilis and Polyascus polygenea 
(Isaeva et al., 2004; Shukalyuk et al., 2005). 
The primary germline cells are known to emerge outside of the future gonad and later 
traverse through several developing somatic tissues on their journey to the emerging gonad 
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using both amoeboid motility and passive morphogenetic movements (Matova & Cooley, 
2001; Kunwar & Lehmann, 2003; Travis, 2007; Cinalli et al., 2008). 
Thus, pluripotent stem cells of asexually reproducing invertebrates are similar to primary 
germ cells in their ability to amoeboid movement and extensive migrations within the 
organism, directed to asexual reproduction sites, to the wound surface resulting from fission 
or damage, or to the gonads, respectively (Isaeva et al., 2009; Isaeva, 2010). In contrast, plant 
stem cells, with the rigid cellulose wall, are unable to migrate within the organism, and only 
passively moving together with the tissue, due to cell proliferation and expansion (Lohman, 
2008). 
2.7 Plasticity of stem cells in morphogenesis 
Comparison of normal morphogenesis with its experimental changes helps us understand 
the plasticity of embryogenesis and blastogenesis. The plasticity of early animal 
embryogenesis is clearly shown in experiments with dissociated cells in vitro demonstrating 
the remarkable potential of cell self-organization (Isaeva et al., 2008a; Presnov et al., 2010). 
More than 100 years ago E. Wilson (1907) performed his famous experiments with 
dissociated sponge cells, reaggregated and developed into small sponges. Later Nikitin 
(1974) showed in experiments with dissociated cells of the sponge Ephydatia fluviatilis that 
homogeneous cell aggregates formed from stem cells (nucleolar amoebocytes, i.e. 
archaeocytes) are able to develop to a whole organism, while aggregates of other cell types 
inevitably died. Similar experimental studies were later carried out on sea urchin embryos: 
it was shown that reaggregates of dissociated embryonic cells in vitro formed “embryoids” 
(Giudice, 1962; Spiegel & Spiegel, 1986) which were able to develop into more or less normal 
larvae (Giudice, 1962) and, after metamorphosis, became fertile sea urchins (Hinegardner, 
1975). Such experiments demonstrate the remarkable self-organization potential of 
embryonic stem cell in vitro (Isaeva et al., 2008a). Chimerical reaggregates of embryonic stem 
cells of sea urchins can form secondary blastula- or gastrula-like embryoids (Isaeva et al., 
2008a; Presnov et al., 2010). This phenomenon is similar to the natural larval cloning by 
budding or fragmentation producing secondary larvae in starfish and other echinoderms 
(Jaeckle, 1994; Vickery & McClintock, 2000; Rinkevich et al., 2009).  
So changes in the initial conditions of morphogenesis in vitro lead to changed self-
organization of an embryonic cell system; similar modifications of embryogenesis may occur 
also in the course of evolution under considerably changed conditions of early development, 
for example, in endoparasitism. The endoparasitic rhizocephalan interna with stem cells is 
“culturing” in the host organism and using host hemolymph as a nutritive medium; these 
extremely favorable conditions lead to stem cell proliferation and expansion of cells and 
tissues. In parasitoid insects with polyembryony, a system similar to cell culture is formed. 
Polyembryony, the development of a whole embryo from one of the early blastomeres, i.e. 
asexual reproduction at an early embryonic stage, is known at least in six animal phyla 
(Craig et al., 1997; Sköld et al., 2009). For instance, among insects, polyembryony has been 
described in some parasitoid members of Hymenoptera and Strepsiptera (Johannsen & Butt, 
1941; Hagan, 1951). Polyembryony has been studied in detail in the parasitoid wasp 
Copidosoma floridanum: the zygote forms a morula, consistsing of about 200 cells; repeatedly 
dividing mitotically active embryonic cells produce more than a thousand of secondary 
morulae, which form a polymorula, or polygerm (Donnell et al., 2004; Corley et al., 2005). 
Polyembryony is similar to budding (Perez, 1931; Ghiselin, 1987), and the latter is quite 
widespread in the animal kingdom as a way of asexual reproduction. In polyembryony, the 
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using both amoeboid motility and passive morphogenetic movements (Matova & Cooley, 
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stage of cleavage, cell reproduction, becomes longer than in common embryonic 
development.  
The embryonic stem cells of mammals in vitro are similar to the pluripotent stem cells of 
rhizocephalans or other asexually reproducing animals. Stem cells in free-living asexually 
reproducing invertebrates use the own parental organism as a nutritive medium. Germ and 
pluripotent stem cells are “privileged”, “predatory” cells inclined to “parasitism” as has 
been displayed for colonial ascidians (Buss, 1999; Pancer et al., 1995; Rinkevich, 2009); these 
cells can survive starvation through “cannibalism” (Kerszberg & Wolpert, 1998). 
Sexual reproduction and early stages of embryogenesis are relatively conservative in all the 
animal kingdom due to the monophyly of metazoans (Sköld et al., 2009). Since asexual 
reproduction emerged in the course of the evolution of different metazoan lineages 
repeatedly and independently, asexual reproduction is more variable and less conservative 
than embryogenesis. The stage of cleavage is missing in blastogenesis, and stem cells can be 
likened to the embryonic cells of the morula stage. The integration of blastogenesis in the 
process of early embryogenesis in animals with polyembryony disrupts the conservatism of 
embryonic development (Isaeva, 2010). Polyembryony and the breaking of the conservatism 
of embryogenesis are known also in plants (Batygina, 2010).  
The data on the asexual reproduction in some arthropods and chordates contradicts the 
dogma that asexual reproduction is common exclusively among the lower animals. In 
particular, the statement that vertebrates are incapable of natural cloning (Blackstone & Jasker, 
2003) is disproved by known facts about facultative polyembryony in mammals, which has 
become obligate in some armadillo species, e.g. in Dasypus novemcinctus (Loughry et al., 1998).  
The self-renewing pool of totipotent stem cells in colonial invertebrates provides the cellular 
basis for realization of the reproductive strategy including both asexual and sexual 
reproduction. The principal difference between the reproductive strategy that includes 
asexual reproduction and the strategy with exclusively sexual reproduction concerns the 
maintenance of the pluri/totipotent stem cell lineage with gametogenic potential during the 
entire life span of an asexually reproducing organism; a self-renewing reserve of pluripotent 
stem cells is the cellular source ensuring the reproductive strategy that includes sexual and 
asexual reproduction. 
The problem of cells dedifferentiation in asexual reproduction and regeneration is less 
obvious, and the solution of this problem requires special markers. The notion of the high 
plasticity of the development and fate of cells in colonial animals (Frank et al., 2009; 
Rinkevich et al., 2009; Sköld et al., 2009), similar to that found in plants (Skold et al., 2009), 
appears sufficiently justified. In plants, however, differentiated cells retain the ability to 
dedifferentiate and become totipotent stem cells (Lohman, 2008; Batygina, 2010); animal 
cells at the stage of terminal differentiation usually have no such ability. 
2.8 Evolutionary transition from preformation to epigenesis in colonial Rhizacephala 
Extavour (2008) considered the transition from epigenesis to preformation as the repeated 
evolutionary event, but she thinks that examples of epigenesis in phyla where preformation 
is plesiomorphic never observed. However, the blastogenesis in colonial species of 
rhizocephalan crustaceans (Arthropoda: Crustacea: Cirripedia: Rhizocephala) involves a 
deep reorganization of development; we observe evolutionary secondary transition from 
preformation to epigenesis. We found germinal bodies in all or most blastomeres of cleaving 
embryos of Polyascus polygenea at stage of 16-32 blastomeres. In each germinal body selective 
expression of mRNA transcript of vasa-like gene and also high selective activity of alkaline 
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phosphatase were revealed (Shukalyuk et al., 2005, 2011). These data indicates the 
evolutionary secondary rearrangement of the developmental mode and transition from 
ancestral preformation with mosaic cleavage and early segregation of the germ line (that is 
plesiomorphic feature in Crustacea and all Arthropoda) to epigenesis with equipotential 
blastomeres containing germinal granules and asexual reproduction resulting in colonial 
organization (Isaeva, 2010). Thus, the evolutionary transition from preformation to 
epigenesis is possible as well as more frequent evolutionary transition from epigenesis to 
preformation. In Rhizocephala, the radical transformation of the ancestral reproductive 
strategy involved all the levels of organization, from molecular and subcellular to species-
specific (Kasyanov, 2001). The cellular basis for the reproductive strategy of Rhizocephala, 
including both sexual and asexual reproduction, is self-renewing pool of pluri/totipotent 
stem cells (Isaeva et al., 2008b, 2009). 
In recent reviews (Blackstone & Jasker, 2003; Sköld et al., 2009) and in modern textbooks, 
crustaceans as well as all other arthropods and the entire Ecdysozoa clade, are considered as 
acolonial and aclonal, though in some rhizocephalan crustaceans the colonial organization 
as result of asexual cloning has already been described (Høeg & Lützen, 1995; Isaeva et al., 
2003, 2004, 2008; Glenner et al., 2003; Shukalyuk et al., 2005). We have shown budding of a 
stolon filled with stem cells in colonial rhizocephalans P. polygenea and P. gracilis (Isaeva et 
al., 2003, 2004, Shukalyuk et al., 2005, 2007). Stem cells in rhizocephalans demonstrate all 
morphological properties shared by stem cells in other studied animals with asexual 
reproduction. The colonial nature of Rhizocephala has probably been denied because their 
colonial interna was not clearly visualized until quite recently. We have visualized the 
process of asexual reproduction by budding with maintaining colonial unity and 
connections between the developing blastozooids and common stolon in P. polygenea and P. 
gracilis, leaving no doubt about the colonial organization of these crustaceans at the 
endoparasitic stage of their life cycle (Isaeva &  Shukalyuk, 2007; Isaeva et al., 2008b; Isaeva 
et al., 2004; Shukalyuk et al., 2005, 2007). 
3. Conclusion 
On the morphological and gene expression levels, germ cells and stem cells are very similar 
(Shukalyuk & Isaeva, 2005; Extavour, 2008; Isaeva et al., 2008b, 2009, 2011; Rinkevich et al., 
2009; Sköld et al., 2009; Isaeva, 2010; Srouji & Extavour, 2011). Pluri/totipotent gametogenic 
stem cells are similar to germ and embryonic stem cells; evidence of the evolutionary 
conserved morphological and functional characteristics of pluripotent stem cells typical also 
to cells of the germ line have been obtained in representatives of such various metazoan 
phyla as Porifera, Cnidaria, Plathelminthes, Arthropoda and Chordata (Isaeva et al., 2003, 
2004, 2005, 2008b, 2009, 2011; Shukalyuk et al., 2005, 2007, 2011; Akhmadieva et al., 2007; 
Isaeva & Akhmadieva, 2011).  
The data supported our hypothesis that pluripotent, potentially gametogenic stem cells 
display evolutionarily conserved features of the morphological and functional organization 
typical for cells of the germ line and embryonic stem cells. In asexually reproducing 
invertebrates, from sponges and hydroids to some arthropods and chordates, stem cells 
share with cells of early embryos evolutionary conserved features presumably involved in 
maintenance of pluri/totipotency, including the gametogenic program. Such invertebrate 
cells capable of both gametogenesis and asexual reproduction (blastogenesis) are similar in 
their potential to mammalian embryonic stem cells. We propose that evolutionary and 
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acolonial and aclonal, though in some rhizocephalan crustaceans the colonial organization 
as result of asexual cloning has already been described (Høeg & Lützen, 1995; Isaeva et al., 
2003, 2004, 2008; Glenner et al., 2003; Shukalyuk et al., 2005). We have shown budding of a 
stolon filled with stem cells in colonial rhizocephalans P. polygenea and P. gracilis (Isaeva et 
al., 2003, 2004, Shukalyuk et al., 2005, 2007). Stem cells in rhizocephalans demonstrate all 
morphological properties shared by stem cells in other studied animals with asexual 
reproduction. The colonial nature of Rhizocephala has probably been denied because their 
colonial interna was not clearly visualized until quite recently. We have visualized the 
process of asexual reproduction by budding with maintaining colonial unity and 
connections between the developing blastozooids and common stolon in P. polygenea and P. 
gracilis, leaving no doubt about the colonial organization of these crustaceans at the 
endoparasitic stage of their life cycle (Isaeva &  Shukalyuk, 2007; Isaeva et al., 2008b; Isaeva 
et al., 2004; Shukalyuk et al., 2005, 2007). 
3. Conclusion 
On the morphological and gene expression levels, germ cells and stem cells are very similar 
(Shukalyuk & Isaeva, 2005; Extavour, 2008; Isaeva et al., 2008b, 2009, 2011; Rinkevich et al., 
2009; Sköld et al., 2009; Isaeva, 2010; Srouji & Extavour, 2011). Pluri/totipotent gametogenic 
stem cells are similar to germ and embryonic stem cells; evidence of the evolutionary 
conserved morphological and functional characteristics of pluripotent stem cells typical also 
to cells of the germ line have been obtained in representatives of such various metazoan 
phyla as Porifera, Cnidaria, Plathelminthes, Arthropoda and Chordata (Isaeva et al., 2003, 
2004, 2005, 2008b, 2009, 2011; Shukalyuk et al., 2005, 2007, 2011; Akhmadieva et al., 2007; 
Isaeva & Akhmadieva, 2011).  
The data supported our hypothesis that pluripotent, potentially gametogenic stem cells 
display evolutionarily conserved features of the morphological and functional organization 
typical for cells of the germ line and embryonic stem cells. In asexually reproducing 
invertebrates, from sponges and hydroids to some arthropods and chordates, stem cells 
share with cells of early embryos evolutionary conserved features presumably involved in 
maintenance of pluri/totipotency, including the gametogenic program. Such invertebrate 
cells capable of both gametogenesis and asexual reproduction (blastogenesis) are similar in 
their potential to mammalian embryonic stem cells. We propose that evolutionary and 
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ontogenetically related cells of early embryos and pluripotent stem cells belong to 
populations of cells that retain a wide or unlimited morphogenetic potential. 
Our results along with literature data allow suggest the existence of evolutionary conservative, 
common for all studied metazoan representatives, from sponges to chordates, cellular, sub-
cellular and molecular bases of pluripotency and “stemness” of stem and germ cells. 
Many authors called pluripotent stem cells of animals with asexual reproduction somatic cells 
(Blackstone & Jasker, 2003; Extavour & Akam, 2003; Extavour, 2008; Rinkevich, 2009; Sköld et 
al., 2009; Funayama et al., 2010). The term somatic embryogenesis (Buss, 1987; Blackstone & 
Jasker, 2003) clearly shows that stem cells providing for asexual reproduction are considered 
as somatic cells. However, pluri/totipotent stem cells in asexually reproducing animals, as 
well as primary germ cells in sexual reproduction, are not belonging to any germ layer, tissue, 
or population of specialized somatic cells (Isaeva et al., 2008b, 2009; Isaeva, 2010). The 
population of these pluripotent stem cells is a diaspora of amoeboid cells, dispersed in the 
organism; these stem cells do not display contact inhibition of cell reproduction and 
movement. The morphological and functional organization of the stem cells capable for both 
gametogenesis (and subsequent embryogenesis) and asexual reproduction (blastogenesis) and 
germ-line cells shares common properties. Our notion of the evolutionary and ontogenetic 
similarity between the stem cells of asexually reproducing animals, cells of the germ line and 
embryonic stem cells (Isaeva et al., 2008b, 2009) brings us back to the concept of Weismann 
(1883), who wrote about the indistinguishability of gametogenic cells and undifferentiated 
cells that preserve the “germ plasm.” It was later proposed that pluripotent gametogenic stem 
cells and getmline cells could be evolutionarily and ontogenetically related (Weissman, 2000; 
Extavour & Akam, 2003; Travis, 2007; Extavour, 2008; Strouji & Extavour, 2011). Primary germ 
cells and pluri/totipotent stem cells share many morphological characters and rely on the 
activity of related genes (Extavour & Akam, 2003; Hayashi et al., 2007; Travis, 2007; Sköld et 
al., 2009; Srouji & Extavour, 2011). Pluripotent stem cells of animals with asexual reproduction 
were termed “primary stem cells” (Skøld et al., 2009); such pluripotent stem cells are 
predecessors of primary germ cells (Blackstone & Jasker 2003; Sköld et al., 2009). Evolutionary 
conserved mechanism ensures germline specification remaining cell pluripotency (Strouji & 
Extavour, 2011). Thus, the pluripotent stem cells are not identical to somatic cells. Besides, 
morphogenesis in animal asexual reproduction does not completely recapitulate 
embryogenesis. So, the term somatic embryogenesis (Buss, 1987; Blackstone & Jasker, 2003) is not 
completely correct, the term blastogenesis seems preferable (Berrill, 1961). 
Stem cells of animals with asexual reproduction, as well as cells of the germ lineage, 
probably originate in the early embryogenesis either from the early totipotent blastomeres 
or from their derivates that retain pluri/totipotency. The author believes that the 
evolutionarily and ontogenetically related cells of early embryos, primary stem and primary 
germ cells belong to cell populations capable of realizing the developmental program, 
including gametogenesis (and, potentially, subsequent embryogenesis) and blastogenesis 
(Isaeva et al., 2008b, 2009; Isaeva, 2010). 
Thus, published and original data indicate evolutionary conservation and similarity of the 
studied morphofunctional properties of stem cells in metazoans with asexual reproduction 
(from sponges and cnidarians to chordates), germline and embryonic stem cells. In 
invertebrates with asexual reproduction, stem cells can differentiate into both germline and 
somatic cells; these pluri/totipotent stem cells represent a source of cells for the life strategy 
realization including sexual and asexual reproduction. Further research on the stem cells of 
various metazoan animals may reveal the evolutionary conserved basis of cellular 
totipotency and potential immortality. 
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field of regenerative medicine, and discoveries and new technology related to embryonic 
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